data_1k42_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1k42 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.524 ' CG2' ' HB2' ' A' ' 165' ' ' ALA . 4.1 p . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.524 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -71.74 -46.61 57.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.173 -0.955 . . . . 0.0 109.487 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 162' ' ' LEU . 38.7 t-20 -82.56 125.83 31.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.207 -0.933 . . . . 0.0 109.496 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.464 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 2.0 mp -112.2 123.35 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.292 -0.88 . . . . 0.0 109.265 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.473 ' HB3' ' HA3' ' A' ' 27' ' ' GLY . 0.8 OUTLIER 69.05 12.9 8.7 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.266 -0.896 . . . . 0.0 109.504 179.973 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -59.14 -24.96 59.29 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.458 ' O ' ' OD2' ' A' ' 160' ' ' ASP . . . -110.99 36.56 4.16 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.214 -1.555 . . . . 0.0 109.214 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.58 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 0.7 OUTLIER 43.64 53.21 6.02 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.368 -1.078 . . . . 0.0 109.422 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.483 ' OE2' ' CG ' ' A' ' 52' ' ' GLU . 7.7 mm-40 -84.04 -49.62 8.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -0.926 . . . . 0.0 109.728 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.461 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 7.3 m -79.58 -16.49 55.8 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.677 -179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.544 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 0.5 OUTLIER -74.51 114.74 36.89 Favored Pre-proline 0 C--N 1.304 -1.389 0 O-C-N 121.185 -0.947 . . . . 0.0 109.422 -179.802 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.2 Cg_endo -77.09 136.9 16.75 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.424 2.082 . . . . 0.0 110.474 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.439 ' C ' ' O ' ' A' ' 14' ' ' PRO . . . -40.02 155.51 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.393 0.616 . . . . 0.0 109.717 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.3 132.6 3.0 Favored Glycine 0 N--CA 1.485 1.961 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.533 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.71 142.45 12.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.252 -1.146 . . . . 0.0 109.011 -179.528 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.6 t -88.42 144.14 9.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-O 121.778 0.799 . . . . 0.0 110.277 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.409 HG23 ' N ' ' A' ' 20' ' ' ASP . 2.3 t -105.03 -26.69 12.04 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 179.145 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.462 ' CB ' ' HG3' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -138.18 101.37 4.38 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 179.453 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.576 HD23 ' CE2' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -55.56 -34.91 65.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.204 -0.935 . . . . 0.0 110.384 -179.004 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.52 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.69 -33.79 72.03 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.061 -1.024 . . . . 0.0 109.334 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.462 ' HG3' ' CB ' ' A' ' 20' ' ' ASP . 1.4 pt-20 -122.15 37.67 4.32 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.303 -0.873 . . . . 0.0 109.369 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -89.2 -73.1 1.28 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.544 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 14.6 t -99.72 127.43 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.307 -1.113 . . . . 0.0 109.259 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 31.6 tp10 -56.76 -35.69 68.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.417 -0.802 . . . . 0.0 109.783 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.473 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -99.14 -2.4 56.91 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 -179.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' TRP . . . . . 0.614 ' CZ3' ' CB ' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -138.79 123.21 18.32 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.088 -1.242 . . . . 0.0 109.845 179.941 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.452 ' HB2' ' CE1' ' A' ' 76' ' ' PHE . 3.9 m-20 -123.47 144.23 49.66 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.571 HD12 ' CD1' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -113.5 166.98 10.98 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.714 -1.242 . . . . 0.0 109.461 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.458 ' OD1' ' O ' ' A' ' 30' ' ' LEU . 8.5 m120 -157.02 124.67 5.39 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.45 -0.781 . . . . 0.0 109.687 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.523 HG11 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.04 136.56 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.383 -0.823 . . . . 0.0 109.457 179.539 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.43 -170.6 23.81 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.4 t -66.74 -9.09 33.01 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.195 -1.18 . . . . 0.0 109.438 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.466 ' HB2' ' HA ' ' A' ' 70' ' ' ASP . 0.6 OUTLIER -73.12 -31.39 64.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.204 -0.935 . . . . 0.0 109.593 -179.964 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.523 ' CG2' HG11 ' A' ' 32' ' ' VAL . 2.1 t -64.64 87.86 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 O-C-N 121.176 -0.952 . . . . 0.0 109.339 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 16.4 m -72.58 -29.0 63.15 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.478 ' O ' HG11 ' A' ' 36' ' ' VAL . 1.2 t-20 -114.57 144.98 32.88 Favored Pre-proline 0 C--N 1.296 -1.746 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.43 ' HD2' ' CG ' ' A' ' 38' ' ' ASN . 34.8 Cg_endo -76.38 111.8 3.34 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 122.359 2.039 . . . . 0.0 110.591 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.534 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.2 Cg_endo -77.57 166.13 26.16 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.371 2.048 . . . . 0.0 109.593 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.522 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 49.0 t -108.16 121.59 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.966 -1.084 . . . . 0.0 110.559 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.576 ' CE2' HD23 ' A' ' 21' ' ' LEU . 27.4 m-85 -110.12 112.47 24.48 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.464 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.533 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 0.9 OUTLIER -153.56 151.32 29.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.1 -1.0 . . . . 0.0 109.801 -179.422 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.463 HG11 ' O ' ' A' ' 56' ' ' VAL . 62.3 t -98.78 148.57 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -0.885 . . . . 0.0 109.255 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.551 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -131.9 147.01 52.44 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.185 -0.947 . . . . 0.0 108.776 179.978 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.551 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 18.1 mt-10 -115.08 113.69 24.37 Favored 'General case' 0 C--N 1.295 -1.8 0 O-C-N 121.576 -0.702 . . . . 0.0 109.548 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.525 ' CG2' HD21 ' A' ' 45' ' ' LEU . 1.7 p -141.5 164.66 29.62 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.31 -0.869 . . . . 0.0 109.41 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.44 ' HA ' ' OD1' ' A' ' 54' ' ' ASN . 0.1 OUTLIER -86.9 15.59 5.73 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.9 . . . . 0.0 109.51 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -102.89 -18.51 15.03 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.242 -0.911 . . . . 0.0 109.436 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.453 ' HB2' ' CG1' ' A' ' 56' ' ' VAL . . . -55.55 144.68 52.97 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.2 -0.938 . . . . 0.0 109.329 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.484 ' HG3' ' CB ' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.29 -42.12 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.571 2.181 . . . . 0.0 110.365 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.483 ' CG ' ' OE2' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -101.42 92.8 5.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.901 . . . . 0.0 109.407 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.93 -115.97 4.35 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.465 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 15.2 m-20 -160.02 37.77 0.18 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -1.147 . . . . 0.0 109.412 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.52 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 62.1 mttt -138.54 134.24 33.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.198 -0.938 . . . . 0.0 109.6 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.463 ' O ' HG11 ' A' ' 44' ' ' VAL . 5.9 m -146.53 174.62 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.313 -0.867 . . . . 0.0 109.229 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.58 ' HB2' ' CE2' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -107.46 103.09 12.34 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.101 -1.0 . . . . 0.0 109.181 179.731 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.641 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.17 120.71 25.21 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.034 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.532 ' CG2' HD21 ' A' ' 57' ' ' LEU . 41.5 t -115.79 144.89 22.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.15 -0.969 . . . . 0.0 109.331 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' THR . . . . . 0.522 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 19.6 m -108.99 92.75 4.18 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.563 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 52.5 t -90.54 115.73 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.236 -0.915 . . . . 0.0 109.272 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -149.51 56.41 0.98 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.248 -0.908 . . . . 0.0 109.828 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 160.9 90.09 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.53 HG12 ' CA ' ' A' ' 149' ' ' TYR . 2.5 m -80.14 -171.32 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.176 -1.19 . . . . 0.0 109.451 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -139.95 -168.44 11.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -86.21 1.41 50.86 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.233 -1.157 . . . . 0.0 109.569 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.578 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 1.2 m120 -116.33 145.02 34.16 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.241 -0.912 . . . . 0.0 109.284 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.577 ' HG2' ' CZ3' ' A' ' 69' ' ' TRP . 36.4 Cg_endo -79.52 38.88 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.607 2.204 . . . . 0.0 111.197 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.578 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 8.2 p90 -162.58 50.05 0.18 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.968 -1.082 . . . . 0.0 109.807 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.466 ' HA ' ' HB2' ' A' ' 35' ' ' SER . 0.4 OUTLIER -70.94 -64.64 0.86 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.126 -0.984 . . . . 0.0 108.924 179.536 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.534 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 4.1 mp -106.4 128.73 60.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 108.996 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.428 ' OE2' ' HB2' ' A' ' 144' ' ' PRO . 71.3 tt0 -138.26 122.68 18.35 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.843 -1.16 . . . . 0.0 110.195 -179.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.614 ' CB ' ' CZ3' ' A' ' 28' ' ' TRP . . . -113.76 107.41 15.7 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.069 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.46 ' OG1' ' HA ' ' A' ' 144' ' ' PRO . 96.7 m -94.4 165.44 12.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.57 -0.706 . . . . 0.0 110.17 -179.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.437 ' O ' ' HB3' ' A' ' 76' ' ' PHE . . . -119.12 137.78 53.36 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.175 -0.953 . . . . 0.0 108.726 178.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.548 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 0.2 OUTLIER -179.12 161.49 1.0 Allowed Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.561 -0.712 . . . . 0.0 109.165 -179.387 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.548 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.2 Cg_endo -82.46 163.32 74.97 Favored 'Cis proline' 0 C--N 1.311 -1.437 0 C-N-CA 123.81 -1.329 . . . . 0.0 110.893 -0.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.515 HG12 ' CD1' ' A' ' 164' ' ' ILE . 96.8 t -123.99 156.45 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.4 -0.813 . . . . 0.0 108.913 179.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ASN . . . . . 0.524 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 52.1 m-20 -121.21 139.8 52.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.115 -0.991 . . . . 0.0 109.854 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.561 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 2.5 m -146.3 -174.0 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.138 -0.976 . . . . 0.0 109.478 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.526 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 0.0 OUTLIER -137.3 146.09 52.52 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.233 -0.917 . . . . 0.0 109.429 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.45 106.14 2.16 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.474 2.116 . . . . 0.0 110.494 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 112.35 -29.7 8.12 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.461 HG13 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.43 149.71 4.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.158 -1.201 . . . . 0.0 109.474 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.462 ' HA ' ' OG1' ' A' ' 133' ' ' THR . 10.8 m -95.47 143.07 27.11 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' TYR . . . . . 0.561 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 12.0 m-85 -120.61 168.49 11.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.171 -0.956 . . . . 0.0 109.604 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' THR . . . . . 0.478 ' CB ' ' O ' ' A' ' 165' ' ' ALA . 5.2 m -118.15 154.47 32.1 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.26 -0.9 . . . . 0.0 109.561 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.682 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 5.1 t80 -130.56 118.96 21.81 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.298 -0.876 . . . . 0.0 109.319 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.5 HG23 ' N ' ' A' ' 90' ' ' ILE . 31.8 m -134.31 144.04 48.07 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.215 -0.928 . . . . 0.0 109.333 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.505 ' C ' ' CD1' ' A' ' 91' ' ' TRP . 14.9 tt -150.62 163.54 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 120.703 -1.248 . . . . 0.0 109.506 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.505 ' CD1' ' C ' ' A' ' 90' ' ' ILE . 20.1 m95 -132.73 124.98 29.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.974 -1.079 . . . . 0.0 109.342 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.526 ' HB2' ' CG2' ' A' ' 121' ' ' ILE . . . -115.88 150.42 37.08 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.288 -0.883 . . . . 0.0 109.459 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.549 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 1.1 ttt85 -164.4 119.12 1.44 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.309 -0.869 . . . . 0.0 109.027 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.39 170.1 8.12 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 110.065 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -66.12 -55.94 13.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.443 -0.785 . . . . 0.0 109.41 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.514 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -104.43 137.3 42.5 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.222 -0.924 . . . . 0.0 109.463 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.585 ' N ' ' CG2' ' A' ' 123' ' ' THR . 19.2 p-10 -61.64 148.35 42.82 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.308 -0.87 . . . . 0.0 109.562 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 108.9 39.43 1.71 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.471 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -119.55 141.15 49.5 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.14 -1.212 . . . . 0.0 108.98 179.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.463 ' HB ' ' HB2' ' A' ' 151' ' ' ALA . 52.0 t -115.94 148.25 18.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 110.712 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.634 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 25.1 t -150.01 164.96 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.457 -0.777 . . . . 0.0 109.203 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.539 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 16.4 t -136.47 144.33 44.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.011 -1.056 . . . . 0.0 109.457 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.629 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.1 OUTLIER -135.99 104.67 5.78 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.224 -0.923 . . . . 0.0 109.924 -179.726 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.503 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 14.0 p -112.77 168.75 9.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.093 -1.005 . . . . 0.0 110.058 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.572 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -127.83 141.45 46.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 CA-C-O 121.386 0.612 . . . . 0.0 109.837 -179.879 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -167.49 143.9 8.58 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.4 p30 -84.66 -169.79 2.8 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.197 -1.179 . . . . 0.0 109.632 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . 0.52 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 11.2 mp0 -77.84 16.95 0.62 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.196 -0.94 . . . . 0.0 110.683 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.476 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 0.8 OUTLIER -113.23 15.46 19.36 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 120.831 -1.168 . . . . 0.0 108.801 179.447 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.476 ' HB2' ' O ' ' A' ' 109' ' ' SER . 9.8 m-30 67.63 16.86 9.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.504 -0.748 . . . . 0.0 109.599 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.528 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 12.8 mm-40 -93.5 157.66 16.1 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.177 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . 0.462 ' OE1' ' HB ' ' A' ' 104' ' ' THR . 8.0 tt0 -137.83 147.15 44.29 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.034 -1.041 . . . . 0.0 109.99 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.468 ' OH ' ' HB3' ' A' ' 107' ' ' ASN . 4.0 m-85 -112.3 -67.4 1.0 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.567 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -92.35 173.42 35.73 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.475 ' CG ' HG21 ' A' ' 104' ' ' THR . 6.8 ttt-85 -178.78 119.46 0.08 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.08 -1.247 . . . . 0.0 110.217 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.577 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -141.91 70.03 1.33 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.396 -0.815 . . . . 0.0 108.803 179.241 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' HIS . . . . . 0.54 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 0.2 OUTLIER -86.64 148.07 25.63 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 110.346 -179.265 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 1.2 mt-10 79.42 66.32 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.466 -0.771 . . . . 0.0 109.557 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . 0.465 ' HA ' ' NE2' ' A' ' 119' ' ' GLN . 7.8 mm100 -118.79 123.73 45.51 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.315 -0.866 . . . . 0.0 109.259 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.23 139.14 58.73 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.429 -0.794 . . . . 0.0 108.972 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.526 ' CG2' ' HB2' ' A' ' 92' ' ' ALA . 5.6 mm -125.95 130.17 72.32 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.08 -1.012 . . . . 0.0 110.14 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.04 -179.28 6.17 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.604 0.716 . . . . 0.0 109.949 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.585 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 74.9 p -75.85 -4.19 39.36 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.793 -0.763 . . . . 0.0 109.183 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.445 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 2.8 mt-10 -106.65 -168.78 1.46 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.327 -0.858 . . . . 0.0 109.311 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' TRP . . . . . 0.549 ' CE2' ' HD3' ' A' ' 93' ' ' ARG . 93.8 m95 -94.38 118.64 31.92 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.208 -0.933 . . . . 0.0 109.691 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -106.88 121.44 44.88 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.289 -0.882 . . . . 0.0 108.985 179.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -79.54 117.05 3.64 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.341 2.027 . . . . 0.0 111.075 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -121.25 138.29 54.3 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.497 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.7 t -151.27 175.81 11.84 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.608 -1.308 . . . . 0.0 111.149 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.682 ' CE2' ' CD1' ' A' ' 88' ' ' TYR . 36.3 p90 -173.22 -172.69 0.84 Allowed 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.095 179.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . 0.412 ' N ' ' CD1' ' A' ' 130' ' ' PHE . 21.7 mt-10 -129.01 155.78 44.86 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.098 -1.001 . . . . 0.0 110.051 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -164.98 139.18 4.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.422 -0.799 . . . . 0.0 109.065 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.462 ' OG1' ' HA ' ' A' ' 85' ' ' THR . 0.8 OUTLIER -117.85 146.19 44.05 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.216 -0.927 . . . . 0.0 109.377 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 4.4 t -44.57 110.49 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.396 -0.815 . . . . 0.0 109.203 179.426 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 65.5 m -61.8 -53.08 60.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.207 -0.933 . . . . 0.0 109.258 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 -102.91 -91.74 0.34 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.359 -0.838 . . . . 0.0 109.218 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.441 ' HA ' HG11 ' A' ' 134' ' ' VAL . 0.5 OUTLIER -162.27 50.59 0.2 Allowed 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.458 -0.776 . . . . 0.0 109.314 179.734 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.466 ' O ' HG23 ' A' ' 80' ' ' VAL . 23.1 mm-40 -88.18 114.63 25.0 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.209 -0.932 . . . . 0.0 109.604 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.6 p -79.19 -12.38 59.97 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.294 -0.879 . . . . 0.0 108.759 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 40.8 t -135.73 134.77 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.391 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.474 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -139.58 172.52 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.194 -0.941 . . . . 0.0 110.057 -179.725 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' ARG . . . . . 0.476 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.4 ptm180 -145.54 132.54 20.28 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.556 -0.715 . . . . 0.0 109.614 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ALA . . . . . 0.572 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -100.24 106.58 42.87 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.292 -0.88 . . . . 0.0 109.655 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.503 ' HD2' ' O ' ' A' ' 104' ' ' THR . 33.7 Cg_endo -76.64 110.56 3.07 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.061 1.841 . . . . 0.0 110.291 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . 0.557 HG12 ' O ' ' A' ' 73' ' ' ALA . 3.2 mm -85.71 124.74 40.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' HIS . . . . . 0.49 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 6.7 m80 -84.57 150.15 25.41 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.972 -1.08 . . . . 0.0 110.984 -178.158 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.634 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 12.1 m-85 -154.91 157.36 37.66 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.125 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.426 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 108.44 50.67 0.74 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 0.53 ' CA ' HG12 ' A' ' 64' ' ' VAL . 27.5 m-85 -121.17 159.77 25.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.378 -1.072 . . . . 0.0 109.227 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.78 -30.39 71.03 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.611 -0.681 . . . . 0.0 109.168 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -77.0 -11.0 59.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.394 -0.816 . . . . 0.0 109.108 179.273 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.55 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 3.8 t30 -109.81 11.62 24.28 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.493 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -90.06 164.76 2.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 O-C-N 121.519 -0.738 . . . . 0.0 109.763 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' GLY . . . . . 0.493 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 53.29 32.7 44.72 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.864 -1.295 . . . . 0.0 109.864 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.7 m-20 -160.53 136.78 8.59 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.137 -1.214 . . . . 0.0 110.04 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' THR . . . . . 0.567 HG22 ' CE1' ' A' ' 158' ' ' TYR . 53.6 m -86.83 121.13 28.9 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.01 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.563 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 0.7 OUTLIER -100.86 118.73 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 120.967 -1.083 . . . . 0.0 110.291 -178.775 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.641 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 2.6 m-85 -97.09 129.42 44.51 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 178.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.625 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -120.37 141.99 38.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 120.749 -1.219 . . . . 0.0 110.091 -178.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' ASP . . . . . 0.464 ' O ' ' HB2' ' A' ' 91' ' ' TRP . 4.5 t70 -173.89 136.41 0.54 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.299 -0.876 . . . . 0.0 108.901 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 124.78 -6.93 8.34 Favored Glycine 0 N--CA 1.486 2.033 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.157 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.582 HD13 ' CE2' ' A' ' 88' ' ' TYR . 0.6 OUTLIER -60.01 94.04 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 O-C-N 120.768 -1.43 . . . . 0.0 108.491 179.899 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . 0.467 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -132.93 145.85 51.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.633 -0.667 . . . . 0.0 109.815 -179.068 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.515 ' CD1' HG12 ' A' ' 78' ' ' VAL . 3.2 mt -123.08 115.65 46.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.235 -0.915 . . . . 0.0 109.202 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . 0.524 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.621 0 O-C-N 121.171 -0.956 . . . . 0.0 109.626 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.507 HG12 ' N ' ' A' ' 4' ' ' ALA . 1.4 p . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.236 0.541 . . . . 0.0 109.553 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.507 ' N ' HG12 ' A' ' 3' ' ' VAL . . . -70.79 -61.19 1.86 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.058 -1.027 . . . . 0.0 109.324 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.473 ' ND2' ' O ' ' A' ' 162' ' ' LEU . 13.0 p-10 -74.92 176.92 6.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.367 -0.833 . . . . 0.0 109.405 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.46 HG22 ' OD1' ' A' ' 7' ' ' ASN . 2.6 mp -128.3 136.83 59.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.286 -0.884 . . . . 0.0 109.717 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.532 ' OD1' ' CB ' ' A' ' 12' ' ' SER . 0.3 OUTLIER 44.92 57.71 4.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.678 179.908 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -56.96 -42.79 92.92 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.481 ' O ' ' HB2' ' A' ' 10' ' ' PHE . . . -107.74 35.62 4.89 Favored Glycine 0 N--CA 1.487 2.088 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.578 ' CZ ' ' HB2' ' A' ' 57' ' ' LEU . 4.1 m-85 63.52 54.73 1.87 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.468 -1.019 . . . . 0.0 109.386 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -82.35 -50.53 8.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.897 . . . . 0.0 109.737 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.532 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 41.3 t -69.9 -42.14 73.77 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.105 -0.997 . . . . 0.0 109.693 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.531 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 0.6 OUTLIER -68.53 125.71 91.99 Favored Pre-proline 0 C--N 1.305 -1.351 0 O-C-N 121.217 -0.927 . . . . 0.0 109.199 -179.882 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.47 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.2 Cg_endo -76.98 146.1 25.53 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 122.462 2.108 . . . . 0.0 111.071 -179.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.47 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -42.05 165.48 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.564 0 CA-C-O 121.214 0.53 . . . . 0.0 109.663 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 130.96 135.27 3.76 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.527 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.57 140.14 15.14 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.34 -1.094 . . . . 0.0 109.029 -179.596 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -84.77 143.67 11.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 CA-C-O 121.763 0.792 . . . . 0.0 110.196 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.4 p -113.56 -27.1 7.99 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.527 ' CB ' ' HG3' ' A' ' 23' ' ' GLU . 20.5 m-20 -133.42 77.83 1.75 Allowed 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.561 HD22 ' CD2' ' A' ' 42' ' ' PHE . 0.5 OUTLIER -44.63 -32.25 1.41 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.323 -0.861 . . . . 0.0 109.708 -179.365 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.528 ' N ' HD11 ' A' ' 21' ' ' LEU . . . -71.11 -47.03 60.44 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.283 -0.885 . . . . 0.0 109.548 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.527 ' HG3' ' CB ' ' A' ' 20' ' ' ASP . 9.1 pt-20 -115.49 38.12 3.36 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.257 -0.902 . . . . 0.0 109.569 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 20' ' ' ASP . . . -106.9 -77.69 1.09 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.575 HG22 ' CD2' ' A' ' 10' ' ' PHE . 5.8 t -92.8 111.0 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.283 -1.128 . . . . 0.0 109.264 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -59.98 -39.86 87.15 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.299 -0.876 . . . . 0.0 109.867 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.455 ' HA3' ' HB2' ' A' ' 7' ' ' ASN . . . -67.56 -35.12 85.86 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' TRP . . . . . 0.574 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -129.64 126.26 37.98 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.153 -1.204 . . . . 0.0 109.67 -179.797 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -115.54 141.25 48.31 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.531 ' CB ' ' HB2' ' A' ' 21' ' ' LEU . 0.9 OUTLIER -116.29 163.13 16.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.716 -1.24 . . . . 0.0 109.53 -179.548 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 71.8 m-80 -156.18 123.15 5.29 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.518 -0.738 . . . . 0.0 109.402 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.526 HG11 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -102.97 133.84 45.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.342 -0.849 . . . . 0.0 109.514 179.571 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.14 167.34 16.89 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -44.86 -26.16 0.38 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -1.142 . . . . 0.0 109.411 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 37' ' ' THR . 6.8 m -53.08 -53.12 55.0 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.19 -0.944 . . . . 0.0 109.455 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.526 ' CG2' HG11 ' A' ' 32' ' ' VAL . 42.2 t -46.18 94.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.2 -0.938 . . . . 0.0 110.196 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.484 ' N ' ' O ' ' A' ' 35' ' ' SER . 82.9 m -78.25 -27.53 47.6 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.336 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.474 ' O ' HG13 ' A' ' 36' ' ' VAL . 20.1 m-20 -114.9 147.36 38.1 Favored Pre-proline 0 C--N 1.297 -1.696 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.32 111.08 3.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.496 2.131 . . . . 0.0 110.768 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.522 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 36.0 Cg_endo -78.69 167.33 22.63 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.495 2.13 . . . . 0.0 109.684 179.551 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.513 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 51.1 t -110.38 121.89 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.953 -1.092 . . . . 0.0 110.47 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.561 ' CD2' HD22 ' A' ' 21' ' ' LEU . 28.2 m-85 -111.01 112.8 24.87 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 178.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.527 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 29.3 tt0 -151.08 160.8 43.68 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.109 -0.994 . . . . 0.0 109.702 -179.383 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.469 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 49.2 t -102.26 133.48 45.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.434 -0.791 . . . . 0.0 109.133 179.555 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.414 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -111.28 118.7 36.62 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.349 -0.845 . . . . 0.0 109.415 -179.606 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.463 ' OE2' ' HE3' ' A' ' 55' ' ' LYS . 6.1 mt-10 -91.65 109.84 21.16 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 4.8 p -141.67 153.89 44.99 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.544 -0.723 . . . . 0.0 109.41 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 89.3 p -78.85 -10.15 59.7 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.228 -0.92 . . . . 0.0 109.484 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.401 ' O ' ' C ' ' A' ' 50' ' ' ALA . 5.4 m-20 -79.81 -18.17 51.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.191 -0.943 . . . . 0.0 109.536 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.405 ' HB1' HG12 ' A' ' 56' ' ' VAL . . . -45.02 147.65 1.13 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.895 . . . . 0.0 109.544 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.492 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.16 -40.59 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.629 2.219 . . . . 0.0 110.355 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.27 115.57 26.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.52 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.05 -124.54 23.35 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -152.74 22.85 0.59 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.164 -1.198 . . . . 0.0 109.499 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.521 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 8.6 mttt -129.37 143.61 50.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.436 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.455 HG13 ' O ' ' A' ' 55' ' ' LYS . 11.9 m -150.24 175.59 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.347 -0.846 . . . . 0.0 109.004 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.578 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -108.43 99.64 9.01 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.057 -1.027 . . . . 0.0 109.033 179.508 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.614 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.23 119.2 23.32 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.524 HG21 ' CD2' ' A' ' 57' ' ' LEU . 43.7 t -115.68 144.85 22.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.134 -0.979 . . . . 0.0 109.212 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' THR . . . . . 0.513 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 9.3 m -108.96 91.69 3.74 Favored 'General case' 0 C--N 1.283 -2.313 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.546 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 48.2 t -89.58 117.41 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.395 -0.815 . . . . 0.0 109.091 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -154.4 58.55 0.7 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.305 -0.872 . . . . 0.0 109.935 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 157.02 84.2 0.05 OUTLIER Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.549 HG11 ' CA ' ' A' ' 149' ' ' TYR . 1.8 m -80.07 -175.85 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.21 -1.171 . . . . 0.0 109.513 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -129.31 -148.52 6.59 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -94.74 -5.89 44.33 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.325 -1.103 . . . . 0.0 109.576 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.568 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 27.8 m-20 -112.74 146.75 35.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.077 -1.014 . . . . 0.0 109.45 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.414 ' O ' ' CE1' ' A' ' 149' ' ' TYR . 36.3 Cg_endo -78.7 12.99 2.02 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.602 2.202 . . . . 0.0 110.931 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.568 ' CZ2' ' OD1' ' A' ' 67' ' ' ASN . 4.2 p90 -133.5 51.86 2.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.035 -1.041 . . . . 0.0 109.659 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.519 ' CA ' HG21 ' A' ' 36' ' ' VAL . 2.6 m-20 -74.24 -64.17 1.08 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.3 -0.875 . . . . 0.0 109.193 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.522 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 2.9 mp -100.22 118.3 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 109.043 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -121.4 127.49 51.23 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.138 -0.976 . . . . 0.0 110.15 -179.565 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.574 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -123.72 108.26 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.26 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.446 HG23 ' C ' ' A' ' 143' ' ' ALA . 86.0 m -104.95 165.76 10.85 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.418 -0.801 . . . . 0.0 109.95 -179.008 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.463 ' O ' ' HB3' ' A' ' 76' ' ' PHE . . . -120.92 140.13 52.27 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.071 -1.018 . . . . 0.0 108.875 178.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.555 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.3 p90 179.53 162.86 0.79 Allowed Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.496 -0.752 . . . . 0.0 109.2 -179.551 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.555 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.8 Cg_endo -82.14 169.31 62.94 Favored 'Cis proline' 0 C--N 1.311 -1.416 0 C-N-CA 123.885 -1.298 . . . . 0.0 110.856 -0.534 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 85.1 t -127.65 156.22 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.388 -0.82 . . . . 0.0 108.891 179.292 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ASN . . . . . 0.47 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 16.5 m-80 -123.44 118.66 27.95 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.16 -0.962 . . . . 0.0 109.94 -179.567 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.556 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 3.0 m -124.63 -173.83 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.27 -0.894 . . . . 0.0 109.541 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.531 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 15.3 mmt180 -136.63 144.93 49.14 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.332 -0.855 . . . . 0.0 109.269 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.19 120.57 5.4 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 122.545 2.163 . . . . 0.0 110.618 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 98.21 -27.76 17.81 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.409 HG11 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.06 149.7 4.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.21 -1.171 . . . . 0.0 109.501 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 28.5 m -95.86 133.03 40.49 Favored 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' TYR . . . . . 0.556 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 7.4 m-85 -111.68 166.76 10.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.896 . . . . 0.0 109.692 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 32.4 m -118.38 154.31 32.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.358 -0.839 . . . . 0.0 109.335 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.69 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 7.6 t80 -129.72 117.98 21.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.159 -0.963 . . . . 0.0 109.548 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.491 HG23 ' N ' ' A' ' 90' ' ' ILE . 18.7 m -135.0 144.26 47.26 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.24 -0.912 . . . . 0.0 109.186 179.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.57 HD13 ' CD1' ' A' ' 103' ' ' PHE . 14.4 tt -150.49 163.78 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 120.817 -1.177 . . . . 0.0 109.562 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.505 ' CD1' ' C ' ' A' ' 90' ' ' ILE . 19.8 m95 -132.73 125.99 31.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.062 -1.024 . . . . 0.0 109.303 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -117.08 151.81 36.01 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.359 -0.838 . . . . 0.0 109.487 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.545 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 8.5 ttp85 -164.14 118.49 1.47 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.188 -0.945 . . . . 0.0 109.188 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -105.37 160.93 14.74 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.301 -0.874 . . . . 0.0 109.951 -179.522 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -58.95 -48.56 81.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.417 -0.802 . . . . 0.0 109.289 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.517 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 2.0 mt-30 -113.91 142.16 46.47 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.273 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.579 ' N ' ' CG2' ' A' ' 123' ' ' THR . 28.4 p-10 -65.14 146.16 55.34 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.23 -0.919 . . . . 0.0 109.485 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 110.91 38.3 1.57 Allowed Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.467 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -120.45 140.66 51.07 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.257 -1.143 . . . . 0.0 109.082 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.516 HG12 ' N ' ' A' ' 101' ' ' VAL . 55.5 t -116.14 145.27 22.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.224 -0.922 . . . . 0.0 110.766 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.568 HG11 ' CE2' ' A' ' 147' ' ' PHE . 39.0 t -143.05 165.86 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.569 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.539 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 4.1 m -123.25 126.22 46.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.069 -1.019 . . . . 0.0 109.9 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.57 ' CD1' HD13 ' A' ' 90' ' ' ILE . 66.8 m-85 -116.79 103.45 10.34 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.028 -1.045 . . . . 0.0 109.322 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.504 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 17.8 p -128.11 164.73 21.8 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.011 -1.055 . . . . 0.0 110.691 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.62 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -129.7 155.95 41.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-O 121.213 0.53 . . . . 0.0 109.964 -179.934 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.521 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -174.11 -173.81 40.47 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.2 p30 -131.24 -169.56 2.2 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.152 -1.205 . . . . 0.0 109.45 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . 0.52 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 3.5 mp0 -68.34 3.81 1.58 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.098 -1.002 . . . . 0.0 111.336 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.475 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 1.4 m -107.1 14.87 25.83 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 120.661 -1.274 . . . . 0.0 109.239 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.475 ' HB2' ' O ' ' A' ' 109' ' ' SER . 13.7 m-30 67.04 7.84 5.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.447 -0.783 . . . . 0.0 109.609 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.521 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 24.4 tt0 -80.07 158.32 26.47 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 4.2 tt0 -136.15 136.5 40.09 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.028 -1.045 . . . . 0.0 110.012 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.573 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 7.3 m-85 -96.17 -70.74 0.7 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.412 -0.805 . . . . 0.0 108.875 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.567 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -81.92 156.48 36.3 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 179.5 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.7 ttt180 -153.36 106.94 3.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.057 -1.261 . . . . 0.0 110.258 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.558 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -146.12 70.0 1.22 Allowed 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.146 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' HIS . . . . . 0.539 ' CB ' ' HB3' ' A' ' 102' ' ' SER . 2.1 p-80 -107.85 160.71 15.53 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.252 -0.905 . . . . 0.0 110.048 -179.449 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 16.5 tt0 77.28 58.56 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.361 -0.837 . . . . 0.0 109.469 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 4.0 mm-40 -130.14 136.98 49.88 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.315 -0.866 . . . . 0.0 109.501 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -70.88 156.28 39.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.472 -0.768 . . . . 0.0 109.065 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.467 HG21 HD13 ' A' ' 121' ' ' ILE . 6.0 mm -133.49 135.67 55.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.148 -0.97 . . . . 0.0 109.873 -179.455 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -82.74 -179.34 7.4 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.672 0.749 . . . . 0.0 110.001 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.579 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 63.7 p -78.45 -1.59 34.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.511 -0.743 . . . . 0.0 109.307 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.414 ' C ' ' HG3' ' A' ' 93' ' ' ARG . 2.5 mt-10 -108.42 -168.87 1.41 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.184 -0.947 . . . . 0.0 109.397 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' TRP . . . . . 0.545 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 95.5 m95 -95.26 121.15 36.61 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.206 -0.934 . . . . 0.0 109.688 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -106.84 121.02 46.3 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.261 -0.899 . . . . 0.0 108.935 179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.25 107.39 2.03 Favored 'Trans proline' 0 C--N 1.311 -1.416 0 C-N-CA 122.456 2.104 . . . . 0.0 111.064 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -111.0 135.5 51.41 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 178.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.493 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.8 t -151.13 175.74 11.85 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 120.701 -1.25 . . . . 0.0 111.078 -179.187 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.69 ' CE2' ' CG ' ' A' ' 88' ' ' TYR . 33.8 p90 -171.89 -177.64 1.99 Allowed 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.192 179.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -127.92 151.11 49.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.191 -0.943 . . . . 0.0 109.757 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.573 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.07 168.15 17.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.44 -0.788 . . . . 0.0 109.255 179.841 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -138.69 147.74 43.13 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.5 -179.663 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.531 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 6.0 t -40.43 110.33 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.607 -0.683 . . . . 0.0 109.367 179.663 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 27.8 m -59.95 -51.58 69.05 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.283 -0.885 . . . . 0.0 109.255 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -106.74 -90.87 0.42 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.384 -0.823 . . . . 0.0 109.213 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.451 ' HA ' HG12 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -163.98 53.97 0.15 Allowed 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.478 -0.764 . . . . 0.0 109.058 179.748 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.483 ' O ' ' CG2' ' A' ' 80' ' ' VAL . 31.6 mm-40 -91.67 113.22 25.43 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.188 -0.945 . . . . 0.0 109.791 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.5 p -79.44 -14.07 59.17 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.275 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.3 t -134.01 132.07 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.464 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -141.59 171.92 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.164 -0.96 . . . . 0.0 110.051 -179.608 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' ARG . . . . . 0.503 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 2.9 ptm180 -143.76 133.12 23.28 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.624 -0.673 . . . . 0.0 109.263 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ALA . . . . . 0.62 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -94.44 108.62 37.82 Favored Pre-proline 0 N--CA 1.487 1.384 0 O-C-N 121.302 -0.874 . . . . 0.0 109.897 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.504 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.4 Cg_endo -76.74 113.49 3.66 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.16 1.907 . . . . 0.0 110.847 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . 0.514 ' N ' ' CD1' ' A' ' 145' ' ' ILE . 1.7 mm -97.26 141.66 15.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 178.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 147' ' ' PHE . 6.2 m80 -105.28 158.32 16.69 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.55 -1.344 . . . . 0.0 111.691 -177.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.644 ' CE2' ' CD1' ' A' ' 159' ' ' ILE . 20.9 m-85 -160.81 158.2 28.05 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.132 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.466 ' O ' HG11 ' A' ' 64' ' ' VAL . . . 108.13 43.8 1.25 Allowed Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 0.549 ' CA ' HG11 ' A' ' 64' ' ' VAL . 61.5 m-85 -117.06 161.42 19.44 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.421 -1.047 . . . . 0.0 109.111 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.52 -29.4 69.48 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.467 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -76.61 -10.52 59.45 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 109.179 179.269 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.575 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 1.5 t30 -109.74 12.3 24.15 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.365 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -89.15 164.22 2.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 O-C-N 121.551 -0.718 . . . . 0.0 109.784 -179.173 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' GLY . . . . . 0.492 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.39 32.61 37.98 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.7 m-20 -160.49 136.82 8.65 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.139 -1.212 . . . . 0.0 110.111 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' THR . . . . . 0.581 HG23 ' CZ ' ' A' ' 158' ' ' TYR . 55.3 m -87.59 120.94 29.41 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.575 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.8 OUTLIER -99.63 117.58 44.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 120.75 -1.219 . . . . 0.0 110.327 -178.781 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.614 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 12.2 m-85 -98.01 135.78 39.21 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 178.447 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.644 ' CD1' ' CE2' ' A' ' 147' ' ' PHE . 1.3 mt -128.16 141.15 47.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 120.768 -1.207 . . . . 0.0 110.44 -178.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' ASP . . . . . 0.467 ' HA ' ' HA2' ' A' ' 9' ' ' GLY . 0.7 OUTLIER -173.8 136.34 0.55 Allowed 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.348 -0.845 . . . . 0.0 108.837 179.633 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 125.19 -8.23 8.0 Favored Glycine 0 N--CA 1.487 2.066 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.366 179.577 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.639 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 4.4 tp -60.2 100.64 0.1 Allowed 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.742 -1.446 . . . . 0.0 108.944 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -133.24 145.75 50.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.455 -0.778 . . . . 0.0 109.778 -179.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.469 ' HA ' ' O ' ' A' ' 87' ' ' THR . 4.4 mp -126.8 109.07 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.288 -0.882 . . . . 0.0 109.425 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . 0.466 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.171 -0.956 . . . . 0.0 109.637 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.46 HG22 ' HB1' ' A' ' 165' ' ' ALA . 4.2 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.518 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -71.64 -59.41 2.77 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.187 -0.945 . . . . 0.0 109.453 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 162' ' ' LEU . 47.4 t-20 -71.26 128.93 37.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.481 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.456 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 2.2 mp -107.7 138.53 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.273 -0.892 . . . . 0.0 109.518 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.523 ' OD1' ' CB ' ' A' ' 12' ' ' SER . 1.0 OUTLIER 66.97 17.31 10.5 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.242 -0.911 . . . . 0.0 109.638 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -61.52 -35.56 91.28 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.524 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -103.59 28.01 17.33 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.578 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 6.5 m-85 50.65 48.03 23.35 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.365 -1.079 . . . . 0.0 109.412 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.438 ' OE1' ' O ' ' A' ' 52' ' ' GLU . 5.6 mm-40 -83.68 -35.81 24.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.236 -0.915 . . . . 0.0 109.67 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.523 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.6 OUTLIER -84.8 -24.81 28.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.234 -0.916 . . . . 0.0 109.663 -179.759 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.541 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 0.7 OUTLIER -78.48 121.57 83.87 Favored Pre-proline 0 N--CA 1.486 1.352 0 O-C-N 121.185 -0.947 . . . . 0.0 109.292 -179.896 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 15' ' ' ALA . 36.1 Cg_endo -77.61 138.95 17.64 Favored 'Trans proline' 0 C--N 1.312 -1.36 0 C-N-CA 122.469 2.112 . . . . 0.0 110.754 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.517 ' HA ' ' CG1' ' A' ' 44' ' ' VAL . . . -41.59 163.53 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.71 137.38 4.45 Favored Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.519 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.23 141.52 12.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.325 -1.103 . . . . 0.0 109.079 -179.688 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.465 HG13 ' HA3' ' A' ' 24' ' ' GLY . 46.1 t -85.69 145.65 7.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 CA-C-O 121.695 0.759 . . . . 0.0 109.921 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 4.1 p -106.36 -22.3 12.85 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -143.94 92.63 2.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.439 -0.788 . . . . 0.0 109.085 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.531 ' HB2' ' CB ' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -49.41 -33.19 13.26 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.293 -0.88 . . . . 0.0 109.899 -179.339 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.527 ' N ' HD13 ' A' ' 21' ' ' LEU . . . -59.66 -43.6 93.89 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.165 -0.959 . . . . 0.0 109.514 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -118.12 35.74 4.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.252 -0.905 . . . . 0.0 109.336 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.465 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -87.18 -71.8 1.29 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.541 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 2.0 t -95.96 123.63 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -1.173 . . . . 0.0 109.209 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -56.38 -32.28 64.63 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.421 -0.8 . . . . 0.0 109.854 -179.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.488 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -102.33 -3.45 50.7 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.94 -1.124 . . . . 0.0 110.305 -179.35 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' TRP . . . . . 0.562 ' CE3' ' HB2' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -139.77 121.65 15.53 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.932 -1.334 . . . . 0.0 109.877 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.556 ' OD1' ' CE2' ' A' ' 76' ' ' PHE . 1.2 m-20 -121.38 143.12 49.39 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.549 HD12 ' CD1' ' A' ' 42' ' ' PHE . 0.9 OUTLIER -113.25 162.46 15.99 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.781 -1.199 . . . . 0.0 109.439 -179.601 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -152.84 121.17 6.28 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.424 -0.797 . . . . 0.0 109.522 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.527 HG12 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.05 135.2 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.4 -0.812 . . . . 0.0 109.675 179.638 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.49 -170.99 25.75 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.04 -4.58 25.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.249 -1.148 . . . . 0.0 109.505 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.465 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 16.0 m -74.11 -31.87 62.96 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.942 . . . . 0.0 109.625 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.527 ' CG2' HG12 ' A' ' 32' ' ' VAL . 2.1 t -67.68 89.46 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 O-C-N 121.132 -0.98 . . . . 0.0 109.364 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 30.4 m -59.74 -28.69 67.58 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.199 -0.938 . . . . 0.0 108.713 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.467 ' O ' HG11 ' A' ' 36' ' ' VAL . 6.5 m-20 -130.88 130.4 22.83 Favored Pre-proline 0 C--N 1.296 -1.753 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.21 123.11 6.46 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.189 1.926 . . . . 0.0 110.55 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.576 ' HG2' ' CZ ' ' A' ' 42' ' ' PHE . 35.4 Cg_endo -77.46 -165.74 0.35 Allowed 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.366 2.044 . . . . 0.0 110.013 179.695 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 53.7 t -116.73 121.43 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.116 -0.99 . . . . 0.0 110.458 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.576 ' CZ ' ' HG2' ' A' ' 40' ' ' PRO . 28.0 m-85 -105.11 112.38 25.49 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.519 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 29.2 tt0 -154.56 159.32 40.83 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.194 -0.941 . . . . 0.0 109.857 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.517 ' CG1' ' HA ' ' A' ' 15' ' ' ALA . 89.1 t -95.2 140.59 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.476 -0.765 . . . . 0.0 109.017 179.277 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 45' ' ' LEU . 0.4 OUTLIER -119.38 120.51 37.12 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.327 -0.858 . . . . 0.0 109.793 -179.32 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -77.35 109.83 11.58 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 121.54 0.686 . . . . 0.0 109.152 179.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.7 p -128.64 129.89 46.49 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.606 -0.684 . . . . 0.0 109.527 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.2 m -72.41 -12.56 61.16 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.239 -0.913 . . . . 0.0 109.397 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.41 ' O ' ' C ' ' A' ' 50' ' ' ALA . 49.7 m-20 -98.4 2.08 47.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.214 -0.929 . . . . 0.0 109.612 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.41 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.31 155.18 0.37 Allowed Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.103 -0.998 . . . . 0.0 109.443 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.521 ' CB ' ' HB2' ' A' ' 91' ' ' TRP . 35.9 Cg_endo -77.91 -35.97 1.25 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.599 2.199 . . . . 0.0 110.335 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.438 ' O ' ' OE1' ' A' ' 11' ' ' GLU . 4.9 tt0 -121.28 97.01 5.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.268 -0.895 . . . . 0.0 109.35 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.8 -115.16 4.07 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -156.63 35.64 0.31 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.226 -1.161 . . . . 0.0 109.405 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 33.0 mttm -145.5 131.1 18.85 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -0.899 . . . . 0.0 109.505 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.472 HG11 ' OD2' ' A' ' 160' ' ' ASP . 3.9 m -139.72 175.36 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.381 -0.825 . . . . 0.0 109.326 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.578 ' HB2' ' CE2' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -101.79 100.46 10.81 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.063 -1.023 . . . . 0.0 108.776 179.306 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.58 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.33 118.21 22.46 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.068 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.532 ' HA ' ' O ' ' A' ' 41' ' ' VAL . 49.3 t -114.9 144.61 22.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.113 -0.992 . . . . 0.0 109.17 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' THR . . . . . 0.515 ' N ' HG13 ' A' ' 59' ' ' VAL . 31.9 m -107.12 93.64 4.66 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.571 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 59.9 t -87.93 123.47 40.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.253 -0.905 . . . . 0.0 109.334 -179.69 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -160.11 60.34 0.35 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.379 -0.825 . . . . 0.0 109.77 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 156.38 89.24 0.07 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.516 HG13 ' CA ' ' A' ' 149' ' ' TYR . 2.4 m -81.06 -177.14 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.218 -1.166 . . . . 0.0 109.674 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -130.99 -161.61 10.34 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -95.99 12.54 30.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -1.119 . . . . 0.0 109.545 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.501 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.9 m-80 -128.33 148.35 67.52 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.194 -0.941 . . . . 0.0 109.508 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.499 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.2 Cg_endo -78.25 11.88 2.24 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.63 2.22 . . . . 0.0 110.963 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.501 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -136.36 58.33 1.74 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.113 -0.992 . . . . 0.0 109.623 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.459 ' OD2' ' O ' ' A' ' 148' ' ' GLY . 0.7 OUTLIER -83.11 -69.18 0.65 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.204 -0.935 . . . . 0.0 109.248 179.825 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.526 ' CD1' ' HG3' ' A' ' 40' ' ' PRO . 4.1 mt -105.94 121.76 58.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.277 -0.89 . . . . 0.0 108.979 179.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -130.17 132.89 46.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.098 -1.001 . . . . 0.0 110.224 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.562 ' HB2' ' CE3' ' A' ' 28' ' ' TRP . . . -121.82 108.47 13.51 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.456 ' OG1' ' HA ' ' A' ' 144' ' ' PRO . 98.3 m -100.2 165.0 11.71 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.386 -0.821 . . . . 0.0 110.006 -179.029 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.452 ' O ' ' HB3' ' A' ' 76' ' ' PHE . . . -118.92 136.42 54.08 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.022 -1.049 . . . . 0.0 108.768 178.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.556 ' CE2' ' OD1' ' A' ' 29' ' ' ASP . 10.1 p90 179.44 160.44 0.76 Allowed Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.585 -0.697 . . . . 0.0 109.276 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.545 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.9 Cg_endo -81.67 164.96 74.89 Favored 'Cis proline' 0 C--N 1.31 -1.465 0 C-N-CA 123.782 -1.341 . . . . 0.0 110.801 -0.495 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.529 HG11 ' CD1' ' A' ' 164' ' ' ILE . 89.1 t -126.81 156.14 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.344 -0.848 . . . . 0.0 109.107 179.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ASN . . . . . 0.518 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 4.3 m-80 -112.43 145.79 39.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.075 -1.016 . . . . 0.0 109.666 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.577 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 1.1 m -153.32 -173.85 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.174 -0.954 . . . . 0.0 109.467 179.749 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.519 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 20.5 mtt180 -136.21 146.01 54.5 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.288 -0.883 . . . . 0.0 109.352 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.459 ' HB3' ' HB3' ' A' ' 137' ' ' GLN . 35.6 Cg_endo -77.82 112.09 3.23 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.511 2.141 . . . . 0.0 110.463 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 100.44 -22.97 37.59 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.575 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -84.12 149.65 4.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.191 -1.182 . . . . 0.0 109.482 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.3 m -92.42 140.48 29.53 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' TYR . . . . . 0.577 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 18.3 m-85 -123.05 164.88 17.75 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.25 -0.906 . . . . 0.0 109.578 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' THR . . . . . 0.459 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 6.1 m -118.35 154.31 32.57 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.398 -0.814 . . . . 0.0 109.51 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.692 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.7 t80 -126.87 120.1 28.4 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.145 -0.972 . . . . 0.0 109.38 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.487 ' O ' ' O ' ' A' ' 161' ' ' GLY . 32.3 m -134.53 142.79 47.11 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.244 -0.91 . . . . 0.0 109.11 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.534 HD12 ' CD2' ' A' ' 103' ' ' PHE . 19.8 tt -150.9 163.45 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.603 -1.311 . . . . 0.0 109.628 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.521 ' HB2' ' CB ' ' A' ' 51' ' ' PRO . 20.3 m95 -132.14 128.62 38.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.976 -1.078 . . . . 0.0 109.385 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.413 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -119.53 148.13 43.65 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.222 -0.924 . . . . 0.0 109.582 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.575 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 8.3 ttp180 -161.02 120.22 2.58 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.162 -0.961 . . . . 0.0 109.15 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -107.07 161.7 14.52 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 110.02 -179.591 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -61.06 -51.18 70.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.377 -0.827 . . . . 0.0 109.319 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.485 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -108.45 137.74 45.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.339 -0.85 . . . . 0.0 109.355 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.582 ' N ' ' CG2' ' A' ' 123' ' ' THR . 5.1 p30 -63.08 146.85 52.36 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.273 -0.892 . . . . 0.0 109.559 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 109.06 38.66 1.8 Allowed Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -119.15 141.36 48.9 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.234 -1.157 . . . . 0.0 109.063 179.601 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.448 ' HB ' ' HB3' ' A' ' 151' ' ' ALA . 54.9 t -116.78 149.88 18.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.277 -0.889 . . . . 0.0 110.636 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.585 HG12 ' CE2' ' A' ' 147' ' ' PHE . 51.9 t -151.14 164.71 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.538 -0.726 . . . . 0.0 109.051 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.526 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 3.8 t -127.92 138.05 52.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.989 -1.07 . . . . 0.0 109.687 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.622 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.0 OUTLIER -130.6 103.86 6.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.086 -1.009 . . . . 0.0 109.807 -179.969 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.504 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 11.6 p -119.43 164.86 15.11 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.091 -1.005 . . . . 0.0 110.064 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -125.67 152.55 32.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.69 -0.631 . . . . 0.0 109.998 -179.734 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.462 ' O ' ' HG2' ' A' ' 142' ' ' ARG . . . 176.46 147.71 6.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.214 -1.555 . . . . 0.0 109.214 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.3 p30 -90.3 -169.59 2.46 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.018 -1.283 . . . . 0.0 109.51 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . 0.518 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 4.1 mp0 -71.1 8.0 1.08 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.184 -0.947 . . . . 0.0 111.245 -179.123 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.47 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 3.7 t -110.52 10.27 23.14 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.712 -1.243 . . . . 0.0 109.215 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.538 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 3.2 m-30 71.87 6.08 5.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.412 -0.805 . . . . 0.0 109.689 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -78.89 95.12 5.34 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 108.672 179.399 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . 0.524 ' CG ' ' O ' ' A' ' 105' ' ' VAL . 1.3 tt0 -83.47 139.69 32.78 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.278 -0.889 . . . . 0.0 110.259 -179.099 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.482 ' N ' ' HG2' ' A' ' 112' ' ' GLU . 3.9 m-85 -102.78 -69.88 0.78 Allowed 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.576 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -85.77 166.17 39.11 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.021 -1.632 . . . . 0.0 109.021 179.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.433 ' NE ' ' OE1' ' A' ' 112' ' ' GLU . 1.2 tpp180 -164.42 109.65 0.99 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.948 -1.325 . . . . 0.0 110.326 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.577 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -142.53 69.88 1.32 Allowed 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.061 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' HIS . . . . . 0.546 ' CD2' ' O ' ' A' ' 117' ' ' HIS . 0.5 OUTLIER -99.11 152.56 19.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.335 -0.853 . . . . 0.0 110.149 -179.31 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . 0.542 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.3 tt0 79.33 68.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -0.787 . . . . 0.0 109.706 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . 0.431 ' HG2' ' C ' ' A' ' 118' ' ' GLU . 1.1 mm-40 -133.42 130.96 39.4 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.293 -0.879 . . . . 0.0 109.475 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 4.8 mt-30 -67.66 153.81 42.88 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.327 -0.858 . . . . 0.0 109.006 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.449 HG12 ' O ' ' A' ' 99' ' ' ALA . 8.1 mm -134.8 135.73 52.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.094 -1.003 . . . . 0.0 110.089 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.32 -179.16 6.91 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.637 0.732 . . . . 0.0 110.067 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.582 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 47.2 p -76.37 -2.48 32.01 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.416 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.426 ' C ' ' HG3' ' A' ' 93' ' ' ARG . 3.9 mm-40 -107.67 -169.0 1.45 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.361 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' TRP . . . . . 0.575 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 97.1 m95 -95.83 122.6 38.79 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.201 -0.937 . . . . 0.0 109.604 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -106.93 121.39 45.03 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.272 -0.892 . . . . 0.0 108.941 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -80.1 109.48 2.37 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.451 2.1 . . . . 0.0 110.895 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -114.34 136.64 52.76 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.494 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.7 t -151.27 175.85 11.8 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 120.685 -1.259 . . . . 0.0 111.152 -179.252 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.692 ' CE2' ' CG ' ' A' ' 88' ' ' TYR . 37.7 p90 -173.41 -172.61 0.81 Allowed 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.819 -1.082 . . . . 0.0 109.221 179.22 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -127.95 156.96 41.83 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.075 -1.016 . . . . 0.0 110.009 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.571 ' CZ ' ' HB2' ' A' ' 86' ' ' TYR . 11.1 p90 -161.23 168.06 24.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.391 -0.818 . . . . 0.0 109.191 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.92 146.2 38.91 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.145 -0.972 . . . . 0.0 109.224 -179.761 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.519 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 2.2 t -62.38 112.95 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.257 -0.902 . . . . 0.0 109.392 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 5.8 t -86.51 -40.48 15.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.401 -0.812 . . . . 0.0 109.85 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.56 ' O ' ' CB ' ' A' ' 137' ' ' GLN . 17.5 t70 -87.63 -16.22 35.06 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.445 -0.784 . . . . 0.0 109.432 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.56 ' CB ' ' O ' ' A' ' 136' ' ' ASP . 2.3 mt-30 86.97 27.28 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -178.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.508 ' HG3' ' ND2' ' A' ' 107' ' ' ASN . 12.5 mm-40 -68.94 122.44 18.65 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.609 -0.682 . . . . 0.0 109.732 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 5.8 p -79.12 -6.97 57.74 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 42.4 t -138.14 138.38 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.364 -0.835 . . . . 0.0 108.824 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.467 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.6 OUTLIER -143.27 172.23 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.121 -0.987 . . . . 0.0 109.904 -179.705 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' ARG . . . . . 0.476 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.2 ptm180 -146.76 132.52 18.95 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.463 -0.773 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ALA . . . . . 0.594 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -99.66 106.95 43.29 Favored Pre-proline 0 C--N 1.303 -1.421 0 O-C-N 121.21 -0.931 . . . . 0.0 109.879 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.504 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.9 Cg_endo -76.79 110.74 3.1 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.113 1.875 . . . . 0.0 110.688 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . 0.536 HG12 ' O ' ' A' ' 73' ' ' ALA . 2.0 mm -91.25 140.15 16.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 178.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' HIS . . . . . 0.54 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 5.9 m80 -107.7 157.86 17.76 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.542 -1.349 . . . . 0.0 111.897 -177.46 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.64 ' CZ ' ' CD1' ' A' ' 159' ' ' ILE . 30.6 m-85 -158.12 160.98 37.88 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 179.013 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.459 ' O ' ' OD2' ' A' ' 70' ' ' ASP . . . 116.77 40.79 0.75 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 0.516 ' CA ' HG13 ' A' ' 64' ' ' VAL . 15.1 m-85 -122.08 159.37 27.23 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.381 -1.07 . . . . 0.0 109.311 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.21 -26.71 67.51 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -179.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.458 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -69.91 -15.28 63.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.436 -0.79 . . . . 0.0 109.269 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.52 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.3 OUTLIER -110.85 8.31 22.22 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 179.366 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.455 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.3 t -83.33 162.57 3.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 121.424 -0.797 . . . . 0.0 109.7 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' GLY . . . . . 0.455 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 50.63 33.47 26.37 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 1.8 m-20 -160.18 139.44 10.88 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.258 -1.143 . . . . 0.0 109.976 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' THR . . . . . 0.576 HG22 ' CZ ' ' A' ' 158' ' ' TYR . 97.7 m -89.32 128.04 35.85 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.205 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.571 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 1.4 mt -108.96 118.83 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.873 -1.142 . . . . 0.0 109.969 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.58 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 8.7 m-85 -100.55 137.77 38.51 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 178.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.64 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -129.34 141.64 46.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 120.777 -1.202 . . . . 0.0 110.381 -178.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 161' ' ' GLY . 49.7 t0 -173.82 136.01 0.53 Allowed 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.5 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . 0.533 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 127.13 -9.02 7.08 Favored Glycine 0 N--CA 1.485 1.915 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.258 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.633 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 1.2 tp -59.43 91.29 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.811 -1.405 . . . . 0.0 108.583 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . 0.459 ' N ' ' O ' ' A' ' 161' ' ' GLY . . . -131.06 146.03 52.23 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.605 -0.685 . . . . 0.0 109.86 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.529 ' CD1' HG11 ' A' ' 78' ' ' VAL . 23.4 mt -126.16 131.47 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.325 -0.86 . . . . 0.0 109.217 179.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . 0.46 ' HB1' HG22 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.202 -0.936 . . . . 0.0 109.677 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.532 ' CG1' ' O ' ' A' ' 5' ' ' ASN . 4.6 p . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.521 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -63.09 -53.78 48.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.107 -0.996 . . . . 0.0 109.732 -179.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.532 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 3.9 t-20 -84.09 149.86 25.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.293 -0.879 . . . . 0.0 109.7 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.471 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 3.7 mt -128.13 129.79 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.358 -0.839 . . . . 0.0 109.157 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.549 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 1.5 m120 65.84 35.1 6.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.203 -0.936 . . . . 0.0 109.59 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.476 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -44.99 -25.73 1.04 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.461 ' HA3' ' OD2' ' A' ' 160' ' ' ASP . . . -145.82 44.93 0.83 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.585 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 4.2 m-85 61.32 51.65 4.16 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.167 -1.196 . . . . 0.0 109.443 179.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.445 ' OE2' ' OD2' ' A' ' 160' ' ' ASP . 62.0 mm-40 -84.34 -27.61 27.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.136 -0.977 . . . . 0.0 109.79 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.504 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 7.9 t -99.75 -13.65 19.19 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.178 -0.951 . . . . 0.0 110.149 -179.361 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.532 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 1.2 m -100.25 133.39 21.49 Favored Pre-proline 0 N--CA 1.489 1.475 0 O-C-N 121.052 -1.03 . . . . 0.0 109.423 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.476 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.5 Cg_endo -77.3 148.37 26.82 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 122.522 2.148 . . . . 0.0 110.84 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.476 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -42.11 166.0 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 121.317 0.579 . . . . 0.0 109.773 179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.09 132.54 3.01 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.529 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -56.55 144.63 8.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.268 -1.136 . . . . 0.0 109.218 -179.367 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.7 t -85.12 144.51 9.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.687 0.756 . . . . 0.0 110.043 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.9 p -106.59 -23.77 12.36 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.458 ' O ' ' N ' ' A' ' 24' ' ' GLY . 0.4 OUTLIER -145.99 88.21 1.8 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.478 -0.764 . . . . 0.0 108.966 179.759 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.526 ' CB ' ' HB2' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -43.46 -32.08 0.82 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 109.624 -179.464 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.521 ' N ' HD11 ' A' ' 21' ' ' LEU . . . -65.42 -49.09 70.49 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.351 -0.843 . . . . 0.0 109.456 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -125.51 43.78 2.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.434 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 20' ' ' ASP . . . -91.86 -66.7 1.13 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.579 ' HB ' ' CE2' ' A' ' 10' ' ' PHE . 41.3 t -120.63 128.66 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.207 -1.172 . . . . 0.0 109.618 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . 0.451 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 13.7 tt0 -67.25 139.38 57.33 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.879 . . . . 0.0 109.606 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.549 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 109.29 -33.78 5.91 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' TRP . . . . . 0.511 ' CZ3' ' HB3' ' A' ' 73' ' ' ALA . 1.2 m95 -140.5 119.98 13.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.191 -1.182 . . . . 0.0 109.454 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -115.98 144.17 44.45 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.526 ' HB2' ' CB ' ' A' ' 21' ' ' LEU . 2.1 mt -118.95 168.03 11.18 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.723 -1.235 . . . . 0.0 109.603 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 70.5 m-20 -160.09 123.75 3.61 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.382 -0.824 . . . . 0.0 109.575 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.46 HG13 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -106.47 136.56 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.337 -0.852 . . . . 0.0 109.743 179.678 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.69 176.16 24.86 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.4 t -58.98 -15.65 14.14 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.18 -1.188 . . . . 0.0 109.418 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.461 ' HB2' ' OD1' ' A' ' 70' ' ' ASP . 7.9 p -63.81 -37.17 86.39 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.243 -0.91 . . . . 0.0 109.636 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.523 ' CG2' ' HB3' ' A' ' 70' ' ' ASP . 2.1 t -67.35 88.55 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 O-C-N 121.144 -0.973 . . . . 0.0 109.194 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 50.1 m -63.41 -28.64 70.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.326 -0.859 . . . . 0.0 108.997 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.486 ' O ' HG13 ' A' ' 36' ' ' VAL . 0.5 OUTLIER -120.92 130.1 25.0 Favored Pre-proline 0 C--N 1.296 -1.721 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.755 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -76.51 121.83 6.19 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.188 1.926 . . . . 0.0 110.524 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.583 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.4 Cg_endo -77.44 -169.93 0.84 Allowed 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.443 2.096 . . . . 0.0 109.865 179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.511 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 53.2 t -114.53 119.4 61.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.092 -1.005 . . . . 0.0 110.586 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.583 ' CE1' ' HG2' ' A' ' 40' ' ' PRO . 2.9 m-85 -104.35 112.34 25.34 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 178.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.529 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 0.0 OUTLIER -157.9 148.58 20.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.052 -1.03 . . . . 0.0 109.962 -179.354 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.575 HG23 ' CE2' ' A' ' 10' ' ' PHE . 2.0 t -92.55 148.68 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.379 -0.825 . . . . 0.0 109.398 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.548 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -133.43 147.45 51.72 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.284 -0.885 . . . . 0.0 108.713 179.931 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.548 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 15.3 pt-20 -121.17 120.41 35.16 Favored 'General case' 0 C--N 1.296 -1.758 0 O-C-N 121.526 -0.734 . . . . 0.0 109.296 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.5 p -144.0 -175.97 4.81 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.44 -0.787 . . . . 0.0 109.483 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -101.02 22.4 12.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.908 . . . . 0.0 109.433 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.7 -14.33 12.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.913 . . . . 0.0 109.481 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.45 144.53 62.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.18 -0.95 . . . . 0.0 109.327 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.525 ' HG3' ' CB ' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -78.44 -42.1 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.617 2.211 . . . . 0.0 110.388 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.406 ' O ' ' OE1' ' A' ' 11' ' ' GLU . 40.6 mm-40 -105.43 97.22 7.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.246 -0.909 . . . . 0.0 109.382 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.48 -117.75 4.71 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.456 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 13.5 p30 -160.09 38.62 0.18 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.226 -1.161 . . . . 0.0 109.542 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.468 ' O ' ' OD2' ' A' ' 160' ' ' ASP . 92.0 mttt -144.84 139.04 27.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.143 -0.973 . . . . 0.0 109.655 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.454 HG13 ' O ' ' A' ' 55' ' ' LYS . 5.3 m -150.13 174.54 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.3 -0.875 . . . . 0.0 109.372 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.585 ' HB2' ' CE1' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -99.92 102.22 13.55 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.161 -0.962 . . . . 0.0 108.943 179.61 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.649 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -82.04 122.85 28.34 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 178.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.525 ' CG2' HD23 ' A' ' 57' ' ' LEU . 47.0 t -117.4 144.18 25.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.135 -0.978 . . . . 0.0 109.304 -179.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' THR . . . . . 0.511 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 55.3 m -108.6 87.87 2.59 Favored 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.304 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.534 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 72.6 t -85.85 125.43 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.23 -0.919 . . . . 0.0 109.308 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.415 ' ND2' HG21 ' A' ' 60' ' ' THR . 3.8 p30 -160.08 55.42 0.35 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.383 -0.823 . . . . 0.0 109.733 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 162.7 89.91 0.07 OUTLIER Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.495 ' CG1' ' C ' ' A' ' 149' ' ' TYR . 2.8 m -81.84 -171.32 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -1.14 . . . . 0.0 109.642 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -138.81 -163.27 9.46 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -78.29 -10.65 59.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -1.135 . . . . 0.0 109.499 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.534 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 1.3 m120 -111.08 145.33 32.23 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.171 -0.956 . . . . 0.0 109.426 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.509 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.5 Cg_endo -78.99 13.6 1.93 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.599 2.199 . . . . 0.0 110.997 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.534 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 3.5 p90 -136.33 51.76 2.0 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.031 -1.043 . . . . 0.0 109.759 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' A' ' 36' ' ' VAL . 0.6 OUTLIER -75.89 -50.24 15.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 109.215 179.685 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.472 HG12 ' HG3' ' A' ' 40' ' ' PRO . 4.6 mp -102.2 119.95 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.399 -0.813 . . . . 0.0 109.174 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.45 128.96 50.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.06 -1.025 . . . . 0.0 109.882 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.562 ' HB1' ' CE1' ' A' ' 147' ' ' PHE . . . -130.11 108.3 9.96 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.338 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.47 ' OG1' ' HA ' ' A' ' 144' ' ' PRO . 75.5 m -103.93 165.26 11.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.545 -0.722 . . . . 0.0 110.018 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.491 ' CB ' ' HG ' ' A' ' 162' ' ' LEU . . . -119.01 137.14 53.73 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.055 -1.028 . . . . 0.0 108.882 178.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.563 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.7 p90 -174.46 163.57 2.65 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.497 -0.752 . . . . 0.0 109.256 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.563 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.4 Cg_endo -83.97 170.6 50.85 Favored 'Cis proline' 0 C--N 1.312 -1.372 0 C-N-CA 124.002 -1.249 . . . . 0.0 110.907 -0.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.525 HG12 ' CD1' ' A' ' 164' ' ' ILE . 85.2 t -130.25 156.27 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ASN . . . . . 0.521 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 1.9 m120 -121.21 132.02 54.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.09 -1.006 . . . . 0.0 109.929 -179.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.547 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.9 m -140.71 -174.07 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.169 -0.957 . . . . 0.0 109.644 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.523 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 0.3 OUTLIER -136.85 144.74 47.93 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 109.266 179.872 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.449 ' HD2' ' HG2' ' A' ' 81' ' ' ARG . 35.6 Cg_endo -77.12 110.48 3.03 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.426 2.084 . . . . 0.0 110.581 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 111.2 -34.98 5.01 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.54 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -84.75 149.78 4.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.146 -1.208 . . . . 0.0 109.433 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 17.8 m -94.58 141.65 28.36 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' TYR . . . . . 0.547 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 8.5 m-85 -119.89 170.91 8.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' THR . . . . . 0.458 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 4.1 m -118.07 153.9 32.96 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.274 -0.891 . . . . 0.0 109.29 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.578 ' HB3' ' CE1' ' A' ' 130' ' ' PHE . 5.3 t80 -134.13 120.3 19.95 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.222 -0.924 . . . . 0.0 109.532 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.487 ' O ' ' O ' ' A' ' 161' ' ' GLY . 15.7 m -135.66 147.37 48.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.233 -0.917 . . . . 0.0 109.03 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.545 HD12 ' CD2' ' A' ' 162' ' ' LEU . 2.2 tt -151.21 163.61 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.966 -1.084 . . . . 0.0 109.219 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.525 ' CB ' ' HG3' ' A' ' 51' ' ' PRO . 19.3 m95 -131.02 125.17 32.56 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.894 -1.129 . . . . 0.0 109.574 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.06 150.46 35.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.303 -0.873 . . . . 0.0 109.367 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.575 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 5.3 ttp85 -164.57 121.86 1.64 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.111 -0.993 . . . . 0.0 109.51 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.429 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -102.84 170.1 8.2 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.158 -0.964 . . . . 0.0 109.764 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . 0.571 ' OE1' ' CE1' ' A' ' 158' ' ' TYR . 0.4 OUTLIER -67.16 -59.16 3.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.417 -0.802 . . . . 0.0 109.378 -179.939 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.452 ' HB2' ' OD1' ' A' ' 155' ' ' ASN . 0.8 OUTLIER -109.97 141.9 42.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.358 -0.839 . . . . 0.0 109.29 179.945 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.521 ' N ' ' CG2' ' A' ' 123' ' ' THR . 0.3 OUTLIER -58.16 144.79 39.33 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.206 -0.934 . . . . 0.0 109.206 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 118.17 31.94 1.47 Allowed Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -123.07 136.95 55.02 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.17 -1.194 . . . . 0.0 108.962 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.526 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 53.0 t -111.61 146.63 16.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 O-C-N 121.184 -0.947 . . . . 0.0 110.624 -179.342 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.569 HG13 ' CE2' ' A' ' 147' ' ' PHE . 89.0 t -155.83 149.88 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.481 -0.762 . . . . 0.0 109.5 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.525 ' CB ' ' HG2' ' A' ' 118' ' ' GLU . 19.5 m -125.29 138.6 54.09 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.202 -0.936 . . . . 0.0 109.69 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.625 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.7 m-85 -120.25 103.22 9.06 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.966 -1.084 . . . . 0.0 109.088 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.474 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 11.4 p -117.04 171.05 8.17 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.235 -0.916 . . . . 0.0 110.02 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.692 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -120.94 164.16 17.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.623 -0.673 . . . . 0.0 110.428 -179.51 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.529 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -176.16 148.59 9.3 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.519 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.5 p30 -89.59 -169.64 2.55 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.208 -1.172 . . . . 0.0 109.112 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . 0.519 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 59.2 mt-30 -78.7 18.36 0.6 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.122 -0.986 . . . . 0.0 110.628 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.47 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 0.2 OUTLIER -113.4 11.61 18.55 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 120.828 -1.17 . . . . 0.0 109.182 179.624 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.505 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.8 m-30 74.22 11.83 4.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.38 -0.825 . . . . 0.0 109.461 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.529 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 54.3 mm-40 -92.23 164.04 13.69 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.181 -0.949 . . . . 0.0 109.027 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . 0.468 ' OE2' ' HB3' ' A' ' 115' ' ' ARG . 9.8 tt0 -127.96 142.77 51.15 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.204 -0.935 . . . . 0.0 109.572 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.47 ' OH ' ' HB3' ' A' ' 107' ' ' ASN . 79.1 m-85 -93.82 -75.88 0.49 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.25 -0.906 . . . . 0.0 108.883 179.484 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.566 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -113.99 170.6 13.38 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.468 ' HB3' ' OE2' ' A' ' 112' ' ' GLU . 3.1 ptm180 -144.14 142.31 30.5 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -1.101 . . . . 0.0 109.012 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.581 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -151.26 162.5 40.79 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.993 -1.067 . . . . 0.0 110.624 -179.169 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' HIS . . . . . 0.622 ' ND1' ' CE1' ' A' ' 103' ' ' PHE . 0.0 OUTLIER 69.96 -153.73 0.13 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.635 -0.666 . . . . 0.0 110.598 178.439 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . 0.601 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.8 mt-10 97.95 28.36 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . 0.461 ' O ' HG11 ' A' ' 100' ' ' VAL . 0.9 OUTLIER -134.44 -164.05 1.46 Allowed 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.463 -0.773 . . . . 0.0 109.731 -179.94 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -67.94 157.69 34.43 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.349 0.595 . . . . 0.0 110.018 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.585 ' CD1' ' NE2' ' A' ' 117' ' ' HIS . 4.9 mm -132.73 140.69 46.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.402 -0.811 . . . . 0.0 109.407 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -82.19 -179.53 7.44 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.439 -0.788 . . . . 0.0 110.412 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.521 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 18.0 p -84.93 1.04 49.09 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 120.081 -0.648 . . . . 0.0 109.419 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.465 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 3.2 mt-10 -104.17 -169.79 1.68 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.242 -0.911 . . . . 0.0 109.428 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' TRP . . . . . 0.575 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 92.0 m95 -98.12 122.77 41.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.304 -0.873 . . . . 0.0 109.533 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.89 121.11 45.94 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.18 -0.95 . . . . 0.0 109.045 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.32 110.45 2.48 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.466 2.111 . . . . 0.0 110.753 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.407 ' CD2' ' CE1' ' A' ' 117' ' ' HIS . 1.0 OUTLIER -115.99 134.69 54.7 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 179.235 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.47 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.5 t -151.36 176.59 11.11 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 120.716 -1.24 . . . . 0.0 110.956 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.582 ' CE2' ' HB3' ' A' ' 132' ' ' PHE . 6.9 p90 -178.37 165.39 1.79 Allowed 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.004 -0.998 . . . . 0.0 108.987 179.498 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -102.91 138.92 39.16 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.123 -0.986 . . . . 0.0 109.965 -179.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.582 ' HB3' ' CE2' ' A' ' 130' ' ' PHE . 22.2 p90 -138.49 155.95 47.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.395 -0.815 . . . . 0.0 109.218 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -131.34 144.12 51.01 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.209 -0.932 . . . . 0.0 109.131 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.523 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 3.7 t -47.69 110.27 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.364 -0.835 . . . . 0.0 109.177 179.658 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -60.56 -51.79 67.93 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.245 -0.91 . . . . 0.0 109.21 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 43.7 m-20 -108.09 -92.35 0.42 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.413 -0.804 . . . . 0.0 109.153 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.416 ' HA ' HG12 ' A' ' 134' ' ' VAL . 3.3 pt20 -160.66 55.51 0.32 Allowed 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.468 -0.77 . . . . 0.0 109.041 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.456 ' O ' HG23 ' A' ' 80' ' ' VAL . 18.8 mm-40 -93.2 113.71 26.0 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.303 -0.873 . . . . 0.0 109.75 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.43 -15.7 57.38 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.2 t -134.57 130.25 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.145 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.473 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -140.48 172.33 11.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.27 -0.894 . . . . 0.0 110.116 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' ARG . . . . . 0.491 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.4 ptm180 -143.66 133.59 24.06 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ALA . . . . . 0.692 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.09 110.03 41.44 Favored Pre-proline 0 N--CA 1.486 1.369 0 O-C-N 121.319 -0.863 . . . . 0.0 109.76 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.491 ' HD3' ' O ' ' A' ' 142' ' ' ARG . 36.0 Cg_endo -77.22 111.24 3.16 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.168 1.912 . . . . 0.0 111.169 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . 0.574 HG23 ' CZ ' ' A' ' 147' ' ' PHE . 2.0 mm -90.68 139.34 17.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' HIS . . . . . 0.545 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 10.7 m80 -109.37 149.51 29.4 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.696 -1.253 . . . . 0.0 112.337 -177.102 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.574 ' CZ ' HG23 ' A' ' 145' ' ' ILE . 2.6 m-85 -153.68 153.8 32.93 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.431 ' C ' HG11 ' A' ' 64' ' ' VAL . . . 131.6 38.23 0.27 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 0.495 ' C ' ' CG1' ' A' ' 64' ' ' VAL . 77.2 m-85 -116.68 163.69 15.75 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.409 -1.054 . . . . 0.0 109.104 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.01 -27.25 67.27 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.485 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -73.02 -7.18 50.04 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.444 -0.785 . . . . 0.0 109.621 179.707 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.526 ' ND2' ' O ' ' A' ' 100' ' ' VAL . 1.5 m-20 -107.08 9.06 30.55 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 179.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.413 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.5 t -87.98 158.69 3.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 O-C-N 121.418 -0.801 . . . . 0.0 109.618 -179.383 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' GLY . . . . . 0.413 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 53.13 35.78 50.31 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.452 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.2 m-20 -160.29 139.22 10.57 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.111 -1.229 . . . . 0.0 110.087 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' THR . . . . . 0.58 ' CG2' ' CE1' ' A' ' 158' ' ' TYR . 73.6 m -92.09 122.39 34.55 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.123 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.534 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 1.4 mt -102.51 119.92 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.726 -1.234 . . . . 0.0 110.005 -178.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.649 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 2.1 m-85 -100.11 142.17 31.96 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 178.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.569 HD13 ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -133.22 138.29 51.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.788 -1.195 . . . . 0.0 110.162 -178.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' ASP . . . . . 0.468 ' OD2' ' O ' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -173.67 136.4 0.57 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.216 -0.928 . . . . 0.0 108.926 179.592 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 131.0 -3.85 5.64 Favored Glycine 0 N--CA 1.485 1.958 0 C-N-CA 119.407 -1.378 . . . . 0.0 110.324 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.545 ' CD2' HD12 ' A' ' 90' ' ' ILE . 0.1 OUTLIER -59.27 97.15 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.754 -1.439 . . . . 0.0 108.614 -179.928 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . 0.46 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -131.54 145.44 51.73 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.348 -0.845 . . . . 0.0 109.778 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.525 ' CD1' HG12 ' A' ' 78' ' ' VAL . 7.5 mt -133.81 124.57 47.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.318 -0.864 . . . . 0.0 109.285 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . 0.51 ' HB1' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.129 -0.982 . . . . 0.0 109.583 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.2 p . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -70.3 -57.9 4.35 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.234 -0.916 . . . . 0.0 109.539 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.437 ' HB3' ' HA ' ' A' ' 163' ' ' ALA . 0.7 OUTLIER -75.3 116.99 16.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.239 -0.913 . . . . 0.0 109.66 -179.753 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.472 ' O ' ' HA3' ' A' ' 27' ' ' GLY . 3.0 mp -103.89 140.88 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.35 -0.844 . . . . 0.0 109.068 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.504 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.7 OUTLIER 61.89 19.17 10.46 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.221 -0.924 . . . . 0.0 109.425 -179.804 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.476 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -61.54 -29.48 71.92 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.527 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -107.83 32.51 7.03 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 179.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.583 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 3.0 m-85 43.8 54.55 5.6 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.395 -1.062 . . . . 0.0 109.534 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -84.22 -36.89 22.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.16 -0.963 . . . . 0.0 109.68 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.469 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 18.6 m -84.01 -26.24 29.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.215 -0.928 . . . . 0.0 109.608 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.531 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 1.3 m -78.82 114.36 43.18 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.172 -0.955 . . . . 0.0 109.43 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.5 Cg_endo -77.86 142.68 20.19 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 C-N-CA 122.414 2.076 . . . . 0.0 110.61 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.463 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -40.11 161.43 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.885 -0.509 . . . . 0.0 109.709 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.82 132.99 3.23 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.024 -1.63 . . . . 0.0 109.024 -179.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.481 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.94 138.45 17.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.3 -1.117 . . . . 0.0 109.325 -179.543 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.456 HG11 ' HA3' ' A' ' 24' ' ' GLY . 48.2 t -83.78 143.73 11.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-O 121.681 0.753 . . . . 0.0 110.096 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.9 p -94.84 -27.02 15.96 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.516 ' HB3' ' CG ' ' A' ' 23' ' ' GLU . 2.7 t0 -141.19 101.7 4.08 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.586 ' CD2' ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -44.78 -30.13 0.91 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.178 -0.951 . . . . 0.0 109.751 -178.966 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.586 ' N ' ' CD2' ' A' ' 21' ' ' LEU . . . -60.35 -53.34 58.77 Favored 'General case' 0 C--N 1.294 -1.842 0 O-C-N 121.6 -0.688 . . . . 0.0 109.678 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.516 ' CG ' ' HB3' ' A' ' 20' ' ' ASP . 1.8 pt-20 -102.15 31.52 3.92 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.249 -0.907 . . . . 0.0 109.409 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.456 ' HA3' HG11 ' A' ' 18' ' ' VAL . . . -71.14 -55.05 8.23 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.781 -1.327 . . . . 0.0 109.781 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.531 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 2.8 t -121.53 143.1 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.16 -1.2 . . . . 0.0 109.663 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -67.49 -56.02 11.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.264 -0.897 . . . . 0.0 109.726 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.504 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -77.15 0.86 66.06 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' TRP . . . . . 0.658 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.7 OUTLIER -137.5 121.54 17.83 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.116 -1.226 . . . . 0.0 109.274 179.653 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.534 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -123.44 118.89 28.46 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.363 -0.836 . . . . 0.0 109.034 179.589 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.505 ' HB2' ' HB2' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -97.85 174.5 6.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.185 -0.947 . . . . 0.0 109.842 -179.477 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.491 ' HA ' HD21 ' A' ' 21' ' ' LEU . 16.8 m120 -160.39 122.92 3.29 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.364 -0.835 . . . . 0.0 109.567 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.523 HG11 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -110.73 135.03 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.168 -0.958 . . . . 0.0 109.651 179.418 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.49 178.38 21.74 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.3 t -58.6 -15.81 13.15 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.199 -1.177 . . . . 0.0 109.39 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.467 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 1.4 p -60.94 -38.1 84.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.648 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' O ' ' A' ' 36' ' ' VAL . 2.1 t -59.9 89.41 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 O-C-N 121.084 -1.01 . . . . 0.0 109.414 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.409 ' N ' ' O ' ' A' ' 35' ' ' SER . 25.4 m -62.73 -28.97 70.32 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.264 -0.898 . . . . 0.0 108.674 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.49 ' O ' HG11 ' A' ' 36' ' ' VAL . 1.8 t-20 -122.91 128.81 25.22 Favored Pre-proline 0 C--N 1.297 -1.688 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.453 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.1 Cg_endo -75.84 116.55 4.46 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.261 1.974 . . . . 0.0 110.729 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.501 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.3 Cg_endo -77.44 -176.26 3.11 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 C-N-CA 122.421 2.081 . . . . 0.0 109.77 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.51 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 55.5 t -113.26 119.68 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.046 -1.034 . . . . 0.0 110.682 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.571 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 3.7 m-85 -101.07 112.38 24.83 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.184 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.481 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 31.6 tt0 -154.08 158.8 41.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.069 -1.02 . . . . 0.0 110.038 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.441 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 58.9 t -99.5 148.21 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.506 -0.747 . . . . 0.0 109.106 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.451 HD23 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -123.35 122.1 37.47 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.295 -0.878 . . . . 0.0 109.787 -179.427 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.466 ' CG ' ' HE3' ' A' ' 55' ' ' LYS . 8.5 mt-10 -98.29 110.01 22.67 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.463 ' O ' ' HB3' ' A' ' 54' ' ' ASN . 3.1 p -142.53 -177.89 5.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.466 -0.771 . . . . 0.0 109.488 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.1 m -104.59 -5.24 21.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.306 -0.871 . . . . 0.0 109.558 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.403 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.9 m-20 -87.01 -16.56 35.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.174 -0.954 . . . . 0.0 109.444 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.403 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.33 149.74 0.71 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.234 -0.916 . . . . 0.0 109.376 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.409 ' HG3' ' HB2' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -77.93 -38.96 0.54 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.592 2.195 . . . . 0.0 110.409 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -121.23 121.28 37.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.295 -0.878 . . . . 0.0 109.397 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 63.93 -120.81 21.44 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.463 ' HB3' ' O ' ' A' ' 47' ' ' THR . 4.8 m120 -158.14 34.48 0.25 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -1.14 . . . . 0.0 109.503 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.524 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 5.4 mttp -140.2 142.17 35.89 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.298 -0.876 . . . . 0.0 109.584 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.518 HG13 ' CB ' ' A' ' 160' ' ' ASP . 4.6 m -149.22 174.85 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -0.899 . . . . 0.0 109.259 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.583 ' HB2' ' CE2' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -105.46 99.39 9.0 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.059 -1.026 . . . . 0.0 108.525 179.057 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.636 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.06 118.91 22.91 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.115 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.536 ' O ' ' CG2' ' A' ' 156' ' ' THR . 40.9 t -112.85 144.2 21.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.188 -0.945 . . . . 0.0 108.99 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' THR . . . . . 0.51 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 80.2 m -109.12 90.53 3.32 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.56 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 53.1 t -88.33 125.54 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.284 -0.885 . . . . 0.0 108.987 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.466 ' ND2' HG23 ' A' ' 60' ' ' THR . 3.6 p30 -159.23 61.15 0.4 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.34 -0.85 . . . . 0.0 109.802 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 144.36 93.9 0.17 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.535 HG13 ' CA ' ' A' ' 149' ' ' TYR . 1.6 m -83.19 178.53 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.259 -1.142 . . . . 0.0 109.596 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -113.93 -154.47 11.21 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.4 m-20 -96.1 -10.12 29.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.317 -1.107 . . . . 0.0 109.491 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.578 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 4.8 m120 -109.8 151.47 42.36 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.309 -0.869 . . . . 0.0 109.381 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.43 12.53 2.09 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.693 2.262 . . . . 0.0 111.075 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.578 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.1 p90 -132.95 53.58 2.01 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.035 -1.041 . . . . 0.0 109.721 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.509 ' CB ' HG21 ' A' ' 36' ' ' VAL . 0.3 OUTLIER -82.48 -69.32 0.63 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.21 -0.931 . . . . 0.0 109.057 179.763 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.468 ' O ' ' O ' ' A' ' 147' ' ' PHE . 6.1 mt -98.47 126.32 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.265 -0.897 . . . . 0.0 108.775 179.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -129.32 139.26 51.81 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.961 -1.087 . . . . 0.0 110.44 -179.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.587 ' HB2' ' CZ3' ' A' ' 28' ' ' TRP . . . -122.49 143.12 49.91 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 178.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.515 HG22 ' N ' ' A' ' 75' ' ' ALA . 12.8 m -143.9 162.23 36.67 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.544 -1.348 . . . . 0.0 110.322 -178.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.515 ' N ' HG22 ' A' ' 74' ' ' THR . . . -123.93 136.18 54.17 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.48 -0.762 . . . . 0.0 109.142 179.191 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.539 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 1.3 p90 178.21 161.94 0.63 Allowed Pre-proline 0 N--CA 1.491 1.617 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.523 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -81.5 167.62 70.42 Favored 'Cis proline' 0 C--N 1.31 -1.491 0 C-N-CA 123.672 -1.387 . . . . 0.0 110.837 -0.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 62.2 t -124.07 150.04 28.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.263 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ASN . . . . . 0.501 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 98.1 m-20 -117.29 108.85 16.12 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.0 -1.063 . . . . 0.0 110.075 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.513 ' CG2' ' O ' ' A' ' 138' ' ' GLU . 3.1 m -114.33 -173.85 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.209 -0.932 . . . . 0.0 109.479 179.478 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.531 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 21.5 mmt180 -137.01 144.81 47.86 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.38 -0.825 . . . . 0.0 109.229 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -76.95 111.24 3.19 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.523 2.149 . . . . 0.0 110.47 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 109.13 -30.88 8.16 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.475 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -84.79 149.68 4.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.235 -1.156 . . . . 0.0 109.452 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.5 t -92.81 136.43 33.25 Favored 'General case' 0 C--N 1.292 -1.922 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' TYR . . . . . 0.475 ' CE1' HG12 ' A' ' 84' ' ' VAL . 20.3 m-85 -119.39 148.98 42.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.688 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' THR . . . . . 0.464 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 17.5 m -113.79 151.77 31.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.312 -0.867 . . . . 0.0 108.985 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.618 ' N ' ' CD1' ' A' ' 88' ' ' TYR . 0.1 OUTLIER -128.81 114.45 16.56 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.178 -0.952 . . . . 0.0 109.628 -179.775 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.484 ' O ' ' O ' ' A' ' 161' ' ' GLY . 41.2 m -118.87 149.29 41.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.351 -0.843 . . . . 0.0 108.971 179.798 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.503 HD12 ' CD2' ' A' ' 103' ' ' PHE . 19.2 tt -150.75 163.51 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 120.821 -1.174 . . . . 0.0 109.755 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.498 ' CD1' ' C ' ' A' ' 90' ' ' ILE . 20.5 m95 -132.27 125.87 32.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.11 -0.994 . . . . 0.0 109.271 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.454 ' HB1' HG23 ' A' ' 121' ' ' ILE . . . -115.55 148.11 39.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.24 -0.913 . . . . 0.0 109.562 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.47 ' HG3' ' O ' ' A' ' 123' ' ' THR . 5.0 ttp180 -160.68 118.02 2.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.197 -0.939 . . . . 0.0 109.007 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -104.41 150.12 24.81 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.405 -0.809 . . . . 0.0 109.889 -179.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . 0.473 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 3.0 mt-10 -52.75 -38.98 61.75 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.451 -0.781 . . . . 0.0 109.263 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.493 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -119.57 137.48 53.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.342 -0.848 . . . . 0.0 109.378 179.978 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.577 ' N ' ' CG2' ' A' ' 123' ' ' THR . 0.5 OUTLIER -63.4 147.59 50.79 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.482 -179.847 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 106.97 38.28 2.19 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.773 -1.331 . . . . 0.0 109.773 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.463 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -121.64 140.11 52.68 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.175 -1.191 . . . . 0.0 109.101 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.487 HG11 ' N ' ' A' ' 101' ' ' VAL . 51.3 t -116.75 158.23 17.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.318 -0.864 . . . . 0.0 110.759 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.643 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 59.3 t -154.56 163.36 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.534 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 34.2 t -118.8 123.06 43.85 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.921 -1.112 . . . . 0.0 109.797 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.62 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 2.3 m-85 -119.25 103.45 9.51 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.173 -0.955 . . . . 0.0 109.633 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.487 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 19.0 p -128.97 167.87 16.83 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.195 -0.941 . . . . 0.0 110.185 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.652 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -128.44 155.67 40.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.732 -0.605 . . . . 0.0 110.341 -179.726 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.53 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -175.68 160.81 29.32 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.548 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 0.9 OUTLIER -99.3 -170.26 1.88 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.125 -1.221 . . . . 0.0 109.418 -179.88 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . 0.548 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 22.1 mt-30 -71.87 8.73 1.1 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.06 -1.025 . . . . 0.0 111.185 -179.18 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.516 ' HB2' ' NE2' ' A' ' 111' ' ' GLN . 2.0 m -108.93 13.52 24.71 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 120.667 -1.271 . . . . 0.0 109.219 179.729 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.5 m-30 73.88 1.69 3.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.454 -0.779 . . . . 0.0 109.641 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.53 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 0.7 OUTLIER -73.11 161.33 30.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.198 -0.939 . . . . 0.0 108.69 179.283 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 3.6 tt0 -138.45 134.78 34.47 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.0 -1.063 . . . . 0.0 109.882 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.572 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 18.9 m-85 -94.8 -71.61 0.66 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.272 -0.893 . . . . 0.0 108.67 179.016 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.58 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -87.67 165.81 35.45 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 108.979 -1.648 . . . . 0.0 108.979 179.369 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.456 ' HG3' ' OE2' ' A' ' 112' ' ' GLU . 50.9 ttt180 -160.94 110.55 1.67 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.997 -1.296 . . . . 0.0 110.474 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.628 ' CD2' ' CD1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -144.97 69.97 1.26 Allowed 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 108.698 -0.852 . . . . 0.0 108.698 179.077 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' HIS . . . . . 0.534 ' CB ' ' OG ' ' A' ' 102' ' ' SER . 19.2 p80 -102.71 157.7 16.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 110.02 -179.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 1.3 tp10 77.98 44.34 0.08 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.388 -0.82 . . . . 0.0 109.403 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . 0.443 ' OE1' ' HB2' ' A' ' 116' ' ' LEU . 0.9 OUTLIER -109.35 136.67 48.42 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.286 -0.884 . . . . 0.0 109.473 179.912 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . 0.463 ' O ' ' CD1' ' A' ' 121' ' ' ILE . 18.9 mm-40 -73.85 155.92 38.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.445 -0.784 . . . . 0.0 109.029 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 99' ' ' ALA . 13.6 mm -134.38 135.81 53.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.081 -1.012 . . . . 0.0 110.071 -179.631 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.61 -179.06 6.25 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 121.638 0.732 . . . . 0.0 110.254 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.577 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 39.2 p -75.22 -0.63 20.1 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.386 179.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.455 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 6.4 mt-10 -110.91 -168.94 1.37 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.922 . . . . 0.0 109.238 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' TRP . . . . . 0.454 ' CE2' ' NE ' ' A' ' 93' ' ' ARG . 94.1 m95 -94.39 124.89 38.69 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.159 -0.963 . . . . 0.0 109.565 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.409 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 2.1 tt0 -106.95 121.2 45.61 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.223 -0.923 . . . . 0.0 109.078 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.09 100.57 1.28 Allowed 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.4 2.067 . . . . 0.0 110.923 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -111.62 133.93 53.54 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.466 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.3 t -151.16 176.78 10.86 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 120.793 -1.192 . . . . 0.0 110.794 -179.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.628 ' CD1' ' CD2' ' A' ' 116' ' ' LEU . 6.3 p90 -166.74 165.8 16.19 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.123 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -118.85 138.89 52.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.129 -0.982 . . . . 0.0 109.891 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.572 ' CE2' ' O ' ' A' ' 113' ' ' TYR . 0.5 OUTLIER -154.77 157.73 38.41 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.375 -0.828 . . . . 0.0 109.128 179.729 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.447 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -121.09 147.66 45.23 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.232 -0.917 . . . . 0.0 109.551 -179.66 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.531 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 5.2 t -41.44 110.05 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.511 -0.743 . . . . 0.0 109.214 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 33.7 t -59.39 -50.64 73.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -0.872 . . . . 0.0 109.205 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -108.23 -91.7 0.43 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.382 -0.824 . . . . 0.0 109.189 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.45 ' HA ' HG12 ' A' ' 134' ' ' VAL . 4.7 pt20 -163.23 54.74 0.18 Allowed 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.513 ' O ' ' CG2' ' A' ' 80' ' ' VAL . 40.4 mm-40 -91.33 111.55 23.09 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.293 -0.879 . . . . 0.0 109.944 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.35 -17.53 54.3 Favored 'General case' 0 N--CA 1.487 1.42 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.233 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.4 t -131.64 132.2 62.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.471 HG23 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -142.65 171.73 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.082 -1.011 . . . . 0.0 110.385 -179.416 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' ARG . . . . . 0.457 ' O ' ' HG2' ' A' ' 142' ' ' ARG . 0.8 OUTLIER -141.9 132.77 25.83 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.806 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ALA . . . . . 0.652 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.15 111.45 50.22 Favored Pre-proline 0 C--N 1.304 -1.396 0 O-C-N 121.162 -0.961 . . . . 0.0 109.4 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.487 ' HD2' ' O ' ' A' ' 104' ' ' THR . 33.2 Cg_endo -74.69 111.95 3.44 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 C-N-CA 122.199 1.933 . . . . 0.0 110.764 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . 0.658 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 2.1 mt -100.17 136.81 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 179.135 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' HIS . . . . . 0.516 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 5.9 m80 -105.72 160.37 15.27 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.525 -1.359 . . . . 0.0 111.105 -178.343 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.643 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 11.1 m-85 -159.74 162.2 34.88 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.493 ' C ' ' CG1' ' A' ' 64' ' ' VAL . . . 107.01 38.91 2.07 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 0.535 ' CA ' HG13 ' A' ' 64' ' ' VAL . 20.5 m-85 -113.42 158.09 21.09 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.489 -1.007 . . . . 0.0 109.287 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.38 -27.29 67.74 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.646 -0.659 . . . . 0.0 109.265 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.466 ' HB2' ' HB ' ' A' ' 100' ' ' VAL . . . -70.57 -15.13 62.74 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.45 -0.781 . . . . 0.0 109.187 179.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.525 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.2 OUTLIER -109.78 11.88 24.24 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.338 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.3 t -84.87 161.48 3.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.492 -0.755 . . . . 0.0 109.821 -179.296 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' GLY . . . . . 0.441 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 51.37 33.88 32.75 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.1 m-20 -160.4 141.84 12.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.22 -1.165 . . . . 0.0 110.226 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' THR . . . . . 0.578 HG21 ' CZ ' ' A' ' 158' ' ' TYR . 85.2 m -89.55 124.45 34.54 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.56 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 1.2 mt -105.02 116.32 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.855 -1.153 . . . . 0.0 110.055 -178.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.636 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 5.8 m-85 -98.91 139.85 33.96 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 178.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.615 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -132.16 139.34 50.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.739 -1.225 . . . . 0.0 110.228 -178.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' A' ' 161' ' ' GLY . 39.9 t0 -173.9 135.95 0.52 Allowed 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.368 -0.832 . . . . 0.0 108.876 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . 0.543 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 127.28 -9.77 6.96 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.41 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.476 ' O ' ' HA3' ' A' ' 8' ' ' GLY . 12.4 tp -59.81 109.13 0.86 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.712 -1.464 . . . . 0.0 108.642 -179.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 88' ' ' TYR . . . -138.87 145.55 40.09 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.457 -0.777 . . . . 0.0 109.985 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.512 HG22 ' CD2' ' A' ' 88' ' ' TYR . 16.5 mt -130.97 109.0 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.37 -0.831 . . . . 0.0 109.18 179.472 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.164 -0.96 . . . . 0.0 109.621 -179.719 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' A' ' 5' ' ' ASN . 4.4 p . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.311 -0.625 . . . . 0.0 109.311 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.5 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -65.46 -43.75 89.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.092 -1.005 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.525 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 21.4 t-20 -85.87 130.94 34.41 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.278 -0.889 . . . . 0.0 109.338 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.413 ' O ' ' HB3' ' A' ' 7' ' ' ASN . 1.7 mp -127.62 126.61 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.223 -0.923 . . . . 0.0 109.613 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.527 ' HB3' ' CA ' ' A' ' 27' ' ' GLY . 0.6 OUTLIER 65.32 10.7 6.71 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.333 -0.854 . . . . 0.0 109.546 179.591 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.43 ' HA3' ' OD1' ' A' ' 5' ' ' ASN . . . -66.06 -33.24 84.86 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 179.412 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.529 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -91.32 16.14 59.58 Favored Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.628 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.579 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 13.2 m-85 61.28 40.27 14.62 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.337 -1.096 . . . . 0.0 109.439 179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -84.65 -43.38 14.44 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.838 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -78.71 -42.29 28.75 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.212 -0.93 . . . . 0.0 109.875 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.522 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 12.8 m -59.81 123.67 72.8 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.33 -0.856 . . . . 0.0 109.586 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.8 Cg_endo -77.87 137.42 15.83 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 122.439 2.092 . . . . 0.0 110.569 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.463 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -41.97 164.63 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.715 -0.616 . . . . 0.0 109.707 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 132.71 131.18 3.17 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 108.999 -1.64 . . . . 0.0 108.999 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.531 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -56.96 142.94 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.167 -1.196 . . . . 0.0 108.943 -179.71 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.459 HG13 ' HA3' ' A' ' 24' ' ' GLY . 54.1 t -90.64 142.47 12.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.456 -0.778 . . . . 0.0 110.386 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 33.3 p -93.03 -30.14 15.46 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 178.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.41 ' O ' ' C ' ' A' ' 21' ' ' LEU . 4.9 m-20 -133.39 99.53 4.55 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.584 ' CD2' ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -44.13 -29.57 0.64 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.207 -0.933 . . . . 0.0 109.764 -178.567 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.584 ' N ' ' CD2' ' A' ' 21' ' ' LEU . . . -59.8 -51.7 68.62 Favored 'General case' 0 C--N 1.294 -1.823 0 O-C-N 121.588 -0.695 . . . . 0.0 109.706 -179.673 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -101.86 31.05 4.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.2 -0.937 . . . . 0.0 109.384 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.459 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -74.1 -59.91 3.78 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.522 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 3.5 t -120.56 137.91 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -1.135 . . . . 0.0 109.555 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -69.44 -42.31 75.14 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.305 -0.872 . . . . 0.0 109.587 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.527 ' CA ' ' HB3' ' A' ' 7' ' ' ASN . . . -76.91 -12.67 84.39 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' TRP . . . . . 0.643 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 1.0 OUTLIER -132.44 123.73 27.23 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.19 -1.182 . . . . 0.0 109.754 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.461 ' OD1' ' CE2' ' A' ' 76' ' ' PHE . 1.8 m-20 -113.83 115.82 28.36 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 178.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.533 ' HB2' ' HB2' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -98.81 168.0 10.41 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.946 -1.096 . . . . 0.0 110.16 -178.581 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.512 ' HA ' HD23 ' A' ' 21' ' ' LEU . 19.5 m120 -160.53 123.43 3.34 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.532 -0.73 . . . . 0.0 109.633 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.537 HG11 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -101.12 131.88 47.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.097 -1.002 . . . . 0.0 109.447 179.263 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.29 178.65 26.74 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.5 m -57.99 -16.75 13.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -1.133 . . . . 0.0 109.345 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.458 ' OG ' ' HA ' ' A' ' 70' ' ' ASP . 1.3 p -61.99 -38.55 89.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.442 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.537 ' CG2' HG11 ' A' ' 32' ' ' VAL . 2.1 t -63.78 89.67 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 O-C-N 121.221 -0.925 . . . . 0.0 109.455 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 45.2 m -71.23 -28.4 64.16 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.846 0.832 . . . . 0.0 108.84 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.489 ' O ' HG11 ' A' ' 36' ' ' VAL . 1.3 m-20 -115.0 139.77 24.71 Favored Pre-proline 0 C--N 1.297 -1.702 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.456 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.4 Cg_endo -76.01 111.76 3.35 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.389 2.059 . . . . 0.0 110.816 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 38' ' ' ASN . 34.9 Cg_endo -77.57 179.61 6.35 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.46 2.106 . . . . 0.0 109.552 179.537 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.53 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 61.9 t -117.18 120.74 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.999 -1.063 . . . . 0.0 110.769 -179.576 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.467 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 90.6 m-85 -106.83 112.24 25.12 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 178.086 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.531 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 0.4 OUTLIER -150.28 148.26 28.65 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.976 -1.078 . . . . 0.0 110.237 -179.261 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 56' ' ' VAL . 4.0 t -101.77 148.19 7.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.519 -0.738 . . . . 0.0 109.117 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.603 ' CD2' ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -150.54 164.32 36.27 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 179.85 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.603 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 19.4 pt-20 -120.04 123.84 44.42 Favored 'General case' 0 C--N 1.291 -1.945 0 O-C-N 121.391 -0.818 . . . . 0.0 109.388 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.528 ' CG2' HD21 ' A' ' 45' ' ' LEU . 6.7 p -117.42 178.98 4.18 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 109.459 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -101.97 8.76 40.94 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.219 -0.926 . . . . 0.0 109.524 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.413 ' O ' ' C ' ' A' ' 50' ' ' ALA . 7.7 m-20 -125.25 8.72 7.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.178 -0.952 . . . . 0.0 109.572 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -43.9 148.78 0.72 Allowed Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.234 -0.916 . . . . 0.0 109.437 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.572 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -77.97 -40.16 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 122.642 2.228 . . . . 0.0 110.384 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -131.71 94.04 3.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.43 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 99.19 -124.29 8.18 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.482 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 76.6 m-20 -155.06 20.33 0.43 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.241 -1.153 . . . . 0.0 109.556 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.46 ' O ' HG13 ' A' ' 56' ' ' VAL . 51.9 mttp -137.62 145.33 42.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.237 -0.914 . . . . 0.0 109.638 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.538 HG21 ' CD1' ' A' ' 45' ' ' LEU . 4.1 m -150.14 174.69 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.32 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.579 ' HB2' ' CE1' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -101.35 102.95 13.87 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 109.016 179.618 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.634 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.92 117.7 22.36 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.533 ' CG2' HD21 ' A' ' 57' ' ' LEU . 39.6 t -111.86 144.64 19.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.052 -1.03 . . . . 0.0 109.076 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' THR . . . . . 0.53 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 16.0 m -109.2 89.27 2.95 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.524 HG22 ' CD1' ' A' ' 157' ' ' ILE . 41.5 t -85.25 128.7 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.334 -0.854 . . . . 0.0 109.16 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.436 ' ND2' HG21 ' A' ' 60' ' ' THR . 2.8 p30 -159.93 61.56 0.36 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.427 -0.795 . . . . 0.0 109.835 -179.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 150.56 93.55 0.11 Allowed Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.526 HG12 ' CA ' ' A' ' 149' ' ' TYR . 2.4 m -79.86 -173.41 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.181 -1.188 . . . . 0.0 109.497 179.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -135.46 -162.02 9.52 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . 0.418 ' C ' ' OD1' ' A' ' 67' ' ' ASN . 23.0 t30 -89.82 10.28 24.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.213 -1.169 . . . . 0.0 109.453 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.578 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.0 m-20 -131.82 148.26 69.21 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.188 -0.945 . . . . 0.0 109.391 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.43 12.99 1.94 Allowed 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.568 2.179 . . . . 0.0 111.022 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.578 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.2 p90 -133.44 55.66 1.89 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.95 -1.094 . . . . 0.0 109.916 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.468 ' HB3' HG21 ' A' ' 36' ' ' VAL . 0.3 OUTLIER -78.68 -68.31 0.66 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 108.862 179.535 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.8 mp -90.19 124.63 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 30' ' ' LEU . 1.6 tt0 -114.7 128.76 56.49 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.031 -1.043 . . . . 0.0 110.729 -179.137 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.634 ' CB ' ' CZ3' ' A' ' 28' ' ' TRP . . . -131.43 107.67 9.07 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.491 HG22 ' N ' ' A' ' 75' ' ' ALA . 52.0 m -117.92 163.87 15.91 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.894 -1.129 . . . . 0.0 110.255 -178.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.491 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.19 137.26 53.75 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.234 -0.916 . . . . 0.0 109.214 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.54 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 0.6 OUTLIER 177.42 162.95 0.55 Allowed Pre-proline 0 N--CA 1.492 1.67 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -179.888 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.518 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.11 167.45 74.52 Favored 'Cis proline' 0 C--N 1.309 -1.52 0 C-N-CA 123.722 -1.366 . . . . 0.0 110.699 -0.242 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.486 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 69.5 t -125.37 151.04 30.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.396 -0.815 . . . . 0.0 108.819 179.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ASN . . . . . 0.5 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 8.5 m-80 -117.15 113.24 21.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.077 -1.014 . . . . 0.0 109.933 -179.51 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.578 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.8 m -117.83 -176.24 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.192 -0.943 . . . . 0.0 109.449 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.539 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 0.0 OUTLIER -134.91 144.97 52.7 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.319 -0.863 . . . . 0.0 109.236 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.434 ' HD2' ' HG3' ' A' ' 81' ' ' ARG . 34.8 Cg_endo -76.19 113.26 3.66 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.49 2.127 . . . . 0.0 110.553 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.6 -31.6 8.1 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.518 HG11 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -85.09 149.79 4.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.256 -1.144 . . . . 0.0 109.466 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 4.3 m -95.37 138.23 33.35 Favored 'General case' 0 C--N 1.292 -1.906 0 CA-C-O 121.296 0.57 . . . . 0.0 109.473 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' TYR . . . . . 0.578 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 12.2 m-85 -117.93 157.4 26.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -0.936 . . . . 0.0 109.616 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' THR . . . . . 0.442 HG23 ' O ' ' A' ' 130' ' ' PHE . 40.1 m -118.1 149.48 40.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -0.879 . . . . 0.0 109.29 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.69 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 0.2 OUTLIER -125.97 107.98 10.97 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -0.891 . . . . 0.0 109.507 -179.884 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 161' ' ' GLY . 48.6 m -115.15 146.64 41.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.29 -0.882 . . . . 0.0 109.098 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.571 HD11 ' CD2' ' A' ' 103' ' ' PHE . 18.9 tt -150.48 163.32 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 120.884 -1.135 . . . . 0.0 109.465 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.575 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 21.0 m95 -131.37 127.1 36.87 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.971 -1.081 . . . . 0.0 109.526 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.451 ' HB1' HG22 ' A' ' 121' ' ' ILE . . . -115.47 146.96 41.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.364 -0.835 . . . . 0.0 109.316 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.504 ' HG3' ' CA ' ' A' ' 124' ' ' GLU . 28.2 ttt-85 -162.16 118.06 1.98 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.125 -0.985 . . . . 0.0 109.182 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.71 166.12 10.69 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.878 -179.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.0 mm-40 -59.46 -49.82 76.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.426 -0.796 . . . . 0.0 109.363 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.406 ' HB2' ' OD1' ' A' ' 155' ' ' ASN . 0.6 OUTLIER -112.35 148.38 34.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.335 -0.853 . . . . 0.0 109.252 179.879 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.581 ' N ' ' CG2' ' A' ' 123' ' ' THR . 2.1 t70 -68.81 163.14 24.87 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.205 -0.935 . . . . 0.0 109.487 -179.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.505 ' N ' ' OD1' ' A' ' 97' ' ' ASP . . . 93.42 39.5 5.03 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.469 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -119.02 142.59 47.68 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.278 -1.131 . . . . 0.0 109.044 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.469 ' HB ' ' HB3' ' A' ' 151' ' ' ALA . 54.3 t -118.87 149.69 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.205 -0.934 . . . . 0.0 110.909 -179.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.582 ' CG1' ' CE2' ' A' ' 147' ' ' PHE . 47.7 t -149.42 165.26 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.524 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 66.5 m -130.54 125.47 34.33 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.976 -1.077 . . . . 0.0 109.392 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.615 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.2 m-85 -122.38 104.18 9.23 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.235 -0.915 . . . . 0.0 110.095 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.512 HG23 ' CA ' ' A' ' 115' ' ' ARG . 17.4 p -121.67 163.49 18.92 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.113 -0.992 . . . . 0.0 109.87 179.437 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.595 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -112.62 118.0 56.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 C-N-CA 119.948 -0.701 . . . . 0.0 110.007 179.701 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -109.46 172.61 16.25 Favored Glycine 0 N--CA 1.487 2.086 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.552 ' CB ' ' O ' ' A' ' 111' ' ' GLN . 17.1 t30 -123.57 171.78 9.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.369 -1.077 . . . . 0.0 109.133 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . 0.411 ' N ' ' CG ' ' A' ' 107' ' ' ASN . 19.1 mt-30 -59.06 -48.17 82.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.972 -1.08 . . . . 0.0 109.675 -179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 2.8 m -83.36 17.96 1.95 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.239 -0.913 . . . . 0.0 110.12 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.548 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.8 m-30 81.14 8.58 1.08 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.479 -0.763 . . . . 0.0 110.189 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.552 ' O ' ' CB ' ' A' ' 107' ' ' ASN . 5.4 mm-40 -71.02 121.82 18.9 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.955 -1.091 . . . . 0.0 108.807 179.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -106.17 139.5 40.59 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.817 -1.177 . . . . 0.0 109.949 -179.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.574 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 4.6 m-85 -107.3 -65.53 1.09 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.576 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -104.74 179.29 24.25 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.052 -1.619 . . . . 0.0 109.052 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.512 ' CA ' HG23 ' A' ' 104' ' ' THR . 0.0 OUTLIER 175.35 119.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.917 -1.343 . . . . 0.0 110.398 179.959 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.579 HD23 ' CE1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -140.84 70.01 1.35 Allowed 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.25 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' HIS . . . . . 0.544 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 17.7 p-80 -89.28 152.7 21.41 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.893 . . . . 0.0 110.129 -179.364 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 4.0 tt0 79.66 72.74 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.402 -0.811 . . . . 0.0 109.598 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . 0.438 ' HG2' ' C ' ' A' ' 118' ' ' GLU . 14.0 mm-40 -134.67 130.18 35.94 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.357 -0.839 . . . . 0.0 109.45 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . 0.46 ' O ' HD13 ' A' ' 121' ' ' ILE . 1.1 mp0 -66.41 152.66 44.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.269 -0.895 . . . . 0.0 109.013 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.46 HD13 ' O ' ' A' ' 120' ' ' GLN . 9.1 mm -136.08 136.07 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 O-C-N 121.068 -1.02 . . . . 0.0 110.099 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.4 -179.04 6.31 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 121.651 0.738 . . . . 0.0 110.125 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.581 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 30.5 p -76.45 1.15 17.3 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.35 179.519 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.504 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 8.6 mt-10 -111.64 -168.95 1.37 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 0.0 109.177 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' TRP . . . . . 0.538 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 97.6 m95 -94.22 123.36 37.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.657 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -106.93 121.36 45.11 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.301 -0.875 . . . . 0.0 108.992 179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.575 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.6 Cg_endo -80.02 104.51 1.68 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.396 2.064 . . . . 0.0 110.947 -179.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -116.98 131.67 56.9 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.459 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.4 t -151.76 177.09 10.75 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.936 -1.102 . . . . 0.0 110.745 -179.489 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.69 ' CE2' ' CD1' ' A' ' 88' ' ' TYR . 12.2 p90 -163.36 178.21 8.31 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.08 179.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 82.4 mt-10 -130.48 138.92 50.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.117 -0.989 . . . . 0.0 109.975 -179.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.576 ' CE2' ' HA2' ' A' ' 114' ' ' GLY . 0.3 OUTLIER -151.06 168.13 25.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.372 -0.83 . . . . 0.0 109.163 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.7 OUTLIER -127.82 146.57 50.56 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.115 -0.991 . . . . 0.0 109.409 -179.507 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.539 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 5.9 t -41.28 110.43 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.618 -0.676 . . . . 0.0 109.266 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -56.1 -46.94 78.92 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.318 -0.864 . . . . 0.0 109.043 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.448 ' O ' ' HG3' ' A' ' 137' ' ' GLN . 2.8 m-20 -118.49 -91.71 0.55 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.429 -0.794 . . . . 0.0 109.173 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.448 ' HG3' ' O ' ' A' ' 136' ' ' ASP . 71.9 mt-30 -159.7 57.37 0.38 Allowed 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.47 -0.769 . . . . 0.0 108.929 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.519 ' O ' ' CG2' ' A' ' 80' ' ' VAL . 16.6 mm-40 -95.7 111.49 23.43 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.293 -0.88 . . . . 0.0 109.765 -179.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.38 -13.79 59.39 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.324 -0.86 . . . . 0.0 108.73 179.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.486 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 39.2 t -132.17 130.6 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.367 -0.833 . . . . 0.0 109.009 179.463 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.465 HG23 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -144.36 171.8 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.254 -0.903 . . . . 0.0 109.824 -179.812 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' ARG . . . . . 0.472 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.5 OUTLIER -146.47 131.83 18.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.489 -0.757 . . . . 0.0 109.522 179.86 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ALA . . . . . 0.595 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -93.34 110.54 47.27 Favored Pre-proline 0 N--CA 1.486 1.372 0 O-C-N 121.259 -0.9 . . . . 0.0 110.168 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.488 ' HD2' ' O ' ' A' ' 104' ' ' THR . 36.0 Cg_endo -77.46 111.06 3.09 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.297 1.998 . . . . 0.0 110.735 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . 0.643 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 1.2 mt -97.8 120.71 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 179.162 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' HIS . . . . . 0.538 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 7.1 m80 -85.83 159.36 19.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.777 -1.202 . . . . 0.0 112.202 -176.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.614 ' CE1' ' CB ' ' A' ' 73' ' ' ALA . 61.6 m-85 -157.57 158.43 35.59 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 179.001 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.426 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 112.19 52.53 0.52 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 0.526 ' CA ' HG12 ' A' ' 64' ' ' VAL . 41.8 m-85 -125.73 158.17 35.54 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.428 -1.042 . . . . 0.0 109.195 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.98 -29.51 69.38 Favored 'General case' 0 C--N 1.296 -1.734 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.469 ' HB3' ' HB ' ' A' ' 100' ' ' VAL . . . -70.86 -9.59 57.94 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 121.738 0.78 . . . . 0.0 109.327 179.299 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.573 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 2.1 t-20 -120.59 12.18 11.45 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.44 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.2 t -82.92 161.69 3.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 O-C-N 121.628 -0.67 . . . . 0.0 109.631 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' GLY . . . . . 0.44 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.7 37.42 51.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.406 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.1 m-20 -160.32 138.37 9.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.128 -1.219 . . . . 0.0 110.17 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' THR . . . . . 0.579 ' CG2' ' CE1' ' A' ' 158' ' ' TYR . 98.0 m -86.26 121.2 28.5 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.039 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.573 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 1.0 OUTLIER -101.87 117.27 46.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.865 -1.147 . . . . 0.0 110.224 -178.874 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.634 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 2.9 m-85 -95.96 135.77 37.28 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 178.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.58 HD11 ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -129.16 137.66 56.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 120.819 -1.176 . . . . 0.0 110.12 -178.601 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' ASP . . . . . 0.529 ' OD1' ' CA ' ' A' ' 9' ' ' GLY . 9.0 t0 -174.08 136.26 0.5 Allowed 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.307 -0.871 . . . . 0.0 109.018 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 128.0 -11.11 6.58 Favored Glycine 0 N--CA 1.485 1.958 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.334 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.505 ' N ' HG13 ' A' ' 90' ' ' ILE . 11.4 tp -59.63 110.19 1.08 Allowed 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.694 -1.474 . . . . 0.0 108.486 -179.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . 0.494 ' HA ' ' CB ' ' A' ' 5' ' ' ASN . . . -139.6 145.65 38.82 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.474 -0.766 . . . . 0.0 110.265 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.474 ' HB ' ' HB1' ' A' ' 4' ' ' ALA . 2.3 mp -126.86 109.02 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.422 -0.799 . . . . 0.0 109.047 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . 0.46 ' HB3' HG21 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.616 0 O-C-N 121.083 -1.011 . . . . 0.0 109.826 -179.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.526 ' CG1' ' O ' ' A' ' 5' ' ' ASN . 3.2 p . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.5 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -68.79 -57.92 4.92 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.188 -0.945 . . . . 0.0 109.854 -179.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.526 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 8.5 p-10 -102.07 141.83 34.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.238 -0.914 . . . . 0.0 109.79 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.475 ' O ' ' HA3' ' A' ' 27' ' ' GLY . 1.8 mp -102.78 150.17 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 0.0 109.555 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.54 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.9 OUTLIER 66.63 17.98 10.69 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.254 -0.904 . . . . 0.0 110.0 179.464 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -59.02 -26.97 61.68 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.855 -1.698 . . . . 0.0 108.855 179.571 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.445 ' O ' ' OD1' ' A' ' 160' ' ' ASP . . . -115.38 37.57 3.42 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.582 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 1.1 m-85 43.58 46.09 5.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.328 -1.101 . . . . 0.0 109.417 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -77.08 -36.14 56.04 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.19 -0.944 . . . . 0.0 109.659 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.519 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 4.5 t -88.3 -21.68 24.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.227 -0.921 . . . . 0.0 109.499 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.537 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 1.2 m -70.81 113.92 22.65 Favored Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.7 Cg_endo -77.48 136.16 15.42 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.392 2.061 . . . . 0.0 110.502 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.44 ' C ' ' O ' ' A' ' 14' ' ' PRO . . . -40.21 154.46 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.897 -0.502 . . . . 0.0 109.65 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.52 131.1 2.96 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 -179.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.521 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.2 139.0 17.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.273 -1.134 . . . . 0.0 109.494 -179.591 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.525 HG11 ' CA ' ' A' ' 24' ' ' GLY . 53.7 t -86.52 142.86 12.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 CA-C-O 121.568 0.699 . . . . 0.0 110.122 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 19.6 p -93.75 -28.43 15.93 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.99 101.05 5.08 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.586 ' CD2' ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -47.29 -30.21 2.96 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.247 -0.908 . . . . 0.0 109.873 -178.842 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.586 ' N ' ' CD2' ' A' ' 21' ' ' LEU . . . -59.72 -47.74 84.46 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.559 -0.713 . . . . 0.0 109.857 -179.642 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -107.58 34.59 3.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.123 -0.985 . . . . 0.0 109.432 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.525 ' CA ' HG11 ' A' ' 18' ' ' VAL . . . -74.55 -50.02 10.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.537 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 4.9 t -119.84 141.49 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.24 -1.153 . . . . 0.0 109.738 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -67.18 -47.18 71.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.345 -0.847 . . . . 0.0 109.433 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.54 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -89.29 0.66 81.49 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' TRP . . . . . 0.597 ' CZ3' ' HB3' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -135.64 121.75 20.17 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.198 -1.177 . . . . 0.0 109.215 179.659 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.539 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -121.65 122.79 40.41 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.366 -0.834 . . . . 0.0 108.912 179.452 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.511 ' HB2' ' HB2' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -99.32 173.5 6.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.756 -179.308 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.501 ' HA ' HD21 ' A' ' 21' ' ' LEU . 62.7 m-80 -160.37 123.45 3.42 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.369 -0.832 . . . . 0.0 109.842 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.53 HG11 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.54 136.25 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.205 -0.935 . . . . 0.0 109.415 179.219 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.01 -178.91 26.5 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 70.2 m -58.79 -16.99 19.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -1.127 . . . . 0.0 109.538 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.467 ' OG ' ' HA ' ' A' ' 70' ' ' ASP . 2.8 p -60.99 -37.0 80.94 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.242 -0.911 . . . . 0.0 109.367 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.53 ' CG2' HG11 ' A' ' 32' ' ' VAL . 2.1 t -62.41 89.39 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 O-C-N 121.27 -0.894 . . . . 0.0 109.334 179.631 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 88.7 m -73.14 -28.07 62.03 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.362 -0.836 . . . . 0.0 108.864 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' A' ' 38' ' ' ASN . 0.0 OUTLIER -112.72 142.99 28.13 Favored Pre-proline 0 C--N 1.297 -1.703 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.584 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -76.41 111.38 3.25 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.384 2.056 . . . . 0.0 110.801 -179.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.524 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.8 Cg_endo -78.05 177.11 9.18 Favored 'Trans proline' 0 C--N 1.312 -1.365 0 C-N-CA 122.521 2.147 . . . . 0.0 109.391 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.53 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 63.2 t -118.03 120.87 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 120.873 -1.142 . . . . 0.0 110.829 -179.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.571 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 96.3 m-85 -110.01 112.89 25.17 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 178.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.521 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 22.8 tt0 -150.93 155.55 39.35 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.006 -1.059 . . . . 0.0 109.845 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.444 HG21 HG23 ' A' ' 13' ' ' THR . 85.2 t -94.49 141.52 14.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.203 179.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.453 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -117.88 118.85 33.12 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.512 -0.743 . . . . 0.0 109.347 -179.663 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.438 ' CD ' ' CE ' ' A' ' 55' ' ' LYS . 6.3 mt-10 -103.55 109.85 21.67 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.61 -0.681 . . . . 0.0 109.394 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.467 ' O ' ' HB2' ' A' ' 54' ' ' ASN . 2.4 p -144.5 -179.54 6.62 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.46 -0.775 . . . . 0.0 109.386 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -102.13 29.71 4.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 109.367 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -119.5 -14.31 9.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 0.0 109.541 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -45.91 154.62 0.56 Allowed Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.147 -0.971 . . . . 0.0 109.521 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.521 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 36.0 Cg_endo -78.04 -34.01 1.86 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.596 2.198 . . . . 0.0 110.419 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -129.1 91.68 3.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.266 -0.896 . . . . 0.0 109.351 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.62 -120.98 6.31 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.544 -1.423 . . . . 0.0 109.544 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.467 ' HB2' ' O ' ' A' ' 47' ' ' THR . 11.9 p30 -160.02 30.16 0.18 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.239 -1.154 . . . . 0.0 109.472 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.528 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 8.2 mttp -135.09 130.74 36.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.305 -0.872 . . . . 0.0 109.547 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.485 ' CB ' ' HB2' ' A' ' 160' ' ' ASP . 4.0 m -149.05 175.62 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.372 -0.83 . . . . 0.0 109.145 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.582 ' HB2' ' CE2' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -105.81 100.91 10.44 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.032 -1.043 . . . . 0.0 108.998 179.441 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.618 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.62 117.87 22.33 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 178.735 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.528 ' O ' ' CG2' ' A' ' 156' ' ' THR . 40.9 t -115.15 144.92 21.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.069 -1.02 . . . . 0.0 109.168 -179.042 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' THR . . . . . 0.53 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 9.9 m -107.19 94.18 4.95 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.573 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 50.8 t -90.27 118.1 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.384 -0.823 . . . . 0.0 109.194 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -153.91 58.66 0.73 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.866 . . . . 0.0 109.941 -179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.51 ' O ' ' ND2' ' A' ' 38' ' ' ASN . . . 158.47 92.49 0.09 OUTLIER Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.537 HG13 ' CA ' ' A' ' 149' ' ' TYR . 2.7 m -84.36 -172.38 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.282 -1.128 . . . . 0.0 109.599 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -138.23 -157.17 7.36 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.4 m120 -96.06 10.03 38.88 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -1.121 . . . . 0.0 109.491 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.578 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 17.5 m-80 -127.35 146.46 58.3 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.212 -0.93 . . . . 0.0 109.42 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.576 ' HG2' ' CZ3' ' A' ' 69' ' ' TRP . 35.8 Cg_endo -78.47 12.54 2.09 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.579 2.186 . . . . 0.0 110.957 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.578 ' CZ2' ' OD1' ' A' ' 67' ' ' ASN . 1.1 p90 -133.56 54.5 1.95 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.987 -1.07 . . . . 0.0 109.853 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.467 ' HA ' ' OG ' ' A' ' 35' ' ' SER . 0.8 OUTLIER -78.4 -69.0 0.59 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.185 -0.947 . . . . 0.0 108.838 179.464 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.524 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 3.2 mp -106.05 128.02 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.155 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.61 138.24 52.1 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.903 -1.123 . . . . 0.0 110.467 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.597 ' HB3' ' CZ3' ' A' ' 28' ' ' TRP . . . -120.35 132.15 55.16 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 178.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.511 HG22 ' N ' ' A' ' 75' ' ' ALA . 16.4 m -135.52 163.1 30.86 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.721 -1.237 . . . . 0.0 110.379 -178.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.511 ' N ' HG22 ' A' ' 74' ' ' THR . . . -122.66 137.56 54.87 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.433 -0.792 . . . . 0.0 109.145 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.539 ' CE2' ' CG ' ' A' ' 29' ' ' ASP . 1.6 p90 179.03 161.31 0.71 Allowed Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.516 -0.74 . . . . 0.0 109.103 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.514 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.3 Cg_endo -80.03 165.41 78.82 Favored 'Cis proline' 0 C--N 1.309 -1.514 0 C-N-CA 123.63 -1.404 . . . . 0.0 110.775 -0.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.492 HG12 ' CD1' ' A' ' 164' ' ' ILE . 92.6 t -120.34 156.47 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.381 -0.824 . . . . 0.0 108.918 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ASN . . . . . 0.5 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 4.5 m-80 -124.13 122.05 36.8 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.17 -0.956 . . . . 0.0 109.961 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.569 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 3.3 m -129.96 -174.01 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.153 -0.967 . . . . 0.0 109.54 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.543 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 0.0 OUTLIER -137.12 143.88 43.79 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.394 -0.816 . . . . 0.0 109.148 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -76.14 115.46 4.14 Favored 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.475 2.117 . . . . 0.0 110.452 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.67 -27.36 20.61 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.497 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.86 149.81 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.186 -1.185 . . . . 0.0 109.549 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 39.0 m -97.14 132.99 42.37 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' TYR . . . . . 0.569 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 12.9 m-85 -111.88 164.83 12.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.582 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' THR . . . . . 0.457 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 12.1 m -115.33 154.1 29.77 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.3 -0.875 . . . . 0.0 109.445 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.671 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 6.2 t80 -131.12 118.56 20.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.258 -0.901 . . . . 0.0 109.236 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.481 ' O ' ' O ' ' A' ' 161' ' ' GLY . 16.6 m -135.74 143.55 45.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.174 -0.954 . . . . 0.0 109.187 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.48 ' C ' ' CD1' ' A' ' 91' ' ' TRP . 17.5 tt -150.51 163.71 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.868 -1.145 . . . . 0.0 109.588 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.521 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 18.2 m95 -130.4 126.34 36.8 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.037 -1.039 . . . . 0.0 109.247 179.626 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -115.79 149.22 38.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.275 -0.891 . . . . 0.0 109.541 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.564 ' CB ' ' CE3' ' A' ' 125' ' ' TRP . 4.9 ttp85 -164.02 120.61 1.66 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.196 -0.94 . . . . 0.0 109.145 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -105.4 160.56 15.04 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.324 -0.86 . . . . 0.0 110.012 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . 0.454 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 0.0 OUTLIER -57.26 -48.96 77.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.436 -0.79 . . . . 0.0 109.172 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.458 ' HA ' HG23 ' A' ' 123' ' ' THR . 16.3 mt-30 -116.44 146.19 42.72 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.336 -0.852 . . . . 0.0 109.166 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.583 ' N ' ' CG2' ' A' ' 123' ' ' THR . 8.5 p30 -65.17 146.29 55.16 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.204 -0.935 . . . . 0.0 109.517 -179.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 112.12 30.87 2.81 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.467 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -118.13 138.18 52.45 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.117 -1.226 . . . . 0.0 109.112 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.502 HG12 ' N ' ' A' ' 101' ' ' VAL . 52.1 t -116.9 158.36 17.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 O-C-N 121.256 -0.902 . . . . 0.0 110.747 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.643 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 72.6 t -153.68 163.04 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.535 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 74.9 m -121.72 125.24 46.13 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.916 -1.115 . . . . 0.0 109.907 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.613 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.2 OUTLIER -119.76 103.56 9.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.062 -1.024 . . . . 0.0 109.737 179.72 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.503 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 18.5 p -127.3 167.95 15.45 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.168 -0.958 . . . . 0.0 110.151 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.652 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -128.16 156.86 40.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.715 -0.615 . . . . 0.0 110.247 -179.793 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.503 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -173.92 -173.17 39.85 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.531 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.4 p30 -126.52 -169.37 2.01 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.18 -1.188 . . . . 0.0 109.049 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . 0.531 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 5.6 mp0 -73.66 11.9 0.74 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.049 -1.032 . . . . 0.0 110.971 -179.4 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.499 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 1.0 OUTLIER -113.19 7.89 18.03 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 120.722 -1.236 . . . . 0.0 109.288 179.658 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.6 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.6 m-30 78.87 1.95 2.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.355 -0.841 . . . . 0.0 109.815 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.503 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 4.9 mm100 -76.04 159.47 30.77 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.106 -0.996 . . . . 0.0 108.729 179.466 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . 0.473 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 5.2 tt0 -138.09 135.3 35.67 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.968 -1.083 . . . . 0.0 110.005 -179.415 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.568 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 6.5 m-85 -95.95 -70.62 0.71 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.06 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.572 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -81.72 162.0 42.79 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.444 ' HA ' HG23 ' A' ' 104' ' ' THR . 7.7 ttm180 -158.05 103.95 1.87 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.974 -1.309 . . . . 0.0 110.337 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.577 HD23 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -144.1 72.85 1.36 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.335 -0.853 . . . . 0.0 108.784 179.087 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' HIS . . . . . 0.535 ' CB ' ' HB3' ' A' ' 102' ' ' SER . 32.1 p-80 -115.82 162.79 16.81 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.121 -0.987 . . . . 0.0 110.049 -179.412 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . 0.531 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 3.2 tt0 77.22 53.31 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.399 -0.813 . . . . 0.0 109.256 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 53.2 mm-40 -126.4 141.69 51.8 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.378 -0.826 . . . . 0.0 109.599 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . 0.454 ' HA ' HG23 ' A' ' 100' ' ' VAL . 46.9 mm-40 -73.64 156.55 37.88 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.467 HG12 ' O ' ' A' ' 99' ' ' ALA . 10.8 mm -133.5 136.9 53.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.025 -1.047 . . . . 0.0 110.129 -179.469 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.64 -179.31 7.1 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.541 -0.724 . . . . 0.0 110.121 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.583 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 61.9 p -78.06 0.49 24.42 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.877 -0.729 . . . . 0.0 109.36 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.455 ' O ' ' HB2' ' A' ' 93' ' ' ARG . 2.8 mt-10 -110.06 -168.83 1.37 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -0.883 . . . . 0.0 109.327 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' TRP . . . . . 0.564 ' CE3' ' CB ' ' A' ' 93' ' ' ARG . 85.6 m95 -98.01 121.91 40.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 109.562 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -106.83 121.35 45.22 Favored Pre-proline 0 N--CA 1.488 1.475 0 O-C-N 121.204 -0.935 . . . . 0.0 108.966 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.77 108.22 2.23 Favored 'Trans proline' 0 C--N 1.312 -1.381 0 C-N-CA 122.292 1.994 . . . . 0.0 110.96 -179.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -112.51 136.02 52.53 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.5 t -151.07 175.94 11.63 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.651 -1.28 . . . . 0.0 111.05 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.671 ' CE2' ' CG ' ' A' ' 88' ' ' TYR . 29.1 p90 -173.87 -178.29 1.53 Allowed 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.346 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -131.14 155.2 47.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.237 -0.914 . . . . 0.0 109.698 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.568 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.02 168.31 17.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.341 -0.849 . . . . 0.0 109.41 179.783 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -133.78 147.68 51.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.187 -0.946 . . . . 0.0 109.516 -179.745 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.543 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 5.2 t -42.01 110.3 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.511 -0.743 . . . . 0.0 109.272 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 67.5 m -58.7 -50.35 74.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 0.0 109.203 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -110.51 -90.79 0.47 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.436 -0.79 . . . . 0.0 109.202 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.458 ' HA ' HG12 ' A' ' 134' ' ' VAL . 0.1 OUTLIER -163.31 56.31 0.18 Allowed 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.55 -0.719 . . . . 0.0 109.11 179.781 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.458 ' O ' HG23 ' A' ' 80' ' ' VAL . 50.0 mm-40 -95.66 112.9 24.52 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.271 -0.893 . . . . 0.0 109.809 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.37 -14.9 58.66 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.29 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.485 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.6 t -133.72 132.91 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.474 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.6 OUTLIER -143.52 172.22 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.184 -0.948 . . . . 0.0 110.285 -179.58 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' ARG . . . . . 0.478 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.6 OUTLIER -140.79 133.22 28.42 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.57 -0.706 . . . . 0.0 109.111 179.978 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ALA . . . . . 0.652 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.48 110.48 45.18 Favored Pre-proline 0 C--N 1.305 -1.339 0 O-C-N 121.135 -0.978 . . . . 0.0 109.625 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.503 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.3 Cg_endo -76.49 110.96 3.16 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 C-N-CA 122.293 1.995 . . . . 0.0 111.089 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . 0.526 ' CB ' ' O ' ' A' ' 73' ' ' ALA . 2.3 mm -97.45 135.3 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 178.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' HIS . . . . . 0.52 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 8.8 m80 -102.24 158.55 16.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.438 -1.414 . . . . 0.0 111.335 -178.102 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.644 ' CZ ' ' CD1' ' A' ' 159' ' ' ILE . 11.1 m-85 -159.1 160.2 35.42 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.327 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.422 ' C ' HG13 ' A' ' 64' ' ' VAL . . . 106.71 48.11 0.99 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 0.537 ' CA ' HG13 ' A' ' 64' ' ' VAL . 17.4 m-85 -125.35 159.35 32.01 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.435 -1.038 . . . . 0.0 109.166 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.83 -27.24 68.74 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.469 ' HB1' ' CG2' ' A' ' 100' ' ' VAL . . . -70.4 -19.42 63.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.367 -0.833 . . . . 0.0 109.199 179.522 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.494 ' OD1' ' N ' ' A' ' 152' ' ' ASN . 0.3 OUTLIER -107.96 10.17 28.45 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.42 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.477 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.2 t -84.65 163.98 2.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 121.437 -0.789 . . . . 0.0 109.686 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' GLY . . . . . 0.477 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 49.88 31.57 17.23 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.455 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 2.2 t-20 -160.14 144.85 14.72 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.149 -1.207 . . . . 0.0 110.113 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' THR . . . . . 0.578 HG22 ' CZ ' ' A' ' 158' ' ' TYR . 52.6 m -92.55 128.83 38.55 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.573 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 1.2 mt -107.7 118.75 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.853 -1.154 . . . . 0.0 109.759 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.618 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 3.4 m-85 -102.96 133.14 48.56 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 178.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.644 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -124.55 142.86 40.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.308 -178.694 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' ASP . . . . . 0.485 ' HB2' ' CB ' ' A' ' 56' ' ' VAL . 19.4 t70 -174.23 136.38 0.49 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.418 -0.801 . . . . 0.0 109.064 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 124.32 -7.76 8.52 Favored Glycine 0 N--CA 1.486 1.988 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.537 179.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.626 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 3.7 tp -59.9 103.97 0.26 Allowed 'General case' 0 N--CA 1.487 1.406 0 O-C-N 120.741 -1.446 . . . . 0.0 108.901 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -136.08 145.65 46.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.514 -0.741 . . . . 0.0 109.86 -179.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.492 ' CD1' HG12 ' A' ' 78' ' ' VAL . 8.4 mt -128.69 109.07 18.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.392 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . 0.43 ' CB ' HG21 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.119 -0.988 . . . . 0.0 109.637 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.507 ' CG2' ' HB1' ' A' ' 165' ' ' ALA . 3.9 p . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.518 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -69.89 -58.85 3.38 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -0.893 . . . . 0.0 109.569 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.505 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 7.7 t30 -77.46 134.49 38.35 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.145 -0.972 . . . . 0.0 109.558 -179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.513 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 62.3 mt -111.72 138.86 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.262 -0.899 . . . . 0.0 109.536 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.547 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 10.2 t-20 76.17 26.48 0.96 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.309 -0.869 . . . . 0.0 109.83 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.27 -34.93 68.64 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 179.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.518 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -119.76 34.44 4.22 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 108.85 -1.7 . . . . 0.0 108.85 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.585 ' CZ ' ' HB2' ' A' ' 57' ' ' LEU . 8.4 m-85 43.84 53.76 6.02 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.375 -1.074 . . . . 0.0 109.358 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.4 ' OE2' ' O ' ' A' ' 52' ' ' GLU . 31.7 mm-40 -83.96 -28.56 27.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.471 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.9 t -86.67 -41.98 13.77 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -0.879 . . . . 0.0 109.541 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.522 ' CB ' HG11 ' A' ' 25' ' ' VAL . 90.8 m -71.97 127.73 90.22 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.9 Cg_endo -77.63 141.13 19.41 Favored 'Trans proline' 0 C--N 1.312 -1.383 0 C-N-CA 122.481 2.121 . . . . 0.0 110.568 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.468 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -41.7 164.35 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.742 -0.599 . . . . 0.0 109.582 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.66 133.7 3.32 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 108.931 -1.668 . . . . 0.0 108.931 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.465 HG23 ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.89 140.2 15.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.277 -1.131 . . . . 0.0 109.207 -179.637 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.528 ' CG1' ' HA3' ' A' ' 24' ' ' GLY . 62.1 t -86.61 142.4 13.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 CA-C-O 121.638 0.732 . . . . 0.0 110.439 -179.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.35 -28.81 12.76 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -131.38 86.73 2.38 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.579 ' CD2' ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -45.33 -29.85 1.14 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.268 -0.895 . . . . 0.0 110.006 -178.953 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.579 ' N ' ' CD2' ' A' ' 21' ' ' LEU . . . -60.22 -49.0 79.34 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.494 -0.754 . . . . 0.0 110.232 -179.53 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -133.67 48.77 2.33 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.961 -1.087 . . . . 0.0 109.732 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.528 ' HA3' ' CG1' ' A' ' 18' ' ' VAL . . . -97.44 -12.37 48.42 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.522 HG11 ' CB ' ' A' ' 13' ' ' THR . 90.8 t -141.24 133.95 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.186 -1.185 . . . . 0.0 109.636 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . 0.509 ' O ' ' ND2' ' A' ' 7' ' ' ASN . 17.7 tt0 -78.36 126.69 31.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.384 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.547 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 101.76 -16.17 56.37 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' TRP . . . . . 0.662 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.2 OUTLIER -137.6 120.24 16.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -1.117 . . . . 0.0 108.426 179.164 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.529 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -121.94 110.66 16.12 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.32 -0.863 . . . . 0.0 109.209 179.935 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.497 ' HB2' ' HB2' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -91.7 173.6 7.79 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.286 -0.884 . . . . 0.0 109.339 -179.73 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.517 ' HA ' HD22 ' A' ' 21' ' ' LEU . 77.7 m-20 -160.62 123.45 3.31 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.205 -0.934 . . . . 0.0 110.366 -179.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.53 HG13 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -109.36 131.32 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.291 -0.88 . . . . 0.0 109.286 178.861 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.79 -172.54 22.76 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -56.67 -31.65 64.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.334 -1.098 . . . . 0.0 109.559 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.468 ' HB2' ' HA ' ' A' ' 70' ' ' ASP . 0.7 OUTLIER -45.98 -42.42 13.05 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.196 -0.94 . . . . 0.0 109.279 -179.869 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.53 ' CG2' HG13 ' A' ' 32' ' ' VAL . 2.1 t -60.77 89.84 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 121.188 -0.945 . . . . 0.0 109.529 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 94.7 m -74.05 -28.13 61.25 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.854 0.835 . . . . 0.0 108.789 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.492 ' O ' HG12 ' A' ' 36' ' ' VAL . 8.2 t30 -114.01 144.48 31.66 Favored Pre-proline 0 C--N 1.297 -1.681 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -75.83 111.07 3.21 Favored 'Trans proline' 0 C--N 1.307 -1.627 0 C-N-CA 122.443 2.095 . . . . 0.0 111.011 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.52 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 36.2 Cg_endo -78.97 174.41 12.22 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.558 2.172 . . . . 0.0 109.607 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.535 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 73.8 t -116.9 120.5 65.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.998 -1.064 . . . . 0.0 110.659 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.492 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 60.6 m-85 -109.04 112.55 24.79 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 178.044 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.465 ' HB2' HG23 ' A' ' 17' ' ' VAL . 28.7 tt0 -150.59 146.96 26.87 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.11 -0.994 . . . . 0.0 109.904 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.431 HG13 ' O ' ' A' ' 56' ' ' VAL . 61.7 t -95.49 148.61 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.392 -0.817 . . . . 0.0 109.232 179.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.567 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -132.64 147.23 52.33 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.175 -0.953 . . . . 0.0 108.895 -179.79 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.567 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 16.9 mt-10 -117.06 114.09 23.26 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.53 -0.731 . . . . 0.0 109.63 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.519 ' CG2' HD23 ' A' ' 45' ' ' LEU . 12.9 p -139.8 174.14 10.82 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.473 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.511 ' HA ' ' ND2' ' A' ' 54' ' ' ASN . 16.9 m -100.06 21.67 12.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.462 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.413 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.0 OUTLIER -111.82 -15.33 13.4 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.182 -0.949 . . . . 0.0 109.534 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.449 ' HB1' ' O ' ' A' ' 53' ' ' GLY . . . -44.17 147.19 0.99 Allowed Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.528 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.06 -40.54 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.548 2.165 . . . . 0.0 110.389 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.4 ' O ' ' OE2' ' A' ' 11' ' ' GLU . 2.5 tp10 -117.87 79.71 1.4 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 109.432 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.449 ' O ' ' HB1' ' A' ' 50' ' ' ALA . . . 102.81 -139.41 14.42 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.511 ' ND2' ' HA ' ' A' ' 48' ' ' SER . 3.0 m120 -142.28 35.35 1.5 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -1.111 . . . . 0.0 109.463 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.517 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 8.9 mttt -144.64 138.3 27.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.279 -0.888 . . . . 0.0 109.555 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.453 HG11 ' O ' ' A' ' 55' ' ' LYS . 4.8 m -150.32 174.39 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.344 -0.847 . . . . 0.0 109.281 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.585 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -108.13 103.51 12.73 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.072 -1.018 . . . . 0.0 108.893 179.45 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.64 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.59 119.17 23.45 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.532 ' CG2' HD21 ' A' ' 57' ' ' LEU . 41.3 t -114.66 144.83 21.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.092 -1.005 . . . . 0.0 109.075 -179.212 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' THR . . . . . 0.535 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 24.0 m -106.4 91.52 3.74 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 179.281 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.581 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 53.8 t -90.86 113.01 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.385 -0.822 . . . . 0.0 109.11 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -153.46 58.02 0.76 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.312 -0.868 . . . . 0.0 109.831 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 162.09 85.09 0.05 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.528 HG11 ' CA ' ' A' ' 149' ' ' TYR . 1.3 m -79.89 175.82 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.211 -1.17 . . . . 0.0 109.46 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.454 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -124.45 -149.91 7.76 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -95.15 -4.54 45.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.302 -1.116 . . . . 0.0 109.609 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.56 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 0.8 OUTLIER -114.78 147.89 39.2 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 109.283 179.991 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -79.02 14.25 1.78 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.717 2.278 . . . . 0.0 111.008 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.56 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.3 p90 -135.34 52.53 2.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.99 -1.069 . . . . 0.0 109.921 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.468 ' HA ' ' HB2' ' A' ' 35' ' ' SER . 0.4 OUTLIER -75.22 -66.45 0.76 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.046 -1.034 . . . . 0.0 108.966 179.552 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.52 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 2.5 mt -101.23 127.79 54.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.305 -0.872 . . . . 0.0 108.659 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.473 ' O ' ' HB3' ' A' ' 30' ' ' LEU . 7.2 mt-10 -126.58 137.71 53.37 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.05 -1.031 . . . . 0.0 110.363 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.584 ' HB2' ' CZ3' ' A' ' 28' ' ' TRP . . . -118.31 123.32 45.07 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 106.998 -1.482 . . . . 0.0 106.998 178.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.511 HG23 ' N ' ' A' ' 75' ' ' ALA . 18.0 m -128.61 163.31 25.31 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 120.441 -1.412 . . . . 0.0 110.459 -178.578 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.511 ' N ' HG23 ' A' ' 74' ' ' THR . . . -129.7 138.32 51.09 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.472 -0.768 . . . . 0.0 109.238 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.546 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 2.2 p90 177.99 160.48 0.59 Allowed Pre-proline 0 N--CA 1.492 1.647 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.523 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -81.65 166.75 71.9 Favored 'Cis proline' 0 C--N 1.31 -1.476 0 C-N-CA 123.686 -1.381 . . . . 0.0 110.799 -0.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 76.5 t -124.69 156.34 32.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.219 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ASN . . . . . 0.518 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 3.6 m120 -123.77 123.05 39.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.915 -1.116 . . . . 0.0 110.417 -179.301 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.58 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 3.0 m -128.19 -173.88 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.115 179.244 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.526 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 1.7 mtt180 -126.96 145.16 52.86 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.246 -0.908 . . . . 0.0 109.438 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.41 120.78 5.38 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.437 2.091 . . . . 0.0 110.493 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.35 -27.43 17.18 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.6 t -85.94 149.72 4.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.271 -1.135 . . . . 0.0 109.439 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 20.8 m -97.74 122.4 40.78 Favored 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' TYR . . . . . 0.58 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 3.6 m-85 -99.77 170.28 8.66 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.922 . . . . 0.0 109.619 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' THR . . . . . 0.466 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 6.5 m -118.23 154.09 32.82 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.404 -0.81 . . . . 0.0 109.431 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.627 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.8 t80 -128.11 121.23 29.1 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.256 -0.903 . . . . 0.0 109.266 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.468 ' O ' ' O ' ' A' ' 161' ' ' GLY . 19.6 m -135.54 145.97 47.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.191 -0.943 . . . . 0.0 109.317 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.506 ' C ' ' CD1' ' A' ' 91' ' ' TRP . 16.7 tt -150.74 163.68 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 120.765 -1.209 . . . . 0.0 109.531 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.577 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 19.7 m95 -133.92 124.73 26.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.884 -1.135 . . . . 0.0 109.057 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.515 ' HB2' ' CG2' ' A' ' 121' ' ' ILE . . . -117.34 150.88 38.1 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.255 -0.903 . . . . 0.0 109.491 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.576 ' HD2' ' CE2' ' A' ' 125' ' ' TRP . 1.0 OUTLIER -164.27 121.83 1.72 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.187 -0.946 . . . . 0.0 108.971 179.981 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.69 167.49 9.73 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -0.922 . . . . 0.0 110.053 -179.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -58.52 -48.77 79.74 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.265 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.459 ' HB2' ' OD1' ' A' ' 155' ' ' ASN . 2.9 mt-30 -118.28 150.97 38.58 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.299 -0.876 . . . . 0.0 109.163 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.579 ' N ' ' CG2' ' A' ' 123' ' ' THR . 0.6 OUTLIER -66.34 145.13 56.06 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.255 -0.903 . . . . 0.0 109.701 -179.778 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 114.07 35.21 1.53 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.462 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -120.2 139.54 52.49 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.269 -1.136 . . . . 0.0 109.246 179.698 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.467 HG12 ' N ' ' A' ' 101' ' ' VAL . 54.2 t -117.94 157.86 19.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 121.325 -0.859 . . . . 0.0 110.759 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.633 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 62.1 t -154.94 162.25 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 179.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.531 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 4.8 m -116.78 129.49 56.13 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.085 -1.009 . . . . 0.0 109.392 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.588 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.2 OUTLIER -123.84 103.92 8.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.145 -0.972 . . . . 0.0 109.734 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.506 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 36.1 p -135.35 169.63 17.18 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.972 -1.08 . . . . 0.0 110.233 179.742 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.588 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -131.99 127.66 58.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-O 121.71 0.767 . . . . 0.0 110.41 179.121 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -122.01 165.78 14.8 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.119 -1.992 . . . . 0.0 108.119 178.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.595 ' OD1' ' CE1' ' A' ' 113' ' ' TYR . 0.0 OUTLIER -125.97 -170.82 2.26 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.922 -1.34 . . . . 0.0 109.272 -179.714 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 13.0 mt-30 -81.22 -19.86 42.31 Favored 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 118.791 -1.164 . . . . 0.0 109.588 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.471 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 2.4 m -82.09 8.78 9.89 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' ' 109' ' ' SER . 16.8 m-30 65.3 24.03 12.14 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.313 -0.867 . . . . 0.0 108.674 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.525 ' CA ' ' OE1' ' A' ' 111' ' ' GLN . 0.7 OUTLIER -86.54 161.8 18.37 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.434 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . 0.454 ' OE1' ' HG3' ' A' ' 115' ' ' ARG . 0.5 OUTLIER -107.68 101.35 10.67 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.336 -0.852 . . . . 0.0 109.891 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.595 ' CE1' ' OD1' ' A' ' 107' ' ' ASN . 2.0 m-30 -70.83 -64.43 0.9 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.586 -0.696 . . . . 0.0 109.72 178.607 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.552 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -115.44 166.38 12.22 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 -179.384 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.611 ' NE ' ' CE1' ' A' ' 117' ' ' HIS . 0.0 OUTLIER -157.81 74.61 0.74 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.242 -1.152 . . . . 0.0 110.691 -179.706 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.637 ' CD2' ' CD2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -131.45 86.47 2.36 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.985 -1.072 . . . . 0.0 108.811 178.495 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' HIS . . . . . 0.611 ' CE1' ' NE ' ' A' ' 115' ' ' ARG . 29.8 p-80 -121.53 163.32 19.04 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -0.862 . . . . 0.0 110.009 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 3.0 tt0 76.89 36.31 0.34 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.42 -0.8 . . . . 0.0 109.373 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 17.3 mm-40 -100.3 135.81 41.15 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.299 -0.876 . . . . 0.0 109.542 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 20.5 mt-30 -71.29 156.03 39.99 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.388 -0.82 . . . . 0.0 108.944 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.515 ' CG2' ' HB2' ' A' ' 92' ' ' ALA . 6.1 mm -134.37 133.42 55.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.092 -1.005 . . . . 0.0 110.132 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.87 -179.42 6.81 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.514 -0.741 . . . . 0.0 109.971 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.579 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 37.9 p -73.96 -2.67 25.02 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.771 -0.772 . . . . 0.0 109.243 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.514 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 0.9 OUTLIER -110.02 175.42 5.45 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.334 -0.854 . . . . 0.0 109.177 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' TRP . . . . . 0.576 ' CE2' ' HD2' ' A' ' 93' ' ' ARG . 95.0 m95 -81.77 122.35 27.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.83 121.02 46.29 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.252 -0.905 . . . . 0.0 108.833 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.577 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.6 Cg_endo -80.17 101.69 1.37 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.412 2.074 . . . . 0.0 111.177 -179.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -103.86 132.25 50.3 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 178.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.478 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -144.15 176.29 9.43 Favored 'General case' 0 C--N 1.295 -1.776 0 O-C-N 120.875 -1.141 . . . . 0.0 110.723 -179.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.637 ' CD2' ' CD2' ' A' ' 116' ' ' LEU . 25.3 p90 -175.11 152.56 1.47 Allowed 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 114.978 -1.01 . . . . 0.0 109.34 179.651 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -101.96 142.49 33.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.257 -0.902 . . . . 0.0 109.68 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.637 ' CD1' ' CE1' ' A' ' 130' ' ' PHE . 8.1 p90 -153.65 137.54 16.25 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.34 -0.85 . . . . 0.0 109.371 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.445 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.8 OUTLIER -98.72 146.58 25.73 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.256 -0.902 . . . . 0.0 108.836 179.923 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 4.1 t -41.55 108.96 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.443 -0.786 . . . . 0.0 109.171 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -48.17 -35.33 11.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.332 -0.855 . . . . 0.0 109.007 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -138.49 -90.79 0.21 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.452 -0.78 . . . . 0.0 109.293 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.47 ' HA ' HG13 ' A' ' 134' ' ' VAL . 5.2 pt20 -158.35 56.05 0.45 Allowed 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.524 -0.735 . . . . 0.0 109.1 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.532 ' O ' ' CG2' ' A' ' 80' ' ' VAL . 31.8 mm-40 -92.58 111.06 22.51 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.2 p -79.31 -18.32 52.83 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 40.2 t -131.66 135.79 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.571 HG23 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -143.6 171.62 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.926 -1.109 . . . . 0.0 110.751 -179.177 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' ARG . . . . . 0.49 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.7 OUTLIER -133.02 132.22 41.6 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.682 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ALA . . . . . 0.588 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -99.36 107.22 43.81 Favored Pre-proline 0 C--N 1.304 -1.374 0 O-C-N 120.976 -1.077 . . . . 0.0 109.382 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.506 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.9 Cg_endo -77.31 110.94 3.09 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.27 1.98 . . . . 0.0 111.341 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . 0.662 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 1.6 mt -99.57 138.91 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' HIS . . . . . 0.581 ' O ' ' CD2' ' A' ' 147' ' ' PHE . 4.8 m80 -103.81 159.11 15.91 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.53 -1.356 . . . . 0.0 111.732 -177.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.633 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 17.1 m-85 -161.24 160.0 29.4 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 105.77 52.22 0.81 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 0.528 ' CA ' HG11 ' A' ' 64' ' ' VAL . 22.8 m-85 -129.0 158.88 37.63 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.531 -0.982 . . . . 0.0 109.165 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.33 -26.51 67.33 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -71.64 -15.81 62.25 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.534 -0.729 . . . . 0.0 109.367 179.555 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.503 ' OD1' ' N ' ' A' ' 152' ' ' ASN . 0.2 OUTLIER -112.05 8.8 20.24 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.444 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.3 t -83.87 164.44 2.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 O-C-N 121.423 -0.798 . . . . 0.0 109.747 -179.303 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' GLY . . . . . 0.492 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 55.89 26.29 47.45 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.911 -1.275 . . . . 0.0 109.911 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.459 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.7 t-20 -160.38 143.01 13.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.98 -1.306 . . . . 0.0 110.202 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' THR . . . . . 0.577 HG23 ' CE1' ' A' ' 158' ' ' TYR . 46.1 m -89.4 121.48 31.69 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 178.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.581 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 1.1 mt -98.03 117.7 43.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 120.882 -1.136 . . . . 0.0 110.097 -178.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.64 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 2.4 m-85 -96.9 130.83 44.14 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.597 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.631 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.1 mt -121.03 142.41 37.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 120.726 -1.234 . . . . 0.0 110.154 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' ASP . . . . . 0.529 ' OD1' ' N ' ' A' ' 161' ' ' GLY . 9.0 t0 -174.14 136.24 0.5 Allowed 'General case' 0 N--CA 1.486 1.366 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . 0.529 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 124.82 -7.73 8.24 Favored Glycine 0 N--CA 1.486 1.985 0 C-N-CA 119.329 -1.415 . . . . 0.0 110.633 179.403 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.619 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 3.2 tp -60.29 100.0 0.09 Allowed 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.58 -1.541 . . . . 0.0 108.895 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . 0.452 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -136.7 145.7 45.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.445 -0.785 . . . . 0.0 109.662 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.48 ' CD1' HG11 ' A' ' 78' ' ' VAL . 25.5 mt -128.58 108.8 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.239 -0.913 . . . . 0.0 109.431 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . 0.507 ' HB1' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.177 -0.952 . . . . 0.0 109.576 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 5' ' ' ASN . 4.4 p . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.476 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -75.86 -39.63 56.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.192 -0.943 . . . . 0.0 109.714 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.527 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 1.2 t30 -92.1 129.45 38.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.706 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.459 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 64.7 mt -113.55 129.96 68.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.243 -0.911 . . . . 0.0 109.346 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.529 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.7 OUTLIER 69.93 28.0 4.31 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.206 -0.934 . . . . 0.0 109.597 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -44.26 -26.95 1.04 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.458 ' O ' ' OD2' ' A' ' 160' ' ' ASP . . . -142.14 52.03 0.67 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.581 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 2.8 m-85 45.27 56.38 5.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.261 -1.14 . . . . 0.0 109.237 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -84.52 -29.64 25.77 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.139 -0.976 . . . . 0.0 110.249 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.6 p -95.0 -47.49 6.38 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.011 -1.056 . . . . 0.0 110.129 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.524 ' CB ' HG11 ' A' ' 25' ' ' VAL . 3.1 m -59.84 135.76 90.04 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.166 -0.959 . . . . 0.0 109.538 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.466 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.9 Cg_endo -77.36 146.14 24.53 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.561 2.174 . . . . 0.0 110.71 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.466 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -44.62 170.76 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 121.299 0.571 . . . . 0.0 109.798 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 140.33 130.56 2.66 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.097 -1.601 . . . . 0.0 109.097 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.527 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.07 139.21 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.224 -1.162 . . . . 0.0 109.166 -179.653 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.531 ' CG1' ' HA3' ' A' ' 24' ' ' GLY . 60.2 t -90.66 142.95 12.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-O 121.625 0.726 . . . . 0.0 110.442 -179.468 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.5 t -100.7 -29.44 12.29 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 19.4 m-20 -131.48 93.92 3.44 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.577 HD21 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -48.86 -29.32 4.53 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.264 -0.897 . . . . 0.0 110.135 -178.626 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.577 ' N ' HD21 ' A' ' 21' ' ' LEU . . . -59.44 -57.04 14.72 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.495 -0.753 . . . . 0.0 110.119 -179.364 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -119.99 41.82 3.09 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.155 -0.965 . . . . 0.0 109.45 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.531 ' HA3' ' CG1' ' A' ' 18' ' ' VAL . . . -77.07 -39.87 26.36 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.952 -1.259 . . . . 0.0 109.952 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.563 ' HB ' ' CE2' ' A' ' 10' ' ' PHE . 46.3 t -141.74 133.72 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.102 -1.234 . . . . 0.0 109.904 -179.62 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 20.6 tp10 -68.68 141.58 55.29 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -0.857 . . . . 0.0 109.224 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.529 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 106.58 -32.14 7.58 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' TRP . . . . . 0.579 ' CZ3' ' HB2' ' A' ' 73' ' ' ALA . 0.1 OUTLIER -135.04 121.0 19.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.152 -1.205 . . . . 0.0 109.109 179.492 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -112.84 109.71 19.34 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.503 ' HB2' ' HB2' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -89.93 173.66 8.11 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.218 -0.926 . . . . 0.0 109.665 -179.139 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.524 ' HA ' HD22 ' A' ' 21' ' ' LEU . 7.1 m120 -160.93 128.02 4.16 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.181 -0.949 . . . . 0.0 110.807 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.531 HG13 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -117.16 130.05 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.209 -0.932 . . . . 0.0 108.993 178.198 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.29 171.7 16.18 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.499 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.4 ' O ' ' C ' ' A' ' 35' ' ' SER . 0.7 OUTLIER -45.6 -29.89 1.34 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.377 -1.073 . . . . 0.0 109.419 179.951 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.489 ' CB ' ' OD1' ' A' ' 70' ' ' ASP . 0.4 OUTLIER -45.88 -53.41 9.85 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.369 -0.832 . . . . 0.0 109.116 179.943 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.535 ' CG1' ' O ' ' A' ' 38' ' ' ASN . 34.7 t -47.63 102.57 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 O-C-N 121.251 -0.905 . . . . 0.0 110.084 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 40.8 m -81.63 -26.19 35.02 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 121.894 0.854 . . . . 0.0 108.764 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.535 ' O ' ' CG1' ' A' ' 36' ' ' VAL . 2.1 m-80 -111.67 147.75 37.43 Favored Pre-proline 0 C--N 1.296 -1.751 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.724 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -77.01 110.85 3.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.485 2.123 . . . . 0.0 110.654 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.489 ' HD3' ' O ' ' A' ' 38' ' ' ASN . 36.4 Cg_endo -80.05 160.98 23.74 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.475 2.117 . . . . 0.0 109.68 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.526 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 54.8 t -109.95 119.78 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.004 -1.06 . . . . 0.0 110.291 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.436 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 76.7 m-85 -105.9 112.16 25.1 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.369 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.527 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 1.3 tm-20 -155.01 147.06 23.64 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.005 -1.059 . . . . 0.0 109.872 -179.437 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.489 ' N ' ' HG2' ' A' ' 43' ' ' GLU . 53.1 t -91.89 148.54 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.493 -0.754 . . . . 0.0 109.193 179.574 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.554 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -131.97 146.9 52.37 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.207 -0.933 . . . . 0.0 108.888 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.554 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 17.4 mt-10 -117.91 115.04 24.13 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.676 -0.64 . . . . 0.0 109.508 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.485 ' CG2' HD23 ' A' ' 45' ' ' LEU . 2.2 p -142.11 172.25 12.94 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.488 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.95 11.7 24.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.248 -0.908 . . . . 0.0 109.484 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -103.33 -15.81 15.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.158 -0.964 . . . . 0.0 109.434 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.401 ' HA ' ' HD3' ' A' ' 51' ' ' PRO . . . -50.33 145.68 9.91 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.234 -0.916 . . . . 0.0 109.403 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.567 ' HG3' ' CE3' ' A' ' 125' ' ' TRP . 35.9 Cg_endo -78.38 -41.91 0.25 Allowed 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.577 2.185 . . . . 0.0 110.375 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -110.91 108.34 18.09 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.255 -0.903 . . . . 0.0 109.298 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.16 -117.16 6.64 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.466 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 50.0 p30 -160.06 29.87 0.18 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -1.173 . . . . 0.0 109.524 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.525 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 60.5 mttt -136.89 138.68 40.97 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.215 -0.928 . . . . 0.0 109.678 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.516 HG11 ' CH2' ' A' ' 125' ' ' TRP . 5.6 m -150.08 174.41 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.299 -0.876 . . . . 0.0 109.203 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.581 ' HB2' ' CE1' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -103.33 102.15 12.09 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.15 -0.969 . . . . 0.0 108.98 179.643 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.65 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.47 119.91 24.34 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.53 ' CG2' HD22 ' A' ' 57' ' ' LEU . 40.5 t -113.18 144.51 20.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.106 -0.997 . . . . 0.0 109.024 -179.172 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' THR . . . . . 0.526 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 19.9 m -110.7 90.59 3.37 Favored 'General case' 0 C--N 1.283 -2.284 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.519 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 43.9 t -86.48 127.78 40.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.273 -0.892 . . . . 0.0 109.211 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -151.07 57.0 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.887 . . . . 0.0 109.844 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.423 ' HA3' ' CG ' ' A' ' 38' ' ' ASN . . . 147.66 103.44 0.33 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.486 ' CG1' ' C ' ' A' ' 149' ' ' TYR . 2.3 m -79.94 -175.82 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.236 -1.155 . . . . 0.0 109.51 179.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -126.61 -178.5 15.34 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.666 -1.373 . . . . 0.0 109.666 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -68.73 -20.27 64.38 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.241 -1.152 . . . . 0.0 109.431 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.574 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.3 m-20 -106.98 152.54 41.02 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.28 -0.887 . . . . 0.0 109.492 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.2 Cg_endo -78.58 12.64 2.09 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 122.646 2.23 . . . . 0.0 110.973 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.574 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.2 p90 -135.57 54.58 1.91 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.991 -1.068 . . . . 0.0 109.631 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.515 ' HB3' ' N ' ' A' ' 36' ' ' VAL . 0.5 OUTLIER -83.37 -48.08 10.77 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.216 -0.927 . . . . 0.0 109.191 179.872 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.532 ' CD1' HG21 ' A' ' 36' ' ' VAL . 3.7 mm -98.72 149.09 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.254 -0.904 . . . . 0.0 108.776 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.523 ' HA ' ' HB3' ' A' ' 146' ' ' HIS . 58.0 tt0 -137.71 160.27 39.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.872 -1.143 . . . . 0.0 110.93 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.579 ' HB2' ' CZ3' ' A' ' 28' ' ' TRP . . . -162.37 106.48 1.16 Allowed 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 179.462 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.518 HG23 ' N ' ' A' ' 75' ' ' ALA . 49.9 m -120.63 166.33 13.81 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.246 -1.534 . . . . 0.0 110.953 -178.004 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.518 ' N ' HG23 ' A' ' 74' ' ' THR . . . -124.7 137.91 54.32 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.476 -0.765 . . . . 0.0 108.96 179.07 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.547 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER 178.17 162.52 0.62 Allowed Pre-proline 0 N--CA 1.492 1.651 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 -179.728 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.511 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.82 167.14 73.74 Favored 'Cis proline' 0 C--N 1.31 -1.472 0 C-N-CA 123.641 -1.4 . . . . 0.0 110.778 -0.357 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.523 ' CG1' HD13 ' A' ' 164' ' ' ILE . 76.7 t -126.27 151.5 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.303 -0.873 . . . . 0.0 108.961 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ASN . . . . . 0.515 ' N ' HG12 ' A' ' 78' ' ' VAL . 47.3 m-20 -114.75 122.79 47.48 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.045 -1.034 . . . . 0.0 109.812 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.473 HG21 ' O ' ' A' ' 138' ' ' GLU . 3.0 m -129.57 -173.82 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.21 -0.932 . . . . 0.0 109.458 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.514 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 0.0 OUTLIER -138.74 145.87 47.92 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.364 -0.835 . . . . 0.0 109.306 179.896 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.46 ' HD2' ' HG2' ' A' ' 81' ' ' ARG . 35.3 Cg_endo -77.33 110.28 2.96 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.465 2.11 . . . . 0.0 110.47 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 113.91 -34.99 4.71 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.533 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -85.0 149.71 4.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.241 -1.152 . . . . 0.0 109.39 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.461 ' HA ' ' OG1' ' A' ' 133' ' ' THR . 11.6 t -95.3 145.31 25.18 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 109.354 -0.609 . . . . 0.0 109.354 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' TYR . . . . . 0.533 ' CE1' HG12 ' A' ' 84' ' ' VAL . 8.6 m-85 -123.29 159.07 29.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.297 -0.877 . . . . 0.0 109.627 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' THR . . . . . 0.457 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 59.1 m -118.06 148.46 42.25 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.32 -0.862 . . . . 0.0 109.282 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.615 ' N ' ' CD1' ' A' ' 88' ' ' TYR . 0.2 OUTLIER -127.04 104.75 8.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.124 -0.985 . . . . 0.0 109.631 -179.927 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.476 ' O ' ' O ' ' A' ' 161' ' ' GLY . 54.7 m -112.8 148.08 35.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.365 -0.834 . . . . 0.0 108.955 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.418 HD13 ' HB2' ' A' ' 162' ' ' LEU . 19.4 tt -150.08 163.51 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.76 -1.212 . . . . 0.0 109.817 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.563 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 70.3 m95 -125.77 129.55 49.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.156 -0.965 . . . . 0.0 109.281 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.99 145.96 47.62 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.283 -0.886 . . . . 0.0 109.513 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.573 ' HD2' ' CE2' ' A' ' 125' ' ' TRP . 16.4 ttt-85 -157.91 118.23 3.39 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.267 -0.896 . . . . 0.0 109.179 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.3 166.8 10.16 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.357 -0.84 . . . . 0.0 109.839 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . 0.463 ' O ' HG22 ' A' ' 123' ' ' THR . 16.0 tt0 -64.18 -52.04 60.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.373 -0.829 . . . . 0.0 109.615 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.428 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -112.03 140.93 46.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 109.52 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.511 ' N ' HG21 ' A' ' 123' ' ' THR . 1.1 m-20 -60.82 149.61 35.39 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.249 -0.907 . . . . 0.0 109.476 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 106.98 33.82 3.14 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.969 -1.253 . . . . 0.0 109.969 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.465 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -114.09 139.73 49.06 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.066 -1.255 . . . . 0.0 109.165 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.492 HG13 ' N ' ' A' ' 101' ' ' VAL . 73.8 t -120.65 149.43 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 110.421 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.566 ' HB ' ' CE1' ' A' ' 103' ' ' PHE . 48.4 t -144.94 166.75 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.471 -0.768 . . . . 0.0 109.029 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 117' ' ' HIS . 5.6 m -124.68 123.47 40.1 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.06 -1.025 . . . . 0.0 109.612 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.63 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.4 m-85 -121.94 103.9 9.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -0.875 . . . . 0.0 109.902 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.522 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 16.5 p -121.38 174.34 6.8 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.098 -1.001 . . . . 0.0 109.88 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.618 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -131.72 154.0 39.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-O 121.492 0.663 . . . . 0.0 110.282 -179.688 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -174.92 158.11 25.7 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.53 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.5 p30 -97.91 -169.32 1.8 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.099 -1.236 . . . . 0.0 109.37 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . 0.53 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 4.5 mp0 -73.11 11.66 0.68 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.1 -1.0 . . . . 0.0 111.105 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.459 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 1.4 m -111.02 13.91 22.0 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 120.595 -1.316 . . . . 0.0 109.139 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.512 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 4.0 m-30 71.47 3.96 4.87 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.484 -0.76 . . . . 0.0 109.619 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.528 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 29.4 tt0 -78.0 162.39 26.79 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.236 -0.915 . . . . 0.0 108.564 179.335 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . 0.473 ' N ' ' CG ' ' A' ' 111' ' ' GLN . 7.1 tt0 -138.22 143.47 40.17 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.994 -1.066 . . . . 0.0 109.89 -179.443 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.569 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 19.7 m-85 -102.4 -70.11 0.76 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.163 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.568 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -98.47 174.31 28.17 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.062 -1.615 . . . . 0.0 109.062 179.428 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.465 ' HB3' ' OE2' ' A' ' 112' ' ' GLU . 0.0 OUTLIER -175.28 129.45 0.28 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.005 -1.291 . . . . 0.0 110.461 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.572 HD22 ' CD1' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -146.9 72.31 1.26 Allowed 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 179.145 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' HIS . . . . . 0.541 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 15.1 p80 -93.31 150.79 20.21 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.321 -0.862 . . . . 0.0 110.181 -179.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . 0.541 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.7 tt0 80.0 47.63 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.653 -0.654 . . . . 0.0 109.458 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 12.7 mm100 -107.98 125.45 51.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.387 -0.821 . . . . 0.0 109.333 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -66.95 153.58 43.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.451 -0.781 . . . . 0.0 109.066 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.465 HG12 ' O ' ' A' ' 99' ' ' ALA . 6.6 mm -135.37 134.48 52.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.195 -0.94 . . . . 0.0 109.961 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -86.06 -179.37 6.74 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.425 -0.797 . . . . 0.0 110.075 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.514 ' O ' ' CZ ' ' A' ' 93' ' ' ARG . 39.6 p -76.96 -3.94 41.45 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.961 -0.696 . . . . 0.0 109.337 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.421 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 1.3 mt-10 -106.27 -173.24 2.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.257 -0.902 . . . . 0.0 109.263 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' TRP . . . . . 0.573 ' CE2' ' HD2' ' A' ' 93' ' ' ARG . 98.2 m95 -91.01 118.04 30.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.571 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -106.86 121.24 45.54 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.176 -0.953 . . . . 0.0 108.953 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.563 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.5 Cg_endo -79.42 105.37 1.87 Allowed 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.311 2.007 . . . . 0.0 111.011 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -112.88 133.43 54.87 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -151.52 177.04 10.72 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 122.435 1.112 . . . . 0.0 110.724 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.584 ' CZ ' ' HB2' ' A' ' 88' ' ' TYR . 3.6 p90 -161.48 -169.67 2.36 Favored 'General case' 0 C--N 1.292 -1.934 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.148 179.429 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . 0.567 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 68.9 mt-10 -138.6 144.1 39.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.006 -1.059 . . . . 0.0 109.982 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.569 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 1.0 OUTLIER -163.63 147.56 10.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.448 -0.783 . . . . 0.0 109.215 179.763 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.461 ' OG1' ' HA ' ' A' ' 85' ' ' THR . 0.5 OUTLIER -116.22 147.93 40.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.879 . . . . 0.0 109.71 -179.537 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.514 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 5.5 t -40.49 110.42 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.602 -0.686 . . . . 0.0 109.291 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 12.4 t -61.98 -53.34 57.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.274 -0.891 . . . . 0.0 109.295 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -101.77 -91.59 0.33 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.367 -0.833 . . . . 0.0 109.21 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.439 ' HA ' HG13 ' A' ' 134' ' ' VAL . 0.1 OUTLIER -163.33 50.81 0.16 Allowed 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.469 -0.769 . . . . 0.0 109.087 179.788 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.473 ' O ' HG21 ' A' ' 80' ' ' VAL . 61.3 mm-40 -87.92 112.08 22.15 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.242 -0.911 . . . . 0.0 109.738 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.5 p -79.39 -14.95 58.61 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.214 -0.929 . . . . 0.0 108.584 179.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 25.8 t -134.29 128.67 52.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.318 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.46 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -139.52 171.83 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.174 -0.954 . . . . 0.0 110.147 -179.629 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' ARG . . . . . 0.496 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.9 ptm180 -141.75 132.82 26.16 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ALA . . . . . 0.618 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -93.4 109.42 40.33 Favored Pre-proline 0 N--CA 1.486 1.365 0 O-C-N 121.228 -0.92 . . . . 0.0 110.202 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.522 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.1 Cg_endo -76.47 110.14 3.0 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.141 1.894 . . . . 0.0 110.9 179.399 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . 0.582 ' CD1' ' CD2' ' A' ' 162' ' ' LEU . 3.0 mt -116.66 108.21 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 179.035 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' HIS . . . . . 0.602 ' N ' ' ND1' ' A' ' 146' ' ' HIS . 0.1 OUTLIER -123.74 160.75 26.59 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.299 -1.501 . . . . 0.0 112.111 -177.142 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.579 ' CD1' ' N ' ' A' ' 147' ' ' PHE . 0.1 OUTLIER -113.53 -168.37 1.33 Allowed 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.628 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.409 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 127.02 32.84 0.66 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 0.486 ' C ' ' CG1' ' A' ' 64' ' ' VAL . 28.6 m-85 -121.34 155.27 35.1 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.297 -1.119 . . . . 0.0 109.283 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.06 -26.27 66.66 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.78 -7.57 46.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.409 -0.807 . . . . 0.0 109.562 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.57 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 2.5 t30 -115.21 14.17 16.89 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.418 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -89.32 159.5 2.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.585 -0.697 . . . . 0.0 109.674 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.55 37.31 49.67 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.428 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 1.9 m-20 -160.31 136.28 8.49 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.074 -1.251 . . . . 0.0 110.175 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' THR . . . . . 0.569 HG22 ' CZ ' ' A' ' 158' ' ' TYR . 45.2 m -86.25 122.25 29.98 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 179.085 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.57 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.8 OUTLIER -102.93 117.93 49.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.881 -1.137 . . . . 0.0 110.34 -178.873 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.65 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 13.9 m-85 -96.57 144.59 26.49 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 178.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.564 HD12 ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -140.99 139.83 33.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.768 -1.207 . . . . 0.0 110.636 -178.813 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' ASP . . . . . 0.458 ' OD2' ' O ' ' A' ' 9' ' ' GLY . 0.5 OUTLIER -174.18 135.58 0.46 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.159 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 128.61 -6.65 6.59 Favored Glycine 0 N--CA 1.486 1.974 0 C-N-CA 119.127 -1.511 . . . . 0.0 111.21 179.183 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.582 ' CD2' ' CD1' ' A' ' 145' ' ' ILE . 8.0 tp -59.73 97.78 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.39 -1.653 . . . . 0.0 108.784 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . 0.454 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -121.94 145.59 47.96 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.565 -0.709 . . . . 0.0 109.931 -179.211 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.523 HD13 ' CG1' ' A' ' 78' ' ' VAL . 52.4 mt -125.65 108.85 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.328 -0.858 . . . . 0.0 109.291 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . 0.526 ' HB1' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.144 -0.972 . . . . 0.0 109.661 -179.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.436 HG12 ' O ' ' A' ' 5' ' ' ASN . 4.2 p . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.517 ' HB1' ' N ' ' A' ' 79' ' ' ASN . . . -68.06 -55.13 13.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.128 -0.982 . . . . 0.0 109.453 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.484 ' HB3' ' HA ' ' A' ' 163' ' ' ALA . 0.4 OUTLIER -69.56 148.74 49.01 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 109.112 179.949 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.461 ' O ' ' HA3' ' A' ' 27' ' ' GLY . 15.4 mm -112.03 148.58 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.383 -0.823 . . . . 0.0 109.207 179.707 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.479 ' HB2' ' HA3' ' A' ' 27' ' ' GLY . 42.6 m-80 45.02 38.77 3.26 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.254 -0.904 . . . . 0.0 109.649 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -56.9 -40.77 90.9 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 107.968 -2.053 . . . . 0.0 107.968 179.077 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.525 ' CA ' ' OD2' ' A' ' 160' ' ' ASP . . . -112.9 18.2 22.04 Favored Glycine 0 N--CA 1.488 2.103 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 178.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.593 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 61.4 m-85 65.66 46.61 2.36 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.478 -1.013 . . . . 0.0 109.683 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -84.66 -28.05 26.67 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.283 -0.885 . . . . 0.0 109.549 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.427 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 0.7 OUTLIER -88.29 -30.78 19.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.592 -179.726 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.541 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 1.1 m -82.02 124.28 79.08 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.216 -0.928 . . . . 0.0 109.564 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.452 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.6 Cg_endo -78.03 138.21 16.19 Favored 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 122.412 2.075 . . . . 0.0 110.457 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -40.32 161.01 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 CA-C-O 121.233 0.539 . . . . 0.0 109.741 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 140.42 131.08 2.71 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.522 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.07 140.63 15.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.282 -1.129 . . . . 0.0 109.187 -179.689 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.464 ' HB ' ' O ' ' A' ' 42' ' ' PHE . 43.7 t -89.91 144.41 9.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.453 -0.779 . . . . 0.0 110.197 -179.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.414 HG21 ' OD2' ' A' ' 20' ' ' ASP . 9.0 t -98.24 -27.56 14.1 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.16 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.523 ' HB2' ' CG ' ' A' ' 23' ' ' GLU . 7.0 m-20 -136.41 103.51 5.3 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.272 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.585 ' CD2' ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -45.84 -30.43 1.69 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.101 -0.999 . . . . 0.0 109.746 -178.781 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.585 ' N ' ' CD2' ' A' ' 21' ' ' LEU . . . -60.05 -49.51 77.37 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 121.643 -0.66 . . . . 0.0 109.796 -179.636 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.523 ' CG ' ' HB2' ' A' ' 20' ' ' ASP . 1.8 pt-20 -101.13 31.07 3.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.424 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.453 ' O ' HG21 ' A' ' 25' ' ' VAL . . . -67.2 -45.73 78.3 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.541 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 77.0 t -141.91 145.28 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -1.166 . . . . 0.0 109.695 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.77 -46.91 70.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.207 -0.933 . . . . 0.0 109.749 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.479 ' HA3' ' HB2' ' A' ' 7' ' ' ASN . . . -81.53 -6.55 89.08 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' TRP . . . . . 0.664 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.2 OUTLIER -133.96 123.71 25.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.155 -1.203 . . . . 0.0 109.091 179.528 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.528 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -126.62 126.98 44.51 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.35 -0.844 . . . . 0.0 108.934 179.586 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.513 ' CD2' ' HB1' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -106.43 170.08 8.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.12 -0.987 . . . . 0.0 109.586 -179.395 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.516 ' HA ' HD21 ' A' ' 21' ' ' LEU . 19.4 m120 -160.53 122.45 3.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 110.241 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.494 HG11 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -103.65 137.54 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.257 -0.902 . . . . 0.0 109.354 178.625 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -86.88 169.72 40.83 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -60.6 -14.44 20.25 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.15 -1.206 . . . . 0.0 109.185 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.426 ' HB3' ' OD1' ' A' ' 67' ' ' ASN . 5.7 p -67.46 -33.72 75.72 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.338 -0.851 . . . . 0.0 109.796 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.534 HG22 ' CB ' ' A' ' 70' ' ' ASP . 2.2 t -67.03 86.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.016 -1.053 . . . . 0.0 109.385 -179.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.411 ' O ' HG21 ' A' ' 37' ' ' THR . 17.7 m -65.81 -29.04 69.46 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.086 -1.009 . . . . 0.0 108.3 179.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 41.8 t30 -131.57 101.08 15.97 Favored Pre-proline 0 C--N 1.295 -1.765 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.2 149.87 36.52 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.368 2.045 . . . . 0.0 110.592 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.53 ' CD ' HG12 ' A' ' 71' ' ' ILE . 36.0 Cg_endo -77.38 -165.49 0.33 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.588 2.192 . . . . 0.0 110.191 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.518 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 56.0 t -108.52 118.88 57.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.331 -0.856 . . . . 0.0 110.13 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.583 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 2.7 m-85 -97.37 111.61 23.79 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.038 -1.039 . . . . 0.0 108.221 178.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.522 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 3.3 tm-20 -153.01 148.51 27.15 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.125 -0.984 . . . . 0.0 110.099 -179.446 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.458 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 61.4 t -102.41 148.45 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.388 -0.82 . . . . 0.0 109.048 179.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.58 ' CD2' ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -150.19 164.28 36.07 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.084 -1.01 . . . . 0.0 108.602 -179.938 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.58 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 13.0 mt-10 -110.68 112.81 24.95 Favored 'General case' 0 C--N 1.293 -1.863 0 O-C-N 121.443 -0.785 . . . . 0.0 109.809 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.516 HG21 ' CD2' ' A' ' 45' ' ' LEU . 1.9 p -106.48 152.99 22.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.453 -0.78 . . . . 0.0 109.458 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 51.9 p -88.25 18.79 4.12 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.345 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.421 ' O ' ' C ' ' A' ' 50' ' ' ALA . 14.7 t0 -132.97 7.81 4.03 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 109.519 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.421 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -43.93 149.22 0.68 Allowed Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.276 -0.89 . . . . 0.0 109.351 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.579 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 35.2 Cg_endo -78.21 -32.96 2.16 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.697 2.265 . . . . 0.0 110.372 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -139.28 77.49 1.62 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.283 -0.885 . . . . 0.0 109.531 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 118.48 -127.15 7.15 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 6.9 t30 -157.57 22.51 0.28 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.26 -1.141 . . . . 0.0 109.413 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.526 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 17.8 mttp -136.58 142.76 43.36 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.29 -0.881 . . . . 0.0 109.412 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.563 HG13 ' CZ2' ' A' ' 125' ' ' TRP . 6.1 m -150.64 174.18 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.217 -0.927 . . . . 0.0 109.563 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.593 ' HB2' ' CE2' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -102.88 103.15 13.28 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.575 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.637 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.96 118.55 23.06 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.526 ' O ' ' CG2' ' A' ' 156' ' ' THR . 46.9 t -113.29 143.9 22.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.096 -1.003 . . . . 0.0 108.6 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' THR . . . . . 0.522 ' N ' HG13 ' A' ' 59' ' ' VAL . 45.7 m -108.66 94.29 4.97 Favored 'General case' 0 C--N 1.283 -2.316 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.535 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 55.5 t -89.03 125.36 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.281 -0.887 . . . . 0.0 108.843 179.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.484 ' ND2' HG23 ' A' ' 60' ' ' THR . 5.7 p30 -160.17 61.58 0.34 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.41 -0.806 . . . . 0.0 109.68 -179.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 149.24 89.81 0.08 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.52 HG12 ' CA ' ' A' ' 149' ' ' TYR . 2.5 m -79.91 -171.93 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.281 -1.129 . . . . 0.0 109.58 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -134.71 -164.43 10.52 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -92.3 19.1 7.39 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -1.139 . . . . 0.0 109.459 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.512 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 30.5 m120 -132.72 148.15 68.37 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.231 -0.918 . . . . 0.0 109.398 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.511 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.3 Cg_endo -78.52 12.52 2.12 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.578 2.186 . . . . 0.0 110.836 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.512 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -136.59 58.83 1.72 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.99 -1.069 . . . . 0.0 109.688 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.534 ' CB ' HG22 ' A' ' 36' ' ' VAL . 1.8 m-20 -77.71 -69.61 0.53 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.122 -0.986 . . . . 0.0 108.963 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.53 HG12 ' CD ' ' A' ' 40' ' ' PRO . 3.0 mt -106.26 126.82 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.396 -0.815 . . . . 0.0 108.904 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -121.92 128.79 51.94 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.078 -1.013 . . . . 0.0 110.504 -179.268 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.581 ' HB2' ' CZ3' ' A' ' 28' ' ' TRP . . . -113.68 108.54 17.26 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.513 HG22 ' N ' ' A' ' 75' ' ' ALA . 40.9 m -115.28 162.48 17.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.513 -1.367 . . . . 0.0 110.137 -178.745 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.513 ' N ' HG22 ' A' ' 74' ' ' THR . . . -123.46 140.1 53.34 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.227 -0.92 . . . . 0.0 109.219 179.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.535 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 3.1 p90 178.98 160.56 0.7 Allowed Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.416 -0.802 . . . . 0.0 109.22 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.532 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.9 Cg_endo -81.58 168.64 67.57 Favored 'Cis proline' 0 C--N 1.311 -1.418 0 C-N-CA 123.699 -1.375 . . . . 0.0 110.696 -0.468 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.476 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 33.3 t -121.22 131.58 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.233 -0.917 . . . . 0.0 108.87 179.355 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ASN . . . . . 0.517 ' N ' ' HB1' ' A' ' 4' ' ' ALA . 26.7 m-80 -94.03 103.97 16.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.079 -1.013 . . . . 0.0 109.975 -179.518 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.576 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.2 m -113.57 -176.6 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.402 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.519 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 0.0 OUTLIER -133.42 142.61 44.77 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.302 -0.874 . . . . 0.0 109.346 179.88 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.63 106.47 2.2 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.448 2.099 . . . . 0.0 110.505 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 113.33 -30.68 7.14 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.458 ' HB ' ' HB3' ' A' ' 81' ' ' ARG . 2.5 t -84.51 149.74 4.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.23 -1.159 . . . . 0.0 109.47 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 19.7 m -90.6 123.65 34.41 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' TYR . . . . . 0.576 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 6.3 m-85 -106.37 154.84 20.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.282 -0.886 . . . . 0.0 109.733 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' THR . . . . . 0.464 HG23 ' N ' ' A' ' 88' ' ' TYR . 59.0 m -118.04 154.36 32.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.433 -0.792 . . . . 0.0 109.238 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.688 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -129.33 127.38 40.97 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.146 -0.971 . . . . 0.0 109.515 -179.84 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.511 ' O ' ' O ' ' A' ' 161' ' ' GLY . 21.6 m -130.5 145.54 51.87 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.266 -0.896 . . . . 0.0 108.78 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.512 ' C ' ' CD1' ' A' ' 91' ' ' TRP . 16.9 tt -151.34 161.91 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 120.554 -1.341 . . . . 0.0 109.741 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.574 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 18.1 m95 -132.63 124.88 29.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.154 -0.966 . . . . 0.0 108.982 179.5 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.98 145.91 47.66 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.741 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.576 ' HG2' ' CZ3' ' A' ' 125' ' ' TRP . 8.8 ptt180 -156.73 179.2 9.5 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -154.47 160.62 41.69 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.091 -1.006 . . . . 0.0 109.868 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . 0.41 ' O ' HG22 ' A' ' 123' ' ' THR . 4.4 tt0 -54.04 -41.19 67.8 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.383 -0.823 . . . . 0.0 109.452 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.472 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 57.4 mt-30 -130.34 143.38 50.74 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.225 -0.922 . . . . 0.0 109.442 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.525 ' OD1' ' CG2' ' A' ' 123' ' ' THR . 2.2 m-20 -57.14 149.37 19.7 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.293 -0.879 . . . . 0.0 109.505 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 111.23 36.99 1.71 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.472 ' HB3' ' OD1' ' A' ' 152' ' ' ASN . . . -125.19 141.8 51.88 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.072 -1.252 . . . . 0.0 109.32 179.695 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.52 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 54.0 t -118.56 151.27 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 110.832 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.64 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 40.7 t -150.02 162.11 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.529 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 54.4 m -124.42 128.83 49.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.09 -1.006 . . . . 0.0 109.31 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.588 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.2 OUTLIER -121.66 103.78 9.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.084 -1.01 . . . . 0.0 109.957 -179.788 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.489 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 20.9 p -128.4 165.02 21.43 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.216 -0.928 . . . . 0.0 109.927 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.629 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -121.62 125.23 73.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.564 0.697 . . . . 0.0 110.167 179.876 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -115.1 179.02 18.14 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.551 ' CB ' ' O ' ' A' ' 111' ' ' GLN . 25.7 t30 -127.83 172.04 11.22 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -1.097 . . . . 0.0 109.077 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . 0.45 ' HB2' ' OE2' ' A' ' 138' ' ' GLU . 31.4 mt-30 -59.17 -47.63 84.59 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.007 -1.058 . . . . 0.0 109.608 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.538 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 46.9 t -84.37 19.36 1.92 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.219 -0.926 . . . . 0.0 110.117 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.56 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.1 m-30 80.61 7.79 1.36 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.36 -0.838 . . . . 0.0 110.186 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.551 ' O ' ' CB ' ' A' ' 107' ' ' ASN . 37.0 mm-40 -69.9 123.99 22.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.994 -1.066 . . . . 0.0 108.736 179.249 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . 0.481 ' HG3' ' N ' ' A' ' 113' ' ' TYR . 1.2 tt0 -104.93 140.41 38.21 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.925 -1.109 . . . . 0.0 110.122 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.576 ' CE2' HG23 ' A' ' 141' ' ' ILE . 5.8 m-85 -108.37 -68.56 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.453 -0.779 . . . . 0.0 108.915 179.198 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.57 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -99.37 171.61 24.42 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 179.478 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.476 ' CG ' ' O ' ' A' ' 115' ' ' ARG . 0.2 OUTLIER -171.03 110.11 0.33 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.044 -1.268 . . . . 0.0 110.381 -179.867 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.633 ' CD2' ' CD1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -145.38 77.29 1.51 Allowed 'General case' 0 N--CA 1.494 1.74 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.168 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' HIS . . . . . 0.54 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 18.5 p80 -104.27 158.04 16.73 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.354 -0.842 . . . . 0.0 110.11 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 30.0 tt0 79.1 78.52 0.06 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.513 -0.742 . . . . 0.0 109.689 179.687 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . 0.451 ' OE1' ' O ' ' A' ' 118' ' ' GLU . 19.5 mm100 -144.24 131.74 21.02 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.251 -0.906 . . . . 0.0 109.467 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . 0.433 ' O ' HD11 ' A' ' 121' ' ' ILE . 10.6 mt-30 -66.66 156.04 36.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 109.066 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.529 ' CG2' ' HA ' ' A' ' 93' ' ' ARG . 13.9 mm -133.21 136.76 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 O-C-N 121.066 -1.021 . . . . 0.0 110.005 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -90.48 -179.17 5.52 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.908 0.861 . . . . 0.0 110.636 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.525 ' CG2' ' OD1' ' A' ' 97' ' ' ASP . 0.8 OUTLIER -68.69 -15.67 63.59 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.416 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.521 ' O ' ' CB ' ' A' ' 93' ' ' ARG . 3.8 mt-10 -100.36 -172.09 2.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.475 -0.766 . . . . 0.0 109.289 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' TRP . . . . . 0.579 ' CE2' ' HD3' ' A' ' 51' ' ' PRO . 98.2 m95 -90.07 135.46 33.64 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.324 -0.86 . . . . 0.0 109.796 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.434 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 0.6 OUTLIER -106.83 121.37 45.16 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.233 -0.917 . . . . 0.0 108.977 179.751 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -79.64 110.1 2.57 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.447 2.098 . . . . 0.0 110.945 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -122.79 133.71 54.44 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 179.189 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.1 t -151.62 176.42 11.37 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 120.625 -1.297 . . . . 0.0 111.057 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.688 ' CE2' ' CD1' ' A' ' 88' ' ' TYR . 10.5 p90 -171.98 178.01 3.09 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.019 179.437 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . 0.474 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 33.5 mt-10 -133.7 153.57 51.6 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.061 -1.025 . . . . 0.0 110.041 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.565 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.14 160.76 19.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.458 -0.776 . . . . 0.0 109.147 179.746 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -119.11 146.2 45.31 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.18 -0.95 . . . . 0.0 109.293 -179.579 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.519 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 2.5 t -56.72 111.94 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.362 -0.836 . . . . 0.0 109.264 179.611 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 3.8 m -83.61 -42.32 16.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.442 -0.786 . . . . 0.0 109.947 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.576 ' O ' ' CB ' ' A' ' 137' ' ' GLN . 33.1 t70 -85.91 -16.64 37.85 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.401 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.576 ' CB ' ' O ' ' A' ' 136' ' ' ASP . 3.2 mm-40 86.32 28.38 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -178.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.523 ' CG ' ' OD1' ' A' ' 107' ' ' ASN . 3.0 mm-40 -74.48 119.4 18.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.606 -0.683 . . . . 0.0 109.795 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 17.3 p -79.34 -3.78 47.83 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.9 t -140.13 132.19 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.352 -0.843 . . . . 0.0 109.131 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.576 HG23 ' CE2' ' A' ' 113' ' ' TYR . 0.6 OUTLIER -144.53 171.98 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.259 -0.901 . . . . 0.0 109.821 -179.861 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' ARG . . . . . 0.483 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.1 ptm180 -139.61 132.26 28.89 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.528 -0.732 . . . . 0.0 109.419 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ALA . . . . . 0.629 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -96.09 108.78 43.31 Favored Pre-proline 0 N--CA 1.486 1.339 0 O-C-N 121.219 -0.926 . . . . 0.0 110.029 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.489 ' HD2' ' O ' ' A' ' 104' ' ' THR . 36.2 Cg_endo -77.73 112.51 3.32 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.324 2.016 . . . . 0.0 111.106 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . 0.664 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 2.4 mt -99.14 134.19 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 178.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' HIS . . . . . 0.487 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 12.8 m80 -97.2 154.83 17.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.34 -1.475 . . . . 0.0 111.607 -177.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.64 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 28.1 m-85 -155.1 157.21 37.16 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 179.284 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.409 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 108.11 53.59 0.65 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 0.52 ' CA ' HG12 ' A' ' 64' ' ' VAL . 22.6 m-85 -129.03 159.47 35.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.245 -1.15 . . . . 0.0 109.39 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.67 -30.15 70.33 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.467 ' HB2' ' HB ' ' A' ' 100' ' ' VAL . . . -71.23 -11.6 61.01 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.369 -0.832 . . . . 0.0 109.049 179.265 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.55 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 1.8 t30 -116.86 13.07 14.93 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 179.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 149' ' ' TYR . 2.2 t -85.15 162.22 2.95 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 O-C-N 121.635 -0.665 . . . . 0.0 109.695 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' GLY . . . . . 0.446 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 54.06 33.19 50.76 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.472 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.0 m-20 -160.47 135.46 7.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.187 -1.184 . . . . 0.0 110.069 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' THR . . . . . 0.566 HG21 ' CE1' ' A' ' 158' ' ' TYR . 42.2 m -85.13 122.43 29.33 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.067 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.55 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -101.13 118.72 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.832 -1.167 . . . . 0.0 110.331 -178.811 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.637 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 3.5 m-85 -95.12 130.81 41.68 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.636 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.4 mt -120.31 142.0 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.915 -1.115 . . . . 0.0 110.078 -178.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' ASP . . . . . 0.525 ' OD2' ' CA ' ' A' ' 9' ' ' GLY . 0.8 OUTLIER -174.38 136.37 0.47 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.108 -0.995 . . . . 0.0 109.252 179.535 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 122.63 -10.4 9.1 Favored Glycine 0 N--CA 1.487 2.069 0 C-N-CA 119.322 -1.418 . . . . 0.0 111.014 179.023 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.485 ' O ' ' HA3' ' A' ' 8' ' ' GLY . 9.9 tp -59.62 97.19 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.53 -1.571 . . . . 0.0 108.903 -179.643 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -134.57 145.55 48.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.537 -0.727 . . . . 0.0 109.985 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.482 HG23 ' CD2' ' A' ' 88' ' ' TYR . 2.6 mm -119.65 108.5 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.284 -0.885 . . . . 0.0 109.204 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . 0.464 ' O ' ' HB ' ' A' ' 87' ' ' THR . . . . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.127 -0.983 . . . . 0.0 109.527 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.497 ' CG1' ' O ' ' A' ' 5' ' ' ASN . 2.9 p . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -75.3 -46.57 32.63 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.186 -0.946 . . . . 0.0 109.587 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.5 ' HB2' ' CG1' ' A' ' 164' ' ' ILE . 0.9 OUTLIER -89.84 124.65 34.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.293 -0.88 . . . . 0.0 109.603 -179.945 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.492 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 1.8 mp -116.83 138.06 48.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.244 -0.91 . . . . 0.0 109.3 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.515 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.3 OUTLIER 74.99 16.52 2.87 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.219 -0.926 . . . . 0.0 109.627 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -60.11 -45.98 95.02 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.527 ' CA ' ' OD2' ' A' ' 160' ' ' ASP . . . -94.77 28.44 11.4 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 179.407 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.576 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 8.4 m-85 44.53 52.01 7.73 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.434 -1.039 . . . . 0.0 109.552 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.457 ' OE1' ' HA3' ' A' ' 53' ' ' GLY . 57.3 mm-40 -84.6 -28.24 26.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.298 -0.876 . . . . 0.0 109.639 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.435 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 0.9 OUTLIER -87.31 -37.08 17.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.198 -0.939 . . . . 0.0 109.762 -179.675 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.464 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 10.1 m -70.82 117.0 51.79 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.153 -0.967 . . . . 0.0 109.354 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 15' ' ' ALA . 35.2 Cg_endo -76.95 138.82 18.85 Favored 'Trans proline' 0 C--N 1.312 -1.378 0 C-N-CA 122.319 2.013 . . . . 0.0 110.396 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.441 ' C ' ' O ' ' A' ' 14' ' ' PRO . . . -39.31 153.88 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.516 0 CA-C-O 121.279 0.561 . . . . 0.0 109.857 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.49 131.37 2.41 Favored Glycine 0 N--CA 1.485 1.966 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.533 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.84 141.13 14.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.227 -1.16 . . . . 0.0 109.213 -179.602 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.475 HG13 ' CA ' ' A' ' 24' ' ' GLY . 47.8 t -86.58 142.37 13.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 CA-C-O 121.722 0.772 . . . . 0.0 110.365 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.411 ' C ' ' OD1' ' A' ' 20' ' ' ASP . 1.8 t -95.34 -28.53 14.92 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.069 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.426 ' O ' ' C ' ' A' ' 21' ' ' LEU . 1.0 OUTLIER -136.31 100.5 4.4 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.325 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.579 ' CD2' ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -43.23 -29.02 0.36 Allowed 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.259 -0.9 . . . . 0.0 109.773 -178.868 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.579 ' N ' ' CD2' ' A' ' 21' ' ' LEU . . . -59.69 -55.06 39.13 Favored 'General case' 0 C--N 1.294 -1.823 0 O-C-N 121.599 -0.688 . . . . 0.0 109.822 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -101.5 31.6 3.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.135 -0.978 . . . . 0.0 109.349 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.475 ' CA ' HG13 ' A' ' 18' ' ' VAL . . . -67.56 -47.18 63.74 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.512 ' HB ' ' CB ' ' A' ' 28' ' ' TRP . 4.3 t -126.61 144.83 35.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.093 -1.24 . . . . 0.0 109.842 -179.638 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -62.49 -65.56 0.67 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.331 -0.855 . . . . 0.0 110.084 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.515 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -76.31 2.5 56.93 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' TRP . . . . . 0.687 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.7 OUTLIER -133.99 122.11 22.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.028 -1.278 . . . . 0.0 109.124 179.549 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.537 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -126.6 128.22 46.46 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.4 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.489 ' HB2' ' HB2' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -104.67 175.98 5.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.972 -1.08 . . . . 0.0 110.236 -178.927 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.513 ' HA ' HD22 ' A' ' 21' ' ' LEU . 16.8 m120 -160.2 122.09 3.22 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.47 -0.769 . . . . 0.0 109.629 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.523 HG13 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -110.6 136.53 46.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.217 -0.927 . . . . 0.0 109.494 179.417 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.45 -179.87 21.03 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.1 m -58.42 -16.3 14.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -1.165 . . . . 0.0 109.294 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.465 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 37.7 m -60.37 -38.85 85.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.257 -0.902 . . . . 0.0 109.592 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 36' ' ' VAL . 2.1 t -62.97 89.29 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.045 -1.034 . . . . 0.0 109.257 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.4 m -59.79 -29.23 68.07 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.242 -0.911 . . . . 0.0 108.69 179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.474 ' O ' HG13 ' A' ' 36' ' ' VAL . 0.5 OUTLIER -129.07 128.79 23.36 Favored Pre-proline 0 C--N 1.296 -1.728 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.448 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.63 122.02 6.23 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.203 1.935 . . . . 0.0 110.523 -179.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.507 ' HG3' ' CD1' ' A' ' 71' ' ' ILE . 35.4 Cg_endo -77.3 -165.68 0.34 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.302 2.002 . . . . 0.0 109.905 179.697 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.504 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 70.2 t -117.34 118.72 59.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.034 -1.041 . . . . 0.0 110.775 -179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.435 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 2.3 m-85 -102.33 111.97 24.48 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.163 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.533 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 1.3 tm-20 -154.1 151.52 29.39 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.062 -1.024 . . . . 0.0 110.118 -179.116 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.444 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 48.0 t -103.75 148.39 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.488 -0.757 . . . . 0.0 109.188 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.6 ' CD2' ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -149.13 164.12 35.63 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.77 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.6 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 9.9 pt-20 -125.47 124.89 42.37 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.333 -0.855 . . . . 0.0 109.551 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.52 ' CG2' HD23 ' A' ' 45' ' ' LEU . 1.3 p -127.24 166.77 17.12 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.388 -0.82 . . . . 0.0 109.461 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 95.6 p -88.24 18.58 4.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.912 . . . . 0.0 109.4 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 50' ' ' ALA . 0.1 OUTLIER -123.96 -0.81 8.39 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.277 -0.889 . . . . 0.0 109.584 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.34 145.84 1.32 Allowed Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.166 -0.959 . . . . 0.0 109.406 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.576 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 36.1 Cg_endo -78.44 -41.94 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.647 2.231 . . . . 0.0 110.396 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -128.26 89.61 2.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.315 -0.865 . . . . 0.0 109.413 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.457 ' HA3' ' OE1' ' A' ' 11' ' ' GLU . . . 105.49 -128.38 9.37 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 9.2 p-10 -152.63 18.24 0.61 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.201 -1.176 . . . . 0.0 109.704 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.466 ' O ' ' OD2' ' A' ' 160' ' ' ASP . 95.1 mttt -138.73 146.6 41.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.15 -0.969 . . . . 0.0 109.665 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.501 HG21 ' CD1' ' A' ' 45' ' ' LEU . 5.4 m -150.1 174.48 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.392 -0.817 . . . . 0.0 109.242 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.576 ' HB2' ' CE2' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -100.43 103.75 15.13 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.12 -0.988 . . . . 0.0 108.964 179.475 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.638 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -82.04 121.9 27.14 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 178.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.53 ' CG2' HD21 ' A' ' 57' ' ' LEU . 44.0 t -115.46 144.17 23.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.113 -0.992 . . . . 0.0 109.084 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' THR . . . . . 0.504 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 95.9 m -107.79 88.48 2.74 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.196 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.562 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 60.1 t -86.77 120.91 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.419 -0.801 . . . . 0.0 109.291 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.485 ' ND2' HG23 ' A' ' 60' ' ' THR . 5.4 p30 -160.23 59.3 0.35 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.423 -0.798 . . . . 0.0 109.835 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 154.57 84.65 0.05 OUTLIER Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.538 HG12 ' CA ' ' A' ' 149' ' ' TYR . 1.7 m -80.66 -176.54 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.24 -1.153 . . . . 0.0 109.396 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -126.99 -159.53 10.21 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 22.8 m-20 -89.48 -9.22 50.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.295 -1.121 . . . . 0.0 109.455 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.484 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 39.6 m-80 -104.77 148.06 35.46 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.241 -0.912 . . . . 0.0 109.388 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.85 13.54 1.92 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.651 2.234 . . . . 0.0 110.942 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.484 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 1.9 p90 -137.72 53.33 1.85 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.98 -1.075 . . . . 0.0 109.744 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.462 ' HB3' HG21 ' A' ' 36' ' ' VAL . 0.4 OUTLIER -75.48 -65.28 0.91 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.174 -0.953 . . . . 0.0 109.095 179.645 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.52 HG13 ' CG2' ' A' ' 36' ' ' VAL . 4.5 mt -105.05 128.68 58.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.275 -0.89 . . . . 0.0 108.709 179.523 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -130.69 130.44 43.86 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.822 -1.174 . . . . 0.0 110.545 -179.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.601 ' HB2' ' CZ3' ' A' ' 28' ' ' TRP . . . -113.66 108.82 17.64 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.473 HG23 ' N ' ' A' ' 75' ' ' ALA . 54.5 m -109.23 162.3 14.42 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.688 -1.257 . . . . 0.0 110.134 -178.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.473 ' N ' HG23 ' A' ' 74' ' ' THR . . . -122.74 138.97 54.47 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.267 -0.895 . . . . 0.0 109.173 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.555 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 4.1 p90 179.36 161.57 0.76 Allowed Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.526 -0.734 . . . . 0.0 109.098 -179.723 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.555 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.7 Cg_endo -81.76 166.32 72.28 Favored 'Cis proline' 0 C--N 1.311 -1.444 0 C-N-CA 123.802 -1.333 . . . . 0.0 110.972 -0.364 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.524 HG13 ' CD1' ' A' ' 164' ' ' ILE . 86.7 t -127.19 156.64 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ASN . . . . . 0.535 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 69.1 m-20 -122.53 139.52 53.81 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.007 -1.058 . . . . 0.0 109.875 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.461 HG11 ' O ' ' A' ' 79' ' ' ASN . 4.0 m -146.04 -174.04 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.226 -0.921 . . . . 0.0 109.758 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.531 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 3.1 ttt85 -138.07 141.38 32.06 Favored Pre-proline 0 N--CA 1.49 1.534 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.498 ' HD2' ' CG ' ' A' ' 81' ' ' ARG . 34.9 Cg_endo -76.12 117.27 4.6 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.467 2.111 . . . . 0.0 110.778 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 107.72 -33.53 6.26 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.422 ' HB ' ' HB3' ' A' ' 81' ' ' ARG . 2.7 t -88.59 149.72 3.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.221 -1.164 . . . . 0.0 109.584 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.3 t -94.19 147.54 23.07 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' TYR . . . . . 0.573 ' CD2' ' O ' ' A' ' 165' ' ' ALA . 7.6 m-85 -122.2 157.46 31.54 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.102 -0.999 . . . . 0.0 109.937 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 47.7 m -111.21 142.12 43.84 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.375 -0.828 . . . . 0.0 109.05 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.702 ' CZ ' ' CE2' ' A' ' 132' ' ' PHE . 0.2 OUTLIER -134.19 128.25 33.62 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.093 -1.004 . . . . 0.0 109.548 -179.522 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.501 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.5 m -134.83 152.79 52.04 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.563 HD12 ' CD2' ' A' ' 103' ' ' PHE . 18.6 tt -150.9 163.4 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.787 -1.196 . . . . 0.0 109.343 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.576 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 17.2 m95 -130.66 124.87 32.61 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.076 -1.015 . . . . 0.0 109.566 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.522 ' HB3' ' CG2' ' A' ' 121' ' ' ILE . . . -113.49 146.81 39.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.3 -0.875 . . . . 0.0 109.204 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.477 ' HG3' ' O ' ' A' ' 123' ' ' THR . 6.5 ttp85 -162.34 119.68 2.08 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.144 -0.973 . . . . 0.0 109.228 -179.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.412 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.35 160.52 15.31 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.22 -0.925 . . . . 0.0 109.937 -179.61 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.08 -44.83 75.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.425 -0.797 . . . . 0.0 109.176 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.454 ' HB2' ' OD1' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -117.68 151.62 36.88 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.872 . . . . 0.0 109.132 179.758 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.524 ' CA ' HG23 ' A' ' 123' ' ' THR . 2.3 p-10 -73.59 146.01 45.02 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.139 -0.976 . . . . 0.0 109.566 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 113.56 37.89 1.26 Allowed Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.473 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -121.66 140.53 52.17 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.188 -1.184 . . . . 0.0 109.128 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.461 ' HB ' ' HB3' ' A' ' 151' ' ' ALA . 50.7 t -116.23 154.3 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.218 -0.926 . . . . 0.0 110.66 -179.427 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.643 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 61.6 t -155.02 166.49 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.688 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.579 ' HB2' ' CD2' ' A' ' 117' ' ' HIS . 30.8 t -136.18 130.81 33.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.027 -1.046 . . . . 0.0 109.643 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.633 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.3 OUTLIER -122.86 104.51 9.32 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.145 -0.972 . . . . 0.0 109.572 -179.965 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.494 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 16.0 p -117.22 170.78 8.41 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.119 -0.988 . . . . 0.0 110.462 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.631 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -127.32 157.71 38.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.834 -0.541 . . . . 0.0 109.726 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 172.98 138.33 2.58 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.521 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.3 p30 -76.98 -169.88 1.46 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.123 -1.222 . . . . 0.0 109.334 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . 0.521 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 1.4 mp0 -77.28 14.91 0.83 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.04 -1.037 . . . . 0.0 110.925 -179.156 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.508 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 0.9 OUTLIER -113.63 6.36 16.91 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 120.785 -1.197 . . . . 0.0 109.344 179.598 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.569 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.6 m-30 77.94 14.84 1.55 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.361 -0.837 . . . . 0.0 109.611 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.45 ' HG2' ' HB2' ' A' ' 109' ' ' SER . 7.9 mm-40 -90.0 94.39 9.78 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 108.655 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . 0.53 ' CG ' ' O ' ' A' ' 105' ' ' VAL . 2.0 tt0 -81.92 142.08 32.77 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.362 -0.836 . . . . 0.0 110.34 -179.06 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.572 ' HB3' ' CD1' ' A' ' 132' ' ' PHE . 4.8 m-85 -109.69 -69.02 0.88 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.207 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -89.34 177.67 44.19 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 179.479 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.521 ' O ' ' CD2' ' A' ' 116' ' ' LEU . 0.6 OUTLIER -177.87 135.83 0.17 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.951 -1.323 . . . . 0.0 110.393 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.567 HD13 ' CD1' ' A' ' 130' ' ' PHE . 0.5 OUTLIER -147.36 69.87 1.16 Allowed 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.304 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' HIS . . . . . 0.579 ' CD2' ' HB2' ' A' ' 102' ' ' SER . 27.2 t-80 -93.77 141.57 28.35 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 110.295 -179.043 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . 0.559 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 4.2 tt0 82.21 36.8 0.06 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.711 -0.618 . . . . 0.0 109.52 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . 0.429 ' O ' HD11 ' A' ' 121' ' ' ILE . 6.9 mm100 -88.55 120.34 29.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.355 -0.841 . . . . 0.0 109.165 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -65.5 140.99 58.63 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.462 -0.774 . . . . 0.0 108.945 179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.522 ' CG2' ' HB3' ' A' ' 92' ' ' ALA . 5.9 mm -125.81 129.68 72.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.109 -0.995 . . . . 0.0 110.126 -179.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -89.86 -178.77 5.57 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.618 0.723 . . . . 0.0 110.094 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.524 HG23 ' CA ' ' A' ' 97' ' ' ASP . 11.6 p -72.87 -2.08 19.32 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 119.914 -0.714 . . . . 0.0 109.352 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.456 ' O ' ' HB2' ' A' ' 93' ' ' ARG . 0.4 OUTLIER -112.44 -168.73 1.36 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.166 -0.959 . . . . 0.0 108.981 179.727 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' TRP . . . . . 0.542 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 95.3 m95 -91.95 130.26 37.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.145 -0.972 . . . . 0.0 109.613 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.429 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 12.1 mm-40 -109.51 121.45 42.33 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.156 -0.965 . . . . 0.0 109.109 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.17 100.41 1.26 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 C-N-CA 122.514 2.143 . . . . 0.0 111.141 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -110.9 137.83 48.05 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.14 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.1 t -144.18 176.21 9.5 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.565 -1.334 . . . . 0.0 111.058 -179.362 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.58 ' CE2' ' CD2' ' A' ' 88' ' ' TYR . 16.9 p90 -173.9 171.06 3.77 Favored 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 115.036 -0.983 . . . . 0.0 109.034 179.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . 0.503 ' HA ' ' CE2' ' A' ' 88' ' ' TYR . 34.3 mt-10 -143.64 142.18 30.92 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.089 -1.007 . . . . 0.0 109.904 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.702 ' CE2' ' CZ ' ' A' ' 88' ' ' TYR . 5.2 p90 -151.11 168.07 25.78 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.35 -0.844 . . . . 0.0 109.145 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.407 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -119.37 147.29 44.51 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.907 . . . . 0.0 109.623 -179.719 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.531 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 3.6 t -43.51 110.43 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.46 -0.775 . . . . 0.0 108.977 179.546 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -58.52 -51.12 71.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.293 -179.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -110.65 -91.16 0.47 Allowed 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.399 -0.813 . . . . 0.0 109.209 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.408 ' HA ' HG11 ' A' ' 134' ' ' VAL . 0.2 OUTLIER -160.94 55.2 0.3 Allowed 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.576 -0.702 . . . . 0.0 109.127 179.737 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.513 ' HG3' ' ND2' ' A' ' 107' ' ' ASN . 7.2 mm-40 -95.01 111.91 23.67 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.213 -0.93 . . . . 0.0 109.851 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.0 p -79.42 -13.46 59.58 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 41.6 t -134.03 136.42 53.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.212 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.46 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -143.36 171.89 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.072 -1.018 . . . . 0.0 110.224 -179.498 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' ARG . . . . . 0.487 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.4 ptm180 -141.37 132.43 26.23 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ALA . . . . . 0.631 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -94.22 109.67 43.78 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.331 -0.856 . . . . 0.0 110.286 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.494 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.9 Cg_endo -77.2 110.68 3.06 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 122.023 1.816 . . . . 0.0 109.664 178.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . 0.687 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 3.3 mt -95.18 124.15 47.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' HIS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 12.8 m80 -84.5 149.36 25.99 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.926 -1.109 . . . . 0.0 111.638 -177.008 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.643 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 10.4 m-85 -154.55 158.43 39.79 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.063 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.474 ' C ' ' CG1' ' A' ' 64' ' ' VAL . . . 109.33 38.77 1.74 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 0.538 ' CA ' HG12 ' A' ' 64' ' ' VAL . 20.9 m-85 -113.99 158.08 21.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.444 -1.033 . . . . 0.0 109.207 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.21 -27.58 68.09 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.43 -14.99 62.77 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.447 -0.783 . . . . 0.0 109.328 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.521 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.2 OUTLIER -109.62 11.25 24.77 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.371 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.481 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -85.79 163.88 2.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 O-C-N 121.523 -0.735 . . . . 0.0 109.881 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' GLY . . . . . 0.481 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.98 31.83 40.73 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.034 -1.227 . . . . 0.0 110.034 179.671 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.454 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.1 m-20 -160.61 139.36 10.28 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.147 -1.207 . . . . 0.0 110.27 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' THR . . . . . 0.574 HG22 ' CE1' ' A' ' 158' ' ' TYR . 80.1 m -87.29 121.2 29.42 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.562 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 1.2 mt -101.89 118.2 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 120.868 -1.145 . . . . 0.0 110.383 -178.65 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.638 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 2.6 m-85 -97.24 138.78 34.2 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 178.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.629 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -130.35 139.78 50.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 C-N-CA 118.767 -1.173 . . . . 0.0 110.014 -178.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' ASP . . . . . 0.527 ' OD2' ' CA ' ' A' ' 9' ' ' GLY . 1.0 OUTLIER -173.94 136.1 0.52 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.371 -0.831 . . . . 0.0 109.136 179.687 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . 0.501 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 126.58 -8.08 7.39 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.688 179.397 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.473 ' O ' ' HA3' ' A' ' 8' ' ' GLY . 10.4 tp -59.61 93.06 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.648 -1.501 . . . . 0.0 108.82 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . 0.449 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -118.22 145.75 44.76 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.694 -0.629 . . . . 0.0 109.9 -179.061 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.524 ' CD1' HG13 ' A' ' 78' ' ' VAL . 20.6 mt -132.68 127.28 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.362 -0.836 . . . . 0.0 109.095 179.607 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . 0.573 ' O ' ' CD2' ' A' ' 86' ' ' TYR . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.201 -0.937 . . . . 0.0 109.599 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.467 ' CG2' ' HB2' ' A' ' 165' ' ' ALA . 4.1 p . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -77.61 -31.31 52.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 109.51 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.46 ' OD1' ' O ' ' A' ' 162' ' ' LEU . 10.2 t-20 -92.19 124.67 36.44 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.24 -0.913 . . . . 0.0 109.689 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.512 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 65.5 mt -110.38 121.63 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.323 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.526 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.1 OUTLIER 76.83 43.8 0.12 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.243 -0.911 . . . . 0.0 109.169 -179.436 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.433 ' O ' ' HB3' ' A' ' 162' ' ' LEU . . . -47.76 -22.57 1.96 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.64 ' O ' ' CB ' ' A' ' 10' ' ' PHE . . . 164.2 60.35 0.02 OUTLIER Glycine 0 N--CA 1.487 2.082 0 C-N-CA 119.609 -1.281 . . . . 0.0 109.964 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.64 ' CB ' ' O ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER 118.4 1.06 0.0 OUTLIER 'General case' 0 N--CA 1.518 2.946 0 C-N-CA 122.832 0.453 . . . . 0.0 111.579 179.115 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.564 ' HG2' ' CD1' ' A' ' 10' ' ' PHE . 9.2 mm-40 -75.73 -60.79 2.16 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.418 -1.426 . . . . 0.0 110.831 -177.757 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' SER . . . . . 0.525 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.3 OUTLIER -75.11 -3.01 30.26 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.048 -1.032 . . . . 0.0 110.025 -179.201 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.532 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 4.4 m -126.1 123.8 24.49 Favored Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.029 -1.045 . . . . 0.0 109.411 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.454 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.4 Cg_endo -77.35 149.11 27.41 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 C-N-CA 122.46 2.107 . . . . 0.0 110.719 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.461 ' HA ' HG12 ' A' ' 44' ' ' VAL . . . -39.96 161.15 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.196 0.522 . . . . 0.0 109.676 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.35 134.49 3.42 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.524 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.47 140.87 14.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.392 -1.063 . . . . 0.0 108.969 -179.569 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -87.93 144.34 9.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.427 -0.796 . . . . 0.0 110.169 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.6 p -105.78 -21.2 13.23 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.391 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -145.32 130.08 18.12 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.566 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.566 ' CD1' ' N ' ' A' ' 22' ' ' ALA . 1.7 pp -87.13 -38.31 16.57 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.088 -1.008 . . . . 0.0 110.179 -179.486 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.566 ' N ' ' CD1' ' A' ' 21' ' ' LEU . . . -59.61 -24.93 64.21 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.155 -0.966 . . . . 0.0 108.87 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -138.66 34.63 2.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.452 -0.78 . . . . 0.0 109.215 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.98 -72.78 1.28 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.532 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 1.6 t -86.08 127.85 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.288 -1.125 . . . . 0.0 109.134 179.73 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . 0.475 ' HB3' ' HB3' ' A' ' 12' ' ' SER . 25.7 tt0 -54.71 -36.45 64.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.351 -0.843 . . . . 0.0 110.1 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.526 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -109.96 8.61 31.57 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.862 -1.161 . . . . 0.0 110.214 -179.367 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' TRP . . . . . 0.626 ' CZ3' ' CB ' ' A' ' 73' ' ' ALA . 0.7 OUTLIER -140.57 119.67 12.81 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.089 -1.242 . . . . 0.0 109.125 179.313 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.579 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 7.3 m-20 -124.81 142.17 51.61 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.188 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.643 ' CD1' ' CD1' ' A' ' 42' ' ' PHE . 3.3 mt -109.48 172.13 7.04 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.846 -1.159 . . . . 0.0 109.794 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -159.95 122.41 3.38 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.767 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.455 HG11 HG22 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.23 137.87 37.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.476 -0.765 . . . . 0.0 109.598 179.302 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -90.73 172.98 37.88 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 72.4 m -62.61 -12.28 22.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.17 -1.194 . . . . 0.0 109.38 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 20.9 p -72.23 -32.64 66.91 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.32 -0.863 . . . . 0.0 109.812 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.531 ' CG1' ' O ' ' A' ' 36' ' ' VAL . 2.2 t -70.34 87.1 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 O-C-N 121.112 -0.992 . . . . 0.0 109.318 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 22.2 m -63.96 -28.98 70.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.194 -0.941 . . . . 0.0 108.484 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.1 t30 -128.86 114.86 19.05 Favored Pre-proline 0 C--N 1.296 -1.74 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -76.45 144.56 25.8 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.167 1.911 . . . . 0.0 110.492 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.564 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.3 Cg_endo -77.27 -164.08 0.25 Allowed 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.557 2.171 . . . . 0.0 110.133 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.518 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 56.8 t -116.09 120.26 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.127 -0.983 . . . . 0.0 110.667 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.643 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 5.5 m-85 -101.78 112.21 24.72 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 178.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.524 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 0.4 OUTLIER -155.93 140.04 16.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.005 -1.059 . . . . 0.0 110.361 -179.451 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.485 ' N ' ' HG2' ' A' ' 43' ' ' GLU . 36.5 t -92.52 148.79 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.577 ' CD2' ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -148.67 165.16 32.17 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.013 -1.055 . . . . 0.0 109.033 -179.558 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.577 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 13.4 mt-10 -111.19 113.89 26.72 Favored 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.452 -0.78 . . . . 0.0 109.644 -178.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.513 ' CG2' HD22 ' A' ' 45' ' ' LEU . 7.7 p -111.71 165.82 11.71 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 41.8 t -94.67 -10.11 32.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.3 m-20 -102.54 -1.79 29.77 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.263 -0.898 . . . . 0.0 109.59 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.425 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.1 147.38 0.94 Allowed Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.165 -0.959 . . . . 0.0 109.43 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.576 ' HB3' ' CE3' ' A' ' 91' ' ' TRP . 35.4 Cg_endo -78.34 -40.85 0.31 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.704 2.269 . . . . 0.0 110.325 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.14 107.06 11.73 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.418 ' O ' ' CG ' ' A' ' 54' ' ' ASN . . . 87.5 -120.5 5.56 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ASN . . . . . 0.472 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 27.7 m120 -160.16 36.28 0.17 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -1.169 . . . . 0.0 109.504 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.64 ' CD ' ' CD2' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -158.91 157.27 31.09 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.31 -0.869 . . . . 0.0 109.765 179.824 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.575 HG11 ' CH2' ' A' ' 125' ' ' TRP . 15.3 m -152.27 174.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.372 -0.83 . . . . 0.0 108.897 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' LEU . . . . . 0.498 ' O ' ' HA ' ' A' ' 158' ' ' TYR . 0.2 OUTLIER -91.44 100.67 13.4 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 178.777 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.638 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -80.34 120.05 23.87 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 119.394 -0.922 . . . . 0.0 108.991 -179.812 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.52 ' O ' ' CG2' ' A' ' 156' ' ' THR . 41.3 t -112.97 144.48 20.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' THR . . . . . 0.489 HG22 ' ND2' ' A' ' 62' ' ' ASN . 59.7 m -109.87 91.14 3.53 Favored 'General case' 0 C--N 1.282 -2.327 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.537 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 52.4 t -89.95 122.82 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.311 -0.868 . . . . 0.0 108.799 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.489 ' ND2' HG22 ' A' ' 60' ' ' THR . 5.0 p30 -160.09 60.96 0.35 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.284 -0.885 . . . . 0.0 109.935 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 158.51 86.48 0.06 OUTLIER Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.531 HG13 ' CA ' ' A' ' 149' ' ' TYR . 2.3 m -82.23 -177.15 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.248 -1.148 . . . . 0.0 109.588 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -136.52 -157.86 7.87 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -96.0 23.73 6.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.326 -1.102 . . . . 0.0 109.566 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.495 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 7.0 m-80 -136.55 148.19 62.78 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.2 -0.937 . . . . 0.0 109.466 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.4 Cg_endo -78.24 11.93 2.22 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.662 2.242 . . . . 0.0 110.926 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.495 ' CZ2' ' OD1' ' A' ' 67' ' ' ASN . 1.3 p90 -136.76 59.56 1.69 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.093 -1.004 . . . . 0.0 109.647 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.525 ' HB3' ' CG2' ' A' ' 36' ' ' VAL . 1.4 m-20 -76.6 -67.59 0.68 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.242 -0.911 . . . . 0.0 109.111 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.518 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 2.2 mt -116.57 123.37 71.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.433 -0.792 . . . . 0.0 109.12 179.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.517 ' CG ' ' O ' ' A' ' 145' ' ' ILE . 20.7 tt0 -129.12 134.33 48.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.972 -1.08 . . . . 0.0 110.335 -179.4 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . 0.626 ' CB ' ' CZ3' ' A' ' 28' ' ' TRP . . . -115.91 107.69 15.31 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 178.855 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.469 ' OG1' ' HA ' ' A' ' 144' ' ' PRO . 99.3 m -103.52 165.06 11.26 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.334 -0.854 . . . . 0.0 109.669 -179.24 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.468 ' HA ' ' O ' ' A' ' 27' ' ' GLY . . . -122.98 137.49 54.94 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.026 -1.046 . . . . 0.0 109.227 179.027 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CZ ' ' HB2' ' A' ' 29' ' ' ASP . 11.2 p90 -176.05 160.32 1.89 Allowed Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.4 -0.812 . . . . 0.0 109.383 -179.766 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.526 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -82.53 170.22 58.1 Favored 'Cis proline' 0 C--N 1.311 -1.395 0 O-C-N 123.652 1.343 . . . . 0.0 111.064 -0.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.512 HG13 ' CD1' ' A' ' 164' ' ' ILE . 96.4 t -131.75 156.9 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.239 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ASN . . . . . 0.525 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 76.1 m-20 -123.24 140.28 53.18 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.922 -1.111 . . . . 0.0 110.289 -179.459 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.525 ' CG2' ' O ' ' A' ' 138' ' ' GLU . 4.3 m -145.48 -173.51 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.304 -0.873 . . . . 0.0 109.387 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.527 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 17.6 mmt180 -136.45 144.73 48.69 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.382 -0.824 . . . . 0.0 109.348 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.73 126.87 8.4 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.457 2.105 . . . . 0.0 110.539 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.22 -25.17 21.61 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.419 HG13 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -86.32 149.61 4.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.239 -1.154 . . . . 0.0 109.496 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 32.8 m -94.86 131.96 40.18 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' TYR . . . . . 0.459 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 14.6 m-85 -113.32 167.31 10.67 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.236 -0.915 . . . . 0.0 109.666 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' THR . . . . . 0.461 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 43.8 m -118.38 152.88 34.99 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.338 -0.851 . . . . 0.0 109.418 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.688 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 7.9 t80 -132.81 114.83 14.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.481 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.485 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.2 m -135.11 146.23 48.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.194 -0.941 . . . . 0.0 109.002 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 15.3 tt -150.96 163.78 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.796 -1.19 . . . . 0.0 109.5 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.576 ' CE3' ' HB3' ' A' ' 51' ' ' PRO . 37.3 m95 -128.76 135.41 49.15 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.862 -1.149 . . . . 0.0 109.375 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.424 ' C ' ' CE3' ' A' ' 125' ' ' TRP . . . -130.0 148.09 51.82 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.213 -0.929 . . . . 0.0 109.747 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.636 ' CB ' ' CD2' ' A' ' 125' ' ' TRP . 11.6 ttt-85 -164.14 121.66 1.74 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.317 -0.864 . . . . 0.0 108.909 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.438 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.04 165.68 11.04 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.305 -0.872 . . . . 0.0 110.086 -179.403 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.07 -56.6 12.06 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.425 -0.797 . . . . 0.0 109.117 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.517 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.5 OUTLIER -101.77 134.93 44.17 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.279 -0.888 . . . . 0.0 109.204 179.701 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.581 ' N ' ' CG2' ' A' ' 123' ' ' THR . 1.2 p30 -60.77 144.95 51.37 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.212 -0.93 . . . . 0.0 109.551 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 112.45 37.82 1.41 Allowed Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.466 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -118.78 139.31 51.8 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.204 -1.174 . . . . 0.0 109.224 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.491 HG13 ' N ' ' A' ' 101' ' ' VAL . 76.0 t -116.46 149.93 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.205 -0.934 . . . . 0.0 110.407 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.584 HG13 ' CE2' ' A' ' 147' ' ' PHE . 43.0 t -146.15 165.77 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.34 -0.85 . . . . 0.0 109.45 179.721 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.54 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 24.2 m -124.77 133.42 53.16 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.146 -0.971 . . . . 0.0 109.681 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.0 OUTLIER -129.1 103.85 7.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.126 -0.984 . . . . 0.0 109.477 179.497 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.505 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 29.2 p -128.14 175.63 8.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.133 -0.979 . . . . 0.0 110.323 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.616 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -133.45 106.34 9.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-O 121.575 0.702 . . . . 0.0 110.316 179.175 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.456 ' O ' ' HG2' ' A' ' 142' ' ' ARG . . . -101.54 132.46 10.97 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 108.052 -2.019 . . . . 0.0 108.052 178.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.584 ' OD1' ' CE1' ' A' ' 113' ' ' TYR . 0.2 OUTLIER -96.87 -170.62 2.08 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.963 -1.316 . . . . 0.0 109.052 -179.399 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 62.1 mt-30 -81.28 -19.8 42.24 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 118.751 -1.18 . . . . 0.0 109.829 -179.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.522 ' HB3' ' CG ' ' A' ' 111' ' ' GLN . 0.6 OUTLIER -81.92 8.82 9.45 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.113 -0.992 . . . . 0.0 108.792 178.979 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' PHE . . . . . 0.45 ' HB2' ' O ' ' A' ' 109' ' ' SER . 18.3 m-30 63.01 21.75 13.08 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.428 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.522 ' CG ' ' HB3' ' A' ' 109' ' ' SER . 2.0 mt-30 -88.36 161.61 17.01 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.649 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.82 102.12 12.22 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.447 -0.783 . . . . 0.0 109.768 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.584 ' CE1' ' OD1' ' A' ' 107' ' ' ASN . 1.9 m-30 -69.41 -67.14 0.5 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.401 -0.812 . . . . 0.0 108.941 178.553 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.541 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -130.55 171.45 20.72 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.497 ' HA ' HG23 ' A' ' 104' ' ' THR . 0.2 OUTLIER -162.78 117.31 1.75 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.029 -1.277 . . . . 0.0 110.723 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.636 ' CD2' ' CD2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -150.62 74.31 1.17 Allowed 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 178.997 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' HIS . . . . . 0.54 ' CB ' ' HB3' ' A' ' 102' ' ' SER . 22.4 p80 -118.3 169.15 9.97 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.193 -0.942 . . . . 0.0 110.134 -179.304 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . 0.512 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 0.2 OUTLIER 77.53 41.04 0.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.517 -0.739 . . . . 0.0 109.294 179.925 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . 0.455 ' HG3' HD13 ' A' ' 121' ' ' ILE . 0.8 OUTLIER -116.03 138.35 51.3 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.316 -0.865 . . . . 0.0 109.668 -179.836 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' GLN . . . . . 0.464 ' O ' HD11 ' A' ' 121' ' ' ILE . 2.4 mt-30 -74.54 156.49 36.8 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.464 HD11 ' O ' ' A' ' 120' ' ' GLN . 5.2 mm -135.19 134.64 52.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.116 -0.99 . . . . 0.0 110.022 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.0 -179.43 7.25 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.523 -0.735 . . . . 0.0 109.947 179.477 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.581 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 70.2 p -75.98 -0.46 21.67 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 119.829 -0.748 . . . . 0.0 109.23 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.453 ' O ' ' HG3' ' A' ' 93' ' ' ARG . 22.5 mm-40 -102.4 -168.91 1.59 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.246 -0.909 . . . . 0.0 109.21 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' TRP . . . . . 0.636 ' CD2' ' CB ' ' A' ' 93' ' ' ARG . 88.4 m95 -103.2 115.17 30.07 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 0.0 109.614 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 -106.68 120.75 47.32 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.11 -0.994 . . . . 0.0 108.986 179.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -80.58 116.28 3.22 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 C-N-CA 122.384 2.056 . . . . 0.0 111.175 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -112.03 135.6 52.46 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.484 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -145.71 176.3 9.75 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 120.822 -1.174 . . . . 0.0 110.801 -179.348 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.688 ' CE2' ' CG ' ' A' ' 88' ' ' TYR . 21.2 p90 -176.89 152.7 0.96 Allowed 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.303 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -105.28 154.91 19.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.752 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 113' ' ' TYR . 0.2 OUTLIER -165.02 160.88 19.43 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.431 -0.793 . . . . 0.0 109.334 179.942 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.7 OUTLIER -124.13 146.42 48.65 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.214 -0.929 . . . . 0.0 108.937 -179.883 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 3.5 t -43.57 109.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.294 -0.879 . . . . 0.0 108.955 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -51.41 -40.05 58.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.123 -0.986 . . . . 0.0 109.149 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -129.81 -90.28 0.48 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.38 -0.825 . . . . 0.0 109.369 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.453 ' HA ' HG12 ' A' ' 134' ' ' VAL . 5.9 pt20 -158.58 52.73 0.42 Allowed 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.479 -0.763 . . . . 0.0 109.279 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . 0.525 ' O ' ' CG2' ' A' ' 80' ' ' VAL . 32.5 mm-40 -85.53 110.15 19.01 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.261 -0.9 . . . . 0.0 109.547 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.3 p -79.48 -16.25 56.38 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.249 -0.907 . . . . 0.0 108.71 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.5 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 42.4 t -132.24 134.31 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.06 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.584 HG22 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -139.81 172.28 12.69 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.051 -1.031 . . . . 0.0 110.447 -179.447 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' ARG . . . . . 0.488 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.0 OUTLIER -143.73 132.07 22.07 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.895 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ALA . . . . . 0.616 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -99.31 106.58 39.88 Favored Pre-proline 0 N--CA 1.487 1.421 0 O-C-N 121.207 -0.933 . . . . 0.0 109.616 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.505 ' HD2' ' O ' ' A' ' 104' ' ' THR . 36.1 Cg_endo -78.04 111.92 3.16 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.206 1.937 . . . . 0.0 110.827 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ILE . . . . . 0.551 HG12 ' O ' ' A' ' 73' ' ' ALA . 2.0 mm -94.31 139.56 18.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 178.343 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' HIS . . . . . 0.539 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 4.5 m80 -107.22 159.75 16.11 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.299 -1.501 . . . . 0.0 112.165 -177.007 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.656 ' CE2' ' CD1' ' A' ' 159' ' ' ILE . 39.0 m-85 -160.72 165.25 30.77 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.472 ' HA3' ' HB2' ' A' ' 70' ' ' ASP . . . 104.52 46.51 1.3 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 0.531 ' CA ' HG13 ' A' ' 64' ' ' VAL . 23.9 m-85 -125.03 161.27 27.1 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.477 -1.013 . . . . 0.0 109.115 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.72 -28.47 68.45 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -75.78 -11.54 60.0 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.434 -0.791 . . . . 0.0 109.065 179.031 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.577 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 1.5 t30 -114.61 11.0 16.88 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.403 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.466 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -88.02 162.81 2.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.495 -0.753 . . . . 0.0 109.868 -179.223 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' GLY . . . . . 0.466 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.42 34.04 41.07 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 3.5 m-20 -160.39 138.71 10.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.177 -1.19 . . . . 0.0 110.013 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' THR . . . . . 0.52 ' CG2' ' O ' ' A' ' 59' ' ' VAL . 53.5 m -89.37 120.44 30.72 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.577 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -100.37 117.44 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.902 -1.124 . . . . 0.0 110.222 -178.894 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.638 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 13.1 m-85 -92.52 143.63 26.16 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 178.381 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.656 ' CD1' ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -142.04 136.22 29.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.604 -1.31 . . . . 0.0 111.025 -178.014 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' ASP . . . . . 0.585 ' OD2' ' CZ ' ' A' ' 10' ' ' PHE . 4.7 t0 -173.23 136.24 0.62 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.245 -0.909 . . . . 0.0 108.586 179.144 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 133.35 -7.29 5.01 Favored Glycine 0 N--CA 1.484 1.896 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.422 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.626 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 7.3 tp -59.33 93.14 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.626 -1.514 . . . . 0.0 108.596 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . 0.444 ' N ' ' O ' ' A' ' 161' ' ' GLY . . . -123.62 145.98 48.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.594 -0.691 . . . . 0.0 109.965 -178.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' ILE . . . . . 0.512 ' CD1' HG13 ' A' ' 78' ' ' VAL . 8.0 mt -132.41 119.58 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.325 -0.86 . . . . 0.0 109.258 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . 0.467 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.772 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.1 tmm? . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -57.09 101.3 0.06 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 0.0 109.427 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.524 ' CG2' ' HB2' ' A' ' 165' ' ' ALA . 4.1 p -87.98 173.5 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.239 -0.913 . . . . 0.0 109.405 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.524 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -71.74 -46.61 57.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.173 -0.955 . . . . 0.0 109.487 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 162' ' ' LEU . 38.7 t-20 -82.56 125.83 31.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.207 -0.933 . . . . 0.0 109.496 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.464 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 2.0 mp -112.2 123.35 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.292 -0.88 . . . . 0.0 109.265 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.473 ' HB3' ' HA3' ' A' ' 27' ' ' GLY . 0.8 OUTLIER 69.05 12.9 8.7 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.266 -0.896 . . . . 0.0 109.504 179.973 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -59.14 -24.96 59.29 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.458 ' O ' ' OD2' ' A' ' 160' ' ' ASP . . . -110.99 36.56 4.16 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.214 -1.555 . . . . 0.0 109.214 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.58 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 0.7 OUTLIER 43.64 53.21 6.02 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.368 -1.078 . . . . 0.0 109.422 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.483 ' OE2' ' CG ' ' A' ' 52' ' ' GLU . 7.7 mm-40 -84.04 -49.62 8.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -0.926 . . . . 0.0 109.728 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.461 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 7.3 m -79.58 -16.49 55.8 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.677 -179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.544 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 0.5 OUTLIER -74.51 114.74 36.89 Favored Pre-proline 0 C--N 1.304 -1.389 0 O-C-N 121.185 -0.947 . . . . 0.0 109.422 -179.802 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.2 Cg_endo -77.09 136.9 16.75 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.424 2.082 . . . . 0.0 110.474 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.439 ' C ' ' O ' ' A' ' 14' ' ' PRO . . . -40.02 155.51 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.393 0.616 . . . . 0.0 109.717 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.3 132.6 3.0 Favored Glycine 0 N--CA 1.485 1.961 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.533 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.71 142.45 12.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.252 -1.146 . . . . 0.0 109.011 -179.528 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.6 t -88.42 144.14 9.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-O 121.778 0.799 . . . . 0.0 110.277 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.409 HG23 ' N ' ' A' ' 20' ' ' ASP . 2.3 t -105.03 -26.69 12.04 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 179.145 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.462 ' CB ' ' HG3' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -138.18 101.37 4.38 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 179.453 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.576 HD23 ' CE2' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -55.56 -34.91 65.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.204 -0.935 . . . . 0.0 110.384 -179.004 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.52 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.69 -33.79 72.03 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.061 -1.024 . . . . 0.0 109.334 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.462 ' HG3' ' CB ' ' A' ' 20' ' ' ASP . 1.4 pt-20 -122.15 37.67 4.32 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.303 -0.873 . . . . 0.0 109.369 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -89.2 -73.1 1.28 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.544 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 14.6 t -99.72 127.43 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.307 -1.113 . . . . 0.0 109.259 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 31.6 tp10 -56.76 -35.69 68.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.417 -0.802 . . . . 0.0 109.783 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.473 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -99.14 -2.4 56.91 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 -179.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.614 ' CZ3' ' CB ' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -138.79 123.21 18.32 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.088 -1.242 . . . . 0.0 109.845 179.941 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.452 ' HB2' ' CE1' ' A' ' 76' ' ' PHE . 3.9 m-20 -123.47 144.23 49.66 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.571 HD12 ' CD1' ' A' ' 42' ' ' PHE . 0.7 OUTLIER -113.5 166.98 10.98 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.714 -1.242 . . . . 0.0 109.461 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.458 ' OD1' ' O ' ' A' ' 30' ' ' LEU . 8.5 m120 -157.02 124.67 5.39 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.45 -0.781 . . . . 0.0 109.687 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.523 HG11 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.04 136.56 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.383 -0.823 . . . . 0.0 109.457 179.539 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.43 -170.6 23.81 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.4 t -66.74 -9.09 33.01 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.195 -1.18 . . . . 0.0 109.438 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.466 ' HB2' ' HA ' ' A' ' 70' ' ' ASP . 0.6 OUTLIER -73.12 -31.39 64.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.204 -0.935 . . . . 0.0 109.593 -179.964 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.523 ' CG2' HG11 ' A' ' 32' ' ' VAL . 2.1 t -64.64 87.86 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 O-C-N 121.176 -0.952 . . . . 0.0 109.339 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 16.4 m -72.58 -29.0 63.15 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.478 ' O ' HG11 ' A' ' 36' ' ' VAL . 1.2 t-20 -114.57 144.98 32.88 Favored Pre-proline 0 C--N 1.296 -1.746 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.43 ' HD2' ' CG ' ' A' ' 38' ' ' ASN . 34.8 Cg_endo -76.38 111.8 3.34 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 122.359 2.039 . . . . 0.0 110.591 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.534 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.2 Cg_endo -77.57 166.13 26.16 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.371 2.048 . . . . 0.0 109.593 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.522 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 49.0 t -108.16 121.59 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.966 -1.084 . . . . 0.0 110.559 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.576 ' CE2' HD23 ' A' ' 21' ' ' LEU . 27.4 m-85 -110.12 112.47 24.48 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.464 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.533 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 0.9 OUTLIER -153.56 151.32 29.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.1 -1.0 . . . . 0.0 109.801 -179.422 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.463 HG11 ' O ' ' A' ' 56' ' ' VAL . 62.3 t -98.78 148.57 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -0.885 . . . . 0.0 109.255 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.551 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -131.9 147.01 52.44 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.185 -0.947 . . . . 0.0 108.776 179.978 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.551 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 18.1 mt-10 -115.08 113.69 24.37 Favored 'General case' 0 C--N 1.295 -1.8 0 O-C-N 121.576 -0.702 . . . . 0.0 109.548 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.525 ' CG2' HD21 ' A' ' 45' ' ' LEU . 1.7 p -141.5 164.66 29.62 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.31 -0.869 . . . . 0.0 109.41 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.44 ' HA ' ' OD1' ' A' ' 54' ' ' ASN . 0.1 OUTLIER -86.9 15.59 5.73 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.9 . . . . 0.0 109.51 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -102.89 -18.51 15.03 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.242 -0.911 . . . . 0.0 109.436 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.453 ' HB2' ' CG1' ' A' ' 56' ' ' VAL . . . -55.55 144.68 52.97 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.2 -0.938 . . . . 0.0 109.329 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.484 ' HG3' ' CB ' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.29 -42.12 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.571 2.181 . . . . 0.0 110.365 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.483 ' CG ' ' OE2' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -101.42 92.8 5.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.901 . . . . 0.0 109.407 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.93 -115.97 4.35 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.465 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 15.2 m-20 -160.02 37.77 0.18 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -1.147 . . . . 0.0 109.412 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.52 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 62.1 mttt -138.54 134.24 33.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.198 -0.938 . . . . 0.0 109.6 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.463 ' O ' HG11 ' A' ' 44' ' ' VAL . 5.9 m -146.53 174.62 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.313 -0.867 . . . . 0.0 109.229 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.58 ' HB2' ' CE2' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -107.46 103.09 12.34 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.101 -1.0 . . . . 0.0 109.181 179.731 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.641 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.17 120.71 25.21 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.034 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.532 ' CG2' HD21 ' A' ' 57' ' ' LEU . 41.5 t -115.79 144.89 22.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.15 -0.969 . . . . 0.0 109.331 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.522 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 19.6 m -108.99 92.75 4.18 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.563 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 52.5 t -90.54 115.73 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.236 -0.915 . . . . 0.0 109.272 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -149.51 56.41 0.98 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.248 -0.908 . . . . 0.0 109.828 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 160.9 90.09 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.53 HG12 ' CA ' ' A' ' 149' ' ' TYR . 2.5 m -80.14 -171.32 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.176 -1.19 . . . . 0.0 109.451 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -139.95 -168.44 11.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -86.21 1.41 50.86 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.233 -1.157 . . . . 0.0 109.569 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.578 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 1.2 m120 -116.33 145.02 34.16 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.241 -0.912 . . . . 0.0 109.284 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.577 ' HG2' ' CZ3' ' A' ' 69' ' ' TRP . 36.4 Cg_endo -79.52 38.88 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.607 2.204 . . . . 0.0 111.197 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.578 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 8.2 p90 -162.58 50.05 0.18 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.968 -1.082 . . . . 0.0 109.807 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.466 ' HA ' ' HB2' ' A' ' 35' ' ' SER . 0.4 OUTLIER -70.94 -64.64 0.86 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.126 -0.984 . . . . 0.0 108.924 179.536 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.534 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 4.1 mp -106.4 128.73 60.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 108.996 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.428 ' OE2' ' HB2' ' A' ' 144' ' ' PRO . 71.3 tt0 -138.26 122.68 18.35 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.843 -1.16 . . . . 0.0 110.195 -179.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.614 ' CB ' ' CZ3' ' A' ' 28' ' ' TRP . . . -113.76 107.41 15.7 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.069 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.46 ' OG1' ' HA ' ' A' ' 144' ' ' PRO . 96.7 m -94.4 165.44 12.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.57 -0.706 . . . . 0.0 110.17 -179.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.437 ' O ' ' HB3' ' A' ' 76' ' ' PHE . . . -119.12 137.78 53.36 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.175 -0.953 . . . . 0.0 108.726 178.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.548 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 0.2 OUTLIER -179.12 161.49 1.0 Allowed Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.561 -0.712 . . . . 0.0 109.165 -179.387 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.548 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.2 Cg_endo -82.46 163.32 74.97 Favored 'Cis proline' 0 C--N 1.311 -1.437 0 C-N-CA 123.81 -1.329 . . . . 0.0 110.893 -0.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.515 HG12 ' CD1' ' A' ' 164' ' ' ILE . 96.8 t -123.99 156.45 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.4 -0.813 . . . . 0.0 108.913 179.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.524 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 52.1 m-20 -121.21 139.8 52.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.115 -0.991 . . . . 0.0 109.854 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.561 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 2.5 m -146.3 -174.0 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.138 -0.976 . . . . 0.0 109.478 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.526 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 0.0 OUTLIER -137.3 146.09 52.52 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.233 -0.917 . . . . 0.0 109.429 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.45 106.14 2.16 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.474 2.116 . . . . 0.0 110.494 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 112.35 -29.7 8.12 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.461 HG13 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.43 149.71 4.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.158 -1.201 . . . . 0.0 109.474 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.462 ' HA ' ' OG1' ' A' ' 133' ' ' THR . 10.8 m -95.47 143.07 27.11 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.561 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 12.0 m-85 -120.61 168.49 11.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.171 -0.956 . . . . 0.0 109.604 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' THR . . . . . 0.478 ' CB ' ' O ' ' A' ' 165' ' ' ALA . 5.2 m -118.15 154.47 32.1 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.26 -0.9 . . . . 0.0 109.561 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.682 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 5.1 t80 -130.56 118.96 21.81 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.298 -0.876 . . . . 0.0 109.319 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.5 HG23 ' N ' ' A' ' 90' ' ' ILE . 31.8 m -134.31 144.04 48.07 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.215 -0.928 . . . . 0.0 109.333 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.505 ' C ' ' CD1' ' A' ' 91' ' ' TRP . 14.9 tt -150.62 163.54 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 120.703 -1.248 . . . . 0.0 109.506 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.505 ' CD1' ' C ' ' A' ' 90' ' ' ILE . 20.1 m95 -132.73 124.98 29.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.974 -1.079 . . . . 0.0 109.342 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.526 ' HB2' ' CG2' ' A' ' 121' ' ' ILE . . . -115.88 150.42 37.08 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.288 -0.883 . . . . 0.0 109.459 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.549 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 1.1 ttt85 -164.4 119.12 1.44 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.309 -0.869 . . . . 0.0 109.027 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.39 170.1 8.12 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 110.065 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -66.12 -55.94 13.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.443 -0.785 . . . . 0.0 109.41 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.514 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -104.43 137.3 42.5 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.222 -0.924 . . . . 0.0 109.463 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.585 ' N ' ' CG2' ' A' ' 123' ' ' THR . 19.2 p-10 -61.64 148.35 42.82 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.308 -0.87 . . . . 0.0 109.562 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 108.9 39.43 1.71 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.471 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -119.55 141.15 49.5 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.14 -1.212 . . . . 0.0 108.98 179.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.463 ' HB ' ' HB2' ' A' ' 151' ' ' ALA . 52.0 t -115.94 148.25 18.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 110.712 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.634 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 25.1 t -150.01 164.96 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.457 -0.777 . . . . 0.0 109.203 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.539 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 16.4 t -136.47 144.33 44.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.011 -1.056 . . . . 0.0 109.457 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.629 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.1 OUTLIER -135.99 104.67 5.78 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.224 -0.923 . . . . 0.0 109.924 -179.726 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.503 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 14.0 p -112.77 168.75 9.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.093 -1.005 . . . . 0.0 110.058 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.572 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -127.83 141.45 46.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 CA-C-O 121.386 0.612 . . . . 0.0 109.837 -179.879 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -167.49 143.9 8.58 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.4 p30 -84.66 -169.79 2.8 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.197 -1.179 . . . . 0.0 109.632 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.52 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 11.2 mp0 -77.84 16.95 0.62 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.196 -0.94 . . . . 0.0 110.683 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.476 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 0.8 OUTLIER -113.23 15.46 19.36 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 120.831 -1.168 . . . . 0.0 108.801 179.447 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.476 ' HB2' ' O ' ' A' ' 109' ' ' SER . 9.8 m-30 67.63 16.86 9.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.504 -0.748 . . . . 0.0 109.599 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.528 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 12.8 mm-40 -93.5 157.66 16.1 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.177 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.462 ' OE1' ' HB ' ' A' ' 104' ' ' THR . 8.0 tt0 -137.83 147.15 44.29 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.034 -1.041 . . . . 0.0 109.99 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.468 ' OH ' ' HB3' ' A' ' 107' ' ' ASN . 4.0 m-85 -112.3 -67.4 1.0 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.567 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -92.35 173.42 35.73 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.475 ' CG ' HG21 ' A' ' 104' ' ' THR . 6.8 ttt-85 -178.78 119.46 0.08 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.08 -1.247 . . . . 0.0 110.217 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.577 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -141.91 70.03 1.33 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.396 -0.815 . . . . 0.0 108.803 179.241 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.54 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 0.2 OUTLIER -86.64 148.07 25.63 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 110.346 -179.265 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 1.2 mt-10 79.42 66.32 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.466 -0.771 . . . . 0.0 109.557 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . 0.465 ' HA ' ' NE2' ' A' ' 119' ' ' GLN . 7.8 mm100 -118.79 123.73 45.51 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.315 -0.866 . . . . 0.0 109.259 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.23 139.14 58.73 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.429 -0.794 . . . . 0.0 108.972 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.526 ' CG2' ' HB2' ' A' ' 92' ' ' ALA . 5.6 mm -125.95 130.17 72.32 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.08 -1.012 . . . . 0.0 110.14 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.04 -179.28 6.17 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.604 0.716 . . . . 0.0 109.949 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.585 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 74.9 p -75.85 -4.19 39.36 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.793 -0.763 . . . . 0.0 109.183 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.445 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 2.8 mt-10 -106.65 -168.78 1.46 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.327 -0.858 . . . . 0.0 109.311 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.549 ' CE2' ' HD3' ' A' ' 93' ' ' ARG . 93.8 m95 -94.38 118.64 31.92 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.208 -0.933 . . . . 0.0 109.691 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -106.88 121.44 44.88 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.289 -0.882 . . . . 0.0 108.985 179.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -79.54 117.05 3.64 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.341 2.027 . . . . 0.0 111.075 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -121.25 138.29 54.3 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.497 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.7 t -151.27 175.81 11.84 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.608 -1.308 . . . . 0.0 111.149 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.682 ' CE2' ' CD1' ' A' ' 88' ' ' TYR . 36.3 p90 -173.22 -172.69 0.84 Allowed 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.095 179.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . 0.412 ' N ' ' CD1' ' A' ' 130' ' ' PHE . 21.7 mt-10 -129.01 155.78 44.86 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.098 -1.001 . . . . 0.0 110.051 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -164.98 139.18 4.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.422 -0.799 . . . . 0.0 109.065 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.462 ' OG1' ' HA ' ' A' ' 85' ' ' THR . 0.8 OUTLIER -117.85 146.19 44.05 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.216 -0.927 . . . . 0.0 109.377 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 4.4 t -44.57 110.49 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.396 -0.815 . . . . 0.0 109.203 179.426 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 65.5 m -61.8 -53.08 60.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.207 -0.933 . . . . 0.0 109.258 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 -102.91 -91.74 0.34 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.359 -0.838 . . . . 0.0 109.218 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.441 ' HA ' HG11 ' A' ' 134' ' ' VAL . 0.5 OUTLIER -162.27 50.59 0.2 Allowed 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.458 -0.776 . . . . 0.0 109.314 179.734 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.466 ' O ' HG23 ' A' ' 80' ' ' VAL . 23.1 mm-40 -88.18 114.63 25.0 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.209 -0.932 . . . . 0.0 109.604 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.6 p -79.19 -12.38 59.97 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.294 -0.879 . . . . 0.0 108.759 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 40.8 t -135.73 134.77 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.391 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.474 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -139.58 172.52 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.194 -0.941 . . . . 0.0 110.057 -179.725 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.476 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.4 ptm180 -145.54 132.54 20.28 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.556 -0.715 . . . . 0.0 109.614 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.572 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -100.24 106.58 42.87 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.292 -0.88 . . . . 0.0 109.655 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.503 ' HD2' ' O ' ' A' ' 104' ' ' THR . 33.7 Cg_endo -76.64 110.56 3.07 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.061 1.841 . . . . 0.0 110.291 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.557 HG12 ' O ' ' A' ' 73' ' ' ALA . 3.2 mm -85.71 124.74 40.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.49 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 6.7 m80 -84.57 150.15 25.41 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.972 -1.08 . . . . 0.0 110.984 -178.158 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.634 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 12.1 m-85 -154.91 157.36 37.66 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.125 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.426 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 108.44 50.67 0.74 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.53 ' CA ' HG12 ' A' ' 64' ' ' VAL . 27.5 m-85 -121.17 159.77 25.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.378 -1.072 . . . . 0.0 109.227 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.78 -30.39 71.03 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.611 -0.681 . . . . 0.0 109.168 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -77.0 -11.0 59.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.394 -0.816 . . . . 0.0 109.108 179.273 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.55 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 3.8 t30 -109.81 11.62 24.28 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.493 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -90.06 164.76 2.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 O-C-N 121.519 -0.738 . . . . 0.0 109.763 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.493 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 53.29 32.7 44.72 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.864 -1.295 . . . . 0.0 109.864 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.7 m-20 -160.53 136.78 8.59 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.137 -1.214 . . . . 0.0 110.04 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.567 HG22 ' CE1' ' A' ' 158' ' ' TYR . 53.6 m -86.83 121.13 28.9 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.01 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.563 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 0.7 OUTLIER -100.86 118.73 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 120.967 -1.083 . . . . 0.0 110.291 -178.775 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.641 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 2.6 m-85 -97.09 129.42 44.51 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 178.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.625 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -120.37 141.99 38.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 120.749 -1.219 . . . . 0.0 110.091 -178.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.464 ' O ' ' HB2' ' A' ' 91' ' ' TRP . 4.5 t70 -173.89 136.41 0.54 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.299 -0.876 . . . . 0.0 108.901 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 124.78 -6.93 8.34 Favored Glycine 0 N--CA 1.486 2.033 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.157 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.582 HD13 ' CE2' ' A' ' 88' ' ' TYR . 0.6 OUTLIER -60.01 94.04 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 O-C-N 120.768 -1.43 . . . . 0.0 108.491 179.899 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . 0.467 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -132.93 145.85 51.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.633 -0.667 . . . . 0.0 109.815 -179.068 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.515 ' CD1' HG12 ' A' ' 78' ' ' VAL . 3.2 mt -123.08 115.65 46.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.235 -0.915 . . . . 0.0 109.202 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.524 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . -142.02 146.69 35.81 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.171 -0.956 . . . . 0.0 109.626 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 4.0 p -84.42 176.58 8.58 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.279 -0.888 . . . . 0.0 109.533 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.424 ' HB2' ' HD2' ' A' ' 168' ' ' PRO . 2.3 pt20 -76.66 159.45 79.21 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.27 -0.894 . . . . 0.0 109.543 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . 0.424 ' HD2' ' HB2' ' A' ' 167' ' ' GLN . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.576 0 C-N-CA 122.674 2.25 . . . . 0.0 110.449 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.489 ' O ' HG13 ' A' ' 3' ' ' VAL . 1.0 OUTLIER -77.38 -23.39 50.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.183 -0.948 . . . . 0.0 109.451 179.992 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.507 HG12 ' N ' ' A' ' 4' ' ' ALA . 1.4 p 43.85 -169.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.359 -0.838 . . . . 0.0 109.553 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.507 ' N ' HG12 ' A' ' 3' ' ' VAL . . . -70.79 -61.19 1.86 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.058 -1.027 . . . . 0.0 109.324 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.473 ' ND2' ' O ' ' A' ' 162' ' ' LEU . 13.0 p-10 -74.92 176.92 6.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.367 -0.833 . . . . 0.0 109.405 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.46 HG22 ' OD1' ' A' ' 7' ' ' ASN . 2.6 mp -128.3 136.83 59.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.286 -0.884 . . . . 0.0 109.717 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.532 ' OD1' ' CB ' ' A' ' 12' ' ' SER . 0.3 OUTLIER 44.92 57.71 4.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.678 179.908 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -56.96 -42.79 92.92 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.481 ' O ' ' HB2' ' A' ' 10' ' ' PHE . . . -107.74 35.62 4.89 Favored Glycine 0 N--CA 1.487 2.088 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.578 ' CZ ' ' HB2' ' A' ' 57' ' ' LEU . 4.1 m-85 63.52 54.73 1.87 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.468 -1.019 . . . . 0.0 109.386 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -82.35 -50.53 8.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.897 . . . . 0.0 109.737 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.532 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 41.3 t -69.9 -42.14 73.77 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.105 -0.997 . . . . 0.0 109.693 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.531 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 0.6 OUTLIER -68.53 125.71 91.99 Favored Pre-proline 0 C--N 1.305 -1.351 0 O-C-N 121.217 -0.927 . . . . 0.0 109.199 -179.882 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.47 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.2 Cg_endo -76.98 146.1 25.53 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 122.462 2.108 . . . . 0.0 111.071 -179.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.47 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -42.05 165.48 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.564 0 CA-C-O 121.214 0.53 . . . . 0.0 109.663 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 130.96 135.27 3.76 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.527 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.57 140.14 15.14 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.34 -1.094 . . . . 0.0 109.029 -179.596 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -84.77 143.67 11.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 CA-C-O 121.763 0.792 . . . . 0.0 110.196 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.4 p -113.56 -27.1 7.99 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.527 ' CB ' ' HG3' ' A' ' 23' ' ' GLU . 20.5 m-20 -133.42 77.83 1.75 Allowed 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.561 HD22 ' CD2' ' A' ' 42' ' ' PHE . 0.5 OUTLIER -44.63 -32.25 1.41 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.323 -0.861 . . . . 0.0 109.708 -179.365 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.528 ' N ' HD11 ' A' ' 21' ' ' LEU . . . -71.11 -47.03 60.44 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.283 -0.885 . . . . 0.0 109.548 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.527 ' HG3' ' CB ' ' A' ' 20' ' ' ASP . 9.1 pt-20 -115.49 38.12 3.36 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.257 -0.902 . . . . 0.0 109.569 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 20' ' ' ASP . . . -106.9 -77.69 1.09 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.575 HG22 ' CD2' ' A' ' 10' ' ' PHE . 5.8 t -92.8 111.0 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.283 -1.128 . . . . 0.0 109.264 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -59.98 -39.86 87.15 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.299 -0.876 . . . . 0.0 109.867 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.455 ' HA3' ' HB2' ' A' ' 7' ' ' ASN . . . -67.56 -35.12 85.86 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.574 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -129.64 126.26 37.98 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.153 -1.204 . . . . 0.0 109.67 -179.797 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -115.54 141.25 48.31 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.531 ' CB ' ' HB2' ' A' ' 21' ' ' LEU . 0.9 OUTLIER -116.29 163.13 16.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.716 -1.24 . . . . 0.0 109.53 -179.548 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 71.8 m-80 -156.18 123.15 5.29 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.518 -0.738 . . . . 0.0 109.402 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.526 HG11 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -102.97 133.84 45.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.342 -0.849 . . . . 0.0 109.514 179.571 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.14 167.34 16.89 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -44.86 -26.16 0.38 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -1.142 . . . . 0.0 109.411 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 37' ' ' THR . 6.8 m -53.08 -53.12 55.0 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.19 -0.944 . . . . 0.0 109.455 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.526 ' CG2' HG11 ' A' ' 32' ' ' VAL . 42.2 t -46.18 94.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.2 -0.938 . . . . 0.0 110.196 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.484 ' N ' ' O ' ' A' ' 35' ' ' SER . 82.9 m -78.25 -27.53 47.6 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.336 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.474 ' O ' HG13 ' A' ' 36' ' ' VAL . 20.1 m-20 -114.9 147.36 38.1 Favored Pre-proline 0 C--N 1.297 -1.696 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.32 111.08 3.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.496 2.131 . . . . 0.0 110.768 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.522 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 36.0 Cg_endo -78.69 167.33 22.63 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.495 2.13 . . . . 0.0 109.684 179.551 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.513 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 51.1 t -110.38 121.89 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.953 -1.092 . . . . 0.0 110.47 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.561 ' CD2' HD22 ' A' ' 21' ' ' LEU . 28.2 m-85 -111.01 112.8 24.87 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 178.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.527 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 29.3 tt0 -151.08 160.8 43.68 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.109 -0.994 . . . . 0.0 109.702 -179.383 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.469 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 49.2 t -102.26 133.48 45.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.434 -0.791 . . . . 0.0 109.133 179.555 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.414 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -111.28 118.7 36.62 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.349 -0.845 . . . . 0.0 109.415 -179.606 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.463 ' OE2' ' HE3' ' A' ' 55' ' ' LYS . 6.1 mt-10 -91.65 109.84 21.16 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 4.8 p -141.67 153.89 44.99 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.544 -0.723 . . . . 0.0 109.41 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 89.3 p -78.85 -10.15 59.7 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.228 -0.92 . . . . 0.0 109.484 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.401 ' O ' ' C ' ' A' ' 50' ' ' ALA . 5.4 m-20 -79.81 -18.17 51.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.191 -0.943 . . . . 0.0 109.536 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.405 ' HB1' HG12 ' A' ' 56' ' ' VAL . . . -45.02 147.65 1.13 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.895 . . . . 0.0 109.544 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.492 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.16 -40.59 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.629 2.219 . . . . 0.0 110.355 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.27 115.57 26.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.52 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.05 -124.54 23.35 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -152.74 22.85 0.59 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.164 -1.198 . . . . 0.0 109.499 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.521 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 8.6 mttt -129.37 143.61 50.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.436 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.455 HG13 ' O ' ' A' ' 55' ' ' LYS . 11.9 m -150.24 175.59 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.347 -0.846 . . . . 0.0 109.004 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.578 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -108.43 99.64 9.01 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.057 -1.027 . . . . 0.0 109.033 179.508 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.614 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.23 119.2 23.32 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.524 HG21 ' CD2' ' A' ' 57' ' ' LEU . 43.7 t -115.68 144.85 22.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.134 -0.979 . . . . 0.0 109.212 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.513 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 9.3 m -108.96 91.69 3.74 Favored 'General case' 0 C--N 1.283 -2.313 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.546 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 48.2 t -89.58 117.41 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.395 -0.815 . . . . 0.0 109.091 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -154.4 58.55 0.7 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.305 -0.872 . . . . 0.0 109.935 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 157.02 84.2 0.05 OUTLIER Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.549 HG11 ' CA ' ' A' ' 149' ' ' TYR . 1.8 m -80.07 -175.85 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.21 -1.171 . . . . 0.0 109.513 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -129.31 -148.52 6.59 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -94.74 -5.89 44.33 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.325 -1.103 . . . . 0.0 109.576 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.568 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 27.8 m-20 -112.74 146.75 35.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.077 -1.014 . . . . 0.0 109.45 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.414 ' O ' ' CE1' ' A' ' 149' ' ' TYR . 36.3 Cg_endo -78.7 12.99 2.02 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.602 2.202 . . . . 0.0 110.931 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.568 ' CZ2' ' OD1' ' A' ' 67' ' ' ASN . 4.2 p90 -133.5 51.86 2.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.035 -1.041 . . . . 0.0 109.659 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.519 ' CA ' HG21 ' A' ' 36' ' ' VAL . 2.6 m-20 -74.24 -64.17 1.08 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.3 -0.875 . . . . 0.0 109.193 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.522 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 2.9 mp -100.22 118.3 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 109.043 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -121.4 127.49 51.23 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.138 -0.976 . . . . 0.0 110.15 -179.565 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.574 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -123.72 108.26 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.26 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.446 HG23 ' C ' ' A' ' 143' ' ' ALA . 86.0 m -104.95 165.76 10.85 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.418 -0.801 . . . . 0.0 109.95 -179.008 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.463 ' O ' ' HB3' ' A' ' 76' ' ' PHE . . . -120.92 140.13 52.27 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.071 -1.018 . . . . 0.0 108.875 178.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.555 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.3 p90 179.53 162.86 0.79 Allowed Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.496 -0.752 . . . . 0.0 109.2 -179.551 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.555 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.8 Cg_endo -82.14 169.31 62.94 Favored 'Cis proline' 0 C--N 1.311 -1.416 0 C-N-CA 123.885 -1.298 . . . . 0.0 110.856 -0.534 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 85.1 t -127.65 156.22 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.388 -0.82 . . . . 0.0 108.891 179.292 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.47 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 16.5 m-80 -123.44 118.66 27.95 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.16 -0.962 . . . . 0.0 109.94 -179.567 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.556 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 3.0 m -124.63 -173.83 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.27 -0.894 . . . . 0.0 109.541 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.531 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 15.3 mmt180 -136.63 144.93 49.14 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.332 -0.855 . . . . 0.0 109.269 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.19 120.57 5.4 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 122.545 2.163 . . . . 0.0 110.618 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 98.21 -27.76 17.81 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.409 HG11 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.06 149.7 4.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.21 -1.171 . . . . 0.0 109.501 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 28.5 m -95.86 133.03 40.49 Favored 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.556 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 7.4 m-85 -111.68 166.76 10.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.896 . . . . 0.0 109.692 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 32.4 m -118.38 154.31 32.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.358 -0.839 . . . . 0.0 109.335 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.69 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 7.6 t80 -129.72 117.98 21.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.159 -0.963 . . . . 0.0 109.548 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.491 HG23 ' N ' ' A' ' 90' ' ' ILE . 18.7 m -135.0 144.26 47.26 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.24 -0.912 . . . . 0.0 109.186 179.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.57 HD13 ' CD1' ' A' ' 103' ' ' PHE . 14.4 tt -150.49 163.78 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 120.817 -1.177 . . . . 0.0 109.562 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.505 ' CD1' ' C ' ' A' ' 90' ' ' ILE . 19.8 m95 -132.73 125.99 31.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.062 -1.024 . . . . 0.0 109.303 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -117.08 151.81 36.01 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.359 -0.838 . . . . 0.0 109.487 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.545 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 8.5 ttp85 -164.14 118.49 1.47 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.188 -0.945 . . . . 0.0 109.188 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -105.37 160.93 14.74 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.301 -0.874 . . . . 0.0 109.951 -179.522 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -58.95 -48.56 81.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.417 -0.802 . . . . 0.0 109.289 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.517 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 2.0 mt-30 -113.91 142.16 46.47 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.273 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.579 ' N ' ' CG2' ' A' ' 123' ' ' THR . 28.4 p-10 -65.14 146.16 55.34 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.23 -0.919 . . . . 0.0 109.485 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 110.91 38.3 1.57 Allowed Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.467 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -120.45 140.66 51.07 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.257 -1.143 . . . . 0.0 109.082 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.516 HG12 ' N ' ' A' ' 101' ' ' VAL . 55.5 t -116.14 145.27 22.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.224 -0.922 . . . . 0.0 110.766 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.568 HG11 ' CE2' ' A' ' 147' ' ' PHE . 39.0 t -143.05 165.86 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.569 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.539 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 4.1 m -123.25 126.22 46.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.069 -1.019 . . . . 0.0 109.9 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.57 ' CD1' HD13 ' A' ' 90' ' ' ILE . 66.8 m-85 -116.79 103.45 10.34 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.028 -1.045 . . . . 0.0 109.322 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.504 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 17.8 p -128.11 164.73 21.8 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.011 -1.055 . . . . 0.0 110.691 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.62 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -129.7 155.95 41.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-O 121.213 0.53 . . . . 0.0 109.964 -179.934 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.521 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -174.11 -173.81 40.47 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.2 p30 -131.24 -169.56 2.2 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.152 -1.205 . . . . 0.0 109.45 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.52 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 3.5 mp0 -68.34 3.81 1.58 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.098 -1.002 . . . . 0.0 111.336 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.475 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 1.4 m -107.1 14.87 25.83 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 120.661 -1.274 . . . . 0.0 109.239 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.475 ' HB2' ' O ' ' A' ' 109' ' ' SER . 13.7 m-30 67.04 7.84 5.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.447 -0.783 . . . . 0.0 109.609 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.521 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 24.4 tt0 -80.07 158.32 26.47 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 4.2 tt0 -136.15 136.5 40.09 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.028 -1.045 . . . . 0.0 110.012 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.573 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 7.3 m-85 -96.17 -70.74 0.7 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.412 -0.805 . . . . 0.0 108.875 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.567 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -81.92 156.48 36.3 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 179.5 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.7 ttt180 -153.36 106.94 3.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.057 -1.261 . . . . 0.0 110.258 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.558 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -146.12 70.0 1.22 Allowed 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.146 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.539 ' CB ' ' HB3' ' A' ' 102' ' ' SER . 2.1 p-80 -107.85 160.71 15.53 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.252 -0.905 . . . . 0.0 110.048 -179.449 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 16.5 tt0 77.28 58.56 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.361 -0.837 . . . . 0.0 109.469 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 4.0 mm-40 -130.14 136.98 49.88 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.315 -0.866 . . . . 0.0 109.501 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -70.88 156.28 39.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.472 -0.768 . . . . 0.0 109.065 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.467 HG21 HD13 ' A' ' 121' ' ' ILE . 6.0 mm -133.49 135.67 55.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.148 -0.97 . . . . 0.0 109.873 -179.455 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -82.74 -179.34 7.4 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.672 0.749 . . . . 0.0 110.001 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.579 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 63.7 p -78.45 -1.59 34.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.511 -0.743 . . . . 0.0 109.307 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.414 ' C ' ' HG3' ' A' ' 93' ' ' ARG . 2.5 mt-10 -108.42 -168.87 1.41 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.184 -0.947 . . . . 0.0 109.397 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.545 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 95.5 m95 -95.26 121.15 36.61 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.206 -0.934 . . . . 0.0 109.688 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -106.84 121.02 46.3 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.261 -0.899 . . . . 0.0 108.935 179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.25 107.39 2.03 Favored 'Trans proline' 0 C--N 1.311 -1.416 0 C-N-CA 122.456 2.104 . . . . 0.0 111.064 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -111.0 135.5 51.41 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 178.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.493 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.8 t -151.13 175.74 11.85 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 120.701 -1.25 . . . . 0.0 111.078 -179.187 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.69 ' CE2' ' CG ' ' A' ' 88' ' ' TYR . 33.8 p90 -171.89 -177.64 1.99 Allowed 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.192 179.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -127.92 151.11 49.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.191 -0.943 . . . . 0.0 109.757 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.573 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.07 168.15 17.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.44 -0.788 . . . . 0.0 109.255 179.841 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -138.69 147.74 43.13 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.5 -179.663 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.531 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 6.0 t -40.43 110.33 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.607 -0.683 . . . . 0.0 109.367 179.663 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 27.8 m -59.95 -51.58 69.05 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.283 -0.885 . . . . 0.0 109.255 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -106.74 -90.87 0.42 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.384 -0.823 . . . . 0.0 109.213 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.451 ' HA ' HG12 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -163.98 53.97 0.15 Allowed 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.478 -0.764 . . . . 0.0 109.058 179.748 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.483 ' O ' ' CG2' ' A' ' 80' ' ' VAL . 31.6 mm-40 -91.67 113.22 25.43 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.188 -0.945 . . . . 0.0 109.791 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.5 p -79.44 -14.07 59.17 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.275 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.3 t -134.01 132.07 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.464 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -141.59 171.92 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.164 -0.96 . . . . 0.0 110.051 -179.608 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.503 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 2.9 ptm180 -143.76 133.12 23.28 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.624 -0.673 . . . . 0.0 109.263 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.62 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -94.44 108.62 37.82 Favored Pre-proline 0 N--CA 1.487 1.384 0 O-C-N 121.302 -0.874 . . . . 0.0 109.897 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.504 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.4 Cg_endo -76.74 113.49 3.66 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.16 1.907 . . . . 0.0 110.847 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.514 ' N ' ' CD1' ' A' ' 145' ' ' ILE . 1.7 mm -97.26 141.66 15.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 178.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 147' ' ' PHE . 6.2 m80 -105.28 158.32 16.69 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.55 -1.344 . . . . 0.0 111.691 -177.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.644 ' CE2' ' CD1' ' A' ' 159' ' ' ILE . 20.9 m-85 -160.81 158.2 28.05 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.132 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.466 ' O ' HG11 ' A' ' 64' ' ' VAL . . . 108.13 43.8 1.25 Allowed Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.549 ' CA ' HG11 ' A' ' 64' ' ' VAL . 61.5 m-85 -117.06 161.42 19.44 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.421 -1.047 . . . . 0.0 109.111 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.52 -29.4 69.48 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.467 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -76.61 -10.52 59.45 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 109.179 179.269 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.575 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 1.5 t30 -109.74 12.3 24.15 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.365 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -89.15 164.22 2.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 O-C-N 121.551 -0.718 . . . . 0.0 109.784 -179.173 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.492 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.39 32.61 37.98 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.7 m-20 -160.49 136.82 8.65 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.139 -1.212 . . . . 0.0 110.111 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.581 HG23 ' CZ ' ' A' ' 158' ' ' TYR . 55.3 m -87.59 120.94 29.41 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.575 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.8 OUTLIER -99.63 117.58 44.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 120.75 -1.219 . . . . 0.0 110.327 -178.781 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.614 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 12.2 m-85 -98.01 135.78 39.21 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 178.447 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.644 ' CD1' ' CE2' ' A' ' 147' ' ' PHE . 1.3 mt -128.16 141.15 47.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 120.768 -1.207 . . . . 0.0 110.44 -178.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.467 ' HA ' ' HA2' ' A' ' 9' ' ' GLY . 0.7 OUTLIER -173.8 136.34 0.55 Allowed 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.348 -0.845 . . . . 0.0 108.837 179.633 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 125.19 -8.23 8.0 Favored Glycine 0 N--CA 1.487 2.066 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.366 179.577 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.639 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 4.4 tp -60.2 100.64 0.1 Allowed 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.742 -1.446 . . . . 0.0 108.944 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -133.24 145.75 50.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.455 -0.778 . . . . 0.0 109.778 -179.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.469 ' HA ' ' O ' ' A' ' 87' ' ' THR . 4.4 mp -126.8 109.07 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.288 -0.882 . . . . 0.0 109.425 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.466 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -156.1 150.49 25.69 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.171 -0.956 . . . . 0.0 109.637 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 8.5 t -74.78 -43.68 53.52 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.513 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -135.46 92.06 17.89 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.219 -0.926 . . . . 0.0 109.516 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo . . . . . 0 C--N 1.309 -1.545 0 C-N-CA 122.627 2.218 . . . . 0.0 110.403 179.995 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 57.4 mt -109.94 157.15 19.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.243 -0.911 . . . . 0.0 109.516 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.46 HG22 ' HB1' ' A' ' 165' ' ' ALA . 4.2 p -104.06 173.06 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.262 -0.899 . . . . 0.0 109.386 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.518 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -71.64 -59.41 2.77 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.187 -0.945 . . . . 0.0 109.453 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 162' ' ' LEU . 47.4 t-20 -71.26 128.93 37.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.481 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.456 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 2.2 mp -107.7 138.53 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.273 -0.892 . . . . 0.0 109.518 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.523 ' OD1' ' CB ' ' A' ' 12' ' ' SER . 1.0 OUTLIER 66.97 17.31 10.5 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.242 -0.911 . . . . 0.0 109.638 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -61.52 -35.56 91.28 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.524 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -103.59 28.01 17.33 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.578 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 6.5 m-85 50.65 48.03 23.35 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.365 -1.079 . . . . 0.0 109.412 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.438 ' OE1' ' O ' ' A' ' 52' ' ' GLU . 5.6 mm-40 -83.68 -35.81 24.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.236 -0.915 . . . . 0.0 109.67 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.523 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.6 OUTLIER -84.8 -24.81 28.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.234 -0.916 . . . . 0.0 109.663 -179.759 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.541 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 0.7 OUTLIER -78.48 121.57 83.87 Favored Pre-proline 0 N--CA 1.486 1.352 0 O-C-N 121.185 -0.947 . . . . 0.0 109.292 -179.896 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 15' ' ' ALA . 36.1 Cg_endo -77.61 138.95 17.64 Favored 'Trans proline' 0 C--N 1.312 -1.36 0 C-N-CA 122.469 2.112 . . . . 0.0 110.754 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.517 ' HA ' ' CG1' ' A' ' 44' ' ' VAL . . . -41.59 163.53 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.71 137.38 4.45 Favored Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.519 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.23 141.52 12.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.325 -1.103 . . . . 0.0 109.079 -179.688 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.465 HG13 ' HA3' ' A' ' 24' ' ' GLY . 46.1 t -85.69 145.65 7.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 CA-C-O 121.695 0.759 . . . . 0.0 109.921 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 4.1 p -106.36 -22.3 12.85 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -143.94 92.63 2.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.439 -0.788 . . . . 0.0 109.085 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.531 ' HB2' ' CB ' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -49.41 -33.19 13.26 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.293 -0.88 . . . . 0.0 109.899 -179.339 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.527 ' N ' HD13 ' A' ' 21' ' ' LEU . . . -59.66 -43.6 93.89 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.165 -0.959 . . . . 0.0 109.514 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -118.12 35.74 4.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.252 -0.905 . . . . 0.0 109.336 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.465 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -87.18 -71.8 1.29 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.541 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 2.0 t -95.96 123.63 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -1.173 . . . . 0.0 109.209 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -56.38 -32.28 64.63 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.421 -0.8 . . . . 0.0 109.854 -179.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.488 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -102.33 -3.45 50.7 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.94 -1.124 . . . . 0.0 110.305 -179.35 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.562 ' CE3' ' HB2' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -139.77 121.65 15.53 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.932 -1.334 . . . . 0.0 109.877 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.556 ' OD1' ' CE2' ' A' ' 76' ' ' PHE . 1.2 m-20 -121.38 143.12 49.39 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.549 HD12 ' CD1' ' A' ' 42' ' ' PHE . 0.9 OUTLIER -113.25 162.46 15.99 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.781 -1.199 . . . . 0.0 109.439 -179.601 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -152.84 121.17 6.28 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.424 -0.797 . . . . 0.0 109.522 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.527 HG12 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.05 135.2 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.4 -0.812 . . . . 0.0 109.675 179.638 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.49 -170.99 25.75 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.04 -4.58 25.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.249 -1.148 . . . . 0.0 109.505 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.465 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 16.0 m -74.11 -31.87 62.96 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.942 . . . . 0.0 109.625 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.527 ' CG2' HG12 ' A' ' 32' ' ' VAL . 2.1 t -67.68 89.46 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 O-C-N 121.132 -0.98 . . . . 0.0 109.364 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 30.4 m -59.74 -28.69 67.58 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.199 -0.938 . . . . 0.0 108.713 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.467 ' O ' HG11 ' A' ' 36' ' ' VAL . 6.5 m-20 -130.88 130.4 22.83 Favored Pre-proline 0 C--N 1.296 -1.753 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.21 123.11 6.46 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.189 1.926 . . . . 0.0 110.55 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.576 ' HG2' ' CZ ' ' A' ' 42' ' ' PHE . 35.4 Cg_endo -77.46 -165.74 0.35 Allowed 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.366 2.044 . . . . 0.0 110.013 179.695 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 53.7 t -116.73 121.43 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.116 -0.99 . . . . 0.0 110.458 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.576 ' CZ ' ' HG2' ' A' ' 40' ' ' PRO . 28.0 m-85 -105.11 112.38 25.49 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.519 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 29.2 tt0 -154.56 159.32 40.83 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.194 -0.941 . . . . 0.0 109.857 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.517 ' CG1' ' HA ' ' A' ' 15' ' ' ALA . 89.1 t -95.2 140.59 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.476 -0.765 . . . . 0.0 109.017 179.277 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 45' ' ' LEU . 0.4 OUTLIER -119.38 120.51 37.12 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.327 -0.858 . . . . 0.0 109.793 -179.32 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -77.35 109.83 11.58 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 121.54 0.686 . . . . 0.0 109.152 179.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.7 p -128.64 129.89 46.49 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.606 -0.684 . . . . 0.0 109.527 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.2 m -72.41 -12.56 61.16 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.239 -0.913 . . . . 0.0 109.397 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.41 ' O ' ' C ' ' A' ' 50' ' ' ALA . 49.7 m-20 -98.4 2.08 47.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.214 -0.929 . . . . 0.0 109.612 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.41 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.31 155.18 0.37 Allowed Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.103 -0.998 . . . . 0.0 109.443 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.521 ' CB ' ' HB2' ' A' ' 91' ' ' TRP . 35.9 Cg_endo -77.91 -35.97 1.25 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.599 2.199 . . . . 0.0 110.335 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.438 ' O ' ' OE1' ' A' ' 11' ' ' GLU . 4.9 tt0 -121.28 97.01 5.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.268 -0.895 . . . . 0.0 109.35 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.8 -115.16 4.07 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -156.63 35.64 0.31 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.226 -1.161 . . . . 0.0 109.405 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 33.0 mttm -145.5 131.1 18.85 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -0.899 . . . . 0.0 109.505 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.472 HG11 ' OD2' ' A' ' 160' ' ' ASP . 3.9 m -139.72 175.36 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.381 -0.825 . . . . 0.0 109.326 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.578 ' HB2' ' CE2' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -101.79 100.46 10.81 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.063 -1.023 . . . . 0.0 108.776 179.306 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.58 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.33 118.21 22.46 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.068 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.532 ' HA ' ' O ' ' A' ' 41' ' ' VAL . 49.3 t -114.9 144.61 22.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.113 -0.992 . . . . 0.0 109.17 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.515 ' N ' HG13 ' A' ' 59' ' ' VAL . 31.9 m -107.12 93.64 4.66 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.571 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 59.9 t -87.93 123.47 40.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.253 -0.905 . . . . 0.0 109.334 -179.69 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -160.11 60.34 0.35 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.379 -0.825 . . . . 0.0 109.77 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 156.38 89.24 0.07 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.516 HG13 ' CA ' ' A' ' 149' ' ' TYR . 2.4 m -81.06 -177.14 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.218 -1.166 . . . . 0.0 109.674 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -130.99 -161.61 10.34 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -95.99 12.54 30.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -1.119 . . . . 0.0 109.545 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.501 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.9 m-80 -128.33 148.35 67.52 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.194 -0.941 . . . . 0.0 109.508 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.499 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.2 Cg_endo -78.25 11.88 2.24 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.63 2.22 . . . . 0.0 110.963 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.501 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -136.36 58.33 1.74 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.113 -0.992 . . . . 0.0 109.623 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.459 ' OD2' ' O ' ' A' ' 148' ' ' GLY . 0.7 OUTLIER -83.11 -69.18 0.65 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.204 -0.935 . . . . 0.0 109.248 179.825 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.526 ' CD1' ' HG3' ' A' ' 40' ' ' PRO . 4.1 mt -105.94 121.76 58.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.277 -0.89 . . . . 0.0 108.979 179.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -130.17 132.89 46.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.098 -1.001 . . . . 0.0 110.224 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.562 ' HB2' ' CE3' ' A' ' 28' ' ' TRP . . . -121.82 108.47 13.51 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.456 ' OG1' ' HA ' ' A' ' 144' ' ' PRO . 98.3 m -100.2 165.0 11.71 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.386 -0.821 . . . . 0.0 110.006 -179.029 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.452 ' O ' ' HB3' ' A' ' 76' ' ' PHE . . . -118.92 136.42 54.08 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.022 -1.049 . . . . 0.0 108.768 178.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.556 ' CE2' ' OD1' ' A' ' 29' ' ' ASP . 10.1 p90 179.44 160.44 0.76 Allowed Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.585 -0.697 . . . . 0.0 109.276 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.545 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.9 Cg_endo -81.67 164.96 74.89 Favored 'Cis proline' 0 C--N 1.31 -1.465 0 C-N-CA 123.782 -1.341 . . . . 0.0 110.801 -0.495 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.529 HG11 ' CD1' ' A' ' 164' ' ' ILE . 89.1 t -126.81 156.14 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.344 -0.848 . . . . 0.0 109.107 179.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.518 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 4.3 m-80 -112.43 145.79 39.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.075 -1.016 . . . . 0.0 109.666 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.577 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 1.1 m -153.32 -173.85 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.174 -0.954 . . . . 0.0 109.467 179.749 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.519 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 20.5 mtt180 -136.21 146.01 54.5 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.288 -0.883 . . . . 0.0 109.352 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.459 ' HB3' ' HB3' ' A' ' 137' ' ' GLN . 35.6 Cg_endo -77.82 112.09 3.23 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.511 2.141 . . . . 0.0 110.463 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 100.44 -22.97 37.59 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.575 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -84.12 149.65 4.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.191 -1.182 . . . . 0.0 109.482 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.3 m -92.42 140.48 29.53 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.577 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 18.3 m-85 -123.05 164.88 17.75 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.25 -0.906 . . . . 0.0 109.578 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' THR . . . . . 0.459 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 6.1 m -118.35 154.31 32.57 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.398 -0.814 . . . . 0.0 109.51 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.692 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.7 t80 -126.87 120.1 28.4 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.145 -0.972 . . . . 0.0 109.38 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.487 ' O ' ' O ' ' A' ' 161' ' ' GLY . 32.3 m -134.53 142.79 47.11 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.244 -0.91 . . . . 0.0 109.11 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.534 HD12 ' CD2' ' A' ' 103' ' ' PHE . 19.8 tt -150.9 163.45 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.603 -1.311 . . . . 0.0 109.628 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.521 ' HB2' ' CB ' ' A' ' 51' ' ' PRO . 20.3 m95 -132.14 128.62 38.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.976 -1.078 . . . . 0.0 109.385 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.413 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -119.53 148.13 43.65 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.222 -0.924 . . . . 0.0 109.582 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.575 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 8.3 ttp180 -161.02 120.22 2.58 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.162 -0.961 . . . . 0.0 109.15 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -107.07 161.7 14.52 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 110.02 -179.591 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -61.06 -51.18 70.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.377 -0.827 . . . . 0.0 109.319 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.485 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -108.45 137.74 45.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.339 -0.85 . . . . 0.0 109.355 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.582 ' N ' ' CG2' ' A' ' 123' ' ' THR . 5.1 p30 -63.08 146.85 52.36 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.273 -0.892 . . . . 0.0 109.559 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 109.06 38.66 1.8 Allowed Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -119.15 141.36 48.9 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.234 -1.157 . . . . 0.0 109.063 179.601 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.448 ' HB ' ' HB3' ' A' ' 151' ' ' ALA . 54.9 t -116.78 149.88 18.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.277 -0.889 . . . . 0.0 110.636 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.585 HG12 ' CE2' ' A' ' 147' ' ' PHE . 51.9 t -151.14 164.71 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.538 -0.726 . . . . 0.0 109.051 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.526 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 3.8 t -127.92 138.05 52.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.989 -1.07 . . . . 0.0 109.687 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.622 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.0 OUTLIER -130.6 103.86 6.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.086 -1.009 . . . . 0.0 109.807 -179.969 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.504 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 11.6 p -119.43 164.86 15.11 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.091 -1.005 . . . . 0.0 110.064 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -125.67 152.55 32.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.69 -0.631 . . . . 0.0 109.998 -179.734 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.462 ' O ' ' HG2' ' A' ' 142' ' ' ARG . . . 176.46 147.71 6.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.214 -1.555 . . . . 0.0 109.214 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.3 p30 -90.3 -169.59 2.46 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.018 -1.283 . . . . 0.0 109.51 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.518 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 4.1 mp0 -71.1 8.0 1.08 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.184 -0.947 . . . . 0.0 111.245 -179.123 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.47 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 3.7 t -110.52 10.27 23.14 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.712 -1.243 . . . . 0.0 109.215 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.538 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 3.2 m-30 71.87 6.08 5.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.412 -0.805 . . . . 0.0 109.689 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -78.89 95.12 5.34 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 108.672 179.399 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.524 ' CG ' ' O ' ' A' ' 105' ' ' VAL . 1.3 tt0 -83.47 139.69 32.78 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.278 -0.889 . . . . 0.0 110.259 -179.099 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.482 ' N ' ' HG2' ' A' ' 112' ' ' GLU . 3.9 m-85 -102.78 -69.88 0.78 Allowed 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.576 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -85.77 166.17 39.11 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.021 -1.632 . . . . 0.0 109.021 179.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.433 ' NE ' ' OE1' ' A' ' 112' ' ' GLU . 1.2 tpp180 -164.42 109.65 0.99 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.948 -1.325 . . . . 0.0 110.326 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.577 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -142.53 69.88 1.32 Allowed 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.061 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.546 ' CD2' ' O ' ' A' ' 117' ' ' HIS . 0.5 OUTLIER -99.11 152.56 19.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.335 -0.853 . . . . 0.0 110.149 -179.31 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.542 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.3 tt0 79.33 68.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -0.787 . . . . 0.0 109.706 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . 0.431 ' HG2' ' C ' ' A' ' 118' ' ' GLU . 1.1 mm-40 -133.42 130.96 39.4 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.293 -0.879 . . . . 0.0 109.475 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 4.8 mt-30 -67.66 153.81 42.88 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.327 -0.858 . . . . 0.0 109.006 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.449 HG12 ' O ' ' A' ' 99' ' ' ALA . 8.1 mm -134.8 135.73 52.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.094 -1.003 . . . . 0.0 110.089 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.32 -179.16 6.91 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.637 0.732 . . . . 0.0 110.067 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.582 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 47.2 p -76.37 -2.48 32.01 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.416 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.426 ' C ' ' HG3' ' A' ' 93' ' ' ARG . 3.9 mm-40 -107.67 -169.0 1.45 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.361 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.575 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 97.1 m95 -95.83 122.6 38.79 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.201 -0.937 . . . . 0.0 109.604 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -106.93 121.39 45.03 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.272 -0.892 . . . . 0.0 108.941 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -80.1 109.48 2.37 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.451 2.1 . . . . 0.0 110.895 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -114.34 136.64 52.76 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.494 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.7 t -151.27 175.85 11.8 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 120.685 -1.259 . . . . 0.0 111.152 -179.252 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.692 ' CE2' ' CG ' ' A' ' 88' ' ' TYR . 37.7 p90 -173.41 -172.61 0.81 Allowed 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.819 -1.082 . . . . 0.0 109.221 179.22 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -127.95 156.96 41.83 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.075 -1.016 . . . . 0.0 110.009 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.571 ' CZ ' ' HB2' ' A' ' 86' ' ' TYR . 11.1 p90 -161.23 168.06 24.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.391 -0.818 . . . . 0.0 109.191 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.92 146.2 38.91 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.145 -0.972 . . . . 0.0 109.224 -179.761 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.519 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 2.2 t -62.38 112.95 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.257 -0.902 . . . . 0.0 109.392 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 5.8 t -86.51 -40.48 15.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.401 -0.812 . . . . 0.0 109.85 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.56 ' O ' ' CB ' ' A' ' 137' ' ' GLN . 17.5 t70 -87.63 -16.22 35.06 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.445 -0.784 . . . . 0.0 109.432 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.56 ' CB ' ' O ' ' A' ' 136' ' ' ASP . 2.3 mt-30 86.97 27.28 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -178.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.508 ' HG3' ' ND2' ' A' ' 107' ' ' ASN . 12.5 mm-40 -68.94 122.44 18.65 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.609 -0.682 . . . . 0.0 109.732 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 5.8 p -79.12 -6.97 57.74 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 42.4 t -138.14 138.38 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.364 -0.835 . . . . 0.0 108.824 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.467 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.6 OUTLIER -143.27 172.23 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.121 -0.987 . . . . 0.0 109.904 -179.705 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.476 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.2 ptm180 -146.76 132.52 18.95 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.463 -0.773 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.594 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -99.66 106.95 43.29 Favored Pre-proline 0 C--N 1.303 -1.421 0 O-C-N 121.21 -0.931 . . . . 0.0 109.879 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.504 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.9 Cg_endo -76.79 110.74 3.1 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.113 1.875 . . . . 0.0 110.688 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.536 HG12 ' O ' ' A' ' 73' ' ' ALA . 2.0 mm -91.25 140.15 16.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 178.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.54 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 5.9 m80 -107.7 157.86 17.76 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.542 -1.349 . . . . 0.0 111.897 -177.46 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.64 ' CZ ' ' CD1' ' A' ' 159' ' ' ILE . 30.6 m-85 -158.12 160.98 37.88 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 179.013 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.459 ' O ' ' OD2' ' A' ' 70' ' ' ASP . . . 116.77 40.79 0.75 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.516 ' CA ' HG13 ' A' ' 64' ' ' VAL . 15.1 m-85 -122.08 159.37 27.23 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.381 -1.07 . . . . 0.0 109.311 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.21 -26.71 67.51 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -179.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.458 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -69.91 -15.28 63.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.436 -0.79 . . . . 0.0 109.269 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.52 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.3 OUTLIER -110.85 8.31 22.22 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 179.366 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.455 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.3 t -83.33 162.57 3.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 121.424 -0.797 . . . . 0.0 109.7 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.455 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 50.63 33.47 26.37 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 1.8 m-20 -160.18 139.44 10.88 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.258 -1.143 . . . . 0.0 109.976 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.576 HG22 ' CZ ' ' A' ' 158' ' ' TYR . 97.7 m -89.32 128.04 35.85 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.205 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.571 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 1.4 mt -108.96 118.83 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.873 -1.142 . . . . 0.0 109.969 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.58 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 8.7 m-85 -100.55 137.77 38.51 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 178.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.64 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -129.34 141.64 46.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 120.777 -1.202 . . . . 0.0 110.381 -178.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 161' ' ' GLY . 49.7 t0 -173.82 136.01 0.53 Allowed 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.5 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.533 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 127.13 -9.02 7.08 Favored Glycine 0 N--CA 1.485 1.915 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.258 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.633 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 1.2 tp -59.43 91.29 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.811 -1.405 . . . . 0.0 108.583 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . 0.459 ' N ' ' O ' ' A' ' 161' ' ' GLY . . . -131.06 146.03 52.23 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.605 -0.685 . . . . 0.0 109.86 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.529 ' CD1' HG11 ' A' ' 78' ' ' VAL . 23.4 mt -126.16 131.47 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.325 -0.86 . . . . 0.0 109.217 179.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.46 ' HB1' HG22 ' A' ' 3' ' ' VAL . . . -158.55 147.53 18.93 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.202 -0.936 . . . . 0.0 109.677 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 3.1 p -73.68 166.5 23.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.295 -0.878 . . . . 0.0 109.528 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.407 ' CD ' ' O ' ' A' ' 167' ' ' GLN . 0.6 OUTLIER -145.47 89.87 6.18 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.277 -0.889 . . . . 0.0 109.402 179.893 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.555 0 C-N-CA 122.652 2.235 . . . . 0.0 110.422 179.985 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.2 tmt? . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 1.6 mp -121.99 131.84 54.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -0.907 . . . . 0.0 109.581 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.532 ' CG1' ' O ' ' A' ' 5' ' ' ASN . 4.6 p -109.86 174.58 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.288 -0.882 . . . . 0.0 109.307 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.521 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -63.09 -53.78 48.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.107 -0.996 . . . . 0.0 109.732 -179.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.532 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 3.9 t-20 -84.09 149.86 25.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.293 -0.879 . . . . 0.0 109.7 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.471 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 3.7 mt -128.13 129.79 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.358 -0.839 . . . . 0.0 109.157 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.549 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 1.5 m120 65.84 35.1 6.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.203 -0.936 . . . . 0.0 109.59 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.476 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -44.99 -25.73 1.04 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.461 ' HA3' ' OD2' ' A' ' 160' ' ' ASP . . . -145.82 44.93 0.83 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.585 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 4.2 m-85 61.32 51.65 4.16 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.167 -1.196 . . . . 0.0 109.443 179.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.445 ' OE2' ' OD2' ' A' ' 160' ' ' ASP . 62.0 mm-40 -84.34 -27.61 27.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.136 -0.977 . . . . 0.0 109.79 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.504 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 7.9 t -99.75 -13.65 19.19 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.178 -0.951 . . . . 0.0 110.149 -179.361 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.532 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 1.2 m -100.25 133.39 21.49 Favored Pre-proline 0 N--CA 1.489 1.475 0 O-C-N 121.052 -1.03 . . . . 0.0 109.423 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.476 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.5 Cg_endo -77.3 148.37 26.82 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 122.522 2.148 . . . . 0.0 110.84 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.476 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -42.11 166.0 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 121.317 0.579 . . . . 0.0 109.773 179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.09 132.54 3.01 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.529 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -56.55 144.63 8.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.268 -1.136 . . . . 0.0 109.218 -179.367 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.7 t -85.12 144.51 9.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.687 0.756 . . . . 0.0 110.043 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.9 p -106.59 -23.77 12.36 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.458 ' O ' ' N ' ' A' ' 24' ' ' GLY . 0.4 OUTLIER -145.99 88.21 1.8 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.478 -0.764 . . . . 0.0 108.966 179.759 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.526 ' CB ' ' HB2' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -43.46 -32.08 0.82 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 109.624 -179.464 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.521 ' N ' HD11 ' A' ' 21' ' ' LEU . . . -65.42 -49.09 70.49 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.351 -0.843 . . . . 0.0 109.456 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -125.51 43.78 2.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.434 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 20' ' ' ASP . . . -91.86 -66.7 1.13 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.579 ' HB ' ' CE2' ' A' ' 10' ' ' PHE . 41.3 t -120.63 128.66 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.207 -1.172 . . . . 0.0 109.618 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . 0.451 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 13.7 tt0 -67.25 139.38 57.33 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.879 . . . . 0.0 109.606 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.549 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 109.29 -33.78 5.91 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.511 ' CZ3' ' HB3' ' A' ' 73' ' ' ALA . 1.2 m95 -140.5 119.98 13.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.191 -1.182 . . . . 0.0 109.454 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -115.98 144.17 44.45 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.526 ' HB2' ' CB ' ' A' ' 21' ' ' LEU . 2.1 mt -118.95 168.03 11.18 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.723 -1.235 . . . . 0.0 109.603 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 70.5 m-20 -160.09 123.75 3.61 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.382 -0.824 . . . . 0.0 109.575 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.46 HG13 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -106.47 136.56 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.337 -0.852 . . . . 0.0 109.743 179.678 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.69 176.16 24.86 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.4 t -58.98 -15.65 14.14 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.18 -1.188 . . . . 0.0 109.418 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.461 ' HB2' ' OD1' ' A' ' 70' ' ' ASP . 7.9 p -63.81 -37.17 86.39 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.243 -0.91 . . . . 0.0 109.636 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.523 ' CG2' ' HB3' ' A' ' 70' ' ' ASP . 2.1 t -67.35 88.55 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 O-C-N 121.144 -0.973 . . . . 0.0 109.194 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 50.1 m -63.41 -28.64 70.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.326 -0.859 . . . . 0.0 108.997 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.486 ' O ' HG13 ' A' ' 36' ' ' VAL . 0.5 OUTLIER -120.92 130.1 25.0 Favored Pre-proline 0 C--N 1.296 -1.721 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.755 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -76.51 121.83 6.19 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.188 1.926 . . . . 0.0 110.524 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.583 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.4 Cg_endo -77.44 -169.93 0.84 Allowed 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.443 2.096 . . . . 0.0 109.865 179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.511 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 53.2 t -114.53 119.4 61.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.092 -1.005 . . . . 0.0 110.586 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.583 ' CE1' ' HG2' ' A' ' 40' ' ' PRO . 2.9 m-85 -104.35 112.34 25.34 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 178.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.529 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 0.0 OUTLIER -157.9 148.58 20.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.052 -1.03 . . . . 0.0 109.962 -179.354 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.575 HG23 ' CE2' ' A' ' 10' ' ' PHE . 2.0 t -92.55 148.68 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.379 -0.825 . . . . 0.0 109.398 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.548 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -133.43 147.45 51.72 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.284 -0.885 . . . . 0.0 108.713 179.931 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.548 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 15.3 pt-20 -121.17 120.41 35.16 Favored 'General case' 0 C--N 1.296 -1.758 0 O-C-N 121.526 -0.734 . . . . 0.0 109.296 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.5 p -144.0 -175.97 4.81 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.44 -0.787 . . . . 0.0 109.483 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -101.02 22.4 12.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.908 . . . . 0.0 109.433 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.7 -14.33 12.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.913 . . . . 0.0 109.481 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.45 144.53 62.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.18 -0.95 . . . . 0.0 109.327 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.525 ' HG3' ' CB ' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -78.44 -42.1 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.617 2.211 . . . . 0.0 110.388 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.406 ' O ' ' OE1' ' A' ' 11' ' ' GLU . 40.6 mm-40 -105.43 97.22 7.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.246 -0.909 . . . . 0.0 109.382 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.48 -117.75 4.71 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.456 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 13.5 p30 -160.09 38.62 0.18 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.226 -1.161 . . . . 0.0 109.542 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.468 ' O ' ' OD2' ' A' ' 160' ' ' ASP . 92.0 mttt -144.84 139.04 27.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.143 -0.973 . . . . 0.0 109.655 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.454 HG13 ' O ' ' A' ' 55' ' ' LYS . 5.3 m -150.13 174.54 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.3 -0.875 . . . . 0.0 109.372 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.585 ' HB2' ' CE1' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -99.92 102.22 13.55 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.161 -0.962 . . . . 0.0 108.943 179.61 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.649 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -82.04 122.85 28.34 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 178.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.525 ' CG2' HD23 ' A' ' 57' ' ' LEU . 47.0 t -117.4 144.18 25.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.135 -0.978 . . . . 0.0 109.304 -179.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.511 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 55.3 m -108.6 87.87 2.59 Favored 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.304 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.534 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 72.6 t -85.85 125.43 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.23 -0.919 . . . . 0.0 109.308 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.415 ' ND2' HG21 ' A' ' 60' ' ' THR . 3.8 p30 -160.08 55.42 0.35 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.383 -0.823 . . . . 0.0 109.733 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 162.7 89.91 0.07 OUTLIER Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.495 ' CG1' ' C ' ' A' ' 149' ' ' TYR . 2.8 m -81.84 -171.32 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -1.14 . . . . 0.0 109.642 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -138.81 -163.27 9.46 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -78.29 -10.65 59.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -1.135 . . . . 0.0 109.499 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.534 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 1.3 m120 -111.08 145.33 32.23 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.171 -0.956 . . . . 0.0 109.426 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.509 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.5 Cg_endo -78.99 13.6 1.93 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.599 2.199 . . . . 0.0 110.997 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.534 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 3.5 p90 -136.33 51.76 2.0 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.031 -1.043 . . . . 0.0 109.759 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' A' ' 36' ' ' VAL . 0.6 OUTLIER -75.89 -50.24 15.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 109.215 179.685 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.472 HG12 ' HG3' ' A' ' 40' ' ' PRO . 4.6 mp -102.2 119.95 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.399 -0.813 . . . . 0.0 109.174 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.45 128.96 50.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.06 -1.025 . . . . 0.0 109.882 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.562 ' HB1' ' CE1' ' A' ' 147' ' ' PHE . . . -130.11 108.3 9.96 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.338 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.47 ' OG1' ' HA ' ' A' ' 144' ' ' PRO . 75.5 m -103.93 165.26 11.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.545 -0.722 . . . . 0.0 110.018 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.491 ' CB ' ' HG ' ' A' ' 162' ' ' LEU . . . -119.01 137.14 53.73 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.055 -1.028 . . . . 0.0 108.882 178.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.563 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.7 p90 -174.46 163.57 2.65 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.497 -0.752 . . . . 0.0 109.256 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.563 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.4 Cg_endo -83.97 170.6 50.85 Favored 'Cis proline' 0 C--N 1.312 -1.372 0 C-N-CA 124.002 -1.249 . . . . 0.0 110.907 -0.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.525 HG12 ' CD1' ' A' ' 164' ' ' ILE . 85.2 t -130.25 156.27 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.521 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 1.9 m120 -121.21 132.02 54.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.09 -1.006 . . . . 0.0 109.929 -179.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.547 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.9 m -140.71 -174.07 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.169 -0.957 . . . . 0.0 109.644 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.523 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 0.3 OUTLIER -136.85 144.74 47.93 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 109.266 179.872 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.449 ' HD2' ' HG2' ' A' ' 81' ' ' ARG . 35.6 Cg_endo -77.12 110.48 3.03 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.426 2.084 . . . . 0.0 110.581 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 111.2 -34.98 5.01 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.54 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -84.75 149.78 4.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.146 -1.208 . . . . 0.0 109.433 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.451 ' O ' ' HB2' ' A' ' 166' ' ' SER . 17.8 m -94.58 141.65 28.36 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.547 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 8.5 m-85 -119.89 170.91 8.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' THR . . . . . 0.458 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 4.1 m -118.07 153.9 32.96 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.274 -0.891 . . . . 0.0 109.29 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.578 ' HB3' ' CE1' ' A' ' 130' ' ' PHE . 5.3 t80 -134.13 120.3 19.95 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.222 -0.924 . . . . 0.0 109.532 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.487 ' O ' ' O ' ' A' ' 161' ' ' GLY . 15.7 m -135.66 147.37 48.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.233 -0.917 . . . . 0.0 109.03 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.545 HD12 ' CD2' ' A' ' 162' ' ' LEU . 2.2 tt -151.21 163.61 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.966 -1.084 . . . . 0.0 109.219 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.525 ' CB ' ' HG3' ' A' ' 51' ' ' PRO . 19.3 m95 -131.02 125.17 32.56 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.894 -1.129 . . . . 0.0 109.574 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.06 150.46 35.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.303 -0.873 . . . . 0.0 109.367 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.575 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 5.3 ttp85 -164.57 121.86 1.64 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.111 -0.993 . . . . 0.0 109.51 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.429 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -102.84 170.1 8.2 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.158 -0.964 . . . . 0.0 109.764 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . 0.571 ' OE1' ' CE1' ' A' ' 158' ' ' TYR . 0.4 OUTLIER -67.16 -59.16 3.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.417 -0.802 . . . . 0.0 109.378 -179.939 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.452 ' HB2' ' OD1' ' A' ' 155' ' ' ASN . 0.8 OUTLIER -109.97 141.9 42.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.358 -0.839 . . . . 0.0 109.29 179.945 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.521 ' N ' ' CG2' ' A' ' 123' ' ' THR . 0.3 OUTLIER -58.16 144.79 39.33 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.206 -0.934 . . . . 0.0 109.206 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 118.17 31.94 1.47 Allowed Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -123.07 136.95 55.02 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.17 -1.194 . . . . 0.0 108.962 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.526 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 53.0 t -111.61 146.63 16.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 O-C-N 121.184 -0.947 . . . . 0.0 110.624 -179.342 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.569 HG13 ' CE2' ' A' ' 147' ' ' PHE . 89.0 t -155.83 149.88 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.481 -0.762 . . . . 0.0 109.5 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.525 ' CB ' ' HG2' ' A' ' 118' ' ' GLU . 19.5 m -125.29 138.6 54.09 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.202 -0.936 . . . . 0.0 109.69 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.625 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.7 m-85 -120.25 103.22 9.06 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.966 -1.084 . . . . 0.0 109.088 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.474 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 11.4 p -117.04 171.05 8.17 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.235 -0.916 . . . . 0.0 110.02 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.692 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -120.94 164.16 17.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.623 -0.673 . . . . 0.0 110.428 -179.51 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.529 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -176.16 148.59 9.3 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.519 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.5 p30 -89.59 -169.64 2.55 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.208 -1.172 . . . . 0.0 109.112 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.519 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 59.2 mt-30 -78.7 18.36 0.6 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.122 -0.986 . . . . 0.0 110.628 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.47 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 0.2 OUTLIER -113.4 11.61 18.55 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 120.828 -1.17 . . . . 0.0 109.182 179.624 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.505 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.8 m-30 74.22 11.83 4.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.38 -0.825 . . . . 0.0 109.461 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.529 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 54.3 mm-40 -92.23 164.04 13.69 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.181 -0.949 . . . . 0.0 109.027 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.468 ' OE2' ' HB3' ' A' ' 115' ' ' ARG . 9.8 tt0 -127.96 142.77 51.15 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.204 -0.935 . . . . 0.0 109.572 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.47 ' OH ' ' HB3' ' A' ' 107' ' ' ASN . 79.1 m-85 -93.82 -75.88 0.49 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.25 -0.906 . . . . 0.0 108.883 179.484 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.566 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -113.99 170.6 13.38 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.468 ' HB3' ' OE2' ' A' ' 112' ' ' GLU . 3.1 ptm180 -144.14 142.31 30.5 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -1.101 . . . . 0.0 109.012 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.581 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -151.26 162.5 40.79 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.993 -1.067 . . . . 0.0 110.624 -179.169 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.622 ' ND1' ' CE1' ' A' ' 103' ' ' PHE . 0.0 OUTLIER 69.96 -153.73 0.13 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.635 -0.666 . . . . 0.0 110.598 178.439 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.601 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.8 mt-10 97.95 28.36 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . 0.461 ' O ' HG11 ' A' ' 100' ' ' VAL . 0.9 OUTLIER -134.44 -164.05 1.46 Allowed 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.463 -0.773 . . . . 0.0 109.731 -179.94 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -67.94 157.69 34.43 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.349 0.595 . . . . 0.0 110.018 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.585 ' CD1' ' NE2' ' A' ' 117' ' ' HIS . 4.9 mm -132.73 140.69 46.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.402 -0.811 . . . . 0.0 109.407 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -82.19 -179.53 7.44 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.439 -0.788 . . . . 0.0 110.412 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.521 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 18.0 p -84.93 1.04 49.09 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 120.081 -0.648 . . . . 0.0 109.419 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.465 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 3.2 mt-10 -104.17 -169.79 1.68 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.242 -0.911 . . . . 0.0 109.428 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.575 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 92.0 m95 -98.12 122.77 41.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.304 -0.873 . . . . 0.0 109.533 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.89 121.11 45.94 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.18 -0.95 . . . . 0.0 109.045 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.32 110.45 2.48 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.466 2.111 . . . . 0.0 110.753 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.407 ' CD2' ' CE1' ' A' ' 117' ' ' HIS . 1.0 OUTLIER -115.99 134.69 54.7 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 179.235 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.47 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.5 t -151.36 176.59 11.11 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 120.716 -1.24 . . . . 0.0 110.956 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.582 ' CE2' ' HB3' ' A' ' 132' ' ' PHE . 6.9 p90 -178.37 165.39 1.79 Allowed 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.004 -0.998 . . . . 0.0 108.987 179.498 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -102.91 138.92 39.16 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.123 -0.986 . . . . 0.0 109.965 -179.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.582 ' HB3' ' CE2' ' A' ' 130' ' ' PHE . 22.2 p90 -138.49 155.95 47.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.395 -0.815 . . . . 0.0 109.218 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -131.34 144.12 51.01 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.209 -0.932 . . . . 0.0 109.131 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.523 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 3.7 t -47.69 110.27 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.364 -0.835 . . . . 0.0 109.177 179.658 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -60.56 -51.79 67.93 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.245 -0.91 . . . . 0.0 109.21 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 43.7 m-20 -108.09 -92.35 0.42 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.413 -0.804 . . . . 0.0 109.153 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.416 ' HA ' HG12 ' A' ' 134' ' ' VAL . 3.3 pt20 -160.66 55.51 0.32 Allowed 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.468 -0.77 . . . . 0.0 109.041 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.456 ' O ' HG23 ' A' ' 80' ' ' VAL . 18.8 mm-40 -93.2 113.71 26.0 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.303 -0.873 . . . . 0.0 109.75 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.43 -15.7 57.38 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.2 t -134.57 130.25 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.145 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.473 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -140.48 172.33 11.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.27 -0.894 . . . . 0.0 110.116 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.491 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.4 ptm180 -143.66 133.59 24.06 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.692 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.09 110.03 41.44 Favored Pre-proline 0 N--CA 1.486 1.369 0 O-C-N 121.319 -0.863 . . . . 0.0 109.76 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.491 ' HD3' ' O ' ' A' ' 142' ' ' ARG . 36.0 Cg_endo -77.22 111.24 3.16 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.168 1.912 . . . . 0.0 111.169 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.574 HG23 ' CZ ' ' A' ' 147' ' ' PHE . 2.0 mm -90.68 139.34 17.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.545 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 10.7 m80 -109.37 149.51 29.4 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.696 -1.253 . . . . 0.0 112.337 -177.102 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.574 ' CZ ' HG23 ' A' ' 145' ' ' ILE . 2.6 m-85 -153.68 153.8 32.93 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.431 ' C ' HG11 ' A' ' 64' ' ' VAL . . . 131.6 38.23 0.27 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.495 ' C ' ' CG1' ' A' ' 64' ' ' VAL . 77.2 m-85 -116.68 163.69 15.75 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.409 -1.054 . . . . 0.0 109.104 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.01 -27.25 67.27 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.485 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -73.02 -7.18 50.04 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.444 -0.785 . . . . 0.0 109.621 179.707 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.526 ' ND2' ' O ' ' A' ' 100' ' ' VAL . 1.5 m-20 -107.08 9.06 30.55 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 179.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.413 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.5 t -87.98 158.69 3.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 O-C-N 121.418 -0.801 . . . . 0.0 109.618 -179.383 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.413 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 53.13 35.78 50.31 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.452 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.2 m-20 -160.29 139.22 10.57 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.111 -1.229 . . . . 0.0 110.087 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.58 ' CG2' ' CE1' ' A' ' 158' ' ' TYR . 73.6 m -92.09 122.39 34.55 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.123 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.534 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 1.4 mt -102.51 119.92 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.726 -1.234 . . . . 0.0 110.005 -178.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.649 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 2.1 m-85 -100.11 142.17 31.96 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 178.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.569 HD13 ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -133.22 138.29 51.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.788 -1.195 . . . . 0.0 110.162 -178.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.468 ' OD2' ' O ' ' A' ' 55' ' ' LYS . 0.8 OUTLIER -173.67 136.4 0.57 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.216 -0.928 . . . . 0.0 108.926 179.592 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 131.0 -3.85 5.64 Favored Glycine 0 N--CA 1.485 1.958 0 C-N-CA 119.407 -1.378 . . . . 0.0 110.324 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.545 ' CD2' HD12 ' A' ' 90' ' ' ILE . 0.1 OUTLIER -59.27 97.15 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.754 -1.439 . . . . 0.0 108.614 -179.928 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . 0.46 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -131.54 145.44 51.73 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.348 -0.845 . . . . 0.0 109.778 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.525 ' CD1' HG12 ' A' ' 78' ' ' VAL . 7.5 mt -133.81 124.57 47.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.318 -0.864 . . . . 0.0 109.285 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.51 ' HB1' ' CG2' ' A' ' 3' ' ' VAL . . . -157.18 147.07 20.68 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.129 -0.982 . . . . 0.0 109.583 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.451 ' HB2' ' O ' ' A' ' 85' ' ' THR . 11.1 t -109.0 161.95 14.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.299 -0.875 . . . . 0.0 109.461 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -87.95 151.36 49.45 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.307 -0.87 . . . . 0.0 109.372 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo . . . . . 0 C--N 1.309 -1.551 0 C-N-CA 122.575 2.183 . . . . 0.0 110.414 -179.979 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 23.8 mt -75.25 123.83 26.0 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.441 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.2 p -108.06 173.29 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -0.944 . . . . 0.0 109.368 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -70.3 -57.9 4.35 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.234 -0.916 . . . . 0.0 109.539 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.437 ' HB3' ' HA ' ' A' ' 163' ' ' ALA . 0.7 OUTLIER -75.3 116.99 16.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.239 -0.913 . . . . 0.0 109.66 -179.753 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.472 ' O ' ' HA3' ' A' ' 27' ' ' GLY . 3.0 mp -103.89 140.88 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.35 -0.844 . . . . 0.0 109.068 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.504 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.7 OUTLIER 61.89 19.17 10.46 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.221 -0.924 . . . . 0.0 109.425 -179.804 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.476 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -61.54 -29.48 71.92 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.527 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -107.83 32.51 7.03 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 179.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.583 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 3.0 m-85 43.8 54.55 5.6 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.395 -1.062 . . . . 0.0 109.534 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -84.22 -36.89 22.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.16 -0.963 . . . . 0.0 109.68 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.469 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 18.6 m -84.01 -26.24 29.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.215 -0.928 . . . . 0.0 109.608 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.531 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 1.3 m -78.82 114.36 43.18 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.172 -0.955 . . . . 0.0 109.43 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.5 Cg_endo -77.86 142.68 20.19 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 C-N-CA 122.414 2.076 . . . . 0.0 110.61 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.463 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -40.11 161.43 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.885 -0.509 . . . . 0.0 109.709 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.82 132.99 3.23 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.024 -1.63 . . . . 0.0 109.024 -179.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.481 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.94 138.45 17.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.3 -1.117 . . . . 0.0 109.325 -179.543 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.456 HG11 ' HA3' ' A' ' 24' ' ' GLY . 48.2 t -83.78 143.73 11.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-O 121.681 0.753 . . . . 0.0 110.096 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.9 p -94.84 -27.02 15.96 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.516 ' HB3' ' CG ' ' A' ' 23' ' ' GLU . 2.7 t0 -141.19 101.7 4.08 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.586 ' CD2' ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -44.78 -30.13 0.91 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.178 -0.951 . . . . 0.0 109.751 -178.966 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.586 ' N ' ' CD2' ' A' ' 21' ' ' LEU . . . -60.35 -53.34 58.77 Favored 'General case' 0 C--N 1.294 -1.842 0 O-C-N 121.6 -0.688 . . . . 0.0 109.678 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.516 ' CG ' ' HB3' ' A' ' 20' ' ' ASP . 1.8 pt-20 -102.15 31.52 3.92 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.249 -0.907 . . . . 0.0 109.409 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.456 ' HA3' HG11 ' A' ' 18' ' ' VAL . . . -71.14 -55.05 8.23 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.781 -1.327 . . . . 0.0 109.781 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.531 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 2.8 t -121.53 143.1 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.16 -1.2 . . . . 0.0 109.663 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -67.49 -56.02 11.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.264 -0.897 . . . . 0.0 109.726 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.504 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -77.15 0.86 66.06 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.658 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.7 OUTLIER -137.5 121.54 17.83 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.116 -1.226 . . . . 0.0 109.274 179.653 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.534 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -123.44 118.89 28.46 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.363 -0.836 . . . . 0.0 109.034 179.589 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.505 ' HB2' ' HB2' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -97.85 174.5 6.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.185 -0.947 . . . . 0.0 109.842 -179.477 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.491 ' HA ' HD21 ' A' ' 21' ' ' LEU . 16.8 m120 -160.39 122.92 3.29 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.364 -0.835 . . . . 0.0 109.567 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.523 HG11 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -110.73 135.03 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.168 -0.958 . . . . 0.0 109.651 179.418 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.49 178.38 21.74 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.3 t -58.6 -15.81 13.15 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.199 -1.177 . . . . 0.0 109.39 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.467 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 1.4 p -60.94 -38.1 84.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.648 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' O ' ' A' ' 36' ' ' VAL . 2.1 t -59.9 89.41 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 O-C-N 121.084 -1.01 . . . . 0.0 109.414 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.409 ' N ' ' O ' ' A' ' 35' ' ' SER . 25.4 m -62.73 -28.97 70.32 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.264 -0.898 . . . . 0.0 108.674 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.49 ' O ' HG11 ' A' ' 36' ' ' VAL . 1.8 t-20 -122.91 128.81 25.22 Favored Pre-proline 0 C--N 1.297 -1.688 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.453 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.1 Cg_endo -75.84 116.55 4.46 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.261 1.974 . . . . 0.0 110.729 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.501 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.3 Cg_endo -77.44 -176.26 3.11 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 C-N-CA 122.421 2.081 . . . . 0.0 109.77 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.51 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 55.5 t -113.26 119.68 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.046 -1.034 . . . . 0.0 110.682 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.571 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 3.7 m-85 -101.07 112.38 24.83 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.184 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.481 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 31.6 tt0 -154.08 158.8 41.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.069 -1.02 . . . . 0.0 110.038 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.441 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 58.9 t -99.5 148.21 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.506 -0.747 . . . . 0.0 109.106 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.451 HD23 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -123.35 122.1 37.47 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.295 -0.878 . . . . 0.0 109.787 -179.427 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.466 ' CG ' ' HE3' ' A' ' 55' ' ' LYS . 8.5 mt-10 -98.29 110.01 22.67 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.463 ' O ' ' HB3' ' A' ' 54' ' ' ASN . 3.1 p -142.53 -177.89 5.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.466 -0.771 . . . . 0.0 109.488 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.1 m -104.59 -5.24 21.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.306 -0.871 . . . . 0.0 109.558 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.403 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.9 m-20 -87.01 -16.56 35.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.174 -0.954 . . . . 0.0 109.444 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.403 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.33 149.74 0.71 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.234 -0.916 . . . . 0.0 109.376 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.409 ' HG3' ' HB2' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -77.93 -38.96 0.54 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.592 2.195 . . . . 0.0 110.409 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -121.23 121.28 37.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.295 -0.878 . . . . 0.0 109.397 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 63.93 -120.81 21.44 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.463 ' HB3' ' O ' ' A' ' 47' ' ' THR . 4.8 m120 -158.14 34.48 0.25 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -1.14 . . . . 0.0 109.503 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.524 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 5.4 mttp -140.2 142.17 35.89 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.298 -0.876 . . . . 0.0 109.584 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.518 HG13 ' CB ' ' A' ' 160' ' ' ASP . 4.6 m -149.22 174.85 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -0.899 . . . . 0.0 109.259 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.583 ' HB2' ' CE2' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -105.46 99.39 9.0 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.059 -1.026 . . . . 0.0 108.525 179.057 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.636 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.06 118.91 22.91 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.115 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.536 ' O ' ' CG2' ' A' ' 156' ' ' THR . 40.9 t -112.85 144.2 21.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.188 -0.945 . . . . 0.0 108.99 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.51 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 80.2 m -109.12 90.53 3.32 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.56 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 53.1 t -88.33 125.54 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.284 -0.885 . . . . 0.0 108.987 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.466 ' ND2' HG23 ' A' ' 60' ' ' THR . 3.6 p30 -159.23 61.15 0.4 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.34 -0.85 . . . . 0.0 109.802 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 144.36 93.9 0.17 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.535 HG13 ' CA ' ' A' ' 149' ' ' TYR . 1.6 m -83.19 178.53 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.259 -1.142 . . . . 0.0 109.596 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -113.93 -154.47 11.21 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.4 m-20 -96.1 -10.12 29.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.317 -1.107 . . . . 0.0 109.491 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.578 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 4.8 m120 -109.8 151.47 42.36 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.309 -0.869 . . . . 0.0 109.381 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.43 12.53 2.09 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.693 2.262 . . . . 0.0 111.075 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.578 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.1 p90 -132.95 53.58 2.01 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.035 -1.041 . . . . 0.0 109.721 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.509 ' CB ' HG21 ' A' ' 36' ' ' VAL . 0.3 OUTLIER -82.48 -69.32 0.63 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.21 -0.931 . . . . 0.0 109.057 179.763 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.468 ' O ' ' O ' ' A' ' 147' ' ' PHE . 6.1 mt -98.47 126.32 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.265 -0.897 . . . . 0.0 108.775 179.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -129.32 139.26 51.81 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.961 -1.087 . . . . 0.0 110.44 -179.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.587 ' HB2' ' CZ3' ' A' ' 28' ' ' TRP . . . -122.49 143.12 49.91 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 178.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.515 HG22 ' N ' ' A' ' 75' ' ' ALA . 12.8 m -143.9 162.23 36.67 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.544 -1.348 . . . . 0.0 110.322 -178.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.515 ' N ' HG22 ' A' ' 74' ' ' THR . . . -123.93 136.18 54.17 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.48 -0.762 . . . . 0.0 109.142 179.191 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.539 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 1.3 p90 178.21 161.94 0.63 Allowed Pre-proline 0 N--CA 1.491 1.617 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.523 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -81.5 167.62 70.42 Favored 'Cis proline' 0 C--N 1.31 -1.491 0 C-N-CA 123.672 -1.387 . . . . 0.0 110.837 -0.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 62.2 t -124.07 150.04 28.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.263 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.501 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 98.1 m-20 -117.29 108.85 16.12 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.0 -1.063 . . . . 0.0 110.075 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.513 ' CG2' ' O ' ' A' ' 138' ' ' GLU . 3.1 m -114.33 -173.85 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.209 -0.932 . . . . 0.0 109.479 179.478 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.531 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 21.5 mmt180 -137.01 144.81 47.86 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.38 -0.825 . . . . 0.0 109.229 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -76.95 111.24 3.19 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.523 2.149 . . . . 0.0 110.47 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 109.13 -30.88 8.16 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.475 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -84.79 149.68 4.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.235 -1.156 . . . . 0.0 109.452 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.437 HG21 ' HA ' ' A' ' 168' ' ' PRO . 8.5 t -92.81 136.43 33.25 Favored 'General case' 0 C--N 1.292 -1.922 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.556 ' CZ ' ' HB3' ' A' ' 166' ' ' SER . 20.3 m-85 -119.39 148.98 42.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.688 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' THR . . . . . 0.464 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 17.5 m -113.79 151.77 31.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.312 -0.867 . . . . 0.0 108.985 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.618 ' N ' ' CD1' ' A' ' 88' ' ' TYR . 0.1 OUTLIER -128.81 114.45 16.56 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.178 -0.952 . . . . 0.0 109.628 -179.775 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.484 ' O ' ' O ' ' A' ' 161' ' ' GLY . 41.2 m -118.87 149.29 41.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.351 -0.843 . . . . 0.0 108.971 179.798 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.503 HD12 ' CD2' ' A' ' 103' ' ' PHE . 19.2 tt -150.75 163.51 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 120.821 -1.174 . . . . 0.0 109.755 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.498 ' CD1' ' C ' ' A' ' 90' ' ' ILE . 20.5 m95 -132.27 125.87 32.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.11 -0.994 . . . . 0.0 109.271 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.454 ' HB1' HG23 ' A' ' 121' ' ' ILE . . . -115.55 148.11 39.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.24 -0.913 . . . . 0.0 109.562 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.47 ' HG3' ' O ' ' A' ' 123' ' ' THR . 5.0 ttp180 -160.68 118.02 2.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.197 -0.939 . . . . 0.0 109.007 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -104.41 150.12 24.81 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.405 -0.809 . . . . 0.0 109.889 -179.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . 0.473 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 3.0 mt-10 -52.75 -38.98 61.75 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.451 -0.781 . . . . 0.0 109.263 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.493 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -119.57 137.48 53.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.342 -0.848 . . . . 0.0 109.378 179.978 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.577 ' N ' ' CG2' ' A' ' 123' ' ' THR . 0.5 OUTLIER -63.4 147.59 50.79 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.482 -179.847 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 106.97 38.28 2.19 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.773 -1.331 . . . . 0.0 109.773 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.463 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -121.64 140.11 52.68 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.175 -1.191 . . . . 0.0 109.101 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.487 HG11 ' N ' ' A' ' 101' ' ' VAL . 51.3 t -116.75 158.23 17.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.318 -0.864 . . . . 0.0 110.759 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.643 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 59.3 t -154.56 163.36 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.534 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 34.2 t -118.8 123.06 43.85 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.921 -1.112 . . . . 0.0 109.797 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.62 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 2.3 m-85 -119.25 103.45 9.51 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.173 -0.955 . . . . 0.0 109.633 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.487 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 19.0 p -128.97 167.87 16.83 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.195 -0.941 . . . . 0.0 110.185 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.652 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -128.44 155.67 40.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.732 -0.605 . . . . 0.0 110.341 -179.726 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.53 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -175.68 160.81 29.32 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.548 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 0.9 OUTLIER -99.3 -170.26 1.88 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.125 -1.221 . . . . 0.0 109.418 -179.88 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.548 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 22.1 mt-30 -71.87 8.73 1.1 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.06 -1.025 . . . . 0.0 111.185 -179.18 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.516 ' HB2' ' NE2' ' A' ' 111' ' ' GLN . 2.0 m -108.93 13.52 24.71 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 120.667 -1.271 . . . . 0.0 109.219 179.729 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.5 m-30 73.88 1.69 3.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.454 -0.779 . . . . 0.0 109.641 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.53 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 0.7 OUTLIER -73.11 161.33 30.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.198 -0.939 . . . . 0.0 108.69 179.283 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 3.6 tt0 -138.45 134.78 34.47 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.0 -1.063 . . . . 0.0 109.882 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.572 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 18.9 m-85 -94.8 -71.61 0.66 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.272 -0.893 . . . . 0.0 108.67 179.016 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.58 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -87.67 165.81 35.45 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 108.979 -1.648 . . . . 0.0 108.979 179.369 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.456 ' HG3' ' OE2' ' A' ' 112' ' ' GLU . 50.9 ttt180 -160.94 110.55 1.67 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.997 -1.296 . . . . 0.0 110.474 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.628 ' CD2' ' CD1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -144.97 69.97 1.26 Allowed 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 108.698 -0.852 . . . . 0.0 108.698 179.077 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.534 ' CB ' ' OG ' ' A' ' 102' ' ' SER . 19.2 p80 -102.71 157.7 16.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 110.02 -179.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 1.3 tp10 77.98 44.34 0.08 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.388 -0.82 . . . . 0.0 109.403 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . 0.443 ' OE1' ' HB2' ' A' ' 116' ' ' LEU . 0.9 OUTLIER -109.35 136.67 48.42 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.286 -0.884 . . . . 0.0 109.473 179.912 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . 0.463 ' O ' ' CD1' ' A' ' 121' ' ' ILE . 18.9 mm-40 -73.85 155.92 38.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.445 -0.784 . . . . 0.0 109.029 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 99' ' ' ALA . 13.6 mm -134.38 135.81 53.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.081 -1.012 . . . . 0.0 110.071 -179.631 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.61 -179.06 6.25 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 121.638 0.732 . . . . 0.0 110.254 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.577 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 39.2 p -75.22 -0.63 20.1 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.386 179.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.455 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 6.4 mt-10 -110.91 -168.94 1.37 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.922 . . . . 0.0 109.238 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.454 ' CE2' ' NE ' ' A' ' 93' ' ' ARG . 94.1 m95 -94.39 124.89 38.69 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.159 -0.963 . . . . 0.0 109.565 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.409 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 2.1 tt0 -106.95 121.2 45.61 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.223 -0.923 . . . . 0.0 109.078 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.09 100.57 1.28 Allowed 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.4 2.067 . . . . 0.0 110.923 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -111.62 133.93 53.54 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.466 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.3 t -151.16 176.78 10.86 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 120.793 -1.192 . . . . 0.0 110.794 -179.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.628 ' CD1' ' CD2' ' A' ' 116' ' ' LEU . 6.3 p90 -166.74 165.8 16.19 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.123 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -118.85 138.89 52.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.129 -0.982 . . . . 0.0 109.891 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.572 ' CE2' ' O ' ' A' ' 113' ' ' TYR . 0.5 OUTLIER -154.77 157.73 38.41 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.375 -0.828 . . . . 0.0 109.128 179.729 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.447 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -121.09 147.66 45.23 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.232 -0.917 . . . . 0.0 109.551 -179.66 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.531 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 5.2 t -41.44 110.05 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.511 -0.743 . . . . 0.0 109.214 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 33.7 t -59.39 -50.64 73.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -0.872 . . . . 0.0 109.205 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -108.23 -91.7 0.43 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.382 -0.824 . . . . 0.0 109.189 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.45 ' HA ' HG12 ' A' ' 134' ' ' VAL . 4.7 pt20 -163.23 54.74 0.18 Allowed 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.513 ' O ' ' CG2' ' A' ' 80' ' ' VAL . 40.4 mm-40 -91.33 111.55 23.09 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.293 -0.879 . . . . 0.0 109.944 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.35 -17.53 54.3 Favored 'General case' 0 N--CA 1.487 1.42 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.233 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.4 t -131.64 132.2 62.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.471 HG23 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -142.65 171.73 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.082 -1.011 . . . . 0.0 110.385 -179.416 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.457 ' O ' ' HG2' ' A' ' 142' ' ' ARG . 0.8 OUTLIER -141.9 132.77 25.83 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.806 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.652 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.15 111.45 50.22 Favored Pre-proline 0 C--N 1.304 -1.396 0 O-C-N 121.162 -0.961 . . . . 0.0 109.4 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.487 ' HD2' ' O ' ' A' ' 104' ' ' THR . 33.2 Cg_endo -74.69 111.95 3.44 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 C-N-CA 122.199 1.933 . . . . 0.0 110.764 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.658 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 2.1 mt -100.17 136.81 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 179.135 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.516 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 5.9 m80 -105.72 160.37 15.27 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.525 -1.359 . . . . 0.0 111.105 -178.343 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.643 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 11.1 m-85 -159.74 162.2 34.88 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.493 ' C ' ' CG1' ' A' ' 64' ' ' VAL . . . 107.01 38.91 2.07 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.535 ' CA ' HG13 ' A' ' 64' ' ' VAL . 20.5 m-85 -113.42 158.09 21.09 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.489 -1.007 . . . . 0.0 109.287 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.38 -27.29 67.74 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.646 -0.659 . . . . 0.0 109.265 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.466 ' HB2' ' HB ' ' A' ' 100' ' ' VAL . . . -70.57 -15.13 62.74 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.45 -0.781 . . . . 0.0 109.187 179.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.525 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.2 OUTLIER -109.78 11.88 24.24 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.338 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.3 t -84.87 161.48 3.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.492 -0.755 . . . . 0.0 109.821 -179.296 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.441 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 51.37 33.88 32.75 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.1 m-20 -160.4 141.84 12.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.22 -1.165 . . . . 0.0 110.226 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.578 HG21 ' CZ ' ' A' ' 158' ' ' TYR . 85.2 m -89.55 124.45 34.54 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.56 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 1.2 mt -105.02 116.32 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.855 -1.153 . . . . 0.0 110.055 -178.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.636 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 5.8 m-85 -98.91 139.85 33.96 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 178.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.615 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -132.16 139.34 50.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.739 -1.225 . . . . 0.0 110.228 -178.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' A' ' 161' ' ' GLY . 39.9 t0 -173.9 135.95 0.52 Allowed 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.368 -0.832 . . . . 0.0 108.876 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.543 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 127.28 -9.77 6.96 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.41 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.476 ' O ' ' HA3' ' A' ' 8' ' ' GLY . 12.4 tp -59.81 109.13 0.86 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.712 -1.464 . . . . 0.0 108.642 -179.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 88' ' ' TYR . . . -138.87 145.55 40.09 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.457 -0.777 . . . . 0.0 109.985 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.512 HG22 ' CD2' ' A' ' 88' ' ' TYR . 16.5 mt -130.97 109.0 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.37 -0.831 . . . . 0.0 109.18 179.472 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.38 171.17 8.51 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.164 -0.96 . . . . 0.0 109.621 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.556 ' HB3' ' CZ ' ' A' ' 86' ' ' TYR . 1.3 p -99.71 93.4 5.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -112.99 92.23 20.55 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.904 . . . . 0.0 109.468 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 166' ' ' SER . 35.4 Cg_endo . . . . . 0 C--N 1.309 -1.522 0 C-N-CA 122.653 2.235 . . . . 0.0 110.455 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.456 ' O ' ' HB ' ' A' ' 3' ' ' VAL . 4.3 mm? -83.75 167.66 16.94 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.354 -0.841 . . . . 0.0 109.477 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' A' ' 5' ' ' ASN . 4.4 p 179.75 173.87 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.253 -0.905 . . . . 0.0 109.311 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.5 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -65.46 -43.75 89.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.092 -1.005 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.525 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 21.4 t-20 -85.87 130.94 34.41 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.278 -0.889 . . . . 0.0 109.338 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.413 ' O ' ' HB3' ' A' ' 7' ' ' ASN . 1.7 mp -127.62 126.61 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.223 -0.923 . . . . 0.0 109.613 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.527 ' HB3' ' CA ' ' A' ' 27' ' ' GLY . 0.6 OUTLIER 65.32 10.7 6.71 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.333 -0.854 . . . . 0.0 109.546 179.591 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.43 ' HA3' ' OD1' ' A' ' 5' ' ' ASN . . . -66.06 -33.24 84.86 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 179.412 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.529 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -91.32 16.14 59.58 Favored Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.628 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.579 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 13.2 m-85 61.28 40.27 14.62 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.337 -1.096 . . . . 0.0 109.439 179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -84.65 -43.38 14.44 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.838 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -78.71 -42.29 28.75 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.212 -0.93 . . . . 0.0 109.875 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.522 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 12.8 m -59.81 123.67 72.8 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.33 -0.856 . . . . 0.0 109.586 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.8 Cg_endo -77.87 137.42 15.83 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 122.439 2.092 . . . . 0.0 110.569 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.463 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -41.97 164.63 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.715 -0.616 . . . . 0.0 109.707 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 132.71 131.18 3.17 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 108.999 -1.64 . . . . 0.0 108.999 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.531 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -56.96 142.94 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.167 -1.196 . . . . 0.0 108.943 -179.71 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.459 HG13 ' HA3' ' A' ' 24' ' ' GLY . 54.1 t -90.64 142.47 12.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.456 -0.778 . . . . 0.0 110.386 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 33.3 p -93.03 -30.14 15.46 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 178.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.41 ' O ' ' C ' ' A' ' 21' ' ' LEU . 4.9 m-20 -133.39 99.53 4.55 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.584 ' CD2' ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -44.13 -29.57 0.64 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.207 -0.933 . . . . 0.0 109.764 -178.567 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.584 ' N ' ' CD2' ' A' ' 21' ' ' LEU . . . -59.8 -51.7 68.62 Favored 'General case' 0 C--N 1.294 -1.823 0 O-C-N 121.588 -0.695 . . . . 0.0 109.706 -179.673 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -101.86 31.05 4.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.2 -0.937 . . . . 0.0 109.384 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.459 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -74.1 -59.91 3.78 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.522 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 3.5 t -120.56 137.91 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -1.135 . . . . 0.0 109.555 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -69.44 -42.31 75.14 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.305 -0.872 . . . . 0.0 109.587 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.527 ' CA ' ' HB3' ' A' ' 7' ' ' ASN . . . -76.91 -12.67 84.39 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.643 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 1.0 OUTLIER -132.44 123.73 27.23 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.19 -1.182 . . . . 0.0 109.754 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.461 ' OD1' ' CE2' ' A' ' 76' ' ' PHE . 1.8 m-20 -113.83 115.82 28.36 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 178.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.533 ' HB2' ' HB2' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -98.81 168.0 10.41 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.946 -1.096 . . . . 0.0 110.16 -178.581 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.512 ' HA ' HD23 ' A' ' 21' ' ' LEU . 19.5 m120 -160.53 123.43 3.34 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.532 -0.73 . . . . 0.0 109.633 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.537 HG11 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -101.12 131.88 47.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.097 -1.002 . . . . 0.0 109.447 179.263 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.29 178.65 26.74 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.5 m -57.99 -16.75 13.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -1.133 . . . . 0.0 109.345 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.458 ' OG ' ' HA ' ' A' ' 70' ' ' ASP . 1.3 p -61.99 -38.55 89.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.442 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.537 ' CG2' HG11 ' A' ' 32' ' ' VAL . 2.1 t -63.78 89.67 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 O-C-N 121.221 -0.925 . . . . 0.0 109.455 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 45.2 m -71.23 -28.4 64.16 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.846 0.832 . . . . 0.0 108.84 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.489 ' O ' HG11 ' A' ' 36' ' ' VAL . 1.3 m-20 -115.0 139.77 24.71 Favored Pre-proline 0 C--N 1.297 -1.702 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.456 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.4 Cg_endo -76.01 111.76 3.35 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.389 2.059 . . . . 0.0 110.816 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 38' ' ' ASN . 34.9 Cg_endo -77.57 179.61 6.35 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.46 2.106 . . . . 0.0 109.552 179.537 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.53 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 61.9 t -117.18 120.74 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.999 -1.063 . . . . 0.0 110.769 -179.576 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.467 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 90.6 m-85 -106.83 112.24 25.12 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 178.086 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.531 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 0.4 OUTLIER -150.28 148.26 28.65 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.976 -1.078 . . . . 0.0 110.237 -179.261 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 56' ' ' VAL . 4.0 t -101.77 148.19 7.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.519 -0.738 . . . . 0.0 109.117 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.603 ' CD2' ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -150.54 164.32 36.27 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 179.85 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.603 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 19.4 pt-20 -120.04 123.84 44.42 Favored 'General case' 0 C--N 1.291 -1.945 0 O-C-N 121.391 -0.818 . . . . 0.0 109.388 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.528 ' CG2' HD21 ' A' ' 45' ' ' LEU . 6.7 p -117.42 178.98 4.18 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 109.459 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -101.97 8.76 40.94 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.219 -0.926 . . . . 0.0 109.524 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.413 ' O ' ' C ' ' A' ' 50' ' ' ALA . 7.7 m-20 -125.25 8.72 7.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.178 -0.952 . . . . 0.0 109.572 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -43.9 148.78 0.72 Allowed Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.234 -0.916 . . . . 0.0 109.437 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.572 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -77.97 -40.16 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 122.642 2.228 . . . . 0.0 110.384 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -131.71 94.04 3.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.43 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 99.19 -124.29 8.18 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.482 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 76.6 m-20 -155.06 20.33 0.43 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.241 -1.153 . . . . 0.0 109.556 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.46 ' O ' HG13 ' A' ' 56' ' ' VAL . 51.9 mttp -137.62 145.33 42.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.237 -0.914 . . . . 0.0 109.638 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.538 HG21 ' CD1' ' A' ' 45' ' ' LEU . 4.1 m -150.14 174.69 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.32 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.579 ' HB2' ' CE1' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -101.35 102.95 13.87 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 109.016 179.618 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.634 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.92 117.7 22.36 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.533 ' CG2' HD21 ' A' ' 57' ' ' LEU . 39.6 t -111.86 144.64 19.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.052 -1.03 . . . . 0.0 109.076 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.53 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 16.0 m -109.2 89.27 2.95 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.524 HG22 ' CD1' ' A' ' 157' ' ' ILE . 41.5 t -85.25 128.7 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.334 -0.854 . . . . 0.0 109.16 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.436 ' ND2' HG21 ' A' ' 60' ' ' THR . 2.8 p30 -159.93 61.56 0.36 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.427 -0.795 . . . . 0.0 109.835 -179.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 150.56 93.55 0.11 Allowed Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.526 HG12 ' CA ' ' A' ' 149' ' ' TYR . 2.4 m -79.86 -173.41 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.181 -1.188 . . . . 0.0 109.497 179.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -135.46 -162.02 9.52 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . 0.418 ' C ' ' OD1' ' A' ' 67' ' ' ASN . 23.0 t30 -89.82 10.28 24.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.213 -1.169 . . . . 0.0 109.453 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.578 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.0 m-20 -131.82 148.26 69.21 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.188 -0.945 . . . . 0.0 109.391 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.43 12.99 1.94 Allowed 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.568 2.179 . . . . 0.0 111.022 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.578 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.2 p90 -133.44 55.66 1.89 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.95 -1.094 . . . . 0.0 109.916 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.468 ' HB3' HG21 ' A' ' 36' ' ' VAL . 0.3 OUTLIER -78.68 -68.31 0.66 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 108.862 179.535 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 2.8 mp -90.19 124.63 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 30' ' ' LEU . 1.6 tt0 -114.7 128.76 56.49 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.031 -1.043 . . . . 0.0 110.729 -179.137 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.634 ' CB ' ' CZ3' ' A' ' 28' ' ' TRP . . . -131.43 107.67 9.07 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.491 HG22 ' N ' ' A' ' 75' ' ' ALA . 52.0 m -117.92 163.87 15.91 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.894 -1.129 . . . . 0.0 110.255 -178.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.491 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.19 137.26 53.75 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.234 -0.916 . . . . 0.0 109.214 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.54 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 0.6 OUTLIER 177.42 162.95 0.55 Allowed Pre-proline 0 N--CA 1.492 1.67 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -179.888 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.518 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.11 167.45 74.52 Favored 'Cis proline' 0 C--N 1.309 -1.52 0 C-N-CA 123.722 -1.366 . . . . 0.0 110.699 -0.242 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.486 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 69.5 t -125.37 151.04 30.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.396 -0.815 . . . . 0.0 108.819 179.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.5 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 8.5 m-80 -117.15 113.24 21.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.077 -1.014 . . . . 0.0 109.933 -179.51 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.578 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.8 m -117.83 -176.24 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.192 -0.943 . . . . 0.0 109.449 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.539 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 0.0 OUTLIER -134.91 144.97 52.7 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.319 -0.863 . . . . 0.0 109.236 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.434 ' HD2' ' HG3' ' A' ' 81' ' ' ARG . 34.8 Cg_endo -76.19 113.26 3.66 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.49 2.127 . . . . 0.0 110.553 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.6 -31.6 8.1 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.518 HG11 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -85.09 149.79 4.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.256 -1.144 . . . . 0.0 109.466 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 4.3 m -95.37 138.23 33.35 Favored 'General case' 0 C--N 1.292 -1.906 0 CA-C-O 121.296 0.57 . . . . 0.0 109.473 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.578 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 12.2 m-85 -117.93 157.4 26.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -0.936 . . . . 0.0 109.616 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' THR . . . . . 0.442 HG23 ' O ' ' A' ' 130' ' ' PHE . 40.1 m -118.1 149.48 40.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -0.879 . . . . 0.0 109.29 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.69 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 0.2 OUTLIER -125.97 107.98 10.97 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -0.891 . . . . 0.0 109.507 -179.884 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 161' ' ' GLY . 48.6 m -115.15 146.64 41.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.29 -0.882 . . . . 0.0 109.098 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.571 HD11 ' CD2' ' A' ' 103' ' ' PHE . 18.9 tt -150.48 163.32 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 120.884 -1.135 . . . . 0.0 109.465 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.575 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 21.0 m95 -131.37 127.1 36.87 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.971 -1.081 . . . . 0.0 109.526 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.451 ' HB1' HG22 ' A' ' 121' ' ' ILE . . . -115.47 146.96 41.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.364 -0.835 . . . . 0.0 109.316 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.504 ' HG3' ' CA ' ' A' ' 124' ' ' GLU . 28.2 ttt-85 -162.16 118.06 1.98 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.125 -0.985 . . . . 0.0 109.182 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.71 166.12 10.69 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.878 -179.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.0 mm-40 -59.46 -49.82 76.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.426 -0.796 . . . . 0.0 109.363 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.406 ' HB2' ' OD1' ' A' ' 155' ' ' ASN . 0.6 OUTLIER -112.35 148.38 34.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.335 -0.853 . . . . 0.0 109.252 179.879 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.581 ' N ' ' CG2' ' A' ' 123' ' ' THR . 2.1 t70 -68.81 163.14 24.87 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.205 -0.935 . . . . 0.0 109.487 -179.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.505 ' N ' ' OD1' ' A' ' 97' ' ' ASP . . . 93.42 39.5 5.03 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.469 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -119.02 142.59 47.68 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.278 -1.131 . . . . 0.0 109.044 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.469 ' HB ' ' HB3' ' A' ' 151' ' ' ALA . 54.3 t -118.87 149.69 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.205 -0.934 . . . . 0.0 110.909 -179.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.582 ' CG1' ' CE2' ' A' ' 147' ' ' PHE . 47.7 t -149.42 165.26 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.524 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 66.5 m -130.54 125.47 34.33 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.976 -1.077 . . . . 0.0 109.392 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.615 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.2 m-85 -122.38 104.18 9.23 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.235 -0.915 . . . . 0.0 110.095 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.512 HG23 ' CA ' ' A' ' 115' ' ' ARG . 17.4 p -121.67 163.49 18.92 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.113 -0.992 . . . . 0.0 109.87 179.437 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.595 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -112.62 118.0 56.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 C-N-CA 119.948 -0.701 . . . . 0.0 110.007 179.701 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -109.46 172.61 16.25 Favored Glycine 0 N--CA 1.487 2.086 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.552 ' CB ' ' O ' ' A' ' 111' ' ' GLN . 17.1 t30 -123.57 171.78 9.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.369 -1.077 . . . . 0.0 109.133 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.411 ' N ' ' CG ' ' A' ' 107' ' ' ASN . 19.1 mt-30 -59.06 -48.17 82.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.972 -1.08 . . . . 0.0 109.675 -179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 2.8 m -83.36 17.96 1.95 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.239 -0.913 . . . . 0.0 110.12 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.548 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.8 m-30 81.14 8.58 1.08 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.479 -0.763 . . . . 0.0 110.189 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.552 ' O ' ' CB ' ' A' ' 107' ' ' ASN . 5.4 mm-40 -71.02 121.82 18.9 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.955 -1.091 . . . . 0.0 108.807 179.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -106.17 139.5 40.59 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.817 -1.177 . . . . 0.0 109.949 -179.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.574 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 4.6 m-85 -107.3 -65.53 1.09 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.576 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -104.74 179.29 24.25 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.052 -1.619 . . . . 0.0 109.052 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.512 ' CA ' HG23 ' A' ' 104' ' ' THR . 0.0 OUTLIER 175.35 119.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.917 -1.343 . . . . 0.0 110.398 179.959 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.579 HD23 ' CE1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -140.84 70.01 1.35 Allowed 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.25 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.544 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 17.7 p-80 -89.28 152.7 21.41 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.893 . . . . 0.0 110.129 -179.364 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 4.0 tt0 79.66 72.74 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.402 -0.811 . . . . 0.0 109.598 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . 0.438 ' HG2' ' C ' ' A' ' 118' ' ' GLU . 14.0 mm-40 -134.67 130.18 35.94 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.357 -0.839 . . . . 0.0 109.45 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . 0.46 ' O ' HD13 ' A' ' 121' ' ' ILE . 1.1 mp0 -66.41 152.66 44.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.269 -0.895 . . . . 0.0 109.013 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.46 HD13 ' O ' ' A' ' 120' ' ' GLN . 9.1 mm -136.08 136.07 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 O-C-N 121.068 -1.02 . . . . 0.0 110.099 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.4 -179.04 6.31 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 121.651 0.738 . . . . 0.0 110.125 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.581 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 30.5 p -76.45 1.15 17.3 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.35 179.519 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.504 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 8.6 mt-10 -111.64 -168.95 1.37 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 0.0 109.177 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.538 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 97.6 m95 -94.22 123.36 37.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.657 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -106.93 121.36 45.11 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.301 -0.875 . . . . 0.0 108.992 179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.575 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.6 Cg_endo -80.02 104.51 1.68 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.396 2.064 . . . . 0.0 110.947 -179.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -116.98 131.67 56.9 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.459 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.4 t -151.76 177.09 10.75 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.936 -1.102 . . . . 0.0 110.745 -179.489 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.69 ' CE2' ' CD1' ' A' ' 88' ' ' TYR . 12.2 p90 -163.36 178.21 8.31 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.08 179.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 82.4 mt-10 -130.48 138.92 50.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.117 -0.989 . . . . 0.0 109.975 -179.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.576 ' CE2' ' HA2' ' A' ' 114' ' ' GLY . 0.3 OUTLIER -151.06 168.13 25.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.372 -0.83 . . . . 0.0 109.163 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.7 OUTLIER -127.82 146.57 50.56 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.115 -0.991 . . . . 0.0 109.409 -179.507 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.539 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 5.9 t -41.28 110.43 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.618 -0.676 . . . . 0.0 109.266 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -56.1 -46.94 78.92 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.318 -0.864 . . . . 0.0 109.043 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.448 ' O ' ' HG3' ' A' ' 137' ' ' GLN . 2.8 m-20 -118.49 -91.71 0.55 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.429 -0.794 . . . . 0.0 109.173 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.448 ' HG3' ' O ' ' A' ' 136' ' ' ASP . 71.9 mt-30 -159.7 57.37 0.38 Allowed 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.47 -0.769 . . . . 0.0 108.929 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.519 ' O ' ' CG2' ' A' ' 80' ' ' VAL . 16.6 mm-40 -95.7 111.49 23.43 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.293 -0.88 . . . . 0.0 109.765 -179.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.38 -13.79 59.39 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.324 -0.86 . . . . 0.0 108.73 179.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.486 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 39.2 t -132.17 130.6 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.367 -0.833 . . . . 0.0 109.009 179.463 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.465 HG23 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -144.36 171.8 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.254 -0.903 . . . . 0.0 109.824 -179.812 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.472 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.5 OUTLIER -146.47 131.83 18.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.489 -0.757 . . . . 0.0 109.522 179.86 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.595 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -93.34 110.54 47.27 Favored Pre-proline 0 N--CA 1.486 1.372 0 O-C-N 121.259 -0.9 . . . . 0.0 110.168 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.488 ' HD2' ' O ' ' A' ' 104' ' ' THR . 36.0 Cg_endo -77.46 111.06 3.09 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.297 1.998 . . . . 0.0 110.735 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.643 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 1.2 mt -97.8 120.71 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 179.162 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.538 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 7.1 m80 -85.83 159.36 19.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.777 -1.202 . . . . 0.0 112.202 -176.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.614 ' CE1' ' CB ' ' A' ' 73' ' ' ALA . 61.6 m-85 -157.57 158.43 35.59 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 179.001 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.426 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 112.19 52.53 0.52 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.526 ' CA ' HG12 ' A' ' 64' ' ' VAL . 41.8 m-85 -125.73 158.17 35.54 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.428 -1.042 . . . . 0.0 109.195 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.98 -29.51 69.38 Favored 'General case' 0 C--N 1.296 -1.734 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.469 ' HB3' ' HB ' ' A' ' 100' ' ' VAL . . . -70.86 -9.59 57.94 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 121.738 0.78 . . . . 0.0 109.327 179.299 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.573 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 2.1 t-20 -120.59 12.18 11.45 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.44 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.2 t -82.92 161.69 3.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 O-C-N 121.628 -0.67 . . . . 0.0 109.631 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.44 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.7 37.42 51.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.406 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.1 m-20 -160.32 138.37 9.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.128 -1.219 . . . . 0.0 110.17 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.579 ' CG2' ' CE1' ' A' ' 158' ' ' TYR . 98.0 m -86.26 121.2 28.5 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.039 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.573 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 1.0 OUTLIER -101.87 117.27 46.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.865 -1.147 . . . . 0.0 110.224 -178.874 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.634 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 2.9 m-85 -95.96 135.77 37.28 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 178.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.58 HD11 ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -129.16 137.66 56.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 120.819 -1.176 . . . . 0.0 110.12 -178.601 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.529 ' OD1' ' CA ' ' A' ' 9' ' ' GLY . 9.0 t0 -174.08 136.26 0.5 Allowed 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.307 -0.871 . . . . 0.0 109.018 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 128.0 -11.11 6.58 Favored Glycine 0 N--CA 1.485 1.958 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.334 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.505 ' N ' HG13 ' A' ' 90' ' ' ILE . 11.4 tp -59.63 110.19 1.08 Allowed 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.694 -1.474 . . . . 0.0 108.486 -179.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . 0.494 ' HA ' ' CB ' ' A' ' 5' ' ' ASN . . . -139.6 145.65 38.82 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.474 -0.766 . . . . 0.0 110.265 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.474 ' HB ' ' HB1' ' A' ' 4' ' ' ALA . 2.3 mp -126.86 109.02 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.422 -0.799 . . . . 0.0 109.047 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.46 ' HB3' HG21 ' A' ' 3' ' ' VAL . . . -126.87 146.94 50.1 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.083 -1.011 . . . . 0.0 109.826 -179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.572 ' HB2' ' CZ ' ' A' ' 86' ' ' TYR . 5.2 t -76.17 138.46 40.7 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.201 -0.937 . . . . 0.0 109.571 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 1.8 pt20 -136.06 158.24 74.18 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.257 -0.902 . . . . 0.0 109.48 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo . . . . . 0 C--N 1.308 -1.565 0 C-N-CA 122.622 2.214 . . . . 0.0 110.45 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.2 ttt . . . . . 0 N--CA 1.492 1.634 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 26.1 mt -96.53 -162.5 0.96 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.453 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.526 ' CG1' ' O ' ' A' ' 5' ' ' ASN . 3.2 p -162.99 178.15 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.226 -0.921 . . . . 0.0 109.363 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.5 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -68.79 -57.92 4.92 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.188 -0.945 . . . . 0.0 109.854 -179.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.526 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 8.5 p-10 -102.07 141.83 34.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.238 -0.914 . . . . 0.0 109.79 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.475 ' O ' ' HA3' ' A' ' 27' ' ' GLY . 1.8 mp -102.78 150.17 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 0.0 109.555 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.54 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.9 OUTLIER 66.63 17.98 10.69 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.254 -0.904 . . . . 0.0 110.0 179.464 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -59.02 -26.97 61.68 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.855 -1.698 . . . . 0.0 108.855 179.571 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.445 ' O ' ' OD1' ' A' ' 160' ' ' ASP . . . -115.38 37.57 3.42 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.582 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 1.1 m-85 43.58 46.09 5.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.328 -1.101 . . . . 0.0 109.417 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -77.08 -36.14 56.04 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.19 -0.944 . . . . 0.0 109.659 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.519 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 4.5 t -88.3 -21.68 24.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.227 -0.921 . . . . 0.0 109.499 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.537 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 1.2 m -70.81 113.92 22.65 Favored Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.7 Cg_endo -77.48 136.16 15.42 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.392 2.061 . . . . 0.0 110.502 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.44 ' C ' ' O ' ' A' ' 14' ' ' PRO . . . -40.21 154.46 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.897 -0.502 . . . . 0.0 109.65 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.52 131.1 2.96 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 -179.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.521 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.2 139.0 17.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.273 -1.134 . . . . 0.0 109.494 -179.591 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.525 HG11 ' CA ' ' A' ' 24' ' ' GLY . 53.7 t -86.52 142.86 12.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 CA-C-O 121.568 0.699 . . . . 0.0 110.122 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 19.6 p -93.75 -28.43 15.93 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.99 101.05 5.08 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.586 ' CD2' ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -47.29 -30.21 2.96 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.247 -0.908 . . . . 0.0 109.873 -178.842 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.586 ' N ' ' CD2' ' A' ' 21' ' ' LEU . . . -59.72 -47.74 84.46 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.559 -0.713 . . . . 0.0 109.857 -179.642 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -107.58 34.59 3.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.123 -0.985 . . . . 0.0 109.432 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.525 ' CA ' HG11 ' A' ' 18' ' ' VAL . . . -74.55 -50.02 10.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.537 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 4.9 t -119.84 141.49 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.24 -1.153 . . . . 0.0 109.738 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -67.18 -47.18 71.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.345 -0.847 . . . . 0.0 109.433 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.54 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -89.29 0.66 81.49 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.597 ' CZ3' ' HB3' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -135.64 121.75 20.17 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.198 -1.177 . . . . 0.0 109.215 179.659 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.539 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -121.65 122.79 40.41 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.366 -0.834 . . . . 0.0 108.912 179.452 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.511 ' HB2' ' HB2' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -99.32 173.5 6.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.756 -179.308 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.501 ' HA ' HD21 ' A' ' 21' ' ' LEU . 62.7 m-80 -160.37 123.45 3.42 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.369 -0.832 . . . . 0.0 109.842 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.53 HG11 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.54 136.25 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.205 -0.935 . . . . 0.0 109.415 179.219 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.01 -178.91 26.5 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 70.2 m -58.79 -16.99 19.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -1.127 . . . . 0.0 109.538 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.467 ' OG ' ' HA ' ' A' ' 70' ' ' ASP . 2.8 p -60.99 -37.0 80.94 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.242 -0.911 . . . . 0.0 109.367 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.53 ' CG2' HG11 ' A' ' 32' ' ' VAL . 2.1 t -62.41 89.39 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 O-C-N 121.27 -0.894 . . . . 0.0 109.334 179.631 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 88.7 m -73.14 -28.07 62.03 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.362 -0.836 . . . . 0.0 108.864 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' A' ' 38' ' ' ASN . 0.0 OUTLIER -112.72 142.99 28.13 Favored Pre-proline 0 C--N 1.297 -1.703 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.584 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -76.41 111.38 3.25 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.384 2.056 . . . . 0.0 110.801 -179.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.524 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.8 Cg_endo -78.05 177.11 9.18 Favored 'Trans proline' 0 C--N 1.312 -1.365 0 C-N-CA 122.521 2.147 . . . . 0.0 109.391 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.53 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 63.2 t -118.03 120.87 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 120.873 -1.142 . . . . 0.0 110.829 -179.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.571 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 96.3 m-85 -110.01 112.89 25.17 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 178.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.521 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 22.8 tt0 -150.93 155.55 39.35 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.006 -1.059 . . . . 0.0 109.845 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.444 HG21 HG23 ' A' ' 13' ' ' THR . 85.2 t -94.49 141.52 14.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.203 179.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.453 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -117.88 118.85 33.12 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.512 -0.743 . . . . 0.0 109.347 -179.663 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.438 ' CD ' ' CE ' ' A' ' 55' ' ' LYS . 6.3 mt-10 -103.55 109.85 21.67 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.61 -0.681 . . . . 0.0 109.394 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.467 ' O ' ' HB2' ' A' ' 54' ' ' ASN . 2.4 p -144.5 -179.54 6.62 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.46 -0.775 . . . . 0.0 109.386 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -102.13 29.71 4.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 109.367 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -119.5 -14.31 9.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 0.0 109.541 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -45.91 154.62 0.56 Allowed Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.147 -0.971 . . . . 0.0 109.521 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.521 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 36.0 Cg_endo -78.04 -34.01 1.86 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.596 2.198 . . . . 0.0 110.419 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -129.1 91.68 3.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.266 -0.896 . . . . 0.0 109.351 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.62 -120.98 6.31 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.544 -1.423 . . . . 0.0 109.544 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.467 ' HB2' ' O ' ' A' ' 47' ' ' THR . 11.9 p30 -160.02 30.16 0.18 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.239 -1.154 . . . . 0.0 109.472 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.528 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 8.2 mttp -135.09 130.74 36.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.305 -0.872 . . . . 0.0 109.547 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.485 ' CB ' ' HB2' ' A' ' 160' ' ' ASP . 4.0 m -149.05 175.62 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.372 -0.83 . . . . 0.0 109.145 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.582 ' HB2' ' CE2' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -105.81 100.91 10.44 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.032 -1.043 . . . . 0.0 108.998 179.441 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.618 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.62 117.87 22.33 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 178.735 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.528 ' O ' ' CG2' ' A' ' 156' ' ' THR . 40.9 t -115.15 144.92 21.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.069 -1.02 . . . . 0.0 109.168 -179.042 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.53 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 9.9 m -107.19 94.18 4.95 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.573 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 50.8 t -90.27 118.1 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.384 -0.823 . . . . 0.0 109.194 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -153.91 58.66 0.73 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.866 . . . . 0.0 109.941 -179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.51 ' O ' ' ND2' ' A' ' 38' ' ' ASN . . . 158.47 92.49 0.09 OUTLIER Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.537 HG13 ' CA ' ' A' ' 149' ' ' TYR . 2.7 m -84.36 -172.38 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.282 -1.128 . . . . 0.0 109.599 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -138.23 -157.17 7.36 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.4 m120 -96.06 10.03 38.88 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -1.121 . . . . 0.0 109.491 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.578 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 17.5 m-80 -127.35 146.46 58.3 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.212 -0.93 . . . . 0.0 109.42 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.576 ' HG2' ' CZ3' ' A' ' 69' ' ' TRP . 35.8 Cg_endo -78.47 12.54 2.09 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.579 2.186 . . . . 0.0 110.957 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.578 ' CZ2' ' OD1' ' A' ' 67' ' ' ASN . 1.1 p90 -133.56 54.5 1.95 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.987 -1.07 . . . . 0.0 109.853 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.467 ' HA ' ' OG ' ' A' ' 35' ' ' SER . 0.8 OUTLIER -78.4 -69.0 0.59 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.185 -0.947 . . . . 0.0 108.838 179.464 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.524 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 3.2 mp -106.05 128.02 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.155 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.61 138.24 52.1 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.903 -1.123 . . . . 0.0 110.467 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.597 ' HB3' ' CZ3' ' A' ' 28' ' ' TRP . . . -120.35 132.15 55.16 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 178.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.511 HG22 ' N ' ' A' ' 75' ' ' ALA . 16.4 m -135.52 163.1 30.86 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.721 -1.237 . . . . 0.0 110.379 -178.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.511 ' N ' HG22 ' A' ' 74' ' ' THR . . . -122.66 137.56 54.87 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.433 -0.792 . . . . 0.0 109.145 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.539 ' CE2' ' CG ' ' A' ' 29' ' ' ASP . 1.6 p90 179.03 161.31 0.71 Allowed Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.516 -0.74 . . . . 0.0 109.103 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.514 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.3 Cg_endo -80.03 165.41 78.82 Favored 'Cis proline' 0 C--N 1.309 -1.514 0 C-N-CA 123.63 -1.404 . . . . 0.0 110.775 -0.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.492 HG12 ' CD1' ' A' ' 164' ' ' ILE . 92.6 t -120.34 156.47 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.381 -0.824 . . . . 0.0 108.918 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.5 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 4.5 m-80 -124.13 122.05 36.8 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.17 -0.956 . . . . 0.0 109.961 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.569 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 3.3 m -129.96 -174.01 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.153 -0.967 . . . . 0.0 109.54 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.543 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 0.0 OUTLIER -137.12 143.88 43.79 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.394 -0.816 . . . . 0.0 109.148 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -76.14 115.46 4.14 Favored 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.475 2.117 . . . . 0.0 110.452 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.67 -27.36 20.61 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.497 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.86 149.81 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.186 -1.185 . . . . 0.0 109.549 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.434 ' O ' ' CB ' ' A' ' 166' ' ' SER . 39.0 m -97.14 132.99 42.37 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.569 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 12.9 m-85 -111.88 164.83 12.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.582 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' THR . . . . . 0.457 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 12.1 m -115.33 154.1 29.77 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.3 -0.875 . . . . 0.0 109.445 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.671 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 6.2 t80 -131.12 118.56 20.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.258 -0.901 . . . . 0.0 109.236 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.481 ' O ' ' O ' ' A' ' 161' ' ' GLY . 16.6 m -135.74 143.55 45.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.174 -0.954 . . . . 0.0 109.187 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.48 ' C ' ' CD1' ' A' ' 91' ' ' TRP . 17.5 tt -150.51 163.71 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.868 -1.145 . . . . 0.0 109.588 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.521 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 18.2 m95 -130.4 126.34 36.8 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.037 -1.039 . . . . 0.0 109.247 179.626 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -115.79 149.22 38.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.275 -0.891 . . . . 0.0 109.541 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.564 ' CB ' ' CE3' ' A' ' 125' ' ' TRP . 4.9 ttp85 -164.02 120.61 1.66 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.196 -0.94 . . . . 0.0 109.145 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -105.4 160.56 15.04 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.324 -0.86 . . . . 0.0 110.012 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . 0.454 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 0.0 OUTLIER -57.26 -48.96 77.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.436 -0.79 . . . . 0.0 109.172 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.458 ' HA ' HG23 ' A' ' 123' ' ' THR . 16.3 mt-30 -116.44 146.19 42.72 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.336 -0.852 . . . . 0.0 109.166 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.583 ' N ' ' CG2' ' A' ' 123' ' ' THR . 8.5 p30 -65.17 146.29 55.16 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.204 -0.935 . . . . 0.0 109.517 -179.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 112.12 30.87 2.81 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.467 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -118.13 138.18 52.45 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.117 -1.226 . . . . 0.0 109.112 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.502 HG12 ' N ' ' A' ' 101' ' ' VAL . 52.1 t -116.9 158.36 17.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 O-C-N 121.256 -0.902 . . . . 0.0 110.747 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.643 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 72.6 t -153.68 163.04 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.535 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 74.9 m -121.72 125.24 46.13 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.916 -1.115 . . . . 0.0 109.907 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.613 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.2 OUTLIER -119.76 103.56 9.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.062 -1.024 . . . . 0.0 109.737 179.72 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.503 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 18.5 p -127.3 167.95 15.45 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.168 -0.958 . . . . 0.0 110.151 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.652 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -128.16 156.86 40.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.715 -0.615 . . . . 0.0 110.247 -179.793 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.503 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -173.92 -173.17 39.85 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.531 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.4 p30 -126.52 -169.37 2.01 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.18 -1.188 . . . . 0.0 109.049 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.531 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 5.6 mp0 -73.66 11.9 0.74 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.049 -1.032 . . . . 0.0 110.971 -179.4 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.499 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 1.0 OUTLIER -113.19 7.89 18.03 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 120.722 -1.236 . . . . 0.0 109.288 179.658 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.6 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.6 m-30 78.87 1.95 2.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.355 -0.841 . . . . 0.0 109.815 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.503 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 4.9 mm100 -76.04 159.47 30.77 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.106 -0.996 . . . . 0.0 108.729 179.466 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.473 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 5.2 tt0 -138.09 135.3 35.67 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.968 -1.083 . . . . 0.0 110.005 -179.415 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.568 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 6.5 m-85 -95.95 -70.62 0.71 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.06 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.572 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -81.72 162.0 42.79 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.444 ' HA ' HG23 ' A' ' 104' ' ' THR . 7.7 ttm180 -158.05 103.95 1.87 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.974 -1.309 . . . . 0.0 110.337 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.577 HD23 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -144.1 72.85 1.36 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.335 -0.853 . . . . 0.0 108.784 179.087 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.535 ' CB ' ' HB3' ' A' ' 102' ' ' SER . 32.1 p-80 -115.82 162.79 16.81 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.121 -0.987 . . . . 0.0 110.049 -179.412 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.531 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 3.2 tt0 77.22 53.31 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.399 -0.813 . . . . 0.0 109.256 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 53.2 mm-40 -126.4 141.69 51.8 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.378 -0.826 . . . . 0.0 109.599 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . 0.454 ' HA ' HG23 ' A' ' 100' ' ' VAL . 46.9 mm-40 -73.64 156.55 37.88 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.467 HG12 ' O ' ' A' ' 99' ' ' ALA . 10.8 mm -133.5 136.9 53.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.025 -1.047 . . . . 0.0 110.129 -179.469 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.64 -179.31 7.1 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.541 -0.724 . . . . 0.0 110.121 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.583 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 61.9 p -78.06 0.49 24.42 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.877 -0.729 . . . . 0.0 109.36 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.455 ' O ' ' HB2' ' A' ' 93' ' ' ARG . 2.8 mt-10 -110.06 -168.83 1.37 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -0.883 . . . . 0.0 109.327 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.564 ' CE3' ' CB ' ' A' ' 93' ' ' ARG . 85.6 m95 -98.01 121.91 40.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 109.562 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -106.83 121.35 45.22 Favored Pre-proline 0 N--CA 1.488 1.475 0 O-C-N 121.204 -0.935 . . . . 0.0 108.966 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.77 108.22 2.23 Favored 'Trans proline' 0 C--N 1.312 -1.381 0 C-N-CA 122.292 1.994 . . . . 0.0 110.96 -179.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -112.51 136.02 52.53 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.5 t -151.07 175.94 11.63 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.651 -1.28 . . . . 0.0 111.05 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.671 ' CE2' ' CG ' ' A' ' 88' ' ' TYR . 29.1 p90 -173.87 -178.29 1.53 Allowed 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.346 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -131.14 155.2 47.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.237 -0.914 . . . . 0.0 109.698 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.568 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.02 168.31 17.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.341 -0.849 . . . . 0.0 109.41 179.783 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -133.78 147.68 51.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.187 -0.946 . . . . 0.0 109.516 -179.745 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.543 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 5.2 t -42.01 110.3 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.511 -0.743 . . . . 0.0 109.272 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 67.5 m -58.7 -50.35 74.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 0.0 109.203 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -110.51 -90.79 0.47 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.436 -0.79 . . . . 0.0 109.202 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.458 ' HA ' HG12 ' A' ' 134' ' ' VAL . 0.1 OUTLIER -163.31 56.31 0.18 Allowed 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.55 -0.719 . . . . 0.0 109.11 179.781 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.458 ' O ' HG23 ' A' ' 80' ' ' VAL . 50.0 mm-40 -95.66 112.9 24.52 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.271 -0.893 . . . . 0.0 109.809 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.37 -14.9 58.66 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.29 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.485 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.6 t -133.72 132.91 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.474 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.6 OUTLIER -143.52 172.22 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.184 -0.948 . . . . 0.0 110.285 -179.58 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.478 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.6 OUTLIER -140.79 133.22 28.42 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.57 -0.706 . . . . 0.0 109.111 179.978 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.652 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.48 110.48 45.18 Favored Pre-proline 0 C--N 1.305 -1.339 0 O-C-N 121.135 -0.978 . . . . 0.0 109.625 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.503 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.3 Cg_endo -76.49 110.96 3.16 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 C-N-CA 122.293 1.995 . . . . 0.0 111.089 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.526 ' CB ' ' O ' ' A' ' 73' ' ' ALA . 2.3 mm -97.45 135.3 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 178.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.52 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 8.8 m80 -102.24 158.55 16.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.438 -1.414 . . . . 0.0 111.335 -178.102 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.644 ' CZ ' ' CD1' ' A' ' 159' ' ' ILE . 11.1 m-85 -159.1 160.2 35.42 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.327 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.422 ' C ' HG13 ' A' ' 64' ' ' VAL . . . 106.71 48.11 0.99 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.537 ' CA ' HG13 ' A' ' 64' ' ' VAL . 17.4 m-85 -125.35 159.35 32.01 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.435 -1.038 . . . . 0.0 109.166 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.83 -27.24 68.74 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.469 ' HB1' ' CG2' ' A' ' 100' ' ' VAL . . . -70.4 -19.42 63.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.367 -0.833 . . . . 0.0 109.199 179.522 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.494 ' OD1' ' N ' ' A' ' 152' ' ' ASN . 0.3 OUTLIER -107.96 10.17 28.45 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.42 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.477 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.2 t -84.65 163.98 2.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 121.437 -0.789 . . . . 0.0 109.686 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.477 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 49.88 31.57 17.23 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.455 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 2.2 t-20 -160.14 144.85 14.72 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.149 -1.207 . . . . 0.0 110.113 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.578 HG22 ' CZ ' ' A' ' 158' ' ' TYR . 52.6 m -92.55 128.83 38.55 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.573 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 1.2 mt -107.7 118.75 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.853 -1.154 . . . . 0.0 109.759 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.618 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 3.4 m-85 -102.96 133.14 48.56 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 178.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.644 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -124.55 142.86 40.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.308 -178.694 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.485 ' HB2' ' CB ' ' A' ' 56' ' ' VAL . 19.4 t70 -174.23 136.38 0.49 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.418 -0.801 . . . . 0.0 109.064 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 124.32 -7.76 8.52 Favored Glycine 0 N--CA 1.486 1.988 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.537 179.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.626 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 3.7 tp -59.9 103.97 0.26 Allowed 'General case' 0 N--CA 1.487 1.406 0 O-C-N 120.741 -1.446 . . . . 0.0 108.901 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -136.08 145.65 46.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.514 -0.741 . . . . 0.0 109.86 -179.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.492 ' CD1' HG12 ' A' ' 78' ' ' VAL . 8.4 mt -128.69 109.07 18.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.392 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.43 ' CB ' HG21 ' A' ' 3' ' ' VAL . . . -153.52 152.38 30.88 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.119 -0.988 . . . . 0.0 109.637 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.46 ' HB3' ' HA ' ' A' ' 86' ' ' TYR . 80.5 p -110.91 162.15 15.12 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.888 . . . . 0.0 109.425 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.454 ' HB3' ' HD2' ' A' ' 168' ' ' PRO . 2.4 mt-30 -95.63 158.67 34.05 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.431 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . 0.454 ' HD2' ' HB3' ' A' ' 167' ' ' GLN . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.56 0 C-N-CA 122.622 2.215 . . . . 0.0 110.419 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.452 -0.574 . . . . 0.0 109.452 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mp -85.09 109.81 18.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.241 -0.912 . . . . 0.0 109.425 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.507 ' CG2' ' HB1' ' A' ' 165' ' ' ALA . 3.9 p -100.98 173.17 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.9 . . . . 0.0 109.546 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.518 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -69.89 -58.85 3.38 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -0.893 . . . . 0.0 109.569 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.505 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 7.7 t30 -77.46 134.49 38.35 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.145 -0.972 . . . . 0.0 109.558 -179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.513 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 62.3 mt -111.72 138.86 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.262 -0.899 . . . . 0.0 109.536 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.547 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 10.2 t-20 76.17 26.48 0.96 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.309 -0.869 . . . . 0.0 109.83 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.27 -34.93 68.64 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 179.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.518 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -119.76 34.44 4.22 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 108.85 -1.7 . . . . 0.0 108.85 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.585 ' CZ ' ' HB2' ' A' ' 57' ' ' LEU . 8.4 m-85 43.84 53.76 6.02 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.375 -1.074 . . . . 0.0 109.358 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.4 ' OE2' ' O ' ' A' ' 52' ' ' GLU . 31.7 mm-40 -83.96 -28.56 27.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.471 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.9 t -86.67 -41.98 13.77 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -0.879 . . . . 0.0 109.541 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.522 ' CB ' HG11 ' A' ' 25' ' ' VAL . 90.8 m -71.97 127.73 90.22 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.9 Cg_endo -77.63 141.13 19.41 Favored 'Trans proline' 0 C--N 1.312 -1.383 0 C-N-CA 122.481 2.121 . . . . 0.0 110.568 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.468 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -41.7 164.35 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.742 -0.599 . . . . 0.0 109.582 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.66 133.7 3.32 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 108.931 -1.668 . . . . 0.0 108.931 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.465 HG23 ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.89 140.2 15.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.277 -1.131 . . . . 0.0 109.207 -179.637 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.528 ' CG1' ' HA3' ' A' ' 24' ' ' GLY . 62.1 t -86.61 142.4 13.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 CA-C-O 121.638 0.732 . . . . 0.0 110.439 -179.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.35 -28.81 12.76 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -131.38 86.73 2.38 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.579 ' CD2' ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -45.33 -29.85 1.14 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.268 -0.895 . . . . 0.0 110.006 -178.953 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.579 ' N ' ' CD2' ' A' ' 21' ' ' LEU . . . -60.22 -49.0 79.34 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.494 -0.754 . . . . 0.0 110.232 -179.53 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -133.67 48.77 2.33 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.961 -1.087 . . . . 0.0 109.732 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.528 ' HA3' ' CG1' ' A' ' 18' ' ' VAL . . . -97.44 -12.37 48.42 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.522 HG11 ' CB ' ' A' ' 13' ' ' THR . 90.8 t -141.24 133.95 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.186 -1.185 . . . . 0.0 109.636 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . 0.509 ' O ' ' ND2' ' A' ' 7' ' ' ASN . 17.7 tt0 -78.36 126.69 31.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.384 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.547 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 101.76 -16.17 56.37 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.662 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.2 OUTLIER -137.6 120.24 16.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -1.117 . . . . 0.0 108.426 179.164 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.529 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -121.94 110.66 16.12 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.32 -0.863 . . . . 0.0 109.209 179.935 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.497 ' HB2' ' HB2' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -91.7 173.6 7.79 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.286 -0.884 . . . . 0.0 109.339 -179.73 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.517 ' HA ' HD22 ' A' ' 21' ' ' LEU . 77.7 m-20 -160.62 123.45 3.31 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.205 -0.934 . . . . 0.0 110.366 -179.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.53 HG13 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -109.36 131.32 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.291 -0.88 . . . . 0.0 109.286 178.861 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.79 -172.54 22.76 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -56.67 -31.65 64.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.334 -1.098 . . . . 0.0 109.559 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.468 ' HB2' ' HA ' ' A' ' 70' ' ' ASP . 0.7 OUTLIER -45.98 -42.42 13.05 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.196 -0.94 . . . . 0.0 109.279 -179.869 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.53 ' CG2' HG13 ' A' ' 32' ' ' VAL . 2.1 t -60.77 89.84 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 121.188 -0.945 . . . . 0.0 109.529 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 94.7 m -74.05 -28.13 61.25 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.854 0.835 . . . . 0.0 108.789 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.492 ' O ' HG12 ' A' ' 36' ' ' VAL . 8.2 t30 -114.01 144.48 31.66 Favored Pre-proline 0 C--N 1.297 -1.681 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -75.83 111.07 3.21 Favored 'Trans proline' 0 C--N 1.307 -1.627 0 C-N-CA 122.443 2.095 . . . . 0.0 111.011 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.52 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 36.2 Cg_endo -78.97 174.41 12.22 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.558 2.172 . . . . 0.0 109.607 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.535 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 73.8 t -116.9 120.5 65.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.998 -1.064 . . . . 0.0 110.659 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.492 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 60.6 m-85 -109.04 112.55 24.79 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 178.044 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.465 ' HB2' HG23 ' A' ' 17' ' ' VAL . 28.7 tt0 -150.59 146.96 26.87 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.11 -0.994 . . . . 0.0 109.904 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.431 HG13 ' O ' ' A' ' 56' ' ' VAL . 61.7 t -95.49 148.61 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.392 -0.817 . . . . 0.0 109.232 179.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.567 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -132.64 147.23 52.33 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.175 -0.953 . . . . 0.0 108.895 -179.79 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.567 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 16.9 mt-10 -117.06 114.09 23.26 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.53 -0.731 . . . . 0.0 109.63 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.519 ' CG2' HD23 ' A' ' 45' ' ' LEU . 12.9 p -139.8 174.14 10.82 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.473 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.511 ' HA ' ' ND2' ' A' ' 54' ' ' ASN . 16.9 m -100.06 21.67 12.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.462 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.413 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.0 OUTLIER -111.82 -15.33 13.4 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.182 -0.949 . . . . 0.0 109.534 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.449 ' HB1' ' O ' ' A' ' 53' ' ' GLY . . . -44.17 147.19 0.99 Allowed Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.528 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.06 -40.54 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.548 2.165 . . . . 0.0 110.389 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.4 ' O ' ' OE2' ' A' ' 11' ' ' GLU . 2.5 tp10 -117.87 79.71 1.4 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 109.432 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.449 ' O ' ' HB1' ' A' ' 50' ' ' ALA . . . 102.81 -139.41 14.42 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.511 ' ND2' ' HA ' ' A' ' 48' ' ' SER . 3.0 m120 -142.28 35.35 1.5 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -1.111 . . . . 0.0 109.463 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.517 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 8.9 mttt -144.64 138.3 27.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.279 -0.888 . . . . 0.0 109.555 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.453 HG11 ' O ' ' A' ' 55' ' ' LYS . 4.8 m -150.32 174.39 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.344 -0.847 . . . . 0.0 109.281 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.585 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -108.13 103.51 12.73 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.072 -1.018 . . . . 0.0 108.893 179.45 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.64 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.59 119.17 23.45 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.532 ' CG2' HD21 ' A' ' 57' ' ' LEU . 41.3 t -114.66 144.83 21.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.092 -1.005 . . . . 0.0 109.075 -179.212 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.535 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 24.0 m -106.4 91.52 3.74 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 179.281 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.581 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 53.8 t -90.86 113.01 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.385 -0.822 . . . . 0.0 109.11 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -153.46 58.02 0.76 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.312 -0.868 . . . . 0.0 109.831 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 162.09 85.09 0.05 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.528 HG11 ' CA ' ' A' ' 149' ' ' TYR . 1.3 m -79.89 175.82 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.211 -1.17 . . . . 0.0 109.46 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.454 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -124.45 -149.91 7.76 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -95.15 -4.54 45.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.302 -1.116 . . . . 0.0 109.609 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.56 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 0.8 OUTLIER -114.78 147.89 39.2 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 109.283 179.991 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -79.02 14.25 1.78 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.717 2.278 . . . . 0.0 111.008 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.56 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.3 p90 -135.34 52.53 2.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.99 -1.069 . . . . 0.0 109.921 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.468 ' HA ' ' HB2' ' A' ' 35' ' ' SER . 0.4 OUTLIER -75.22 -66.45 0.76 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.046 -1.034 . . . . 0.0 108.966 179.552 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.52 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 2.5 mt -101.23 127.79 54.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.305 -0.872 . . . . 0.0 108.659 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.473 ' O ' ' HB3' ' A' ' 30' ' ' LEU . 7.2 mt-10 -126.58 137.71 53.37 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.05 -1.031 . . . . 0.0 110.363 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.584 ' HB2' ' CZ3' ' A' ' 28' ' ' TRP . . . -118.31 123.32 45.07 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 106.998 -1.482 . . . . 0.0 106.998 178.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.511 HG23 ' N ' ' A' ' 75' ' ' ALA . 18.0 m -128.61 163.31 25.31 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 120.441 -1.412 . . . . 0.0 110.459 -178.578 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.511 ' N ' HG23 ' A' ' 74' ' ' THR . . . -129.7 138.32 51.09 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.472 -0.768 . . . . 0.0 109.238 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.546 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 2.2 p90 177.99 160.48 0.59 Allowed Pre-proline 0 N--CA 1.492 1.647 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.523 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -81.65 166.75 71.9 Favored 'Cis proline' 0 C--N 1.31 -1.476 0 C-N-CA 123.686 -1.381 . . . . 0.0 110.799 -0.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 76.5 t -124.69 156.34 32.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.219 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.518 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 3.6 m120 -123.77 123.05 39.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.915 -1.116 . . . . 0.0 110.417 -179.301 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.58 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 3.0 m -128.19 -173.88 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.115 179.244 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.526 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 1.7 mtt180 -126.96 145.16 52.86 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.246 -0.908 . . . . 0.0 109.438 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.41 120.78 5.38 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.437 2.091 . . . . 0.0 110.493 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.35 -27.43 17.18 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.6 t -85.94 149.72 4.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.271 -1.135 . . . . 0.0 109.439 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 20.8 m -97.74 122.4 40.78 Favored 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.58 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 3.6 m-85 -99.77 170.28 8.66 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.922 . . . . 0.0 109.619 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' THR . . . . . 0.466 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 6.5 m -118.23 154.09 32.82 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.404 -0.81 . . . . 0.0 109.431 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.627 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.8 t80 -128.11 121.23 29.1 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.256 -0.903 . . . . 0.0 109.266 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.468 ' O ' ' O ' ' A' ' 161' ' ' GLY . 19.6 m -135.54 145.97 47.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.191 -0.943 . . . . 0.0 109.317 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.506 ' C ' ' CD1' ' A' ' 91' ' ' TRP . 16.7 tt -150.74 163.68 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 120.765 -1.209 . . . . 0.0 109.531 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.577 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 19.7 m95 -133.92 124.73 26.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.884 -1.135 . . . . 0.0 109.057 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.515 ' HB2' ' CG2' ' A' ' 121' ' ' ILE . . . -117.34 150.88 38.1 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.255 -0.903 . . . . 0.0 109.491 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.576 ' HD2' ' CE2' ' A' ' 125' ' ' TRP . 1.0 OUTLIER -164.27 121.83 1.72 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.187 -0.946 . . . . 0.0 108.971 179.981 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.69 167.49 9.73 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -0.922 . . . . 0.0 110.053 -179.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -58.52 -48.77 79.74 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.265 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.459 ' HB2' ' OD1' ' A' ' 155' ' ' ASN . 2.9 mt-30 -118.28 150.97 38.58 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.299 -0.876 . . . . 0.0 109.163 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.579 ' N ' ' CG2' ' A' ' 123' ' ' THR . 0.6 OUTLIER -66.34 145.13 56.06 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.255 -0.903 . . . . 0.0 109.701 -179.778 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 114.07 35.21 1.53 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.462 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -120.2 139.54 52.49 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.269 -1.136 . . . . 0.0 109.246 179.698 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.467 HG12 ' N ' ' A' ' 101' ' ' VAL . 54.2 t -117.94 157.86 19.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 121.325 -0.859 . . . . 0.0 110.759 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.633 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 62.1 t -154.94 162.25 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 179.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.531 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 4.8 m -116.78 129.49 56.13 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.085 -1.009 . . . . 0.0 109.392 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.588 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.2 OUTLIER -123.84 103.92 8.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.145 -0.972 . . . . 0.0 109.734 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.506 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 36.1 p -135.35 169.63 17.18 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.972 -1.08 . . . . 0.0 110.233 179.742 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.588 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -131.99 127.66 58.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-O 121.71 0.767 . . . . 0.0 110.41 179.121 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -122.01 165.78 14.8 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.119 -1.992 . . . . 0.0 108.119 178.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.595 ' OD1' ' CE1' ' A' ' 113' ' ' TYR . 0.0 OUTLIER -125.97 -170.82 2.26 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.922 -1.34 . . . . 0.0 109.272 -179.714 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 13.0 mt-30 -81.22 -19.86 42.31 Favored 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 118.791 -1.164 . . . . 0.0 109.588 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.471 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 2.4 m -82.09 8.78 9.89 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' ' 109' ' ' SER . 16.8 m-30 65.3 24.03 12.14 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.313 -0.867 . . . . 0.0 108.674 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.525 ' CA ' ' OE1' ' A' ' 111' ' ' GLN . 0.7 OUTLIER -86.54 161.8 18.37 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.434 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.454 ' OE1' ' HG3' ' A' ' 115' ' ' ARG . 0.5 OUTLIER -107.68 101.35 10.67 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.336 -0.852 . . . . 0.0 109.891 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.595 ' CE1' ' OD1' ' A' ' 107' ' ' ASN . 2.0 m-30 -70.83 -64.43 0.9 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.586 -0.696 . . . . 0.0 109.72 178.607 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.552 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -115.44 166.38 12.22 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 -179.384 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.611 ' NE ' ' CE1' ' A' ' 117' ' ' HIS . 0.0 OUTLIER -157.81 74.61 0.74 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.242 -1.152 . . . . 0.0 110.691 -179.706 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.637 ' CD2' ' CD2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -131.45 86.47 2.36 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.985 -1.072 . . . . 0.0 108.811 178.495 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.611 ' CE1' ' NE ' ' A' ' 115' ' ' ARG . 29.8 p-80 -121.53 163.32 19.04 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -0.862 . . . . 0.0 110.009 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 3.0 tt0 76.89 36.31 0.34 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.42 -0.8 . . . . 0.0 109.373 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 17.3 mm-40 -100.3 135.81 41.15 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.299 -0.876 . . . . 0.0 109.542 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 20.5 mt-30 -71.29 156.03 39.99 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.388 -0.82 . . . . 0.0 108.944 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.515 ' CG2' ' HB2' ' A' ' 92' ' ' ALA . 6.1 mm -134.37 133.42 55.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.092 -1.005 . . . . 0.0 110.132 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.87 -179.42 6.81 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.514 -0.741 . . . . 0.0 109.971 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.579 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 37.9 p -73.96 -2.67 25.02 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.771 -0.772 . . . . 0.0 109.243 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.514 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 0.9 OUTLIER -110.02 175.42 5.45 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.334 -0.854 . . . . 0.0 109.177 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.576 ' CE2' ' HD2' ' A' ' 93' ' ' ARG . 95.0 m95 -81.77 122.35 27.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.83 121.02 46.29 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.252 -0.905 . . . . 0.0 108.833 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.577 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.6 Cg_endo -80.17 101.69 1.37 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.412 2.074 . . . . 0.0 111.177 -179.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -103.86 132.25 50.3 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 178.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.478 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -144.15 176.29 9.43 Favored 'General case' 0 C--N 1.295 -1.776 0 O-C-N 120.875 -1.141 . . . . 0.0 110.723 -179.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.637 ' CD2' ' CD2' ' A' ' 116' ' ' LEU . 25.3 p90 -175.11 152.56 1.47 Allowed 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 114.978 -1.01 . . . . 0.0 109.34 179.651 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -101.96 142.49 33.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.257 -0.902 . . . . 0.0 109.68 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.637 ' CD1' ' CE1' ' A' ' 130' ' ' PHE . 8.1 p90 -153.65 137.54 16.25 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.34 -0.85 . . . . 0.0 109.371 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.445 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.8 OUTLIER -98.72 146.58 25.73 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.256 -0.902 . . . . 0.0 108.836 179.923 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 4.1 t -41.55 108.96 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.443 -0.786 . . . . 0.0 109.171 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -48.17 -35.33 11.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.332 -0.855 . . . . 0.0 109.007 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -138.49 -90.79 0.21 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.452 -0.78 . . . . 0.0 109.293 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.47 ' HA ' HG13 ' A' ' 134' ' ' VAL . 5.2 pt20 -158.35 56.05 0.45 Allowed 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.524 -0.735 . . . . 0.0 109.1 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.532 ' O ' ' CG2' ' A' ' 80' ' ' VAL . 31.8 mm-40 -92.58 111.06 22.51 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.2 p -79.31 -18.32 52.83 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 40.2 t -131.66 135.79 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.571 HG23 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -143.6 171.62 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.926 -1.109 . . . . 0.0 110.751 -179.177 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.49 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.7 OUTLIER -133.02 132.22 41.6 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.682 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.588 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -99.36 107.22 43.81 Favored Pre-proline 0 C--N 1.304 -1.374 0 O-C-N 120.976 -1.077 . . . . 0.0 109.382 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.506 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.9 Cg_endo -77.31 110.94 3.09 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.27 1.98 . . . . 0.0 111.341 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.662 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 1.6 mt -99.57 138.91 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.581 ' O ' ' CD2' ' A' ' 147' ' ' PHE . 4.8 m80 -103.81 159.11 15.91 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.53 -1.356 . . . . 0.0 111.732 -177.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.633 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 17.1 m-85 -161.24 160.0 29.4 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 105.77 52.22 0.81 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.528 ' CA ' HG11 ' A' ' 64' ' ' VAL . 22.8 m-85 -129.0 158.88 37.63 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.531 -0.982 . . . . 0.0 109.165 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.33 -26.51 67.33 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -71.64 -15.81 62.25 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.534 -0.729 . . . . 0.0 109.367 179.555 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.503 ' OD1' ' N ' ' A' ' 152' ' ' ASN . 0.2 OUTLIER -112.05 8.8 20.24 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.444 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.3 t -83.87 164.44 2.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 O-C-N 121.423 -0.798 . . . . 0.0 109.747 -179.303 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.492 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 55.89 26.29 47.45 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.911 -1.275 . . . . 0.0 109.911 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.459 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.7 t-20 -160.38 143.01 13.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.98 -1.306 . . . . 0.0 110.202 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.577 HG23 ' CE1' ' A' ' 158' ' ' TYR . 46.1 m -89.4 121.48 31.69 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 178.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.581 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 1.1 mt -98.03 117.7 43.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 120.882 -1.136 . . . . 0.0 110.097 -178.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.64 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 2.4 m-85 -96.9 130.83 44.14 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.597 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.631 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.1 mt -121.03 142.41 37.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 120.726 -1.234 . . . . 0.0 110.154 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.529 ' OD1' ' N ' ' A' ' 161' ' ' GLY . 9.0 t0 -174.14 136.24 0.5 Allowed 'General case' 0 N--CA 1.486 1.366 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.529 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 124.82 -7.73 8.24 Favored Glycine 0 N--CA 1.486 1.985 0 C-N-CA 119.329 -1.415 . . . . 0.0 110.633 179.403 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.619 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 3.2 tp -60.29 100.0 0.09 Allowed 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.58 -1.541 . . . . 0.0 108.895 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . 0.452 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -136.7 145.7 45.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.445 -0.785 . . . . 0.0 109.662 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.48 ' CD1' HG11 ' A' ' 78' ' ' VAL . 25.5 mt -128.58 108.8 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.239 -0.913 . . . . 0.0 109.431 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.507 ' HB1' ' CG2' ' A' ' 3' ' ' VAL . . . -146.47 147.36 31.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.177 -0.952 . . . . 0.0 109.576 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.7 p -67.11 -174.8 0.39 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.378 -0.826 . . . . 0.0 109.538 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.432 ' HB3' ' HD2' ' A' ' 168' ' ' PRO . 0.0 OUTLIER -72.77 168.48 23.94 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.322 -0.861 . . . . 0.0 109.44 -179.97 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . 0.432 ' HD2' ' HB3' ' A' ' 167' ' ' GLN . 35.8 Cg_endo . . . . . 0 C--N 1.309 -1.516 0 C-N-CA 122.623 2.216 . . . . 0.0 110.457 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.4 ttt . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.492 ' CD2' ' N ' ' A' ' 2' ' ' LEU . 3.9 mm? -101.92 169.73 8.59 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.31 -0.869 . . . . 0.0 109.413 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 5' ' ' ASN . 4.4 p -153.93 173.73 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.38 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.476 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -75.86 -39.63 56.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.192 -0.943 . . . . 0.0 109.714 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.527 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 1.2 t30 -92.1 129.45 38.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.706 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.459 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 64.7 mt -113.55 129.96 68.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.243 -0.911 . . . . 0.0 109.346 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.529 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.7 OUTLIER 69.93 28.0 4.31 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.206 -0.934 . . . . 0.0 109.597 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -44.26 -26.95 1.04 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.458 ' O ' ' OD2' ' A' ' 160' ' ' ASP . . . -142.14 52.03 0.67 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.581 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 2.8 m-85 45.27 56.38 5.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.261 -1.14 . . . . 0.0 109.237 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -84.52 -29.64 25.77 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.139 -0.976 . . . . 0.0 110.249 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.6 p -95.0 -47.49 6.38 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.011 -1.056 . . . . 0.0 110.129 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.524 ' CB ' HG11 ' A' ' 25' ' ' VAL . 3.1 m -59.84 135.76 90.04 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.166 -0.959 . . . . 0.0 109.538 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.466 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.9 Cg_endo -77.36 146.14 24.53 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.561 2.174 . . . . 0.0 110.71 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.466 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -44.62 170.76 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 121.299 0.571 . . . . 0.0 109.798 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 140.33 130.56 2.66 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.097 -1.601 . . . . 0.0 109.097 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.527 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.07 139.21 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.224 -1.162 . . . . 0.0 109.166 -179.653 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.531 ' CG1' ' HA3' ' A' ' 24' ' ' GLY . 60.2 t -90.66 142.95 12.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-O 121.625 0.726 . . . . 0.0 110.442 -179.468 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.5 t -100.7 -29.44 12.29 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 19.4 m-20 -131.48 93.92 3.44 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.577 HD21 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -48.86 -29.32 4.53 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.264 -0.897 . . . . 0.0 110.135 -178.626 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.577 ' N ' HD21 ' A' ' 21' ' ' LEU . . . -59.44 -57.04 14.72 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.495 -0.753 . . . . 0.0 110.119 -179.364 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -119.99 41.82 3.09 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.155 -0.965 . . . . 0.0 109.45 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.531 ' HA3' ' CG1' ' A' ' 18' ' ' VAL . . . -77.07 -39.87 26.36 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.952 -1.259 . . . . 0.0 109.952 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.563 ' HB ' ' CE2' ' A' ' 10' ' ' PHE . 46.3 t -141.74 133.72 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.102 -1.234 . . . . 0.0 109.904 -179.62 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 20.6 tp10 -68.68 141.58 55.29 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -0.857 . . . . 0.0 109.224 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.529 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 106.58 -32.14 7.58 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.579 ' CZ3' ' HB2' ' A' ' 73' ' ' ALA . 0.1 OUTLIER -135.04 121.0 19.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.152 -1.205 . . . . 0.0 109.109 179.492 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -112.84 109.71 19.34 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.503 ' HB2' ' HB2' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -89.93 173.66 8.11 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.218 -0.926 . . . . 0.0 109.665 -179.139 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.524 ' HA ' HD22 ' A' ' 21' ' ' LEU . 7.1 m120 -160.93 128.02 4.16 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.181 -0.949 . . . . 0.0 110.807 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.531 HG13 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -117.16 130.05 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.209 -0.932 . . . . 0.0 108.993 178.198 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.29 171.7 16.18 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.499 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.4 ' O ' ' C ' ' A' ' 35' ' ' SER . 0.7 OUTLIER -45.6 -29.89 1.34 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.377 -1.073 . . . . 0.0 109.419 179.951 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.489 ' CB ' ' OD1' ' A' ' 70' ' ' ASP . 0.4 OUTLIER -45.88 -53.41 9.85 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.369 -0.832 . . . . 0.0 109.116 179.943 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.535 ' CG1' ' O ' ' A' ' 38' ' ' ASN . 34.7 t -47.63 102.57 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 O-C-N 121.251 -0.905 . . . . 0.0 110.084 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 40.8 m -81.63 -26.19 35.02 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 121.894 0.854 . . . . 0.0 108.764 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.535 ' O ' ' CG1' ' A' ' 36' ' ' VAL . 2.1 m-80 -111.67 147.75 37.43 Favored Pre-proline 0 C--N 1.296 -1.751 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.724 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -77.01 110.85 3.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.485 2.123 . . . . 0.0 110.654 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.489 ' HD3' ' O ' ' A' ' 38' ' ' ASN . 36.4 Cg_endo -80.05 160.98 23.74 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.475 2.117 . . . . 0.0 109.68 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.526 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 54.8 t -109.95 119.78 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.004 -1.06 . . . . 0.0 110.291 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.436 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 76.7 m-85 -105.9 112.16 25.1 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.369 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.527 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 1.3 tm-20 -155.01 147.06 23.64 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.005 -1.059 . . . . 0.0 109.872 -179.437 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.489 ' N ' ' HG2' ' A' ' 43' ' ' GLU . 53.1 t -91.89 148.54 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.493 -0.754 . . . . 0.0 109.193 179.574 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.554 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -131.97 146.9 52.37 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.207 -0.933 . . . . 0.0 108.888 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.554 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 17.4 mt-10 -117.91 115.04 24.13 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.676 -0.64 . . . . 0.0 109.508 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.485 ' CG2' HD23 ' A' ' 45' ' ' LEU . 2.2 p -142.11 172.25 12.94 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.488 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.95 11.7 24.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.248 -0.908 . . . . 0.0 109.484 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -103.33 -15.81 15.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.158 -0.964 . . . . 0.0 109.434 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.401 ' HA ' ' HD3' ' A' ' 51' ' ' PRO . . . -50.33 145.68 9.91 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.234 -0.916 . . . . 0.0 109.403 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.567 ' HG3' ' CE3' ' A' ' 125' ' ' TRP . 35.9 Cg_endo -78.38 -41.91 0.25 Allowed 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.577 2.185 . . . . 0.0 110.375 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -110.91 108.34 18.09 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.255 -0.903 . . . . 0.0 109.298 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.16 -117.16 6.64 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.466 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 50.0 p30 -160.06 29.87 0.18 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -1.173 . . . . 0.0 109.524 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.525 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 60.5 mttt -136.89 138.68 40.97 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.215 -0.928 . . . . 0.0 109.678 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.516 HG11 ' CH2' ' A' ' 125' ' ' TRP . 5.6 m -150.08 174.41 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.299 -0.876 . . . . 0.0 109.203 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.581 ' HB2' ' CE1' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -103.33 102.15 12.09 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.15 -0.969 . . . . 0.0 108.98 179.643 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.65 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.47 119.91 24.34 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.53 ' CG2' HD22 ' A' ' 57' ' ' LEU . 40.5 t -113.18 144.51 20.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.106 -0.997 . . . . 0.0 109.024 -179.172 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.526 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 19.9 m -110.7 90.59 3.37 Favored 'General case' 0 C--N 1.283 -2.284 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.519 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 43.9 t -86.48 127.78 40.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.273 -0.892 . . . . 0.0 109.211 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -151.07 57.0 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.887 . . . . 0.0 109.844 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.423 ' HA3' ' CG ' ' A' ' 38' ' ' ASN . . . 147.66 103.44 0.33 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.486 ' CG1' ' C ' ' A' ' 149' ' ' TYR . 2.3 m -79.94 -175.82 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.236 -1.155 . . . . 0.0 109.51 179.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -126.61 -178.5 15.34 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.666 -1.373 . . . . 0.0 109.666 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -68.73 -20.27 64.38 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.241 -1.152 . . . . 0.0 109.431 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.574 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.3 m-20 -106.98 152.54 41.02 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.28 -0.887 . . . . 0.0 109.492 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.2 Cg_endo -78.58 12.64 2.09 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 122.646 2.23 . . . . 0.0 110.973 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.574 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.2 p90 -135.57 54.58 1.91 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.991 -1.068 . . . . 0.0 109.631 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.515 ' HB3' ' N ' ' A' ' 36' ' ' VAL . 0.5 OUTLIER -83.37 -48.08 10.77 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.216 -0.927 . . . . 0.0 109.191 179.872 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.532 ' CD1' HG21 ' A' ' 36' ' ' VAL . 3.7 mm -98.72 149.09 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.254 -0.904 . . . . 0.0 108.776 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.523 ' HA ' ' HB3' ' A' ' 146' ' ' HIS . 58.0 tt0 -137.71 160.27 39.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.872 -1.143 . . . . 0.0 110.93 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.579 ' HB2' ' CZ3' ' A' ' 28' ' ' TRP . . . -162.37 106.48 1.16 Allowed 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 179.462 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.518 HG23 ' N ' ' A' ' 75' ' ' ALA . 49.9 m -120.63 166.33 13.81 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.246 -1.534 . . . . 0.0 110.953 -178.004 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.518 ' N ' HG23 ' A' ' 74' ' ' THR . . . -124.7 137.91 54.32 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.476 -0.765 . . . . 0.0 108.96 179.07 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.547 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER 178.17 162.52 0.62 Allowed Pre-proline 0 N--CA 1.492 1.651 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 -179.728 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.511 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.82 167.14 73.74 Favored 'Cis proline' 0 C--N 1.31 -1.472 0 C-N-CA 123.641 -1.4 . . . . 0.0 110.778 -0.357 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.523 ' CG1' HD13 ' A' ' 164' ' ' ILE . 76.7 t -126.27 151.5 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.303 -0.873 . . . . 0.0 108.961 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.515 ' N ' HG12 ' A' ' 78' ' ' VAL . 47.3 m-20 -114.75 122.79 47.48 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.045 -1.034 . . . . 0.0 109.812 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.473 HG21 ' O ' ' A' ' 138' ' ' GLU . 3.0 m -129.57 -173.82 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.21 -0.932 . . . . 0.0 109.458 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.514 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 0.0 OUTLIER -138.74 145.87 47.92 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.364 -0.835 . . . . 0.0 109.306 179.896 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.46 ' HD2' ' HG2' ' A' ' 81' ' ' ARG . 35.3 Cg_endo -77.33 110.28 2.96 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.465 2.11 . . . . 0.0 110.47 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 113.91 -34.99 4.71 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.533 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -85.0 149.71 4.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.241 -1.152 . . . . 0.0 109.39 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.461 ' HA ' ' OG1' ' A' ' 133' ' ' THR . 11.6 t -95.3 145.31 25.18 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 109.354 -0.609 . . . . 0.0 109.354 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.533 ' CE1' HG12 ' A' ' 84' ' ' VAL . 8.6 m-85 -123.29 159.07 29.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.297 -0.877 . . . . 0.0 109.627 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' THR . . . . . 0.457 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 59.1 m -118.06 148.46 42.25 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.32 -0.862 . . . . 0.0 109.282 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.615 ' N ' ' CD1' ' A' ' 88' ' ' TYR . 0.2 OUTLIER -127.04 104.75 8.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.124 -0.985 . . . . 0.0 109.631 -179.927 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.476 ' O ' ' O ' ' A' ' 161' ' ' GLY . 54.7 m -112.8 148.08 35.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.365 -0.834 . . . . 0.0 108.955 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.418 HD13 ' HB2' ' A' ' 162' ' ' LEU . 19.4 tt -150.08 163.51 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.76 -1.212 . . . . 0.0 109.817 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.563 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 70.3 m95 -125.77 129.55 49.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.156 -0.965 . . . . 0.0 109.281 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.99 145.96 47.62 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.283 -0.886 . . . . 0.0 109.513 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.573 ' HD2' ' CE2' ' A' ' 125' ' ' TRP . 16.4 ttt-85 -157.91 118.23 3.39 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.267 -0.896 . . . . 0.0 109.179 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.3 166.8 10.16 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.357 -0.84 . . . . 0.0 109.839 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . 0.463 ' O ' HG22 ' A' ' 123' ' ' THR . 16.0 tt0 -64.18 -52.04 60.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.373 -0.829 . . . . 0.0 109.615 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.428 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -112.03 140.93 46.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 109.52 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.511 ' N ' HG21 ' A' ' 123' ' ' THR . 1.1 m-20 -60.82 149.61 35.39 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.249 -0.907 . . . . 0.0 109.476 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 106.98 33.82 3.14 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.969 -1.253 . . . . 0.0 109.969 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.465 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -114.09 139.73 49.06 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.066 -1.255 . . . . 0.0 109.165 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.492 HG13 ' N ' ' A' ' 101' ' ' VAL . 73.8 t -120.65 149.43 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 110.421 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.566 ' HB ' ' CE1' ' A' ' 103' ' ' PHE . 48.4 t -144.94 166.75 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.471 -0.768 . . . . 0.0 109.029 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 117' ' ' HIS . 5.6 m -124.68 123.47 40.1 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.06 -1.025 . . . . 0.0 109.612 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.63 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.4 m-85 -121.94 103.9 9.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -0.875 . . . . 0.0 109.902 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.522 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 16.5 p -121.38 174.34 6.8 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.098 -1.001 . . . . 0.0 109.88 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.618 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -131.72 154.0 39.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-O 121.492 0.663 . . . . 0.0 110.282 -179.688 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -174.92 158.11 25.7 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.53 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.5 p30 -97.91 -169.32 1.8 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.099 -1.236 . . . . 0.0 109.37 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.53 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 4.5 mp0 -73.11 11.66 0.68 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.1 -1.0 . . . . 0.0 111.105 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.459 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 1.4 m -111.02 13.91 22.0 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 120.595 -1.316 . . . . 0.0 109.139 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.512 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 4.0 m-30 71.47 3.96 4.87 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.484 -0.76 . . . . 0.0 109.619 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.528 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 29.4 tt0 -78.0 162.39 26.79 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.236 -0.915 . . . . 0.0 108.564 179.335 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.473 ' N ' ' CG ' ' A' ' 111' ' ' GLN . 7.1 tt0 -138.22 143.47 40.17 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.994 -1.066 . . . . 0.0 109.89 -179.443 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.569 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 19.7 m-85 -102.4 -70.11 0.76 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.163 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.568 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -98.47 174.31 28.17 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.062 -1.615 . . . . 0.0 109.062 179.428 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.465 ' HB3' ' OE2' ' A' ' 112' ' ' GLU . 0.0 OUTLIER -175.28 129.45 0.28 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.005 -1.291 . . . . 0.0 110.461 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.572 HD22 ' CD1' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -146.9 72.31 1.26 Allowed 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 179.145 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.541 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 15.1 p80 -93.31 150.79 20.21 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.321 -0.862 . . . . 0.0 110.181 -179.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.541 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.7 tt0 80.0 47.63 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.653 -0.654 . . . . 0.0 109.458 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 12.7 mm100 -107.98 125.45 51.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.387 -0.821 . . . . 0.0 109.333 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -66.95 153.58 43.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.451 -0.781 . . . . 0.0 109.066 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.465 HG12 ' O ' ' A' ' 99' ' ' ALA . 6.6 mm -135.37 134.48 52.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.195 -0.94 . . . . 0.0 109.961 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -86.06 -179.37 6.74 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.425 -0.797 . . . . 0.0 110.075 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.514 ' O ' ' CZ ' ' A' ' 93' ' ' ARG . 39.6 p -76.96 -3.94 41.45 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.961 -0.696 . . . . 0.0 109.337 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.421 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 1.3 mt-10 -106.27 -173.24 2.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.257 -0.902 . . . . 0.0 109.263 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.573 ' CE2' ' HD2' ' A' ' 93' ' ' ARG . 98.2 m95 -91.01 118.04 30.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.571 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -106.86 121.24 45.54 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.176 -0.953 . . . . 0.0 108.953 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.563 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.5 Cg_endo -79.42 105.37 1.87 Allowed 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.311 2.007 . . . . 0.0 111.011 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -112.88 133.43 54.87 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -151.52 177.04 10.72 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 122.435 1.112 . . . . 0.0 110.724 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.584 ' CZ ' ' HB2' ' A' ' 88' ' ' TYR . 3.6 p90 -161.48 -169.67 2.36 Favored 'General case' 0 C--N 1.292 -1.934 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.148 179.429 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . 0.567 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 68.9 mt-10 -138.6 144.1 39.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.006 -1.059 . . . . 0.0 109.982 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.569 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 1.0 OUTLIER -163.63 147.56 10.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.448 -0.783 . . . . 0.0 109.215 179.763 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.461 ' OG1' ' HA ' ' A' ' 85' ' ' THR . 0.5 OUTLIER -116.22 147.93 40.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.879 . . . . 0.0 109.71 -179.537 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.514 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 5.5 t -40.49 110.42 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.602 -0.686 . . . . 0.0 109.291 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 12.4 t -61.98 -53.34 57.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.274 -0.891 . . . . 0.0 109.295 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -101.77 -91.59 0.33 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.367 -0.833 . . . . 0.0 109.21 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.439 ' HA ' HG13 ' A' ' 134' ' ' VAL . 0.1 OUTLIER -163.33 50.81 0.16 Allowed 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.469 -0.769 . . . . 0.0 109.087 179.788 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.473 ' O ' HG21 ' A' ' 80' ' ' VAL . 61.3 mm-40 -87.92 112.08 22.15 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.242 -0.911 . . . . 0.0 109.738 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.5 p -79.39 -14.95 58.61 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.214 -0.929 . . . . 0.0 108.584 179.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 25.8 t -134.29 128.67 52.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.318 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.46 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -139.52 171.83 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.174 -0.954 . . . . 0.0 110.147 -179.629 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.496 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.9 ptm180 -141.75 132.82 26.16 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.618 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -93.4 109.42 40.33 Favored Pre-proline 0 N--CA 1.486 1.365 0 O-C-N 121.228 -0.92 . . . . 0.0 110.202 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.522 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.1 Cg_endo -76.47 110.14 3.0 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.141 1.894 . . . . 0.0 110.9 179.399 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.582 ' CD1' ' CD2' ' A' ' 162' ' ' LEU . 3.0 mt -116.66 108.21 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 179.035 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.602 ' N ' ' ND1' ' A' ' 146' ' ' HIS . 0.1 OUTLIER -123.74 160.75 26.59 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.299 -1.501 . . . . 0.0 112.111 -177.142 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.579 ' CD1' ' N ' ' A' ' 147' ' ' PHE . 0.1 OUTLIER -113.53 -168.37 1.33 Allowed 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.628 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.409 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 127.02 32.84 0.66 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.486 ' C ' ' CG1' ' A' ' 64' ' ' VAL . 28.6 m-85 -121.34 155.27 35.1 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.297 -1.119 . . . . 0.0 109.283 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.06 -26.27 66.66 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.78 -7.57 46.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.409 -0.807 . . . . 0.0 109.562 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.57 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 2.5 t30 -115.21 14.17 16.89 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.418 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -89.32 159.5 2.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.585 -0.697 . . . . 0.0 109.674 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.55 37.31 49.67 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.428 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 1.9 m-20 -160.31 136.28 8.49 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.074 -1.251 . . . . 0.0 110.175 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.569 HG22 ' CZ ' ' A' ' 158' ' ' TYR . 45.2 m -86.25 122.25 29.98 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 179.085 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.57 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.8 OUTLIER -102.93 117.93 49.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.881 -1.137 . . . . 0.0 110.34 -178.873 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.65 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 13.9 m-85 -96.57 144.59 26.49 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 178.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.564 HD12 ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -140.99 139.83 33.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.768 -1.207 . . . . 0.0 110.636 -178.813 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.458 ' OD2' ' O ' ' A' ' 9' ' ' GLY . 0.5 OUTLIER -174.18 135.58 0.46 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.159 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 128.61 -6.65 6.59 Favored Glycine 0 N--CA 1.486 1.974 0 C-N-CA 119.127 -1.511 . . . . 0.0 111.21 179.183 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.582 ' CD2' ' CD1' ' A' ' 145' ' ' ILE . 8.0 tp -59.73 97.78 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.39 -1.653 . . . . 0.0 108.784 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . 0.454 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -121.94 145.59 47.96 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.565 -0.709 . . . . 0.0 109.931 -179.211 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.523 HD13 ' CG1' ' A' ' 78' ' ' VAL . 52.4 mt -125.65 108.85 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.328 -0.858 . . . . 0.0 109.291 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.526 ' HB1' ' CG2' ' A' ' 3' ' ' VAL . . . -152.36 149.84 29.07 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.144 -0.972 . . . . 0.0 109.661 -179.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.454 ' HB3' ' O ' ' A' ' 85' ' ' THR . 0.3 OUTLIER -87.67 159.5 18.5 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.285 -0.884 . . . . 0.0 109.47 179.92 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.435 ' HB2' ' HD2' ' A' ' 168' ' ' PRO . 17.7 pt20 -71.53 159.01 86.75 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.451 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 167' ' ' GLN . 35.7 Cg_endo . . . . . 0 C--N 1.309 -1.529 0 C-N-CA 122.631 2.221 . . . . 0.0 110.445 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.6 ttt . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.315 0.579 . . . . 0.0 109.459 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mp -87.45 178.83 6.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.23 -0.919 . . . . 0.0 109.506 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.436 HG12 ' O ' ' A' ' 5' ' ' ASN . 4.2 p -162.8 173.31 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.236 -0.915 . . . . 0.0 109.385 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.517 ' HB1' ' N ' ' A' ' 79' ' ' ASN . . . -68.06 -55.13 13.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.128 -0.982 . . . . 0.0 109.453 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.484 ' HB3' ' HA ' ' A' ' 163' ' ' ALA . 0.4 OUTLIER -69.56 148.74 49.01 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 109.112 179.949 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.461 ' O ' ' HA3' ' A' ' 27' ' ' GLY . 15.4 mm -112.03 148.58 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.383 -0.823 . . . . 0.0 109.207 179.707 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.479 ' HB2' ' HA3' ' A' ' 27' ' ' GLY . 42.6 m-80 45.02 38.77 3.26 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.254 -0.904 . . . . 0.0 109.649 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -56.9 -40.77 90.9 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 107.968 -2.053 . . . . 0.0 107.968 179.077 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.525 ' CA ' ' OD2' ' A' ' 160' ' ' ASP . . . -112.9 18.2 22.04 Favored Glycine 0 N--CA 1.488 2.103 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 178.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.593 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 61.4 m-85 65.66 46.61 2.36 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.478 -1.013 . . . . 0.0 109.683 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -84.66 -28.05 26.67 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.283 -0.885 . . . . 0.0 109.549 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.427 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 0.7 OUTLIER -88.29 -30.78 19.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.592 -179.726 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.541 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 1.1 m -82.02 124.28 79.08 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.216 -0.928 . . . . 0.0 109.564 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.452 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.6 Cg_endo -78.03 138.21 16.19 Favored 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 122.412 2.075 . . . . 0.0 110.457 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -40.32 161.01 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 CA-C-O 121.233 0.539 . . . . 0.0 109.741 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 140.42 131.08 2.71 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.522 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.07 140.63 15.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.282 -1.129 . . . . 0.0 109.187 -179.689 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.464 ' HB ' ' O ' ' A' ' 42' ' ' PHE . 43.7 t -89.91 144.41 9.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.453 -0.779 . . . . 0.0 110.197 -179.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.414 HG21 ' OD2' ' A' ' 20' ' ' ASP . 9.0 t -98.24 -27.56 14.1 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.16 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.523 ' HB2' ' CG ' ' A' ' 23' ' ' GLU . 7.0 m-20 -136.41 103.51 5.3 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.272 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.585 ' CD2' ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -45.84 -30.43 1.69 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.101 -0.999 . . . . 0.0 109.746 -178.781 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.585 ' N ' ' CD2' ' A' ' 21' ' ' LEU . . . -60.05 -49.51 77.37 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 121.643 -0.66 . . . . 0.0 109.796 -179.636 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.523 ' CG ' ' HB2' ' A' ' 20' ' ' ASP . 1.8 pt-20 -101.13 31.07 3.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.424 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.453 ' O ' HG21 ' A' ' 25' ' ' VAL . . . -67.2 -45.73 78.3 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.541 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 77.0 t -141.91 145.28 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -1.166 . . . . 0.0 109.695 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.77 -46.91 70.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.207 -0.933 . . . . 0.0 109.749 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.479 ' HA3' ' HB2' ' A' ' 7' ' ' ASN . . . -81.53 -6.55 89.08 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.664 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.2 OUTLIER -133.96 123.71 25.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.155 -1.203 . . . . 0.0 109.091 179.528 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.528 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -126.62 126.98 44.51 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.35 -0.844 . . . . 0.0 108.934 179.586 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.513 ' CD2' ' HB1' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -106.43 170.08 8.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.12 -0.987 . . . . 0.0 109.586 -179.395 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.516 ' HA ' HD21 ' A' ' 21' ' ' LEU . 19.4 m120 -160.53 122.45 3.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 110.241 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.494 HG11 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -103.65 137.54 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.257 -0.902 . . . . 0.0 109.354 178.625 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -86.88 169.72 40.83 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -60.6 -14.44 20.25 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.15 -1.206 . . . . 0.0 109.185 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.426 ' HB3' ' OD1' ' A' ' 67' ' ' ASN . 5.7 p -67.46 -33.72 75.72 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.338 -0.851 . . . . 0.0 109.796 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.534 HG22 ' CB ' ' A' ' 70' ' ' ASP . 2.2 t -67.03 86.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.016 -1.053 . . . . 0.0 109.385 -179.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.411 ' O ' HG21 ' A' ' 37' ' ' THR . 17.7 m -65.81 -29.04 69.46 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.086 -1.009 . . . . 0.0 108.3 179.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 41.8 t30 -131.57 101.08 15.97 Favored Pre-proline 0 C--N 1.295 -1.765 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.2 149.87 36.52 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.368 2.045 . . . . 0.0 110.592 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.53 ' CD ' HG12 ' A' ' 71' ' ' ILE . 36.0 Cg_endo -77.38 -165.49 0.33 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.588 2.192 . . . . 0.0 110.191 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.518 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 56.0 t -108.52 118.88 57.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.331 -0.856 . . . . 0.0 110.13 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.583 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 2.7 m-85 -97.37 111.61 23.79 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.038 -1.039 . . . . 0.0 108.221 178.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.522 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 3.3 tm-20 -153.01 148.51 27.15 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.125 -0.984 . . . . 0.0 110.099 -179.446 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.458 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 61.4 t -102.41 148.45 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.388 -0.82 . . . . 0.0 109.048 179.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.58 ' CD2' ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -150.19 164.28 36.07 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.084 -1.01 . . . . 0.0 108.602 -179.938 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.58 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 13.0 mt-10 -110.68 112.81 24.95 Favored 'General case' 0 C--N 1.293 -1.863 0 O-C-N 121.443 -0.785 . . . . 0.0 109.809 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.516 HG21 ' CD2' ' A' ' 45' ' ' LEU . 1.9 p -106.48 152.99 22.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.453 -0.78 . . . . 0.0 109.458 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 51.9 p -88.25 18.79 4.12 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.345 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.421 ' O ' ' C ' ' A' ' 50' ' ' ALA . 14.7 t0 -132.97 7.81 4.03 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 109.519 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.421 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -43.93 149.22 0.68 Allowed Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.276 -0.89 . . . . 0.0 109.351 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.579 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 35.2 Cg_endo -78.21 -32.96 2.16 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.697 2.265 . . . . 0.0 110.372 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -139.28 77.49 1.62 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.283 -0.885 . . . . 0.0 109.531 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 118.48 -127.15 7.15 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 6.9 t30 -157.57 22.51 0.28 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.26 -1.141 . . . . 0.0 109.413 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.526 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 17.8 mttp -136.58 142.76 43.36 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.29 -0.881 . . . . 0.0 109.412 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.563 HG13 ' CZ2' ' A' ' 125' ' ' TRP . 6.1 m -150.64 174.18 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.217 -0.927 . . . . 0.0 109.563 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.593 ' HB2' ' CE2' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -102.88 103.15 13.28 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.575 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.637 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.96 118.55 23.06 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.526 ' O ' ' CG2' ' A' ' 156' ' ' THR . 46.9 t -113.29 143.9 22.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.096 -1.003 . . . . 0.0 108.6 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.522 ' N ' HG13 ' A' ' 59' ' ' VAL . 45.7 m -108.66 94.29 4.97 Favored 'General case' 0 C--N 1.283 -2.316 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.535 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 55.5 t -89.03 125.36 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.281 -0.887 . . . . 0.0 108.843 179.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.484 ' ND2' HG23 ' A' ' 60' ' ' THR . 5.7 p30 -160.17 61.58 0.34 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.41 -0.806 . . . . 0.0 109.68 -179.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 149.24 89.81 0.08 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.52 HG12 ' CA ' ' A' ' 149' ' ' TYR . 2.5 m -79.91 -171.93 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.281 -1.129 . . . . 0.0 109.58 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -134.71 -164.43 10.52 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -92.3 19.1 7.39 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -1.139 . . . . 0.0 109.459 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.512 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 30.5 m120 -132.72 148.15 68.37 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.231 -0.918 . . . . 0.0 109.398 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.511 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.3 Cg_endo -78.52 12.52 2.12 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.578 2.186 . . . . 0.0 110.836 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.512 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -136.59 58.83 1.72 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.99 -1.069 . . . . 0.0 109.688 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.534 ' CB ' HG22 ' A' ' 36' ' ' VAL . 1.8 m-20 -77.71 -69.61 0.53 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.122 -0.986 . . . . 0.0 108.963 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.53 HG12 ' CD ' ' A' ' 40' ' ' PRO . 3.0 mt -106.26 126.82 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.396 -0.815 . . . . 0.0 108.904 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -121.92 128.79 51.94 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.078 -1.013 . . . . 0.0 110.504 -179.268 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.581 ' HB2' ' CZ3' ' A' ' 28' ' ' TRP . . . -113.68 108.54 17.26 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.513 HG22 ' N ' ' A' ' 75' ' ' ALA . 40.9 m -115.28 162.48 17.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.513 -1.367 . . . . 0.0 110.137 -178.745 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.513 ' N ' HG22 ' A' ' 74' ' ' THR . . . -123.46 140.1 53.34 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.227 -0.92 . . . . 0.0 109.219 179.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.535 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 3.1 p90 178.98 160.56 0.7 Allowed Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.416 -0.802 . . . . 0.0 109.22 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.532 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.9 Cg_endo -81.58 168.64 67.57 Favored 'Cis proline' 0 C--N 1.311 -1.418 0 C-N-CA 123.699 -1.375 . . . . 0.0 110.696 -0.468 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.476 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 33.3 t -121.22 131.58 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.233 -0.917 . . . . 0.0 108.87 179.355 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.517 ' N ' ' HB1' ' A' ' 4' ' ' ALA . 26.7 m-80 -94.03 103.97 16.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.079 -1.013 . . . . 0.0 109.975 -179.518 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.576 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.2 m -113.57 -176.6 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.402 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.519 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 0.0 OUTLIER -133.42 142.61 44.77 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.302 -0.874 . . . . 0.0 109.346 179.88 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.63 106.47 2.2 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.448 2.099 . . . . 0.0 110.505 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 113.33 -30.68 7.14 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.458 ' HB ' ' HB3' ' A' ' 81' ' ' ARG . 2.5 t -84.51 149.74 4.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.23 -1.159 . . . . 0.0 109.47 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 19.7 m -90.6 123.65 34.41 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.576 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 6.3 m-85 -106.37 154.84 20.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.282 -0.886 . . . . 0.0 109.733 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' THR . . . . . 0.464 HG23 ' N ' ' A' ' 88' ' ' TYR . 59.0 m -118.04 154.36 32.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.433 -0.792 . . . . 0.0 109.238 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.688 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -129.33 127.38 40.97 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.146 -0.971 . . . . 0.0 109.515 -179.84 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.511 ' O ' ' O ' ' A' ' 161' ' ' GLY . 21.6 m -130.5 145.54 51.87 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.266 -0.896 . . . . 0.0 108.78 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.512 ' C ' ' CD1' ' A' ' 91' ' ' TRP . 16.9 tt -151.34 161.91 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 120.554 -1.341 . . . . 0.0 109.741 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.574 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 18.1 m95 -132.63 124.88 29.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.154 -0.966 . . . . 0.0 108.982 179.5 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.98 145.91 47.66 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.741 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.576 ' HG2' ' CZ3' ' A' ' 125' ' ' TRP . 8.8 ptt180 -156.73 179.2 9.5 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -154.47 160.62 41.69 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.091 -1.006 . . . . 0.0 109.868 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . 0.41 ' O ' HG22 ' A' ' 123' ' ' THR . 4.4 tt0 -54.04 -41.19 67.8 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.383 -0.823 . . . . 0.0 109.452 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.472 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 57.4 mt-30 -130.34 143.38 50.74 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.225 -0.922 . . . . 0.0 109.442 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.525 ' OD1' ' CG2' ' A' ' 123' ' ' THR . 2.2 m-20 -57.14 149.37 19.7 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.293 -0.879 . . . . 0.0 109.505 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 111.23 36.99 1.71 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.472 ' HB3' ' OD1' ' A' ' 152' ' ' ASN . . . -125.19 141.8 51.88 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.072 -1.252 . . . . 0.0 109.32 179.695 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.52 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 54.0 t -118.56 151.27 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 110.832 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.64 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 40.7 t -150.02 162.11 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.529 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 54.4 m -124.42 128.83 49.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.09 -1.006 . . . . 0.0 109.31 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.588 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.2 OUTLIER -121.66 103.78 9.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.084 -1.01 . . . . 0.0 109.957 -179.788 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.489 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 20.9 p -128.4 165.02 21.43 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.216 -0.928 . . . . 0.0 109.927 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.629 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -121.62 125.23 73.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.564 0.697 . . . . 0.0 110.167 179.876 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -115.1 179.02 18.14 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.551 ' CB ' ' O ' ' A' ' 111' ' ' GLN . 25.7 t30 -127.83 172.04 11.22 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -1.097 . . . . 0.0 109.077 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.45 ' HB2' ' OE2' ' A' ' 138' ' ' GLU . 31.4 mt-30 -59.17 -47.63 84.59 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.007 -1.058 . . . . 0.0 109.608 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.538 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 46.9 t -84.37 19.36 1.92 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.219 -0.926 . . . . 0.0 110.117 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.56 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.1 m-30 80.61 7.79 1.36 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.36 -0.838 . . . . 0.0 110.186 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.551 ' O ' ' CB ' ' A' ' 107' ' ' ASN . 37.0 mm-40 -69.9 123.99 22.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.994 -1.066 . . . . 0.0 108.736 179.249 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.481 ' HG3' ' N ' ' A' ' 113' ' ' TYR . 1.2 tt0 -104.93 140.41 38.21 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.925 -1.109 . . . . 0.0 110.122 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.576 ' CE2' HG23 ' A' ' 141' ' ' ILE . 5.8 m-85 -108.37 -68.56 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.453 -0.779 . . . . 0.0 108.915 179.198 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.57 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -99.37 171.61 24.42 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 179.478 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.476 ' CG ' ' O ' ' A' ' 115' ' ' ARG . 0.2 OUTLIER -171.03 110.11 0.33 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.044 -1.268 . . . . 0.0 110.381 -179.867 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.633 ' CD2' ' CD1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -145.38 77.29 1.51 Allowed 'General case' 0 N--CA 1.494 1.74 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.168 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.54 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 18.5 p80 -104.27 158.04 16.73 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.354 -0.842 . . . . 0.0 110.11 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 30.0 tt0 79.1 78.52 0.06 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.513 -0.742 . . . . 0.0 109.689 179.687 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . 0.451 ' OE1' ' O ' ' A' ' 118' ' ' GLU . 19.5 mm100 -144.24 131.74 21.02 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.251 -0.906 . . . . 0.0 109.467 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . 0.433 ' O ' HD11 ' A' ' 121' ' ' ILE . 10.6 mt-30 -66.66 156.04 36.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 109.066 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.529 ' CG2' ' HA ' ' A' ' 93' ' ' ARG . 13.9 mm -133.21 136.76 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 O-C-N 121.066 -1.021 . . . . 0.0 110.005 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -90.48 -179.17 5.52 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.908 0.861 . . . . 0.0 110.636 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.525 ' CG2' ' OD1' ' A' ' 97' ' ' ASP . 0.8 OUTLIER -68.69 -15.67 63.59 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.416 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.521 ' O ' ' CB ' ' A' ' 93' ' ' ARG . 3.8 mt-10 -100.36 -172.09 2.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.475 -0.766 . . . . 0.0 109.289 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.579 ' CE2' ' HD3' ' A' ' 51' ' ' PRO . 98.2 m95 -90.07 135.46 33.64 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.324 -0.86 . . . . 0.0 109.796 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.434 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 0.6 OUTLIER -106.83 121.37 45.16 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.233 -0.917 . . . . 0.0 108.977 179.751 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -79.64 110.1 2.57 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.447 2.098 . . . . 0.0 110.945 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -122.79 133.71 54.44 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 179.189 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.1 t -151.62 176.42 11.37 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 120.625 -1.297 . . . . 0.0 111.057 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.688 ' CE2' ' CD1' ' A' ' 88' ' ' TYR . 10.5 p90 -171.98 178.01 3.09 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.019 179.437 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . 0.474 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 33.5 mt-10 -133.7 153.57 51.6 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.061 -1.025 . . . . 0.0 110.041 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.565 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.14 160.76 19.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.458 -0.776 . . . . 0.0 109.147 179.746 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -119.11 146.2 45.31 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.18 -0.95 . . . . 0.0 109.293 -179.579 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.519 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 2.5 t -56.72 111.94 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.362 -0.836 . . . . 0.0 109.264 179.611 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 3.8 m -83.61 -42.32 16.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.442 -0.786 . . . . 0.0 109.947 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.576 ' O ' ' CB ' ' A' ' 137' ' ' GLN . 33.1 t70 -85.91 -16.64 37.85 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.401 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.576 ' CB ' ' O ' ' A' ' 136' ' ' ASP . 3.2 mm-40 86.32 28.38 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -178.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.523 ' CG ' ' OD1' ' A' ' 107' ' ' ASN . 3.0 mm-40 -74.48 119.4 18.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.606 -0.683 . . . . 0.0 109.795 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 17.3 p -79.34 -3.78 47.83 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.9 t -140.13 132.19 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.352 -0.843 . . . . 0.0 109.131 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.576 HG23 ' CE2' ' A' ' 113' ' ' TYR . 0.6 OUTLIER -144.53 171.98 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.259 -0.901 . . . . 0.0 109.821 -179.861 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.483 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.1 ptm180 -139.61 132.26 28.89 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.528 -0.732 . . . . 0.0 109.419 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.629 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -96.09 108.78 43.31 Favored Pre-proline 0 N--CA 1.486 1.339 0 O-C-N 121.219 -0.926 . . . . 0.0 110.029 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.489 ' HD2' ' O ' ' A' ' 104' ' ' THR . 36.2 Cg_endo -77.73 112.51 3.32 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.324 2.016 . . . . 0.0 111.106 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.664 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 2.4 mt -99.14 134.19 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 178.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.487 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 12.8 m80 -97.2 154.83 17.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.34 -1.475 . . . . 0.0 111.607 -177.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.64 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 28.1 m-85 -155.1 157.21 37.16 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 179.284 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.409 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 108.11 53.59 0.65 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.52 ' CA ' HG12 ' A' ' 64' ' ' VAL . 22.6 m-85 -129.03 159.47 35.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.245 -1.15 . . . . 0.0 109.39 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.67 -30.15 70.33 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.467 ' HB2' ' HB ' ' A' ' 100' ' ' VAL . . . -71.23 -11.6 61.01 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.369 -0.832 . . . . 0.0 109.049 179.265 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.55 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 1.8 t30 -116.86 13.07 14.93 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 179.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 149' ' ' TYR . 2.2 t -85.15 162.22 2.95 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 O-C-N 121.635 -0.665 . . . . 0.0 109.695 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.446 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 54.06 33.19 50.76 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.472 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.0 m-20 -160.47 135.46 7.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.187 -1.184 . . . . 0.0 110.069 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.566 HG21 ' CE1' ' A' ' 158' ' ' TYR . 42.2 m -85.13 122.43 29.33 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.067 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.55 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -101.13 118.72 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.832 -1.167 . . . . 0.0 110.331 -178.811 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.637 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 3.5 m-85 -95.12 130.81 41.68 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.636 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.4 mt -120.31 142.0 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.915 -1.115 . . . . 0.0 110.078 -178.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.525 ' OD2' ' CA ' ' A' ' 9' ' ' GLY . 0.8 OUTLIER -174.38 136.37 0.47 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.108 -0.995 . . . . 0.0 109.252 179.535 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 122.63 -10.4 9.1 Favored Glycine 0 N--CA 1.487 2.069 0 C-N-CA 119.322 -1.418 . . . . 0.0 111.014 179.023 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.485 ' O ' ' HA3' ' A' ' 8' ' ' GLY . 9.9 tp -59.62 97.19 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.53 -1.571 . . . . 0.0 108.903 -179.643 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -134.57 145.55 48.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.537 -0.727 . . . . 0.0 109.985 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.482 HG23 ' CD2' ' A' ' 88' ' ' TYR . 2.6 mm -119.65 108.5 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.284 -0.885 . . . . 0.0 109.204 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.464 ' O ' ' HB ' ' A' ' 87' ' ' THR . . . -140.78 145.01 35.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.127 -0.983 . . . . 0.0 109.527 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 4.2 p -74.37 176.67 6.53 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.294 -0.879 . . . . 0.0 109.559 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -154.71 150.63 21.96 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.241 -0.912 . . . . 0.0 109.376 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo . . . . . 0 C--N 1.309 -1.542 0 C-N-CA 122.638 2.226 . . . . 0.0 110.389 -179.98 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.7 ttt . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mt -102.36 105.92 16.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.32 -0.863 . . . . 0.0 109.396 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.497 ' CG1' ' O ' ' A' ' 5' ' ' ASN . 2.9 p -102.12 171.27 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.2 -0.937 . . . . 0.0 109.403 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -75.3 -46.57 32.63 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.186 -0.946 . . . . 0.0 109.587 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.5 ' HB2' ' CG1' ' A' ' 164' ' ' ILE . 0.9 OUTLIER -89.84 124.65 34.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.293 -0.88 . . . . 0.0 109.603 -179.945 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.492 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 1.8 mp -116.83 138.06 48.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.244 -0.91 . . . . 0.0 109.3 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.515 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.3 OUTLIER 74.99 16.52 2.87 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.219 -0.926 . . . . 0.0 109.627 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -60.11 -45.98 95.02 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.527 ' CA ' ' OD2' ' A' ' 160' ' ' ASP . . . -94.77 28.44 11.4 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 179.407 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.576 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 8.4 m-85 44.53 52.01 7.73 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.434 -1.039 . . . . 0.0 109.552 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.457 ' OE1' ' HA3' ' A' ' 53' ' ' GLY . 57.3 mm-40 -84.6 -28.24 26.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.298 -0.876 . . . . 0.0 109.639 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.435 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 0.9 OUTLIER -87.31 -37.08 17.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.198 -0.939 . . . . 0.0 109.762 -179.675 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.464 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 10.1 m -70.82 117.0 51.79 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.153 -0.967 . . . . 0.0 109.354 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 15' ' ' ALA . 35.2 Cg_endo -76.95 138.82 18.85 Favored 'Trans proline' 0 C--N 1.312 -1.378 0 C-N-CA 122.319 2.013 . . . . 0.0 110.396 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.441 ' C ' ' O ' ' A' ' 14' ' ' PRO . . . -39.31 153.88 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.516 0 CA-C-O 121.279 0.561 . . . . 0.0 109.857 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.49 131.37 2.41 Favored Glycine 0 N--CA 1.485 1.966 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.533 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.84 141.13 14.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.227 -1.16 . . . . 0.0 109.213 -179.602 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.475 HG13 ' CA ' ' A' ' 24' ' ' GLY . 47.8 t -86.58 142.37 13.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 CA-C-O 121.722 0.772 . . . . 0.0 110.365 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.411 ' C ' ' OD1' ' A' ' 20' ' ' ASP . 1.8 t -95.34 -28.53 14.92 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.069 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.426 ' O ' ' C ' ' A' ' 21' ' ' LEU . 1.0 OUTLIER -136.31 100.5 4.4 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.325 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.579 ' CD2' ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -43.23 -29.02 0.36 Allowed 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.259 -0.9 . . . . 0.0 109.773 -178.868 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.579 ' N ' ' CD2' ' A' ' 21' ' ' LEU . . . -59.69 -55.06 39.13 Favored 'General case' 0 C--N 1.294 -1.823 0 O-C-N 121.599 -0.688 . . . . 0.0 109.822 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -101.5 31.6 3.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.135 -0.978 . . . . 0.0 109.349 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.475 ' CA ' HG13 ' A' ' 18' ' ' VAL . . . -67.56 -47.18 63.74 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.512 ' HB ' ' CB ' ' A' ' 28' ' ' TRP . 4.3 t -126.61 144.83 35.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.093 -1.24 . . . . 0.0 109.842 -179.638 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -62.49 -65.56 0.67 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.331 -0.855 . . . . 0.0 110.084 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.515 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -76.31 2.5 56.93 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.687 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.7 OUTLIER -133.99 122.11 22.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.028 -1.278 . . . . 0.0 109.124 179.549 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.537 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -126.6 128.22 46.46 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.4 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.489 ' HB2' ' HB2' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -104.67 175.98 5.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.972 -1.08 . . . . 0.0 110.236 -178.927 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.513 ' HA ' HD22 ' A' ' 21' ' ' LEU . 16.8 m120 -160.2 122.09 3.22 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.47 -0.769 . . . . 0.0 109.629 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.523 HG13 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -110.6 136.53 46.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.217 -0.927 . . . . 0.0 109.494 179.417 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.45 -179.87 21.03 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.1 m -58.42 -16.3 14.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -1.165 . . . . 0.0 109.294 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.465 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 37.7 m -60.37 -38.85 85.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.257 -0.902 . . . . 0.0 109.592 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 36' ' ' VAL . 2.1 t -62.97 89.29 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.045 -1.034 . . . . 0.0 109.257 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.4 m -59.79 -29.23 68.07 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.242 -0.911 . . . . 0.0 108.69 179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.474 ' O ' HG13 ' A' ' 36' ' ' VAL . 0.5 OUTLIER -129.07 128.79 23.36 Favored Pre-proline 0 C--N 1.296 -1.728 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.448 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.63 122.02 6.23 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.203 1.935 . . . . 0.0 110.523 -179.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.507 ' HG3' ' CD1' ' A' ' 71' ' ' ILE . 35.4 Cg_endo -77.3 -165.68 0.34 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.302 2.002 . . . . 0.0 109.905 179.697 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.504 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 70.2 t -117.34 118.72 59.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.034 -1.041 . . . . 0.0 110.775 -179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.435 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 2.3 m-85 -102.33 111.97 24.48 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.163 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.533 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 1.3 tm-20 -154.1 151.52 29.39 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.062 -1.024 . . . . 0.0 110.118 -179.116 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.444 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 48.0 t -103.75 148.39 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.488 -0.757 . . . . 0.0 109.188 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.6 ' CD2' ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -149.13 164.12 35.63 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.77 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.6 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 9.9 pt-20 -125.47 124.89 42.37 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.333 -0.855 . . . . 0.0 109.551 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.52 ' CG2' HD23 ' A' ' 45' ' ' LEU . 1.3 p -127.24 166.77 17.12 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.388 -0.82 . . . . 0.0 109.461 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 95.6 p -88.24 18.58 4.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.912 . . . . 0.0 109.4 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 50' ' ' ALA . 0.1 OUTLIER -123.96 -0.81 8.39 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.277 -0.889 . . . . 0.0 109.584 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.34 145.84 1.32 Allowed Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.166 -0.959 . . . . 0.0 109.406 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.576 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 36.1 Cg_endo -78.44 -41.94 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.647 2.231 . . . . 0.0 110.396 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -128.26 89.61 2.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.315 -0.865 . . . . 0.0 109.413 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.457 ' HA3' ' OE1' ' A' ' 11' ' ' GLU . . . 105.49 -128.38 9.37 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 9.2 p-10 -152.63 18.24 0.61 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.201 -1.176 . . . . 0.0 109.704 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.466 ' O ' ' OD2' ' A' ' 160' ' ' ASP . 95.1 mttt -138.73 146.6 41.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.15 -0.969 . . . . 0.0 109.665 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.501 HG21 ' CD1' ' A' ' 45' ' ' LEU . 5.4 m -150.1 174.48 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.392 -0.817 . . . . 0.0 109.242 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.576 ' HB2' ' CE2' ' A' ' 10' ' ' PHE . 0.2 OUTLIER -100.43 103.75 15.13 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.12 -0.988 . . . . 0.0 108.964 179.475 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.638 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -82.04 121.9 27.14 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 178.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.53 ' CG2' HD21 ' A' ' 57' ' ' LEU . 44.0 t -115.46 144.17 23.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.113 -0.992 . . . . 0.0 109.084 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.504 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 95.9 m -107.79 88.48 2.74 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.196 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.562 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 60.1 t -86.77 120.91 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.419 -0.801 . . . . 0.0 109.291 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.485 ' ND2' HG23 ' A' ' 60' ' ' THR . 5.4 p30 -160.23 59.3 0.35 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.423 -0.798 . . . . 0.0 109.835 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 154.57 84.65 0.05 OUTLIER Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.538 HG12 ' CA ' ' A' ' 149' ' ' TYR . 1.7 m -80.66 -176.54 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.24 -1.153 . . . . 0.0 109.396 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -126.99 -159.53 10.21 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 22.8 m-20 -89.48 -9.22 50.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.295 -1.121 . . . . 0.0 109.455 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.484 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 39.6 m-80 -104.77 148.06 35.46 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.241 -0.912 . . . . 0.0 109.388 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.85 13.54 1.92 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.651 2.234 . . . . 0.0 110.942 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.484 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 1.9 p90 -137.72 53.33 1.85 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.98 -1.075 . . . . 0.0 109.744 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.462 ' HB3' HG21 ' A' ' 36' ' ' VAL . 0.4 OUTLIER -75.48 -65.28 0.91 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.174 -0.953 . . . . 0.0 109.095 179.645 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.52 HG13 ' CG2' ' A' ' 36' ' ' VAL . 4.5 mt -105.05 128.68 58.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.275 -0.89 . . . . 0.0 108.709 179.523 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -130.69 130.44 43.86 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.822 -1.174 . . . . 0.0 110.545 -179.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.601 ' HB2' ' CZ3' ' A' ' 28' ' ' TRP . . . -113.66 108.82 17.64 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.473 HG23 ' N ' ' A' ' 75' ' ' ALA . 54.5 m -109.23 162.3 14.42 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.688 -1.257 . . . . 0.0 110.134 -178.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.473 ' N ' HG23 ' A' ' 74' ' ' THR . . . -122.74 138.97 54.47 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.267 -0.895 . . . . 0.0 109.173 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.555 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 4.1 p90 179.36 161.57 0.76 Allowed Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.526 -0.734 . . . . 0.0 109.098 -179.723 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.555 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.7 Cg_endo -81.76 166.32 72.28 Favored 'Cis proline' 0 C--N 1.311 -1.444 0 C-N-CA 123.802 -1.333 . . . . 0.0 110.972 -0.364 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.524 HG13 ' CD1' ' A' ' 164' ' ' ILE . 86.7 t -127.19 156.64 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.535 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 69.1 m-20 -122.53 139.52 53.81 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.007 -1.058 . . . . 0.0 109.875 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.461 HG11 ' O ' ' A' ' 79' ' ' ASN . 4.0 m -146.04 -174.04 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.226 -0.921 . . . . 0.0 109.758 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.531 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 3.1 ttt85 -138.07 141.38 32.06 Favored Pre-proline 0 N--CA 1.49 1.534 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.498 ' HD2' ' CG ' ' A' ' 81' ' ' ARG . 34.9 Cg_endo -76.12 117.27 4.6 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.467 2.111 . . . . 0.0 110.778 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 107.72 -33.53 6.26 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.422 ' HB ' ' HB3' ' A' ' 81' ' ' ARG . 2.7 t -88.59 149.72 3.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.221 -1.164 . . . . 0.0 109.584 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.3 t -94.19 147.54 23.07 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.631 ' CZ ' ' CB ' ' A' ' 166' ' ' SER . 7.6 m-85 -122.2 157.46 31.54 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.102 -0.999 . . . . 0.0 109.937 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 47.7 m -111.21 142.12 43.84 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.375 -0.828 . . . . 0.0 109.05 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.702 ' CZ ' ' CE2' ' A' ' 132' ' ' PHE . 0.2 OUTLIER -134.19 128.25 33.62 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.093 -1.004 . . . . 0.0 109.548 -179.522 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.501 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.5 m -134.83 152.79 52.04 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.563 HD12 ' CD2' ' A' ' 103' ' ' PHE . 18.6 tt -150.9 163.4 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.787 -1.196 . . . . 0.0 109.343 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.576 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 17.2 m95 -130.66 124.87 32.61 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.076 -1.015 . . . . 0.0 109.566 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.522 ' HB3' ' CG2' ' A' ' 121' ' ' ILE . . . -113.49 146.81 39.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.3 -0.875 . . . . 0.0 109.204 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.477 ' HG3' ' O ' ' A' ' 123' ' ' THR . 6.5 ttp85 -162.34 119.68 2.08 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.144 -0.973 . . . . 0.0 109.228 -179.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.412 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.35 160.52 15.31 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.22 -0.925 . . . . 0.0 109.937 -179.61 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.08 -44.83 75.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.425 -0.797 . . . . 0.0 109.176 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.454 ' HB2' ' OD1' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -117.68 151.62 36.88 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.872 . . . . 0.0 109.132 179.758 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.524 ' CA ' HG23 ' A' ' 123' ' ' THR . 2.3 p-10 -73.59 146.01 45.02 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.139 -0.976 . . . . 0.0 109.566 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 113.56 37.89 1.26 Allowed Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.473 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -121.66 140.53 52.17 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.188 -1.184 . . . . 0.0 109.128 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.461 ' HB ' ' HB3' ' A' ' 151' ' ' ALA . 50.7 t -116.23 154.3 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.218 -0.926 . . . . 0.0 110.66 -179.427 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.643 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 61.6 t -155.02 166.49 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.688 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.579 ' HB2' ' CD2' ' A' ' 117' ' ' HIS . 30.8 t -136.18 130.81 33.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.027 -1.046 . . . . 0.0 109.643 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.633 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.3 OUTLIER -122.86 104.51 9.32 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.145 -0.972 . . . . 0.0 109.572 -179.965 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.494 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 16.0 p -117.22 170.78 8.41 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.119 -0.988 . . . . 0.0 110.462 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.631 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -127.32 157.71 38.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.834 -0.541 . . . . 0.0 109.726 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 172.98 138.33 2.58 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.521 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.3 p30 -76.98 -169.88 1.46 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.123 -1.222 . . . . 0.0 109.334 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.521 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 1.4 mp0 -77.28 14.91 0.83 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.04 -1.037 . . . . 0.0 110.925 -179.156 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.508 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 0.9 OUTLIER -113.63 6.36 16.91 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 120.785 -1.197 . . . . 0.0 109.344 179.598 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.569 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.6 m-30 77.94 14.84 1.55 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.361 -0.837 . . . . 0.0 109.611 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.45 ' HG2' ' HB2' ' A' ' 109' ' ' SER . 7.9 mm-40 -90.0 94.39 9.78 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 108.655 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.53 ' CG ' ' O ' ' A' ' 105' ' ' VAL . 2.0 tt0 -81.92 142.08 32.77 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.362 -0.836 . . . . 0.0 110.34 -179.06 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.572 ' HB3' ' CD1' ' A' ' 132' ' ' PHE . 4.8 m-85 -109.69 -69.02 0.88 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.207 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -89.34 177.67 44.19 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 179.479 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.521 ' O ' ' CD2' ' A' ' 116' ' ' LEU . 0.6 OUTLIER -177.87 135.83 0.17 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.951 -1.323 . . . . 0.0 110.393 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.567 HD13 ' CD1' ' A' ' 130' ' ' PHE . 0.5 OUTLIER -147.36 69.87 1.16 Allowed 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.304 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.579 ' CD2' ' HB2' ' A' ' 102' ' ' SER . 27.2 t-80 -93.77 141.57 28.35 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 110.295 -179.043 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.559 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 4.2 tt0 82.21 36.8 0.06 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.711 -0.618 . . . . 0.0 109.52 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . 0.429 ' O ' HD11 ' A' ' 121' ' ' ILE . 6.9 mm100 -88.55 120.34 29.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.355 -0.841 . . . . 0.0 109.165 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -65.5 140.99 58.63 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.462 -0.774 . . . . 0.0 108.945 179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.522 ' CG2' ' HB3' ' A' ' 92' ' ' ALA . 5.9 mm -125.81 129.68 72.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.109 -0.995 . . . . 0.0 110.126 -179.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -89.86 -178.77 5.57 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.618 0.723 . . . . 0.0 110.094 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.524 HG23 ' CA ' ' A' ' 97' ' ' ASP . 11.6 p -72.87 -2.08 19.32 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 119.914 -0.714 . . . . 0.0 109.352 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.456 ' O ' ' HB2' ' A' ' 93' ' ' ARG . 0.4 OUTLIER -112.44 -168.73 1.36 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.166 -0.959 . . . . 0.0 108.981 179.727 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.542 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 95.3 m95 -91.95 130.26 37.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.145 -0.972 . . . . 0.0 109.613 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.429 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 12.1 mm-40 -109.51 121.45 42.33 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.156 -0.965 . . . . 0.0 109.109 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.17 100.41 1.26 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 C-N-CA 122.514 2.143 . . . . 0.0 111.141 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -110.9 137.83 48.05 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.14 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.1 t -144.18 176.21 9.5 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.565 -1.334 . . . . 0.0 111.058 -179.362 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.58 ' CE2' ' CD2' ' A' ' 88' ' ' TYR . 16.9 p90 -173.9 171.06 3.77 Favored 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 115.036 -0.983 . . . . 0.0 109.034 179.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . 0.503 ' HA ' ' CE2' ' A' ' 88' ' ' TYR . 34.3 mt-10 -143.64 142.18 30.92 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.089 -1.007 . . . . 0.0 109.904 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.702 ' CE2' ' CZ ' ' A' ' 88' ' ' TYR . 5.2 p90 -151.11 168.07 25.78 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.35 -0.844 . . . . 0.0 109.145 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.407 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -119.37 147.29 44.51 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.907 . . . . 0.0 109.623 -179.719 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.531 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 3.6 t -43.51 110.43 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.46 -0.775 . . . . 0.0 108.977 179.546 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -58.52 -51.12 71.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.293 -179.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -110.65 -91.16 0.47 Allowed 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.399 -0.813 . . . . 0.0 109.209 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.408 ' HA ' HG11 ' A' ' 134' ' ' VAL . 0.2 OUTLIER -160.94 55.2 0.3 Allowed 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.576 -0.702 . . . . 0.0 109.127 179.737 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.513 ' HG3' ' ND2' ' A' ' 107' ' ' ASN . 7.2 mm-40 -95.01 111.91 23.67 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.213 -0.93 . . . . 0.0 109.851 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.0 p -79.42 -13.46 59.58 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 41.6 t -134.03 136.42 53.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.212 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.46 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -143.36 171.89 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.072 -1.018 . . . . 0.0 110.224 -179.498 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.487 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.4 ptm180 -141.37 132.43 26.23 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.631 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -94.22 109.67 43.78 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.331 -0.856 . . . . 0.0 110.286 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.494 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.9 Cg_endo -77.2 110.68 3.06 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 122.023 1.816 . . . . 0.0 109.664 178.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.687 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 3.3 mt -95.18 124.15 47.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 12.8 m80 -84.5 149.36 25.99 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.926 -1.109 . . . . 0.0 111.638 -177.008 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.643 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 10.4 m-85 -154.55 158.43 39.79 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.063 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.474 ' C ' ' CG1' ' A' ' 64' ' ' VAL . . . 109.33 38.77 1.74 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.538 ' CA ' HG12 ' A' ' 64' ' ' VAL . 20.9 m-85 -113.99 158.08 21.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.444 -1.033 . . . . 0.0 109.207 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.21 -27.58 68.09 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.43 -14.99 62.77 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.447 -0.783 . . . . 0.0 109.328 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.521 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.2 OUTLIER -109.62 11.25 24.77 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.371 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.481 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -85.79 163.88 2.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 O-C-N 121.523 -0.735 . . . . 0.0 109.881 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.481 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.98 31.83 40.73 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.034 -1.227 . . . . 0.0 110.034 179.671 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.454 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.1 m-20 -160.61 139.36 10.28 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.147 -1.207 . . . . 0.0 110.27 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.574 HG22 ' CE1' ' A' ' 158' ' ' TYR . 80.1 m -87.29 121.2 29.42 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.562 ' CD1' ' CG2' ' A' ' 61' ' ' VAL . 1.2 mt -101.89 118.2 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 120.868 -1.145 . . . . 0.0 110.383 -178.65 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.638 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 2.6 m-85 -97.24 138.78 34.2 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 178.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.629 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -130.35 139.78 50.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 C-N-CA 118.767 -1.173 . . . . 0.0 110.014 -178.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.527 ' OD2' ' CA ' ' A' ' 9' ' ' GLY . 1.0 OUTLIER -173.94 136.1 0.52 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.371 -0.831 . . . . 0.0 109.136 179.687 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.501 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 126.58 -8.08 7.39 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.688 179.397 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.473 ' O ' ' HA3' ' A' ' 8' ' ' GLY . 10.4 tp -59.61 93.06 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.648 -1.501 . . . . 0.0 108.82 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . 0.449 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -118.22 145.75 44.76 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.694 -0.629 . . . . 0.0 109.9 -179.061 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.524 ' CD1' HG13 ' A' ' 78' ' ' VAL . 20.6 mt -132.68 127.28 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.362 -0.836 . . . . 0.0 109.095 179.607 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.573 ' O ' ' CD2' ' A' ' 86' ' ' TYR . . . -133.04 171.22 14.28 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -0.937 . . . . 0.0 109.599 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.631 ' CB ' ' CZ ' ' A' ' 86' ' ' TYR . 4.0 p -107.42 -15.63 14.57 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.183 -0.948 . . . . 0.0 109.464 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.449 ' HB3' ' HD2' ' A' ' 168' ' ' PRO . 13.0 mm-40 -134.06 163.12 53.44 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 109.568 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . 0.449 ' HD2' ' HB3' ' A' ' 167' ' ' GLN . 35.5 Cg_endo . . . . . 0 C--N 1.31 -1.489 0 C-N-CA 122.638 2.226 . . . . 0.0 110.344 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.4 ttt . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.8 mt -67.11 91.18 0.21 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.284 -0.885 . . . . 0.0 109.473 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.467 ' CG2' ' HB2' ' A' ' 165' ' ' ALA . 4.1 p -56.68 173.53 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.292 -0.88 . . . . 0.0 109.336 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 79' ' ' ASN . . . -77.61 -31.31 52.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 109.51 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.46 ' OD1' ' O ' ' A' ' 162' ' ' LEU . 10.2 t-20 -92.19 124.67 36.44 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.24 -0.913 . . . . 0.0 109.689 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.512 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 65.5 mt -110.38 121.63 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.323 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.526 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.1 OUTLIER 76.83 43.8 0.12 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.243 -0.911 . . . . 0.0 109.169 -179.436 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.433 ' O ' ' HB3' ' A' ' 162' ' ' LEU . . . -47.76 -22.57 1.96 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.64 ' O ' ' CB ' ' A' ' 10' ' ' PHE . . . 164.2 60.35 0.02 OUTLIER Glycine 0 N--CA 1.487 2.082 0 C-N-CA 119.609 -1.281 . . . . 0.0 109.964 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.64 ' CB ' ' O ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER 118.4 1.06 0.0 OUTLIER 'General case' 0 N--CA 1.518 2.946 0 C-N-CA 122.832 0.453 . . . . 0.0 111.579 179.115 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.564 ' HG2' ' CD1' ' A' ' 10' ' ' PHE . 9.2 mm-40 -75.73 -60.79 2.16 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.418 -1.426 . . . . 0.0 110.831 -177.757 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.525 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.3 OUTLIER -75.11 -3.01 30.26 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.048 -1.032 . . . . 0.0 110.025 -179.201 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.532 ' OG1' ' CG1' ' A' ' 25' ' ' VAL . 4.4 m -126.1 123.8 24.49 Favored Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.029 -1.045 . . . . 0.0 109.411 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.454 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.4 Cg_endo -77.35 149.11 27.41 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 C-N-CA 122.46 2.107 . . . . 0.0 110.719 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.461 ' HA ' HG12 ' A' ' 44' ' ' VAL . . . -39.96 161.15 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.196 0.522 . . . . 0.0 109.676 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.35 134.49 3.42 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.524 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.47 140.87 14.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.392 -1.063 . . . . 0.0 108.969 -179.569 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -87.93 144.34 9.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.427 -0.796 . . . . 0.0 110.169 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.6 p -105.78 -21.2 13.23 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.391 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -145.32 130.08 18.12 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.566 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.566 ' CD1' ' N ' ' A' ' 22' ' ' ALA . 1.7 pp -87.13 -38.31 16.57 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.088 -1.008 . . . . 0.0 110.179 -179.486 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.566 ' N ' ' CD1' ' A' ' 21' ' ' LEU . . . -59.61 -24.93 64.21 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.155 -0.966 . . . . 0.0 108.87 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -138.66 34.63 2.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.452 -0.78 . . . . 0.0 109.215 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.98 -72.78 1.28 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.532 ' CG1' ' OG1' ' A' ' 13' ' ' THR . 1.6 t -86.08 127.85 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.288 -1.125 . . . . 0.0 109.134 179.73 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . 0.475 ' HB3' ' HB3' ' A' ' 12' ' ' SER . 25.7 tt0 -54.71 -36.45 64.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.351 -0.843 . . . . 0.0 110.1 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.526 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -109.96 8.61 31.57 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.862 -1.161 . . . . 0.0 110.214 -179.367 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.626 ' CZ3' ' CB ' ' A' ' 73' ' ' ALA . 0.7 OUTLIER -140.57 119.67 12.81 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.089 -1.242 . . . . 0.0 109.125 179.313 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.579 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 7.3 m-20 -124.81 142.17 51.61 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.188 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.643 ' CD1' ' CD1' ' A' ' 42' ' ' PHE . 3.3 mt -109.48 172.13 7.04 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.846 -1.159 . . . . 0.0 109.794 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -159.95 122.41 3.38 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.767 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.455 HG11 HG22 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.23 137.87 37.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.476 -0.765 . . . . 0.0 109.598 179.302 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -90.73 172.98 37.88 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 72.4 m -62.61 -12.28 22.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.17 -1.194 . . . . 0.0 109.38 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 20.9 p -72.23 -32.64 66.91 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.32 -0.863 . . . . 0.0 109.812 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.531 ' CG1' ' O ' ' A' ' 36' ' ' VAL . 2.2 t -70.34 87.1 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 O-C-N 121.112 -0.992 . . . . 0.0 109.318 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 22.2 m -63.96 -28.98 70.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.194 -0.941 . . . . 0.0 108.484 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.1 t30 -128.86 114.86 19.05 Favored Pre-proline 0 C--N 1.296 -1.74 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -76.45 144.56 25.8 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.167 1.911 . . . . 0.0 110.492 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.564 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.3 Cg_endo -77.27 -164.08 0.25 Allowed 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.557 2.171 . . . . 0.0 110.133 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.518 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 56.8 t -116.09 120.26 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.127 -0.983 . . . . 0.0 110.667 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.643 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 5.5 m-85 -101.78 112.21 24.72 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 178.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.524 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 0.4 OUTLIER -155.93 140.04 16.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.005 -1.059 . . . . 0.0 110.361 -179.451 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.485 ' N ' ' HG2' ' A' ' 43' ' ' GLU . 36.5 t -92.52 148.79 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.577 ' CD2' ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -148.67 165.16 32.17 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.013 -1.055 . . . . 0.0 109.033 -179.558 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.577 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 13.4 mt-10 -111.19 113.89 26.72 Favored 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.452 -0.78 . . . . 0.0 109.644 -178.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.513 ' CG2' HD22 ' A' ' 45' ' ' LEU . 7.7 p -111.71 165.82 11.71 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 41.8 t -94.67 -10.11 32.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.3 m-20 -102.54 -1.79 29.77 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.263 -0.898 . . . . 0.0 109.59 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.425 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.1 147.38 0.94 Allowed Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.165 -0.959 . . . . 0.0 109.43 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.576 ' HB3' ' CE3' ' A' ' 91' ' ' TRP . 35.4 Cg_endo -78.34 -40.85 0.31 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.704 2.269 . . . . 0.0 110.325 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.14 107.06 11.73 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.418 ' O ' ' CG ' ' A' ' 54' ' ' ASN . . . 87.5 -120.5 5.56 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.472 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 27.7 m120 -160.16 36.28 0.17 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -1.169 . . . . 0.0 109.504 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.64 ' CD ' ' CD2' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -158.91 157.27 31.09 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.31 -0.869 . . . . 0.0 109.765 179.824 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.575 HG11 ' CH2' ' A' ' 125' ' ' TRP . 15.3 m -152.27 174.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.372 -0.83 . . . . 0.0 108.897 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.498 ' O ' ' HA ' ' A' ' 158' ' ' TYR . 0.2 OUTLIER -91.44 100.67 13.4 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 178.777 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.638 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -80.34 120.05 23.87 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 119.394 -0.922 . . . . 0.0 108.991 -179.812 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.52 ' O ' ' CG2' ' A' ' 156' ' ' THR . 41.3 t -112.97 144.48 20.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.489 HG22 ' ND2' ' A' ' 62' ' ' ASN . 59.7 m -109.87 91.14 3.53 Favored 'General case' 0 C--N 1.282 -2.327 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.537 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 52.4 t -89.95 122.82 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.311 -0.868 . . . . 0.0 108.799 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.489 ' ND2' HG22 ' A' ' 60' ' ' THR . 5.0 p30 -160.09 60.96 0.35 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.284 -0.885 . . . . 0.0 109.935 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 158.51 86.48 0.06 OUTLIER Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.531 HG13 ' CA ' ' A' ' 149' ' ' TYR . 2.3 m -82.23 -177.15 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.248 -1.148 . . . . 0.0 109.588 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -136.52 -157.86 7.87 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -96.0 23.73 6.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.326 -1.102 . . . . 0.0 109.566 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.495 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 7.0 m-80 -136.55 148.19 62.78 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.2 -0.937 . . . . 0.0 109.466 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.4 Cg_endo -78.24 11.93 2.22 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.662 2.242 . . . . 0.0 110.926 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.495 ' CZ2' ' OD1' ' A' ' 67' ' ' ASN . 1.3 p90 -136.76 59.56 1.69 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.093 -1.004 . . . . 0.0 109.647 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.525 ' HB3' ' CG2' ' A' ' 36' ' ' VAL . 1.4 m-20 -76.6 -67.59 0.68 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.242 -0.911 . . . . 0.0 109.111 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.518 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 2.2 mt -116.57 123.37 71.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.433 -0.792 . . . . 0.0 109.12 179.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.517 ' CG ' ' O ' ' A' ' 145' ' ' ILE . 20.7 tt0 -129.12 134.33 48.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.972 -1.08 . . . . 0.0 110.335 -179.4 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.626 ' CB ' ' CZ3' ' A' ' 28' ' ' TRP . . . -115.91 107.69 15.31 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 178.855 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.469 ' OG1' ' HA ' ' A' ' 144' ' ' PRO . 99.3 m -103.52 165.06 11.26 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.334 -0.854 . . . . 0.0 109.669 -179.24 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.468 ' HA ' ' O ' ' A' ' 27' ' ' GLY . . . -122.98 137.49 54.94 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.026 -1.046 . . . . 0.0 109.227 179.027 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CZ ' ' HB2' ' A' ' 29' ' ' ASP . 11.2 p90 -176.05 160.32 1.89 Allowed Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.4 -0.812 . . . . 0.0 109.383 -179.766 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.526 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -82.53 170.22 58.1 Favored 'Cis proline' 0 C--N 1.311 -1.395 0 O-C-N 123.652 1.343 . . . . 0.0 111.064 -0.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.512 HG13 ' CD1' ' A' ' 164' ' ' ILE . 96.4 t -131.75 156.9 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.239 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.525 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 76.1 m-20 -123.24 140.28 53.18 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.922 -1.111 . . . . 0.0 110.289 -179.459 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.525 ' CG2' ' O ' ' A' ' 138' ' ' GLU . 4.3 m -145.48 -173.51 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.304 -0.873 . . . . 0.0 109.387 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.527 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 17.6 mmt180 -136.45 144.73 48.69 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.382 -0.824 . . . . 0.0 109.348 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.73 126.87 8.4 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.457 2.105 . . . . 0.0 110.539 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.22 -25.17 21.61 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.419 HG13 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -86.32 149.61 4.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.239 -1.154 . . . . 0.0 109.496 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 32.8 m -94.86 131.96 40.18 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.459 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 14.6 m-85 -113.32 167.31 10.67 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.236 -0.915 . . . . 0.0 109.666 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' THR . . . . . 0.461 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 43.8 m -118.38 152.88 34.99 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.338 -0.851 . . . . 0.0 109.418 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.688 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 7.9 t80 -132.81 114.83 14.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.481 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.485 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.2 m -135.11 146.23 48.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.194 -0.941 . . . . 0.0 109.002 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 15.3 tt -150.96 163.78 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.796 -1.19 . . . . 0.0 109.5 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.576 ' CE3' ' HB3' ' A' ' 51' ' ' PRO . 37.3 m95 -128.76 135.41 49.15 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.862 -1.149 . . . . 0.0 109.375 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.424 ' C ' ' CE3' ' A' ' 125' ' ' TRP . . . -130.0 148.09 51.82 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.213 -0.929 . . . . 0.0 109.747 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.636 ' CB ' ' CD2' ' A' ' 125' ' ' TRP . 11.6 ttt-85 -164.14 121.66 1.74 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.317 -0.864 . . . . 0.0 108.909 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.438 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.04 165.68 11.04 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.305 -0.872 . . . . 0.0 110.086 -179.403 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.07 -56.6 12.06 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.425 -0.797 . . . . 0.0 109.117 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.517 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.5 OUTLIER -101.77 134.93 44.17 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.279 -0.888 . . . . 0.0 109.204 179.701 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.581 ' N ' ' CG2' ' A' ' 123' ' ' THR . 1.2 p30 -60.77 144.95 51.37 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.212 -0.93 . . . . 0.0 109.551 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 112.45 37.82 1.41 Allowed Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.466 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -118.78 139.31 51.8 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.204 -1.174 . . . . 0.0 109.224 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.491 HG13 ' N ' ' A' ' 101' ' ' VAL . 76.0 t -116.46 149.93 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.205 -0.934 . . . . 0.0 110.407 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.584 HG13 ' CE2' ' A' ' 147' ' ' PHE . 43.0 t -146.15 165.77 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.34 -0.85 . . . . 0.0 109.45 179.721 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.54 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 24.2 m -124.77 133.42 53.16 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.146 -0.971 . . . . 0.0 109.681 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.0 OUTLIER -129.1 103.85 7.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.126 -0.984 . . . . 0.0 109.477 179.497 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.505 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 29.2 p -128.14 175.63 8.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.133 -0.979 . . . . 0.0 110.323 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.616 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -133.45 106.34 9.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-O 121.575 0.702 . . . . 0.0 110.316 179.175 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.456 ' O ' ' HG2' ' A' ' 142' ' ' ARG . . . -101.54 132.46 10.97 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 108.052 -2.019 . . . . 0.0 108.052 178.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.584 ' OD1' ' CE1' ' A' ' 113' ' ' TYR . 0.2 OUTLIER -96.87 -170.62 2.08 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.963 -1.316 . . . . 0.0 109.052 -179.399 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 62.1 mt-30 -81.28 -19.8 42.24 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 118.751 -1.18 . . . . 0.0 109.829 -179.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.522 ' HB3' ' CG ' ' A' ' 111' ' ' GLN . 0.6 OUTLIER -81.92 8.82 9.45 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.113 -0.992 . . . . 0.0 108.792 178.979 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.45 ' HB2' ' O ' ' A' ' 109' ' ' SER . 18.3 m-30 63.01 21.75 13.08 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.428 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.522 ' CG ' ' HB3' ' A' ' 109' ' ' SER . 2.0 mt-30 -88.36 161.61 17.01 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.649 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.82 102.12 12.22 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.447 -0.783 . . . . 0.0 109.768 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.584 ' CE1' ' OD1' ' A' ' 107' ' ' ASN . 1.9 m-30 -69.41 -67.14 0.5 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.401 -0.812 . . . . 0.0 108.941 178.553 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.541 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -130.55 171.45 20.72 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.497 ' HA ' HG23 ' A' ' 104' ' ' THR . 0.2 OUTLIER -162.78 117.31 1.75 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.029 -1.277 . . . . 0.0 110.723 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.636 ' CD2' ' CD2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -150.62 74.31 1.17 Allowed 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 178.997 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.54 ' CB ' ' HB3' ' A' ' 102' ' ' SER . 22.4 p80 -118.3 169.15 9.97 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.193 -0.942 . . . . 0.0 110.134 -179.304 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.512 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 0.2 OUTLIER 77.53 41.04 0.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.517 -0.739 . . . . 0.0 109.294 179.925 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . 0.455 ' HG3' HD13 ' A' ' 121' ' ' ILE . 0.8 OUTLIER -116.03 138.35 51.3 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.316 -0.865 . . . . 0.0 109.668 -179.836 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . 0.464 ' O ' HD11 ' A' ' 121' ' ' ILE . 2.4 mt-30 -74.54 156.49 36.8 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.464 HD11 ' O ' ' A' ' 120' ' ' GLN . 5.2 mm -135.19 134.64 52.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.116 -0.99 . . . . 0.0 110.022 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.0 -179.43 7.25 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.523 -0.735 . . . . 0.0 109.947 179.477 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.581 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 70.2 p -75.98 -0.46 21.67 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 119.829 -0.748 . . . . 0.0 109.23 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.453 ' O ' ' HG3' ' A' ' 93' ' ' ARG . 22.5 mm-40 -102.4 -168.91 1.59 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.246 -0.909 . . . . 0.0 109.21 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.636 ' CD2' ' CB ' ' A' ' 93' ' ' ARG . 88.4 m95 -103.2 115.17 30.07 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 0.0 109.614 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 -106.68 120.75 47.32 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.11 -0.994 . . . . 0.0 108.986 179.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -80.58 116.28 3.22 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 C-N-CA 122.384 2.056 . . . . 0.0 111.175 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -112.03 135.6 52.46 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.484 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -145.71 176.3 9.75 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 120.822 -1.174 . . . . 0.0 110.801 -179.348 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.688 ' CE2' ' CG ' ' A' ' 88' ' ' TYR . 21.2 p90 -176.89 152.7 0.96 Allowed 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.303 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -105.28 154.91 19.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.752 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 113' ' ' TYR . 0.2 OUTLIER -165.02 160.88 19.43 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.431 -0.793 . . . . 0.0 109.334 179.942 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.7 OUTLIER -124.13 146.42 48.65 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.214 -0.929 . . . . 0.0 108.937 -179.883 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 3.5 t -43.57 109.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.294 -0.879 . . . . 0.0 108.955 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -51.41 -40.05 58.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.123 -0.986 . . . . 0.0 109.149 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -129.81 -90.28 0.48 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.38 -0.825 . . . . 0.0 109.369 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.453 ' HA ' HG12 ' A' ' 134' ' ' VAL . 5.9 pt20 -158.58 52.73 0.42 Allowed 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.479 -0.763 . . . . 0.0 109.279 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.525 ' O ' ' CG2' ' A' ' 80' ' ' VAL . 32.5 mm-40 -85.53 110.15 19.01 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.261 -0.9 . . . . 0.0 109.547 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.3 p -79.48 -16.25 56.38 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.249 -0.907 . . . . 0.0 108.71 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.5 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 42.4 t -132.24 134.31 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.06 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.584 HG22 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -139.81 172.28 12.69 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.051 -1.031 . . . . 0.0 110.447 -179.447 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.488 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.0 OUTLIER -143.73 132.07 22.07 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.895 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.616 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -99.31 106.58 39.88 Favored Pre-proline 0 N--CA 1.487 1.421 0 O-C-N 121.207 -0.933 . . . . 0.0 109.616 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.505 ' HD2' ' O ' ' A' ' 104' ' ' THR . 36.1 Cg_endo -78.04 111.92 3.16 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.206 1.937 . . . . 0.0 110.827 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.551 HG12 ' O ' ' A' ' 73' ' ' ALA . 2.0 mm -94.31 139.56 18.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 178.343 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.539 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 4.5 m80 -107.22 159.75 16.11 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.299 -1.501 . . . . 0.0 112.165 -177.007 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.656 ' CE2' ' CD1' ' A' ' 159' ' ' ILE . 39.0 m-85 -160.72 165.25 30.77 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.472 ' HA3' ' HB2' ' A' ' 70' ' ' ASP . . . 104.52 46.51 1.3 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.531 ' CA ' HG13 ' A' ' 64' ' ' VAL . 23.9 m-85 -125.03 161.27 27.1 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.477 -1.013 . . . . 0.0 109.115 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.72 -28.47 68.45 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -75.78 -11.54 60.0 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.434 -0.791 . . . . 0.0 109.065 179.031 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.577 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 1.5 t30 -114.61 11.0 16.88 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.403 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.466 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -88.02 162.81 2.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.495 -0.753 . . . . 0.0 109.868 -179.223 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.466 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.42 34.04 41.07 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 3.5 m-20 -160.39 138.71 10.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.177 -1.19 . . . . 0.0 110.013 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.52 ' CG2' ' O ' ' A' ' 59' ' ' VAL . 53.5 m -89.37 120.44 30.72 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.577 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -100.37 117.44 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.902 -1.124 . . . . 0.0 110.222 -178.894 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.638 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 13.1 m-85 -92.52 143.63 26.16 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 178.381 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.656 ' CD1' ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -142.04 136.22 29.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.604 -1.31 . . . . 0.0 111.025 -178.014 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.585 ' OD2' ' CZ ' ' A' ' 10' ' ' PHE . 4.7 t0 -173.23 136.24 0.62 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.245 -0.909 . . . . 0.0 108.586 179.144 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 133.35 -7.29 5.01 Favored Glycine 0 N--CA 1.484 1.896 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.422 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.626 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 7.3 tp -59.33 93.14 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.626 -1.514 . . . . 0.0 108.596 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . 0.444 ' N ' ' O ' ' A' ' 161' ' ' GLY . . . -123.62 145.98 48.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.594 -0.691 . . . . 0.0 109.965 -178.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.512 ' CD1' HG13 ' A' ' 78' ' ' VAL . 8.0 mt -132.41 119.58 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.325 -0.86 . . . . 0.0 109.258 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.467 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . -153.01 144.55 23.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.772 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' SER . . . . . 0.447 ' HA ' ' HA ' ' A' ' 86' ' ' TYR . 0.7 OUTLIER -43.71 -64.76 0.6 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.354 -0.841 . . . . 0.0 109.535 179.837 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.18 168.27 18.54 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.279 -0.888 . . . . 0.0 109.494 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo . . . . . 0 C--N 1.309 -1.528 0 C-N-CA 122.63 2.22 . . . . 0.0 110.401 -179.984 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.629 HG22 ' O ' ' A' ' 164' ' ' ILE . 4.1 p . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.76 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -71.74 -46.61 57.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.173 -0.955 . . . . 0.0 109.487 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.852 ' HB2' HD12 ' A' ' 164' ' ' ILE . 38.7 t-20 -82.56 125.83 31.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.207 -0.933 . . . . 0.0 109.496 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.472 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 2.0 mp -112.2 123.35 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.292 -0.88 . . . . 0.0 109.265 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.483 ' HB3' ' HA3' ' A' ' 27' ' ' GLY . 0.8 OUTLIER 69.05 12.9 8.7 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.266 -0.896 . . . . 0.0 109.504 179.973 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -59.14 -24.96 59.29 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.458 ' O ' ' OD2' ' A' ' 160' ' ' ASP . . . -110.99 36.56 4.16 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.214 -1.555 . . . . 0.0 109.214 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.733 ' HD2' HG21 ' A' ' 25' ' ' VAL . 0.7 OUTLIER 43.64 53.21 6.02 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.368 -1.078 . . . . 0.0 109.422 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.483 ' OE2' ' CG ' ' A' ' 52' ' ' GLU . 7.7 mm-40 -84.04 -49.62 8.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -0.926 . . . . 0.0 109.728 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.451 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 7.3 m -79.58 -16.49 55.8 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.677 -179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . 1.048 ' OG1' HG13 ' A' ' 25' ' ' VAL . 0.5 OUTLIER -74.51 114.74 36.89 Favored Pre-proline 0 C--N 1.304 -1.389 0 O-C-N 121.185 -0.947 . . . . 0.0 109.422 -179.802 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.2 Cg_endo -77.09 136.9 16.75 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.424 2.082 . . . . 0.0 110.474 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.47 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -40.02 155.51 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.393 0.616 . . . . 0.0 109.717 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.3 132.6 3.0 Favored Glycine 0 N--CA 1.485 1.961 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.531 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.71 142.45 12.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.252 -1.146 . . . . 0.0 109.011 -179.528 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.6 t -88.42 144.14 9.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-O 121.778 0.799 . . . . 0.0 110.277 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.3 t -105.03 -26.69 12.04 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 179.145 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.48 ' CB ' ' HG3' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -138.18 101.37 4.38 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 179.453 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.969 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.7 OUTLIER -55.56 -34.91 65.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.204 -0.935 . . . . 0.0 110.384 -179.004 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.946 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.69 -33.79 72.03 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.061 -1.024 . . . . 0.0 109.334 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.48 ' HG3' ' CB ' ' A' ' 20' ' ' ASP . 1.4 pt-20 -122.15 37.67 4.32 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.303 -0.873 . . . . 0.0 109.369 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -89.2 -73.1 1.28 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 1.048 HG13 ' OG1' ' A' ' 13' ' ' THR . 14.6 t -99.72 127.43 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.307 -1.113 . . . . 0.0 109.259 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 31.6 tp10 -56.76 -35.69 68.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.417 -0.802 . . . . 0.0 109.783 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.483 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -99.14 -2.4 56.91 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 -179.503 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' TRP . . . . . 0.614 ' CZ3' ' CB ' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -138.79 123.21 18.32 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.088 -1.242 . . . . 0.0 109.845 179.941 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.744 ' C ' HD23 ' A' ' 30' ' ' LEU . 3.9 m-20 -123.47 144.23 49.66 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.969 ' O ' HD13 ' A' ' 21' ' ' LEU . 0.7 OUTLIER -113.5 166.98 10.98 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.714 -1.242 . . . . 0.0 109.461 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.458 ' OD1' ' O ' ' A' ' 30' ' ' LEU . 8.5 m120 -157.02 124.67 5.39 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.45 -0.781 . . . . 0.0 109.687 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.045 ' CG1' HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.04 136.56 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.383 -0.823 . . . . 0.0 109.457 179.539 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.43 -170.6 23.81 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.4 t -66.74 -9.09 33.01 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.195 -1.18 . . . . 0.0 109.438 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.473 ' HB2' ' HA ' ' A' ' 70' ' ' ASP . 0.6 OUTLIER -73.12 -31.39 64.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.204 -0.935 . . . . 0.0 109.593 -179.964 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 1.045 HG21 ' CG1' ' A' ' 32' ' ' VAL . 2.1 t -64.64 87.86 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 O-C-N 121.176 -0.952 . . . . 0.0 109.339 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 16.4 m -72.58 -29.0 63.15 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.431 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.624 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.2 t-20 -114.57 144.98 32.88 Favored Pre-proline 0 C--N 1.296 -1.746 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.607 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.446 ' HD2' ' CG ' ' A' ' 38' ' ' ASN . 34.8 Cg_endo -76.38 111.8 3.34 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 122.359 2.039 . . . . 0.0 110.591 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.55 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.2 Cg_endo -77.57 166.13 26.16 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.371 2.048 . . . . 0.0 109.593 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.532 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 49.0 t -108.16 121.59 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.966 -1.084 . . . . 0.0 110.559 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.629 ' CE2' HD23 ' A' ' 21' ' ' LEU . 27.4 m-85 -110.12 112.47 24.48 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.464 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.531 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 0.9 OUTLIER -153.56 151.32 29.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.1 -1.0 . . . . 0.0 109.801 -179.422 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.459 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 62.3 t -98.78 148.57 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -0.885 . . . . 0.0 109.255 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.758 HD21 ' CG2' ' A' ' 47' ' ' THR . 0.4 OUTLIER -131.9 147.01 52.44 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.185 -0.947 . . . . 0.0 108.776 179.978 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.56 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 18.1 mt-10 -115.08 113.69 24.37 Favored 'General case' 0 C--N 1.295 -1.8 0 O-C-N 121.576 -0.702 . . . . 0.0 109.548 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.758 ' CG2' HD21 ' A' ' 45' ' ' LEU . 1.7 p -141.5 164.66 29.62 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.31 -0.869 . . . . 0.0 109.41 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.448 ' HA ' ' OD1' ' A' ' 54' ' ' ASN . 0.1 OUTLIER -86.9 15.59 5.73 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.9 . . . . 0.0 109.51 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -102.89 -18.51 15.03 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.242 -0.911 . . . . 0.0 109.436 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.721 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -55.55 144.68 52.97 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.2 -0.938 . . . . 0.0 109.329 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.515 ' HG3' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.29 -42.12 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.571 2.181 . . . . 0.0 110.365 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.483 ' CG ' ' OE2' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -101.42 92.8 5.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.901 . . . . 0.0 109.407 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.93 -115.97 4.35 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.721 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 15.2 m-20 -160.02 37.77 0.18 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -1.147 . . . . 0.0 109.412 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.52 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 62.1 mttt -138.54 134.24 33.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.198 -0.938 . . . . 0.0 109.6 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.659 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.9 m -146.53 174.62 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.313 -0.867 . . . . 0.0 109.229 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.789 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -107.46 103.09 12.34 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.101 -1.0 . . . . 0.0 109.181 179.731 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.684 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.17 120.71 25.21 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.034 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.824 ' O ' HG23 ' A' ' 156' ' ' THR . 41.5 t -115.79 144.89 22.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.15 -0.969 . . . . 0.0 109.331 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.601 HG22 ' OD1' ' A' ' 62' ' ' ASN . 19.6 m -108.99 92.75 4.18 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.563 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 52.5 t -90.54 115.73 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.236 -0.915 . . . . 0.0 109.272 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.601 ' OD1' HG22 ' A' ' 60' ' ' THR . 0.8 OUTLIER -149.51 56.41 0.98 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.248 -0.908 . . . . 0.0 109.828 -179.767 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 160.9 90.09 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.779 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.5 m -80.14 -171.32 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.176 -1.19 . . . . 0.0 109.451 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -139.95 -168.44 11.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -86.21 1.41 50.86 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.233 -1.157 . . . . 0.0 109.569 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.603 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 1.2 m120 -116.33 145.02 34.16 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.241 -0.912 . . . . 0.0 109.284 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.584 ' HG2' ' CZ3' ' A' ' 69' ' ' TRP . 36.4 Cg_endo -79.52 38.88 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.607 2.204 . . . . 0.0 111.197 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.603 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 8.2 p90 -162.58 50.05 0.18 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.968 -1.082 . . . . 0.0 109.807 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.649 ' HB2' HD12 ' A' ' 71' ' ' ILE . 0.4 OUTLIER -70.94 -64.64 0.86 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.126 -0.984 . . . . 0.0 108.924 179.536 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.649 HD12 ' HB2' ' A' ' 70' ' ' ASP . 4.1 mp -106.4 128.73 60.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 108.996 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.452 ' OE2' ' HB2' ' A' ' 144' ' ' PRO . 71.3 tt0 -138.26 122.68 18.35 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.843 -1.16 . . . . 0.0 110.195 -179.551 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.635 ' CB ' HD22 ' A' ' 30' ' ' LEU . . . -113.76 107.41 15.7 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.069 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.55 HG22 ' N ' ' A' ' 75' ' ' ALA . 96.7 m -94.4 165.44 12.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.57 -0.706 . . . . 0.0 110.17 -179.107 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.55 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.12 137.78 53.36 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.175 -0.953 . . . . 0.0 108.726 178.663 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.536 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 0.2 OUTLIER -179.12 161.49 1.0 Allowed Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.561 -0.712 . . . . 0.0 109.165 -179.387 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.536 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.2 Cg_endo -82.46 163.32 74.97 Favored 'Cis proline' 0 C--N 1.311 -1.437 0 C-N-CA 123.81 -1.329 . . . . 0.0 110.893 -0.752 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.761 HG11 HD13 ' A' ' 164' ' ' ILE . 96.8 t -123.99 156.45 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.4 -0.813 . . . . 0.0 108.913 179.206 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ASN . . . . . 0.76 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 52.1 m-20 -121.21 139.8 52.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.115 -0.991 . . . . 0.0 109.854 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.565 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 2.5 m -146.3 -174.0 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.138 -0.976 . . . . 0.0 109.478 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.691 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -137.3 146.09 52.52 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.233 -0.917 . . . . 0.0 109.429 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.45 106.14 2.16 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.474 2.116 . . . . 0.0 110.494 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 112.35 -29.7 8.12 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.475 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.43 149.71 4.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.158 -1.201 . . . . 0.0 109.474 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.471 ' HA ' ' OG1' ' A' ' 133' ' ' THR . 10.8 m -95.47 143.07 27.11 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' TYR . . . . . 0.565 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 12.0 m-85 -120.61 168.49 11.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.171 -0.956 . . . . 0.0 109.604 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.478 ' CB ' ' O ' ' A' ' 165' ' ' ALA . 5.2 m -118.15 154.47 32.1 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.26 -0.9 . . . . 0.0 109.561 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.682 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 5.1 t80 -130.56 118.96 21.81 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.298 -0.876 . . . . 0.0 109.319 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.474 ' O ' ' O ' ' A' ' 161' ' ' GLY . 31.8 m -134.31 144.04 48.07 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.215 -0.928 . . . . 0.0 109.333 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.552 HD13 ' CD2' ' A' ' 103' ' ' PHE . 14.9 tt -150.62 163.54 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 120.703 -1.248 . . . . 0.0 109.506 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.515 ' HB2' ' HG3' ' A' ' 51' ' ' PRO . 20.1 m95 -132.73 124.98 29.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.974 -1.079 . . . . 0.0 109.342 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.88 150.42 37.08 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.288 -0.883 . . . . 0.0 109.459 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.552 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 1.1 ttt85 -164.4 119.12 1.44 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.309 -0.869 . . . . 0.0 109.027 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.39 170.1 8.12 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 110.065 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -66.12 -55.94 13.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.443 -0.785 . . . . 0.0 109.41 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.514 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -104.43 137.3 42.5 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.222 -0.924 . . . . 0.0 109.463 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.585 ' N ' ' CG2' ' A' ' 123' ' ' THR . 19.2 p-10 -61.64 148.35 42.82 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.308 -0.87 . . . . 0.0 109.562 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 108.9 39.43 1.71 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.506 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -119.55 141.15 49.5 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.14 -1.212 . . . . 0.0 108.98 179.657 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.401 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 52.0 t -115.94 148.25 18.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 110.712 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.634 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 25.1 t -150.01 164.96 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.457 -0.777 . . . . 0.0 109.203 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.539 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 16.4 t -136.47 144.33 44.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.011 -1.056 . . . . 0.0 109.457 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.629 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.1 OUTLIER -135.99 104.67 5.78 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.224 -0.923 . . . . 0.0 109.924 -179.726 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.507 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 14.0 p -112.77 168.75 9.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.093 -1.005 . . . . 0.0 110.058 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -127.83 141.45 46.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 CA-C-O 121.386 0.612 . . . . 0.0 109.837 -179.879 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -167.49 143.9 8.58 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.4 p30 -84.66 -169.79 2.8 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.197 -1.179 . . . . 0.0 109.632 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' GLN . . . . . 0.52 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 11.2 mp0 -77.84 16.95 0.62 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.196 -0.94 . . . . 0.0 110.683 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.463 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 0.8 OUTLIER -113.23 15.46 19.36 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 120.831 -1.168 . . . . 0.0 108.801 179.447 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.463 ' HB2' ' O ' ' A' ' 109' ' ' SER . 9.8 m-30 67.63 16.86 9.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.504 -0.748 . . . . 0.0 109.599 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.528 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 12.8 mm-40 -93.5 157.66 16.1 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.177 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' GLU . . . . . 0.471 ' OE2' ' HB2' ' A' ' 115' ' ' ARG . 8.0 tt0 -137.83 147.15 44.29 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.034 -1.041 . . . . 0.0 109.99 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.509 ' CE2' HG21 ' A' ' 141' ' ' ILE . 4.0 m-85 -112.3 -67.4 1.0 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.237 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.587 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -92.35 173.42 35.73 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.471 ' HB2' ' OE2' ' A' ' 112' ' ' GLU . 6.8 ttt-85 -178.78 119.46 0.08 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.08 -1.247 . . . . 0.0 110.217 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.646 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -141.91 70.03 1.33 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.396 -0.815 . . . . 0.0 108.803 179.241 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 117' ' ' HIS . . . . . 0.54 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 0.2 OUTLIER -86.64 148.07 25.63 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 110.346 -179.265 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 1.2 mt-10 79.42 66.32 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.466 -0.771 . . . . 0.0 109.557 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' GLN . . . . . 0.472 ' HA ' ' NE2' ' A' ' 119' ' ' GLN . 7.8 mm100 -118.79 123.73 45.51 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.315 -0.866 . . . . 0.0 109.259 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.553 ' O ' HD13 ' A' ' 121' ' ' ILE . 0.0 OUTLIER -64.23 139.14 58.73 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.429 -0.794 . . . . 0.0 108.972 179.78 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 120' ' ' GLN . 5.6 mm -125.95 130.17 72.32 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.08 -1.012 . . . . 0.0 110.14 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.04 -179.28 6.17 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.604 0.716 . . . . 0.0 109.949 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.585 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 74.9 p -75.85 -4.19 39.36 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.793 -0.763 . . . . 0.0 109.183 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 2.8 mt-10 -106.65 -168.78 1.46 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.327 -0.858 . . . . 0.0 109.311 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' TRP . . . . . 0.552 ' CE2' ' HD3' ' A' ' 93' ' ' ARG . 93.8 m95 -94.38 118.64 31.92 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.208 -0.933 . . . . 0.0 109.691 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -106.88 121.44 44.88 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.289 -0.882 . . . . 0.0 108.985 179.723 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -79.54 117.05 3.64 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.341 2.027 . . . . 0.0 111.075 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -121.25 138.29 54.3 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.7 t -151.27 175.81 11.84 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.608 -1.308 . . . . 0.0 111.149 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.682 ' CE2' ' CD1' ' A' ' 88' ' ' TYR . 36.3 p90 -173.22 -172.69 0.84 Allowed 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.095 179.135 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' GLU . . . . . 0.412 ' N ' ' CD1' ' A' ' 130' ' ' PHE . 21.7 mt-10 -129.01 155.78 44.86 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.098 -1.001 . . . . 0.0 110.051 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -164.98 139.18 4.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.422 -0.799 . . . . 0.0 109.065 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.471 ' OG1' ' HA ' ' A' ' 85' ' ' THR . 0.8 OUTLIER -117.85 146.19 44.05 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.216 -0.927 . . . . 0.0 109.377 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.691 HG21 ' O ' ' A' ' 81' ' ' ARG . 4.4 t -44.57 110.49 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.396 -0.815 . . . . 0.0 109.203 179.426 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 65.5 m -61.8 -53.08 60.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.207 -0.933 . . . . 0.0 109.258 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 -102.91 -91.74 0.34 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.359 -0.838 . . . . 0.0 109.218 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -162.27 50.59 0.2 Allowed 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.458 -0.776 . . . . 0.0 109.314 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.51 ' O ' HG23 ' A' ' 80' ' ' VAL . 23.1 mm-40 -88.18 114.63 25.0 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.209 -0.932 . . . . 0.0 109.604 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.6 p -79.19 -12.38 59.97 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.294 -0.879 . . . . 0.0 108.759 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.492 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 40.8 t -135.73 134.77 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.391 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.509 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -139.58 172.52 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.194 -0.941 . . . . 0.0 110.057 -179.725 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 142' ' ' ARG . . . . . 0.493 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.4 ptm180 -145.54 132.54 20.28 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.556 -0.715 . . . . 0.0 109.614 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ALA . . . . . 0.596 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -100.24 106.58 42.87 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.292 -0.88 . . . . 0.0 109.655 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.507 ' HD2' ' O ' ' A' ' 104' ' ' THR . 33.7 Cg_endo -76.64 110.56 3.07 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.061 1.841 . . . . 0.0 110.291 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.633 ' N ' HD13 ' A' ' 145' ' ' ILE . 3.2 mm -85.71 124.74 40.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' HIS . . . . . 0.499 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 6.7 m80 -84.57 150.15 25.41 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.972 -1.08 . . . . 0.0 110.984 -178.158 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.66 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 12.1 m-85 -154.91 157.36 37.66 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.125 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.599 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 108.44 50.67 0.74 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.779 ' C ' HG11 ' A' ' 64' ' ' VAL . 27.5 m-85 -121.17 159.77 25.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.378 -1.072 . . . . 0.0 109.227 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.487 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -65.78 -30.39 71.03 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.611 -0.681 . . . . 0.0 109.168 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.467 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -77.0 -11.0 59.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.394 -0.816 . . . . 0.0 109.108 179.273 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.577 ' ND2' HD13 ' A' ' 157' ' ' ILE . 3.8 t30 -109.81 11.62 24.28 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.55 HG23 HG13 ' A' ' 64' ' ' VAL . 2.4 t -90.06 164.76 2.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 O-C-N 121.519 -0.738 . . . . 0.0 109.763 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 154' ' ' GLY . . . . . 0.493 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 53.29 32.7 44.72 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.864 -1.295 . . . . 0.0 109.864 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.7 m-20 -160.53 136.78 8.59 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.137 -1.214 . . . . 0.0 110.04 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 156' ' ' THR . . . . . 0.824 HG23 ' O ' ' A' ' 59' ' ' VAL . 53.6 m -86.83 121.13 28.9 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.01 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.577 HD13 ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -100.86 118.73 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 120.967 -1.083 . . . . 0.0 110.291 -178.775 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.684 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.6 m-85 -97.09 129.42 44.51 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 178.613 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.66 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -120.37 141.99 38.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 120.749 -1.219 . . . . 0.0 110.091 -178.801 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 160' ' ' ASP . . . . . 0.659 ' CB ' HG12 ' A' ' 56' ' ' VAL . 4.5 t70 -173.89 136.41 0.54 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.299 -0.876 . . . . 0.0 108.901 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 161' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 124.78 -6.93 8.34 Favored Glycine 0 N--CA 1.486 2.033 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.157 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.601 HD11 ' CE2' ' A' ' 88' ' ' TYR . 0.6 OUTLIER -60.01 94.04 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 O-C-N 120.768 -1.43 . . . . 0.0 108.491 179.899 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 163' ' ' ALA . . . . . 0.494 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -132.93 145.85 51.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.633 -0.667 . . . . 0.0 109.815 -179.068 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.852 HD12 ' HB2' ' A' ' 5' ' ' ASN . 3.2 mt -123.08 115.65 46.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.235 -0.915 . . . . 0.0 109.202 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.5 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.621 0 O-C-N 121.171 -0.956 . . . . 0.0 109.626 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.874 ' CG2' ' HB2' ' A' ' 165' ' ' ALA . 1.4 p . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.236 0.541 . . . . 0.0 109.553 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.713 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -70.79 -61.19 1.86 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.058 -1.027 . . . . 0.0 109.324 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.599 ' HB3' HD13 ' A' ' 164' ' ' ILE . 13.0 p-10 -74.92 176.92 6.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.367 -0.833 . . . . 0.0 109.405 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.669 HG22 ' ND2' ' A' ' 7' ' ' ASN . 2.6 mp -128.3 136.83 59.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.286 -0.884 . . . . 0.0 109.717 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.669 ' ND2' HG22 ' A' ' 6' ' ' ILE . 0.3 OUTLIER 44.92 57.71 4.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.678 179.908 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.497 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -56.96 -42.79 92.92 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.504 ' HA2' ' HA ' ' A' ' 160' ' ' ASP . . . -107.74 35.62 4.89 Favored Glycine 0 N--CA 1.487 2.088 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.994 ' CE2' HG21 ' A' ' 25' ' ' VAL . 4.1 m-85 63.52 54.73 1.87 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.468 -1.019 . . . . 0.0 109.386 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -82.35 -50.53 8.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.897 . . . . 0.0 109.737 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.532 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 41.3 t -69.9 -42.14 73.77 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.105 -0.997 . . . . 0.0 109.693 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.956 ' OG1' HG13 ' A' ' 25' ' ' VAL . 0.6 OUTLIER -68.53 125.71 91.99 Favored Pre-proline 0 C--N 1.305 -1.351 0 O-C-N 121.217 -0.927 . . . . 0.0 109.199 -179.882 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.47 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.2 Cg_endo -76.98 146.1 25.53 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 122.462 2.108 . . . . 0.0 111.071 -179.493 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.804 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -42.05 165.48 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.564 0 CA-C-O 121.214 0.53 . . . . 0.0 109.663 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 130.96 135.27 3.76 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.531 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.57 140.14 15.14 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.34 -1.094 . . . . 0.0 109.029 -179.596 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -84.77 143.67 11.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 CA-C-O 121.763 0.792 . . . . 0.0 110.196 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.4 p -113.56 -27.1 7.99 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.553 ' CB ' ' HG3' ' A' ' 23' ' ' GLU . 20.5 m-20 -133.42 77.83 1.75 Allowed 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.923 HD12 ' N ' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -44.63 -32.25 1.41 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.323 -0.861 . . . . 0.0 109.708 -179.365 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.923 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -71.11 -47.03 60.44 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.283 -0.885 . . . . 0.0 109.548 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.553 ' HG3' ' CB ' ' A' ' 20' ' ' ASP . 9.1 pt-20 -115.49 38.12 3.36 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.257 -0.902 . . . . 0.0 109.569 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 20' ' ' ASP . . . -106.9 -77.69 1.09 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.994 HG21 ' CE2' ' A' ' 10' ' ' PHE . 5.8 t -92.8 111.0 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.283 -1.128 . . . . 0.0 109.264 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -59.98 -39.86 87.15 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.299 -0.876 . . . . 0.0 109.867 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.461 ' HA3' ' HB2' ' A' ' 7' ' ' ASN . . . -67.56 -35.12 85.86 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.454 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' TRP . . . . . 0.535 ' CE3' ' HB1' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -129.64 126.26 37.98 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.153 -1.204 . . . . 0.0 109.67 -179.797 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.727 ' C ' HD23 ' A' ' 30' ' ' LEU . 6.3 m-20 -115.54 141.25 48.31 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.829 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.902 ' O ' HD13 ' A' ' 21' ' ' LEU . 0.9 OUTLIER -116.29 163.13 16.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.716 -1.24 . . . . 0.0 109.53 -179.548 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 71.8 m-80 -156.18 123.15 5.29 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.518 -0.738 . . . . 0.0 109.402 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.005 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -102.97 133.84 45.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.342 -0.849 . . . . 0.0 109.514 179.571 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.14 167.34 16.89 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -44.86 -26.16 0.38 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -1.142 . . . . 0.0 109.411 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.491 ' CB ' ' HB2' ' A' ' 67' ' ' ASN . 6.8 m -53.08 -53.12 55.0 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.19 -0.944 . . . . 0.0 109.455 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 1.005 HG21 HG12 ' A' ' 32' ' ' VAL . 42.2 t -46.18 94.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.2 -0.938 . . . . 0.0 110.196 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.484 ' N ' ' O ' ' A' ' 35' ' ' SER . 82.9 m -78.25 -27.53 47.6 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.336 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.512 ' O ' HG12 ' A' ' 36' ' ' VAL . 20.1 m-20 -114.9 147.36 38.1 Favored Pre-proline 0 C--N 1.297 -1.696 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.32 111.08 3.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.496 2.131 . . . . 0.0 110.768 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.538 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 36.0 Cg_endo -78.69 167.33 22.63 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.495 2.13 . . . . 0.0 109.684 179.551 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.524 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 51.1 t -110.38 121.89 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.953 -1.092 . . . . 0.0 110.47 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.634 ' CD2' HD23 ' A' ' 21' ' ' LEU . 28.2 m-85 -111.01 112.8 24.87 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 178.503 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.531 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 29.3 tt0 -151.08 160.8 43.68 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.109 -0.994 . . . . 0.0 109.702 -179.383 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.476 HG13 ' O ' ' A' ' 56' ' ' VAL . 49.2 t -102.26 133.48 45.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.434 -0.791 . . . . 0.0 109.133 179.555 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.508 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -111.28 118.7 36.62 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.349 -0.845 . . . . 0.0 109.415 -179.606 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.804 ' HG3' ' HB2' ' A' ' 15' ' ' ALA . 6.1 mt-10 -91.65 109.84 21.16 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 4.8 p -141.67 153.89 44.99 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.544 -0.723 . . . . 0.0 109.41 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 89.3 p -78.85 -10.15 59.7 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.228 -0.92 . . . . 0.0 109.484 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.401 ' O ' ' C ' ' A' ' 50' ' ' ALA . 5.4 m-20 -79.81 -18.17 51.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.191 -0.943 . . . . 0.0 109.536 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.405 ' HA ' ' HD3' ' A' ' 51' ' ' PRO . . . -45.02 147.65 1.13 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.895 . . . . 0.0 109.544 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.512 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.16 -40.59 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.629 2.219 . . . . 0.0 110.355 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.27 115.57 26.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.52 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.05 -124.54 23.35 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -152.74 22.85 0.59 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.164 -1.198 . . . . 0.0 109.499 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.521 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 8.6 mttt -129.37 143.61 50.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.436 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.627 HG12 ' CB ' ' A' ' 160' ' ' ASP . 11.9 m -150.24 175.59 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.347 -0.846 . . . . 0.0 109.004 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.685 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -108.43 99.64 9.01 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.057 -1.027 . . . . 0.0 109.033 179.508 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.614 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.23 119.2 23.32 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.818 ' O ' HG23 ' A' ' 156' ' ' THR . 43.7 t -115.68 144.85 22.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.134 -0.979 . . . . 0.0 109.212 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.524 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 9.3 m -108.96 91.69 3.74 Favored 'General case' 0 C--N 1.283 -2.313 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.546 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 48.2 t -89.58 117.41 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.395 -0.815 . . . . 0.0 109.091 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -154.4 58.55 0.7 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.305 -0.872 . . . . 0.0 109.935 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 157.02 84.2 0.05 OUTLIER Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.772 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.706 HG12 ' C ' ' A' ' 148' ' ' GLY . 1.8 m -80.07 -175.85 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.21 -1.171 . . . . 0.0 109.513 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -129.31 -148.52 6.59 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -94.74 -5.89 44.33 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.325 -1.103 . . . . 0.0 109.576 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.568 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 27.8 m-20 -112.74 146.75 35.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.077 -1.014 . . . . 0.0 109.45 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.414 ' O ' ' CE1' ' A' ' 149' ' ' TYR . 36.3 Cg_endo -78.7 12.99 2.02 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.602 2.202 . . . . 0.0 110.931 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.568 ' CZ2' ' OD1' ' A' ' 67' ' ' ASN . 4.2 p90 -133.5 51.86 2.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.035 -1.041 . . . . 0.0 109.659 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.484 ' O ' ' CG2' ' A' ' 36' ' ' VAL . 2.6 m-20 -74.24 -64.17 1.08 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.3 -0.875 . . . . 0.0 109.193 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.581 HG22 ' HB2' ' A' ' 147' ' ' PHE . 2.9 mp -100.22 118.3 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 109.043 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -121.4 127.49 51.23 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.138 -0.976 . . . . 0.0 110.15 -179.565 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.888 ' HB3' ' CE1' ' A' ' 147' ' ' PHE . . . -123.72 108.26 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.26 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.561 HG22 ' N ' ' A' ' 75' ' ' ALA . 86.0 m -104.95 165.76 10.85 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.418 -0.801 . . . . 0.0 109.95 -179.008 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.561 ' N ' HG22 ' A' ' 74' ' ' THR . . . -120.92 140.13 52.27 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.071 -1.018 . . . . 0.0 108.875 178.753 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.568 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.3 p90 179.53 162.86 0.79 Allowed Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.496 -0.752 . . . . 0.0 109.2 -179.551 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.568 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.8 Cg_endo -82.14 169.31 62.94 Favored 'Cis proline' 0 C--N 1.311 -1.416 0 C-N-CA 123.885 -1.298 . . . . 0.0 110.856 -0.534 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 85.1 t -127.65 156.22 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.388 -0.82 . . . . 0.0 108.891 179.292 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ASN . . . . . 0.541 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 16.5 m-80 -123.44 118.66 27.95 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.16 -0.962 . . . . 0.0 109.94 -179.567 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.556 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 3.0 m -124.63 -173.83 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.27 -0.894 . . . . 0.0 109.541 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.664 ' O ' HG21 ' A' ' 134' ' ' VAL . 15.3 mmt180 -136.63 144.93 49.14 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.332 -0.855 . . . . 0.0 109.269 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.19 120.57 5.4 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 122.545 2.163 . . . . 0.0 110.618 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 98.21 -27.76 17.81 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.417 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.06 149.7 4.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.21 -1.171 . . . . 0.0 109.501 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 28.5 m -95.86 133.03 40.49 Favored 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' TYR . . . . . 0.556 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 7.4 m-85 -111.68 166.76 10.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.896 . . . . 0.0 109.692 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.479 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 32.4 m -118.38 154.31 32.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.358 -0.839 . . . . 0.0 109.335 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.69 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 7.6 t80 -129.72 117.98 21.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.159 -0.963 . . . . 0.0 109.548 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.476 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.7 m -135.0 144.26 47.26 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.24 -0.912 . . . . 0.0 109.186 179.794 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.756 HD12 ' HB2' ' A' ' 162' ' ' LEU . 14.4 tt -150.49 163.78 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 120.817 -1.177 . . . . 0.0 109.562 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.512 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 19.8 m95 -132.73 125.99 31.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.062 -1.024 . . . . 0.0 109.303 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -117.08 151.81 36.01 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.359 -0.838 . . . . 0.0 109.487 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.56 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 8.5 ttp85 -164.14 118.49 1.47 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.188 -0.945 . . . . 0.0 109.188 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -105.37 160.93 14.74 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.301 -0.874 . . . . 0.0 109.951 -179.522 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -58.95 -48.56 81.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.417 -0.802 . . . . 0.0 109.289 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.517 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 2.0 mt-30 -113.91 142.16 46.47 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.273 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.582 ' N ' HG22 ' A' ' 123' ' ' THR . 28.4 p-10 -65.14 146.16 55.34 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.23 -0.919 . . . . 0.0 109.485 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 110.91 38.3 1.57 Allowed Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.494 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -120.45 140.66 51.07 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.257 -1.143 . . . . 0.0 109.082 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.422 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 55.5 t -116.14 145.27 22.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.224 -0.922 . . . . 0.0 110.766 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.7 HG13 ' CE2' ' A' ' 147' ' ' PHE . 39.0 t -143.05 165.86 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.569 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.536 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 4.1 m -123.25 126.22 46.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.069 -1.019 . . . . 0.0 109.9 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.537 ' CD1' HD13 ' A' ' 90' ' ' ILE . 66.8 m-85 -116.79 103.45 10.34 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.028 -1.045 . . . . 0.0 109.322 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.504 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 17.8 p -128.11 164.73 21.8 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.011 -1.055 . . . . 0.0 110.691 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.653 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -129.7 155.95 41.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-O 121.213 0.53 . . . . 0.0 109.964 -179.934 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.521 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -174.11 -173.81 40.47 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.2 p30 -131.24 -169.56 2.2 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.152 -1.205 . . . . 0.0 109.45 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' GLN . . . . . 0.52 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 3.5 mp0 -68.34 3.81 1.58 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.098 -1.002 . . . . 0.0 111.336 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.462 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 1.4 m -107.1 14.87 25.83 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 120.661 -1.274 . . . . 0.0 109.239 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.462 ' HB2' ' O ' ' A' ' 109' ' ' SER . 13.7 m-30 67.04 7.84 5.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.447 -0.783 . . . . 0.0 109.609 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.521 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 6.0 tt0 -80.07 158.32 26.47 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' GLU . . . . . 0.49 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 4.2 tt0 -136.15 136.5 40.09 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.028 -1.045 . . . . 0.0 110.012 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.573 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 7.3 m-85 -96.17 -70.74 0.7 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.412 -0.805 . . . . 0.0 108.875 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.58 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -81.92 156.48 36.3 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 179.5 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.7 ttt180 -153.36 106.94 3.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.057 -1.261 . . . . 0.0 110.258 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.716 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -146.12 70.0 1.22 Allowed 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.146 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 117' ' ' HIS . . . . . 0.536 ' CB ' ' HB3' ' A' ' 102' ' ' SER . 4.1 p80 -107.85 160.71 15.53 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.252 -0.905 . . . . 0.0 110.048 -179.449 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 16.5 tt0 77.28 58.56 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.361 -0.837 . . . . 0.0 109.469 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 4.0 mm-40 -130.14 136.98 49.88 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.315 -0.866 . . . . 0.0 109.501 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.447 ' O ' HD13 ' A' ' 121' ' ' ILE . 47.9 mt-30 -70.88 156.28 39.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.472 -0.768 . . . . 0.0 109.065 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 99' ' ' ALA . 6.0 mm -133.49 135.67 55.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.148 -0.97 . . . . 0.0 109.873 -179.455 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -82.74 -179.34 7.4 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.672 0.749 . . . . 0.0 110.001 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.582 HG22 ' N ' ' A' ' 97' ' ' ASP . 63.7 p -78.45 -1.59 34.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.511 -0.743 . . . . 0.0 109.307 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.411 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 2.5 mt-10 -108.42 -168.87 1.41 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.184 -0.947 . . . . 0.0 109.397 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' TRP . . . . . 0.56 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 95.5 m95 -95.26 121.15 36.61 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.206 -0.934 . . . . 0.0 109.688 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -106.84 121.02 46.3 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.261 -0.899 . . . . 0.0 108.935 179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.407 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.8 Cg_endo -80.25 107.39 2.03 Favored 'Trans proline' 0 C--N 1.311 -1.416 0 C-N-CA 122.456 2.104 . . . . 0.0 111.064 -179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -111.0 135.5 51.41 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 178.731 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.8 t -151.13 175.74 11.85 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 120.701 -1.25 . . . . 0.0 111.078 -179.187 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.716 ' CE2' HD21 ' A' ' 116' ' ' LEU . 33.8 p90 -171.89 -177.64 1.99 Allowed 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.192 179.285 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -127.92 151.11 49.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.191 -0.943 . . . . 0.0 109.757 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.573 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.07 168.15 17.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.44 -0.788 . . . . 0.0 109.255 179.841 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -138.69 147.74 43.13 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.5 -179.663 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.664 HG21 ' O ' ' A' ' 81' ' ' ARG . 6.0 t -40.43 110.33 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.607 -0.683 . . . . 0.0 109.367 179.663 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 27.8 m -59.95 -51.58 69.05 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.283 -0.885 . . . . 0.0 109.255 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -106.74 -90.87 0.42 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.384 -0.823 . . . . 0.0 109.213 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -163.98 53.97 0.15 Allowed 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.478 -0.764 . . . . 0.0 109.058 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.55 ' O ' HG23 ' A' ' 80' ' ' VAL . 31.6 mm-40 -91.67 113.22 25.43 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.188 -0.945 . . . . 0.0 109.791 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.5 p -79.44 -14.07 59.17 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.275 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.3 t -134.01 132.07 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.128 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.509 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -141.59 171.92 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.164 -0.96 . . . . 0.0 110.051 -179.608 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 142' ' ' ARG . . . . . 0.519 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 2.9 ptm180 -143.76 133.12 23.28 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.624 -0.673 . . . . 0.0 109.263 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ALA . . . . . 0.759 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -94.44 108.62 37.82 Favored Pre-proline 0 N--CA 1.487 1.384 0 O-C-N 121.302 -0.874 . . . . 0.0 109.897 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.658 ' C ' HD13 ' A' ' 145' ' ' ILE . 35.4 Cg_endo -76.74 113.49 3.66 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.16 1.907 . . . . 0.0 110.847 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.723 ' N ' HD13 ' A' ' 145' ' ' ILE . 1.7 mm -97.26 141.66 15.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 178.802 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 147' ' ' PHE . 6.2 m80 -105.28 158.32 16.69 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.55 -1.344 . . . . 0.0 111.691 -177.634 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.888 ' CE1' ' HB3' ' A' ' 73' ' ' ALA . 20.9 m-85 -160.81 158.2 28.05 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.132 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.706 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 108.13 43.8 1.25 Allowed Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.686 ' C ' HG11 ' A' ' 64' ' ' VAL . 61.5 m-85 -117.06 161.42 19.44 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.421 -1.047 . . . . 0.0 109.111 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.52 -29.4 69.48 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.472 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -76.61 -10.52 59.45 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 109.179 179.269 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.624 ' ND2' HD13 ' A' ' 157' ' ' ILE . 1.5 t30 -109.74 12.3 24.15 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.365 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -89.15 164.22 2.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 O-C-N 121.551 -0.718 . . . . 0.0 109.784 -179.173 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' GLY . . . . . 0.492 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.39 32.61 37.98 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.7 m-20 -160.49 136.82 8.65 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.139 -1.212 . . . . 0.0 110.111 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 156' ' ' THR . . . . . 0.818 HG23 ' O ' ' A' ' 59' ' ' VAL . 55.3 m -87.59 120.94 29.41 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.624 HD13 ' ND2' ' A' ' 152' ' ' ASN . 0.8 OUTLIER -99.63 117.58 44.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 120.75 -1.219 . . . . 0.0 110.327 -178.781 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.614 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 12.2 m-85 -98.01 135.78 39.21 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 178.447 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.644 ' CD1' ' CE2' ' A' ' 147' ' ' PHE . 1.3 mt -128.16 141.15 47.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 120.768 -1.207 . . . . 0.0 110.44 -178.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 160' ' ' ASP . . . . . 0.627 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.7 OUTLIER -173.8 136.34 0.55 Allowed 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.348 -0.845 . . . . 0.0 108.837 179.633 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 161' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 125.19 -8.23 8.0 Favored Glycine 0 N--CA 1.487 2.066 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.366 179.577 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.759 HD21 ' HB3' ' A' ' 143' ' ' ALA . 4.4 tp -60.2 100.64 0.1 Allowed 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.742 -1.446 . . . . 0.0 108.944 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 163' ' ' ALA . . . . . 0.543 ' C ' HD12 ' A' ' 164' ' ' ILE . . . -133.24 145.75 50.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.455 -0.778 . . . . 0.0 109.778 -179.145 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.702 HD12 ' N ' ' A' ' 164' ' ' ILE . 4.4 mp -126.8 109.07 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.288 -0.882 . . . . 0.0 109.425 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.874 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.171 -0.956 . . . . 0.0 109.637 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.846 HG23 ' HB2' ' A' ' 165' ' ' ALA . 4.2 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.922 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -71.64 -59.41 2.77 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.187 -0.945 . . . . 0.0 109.453 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 162' ' ' LEU . 47.4 t-20 -71.26 128.93 37.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.481 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.464 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 2.2 mp -107.7 138.53 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.273 -0.892 . . . . 0.0 109.518 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.523 ' OD1' ' CB ' ' A' ' 12' ' ' SER . 1.0 OUTLIER 66.97 17.31 10.5 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.242 -0.911 . . . . 0.0 109.638 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.5 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -61.52 -35.56 91.28 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.524 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -103.59 28.01 17.33 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.681 ' CD2' HG11 ' A' ' 25' ' ' VAL . 6.5 m-85 50.65 48.03 23.35 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.365 -1.079 . . . . 0.0 109.412 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.438 ' OE1' ' O ' ' A' ' 52' ' ' GLU . 5.6 mm-40 -83.68 -35.81 24.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.236 -0.915 . . . . 0.0 109.67 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.523 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.6 OUTLIER -84.8 -24.81 28.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.234 -0.916 . . . . 0.0 109.663 -179.759 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.9 ' OG1' HG13 ' A' ' 25' ' ' VAL . 0.7 OUTLIER -78.48 121.57 83.87 Favored Pre-proline 0 N--CA 1.486 1.352 0 O-C-N 121.185 -0.947 . . . . 0.0 109.292 -179.896 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 15' ' ' ALA . 36.1 Cg_endo -77.61 138.95 17.64 Favored 'Trans proline' 0 C--N 1.312 -1.36 0 C-N-CA 122.469 2.112 . . . . 0.0 110.754 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.522 ' HA ' ' CG1' ' A' ' 44' ' ' VAL . . . -41.59 163.53 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.71 137.38 4.45 Favored Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.529 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.23 141.52 12.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.325 -1.103 . . . . 0.0 109.079 -179.688 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.479 HG23 ' HA ' ' A' ' 43' ' ' GLU . 46.1 t -85.69 145.65 7.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 CA-C-O 121.695 0.759 . . . . 0.0 109.921 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 4.1 p -106.36 -22.3 12.85 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.411 ' HB3' ' HG3' ' A' ' 23' ' ' GLU . 0.4 OUTLIER -143.94 92.63 2.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.439 -0.788 . . . . 0.0 109.085 179.692 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.969 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -49.41 -33.19 13.26 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.293 -0.88 . . . . 0.0 109.899 -179.339 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.919 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.66 -43.6 93.89 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.165 -0.959 . . . . 0.0 109.514 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.411 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 3.3 pt-20 -118.12 35.74 4.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.252 -0.905 . . . . 0.0 109.336 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.18 -71.8 1.29 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.9 HG13 ' OG1' ' A' ' 13' ' ' THR . 2.0 t -95.96 123.63 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -1.173 . . . . 0.0 109.209 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -56.38 -32.28 64.63 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.421 -0.8 . . . . 0.0 109.854 -179.623 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.492 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -102.33 -3.45 50.7 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.94 -1.124 . . . . 0.0 110.305 -179.35 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' TRP . . . . . 0.585 ' CE3' ' HB1' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -139.77 121.65 15.53 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.932 -1.334 . . . . 0.0 109.877 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.717 ' C ' HD23 ' A' ' 30' ' ' LEU . 1.2 m-20 -121.38 143.12 49.39 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.813 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.969 ' O ' HD13 ' A' ' 21' ' ' LEU . 0.9 OUTLIER -113.25 162.46 15.99 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.781 -1.199 . . . . 0.0 109.439 -179.601 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -152.84 121.17 6.28 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.424 -0.797 . . . . 0.0 109.522 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.868 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.05 135.2 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.4 -0.812 . . . . 0.0 109.675 179.638 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.49 -170.99 25.75 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.04 -4.58 25.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.249 -1.148 . . . . 0.0 109.505 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.484 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 16.0 m -74.11 -31.87 62.96 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.942 . . . . 0.0 109.625 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.868 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -67.68 89.46 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 O-C-N 121.132 -0.98 . . . . 0.0 109.364 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 30.4 m -59.74 -28.69 67.58 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.199 -0.938 . . . . 0.0 108.713 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.687 ' O ' HG13 ' A' ' 36' ' ' VAL . 6.5 m-20 -130.88 130.4 22.83 Favored Pre-proline 0 C--N 1.296 -1.753 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.21 123.11 6.46 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.189 1.926 . . . . 0.0 110.55 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.586 ' HG2' ' CZ ' ' A' ' 42' ' ' PHE . 35.4 Cg_endo -77.46 -165.74 0.35 Allowed 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.366 2.044 . . . . 0.0 110.013 179.695 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.55 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 53.7 t -116.73 121.43 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.116 -0.99 . . . . 0.0 110.458 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.631 ' CE2' HD23 ' A' ' 21' ' ' LEU . 28.0 m-85 -105.11 112.38 25.49 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.529 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 29.2 tt0 -154.56 159.32 40.83 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.194 -0.941 . . . . 0.0 109.857 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.522 ' CG1' ' HA ' ' A' ' 15' ' ' ALA . 89.1 t -95.2 140.59 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.476 -0.765 . . . . 0.0 109.017 179.277 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.435 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.4 OUTLIER -119.38 120.51 37.12 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.327 -0.858 . . . . 0.0 109.793 -179.32 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -77.35 109.83 11.58 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 121.54 0.686 . . . . 0.0 109.152 179.737 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.7 p -128.64 129.89 46.49 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.606 -0.684 . . . . 0.0 109.527 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.2 m -72.41 -12.56 61.16 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.239 -0.913 . . . . 0.0 109.397 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.41 ' O ' ' C ' ' A' ' 50' ' ' ALA . 49.7 m-20 -98.4 2.08 47.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.214 -0.929 . . . . 0.0 109.612 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.529 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -44.31 155.18 0.37 Allowed Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.103 -0.998 . . . . 0.0 109.443 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.533 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.9 Cg_endo -77.91 -35.97 1.25 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.599 2.199 . . . . 0.0 110.335 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.438 ' O ' ' OE1' ' A' ' 11' ' ' GLU . 4.9 tt0 -121.28 97.01 5.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.268 -0.895 . . . . 0.0 109.35 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.8 -115.16 4.07 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.529 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 2.6 m120 -156.63 35.64 0.31 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.226 -1.161 . . . . 0.0 109.405 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.487 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 33.0 mttm -145.5 131.1 18.85 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -0.899 . . . . 0.0 109.505 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.662 HG12 ' OD2' ' A' ' 160' ' ' ASP . 3.9 m -139.72 175.36 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.381 -0.825 . . . . 0.0 109.326 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.723 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -101.79 100.46 10.81 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.063 -1.023 . . . . 0.0 108.776 179.306 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.584 ' HB1' ' CE2' ' A' ' 158' ' ' TYR . . . -81.33 118.21 22.46 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.068 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.837 ' O ' HG23 ' A' ' 156' ' ' THR . 49.3 t -114.9 144.61 22.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.113 -0.992 . . . . 0.0 109.17 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.519 HG22 ' OD1' ' A' ' 62' ' ' ASN . 31.9 m -107.12 93.64 4.66 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.706 HG21 ' CD1' ' A' ' 157' ' ' ILE . 59.9 t -87.93 123.47 40.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.253 -0.905 . . . . 0.0 109.334 -179.69 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.519 ' OD1' HG22 ' A' ' 60' ' ' THR . 0.8 OUTLIER -160.11 60.34 0.35 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.379 -0.825 . . . . 0.0 109.77 -179.89 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 156.38 89.24 0.07 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.798 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.4 m -81.06 -177.14 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.218 -1.166 . . . . 0.0 109.674 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.484 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -130.99 -161.61 10.34 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -95.99 12.54 30.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -1.119 . . . . 0.0 109.545 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.514 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 8.1 m120 -128.33 148.35 67.52 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.194 -0.941 . . . . 0.0 109.508 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.495 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.2 Cg_endo -78.25 11.88 2.24 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.63 2.22 . . . . 0.0 110.963 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.514 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -136.36 58.33 1.74 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.113 -0.992 . . . . 0.0 109.623 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.484 ' CB ' HG23 ' A' ' 36' ' ' VAL . 0.7 OUTLIER -83.11 -69.18 0.65 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.204 -0.935 . . . . 0.0 109.248 179.825 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.541 HG13 ' CG2' ' A' ' 36' ' ' VAL . 4.1 mt -105.94 121.76 58.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.277 -0.89 . . . . 0.0 108.979 179.795 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -130.17 132.89 46.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.098 -1.001 . . . . 0.0 110.224 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.592 ' CB ' HD22 ' A' ' 30' ' ' LEU . . . -121.82 108.47 13.51 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.559 HG22 ' N ' ' A' ' 75' ' ' ALA . 98.3 m -100.2 165.0 11.71 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.386 -0.821 . . . . 0.0 110.006 -179.029 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.559 ' N ' HG22 ' A' ' 74' ' ' THR . . . -118.92 136.42 54.08 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.022 -1.049 . . . . 0.0 108.768 178.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.556 ' CE2' ' OD1' ' A' ' 29' ' ' ASP . 10.1 p90 179.44 160.44 0.76 Allowed Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.585 -0.697 . . . . 0.0 109.276 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.532 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.9 Cg_endo -81.67 164.96 74.89 Favored 'Cis proline' 0 C--N 1.31 -1.465 0 C-N-CA 123.782 -1.341 . . . . 0.0 110.801 -0.495 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 89.1 t -126.81 156.14 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.344 -0.848 . . . . 0.0 109.107 179.269 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ASN . . . . . 0.922 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 4.3 m-80 -112.43 145.79 39.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.075 -1.016 . . . . 0.0 109.666 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.581 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 1.1 m -153.32 -173.85 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.174 -0.954 . . . . 0.0 109.467 179.749 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.763 ' O ' HG21 ' A' ' 134' ' ' VAL . 20.5 mtt180 -136.21 146.01 54.5 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.288 -0.883 . . . . 0.0 109.352 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.492 ' HB3' ' HB3' ' A' ' 137' ' ' GLN . 35.6 Cg_endo -77.82 112.09 3.23 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.511 2.141 . . . . 0.0 110.463 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 100.44 -22.97 37.59 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.601 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -84.12 149.65 4.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.191 -1.182 . . . . 0.0 109.482 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.3 m -92.42 140.48 29.53 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' TYR . . . . . 0.601 ' CE1' HG12 ' A' ' 84' ' ' VAL . 18.3 m-85 -123.05 164.88 17.75 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.25 -0.906 . . . . 0.0 109.578 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.47 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 6.1 m -118.35 154.31 32.57 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.398 -0.814 . . . . 0.0 109.51 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.692 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.7 t80 -126.87 120.1 28.4 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.145 -0.972 . . . . 0.0 109.38 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.487 ' O ' ' O ' ' A' ' 161' ' ' GLY . 32.3 m -134.53 142.79 47.11 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.244 -0.91 . . . . 0.0 109.11 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.796 HD13 ' CD2' ' A' ' 103' ' ' PHE . 19.8 tt -150.9 163.45 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.603 -1.311 . . . . 0.0 109.628 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.533 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 20.3 m95 -132.14 128.62 38.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.976 -1.078 . . . . 0.0 109.385 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -119.53 148.13 43.65 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.222 -0.924 . . . . 0.0 109.582 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.586 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 8.3 ttp180 -161.02 120.22 2.58 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.162 -0.961 . . . . 0.0 109.15 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.481 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -107.07 161.7 14.52 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 110.02 -179.591 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -61.06 -51.18 70.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.377 -0.827 . . . . 0.0 109.319 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.485 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -108.45 137.74 45.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.339 -0.85 . . . . 0.0 109.355 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.582 ' N ' ' CG2' ' A' ' 123' ' ' THR . 5.1 p30 -63.08 146.85 52.36 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.273 -0.892 . . . . 0.0 109.559 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 109.06 38.66 1.8 Allowed Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -119.15 141.36 48.9 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.234 -1.157 . . . . 0.0 109.063 179.601 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.427 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 54.9 t -116.78 149.88 18.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.277 -0.889 . . . . 0.0 110.636 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.722 HG13 ' CE2' ' A' ' 147' ' ' PHE . 51.9 t -151.14 164.71 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.538 -0.726 . . . . 0.0 109.051 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.526 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 3.8 t -127.92 138.05 52.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.989 -1.07 . . . . 0.0 109.687 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.796 ' CD2' HD13 ' A' ' 90' ' ' ILE . 1.0 OUTLIER -130.6 103.86 6.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.086 -1.009 . . . . 0.0 109.807 -179.969 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.509 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 11.6 p -119.43 164.86 15.11 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.091 -1.005 . . . . 0.0 110.064 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.623 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -125.67 152.55 32.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.69 -0.631 . . . . 0.0 109.998 -179.734 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.469 ' O ' ' HG2' ' A' ' 142' ' ' ARG . . . 176.46 147.71 6.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.214 -1.555 . . . . 0.0 109.214 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.3 p30 -90.3 -169.59 2.46 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.018 -1.283 . . . . 0.0 109.51 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' GLN . . . . . 0.518 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 4.1 mp0 -71.1 8.0 1.08 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.184 -0.947 . . . . 0.0 111.245 -179.123 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.455 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 3.7 t -110.52 10.27 23.14 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.712 -1.243 . . . . 0.0 109.215 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.538 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 3.2 m-30 71.87 6.08 5.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.412 -0.805 . . . . 0.0 109.689 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -78.89 95.12 5.34 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 108.672 179.399 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' GLU . . . . . 0.524 ' CG ' ' O ' ' A' ' 105' ' ' VAL . 1.3 tt0 -83.47 139.69 32.78 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.278 -0.889 . . . . 0.0 110.259 -179.099 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.523 ' CE2' HG21 ' A' ' 141' ' ' ILE . 3.9 m-85 -102.78 -69.88 0.78 Allowed 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.601 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -85.77 166.17 39.11 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.021 -1.632 . . . . 0.0 109.021 179.401 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.473 ' C ' HD23 ' A' ' 116' ' ' LEU . 1.2 tpp180 -164.42 109.65 0.99 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.948 -1.325 . . . . 0.0 110.326 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.771 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -142.53 69.88 1.32 Allowed 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.061 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 117' ' ' HIS . . . . . 0.542 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 0.0 OUTLIER -99.11 152.56 19.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.335 -0.853 . . . . 0.0 110.149 -179.31 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.542 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.3 tt0 79.33 68.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -0.787 . . . . 0.0 109.706 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' GLN . . . . . 0.431 ' HG2' ' C ' ' A' ' 118' ' ' GLU . 1.1 mm-40 -133.42 130.96 39.4 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.293 -0.879 . . . . 0.0 109.475 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.724 ' O ' HD13 ' A' ' 121' ' ' ILE . 4.8 mt-30 -67.66 153.81 42.88 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.327 -0.858 . . . . 0.0 109.006 179.702 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.724 HD13 ' O ' ' A' ' 120' ' ' GLN . 8.1 mm -134.8 135.73 52.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.094 -1.003 . . . . 0.0 110.089 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.32 -179.16 6.91 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.637 0.732 . . . . 0.0 110.067 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.582 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 47.2 p -76.37 -2.48 32.01 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.416 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.412 ' C ' ' HG3' ' A' ' 93' ' ' ARG . 3.9 mm-40 -107.67 -169.0 1.45 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.361 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' TRP . . . . . 0.586 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 97.1 m95 -95.83 122.6 38.79 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.201 -0.937 . . . . 0.0 109.604 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -106.93 121.39 45.03 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.272 -0.892 . . . . 0.0 108.941 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -80.1 109.48 2.37 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.451 2.1 . . . . 0.0 110.895 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -114.34 136.64 52.76 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.7 t -151.27 175.85 11.8 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 120.685 -1.259 . . . . 0.0 111.152 -179.252 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.771 ' CE2' HD21 ' A' ' 116' ' ' LEU . 37.7 p90 -173.41 -172.61 0.81 Allowed 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.819 -1.082 . . . . 0.0 109.221 179.22 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -127.95 156.96 41.83 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.075 -1.016 . . . . 0.0 110.009 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.596 ' CZ ' ' HB2' ' A' ' 86' ' ' TYR . 11.1 p90 -161.23 168.06 24.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.391 -0.818 . . . . 0.0 109.191 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.92 146.2 38.91 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.145 -0.972 . . . . 0.0 109.224 -179.761 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.763 HG21 ' O ' ' A' ' 81' ' ' ARG . 2.2 t -62.38 112.95 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.257 -0.902 . . . . 0.0 109.392 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 5.8 t -86.51 -40.48 15.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.401 -0.812 . . . . 0.0 109.85 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.56 ' O ' ' CB ' ' A' ' 137' ' ' GLN . 17.5 t70 -87.63 -16.22 35.06 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.445 -0.784 . . . . 0.0 109.432 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' GLN . . . . . 0.674 ' H ' HG12 ' A' ' 134' ' ' VAL . 2.3 mt-30 86.97 27.28 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -178.621 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.513 ' HG3' ' ND2' ' A' ' 107' ' ' ASN . 12.5 mm-40 -68.94 122.44 18.65 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.609 -0.682 . . . . 0.0 109.732 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 5.8 p -79.12 -6.97 57.74 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.174 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 42.4 t -138.14 138.38 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.364 -0.835 . . . . 0.0 108.824 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.564 HD11 HD13 ' A' ' 164' ' ' ILE . 0.6 OUTLIER -143.27 172.23 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.121 -0.987 . . . . 0.0 109.904 -179.705 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 142' ' ' ARG . . . . . 0.49 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.2 ptm180 -146.76 132.52 18.95 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.463 -0.773 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ALA . . . . . 0.748 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -99.66 106.95 43.29 Favored Pre-proline 0 C--N 1.303 -1.421 0 O-C-N 121.21 -0.931 . . . . 0.0 109.879 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.54 ' C ' HD13 ' A' ' 145' ' ' ILE . 34.9 Cg_endo -76.79 110.74 3.1 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.113 1.875 . . . . 0.0 110.688 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.72 ' N ' HD13 ' A' ' 145' ' ' ILE . 2.0 mm -91.25 140.15 16.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 178.77 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' HIS . . . . . 0.648 ' N ' ' CD2' ' A' ' 146' ' ' HIS . 9.0 m-70 -107.7 157.86 17.76 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.542 -1.349 . . . . 0.0 111.897 -177.46 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.722 ' CE2' HG13 ' A' ' 101' ' ' VAL . 30.6 m-85 -158.12 160.98 37.88 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 179.013 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.496 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 116.77 40.79 0.75 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.798 ' C ' HG11 ' A' ' 64' ' ' VAL . 15.1 m-85 -122.08 159.37 27.23 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.381 -1.07 . . . . 0.0 109.311 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.527 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.21 -26.71 67.51 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -69.91 -15.28 63.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.436 -0.79 . . . . 0.0 109.269 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.52 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.3 OUTLIER -110.85 8.31 22.22 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 179.366 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.626 HG23 HG13 ' A' ' 64' ' ' VAL . 2.3 t -83.33 162.57 3.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 121.424 -0.797 . . . . 0.0 109.7 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' GLY . . . . . 0.455 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 50.63 33.47 26.37 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 1.8 m-20 -160.18 139.44 10.88 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.258 -1.143 . . . . 0.0 109.976 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 156' ' ' THR . . . . . 0.837 HG23 ' O ' ' A' ' 59' ' ' VAL . 97.7 m -89.32 128.04 35.85 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.205 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.706 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.4 mt -108.96 118.83 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.873 -1.142 . . . . 0.0 109.969 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.584 ' CE2' ' HB1' ' A' ' 58' ' ' ALA . 8.7 m-85 -100.55 137.77 38.51 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 178.561 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.669 HD11 ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -129.34 141.64 46.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 120.777 -1.202 . . . . 0.0 110.381 -178.656 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 160' ' ' ASP . . . . . 0.662 ' OD2' HG12 ' A' ' 56' ' ' VAL . 49.7 t0 -173.82 136.01 0.53 Allowed 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.5 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' GLY . . . . . 0.533 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 127.13 -9.02 7.08 Favored Glycine 0 N--CA 1.485 1.915 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.258 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.748 HD21 ' HB3' ' A' ' 143' ' ' ALA . 1.2 tp -59.43 91.29 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.811 -1.405 . . . . 0.0 108.583 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 163' ' ' ALA . . . . . 0.459 ' N ' ' O ' ' A' ' 161' ' ' GLY . . . -131.06 146.03 52.23 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.605 -0.685 . . . . 0.0 109.86 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.716 ' O ' HG22 ' A' ' 3' ' ' VAL . 23.4 mt -126.16 131.47 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.325 -0.86 . . . . 0.0 109.217 179.471 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.846 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.202 -0.936 . . . . 0.0 109.677 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.652 HG22 ' O ' ' A' ' 164' ' ' ILE . 4.6 p . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.597 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -63.09 -53.78 48.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.107 -0.996 . . . . 0.0 109.732 -179.633 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.532 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 3.9 t-20 -84.09 149.86 25.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.293 -0.879 . . . . 0.0 109.7 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.476 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 3.7 mt -128.13 129.79 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.358 -0.839 . . . . 0.0 109.157 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.565 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 1.5 m120 65.84 35.1 6.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.203 -0.936 . . . . 0.0 109.59 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -44.99 -25.73 1.04 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.454 ' HA3' ' OD2' ' A' ' 160' ' ' ASP . . . -145.82 44.93 0.83 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.902 ' CD2' HG11 ' A' ' 25' ' ' VAL . 4.2 m-85 61.32 51.65 4.16 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.167 -1.196 . . . . 0.0 109.443 179.581 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.445 ' OE2' ' OD2' ' A' ' 160' ' ' ASP . 62.0 mm-40 -84.34 -27.61 27.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.136 -0.977 . . . . 0.0 109.79 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.504 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 7.9 t -99.75 -13.65 19.19 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.178 -0.951 . . . . 0.0 110.149 -179.361 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . 1.048 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.2 m -100.25 133.39 21.49 Favored Pre-proline 0 N--CA 1.489 1.475 0 O-C-N 121.052 -1.03 . . . . 0.0 109.423 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.476 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.5 Cg_endo -77.3 148.37 26.82 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 122.522 2.148 . . . . 0.0 110.84 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.476 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -42.11 166.0 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 121.317 0.579 . . . . 0.0 109.773 179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.09 132.54 3.01 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.526 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -56.55 144.63 8.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.268 -1.136 . . . . 0.0 109.218 -179.367 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.515 HG13 ' HA3' ' A' ' 24' ' ' GLY . 47.7 t -85.12 144.51 9.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.687 0.756 . . . . 0.0 110.043 -179.773 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.9 p -106.59 -23.77 12.36 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.458 ' O ' ' N ' ' A' ' 24' ' ' GLY . 0.4 OUTLIER -145.99 88.21 1.8 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.478 -0.764 . . . . 0.0 108.966 179.759 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.911 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -43.46 -32.08 0.82 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 109.624 -179.464 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.906 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -65.42 -49.09 70.49 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.351 -0.843 . . . . 0.0 109.456 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -125.51 43.78 2.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.434 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.515 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -91.86 -66.7 1.13 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 1.048 HG13 ' OG1' ' A' ' 13' ' ' THR . 41.3 t -120.63 128.66 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.207 -1.172 . . . . 0.0 109.618 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.451 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 13.7 tt0 -67.25 139.38 57.33 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.879 . . . . 0.0 109.606 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.565 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 109.29 -33.78 5.91 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' TRP . . . . . 0.67 ' CZ3' HD12 ' A' ' 159' ' ' ILE . 1.2 m95 -140.5 119.98 13.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.191 -1.182 . . . . 0.0 109.454 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.522 ' C ' HD23 ' A' ' 30' ' ' LEU . 11.0 m-20 -115.98 144.17 44.45 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.133 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.911 ' O ' HD13 ' A' ' 21' ' ' LEU . 2.1 mt -118.95 168.03 11.18 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.723 -1.235 . . . . 0.0 109.603 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 70.5 m-20 -160.09 123.75 3.61 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.382 -0.824 . . . . 0.0 109.575 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.801 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -106.47 136.56 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.337 -0.852 . . . . 0.0 109.743 179.678 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.69 176.16 24.86 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.4 t -58.98 -15.65 14.14 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.18 -1.188 . . . . 0.0 109.418 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.466 ' HB2' ' OD1' ' A' ' 70' ' ' ASP . 7.9 p -63.81 -37.17 86.39 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.243 -0.91 . . . . 0.0 109.636 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.823 HG23 ' HB3' ' A' ' 70' ' ' ASP . 2.1 t -67.35 88.55 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 O-C-N 121.144 -0.973 . . . . 0.0 109.194 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 50.1 m -63.41 -28.64 70.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.326 -0.859 . . . . 0.0 108.997 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.673 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.3 m-80 -120.92 130.1 25.0 Favored Pre-proline 0 C--N 1.296 -1.721 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -76.51 121.83 6.19 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.188 1.926 . . . . 0.0 110.524 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.593 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.4 Cg_endo -77.44 -169.93 0.84 Allowed 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.443 2.096 . . . . 0.0 109.865 179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.521 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 53.2 t -114.53 119.4 61.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.092 -1.005 . . . . 0.0 110.586 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.593 ' CE1' ' HG2' ' A' ' 40' ' ' PRO . 2.9 m-85 -104.35 112.34 25.34 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 178.251 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.526 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 0.0 OUTLIER -157.9 148.58 20.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.052 -1.03 . . . . 0.0 109.962 -179.354 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.584 HG22 ' CE2' ' A' ' 10' ' ' PHE . 2.0 t -92.55 148.68 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.379 -0.825 . . . . 0.0 109.398 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.555 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -133.43 147.45 51.72 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.284 -0.885 . . . . 0.0 108.713 179.931 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.555 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 15.3 pt-20 -121.17 120.41 35.16 Favored 'General case' 0 C--N 1.296 -1.758 0 O-C-N 121.526 -0.734 . . . . 0.0 109.296 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.487 ' CG2' HD21 ' A' ' 45' ' ' LEU . 1.5 p -144.0 -175.97 4.81 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.44 -0.787 . . . . 0.0 109.483 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -101.02 22.4 12.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.908 . . . . 0.0 109.433 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.7 -14.33 12.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.913 . . . . 0.0 109.481 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.721 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -56.45 144.53 62.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.18 -0.95 . . . . 0.0 109.327 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.555 ' HG3' ' CB ' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -78.44 -42.1 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.617 2.211 . . . . 0.0 110.388 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.406 ' O ' ' OE1' ' A' ' 11' ' ' GLU . 40.6 mm-40 -105.43 97.22 7.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.246 -0.909 . . . . 0.0 109.382 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.48 -117.75 4.71 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.721 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 13.5 p30 -160.09 38.62 0.18 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.226 -1.161 . . . . 0.0 109.542 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.482 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 92.0 mttt -144.84 139.04 27.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.143 -0.973 . . . . 0.0 109.655 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.636 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.3 m -150.13 174.54 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.3 -0.875 . . . . 0.0 109.372 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.616 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -99.92 102.22 13.55 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.161 -0.962 . . . . 0.0 108.943 179.61 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.649 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -82.04 122.85 28.34 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 178.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.833 ' O ' HG23 ' A' ' 156' ' ' THR . 47.0 t -117.4 144.18 25.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.135 -0.978 . . . . 0.0 109.304 -179.101 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.672 HG22 ' OD1' ' A' ' 62' ' ' ASN . 55.3 m -108.6 87.87 2.59 Favored 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.304 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.657 HG21 ' CD1' ' A' ' 157' ' ' ILE . 72.6 t -85.85 125.43 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.23 -0.919 . . . . 0.0 109.308 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.672 ' OD1' HG22 ' A' ' 60' ' ' THR . 0.6 OUTLIER -160.08 55.42 0.35 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.383 -0.823 . . . . 0.0 109.733 -179.694 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 162.7 89.91 0.07 OUTLIER Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.892 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.8 m -81.84 -171.32 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -1.14 . . . . 0.0 109.642 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -138.81 -163.27 9.46 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -78.29 -10.65 59.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -1.135 . . . . 0.0 109.499 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.553 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 1.3 m120 -111.08 145.33 32.23 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.171 -0.956 . . . . 0.0 109.426 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.505 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.5 Cg_endo -78.99 13.6 1.93 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.599 2.199 . . . . 0.0 110.997 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.553 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 3.5 p90 -136.33 51.76 2.0 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.031 -1.043 . . . . 0.0 109.759 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.823 ' HB3' HG23 ' A' ' 36' ' ' VAL . 0.6 OUTLIER -75.89 -50.24 15.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 109.215 179.685 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.686 HD12 ' HB2' ' A' ' 70' ' ' ASP . 4.6 mp -102.2 119.95 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.399 -0.813 . . . . 0.0 109.174 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.45 128.96 50.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.06 -1.025 . . . . 0.0 109.882 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.61 ' HB3' ' CE1' ' A' ' 147' ' ' PHE . . . -130.11 108.3 9.96 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.338 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.566 HG22 ' N ' ' A' ' 75' ' ' ALA . 75.5 m -103.93 165.26 11.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.545 -0.722 . . . . 0.0 110.018 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.566 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.01 137.14 53.73 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.055 -1.028 . . . . 0.0 108.882 178.767 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.561 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.7 p90 -174.46 163.57 2.65 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.497 -0.752 . . . . 0.0 109.256 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.561 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.4 Cg_endo -83.97 170.6 50.85 Favored 'Cis proline' 0 C--N 1.312 -1.372 0 C-N-CA 124.002 -1.249 . . . . 0.0 110.907 -0.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.953 HG11 HD13 ' A' ' 164' ' ' ILE . 85.2 t -130.25 156.27 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ASN . . . . . 0.526 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 1.9 m120 -121.21 132.02 54.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.09 -1.006 . . . . 0.0 109.929 -179.636 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.555 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.9 m -140.71 -174.07 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.169 -0.957 . . . . 0.0 109.644 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.745 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.3 OUTLIER -136.85 144.74 47.93 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 109.266 179.872 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.472 ' HD2' ' HG2' ' A' ' 81' ' ' ARG . 35.6 Cg_endo -77.12 110.48 3.03 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.426 2.084 . . . . 0.0 110.581 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 111.2 -34.98 5.01 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.551 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -84.75 149.78 4.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.146 -1.208 . . . . 0.0 109.433 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 17.8 m -94.58 141.65 28.36 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' TYR . . . . . 0.555 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 8.5 m-85 -119.89 170.91 8.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 4.1 m -118.07 153.9 32.96 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.274 -0.891 . . . . 0.0 109.29 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.763 ' CE1' HD11 ' A' ' 116' ' ' LEU . 5.3 t80 -134.13 120.3 19.95 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.222 -0.924 . . . . 0.0 109.532 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.487 ' O ' ' O ' ' A' ' 161' ' ' GLY . 15.7 m -135.66 147.37 48.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.233 -0.917 . . . . 0.0 109.03 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.662 HD12 ' CA ' ' A' ' 162' ' ' LEU . 2.2 tt -151.21 163.61 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.966 -1.084 . . . . 0.0 109.219 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.555 ' CB ' ' HG3' ' A' ' 51' ' ' PRO . 19.3 m95 -131.02 125.17 32.56 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.894 -1.129 . . . . 0.0 109.574 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.581 ' HB2' ' CZ ' ' A' ' 103' ' ' PHE . . . -115.06 150.46 35.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.303 -0.873 . . . . 0.0 109.367 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.595 ' HB3' ' CZ3' ' A' ' 125' ' ' TRP . 5.3 ttp85 -164.57 121.86 1.64 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.111 -0.993 . . . . 0.0 109.51 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -102.84 170.1 8.2 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.158 -0.964 . . . . 0.0 109.764 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' GLU . . . . . 0.571 ' OE1' ' CE1' ' A' ' 158' ' ' TYR . 0.4 OUTLIER -67.16 -59.16 3.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.417 -0.802 . . . . 0.0 109.378 -179.939 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.482 ' C ' HG22 ' A' ' 123' ' ' THR . 0.8 OUTLIER -109.97 141.9 42.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.358 -0.839 . . . . 0.0 109.29 179.945 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.654 ' N ' HG22 ' A' ' 123' ' ' THR . 0.3 OUTLIER -58.16 144.79 39.33 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.206 -0.934 . . . . 0.0 109.206 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 118.17 31.94 1.47 Allowed Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -123.07 136.95 55.02 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.17 -1.194 . . . . 0.0 108.962 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.526 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 53.0 t -111.61 146.63 16.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 O-C-N 121.184 -0.947 . . . . 0.0 110.624 -179.342 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.904 HG21 HG21 ' A' ' 157' ' ' ILE . 89.0 t -155.83 149.88 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.481 -0.762 . . . . 0.0 109.5 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.518 ' CB ' ' HG2' ' A' ' 118' ' ' GLU . 19.5 m -125.29 138.6 54.09 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.202 -0.936 . . . . 0.0 109.69 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.625 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.7 m-85 -120.25 103.22 9.06 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.966 -1.084 . . . . 0.0 109.088 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.504 HG22 ' HA ' ' A' ' 115' ' ' ARG . 11.4 p -117.04 171.05 8.17 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.235 -0.916 . . . . 0.0 110.02 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.729 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -120.94 164.16 17.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.623 -0.673 . . . . 0.0 110.428 -179.51 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.529 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -176.16 148.59 9.3 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.52 ' HB3' ' OH ' ' A' ' 113' ' ' TYR . 1.5 p30 -89.59 -169.64 2.55 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.208 -1.172 . . . . 0.0 109.112 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' GLN . . . . . 0.519 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 59.2 mt-30 -78.7 18.36 0.6 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.122 -0.986 . . . . 0.0 110.628 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 0.2 OUTLIER -113.4 11.61 18.55 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 120.828 -1.17 . . . . 0.0 109.182 179.624 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.505 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.8 m-30 74.22 11.83 4.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.38 -0.825 . . . . 0.0 109.461 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.529 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 54.3 mm-40 -92.23 164.04 13.69 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.181 -0.949 . . . . 0.0 109.027 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' GLU . . . . . 0.491 ' HA ' ' HA2' ' A' ' 106' ' ' GLY . 9.8 tt0 -127.96 142.77 51.15 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.204 -0.935 . . . . 0.0 109.572 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.52 ' OH ' ' HB3' ' A' ' 107' ' ' ASN . 79.1 m-85 -93.82 -75.88 0.49 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.25 -0.906 . . . . 0.0 108.883 179.484 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.573 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -113.99 170.6 13.38 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.504 ' HA ' HG22 ' A' ' 104' ' ' THR . 3.1 ptm180 -144.14 142.31 30.5 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -1.101 . . . . 0.0 109.012 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.763 HD11 ' CE1' ' A' ' 88' ' ' TYR . 0.0 OUTLIER -151.26 162.5 40.79 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.993 -1.067 . . . . 0.0 110.624 -179.169 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 117' ' ' HIS . . . . . 0.622 ' ND1' ' CE1' ' A' ' 103' ' ' PHE . 0.0 OUTLIER 69.96 -153.73 0.13 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.635 -0.666 . . . . 0.0 110.598 178.439 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.601 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.8 mt-10 97.95 28.36 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' GLN . . . . . 0.489 ' O ' HG13 ' A' ' 100' ' ' VAL . 5.5 mt-30 -134.44 -164.05 1.46 Allowed 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.463 -0.773 . . . . 0.0 109.731 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.442 ' HA ' HG22 ' A' ' 100' ' ' VAL . 21.1 mt-30 -67.94 157.69 34.43 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.349 0.595 . . . . 0.0 110.018 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.585 ' CD1' ' NE2' ' A' ' 117' ' ' HIS . 4.9 mm -132.73 140.69 46.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.402 -0.811 . . . . 0.0 109.407 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -82.19 -179.53 7.44 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.439 -0.788 . . . . 0.0 110.412 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.654 HG22 ' N ' ' A' ' 97' ' ' ASP . 18.0 p -84.93 1.04 49.09 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 120.081 -0.648 . . . . 0.0 109.419 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.482 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 3.2 mt-10 -104.17 -169.79 1.68 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.242 -0.911 . . . . 0.0 109.428 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' TRP . . . . . 0.595 ' CZ3' ' HB3' ' A' ' 93' ' ' ARG . 92.0 m95 -98.12 122.77 41.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.304 -0.873 . . . . 0.0 109.533 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.89 121.11 45.94 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.18 -0.95 . . . . 0.0 109.045 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.32 110.45 2.48 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.466 2.111 . . . . 0.0 110.753 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.407 ' CD2' ' CE1' ' A' ' 117' ' ' HIS . 1.0 OUTLIER -115.99 134.69 54.7 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 179.235 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.443 ' OG1' ' OG1' ' A' ' 89' ' ' THR . 14.5 t -151.36 176.59 11.11 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 120.716 -1.24 . . . . 0.0 110.956 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.626 ' CE1' HD21 ' A' ' 116' ' ' LEU . 6.9 p90 -178.37 165.39 1.79 Allowed 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.004 -0.998 . . . . 0.0 108.987 179.498 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -102.91 138.92 39.16 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.123 -0.986 . . . . 0.0 109.965 -179.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.597 ' HB3' ' CE2' ' A' ' 130' ' ' PHE . 22.2 p90 -138.49 155.95 47.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.395 -0.815 . . . . 0.0 109.218 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -131.34 144.12 51.01 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.209 -0.932 . . . . 0.0 109.131 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.745 HG21 ' O ' ' A' ' 81' ' ' ARG . 3.7 t -47.69 110.27 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.364 -0.835 . . . . 0.0 109.177 179.658 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -60.56 -51.79 67.93 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.245 -0.91 . . . . 0.0 109.21 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 43.7 m-20 -108.09 -92.35 0.42 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.413 -0.804 . . . . 0.0 109.153 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -160.66 55.51 0.32 Allowed 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.468 -0.77 . . . . 0.0 109.041 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.508 ' O ' HG23 ' A' ' 80' ' ' VAL . 18.8 mm-40 -93.2 113.71 26.0 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.303 -0.873 . . . . 0.0 109.75 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.43 -15.7 57.38 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.2 t -134.57 130.25 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.145 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.479 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -140.48 172.33 11.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.27 -0.894 . . . . 0.0 110.116 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 142' ' ' ARG . . . . . 0.523 ' HB2' ' HB3' ' A' ' 76' ' ' PHE . 1.4 ptm180 -143.66 133.59 24.06 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ALA . . . . . 0.729 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.09 110.03 41.44 Favored Pre-proline 0 N--CA 1.486 1.369 0 O-C-N 121.319 -0.863 . . . . 0.0 109.76 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.516 ' HD2' ' HA ' ' A' ' 105' ' ' VAL . 36.0 Cg_endo -77.22 111.24 3.16 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.168 1.912 . . . . 0.0 111.169 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.689 ' N ' HD13 ' A' ' 145' ' ' ILE . 2.0 mm -90.68 139.34 17.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' HIS . . . . . 0.622 ' N ' ' CD2' ' A' ' 146' ' ' HIS . 14.1 m-70 -109.37 149.51 29.4 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.696 -1.253 . . . . 0.0 112.337 -177.102 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.648 ' CE2' HG13 ' A' ' 101' ' ' VAL . 2.6 m-85 -153.68 153.8 32.93 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 131.6 38.23 0.27 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.892 ' C ' HG11 ' A' ' 64' ' ' VAL . 77.2 m-85 -116.68 163.69 15.75 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.409 -1.054 . . . . 0.0 109.104 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.01 -27.25 67.27 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -73.02 -7.18 50.04 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.444 -0.785 . . . . 0.0 109.621 179.707 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.581 ' HB3' HD11 ' A' ' 157' ' ' ILE . 1.5 m-20 -107.08 9.06 30.55 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 179.254 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.413 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.5 t -87.98 158.69 3.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 O-C-N 121.418 -0.801 . . . . 0.0 109.618 -179.383 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' GLY . . . . . 0.413 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 53.13 35.78 50.31 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.461 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.2 m-20 -160.29 139.22 10.57 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.111 -1.229 . . . . 0.0 110.087 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' THR . . . . . 0.833 HG23 ' O ' ' A' ' 59' ' ' VAL . 73.6 m -92.09 122.39 34.55 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.123 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.904 HG21 HG21 ' A' ' 101' ' ' VAL . 1.4 mt -102.51 119.92 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.726 -1.234 . . . . 0.0 110.005 -178.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.713 ' CE1' HG22 ' A' ' 156' ' ' THR . 2.1 m-85 -100.11 142.17 31.96 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 178.701 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.67 HD12 ' CZ3' ' A' ' 28' ' ' TRP . 1.2 mt -133.22 138.29 51.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.788 -1.195 . . . . 0.0 110.162 -178.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 160' ' ' ASP . . . . . 0.636 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.8 OUTLIER -173.67 136.4 0.57 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.216 -0.928 . . . . 0.0 108.926 179.592 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 161' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 131.0 -3.85 5.64 Favored Glycine 0 N--CA 1.485 1.958 0 C-N-CA 119.407 -1.378 . . . . 0.0 110.324 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.662 ' CA ' HD12 ' A' ' 90' ' ' ILE . 0.1 OUTLIER -59.27 97.15 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.754 -1.439 . . . . 0.0 108.614 -179.928 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 163' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -131.54 145.44 51.73 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.348 -0.845 . . . . 0.0 109.778 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.953 HD13 HG11 ' A' ' 78' ' ' VAL . 7.5 mt -133.81 124.57 47.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.318 -0.864 . . . . 0.0 109.285 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.527 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.129 -0.982 . . . . 0.0 109.583 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.569 HG22 ' H ' ' A' ' 4' ' ' ALA . 4.2 p . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.735 ' HB3' ' O ' ' A' ' 164' ' ' ILE . . . -70.3 -57.9 4.35 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.234 -0.916 . . . . 0.0 109.539 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.471 ' HB3' ' HA ' ' A' ' 163' ' ' ALA . 4.0 t-20 -75.3 116.99 16.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.239 -0.913 . . . . 0.0 109.66 -179.753 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.625 HD12 ' O ' ' A' ' 4' ' ' ALA . 3.0 mp -103.89 140.88 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.35 -0.844 . . . . 0.0 109.068 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.508 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.7 OUTLIER 61.89 19.17 10.46 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.221 -0.924 . . . . 0.0 109.425 -179.804 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.488 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -61.54 -29.48 71.92 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.527 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -107.83 32.51 7.03 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 179.436 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.648 ' CD2' HG11 ' A' ' 25' ' ' VAL . 3.0 m-85 43.8 54.55 5.6 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.395 -1.062 . . . . 0.0 109.534 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -84.22 -36.89 22.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.16 -0.963 . . . . 0.0 109.68 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.465 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 18.6 m -84.01 -26.24 29.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.215 -0.928 . . . . 0.0 109.608 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.92 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.3 m -78.82 114.36 43.18 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.172 -0.955 . . . . 0.0 109.43 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.465 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.5 Cg_endo -77.86 142.68 20.19 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 C-N-CA 122.414 2.076 . . . . 0.0 110.61 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.71 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -40.11 161.43 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.885 -0.509 . . . . 0.0 109.709 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.82 132.99 3.23 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.024 -1.63 . . . . 0.0 109.024 -179.622 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.586 HG23 ' CD ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.94 138.45 17.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.3 -1.117 . . . . 0.0 109.325 -179.543 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.696 HG23 ' HA ' ' A' ' 43' ' ' GLU . 48.2 t -83.78 143.73 11.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-O 121.681 0.753 . . . . 0.0 110.096 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.9 p -94.84 -27.02 15.96 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.536 ' HB3' ' CG ' ' A' ' 23' ' ' GLU . 2.7 t0 -141.19 101.7 4.08 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 1.106 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -44.78 -30.13 0.91 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.178 -0.951 . . . . 0.0 109.751 -178.966 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.106 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -60.35 -53.34 58.77 Favored 'General case' 0 C--N 1.294 -1.842 0 O-C-N 121.6 -0.688 . . . . 0.0 109.678 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.536 ' CG ' ' HB3' ' A' ' 20' ' ' ASP . 1.8 pt-20 -102.15 31.52 3.92 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.249 -0.907 . . . . 0.0 109.409 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.52 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -71.14 -55.05 8.23 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.781 -1.327 . . . . 0.0 109.781 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.92 HG13 ' OG1' ' A' ' 13' ' ' THR . 2.8 t -121.53 143.1 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.16 -1.2 . . . . 0.0 109.663 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -67.49 -56.02 11.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.264 -0.897 . . . . 0.0 109.726 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.508 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -77.15 0.86 66.06 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' TRP . . . . . 0.658 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.7 OUTLIER -137.5 121.54 17.83 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.116 -1.226 . . . . 0.0 109.274 179.653 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.534 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -123.44 118.89 28.46 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.363 -0.836 . . . . 0.0 109.034 179.589 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.72 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -97.85 174.5 6.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.185 -0.947 . . . . 0.0 109.842 -179.477 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -160.39 122.92 3.29 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.364 -0.835 . . . . 0.0 109.567 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.856 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -110.73 135.03 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.168 -0.958 . . . . 0.0 109.651 179.418 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.49 178.38 21.74 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.3 t -58.6 -15.81 13.15 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.199 -1.177 . . . . 0.0 109.39 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.487 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 1.4 p -60.94 -38.1 84.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.648 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.856 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -59.9 89.41 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 O-C-N 121.084 -1.01 . . . . 0.0 109.414 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.409 ' N ' ' O ' ' A' ' 35' ' ' SER . 25.4 m -62.73 -28.97 70.32 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.264 -0.898 . . . . 0.0 108.674 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.706 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.8 t-20 -122.91 128.81 25.22 Favored Pre-proline 0 C--N 1.297 -1.688 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.453 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.1 Cg_endo -75.84 116.55 4.46 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.261 1.974 . . . . 0.0 110.729 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.509 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.3 Cg_endo -77.44 -176.26 3.11 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 C-N-CA 122.421 2.081 . . . . 0.0 109.77 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 55.5 t -113.26 119.68 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.046 -1.034 . . . . 0.0 110.682 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.591 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 3.7 m-85 -101.07 112.38 24.83 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.184 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.696 ' HA ' HG23 ' A' ' 18' ' ' VAL . 31.6 tt0 -154.08 158.8 41.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.069 -1.02 . . . . 0.0 110.038 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.441 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 58.9 t -99.5 148.21 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.506 -0.747 . . . . 0.0 109.106 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.502 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -123.35 122.1 37.47 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.295 -0.878 . . . . 0.0 109.787 -179.427 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.71 ' HG3' ' HB2' ' A' ' 15' ' ' ALA . 8.5 mt-10 -98.29 110.01 22.67 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.46 ' O ' ' HB3' ' A' ' 54' ' ' ASN . 3.1 p -142.53 -177.89 5.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.466 -0.771 . . . . 0.0 109.488 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.1 m -104.59 -5.24 21.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.306 -0.871 . . . . 0.0 109.558 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.403 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.9 m-20 -87.01 -16.56 35.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.174 -0.954 . . . . 0.0 109.444 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.403 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.33 149.74 0.71 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.234 -0.916 . . . . 0.0 109.376 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.459 ' HG3' ' HB2' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -77.93 -38.96 0.54 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.592 2.195 . . . . 0.0 110.409 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -121.23 121.28 37.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.295 -0.878 . . . . 0.0 109.397 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 63.93 -120.81 21.44 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.46 ' HB3' ' O ' ' A' ' 47' ' ' THR . 4.8 m120 -158.14 34.48 0.25 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -1.14 . . . . 0.0 109.503 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.524 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 5.4 mttp -140.2 142.17 35.89 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.298 -0.876 . . . . 0.0 109.584 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.54 HG12 ' OD2' ' A' ' 160' ' ' ASP . 4.6 m -149.22 174.85 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -0.899 . . . . 0.0 109.259 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.632 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -105.46 99.39 9.0 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.059 -1.026 . . . . 0.0 108.525 179.057 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.636 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.06 118.91 22.91 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.115 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.801 ' O ' HG23 ' A' ' 156' ' ' THR . 40.9 t -112.85 144.2 21.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.188 -0.945 . . . . 0.0 108.99 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.68 HG22 ' OD1' ' A' ' 62' ' ' ASN . 80.2 m -109.12 90.53 3.32 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.658 HG21 ' CD1' ' A' ' 157' ' ' ILE . 53.1 t -88.33 125.54 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.284 -0.885 . . . . 0.0 108.987 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.68 ' OD1' HG22 ' A' ' 60' ' ' THR . 0.6 OUTLIER -159.23 61.15 0.4 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.34 -0.85 . . . . 0.0 109.802 -179.674 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 144.36 93.9 0.17 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.727 HG12 ' C ' ' A' ' 148' ' ' GLY . 1.6 m -83.19 178.53 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.259 -1.142 . . . . 0.0 109.596 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.487 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -113.93 -154.47 11.21 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.4 m-20 -96.1 -10.12 29.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.317 -1.107 . . . . 0.0 109.491 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.597 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 4.8 m120 -109.8 151.47 42.36 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.309 -0.869 . . . . 0.0 109.381 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.43 12.53 2.09 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.693 2.262 . . . . 0.0 111.075 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.597 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.1 p90 -132.95 53.58 2.01 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.035 -1.041 . . . . 0.0 109.721 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.612 ' C ' HG23 ' A' ' 36' ' ' VAL . 0.3 OUTLIER -82.48 -69.32 0.63 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.21 -0.931 . . . . 0.0 109.057 179.763 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.491 ' HB ' ' HB3' ' A' ' 147' ' ' PHE . 6.1 mt -98.47 126.32 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.265 -0.897 . . . . 0.0 108.775 179.491 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -129.32 139.26 51.81 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.961 -1.087 . . . . 0.0 110.44 -179.358 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.72 ' HA ' HD23 ' A' ' 30' ' ' LEU . . . -122.49 143.12 49.91 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 178.593 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.521 HG22 ' N ' ' A' ' 75' ' ' ALA . 12.8 m -143.9 162.23 36.67 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.544 -1.348 . . . . 0.0 110.322 -178.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.521 ' N ' HG22 ' A' ' 74' ' ' THR . . . -123.93 136.18 54.17 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.48 -0.762 . . . . 0.0 109.142 179.191 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.539 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 1.3 p90 178.21 161.94 0.63 Allowed Pre-proline 0 N--CA 1.491 1.617 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.535 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -81.5 167.62 70.42 Favored 'Cis proline' 0 C--N 1.31 -1.491 0 C-N-CA 123.672 -1.387 . . . . 0.0 110.837 -0.678 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.654 HG11 HD12 ' A' ' 164' ' ' ILE . 62.2 t -124.07 150.04 28.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.263 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ASN . . . . . 0.522 ' O ' ' HB2' ' A' ' 4' ' ' ALA . 98.1 m-20 -117.29 108.85 16.12 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.0 -1.063 . . . . 0.0 110.075 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.572 HG23 ' O ' ' A' ' 138' ' ' GLU . 3.1 m -114.33 -173.85 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.209 -0.932 . . . . 0.0 109.479 179.478 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.704 ' O ' HG21 ' A' ' 134' ' ' VAL . 21.5 mmt180 -137.01 144.81 47.86 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.38 -0.825 . . . . 0.0 109.229 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -76.95 111.24 3.19 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.523 2.149 . . . . 0.0 110.47 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 109.13 -30.88 8.16 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.495 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -84.79 149.68 4.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.235 -1.156 . . . . 0.0 109.452 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.5 t -92.81 136.43 33.25 Favored 'General case' 0 C--N 1.292 -1.922 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' TYR . . . . . 0.495 ' CE1' HG12 ' A' ' 84' ' ' VAL . 20.3 m-85 -119.39 148.98 42.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.688 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.474 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 17.5 m -113.79 151.77 31.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.312 -0.867 . . . . 0.0 108.985 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.618 ' N ' ' CD1' ' A' ' 88' ' ' TYR . 0.1 OUTLIER -128.81 114.45 16.56 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.178 -0.952 . . . . 0.0 109.628 -179.775 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.484 ' O ' ' O ' ' A' ' 161' ' ' GLY . 41.2 m -118.87 149.29 41.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.351 -0.843 . . . . 0.0 108.971 179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.789 HD13 ' CD2' ' A' ' 103' ' ' PHE . 19.2 tt -150.75 163.51 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 120.821 -1.174 . . . . 0.0 109.755 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.498 ' CD1' ' C ' ' A' ' 90' ' ' ILE . 20.5 m95 -132.27 125.87 32.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.11 -0.994 . . . . 0.0 109.271 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -115.55 148.11 39.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.24 -0.913 . . . . 0.0 109.562 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.484 ' HD2' ' HA ' ' A' ' 124' ' ' GLU . 5.0 ttp180 -160.68 118.02 2.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.197 -0.939 . . . . 0.0 109.007 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.478 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -104.41 150.12 24.81 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.405 -0.809 . . . . 0.0 109.889 -179.596 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' GLU . . . . . 0.489 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 3.0 mt-10 -52.75 -38.98 61.75 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.451 -0.781 . . . . 0.0 109.263 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.493 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -119.57 137.48 53.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.342 -0.848 . . . . 0.0 109.378 179.978 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.577 ' N ' ' CG2' ' A' ' 123' ' ' THR . 0.5 OUTLIER -63.4 147.59 50.79 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.482 -179.847 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 106.97 38.28 2.19 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.773 -1.331 . . . . 0.0 109.773 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.468 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -121.64 140.11 52.68 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.175 -1.191 . . . . 0.0 109.101 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.461 ' HB ' ' OD1' ' A' ' 152' ' ' ASN . 51.3 t -116.75 158.23 17.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.318 -0.864 . . . . 0.0 110.759 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.784 HG22 ' CE1' ' A' ' 147' ' ' PHE . 59.3 t -154.56 163.36 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.536 ' HB3' ' HB2' ' A' ' 146' ' ' HIS . 34.2 t -118.8 123.06 43.85 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.921 -1.112 . . . . 0.0 109.797 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.789 ' CD2' HD13 ' A' ' 90' ' ' ILE . 2.3 m-85 -119.25 103.45 9.51 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.173 -0.955 . . . . 0.0 109.633 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.487 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 19.0 p -128.97 167.87 16.83 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.195 -0.941 . . . . 0.0 110.185 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.688 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -128.44 155.67 40.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.732 -0.605 . . . . 0.0 110.341 -179.726 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.53 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -175.68 160.81 29.32 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.548 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 0.9 OUTLIER -99.3 -170.26 1.88 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.125 -1.221 . . . . 0.0 109.418 -179.88 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 108' ' ' GLN . . . . . 0.548 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 22.1 mt-30 -71.87 8.73 1.1 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.06 -1.025 . . . . 0.0 111.185 -179.18 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.545 ' HB2' ' NE2' ' A' ' 111' ' ' GLN . 2.0 m -108.93 13.52 24.71 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 120.667 -1.271 . . . . 0.0 109.219 179.729 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.5 m-30 73.88 1.69 3.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.454 -0.779 . . . . 0.0 109.641 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.545 ' NE2' ' HB2' ' A' ' 109' ' ' SER . 0.7 OUTLIER -73.11 161.33 30.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.198 -0.939 . . . . 0.0 108.69 179.283 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 112' ' ' GLU . . . . . 0.491 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 3.6 tt0 -138.45 134.78 34.47 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.0 -1.063 . . . . 0.0 109.882 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.572 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 18.9 m-85 -94.8 -71.61 0.66 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.272 -0.893 . . . . 0.0 108.67 179.016 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.592 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -87.67 165.81 35.45 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 108.979 -1.648 . . . . 0.0 108.979 179.369 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.485 ' HA ' HG22 ' A' ' 104' ' ' THR . 50.9 ttt180 -160.94 110.55 1.67 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.997 -1.296 . . . . 0.0 110.474 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.832 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -144.97 69.97 1.26 Allowed 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 108.698 -0.852 . . . . 0.0 108.698 179.077 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 117' ' ' HIS . . . . . 0.534 ' CB ' ' OG ' ' A' ' 102' ' ' SER . 56.6 p-80 -102.71 157.7 16.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 110.02 -179.337 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 1.3 tp10 77.98 44.34 0.08 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.388 -0.82 . . . . 0.0 109.403 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' GLN . . . . . 0.463 ' OE1' ' HB2' ' A' ' 116' ' ' LEU . 0.9 OUTLIER -109.35 136.67 48.42 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.286 -0.884 . . . . 0.0 109.473 179.912 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.984 ' O ' HD13 ' A' ' 121' ' ' ILE . 18.9 mm-40 -73.85 155.92 38.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.445 -0.784 . . . . 0.0 109.029 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.984 HD13 ' O ' ' A' ' 120' ' ' GLN . 13.6 mm -134.38 135.81 53.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.081 -1.012 . . . . 0.0 110.071 -179.631 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.61 -179.06 6.25 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 121.638 0.732 . . . . 0.0 110.254 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.577 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 39.2 p -75.22 -0.63 20.1 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.386 179.562 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.484 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 6.4 mt-10 -110.91 -168.94 1.37 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.922 . . . . 0.0 109.238 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' TRP . . . . . 0.463 ' HA ' ' O ' ' A' ' 92' ' ' ALA . 94.1 m95 -94.39 124.89 38.69 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.159 -0.963 . . . . 0.0 109.565 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.418 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 2.1 tt0 -106.95 121.2 45.61 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.223 -0.923 . . . . 0.0 109.078 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.09 100.57 1.28 Allowed 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.4 2.067 . . . . 0.0 110.923 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -111.62 133.93 53.54 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.44 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.3 t -151.16 176.78 10.86 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 120.793 -1.192 . . . . 0.0 110.794 -179.445 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.832 ' CE1' HD21 ' A' ' 116' ' ' LEU . 6.3 p90 -166.74 165.8 16.19 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.123 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -118.85 138.89 52.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.129 -0.982 . . . . 0.0 109.891 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.572 ' CE2' ' O ' ' A' ' 113' ' ' TYR . 0.5 OUTLIER -154.77 157.73 38.41 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.375 -0.828 . . . . 0.0 109.128 179.729 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.447 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -121.09 147.66 45.23 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.232 -0.917 . . . . 0.0 109.551 -179.66 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.704 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.2 t -41.44 110.05 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.511 -0.743 . . . . 0.0 109.214 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 33.7 t -59.39 -50.64 73.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -0.872 . . . . 0.0 109.205 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -108.23 -91.7 0.43 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.382 -0.824 . . . . 0.0 109.189 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -163.23 54.74 0.18 Allowed 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.572 ' O ' HG23 ' A' ' 80' ' ' VAL . 40.4 mm-40 -91.33 111.55 23.09 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.293 -0.879 . . . . 0.0 109.944 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.35 -17.53 54.3 Favored 'General case' 0 N--CA 1.487 1.42 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.233 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.4 t -131.64 132.2 62.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.513 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -142.65 171.73 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.082 -1.011 . . . . 0.0 110.385 -179.416 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 142' ' ' ARG . . . . . 0.471 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.8 OUTLIER -141.9 132.77 25.83 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.806 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ALA . . . . . 0.688 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.15 111.45 50.22 Favored Pre-proline 0 C--N 1.304 -1.396 0 O-C-N 121.162 -0.961 . . . . 0.0 109.4 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.487 ' HD2' ' O ' ' A' ' 104' ' ' THR . 33.2 Cg_endo -74.69 111.95 3.44 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 C-N-CA 122.199 1.933 . . . . 0.0 110.764 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.658 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 2.1 mt -100.17 136.81 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 179.135 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' HIS . . . . . 0.536 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 5.9 m80 -105.72 160.37 15.27 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.525 -1.359 . . . . 0.0 111.105 -178.343 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.795 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 11.1 m-85 -159.74 162.2 34.88 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.727 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 107.01 38.91 2.07 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.641 ' C ' HG11 ' A' ' 64' ' ' VAL . 20.5 m-85 -113.42 158.09 21.09 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.489 -1.007 . . . . 0.0 109.287 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.38 -27.29 67.74 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.646 -0.659 . . . . 0.0 109.265 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.57 -15.13 62.74 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.45 -0.781 . . . . 0.0 109.187 179.469 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.525 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.2 OUTLIER -109.78 11.88 24.24 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.338 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.541 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.3 t -84.87 161.48 3.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.492 -0.755 . . . . 0.0 109.821 -179.296 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' GLY . . . . . 0.441 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 51.37 33.88 32.75 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.1 m-20 -160.4 141.84 12.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.22 -1.165 . . . . 0.0 110.226 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 156' ' ' THR . . . . . 0.801 HG23 ' O ' ' A' ' 59' ' ' VAL . 85.2 m -89.55 124.45 34.54 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.658 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.2 mt -105.02 116.32 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.855 -1.153 . . . . 0.0 110.055 -178.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.636 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 5.8 m-85 -98.91 139.85 33.96 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 178.518 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.795 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -132.16 139.34 50.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.739 -1.225 . . . . 0.0 110.228 -178.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 160' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' A' ' 161' ' ' GLY . 39.9 t0 -173.9 135.95 0.52 Allowed 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.368 -0.832 . . . . 0.0 108.876 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' GLY . . . . . 0.543 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 127.28 -9.77 6.96 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.41 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.488 ' O ' ' HA3' ' A' ' 8' ' ' GLY . 12.4 tp -59.81 109.13 0.86 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.712 -1.464 . . . . 0.0 108.642 -179.818 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 163' ' ' ALA . . . . . 0.479 ' O ' ' HA ' ' A' ' 88' ' ' TYR . . . -138.87 145.55 40.09 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.457 -0.777 . . . . 0.0 109.985 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.735 ' O ' ' HB3' ' A' ' 4' ' ' ALA . 16.5 mt -130.97 109.0 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.37 -0.831 . . . . 0.0 109.18 179.472 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.509 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.164 -0.96 . . . . 0.0 109.621 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.616 HG22 ' O ' ' A' ' 164' ' ' ILE . 4.4 p . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.311 -0.625 . . . . 0.0 109.311 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.759 ' HB3' ' O ' ' A' ' 164' ' ' ILE . . . -65.46 -43.75 89.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.092 -1.005 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.644 ' HB2' HD12 ' A' ' 164' ' ' ILE . 21.4 t-20 -85.87 130.94 34.41 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.278 -0.889 . . . . 0.0 109.338 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.42 ' O ' ' HB3' ' A' ' 7' ' ' ASN . 1.7 mp -127.62 126.61 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.223 -0.923 . . . . 0.0 109.613 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.527 ' HB3' ' CA ' ' A' ' 27' ' ' GLY . 0.6 OUTLIER 65.32 10.7 6.71 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.333 -0.854 . . . . 0.0 109.546 179.591 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.426 ' HA3' ' OD1' ' A' ' 5' ' ' ASN . . . -66.06 -33.24 84.86 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 179.412 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.529 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -91.32 16.14 59.58 Favored Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.628 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.604 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 13.2 m-85 61.28 40.27 14.62 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.337 -1.096 . . . . 0.0 109.439 179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -84.65 -43.38 14.44 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.838 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -78.71 -42.29 28.75 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.212 -0.93 . . . . 0.0 109.875 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.87 ' OG1' HG13 ' A' ' 25' ' ' VAL . 12.8 m -59.81 123.67 72.8 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.33 -0.856 . . . . 0.0 109.586 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.8 Cg_endo -77.87 137.42 15.83 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 122.439 2.092 . . . . 0.0 110.569 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.463 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -41.97 164.63 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.715 -0.616 . . . . 0.0 109.707 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 132.71 131.18 3.17 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 108.999 -1.64 . . . . 0.0 108.999 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.542 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -56.96 142.94 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.167 -1.196 . . . . 0.0 108.943 -179.71 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.468 HG13 ' HA2' ' A' ' 24' ' ' GLY . 54.1 t -90.64 142.47 12.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.456 -0.778 . . . . 0.0 110.386 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 33.3 p -93.03 -30.14 15.46 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 178.855 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.41 ' O ' ' C ' ' A' ' 21' ' ' LEU . 4.9 m-20 -133.39 99.53 4.55 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 1.098 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -44.13 -29.57 0.64 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.207 -0.933 . . . . 0.0 109.764 -178.567 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.098 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.8 -51.7 68.62 Favored 'General case' 0 C--N 1.294 -1.823 0 O-C-N 121.588 -0.695 . . . . 0.0 109.706 -179.673 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -101.86 31.05 4.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.2 -0.937 . . . . 0.0 109.384 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.468 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -74.1 -59.91 3.78 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.87 HG13 ' OG1' ' A' ' 13' ' ' THR . 3.5 t -120.56 137.91 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -1.135 . . . . 0.0 109.555 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -69.44 -42.31 75.14 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.305 -0.872 . . . . 0.0 109.587 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.527 ' CA ' ' HB3' ' A' ' 7' ' ' ASN . . . -76.91 -12.67 84.39 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' TRP . . . . . 1.049 ' CZ2' HD13 ' A' ' 145' ' ' ILE . 1.0 OUTLIER -132.44 123.73 27.23 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.19 -1.182 . . . . 0.0 109.754 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.461 ' OD1' ' CE2' ' A' ' 76' ' ' PHE . 1.8 m-20 -113.83 115.82 28.36 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 178.836 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.914 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -98.81 168.0 10.41 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.946 -1.096 . . . . 0.0 110.16 -178.581 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 72' ' ' GLU . 19.5 m120 -160.53 123.43 3.34 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.532 -0.73 . . . . 0.0 109.633 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.005 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -101.12 131.88 47.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.097 -1.002 . . . . 0.0 109.447 179.263 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.29 178.65 26.74 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.5 m -57.99 -16.75 13.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -1.133 . . . . 0.0 109.345 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.471 ' HB3' ' HB2' ' A' ' 67' ' ' ASN . 1.3 p -61.99 -38.55 89.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.442 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 1.005 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -63.78 89.67 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 O-C-N 121.221 -0.925 . . . . 0.0 109.455 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 45.2 m -71.23 -28.4 64.16 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.846 0.832 . . . . 0.0 108.84 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.656 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.3 m-20 -115.0 139.77 24.71 Favored Pre-proline 0 C--N 1.297 -1.702 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.655 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.484 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.4 Cg_endo -76.01 111.76 3.35 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.389 2.059 . . . . 0.0 110.816 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 38' ' ' ASN . 34.9 Cg_endo -77.57 179.61 6.35 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.46 2.106 . . . . 0.0 109.552 179.537 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.54 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 61.9 t -117.18 120.74 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.999 -1.063 . . . . 0.0 110.769 -179.576 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.485 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 90.6 m-85 -106.83 112.24 25.12 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 178.086 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.542 ' HG3' HG23 ' A' ' 17' ' ' VAL . 0.4 OUTLIER -150.28 148.26 28.65 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.976 -1.078 . . . . 0.0 110.237 -179.261 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.0 t -101.77 148.19 7.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.519 -0.738 . . . . 0.0 109.117 179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 1.077 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -150.54 164.32 36.27 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 179.85 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 1.077 ' N ' HD22 ' A' ' 45' ' ' LEU . 19.4 pt-20 -120.04 123.84 44.42 Favored 'General case' 0 C--N 1.291 -1.945 0 O-C-N 121.391 -0.818 . . . . 0.0 109.388 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.985 HG23 HD21 ' A' ' 45' ' ' LEU . 6.7 p -117.42 178.98 4.18 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 109.459 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -101.97 8.76 40.94 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.219 -0.926 . . . . 0.0 109.524 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.413 ' O ' ' C ' ' A' ' 50' ' ' ALA . 7.7 m-20 -125.25 8.72 7.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.178 -0.952 . . . . 0.0 109.572 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -43.9 148.78 0.72 Allowed Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.234 -0.916 . . . . 0.0 109.437 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.601 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -77.97 -40.16 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 122.642 2.228 . . . . 0.0 110.384 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -131.71 94.04 3.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.43 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 99.19 -124.29 8.18 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.493 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 76.6 m-20 -155.06 20.33 0.43 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.241 -1.153 . . . . 0.0 109.556 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 51.9 mttp -137.62 145.33 42.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.237 -0.914 . . . . 0.0 109.638 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.644 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.1 m -150.14 174.69 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.32 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.732 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -101.35 102.95 13.87 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 109.016 179.618 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.709 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.92 117.7 22.36 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.779 ' O ' HG23 ' A' ' 156' ' ' THR . 39.6 t -111.86 144.64 19.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.052 -1.03 . . . . 0.0 109.076 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.54 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 16.0 m -109.2 89.27 2.95 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.534 HG21 ' CD1' ' A' ' 157' ' ' ILE . 41.5 t -85.25 128.7 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.334 -0.854 . . . . 0.0 109.16 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -159.93 61.56 0.36 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.427 -0.795 . . . . 0.0 109.835 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 150.56 93.55 0.11 Allowed Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.69 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.4 m -79.86 -173.41 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.181 -1.188 . . . . 0.0 109.497 179.776 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -135.46 -162.02 9.52 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ASN . . . . . 0.418 ' C ' ' OD1' ' A' ' 67' ' ' ASN . 23.0 t30 -89.82 10.28 24.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.213 -1.169 . . . . 0.0 109.453 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.594 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.0 m-20 -131.82 148.26 69.21 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.188 -0.945 . . . . 0.0 109.391 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.43 12.99 1.94 Allowed 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.568 2.179 . . . . 0.0 111.022 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.594 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.2 p90 -133.44 55.66 1.89 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.95 -1.094 . . . . 0.0 109.916 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.52 ' C ' HG23 ' A' ' 36' ' ' VAL . 0.3 OUTLIER -78.68 -68.31 0.66 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 108.862 179.535 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.412 ' HB ' ' HB2' ' A' ' 147' ' ' PHE . 2.8 mp -90.19 124.63 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.472 ' HB3' ' O ' ' A' ' 31' ' ' ASN . 1.6 tt0 -114.7 128.76 56.49 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.031 -1.043 . . . . 0.0 110.729 -179.137 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 1.083 ' HB3' ' CE1' ' A' ' 147' ' ' PHE . . . -131.43 107.67 9.07 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.471 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.558 HG22 ' N ' ' A' ' 75' ' ' ALA . 52.0 m -117.92 163.87 15.91 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.894 -1.129 . . . . 0.0 110.255 -178.252 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.558 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.19 137.26 53.75 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.234 -0.916 . . . . 0.0 109.214 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.54 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 0.6 OUTLIER 177.42 162.95 0.55 Allowed Pre-proline 0 N--CA 1.492 1.67 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -179.888 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.511 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.11 167.45 74.52 Favored 'Cis proline' 0 C--N 1.309 -1.52 0 C-N-CA 123.722 -1.366 . . . . 0.0 110.699 -0.242 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.541 ' CG1' ' HB1' ' A' ' 4' ' ' ALA . 69.5 t -125.37 151.04 30.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.396 -0.815 . . . . 0.0 108.819 179.361 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ASN . . . . . 0.593 ' O ' ' HB2' ' A' ' 4' ' ' ALA . 8.5 m-80 -117.15 113.24 21.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.077 -1.014 . . . . 0.0 109.933 -179.51 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.587 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.8 m -117.83 -176.24 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.192 -0.943 . . . . 0.0 109.449 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.722 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -134.91 144.97 52.7 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.319 -0.863 . . . . 0.0 109.236 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.474 ' HD2' ' HG3' ' A' ' 81' ' ' ARG . 34.8 Cg_endo -76.19 113.26 3.66 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.49 2.127 . . . . 0.0 110.553 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.6 -31.6 8.1 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.533 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -85.09 149.79 4.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.256 -1.144 . . . . 0.0 109.466 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 4.3 m -95.37 138.23 33.35 Favored 'General case' 0 C--N 1.292 -1.906 0 CA-C-O 121.296 0.57 . . . . 0.0 109.473 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' TYR . . . . . 0.587 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 12.2 m-85 -117.93 157.4 26.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -0.936 . . . . 0.0 109.616 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 40.1 m -118.1 149.48 40.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -0.879 . . . . 0.0 109.29 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.69 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 0.2 OUTLIER -125.97 107.98 10.97 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -0.891 . . . . 0.0 109.507 -179.884 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 161' ' ' GLY . 48.6 m -115.15 146.64 41.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.29 -0.882 . . . . 0.0 109.098 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.816 HD13 ' CD2' ' A' ' 103' ' ' PHE . 18.9 tt -150.48 163.32 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 120.884 -1.135 . . . . 0.0 109.465 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.601 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 21.0 m95 -131.37 127.1 36.87 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.971 -1.081 . . . . 0.0 109.526 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.47 146.96 41.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.364 -0.835 . . . . 0.0 109.316 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.501 ' HG3' ' CA ' ' A' ' 124' ' ' GLU . 28.2 ttt-85 -162.16 118.06 1.98 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.125 -0.985 . . . . 0.0 109.182 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.71 166.12 10.69 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.878 -179.527 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.0 mm-40 -59.46 -49.82 76.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.426 -0.796 . . . . 0.0 109.363 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.575 ' C ' HG22 ' A' ' 123' ' ' THR . 0.6 OUTLIER -112.35 148.38 34.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.335 -0.853 . . . . 0.0 109.252 179.879 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.778 ' N ' HG22 ' A' ' 123' ' ' THR . 2.1 t70 -68.81 163.14 24.87 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.205 -0.935 . . . . 0.0 109.487 -179.766 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.505 ' N ' ' OD1' ' A' ' 97' ' ' ASP . . . 93.42 39.5 5.03 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.905 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -119.02 142.59 47.68 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.278 -1.131 . . . . 0.0 109.044 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.443 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 54.3 t -118.87 149.69 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.205 -0.934 . . . . 0.0 110.909 -179.235 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.702 HG13 ' CE2' ' A' ' 147' ' ' PHE . 47.7 t -149.42 165.26 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.521 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 66.5 m -130.54 125.47 34.33 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.976 -1.077 . . . . 0.0 109.392 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.816 ' CD2' HD13 ' A' ' 90' ' ' ILE . 1.2 m-85 -122.38 104.18 9.23 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.235 -0.915 . . . . 0.0 110.095 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.541 HG22 ' CA ' ' A' ' 115' ' ' ARG . 17.4 p -121.67 163.49 18.92 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.113 -0.992 . . . . 0.0 109.87 179.437 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -112.62 118.0 56.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 C-N-CA 119.948 -0.701 . . . . 0.0 110.007 179.701 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -109.46 172.61 16.25 Favored Glycine 0 N--CA 1.487 2.086 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.552 ' CB ' ' O ' ' A' ' 111' ' ' GLN . 17.1 t30 -123.57 171.78 9.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.369 -1.077 . . . . 0.0 109.133 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' GLN . . . . . 0.411 ' N ' ' CG ' ' A' ' 107' ' ' ASN . 19.1 mt-30 -59.06 -48.17 82.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.972 -1.08 . . . . 0.0 109.675 -179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 2.8 m -83.36 17.96 1.95 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.239 -0.913 . . . . 0.0 110.12 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.548 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.8 m-30 81.14 8.58 1.08 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.479 -0.763 . . . . 0.0 110.189 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.552 ' O ' ' CB ' ' A' ' 107' ' ' ASN . 5.4 mm-40 -71.02 121.82 18.9 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.955 -1.091 . . . . 0.0 108.807 179.257 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -106.17 139.5 40.59 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.817 -1.177 . . . . 0.0 109.949 -179.328 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.574 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 4.6 m-85 -107.3 -65.53 1.09 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.589 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -104.74 179.29 24.25 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.052 -1.619 . . . . 0.0 109.052 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.541 ' CA ' HG22 ' A' ' 104' ' ' THR . 0.0 OUTLIER 175.35 119.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.917 -1.343 . . . . 0.0 110.398 179.959 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.897 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -140.84 70.01 1.35 Allowed 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.25 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 117' ' ' HIS . . . . . 0.544 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 17.7 p-80 -89.28 152.7 21.41 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.893 . . . . 0.0 110.129 -179.364 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 4.0 tt0 79.66 72.74 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.402 -0.811 . . . . 0.0 109.598 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' GLN . . . . . 0.434 ' HG2' ' C ' ' A' ' 118' ' ' GLU . 14.0 mm-40 -134.67 130.18 35.94 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.357 -0.839 . . . . 0.0 109.45 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.696 ' O ' HD13 ' A' ' 121' ' ' ILE . 1.1 mp0 -66.41 152.66 44.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.269 -0.895 . . . . 0.0 109.013 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.696 HD13 ' O ' ' A' ' 120' ' ' GLN . 9.1 mm -136.08 136.07 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 O-C-N 121.068 -1.02 . . . . 0.0 110.099 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.427 HG22 ' OD2' ' A' ' 97' ' ' ASP . 0.6 OUTLIER -87.4 -179.04 6.31 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 121.651 0.738 . . . . 0.0 110.125 179.641 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.778 HG22 ' N ' ' A' ' 97' ' ' ASP . 30.5 p -76.45 1.15 17.3 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.35 179.519 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.501 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 8.6 mt-10 -111.64 -168.95 1.37 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 0.0 109.177 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' TRP . . . . . 0.529 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 97.6 m95 -94.22 123.36 37.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.657 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.407 ' OE1' ' HD2' ' A' ' 127' ' ' PRO . 12.2 mm-40 -106.93 121.36 45.11 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.301 -0.875 . . . . 0.0 108.992 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.591 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.6 Cg_endo -80.02 104.51 1.68 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.396 2.064 . . . . 0.0 110.947 -179.755 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -116.98 131.67 56.9 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.559 ' HG1' ' C ' ' A' ' 88' ' ' TYR . 14.4 t -151.76 177.09 10.75 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.936 -1.102 . . . . 0.0 110.745 -179.489 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.897 ' CE1' HD21 ' A' ' 116' ' ' LEU . 12.2 p90 -163.36 178.21 8.31 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.08 179.533 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 82.4 mt-10 -130.48 138.92 50.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.117 -0.989 . . . . 0.0 109.975 -179.658 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.589 ' CE2' ' HA2' ' A' ' 114' ' ' GLY . 0.3 OUTLIER -151.06 168.13 25.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.372 -0.83 . . . . 0.0 109.163 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.7 OUTLIER -127.82 146.57 50.56 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.115 -0.991 . . . . 0.0 109.409 -179.507 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.722 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.9 t -41.28 110.43 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.618 -0.676 . . . . 0.0 109.266 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -56.1 -46.94 78.92 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.318 -0.864 . . . . 0.0 109.043 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.472 ' O ' ' HG3' ' A' ' 137' ' ' GLN . 2.8 m-20 -118.49 -91.71 0.55 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.429 -0.794 . . . . 0.0 109.173 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' GLN . . . . . 0.472 ' HG3' ' O ' ' A' ' 136' ' ' ASP . 71.9 mt-30 -159.7 57.37 0.38 Allowed 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.47 -0.769 . . . . 0.0 108.929 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.565 ' O ' HG23 ' A' ' 80' ' ' VAL . 16.6 mm-40 -95.7 111.49 23.43 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.293 -0.88 . . . . 0.0 109.765 -179.662 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.38 -13.79 59.39 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.324 -0.86 . . . . 0.0 108.73 179.492 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 39.2 t -132.17 130.6 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.367 -0.833 . . . . 0.0 109.009 179.463 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.545 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -144.36 171.8 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.254 -0.903 . . . . 0.0 109.824 -179.812 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 142' ' ' ARG . . . . . 0.507 ' HB2' ' HB3' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -146.47 131.83 18.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.489 -0.757 . . . . 0.0 109.522 179.86 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ALA . . . . . 0.613 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -93.34 110.54 47.27 Favored Pre-proline 0 N--CA 1.486 1.372 0 O-C-N 121.259 -0.9 . . . . 0.0 110.168 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.486 ' HD2' ' O ' ' A' ' 104' ' ' THR . 36.0 Cg_endo -77.46 111.06 3.09 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.297 1.998 . . . . 0.0 110.735 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 1.049 HD13 ' CZ2' ' A' ' 28' ' ' TRP . 1.2 mt -97.8 120.71 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 179.162 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' HIS . . . . . 0.538 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 7.1 m80 -85.83 159.36 19.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.777 -1.202 . . . . 0.0 112.202 -176.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 1.083 ' CE1' ' HB3' ' A' ' 73' ' ' ALA . 61.6 m-85 -157.57 158.43 35.59 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 179.001 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.556 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 112.19 52.53 0.52 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.69 ' C ' HG11 ' A' ' 64' ' ' VAL . 41.8 m-85 -125.73 158.17 35.54 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.428 -1.042 . . . . 0.0 109.195 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.474 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.98 -29.51 69.38 Favored 'General case' 0 C--N 1.296 -1.734 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.86 -9.59 57.94 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 121.738 0.78 . . . . 0.0 109.327 179.299 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.905 ' OD1' ' HB1' ' A' ' 99' ' ' ALA . 2.1 t-20 -120.59 12.18 11.45 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.521 ' CG2' HG13 ' A' ' 64' ' ' VAL . 2.2 t -82.92 161.69 3.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 O-C-N 121.628 -0.67 . . . . 0.0 109.631 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' GLY . . . . . 0.44 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.7 37.42 51.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.428 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.1 m-20 -160.32 138.37 9.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.128 -1.219 . . . . 0.0 110.17 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 59' ' ' VAL . 98.0 m -86.26 121.2 28.5 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.039 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.573 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 1.0 OUTLIER -101.87 117.27 46.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.865 -1.147 . . . . 0.0 110.224 -178.874 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.709 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.9 m-85 -95.96 135.77 37.28 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 178.598 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.634 HD13 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -129.16 137.66 56.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 120.819 -1.176 . . . . 0.0 110.12 -178.601 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 160' ' ' ASP . . . . . 0.644 ' CB ' HG12 ' A' ' 56' ' ' VAL . 9.0 t0 -174.08 136.26 0.5 Allowed 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.307 -0.871 . . . . 0.0 109.018 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 161' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 128.0 -11.11 6.58 Favored Glycine 0 N--CA 1.485 1.958 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.334 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.522 HD23 ' HB2' ' A' ' 75' ' ' ALA . 11.4 tp -59.63 110.19 1.08 Allowed 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.694 -1.474 . . . . 0.0 108.486 -179.721 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 163' ' ' ALA . . . . . 0.506 ' HA ' ' CB ' ' A' ' 5' ' ' ASN . . . -139.6 145.65 38.82 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.474 -0.766 . . . . 0.0 110.265 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.759 ' O ' ' HB3' ' A' ' 4' ' ' ALA . 2.3 mp -126.86 109.02 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.422 -0.799 . . . . 0.0 109.047 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.494 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.616 0 O-C-N 121.083 -1.011 . . . . 0.0 109.826 -179.68 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.992 HG23 ' HB2' ' A' ' 165' ' ' ALA . 3.2 p . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.632 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -68.79 -57.92 4.92 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.188 -0.945 . . . . 0.0 109.854 -179.741 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.875 ' HB3' HG22 ' A' ' 78' ' ' VAL . 8.5 p-10 -102.07 141.83 34.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.238 -0.914 . . . . 0.0 109.79 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.5 ' O ' ' HA3' ' A' ' 27' ' ' GLY . 1.8 mp -102.78 150.17 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 0.0 109.555 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.541 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.9 OUTLIER 66.63 17.98 10.69 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.254 -0.904 . . . . 0.0 110.0 179.464 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -59.02 -26.97 61.68 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.855 -1.698 . . . . 0.0 108.855 179.571 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.445 ' O ' ' OD1' ' A' ' 160' ' ' ASP . . . -115.38 37.57 3.42 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.605 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 1.1 m-85 43.58 46.09 5.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.328 -1.101 . . . . 0.0 109.417 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -77.08 -36.14 56.04 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.19 -0.944 . . . . 0.0 109.659 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.519 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 4.5 t -88.3 -21.68 24.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.227 -0.921 . . . . 0.0 109.499 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . 1.03 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.2 m -70.81 113.92 22.65 Favored Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.7 Cg_endo -77.48 136.16 15.42 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.392 2.061 . . . . 0.0 110.502 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.6 ' HB2' ' HB2' ' A' ' 46' ' ' GLU . . . -40.21 154.46 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.897 -0.502 . . . . 0.0 109.65 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.52 131.1 2.96 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 -179.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.527 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.2 139.0 17.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.273 -1.134 . . . . 0.0 109.494 -179.591 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.438 HG13 ' HA2' ' A' ' 24' ' ' GLY . 53.7 t -86.52 142.86 12.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 CA-C-O 121.568 0.699 . . . . 0.0 110.122 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 19.6 p -93.75 -28.43 15.93 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.99 101.05 5.08 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 1.102 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -47.29 -30.21 2.96 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.247 -0.908 . . . . 0.0 109.873 -178.842 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.102 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.72 -47.74 84.46 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.559 -0.713 . . . . 0.0 109.857 -179.642 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -107.58 34.59 3.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.123 -0.985 . . . . 0.0 109.432 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.438 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -74.55 -50.02 10.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 1.03 HG13 ' OG1' ' A' ' 13' ' ' THR . 4.9 t -119.84 141.49 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.24 -1.153 . . . . 0.0 109.738 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -67.18 -47.18 71.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.345 -0.847 . . . . 0.0 109.433 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.541 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -89.29 0.66 81.49 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' TRP . . . . . 0.696 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -135.64 121.75 20.17 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.198 -1.177 . . . . 0.0 109.215 179.659 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.539 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -121.65 122.79 40.41 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.366 -0.834 . . . . 0.0 108.912 179.452 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.828 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -99.32 173.5 6.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.756 -179.308 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 62.7 m-80 -160.37 123.45 3.42 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.369 -0.832 . . . . 0.0 109.842 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.958 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.54 136.25 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.205 -0.935 . . . . 0.0 109.415 179.219 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.01 -178.91 26.5 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 70.2 m -58.79 -16.99 19.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -1.127 . . . . 0.0 109.538 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.492 ' HB3' ' HB2' ' A' ' 67' ' ' ASN . 2.8 p -60.99 -37.0 80.94 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.242 -0.911 . . . . 0.0 109.367 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.958 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -62.41 89.39 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 O-C-N 121.27 -0.894 . . . . 0.0 109.334 179.631 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 88.7 m -73.14 -28.07 62.03 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.362 -0.836 . . . . 0.0 108.864 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.638 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.5 p-10 -112.72 142.99 28.13 Favored Pre-proline 0 C--N 1.297 -1.703 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -76.41 111.38 3.25 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.384 2.056 . . . . 0.0 110.801 -179.599 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.542 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.8 Cg_endo -78.05 177.11 9.18 Favored 'Trans proline' 0 C--N 1.312 -1.365 0 C-N-CA 122.521 2.147 . . . . 0.0 109.391 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.543 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 63.2 t -118.03 120.87 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 120.873 -1.142 . . . . 0.0 110.829 -179.602 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.591 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 96.3 m-85 -110.01 112.89 25.17 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 178.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.527 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 22.8 tt0 -150.93 155.55 39.35 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.006 -1.059 . . . . 0.0 109.845 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.67 HG21 HG22 ' A' ' 13' ' ' THR . 85.2 t -94.49 141.52 14.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.203 179.491 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.507 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -117.88 118.85 33.12 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.512 -0.743 . . . . 0.0 109.347 -179.663 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.6 ' HB2' ' HB2' ' A' ' 15' ' ' ALA . 6.3 mt-10 -103.55 109.85 21.67 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.61 -0.681 . . . . 0.0 109.394 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.483 ' O ' ' HB2' ' A' ' 54' ' ' ASN . 2.4 p -144.5 -179.54 6.62 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.46 -0.775 . . . . 0.0 109.386 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -102.13 29.71 4.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 109.367 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -119.5 -14.31 9.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 0.0 109.541 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.465 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -45.91 154.62 0.56 Allowed Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.147 -0.971 . . . . 0.0 109.521 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.542 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 36.0 Cg_endo -78.04 -34.01 1.86 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.596 2.198 . . . . 0.0 110.419 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -129.1 91.68 3.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.266 -0.896 . . . . 0.0 109.351 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.62 -120.98 6.31 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.544 -1.423 . . . . 0.0 109.544 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.483 ' HB2' ' O ' ' A' ' 47' ' ' THR . 11.9 p30 -160.02 30.16 0.18 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.239 -1.154 . . . . 0.0 109.472 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.528 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 8.2 mttp -135.09 130.74 36.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.305 -0.872 . . . . 0.0 109.547 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.678 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.0 m -149.05 175.62 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.372 -0.83 . . . . 0.0 109.145 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.731 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -105.81 100.91 10.44 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.032 -1.043 . . . . 0.0 108.998 179.441 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.618 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.62 117.87 22.33 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 178.735 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.767 ' O ' HG23 ' A' ' 156' ' ' THR . 40.9 t -115.15 144.92 21.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.069 -1.02 . . . . 0.0 109.168 -179.042 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.543 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 9.9 m -107.19 94.18 4.95 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.652 HG21 ' CD1' ' A' ' 157' ' ' ILE . 50.8 t -90.27 118.1 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.384 -0.823 . . . . 0.0 109.194 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -153.91 58.66 0.73 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.866 . . . . 0.0 109.941 -179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.422 ' HA3' ' CG ' ' A' ' 38' ' ' ASN . . . 158.47 92.49 0.09 OUTLIER Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.692 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.744 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.7 m -84.36 -172.38 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.282 -1.128 . . . . 0.0 109.599 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -138.23 -157.17 7.36 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.4 m120 -96.06 10.03 38.88 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -1.121 . . . . 0.0 109.491 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.578 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 17.5 m-80 -127.35 146.46 58.3 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.212 -0.93 . . . . 0.0 109.42 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.586 ' HG2' ' CZ3' ' A' ' 69' ' ' TRP . 35.8 Cg_endo -78.47 12.54 2.09 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.579 2.186 . . . . 0.0 110.957 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.586 ' CZ3' ' HG2' ' A' ' 68' ' ' PRO . 1.1 p90 -133.56 54.5 1.95 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.987 -1.07 . . . . 0.0 109.853 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.476 ' HA ' ' OG ' ' A' ' 35' ' ' SER . 0.8 OUTLIER -78.4 -69.0 0.59 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.185 -0.947 . . . . 0.0 108.838 179.464 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.542 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 3.2 mp -106.05 128.02 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.155 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.61 138.24 52.1 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.903 -1.123 . . . . 0.0 110.467 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.828 ' HA ' HD23 ' A' ' 30' ' ' LEU . . . -120.35 132.15 55.16 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 178.716 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.531 HG22 ' N ' ' A' ' 75' ' ' ALA . 16.4 m -135.52 163.1 30.86 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.721 -1.237 . . . . 0.0 110.379 -178.618 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.56 ' HB2' ' NE1' ' A' ' 28' ' ' TRP . . . -122.66 137.56 54.87 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.433 -0.792 . . . . 0.0 109.145 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.539 ' CE2' ' CG ' ' A' ' 29' ' ' ASP . 1.6 p90 179.03 161.31 0.71 Allowed Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.516 -0.74 . . . . 0.0 109.103 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.531 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.3 Cg_endo -80.03 165.41 78.82 Favored 'Cis proline' 0 C--N 1.309 -1.514 0 C-N-CA 123.63 -1.404 . . . . 0.0 110.775 -0.147 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.875 HG22 ' HB3' ' A' ' 5' ' ' ASN . 92.6 t -120.34 156.47 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.381 -0.824 . . . . 0.0 108.918 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ASN . . . . . 0.571 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 4.5 m-80 -124.13 122.05 36.8 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.17 -0.956 . . . . 0.0 109.961 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.57 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 3.3 m -129.96 -174.01 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.153 -0.967 . . . . 0.0 109.54 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.652 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -137.12 143.88 43.79 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.394 -0.816 . . . . 0.0 109.148 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -76.14 115.46 4.14 Favored 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.475 2.117 . . . . 0.0 110.452 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.67 -27.36 20.61 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.512 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.86 149.81 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.186 -1.185 . . . . 0.0 109.549 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 39.0 m -97.14 132.99 42.37 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' TYR . . . . . 0.57 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 12.9 m-85 -111.88 164.83 12.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.582 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.467 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 12.1 m -115.33 154.1 29.77 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.3 -0.875 . . . . 0.0 109.445 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.671 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 6.2 t80 -131.12 118.56 20.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.258 -0.901 . . . . 0.0 109.236 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.481 ' O ' ' O ' ' A' ' 161' ' ' GLY . 16.6 m -135.74 143.55 45.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.174 -0.954 . . . . 0.0 109.187 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.734 HD12 ' HB2' ' A' ' 162' ' ' LEU . 17.5 tt -150.51 163.71 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.868 -1.145 . . . . 0.0 109.588 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.542 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 18.2 m95 -130.4 126.34 36.8 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.037 -1.039 . . . . 0.0 109.247 179.626 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -115.79 149.22 38.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.275 -0.891 . . . . 0.0 109.541 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.576 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 4.9 ttp85 -164.02 120.61 1.66 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.196 -0.94 . . . . 0.0 109.145 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.479 ' HB1' ' O ' ' A' ' 156' ' ' THR . . . -105.4 160.56 15.04 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.324 -0.86 . . . . 0.0 110.012 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' GLU . . . . . 0.476 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 0.0 OUTLIER -57.26 -48.96 77.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.436 -0.79 . . . . 0.0 109.172 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.529 ' C ' HG22 ' A' ' 123' ' ' THR . 16.3 mt-30 -116.44 146.19 42.72 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.336 -0.852 . . . . 0.0 109.166 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.639 ' N ' HG22 ' A' ' 123' ' ' THR . 8.5 p30 -65.17 146.29 55.16 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.204 -0.935 . . . . 0.0 109.517 -179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 112.12 30.87 2.81 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.477 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -118.13 138.18 52.45 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.117 -1.226 . . . . 0.0 109.112 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.641 HG22 ' HA ' ' A' ' 120' ' ' GLN . 52.1 t -116.9 158.36 17.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 O-C-N 121.256 -0.902 . . . . 0.0 110.747 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.877 HG22 ' CE1' ' A' ' 147' ' ' PHE . 72.6 t -153.68 163.04 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.547 ' CB ' ' HB2' ' A' ' 117' ' ' HIS . 74.9 m -121.72 125.24 46.13 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.916 -1.115 . . . . 0.0 109.907 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.613 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.2 OUTLIER -119.76 103.56 9.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.062 -1.024 . . . . 0.0 109.737 179.72 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.503 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 18.5 p -127.3 167.95 15.45 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.168 -0.958 . . . . 0.0 110.151 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.688 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -128.16 156.86 40.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.715 -0.615 . . . . 0.0 110.247 -179.793 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.503 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -173.92 -173.17 39.85 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.608 ' CB ' HG22 ' A' ' 141' ' ' ILE . 1.4 p30 -126.52 -169.37 2.01 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.18 -1.188 . . . . 0.0 109.049 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' GLN . . . . . 0.531 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 5.6 mp0 -73.66 11.9 0.74 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.049 -1.032 . . . . 0.0 110.971 -179.4 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.499 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 1.0 OUTLIER -113.19 7.89 18.03 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 120.722 -1.236 . . . . 0.0 109.288 179.658 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.6 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.6 m-30 78.87 1.95 2.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.355 -0.841 . . . . 0.0 109.815 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.503 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 4.9 mm100 -76.04 159.47 30.77 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.106 -0.996 . . . . 0.0 108.729 179.466 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' GLU . . . . . 0.495 ' HA ' ' HA2' ' A' ' 106' ' ' GLY . 5.2 tt0 -138.09 135.3 35.67 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.968 -1.083 . . . . 0.0 110.005 -179.415 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.568 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 6.5 m-85 -95.95 -70.62 0.71 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.06 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.586 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -81.72 162.0 42.79 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.358 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.466 ' HA ' HG22 ' A' ' 104' ' ' THR . 7.7 ttm180 -158.05 103.95 1.87 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.974 -1.309 . . . . 0.0 110.337 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.72 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -144.1 72.85 1.36 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.335 -0.853 . . . . 0.0 108.784 179.087 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 117' ' ' HIS . . . . . 0.547 ' HB2' ' CB ' ' A' ' 102' ' ' SER . 32.1 p-80 -115.82 162.79 16.81 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.121 -0.987 . . . . 0.0 110.049 -179.412 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.531 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 3.2 tt0 77.22 53.31 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.399 -0.813 . . . . 0.0 109.256 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' GLN . . . . . 0.407 ' O ' HG13 ' A' ' 100' ' ' VAL . 53.2 mm-40 -126.4 141.69 51.8 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.378 -0.826 . . . . 0.0 109.599 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.641 ' HA ' HG22 ' A' ' 100' ' ' VAL . 46.9 mm-40 -73.64 156.55 37.88 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.62 HD13 ' O ' ' A' ' 120' ' ' GLN . 10.8 mm -133.5 136.9 53.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.025 -1.047 . . . . 0.0 110.129 -179.469 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.64 -179.31 7.1 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.541 -0.724 . . . . 0.0 110.121 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.639 HG22 ' N ' ' A' ' 97' ' ' ASP . 61.9 p -78.06 0.49 24.42 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.877 -0.729 . . . . 0.0 109.36 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.436 ' O ' ' HB2' ' A' ' 93' ' ' ARG . 2.8 mt-10 -110.06 -168.83 1.37 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -0.883 . . . . 0.0 109.327 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' TRP . . . . . 0.576 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 85.6 m95 -98.01 121.91 40.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 109.562 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -106.83 121.35 45.22 Favored Pre-proline 0 N--CA 1.488 1.475 0 O-C-N 121.204 -0.935 . . . . 0.0 108.966 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.77 108.22 2.23 Favored 'Trans proline' 0 C--N 1.312 -1.381 0 C-N-CA 122.292 1.994 . . . . 0.0 110.96 -179.61 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -112.51 136.02 52.53 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.462 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.5 t -151.07 175.94 11.63 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.651 -1.28 . . . . 0.0 111.05 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.72 ' CE2' HD21 ' A' ' 116' ' ' LEU . 29.1 p90 -173.87 -178.29 1.53 Allowed 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.346 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -131.14 155.2 47.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.237 -0.914 . . . . 0.0 109.698 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.568 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.02 168.31 17.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.341 -0.849 . . . . 0.0 109.41 179.783 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -133.78 147.68 51.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.187 -0.946 . . . . 0.0 109.516 -179.745 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.652 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.2 t -42.01 110.3 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.511 -0.743 . . . . 0.0 109.272 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 67.5 m -58.7 -50.35 74.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 0.0 109.203 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -110.51 -90.79 0.47 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.436 -0.79 . . . . 0.0 109.202 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -163.31 56.31 0.18 Allowed 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.55 -0.719 . . . . 0.0 109.11 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.498 ' O ' HG23 ' A' ' 80' ' ' VAL . 50.0 mm-40 -95.66 112.9 24.52 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.271 -0.893 . . . . 0.0 109.809 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.37 -14.9 58.66 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.29 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.6 t -133.72 132.91 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.608 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.6 OUTLIER -143.52 172.22 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.184 -0.948 . . . . 0.0 110.285 -179.58 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 142' ' ' ARG . . . . . 0.498 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.6 OUTLIER -140.79 133.22 28.42 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.57 -0.706 . . . . 0.0 109.111 179.978 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ALA . . . . . 0.688 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.48 110.48 45.18 Favored Pre-proline 0 C--N 1.305 -1.339 0 O-C-N 121.135 -0.978 . . . . 0.0 109.625 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.503 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.3 Cg_endo -76.49 110.96 3.16 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 C-N-CA 122.293 1.995 . . . . 0.0 111.089 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.531 ' HB ' ' O ' ' A' ' 73' ' ' ALA . 2.3 mm -97.45 135.3 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 178.523 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' HIS . . . . . 0.513 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 8.8 m80 -102.24 158.55 16.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.438 -1.414 . . . . 0.0 111.335 -178.102 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.877 ' CE1' HG22 ' A' ' 101' ' ' VAL . 11.1 m-85 -159.1 160.2 35.42 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.327 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.537 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 106.71 48.11 0.99 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.744 ' C ' HG11 ' A' ' 64' ' ' VAL . 17.4 m-85 -125.35 159.35 32.01 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.435 -1.038 . . . . 0.0 109.166 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.499 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -64.83 -27.24 68.74 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.469 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.4 -19.42 63.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.367 -0.833 . . . . 0.0 109.199 179.522 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.494 ' OD1' ' N ' ' A' ' 152' ' ' ASN . 0.3 OUTLIER -107.96 10.17 28.45 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.42 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.538 HG23 HG13 ' A' ' 64' ' ' VAL . 2.2 t -84.65 163.98 2.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 121.437 -0.789 . . . . 0.0 109.686 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' GLY . . . . . 0.477 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 49.88 31.57 17.23 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.441 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 2.2 t-20 -160.14 144.85 14.72 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.149 -1.207 . . . . 0.0 110.113 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 156' ' ' THR . . . . . 0.767 HG23 ' O ' ' A' ' 59' ' ' VAL . 52.6 m -92.55 128.83 38.55 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.733 HG21 ' CG2' ' A' ' 101' ' ' VAL . 1.2 mt -107.7 118.75 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.853 -1.154 . . . . 0.0 109.759 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.618 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 3.4 m-85 -102.96 133.14 48.56 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 178.73 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.86 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -124.55 142.86 40.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.308 -178.694 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 160' ' ' ASP . . . . . 0.678 ' CB ' HG12 ' A' ' 56' ' ' VAL . 19.4 t70 -174.23 136.38 0.49 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.418 -0.801 . . . . 0.0 109.064 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 161' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 124.32 -7.76 8.52 Favored Glycine 0 N--CA 1.486 1.988 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.537 179.516 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.734 ' HB2' HD12 ' A' ' 90' ' ' ILE . 3.7 tp -59.9 103.97 0.26 Allowed 'General case' 0 N--CA 1.487 1.406 0 O-C-N 120.741 -1.446 . . . . 0.0 108.901 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -136.08 145.65 46.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.514 -0.741 . . . . 0.0 109.86 -179.226 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.629 HD13 HG11 ' A' ' 78' ' ' VAL . 8.4 mt -128.69 109.07 18.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.392 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.992 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.119 -0.988 . . . . 0.0 109.637 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.857 HG23 ' HB2' ' A' ' 165' ' ' ALA . 3.9 p . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.573 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -69.89 -58.85 3.38 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -0.893 . . . . 0.0 109.569 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.614 ' HA ' HG22 ' A' ' 78' ' ' VAL . 7.7 t30 -77.46 134.49 38.35 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.145 -0.972 . . . . 0.0 109.558 -179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.513 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 62.3 mt -111.72 138.86 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.262 -0.899 . . . . 0.0 109.536 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.58 ' ND2' ' HA ' ' A' ' 10' ' ' PHE . 1.5 t30 76.17 26.48 0.96 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.309 -0.869 . . . . 0.0 109.83 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.41 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -57.27 -34.93 68.64 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 179.284 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.52 ' HA3' ' OD1' ' A' ' 160' ' ' ASP . . . -119.76 34.44 4.22 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 108.85 -1.7 . . . . 0.0 108.85 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.697 ' HD2' HG11 ' A' ' 25' ' ' VAL . 8.4 m-85 43.84 53.76 6.02 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.375 -1.074 . . . . 0.0 109.358 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.422 ' HA ' ' HD3' ' A' ' 55' ' ' LYS . 31.7 mm-40 -83.96 -28.56 27.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.471 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.9 t -86.67 -41.98 13.77 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -0.879 . . . . 0.0 109.541 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.966 HG21 HG22 ' A' ' 25' ' ' VAL . 90.8 m -71.97 127.73 90.22 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.9 Cg_endo -77.63 141.13 19.41 Favored 'Trans proline' 0 C--N 1.312 -1.383 0 C-N-CA 122.481 2.121 . . . . 0.0 110.568 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.468 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -41.7 164.35 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.742 -0.599 . . . . 0.0 109.582 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.66 133.7 3.32 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 108.931 -1.668 . . . . 0.0 108.931 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.466 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.89 140.2 15.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.277 -1.131 . . . . 0.0 109.207 -179.637 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.768 HG13 ' HA3' ' A' ' 24' ' ' GLY . 62.1 t -86.61 142.4 13.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 CA-C-O 121.638 0.732 . . . . 0.0 110.439 -179.416 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.35 -28.81 12.76 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -131.38 86.73 2.38 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 1.101 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -45.33 -29.85 1.14 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.268 -0.895 . . . . 0.0 110.006 -178.953 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.101 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -60.22 -49.0 79.34 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.494 -0.754 . . . . 0.0 110.232 -179.53 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -133.67 48.77 2.33 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.961 -1.087 . . . . 0.0 109.732 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.768 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -97.44 -12.37 48.42 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.966 HG22 HG21 ' A' ' 13' ' ' THR . 90.8 t -141.24 133.95 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.186 -1.185 . . . . 0.0 109.636 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.472 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 17.7 tt0 -78.36 126.69 31.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.384 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.549 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 101.76 -16.17 56.37 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' TRP . . . . . 1.015 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.2 OUTLIER -137.6 120.24 16.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -1.117 . . . . 0.0 108.426 179.164 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.529 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -121.94 110.66 16.12 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.32 -0.863 . . . . 0.0 109.209 179.935 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.837 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -91.7 173.6 7.79 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.286 -0.884 . . . . 0.0 109.339 -179.73 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.457 ' HA ' HD21 ' A' ' 21' ' ' LEU . 77.7 m-20 -160.62 123.45 3.31 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.205 -0.934 . . . . 0.0 110.366 -179.675 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.981 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -109.36 131.32 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.291 -0.88 . . . . 0.0 109.286 178.861 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.79 -172.54 22.76 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -56.67 -31.65 64.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.334 -1.098 . . . . 0.0 109.559 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.48 ' HB2' ' HA ' ' A' ' 70' ' ' ASP . 0.7 OUTLIER -45.98 -42.42 13.05 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.196 -0.94 . . . . 0.0 109.279 -179.869 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.981 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -60.77 89.84 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 121.188 -0.945 . . . . 0.0 109.529 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 94.7 m -74.05 -28.13 61.25 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.854 0.835 . . . . 0.0 108.789 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.649 ' O ' HG13 ' A' ' 36' ' ' VAL . 8.2 t30 -114.01 144.48 31.66 Favored Pre-proline 0 C--N 1.297 -1.681 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.405 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.2 Cg_endo -75.83 111.07 3.21 Favored 'Trans proline' 0 C--N 1.307 -1.627 0 C-N-CA 122.443 2.095 . . . . 0.0 111.011 -179.374 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.538 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 36.2 Cg_endo -78.97 174.41 12.22 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.558 2.172 . . . . 0.0 109.607 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.549 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 73.8 t -116.9 120.5 65.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.998 -1.064 . . . . 0.0 110.659 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.752 ' HZ ' HG23 ' A' ' 71' ' ' ILE . 60.6 m-85 -109.04 112.55 24.79 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 178.044 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.466 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 28.7 tt0 -150.59 146.96 26.87 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.11 -0.994 . . . . 0.0 109.904 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.7 t -95.49 148.61 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.392 -0.817 . . . . 0.0 109.232 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.867 HD21 ' CG2' ' A' ' 47' ' ' THR . 0.4 OUTLIER -132.64 147.23 52.33 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.175 -0.953 . . . . 0.0 108.895 -179.79 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.577 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 16.9 mt-10 -117.06 114.09 23.26 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.53 -0.731 . . . . 0.0 109.63 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.867 ' CG2' HD21 ' A' ' 45' ' ' LEU . 12.9 p -139.8 174.14 10.82 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.473 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.521 ' HA ' ' ND2' ' A' ' 54' ' ' ASN . 16.9 m -100.06 21.67 12.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.462 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.413 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.0 OUTLIER -111.82 -15.33 13.4 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.182 -0.949 . . . . 0.0 109.534 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.437 ' HB3' ' O ' ' A' ' 53' ' ' GLY . . . -44.17 147.19 0.99 Allowed Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.549 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.06 -40.54 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.548 2.165 . . . . 0.0 110.389 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.4 ' O ' ' OE2' ' A' ' 11' ' ' GLU . 2.5 tp10 -117.87 79.71 1.4 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 109.432 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.449 ' O ' ' OD1' ' A' ' 54' ' ' ASN . . . 102.81 -139.41 14.42 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.521 ' ND2' ' HA ' ' A' ' 48' ' ' SER . 3.0 m120 -142.28 35.35 1.5 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -1.111 . . . . 0.0 109.463 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.537 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 8.9 mttt -144.64 138.3 27.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.279 -0.888 . . . . 0.0 109.555 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.598 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.8 m -150.32 174.39 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.344 -0.847 . . . . 0.0 109.281 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.791 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -108.13 103.51 12.73 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.072 -1.018 . . . . 0.0 108.893 179.45 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.719 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.59 119.17 23.45 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.826 ' O ' HG23 ' A' ' 156' ' ' THR . 41.3 t -114.66 144.83 21.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.092 -1.005 . . . . 0.0 109.075 -179.212 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.631 HG22 ' OD1' ' A' ' 62' ' ' ASN . 24.0 m -106.4 91.52 3.74 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 179.281 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.647 HG21 ' CD1' ' A' ' 157' ' ' ILE . 53.8 t -90.86 113.01 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.385 -0.822 . . . . 0.0 109.11 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.631 ' OD1' HG22 ' A' ' 60' ' ' THR . 3.1 p-10 -153.46 58.02 0.76 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.312 -0.868 . . . . 0.0 109.831 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 162.09 85.09 0.05 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.569 HG11 ' C ' ' A' ' 149' ' ' TYR . 1.3 m -79.89 175.82 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.211 -1.17 . . . . 0.0 109.46 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -124.45 -149.91 7.76 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -95.15 -4.54 45.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.302 -1.116 . . . . 0.0 109.609 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.582 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 0.8 OUTLIER -114.78 147.89 39.2 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 109.283 179.991 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -79.02 14.25 1.78 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.717 2.278 . . . . 0.0 111.008 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.582 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.3 p90 -135.34 52.53 2.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.99 -1.069 . . . . 0.0 109.921 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.511 ' C ' HG23 ' A' ' 36' ' ' VAL . 0.4 OUTLIER -75.22 -66.45 0.76 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.046 -1.034 . . . . 0.0 108.966 179.552 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.752 HG23 ' HZ ' ' A' ' 42' ' ' PHE . 2.5 mt -101.23 127.79 54.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.305 -0.872 . . . . 0.0 108.659 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.465 ' O ' ' HB3' ' A' ' 30' ' ' LEU . 7.2 mt-10 -126.58 137.71 53.37 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.05 -1.031 . . . . 0.0 110.363 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 1.015 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -118.31 123.32 45.07 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 106.998 -1.482 . . . . 0.0 106.998 178.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.541 HG22 ' N ' ' A' ' 75' ' ' ALA . 18.0 m -128.61 163.31 25.31 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 120.441 -1.412 . . . . 0.0 110.459 -178.578 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.541 ' N ' HG22 ' A' ' 74' ' ' THR . . . -129.7 138.32 51.09 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.472 -0.768 . . . . 0.0 109.238 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.546 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 2.2 p90 177.99 160.48 0.59 Allowed Pre-proline 0 N--CA 1.492 1.647 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.526 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -81.65 166.75 71.9 Favored 'Cis proline' 0 C--N 1.31 -1.476 0 C-N-CA 123.686 -1.381 . . . . 0.0 110.799 -0.568 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.866 HG11 HD12 ' A' ' 164' ' ' ILE . 76.5 t -124.69 156.34 32.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.219 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ASN . . . . . 0.518 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 3.6 m120 -123.77 123.05 39.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.915 -1.116 . . . . 0.0 110.417 -179.301 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.685 HG12 ' CD2' ' A' ' 86' ' ' TYR . 3.0 m -128.19 -173.88 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.115 179.244 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.832 ' O ' HG21 ' A' ' 134' ' ' VAL . 1.7 mtt180 -126.96 145.16 52.86 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.246 -0.908 . . . . 0.0 109.438 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.41 120.78 5.38 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.437 2.091 . . . . 0.0 110.493 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.35 -27.43 17.18 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.6 t -85.94 149.72 4.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.271 -1.135 . . . . 0.0 109.439 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 20.8 m -97.74 122.4 40.78 Favored 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' TYR . . . . . 0.685 ' CD2' HG12 ' A' ' 80' ' ' VAL . 3.6 m-85 -99.77 170.28 8.66 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.922 . . . . 0.0 109.619 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.477 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 6.5 m -118.23 154.09 32.82 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.404 -0.81 . . . . 0.0 109.431 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.627 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.8 t80 -128.11 121.23 29.1 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.256 -0.903 . . . . 0.0 109.266 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.468 ' O ' ' O ' ' A' ' 161' ' ' GLY . 19.6 m -135.54 145.97 47.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.191 -0.943 . . . . 0.0 109.317 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.688 HD13 ' HD2' ' A' ' 103' ' ' PHE . 16.7 tt -150.74 163.68 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 120.765 -1.209 . . . . 0.0 109.531 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.596 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 19.7 m95 -133.92 124.73 26.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.884 -1.135 . . . . 0.0 109.057 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -117.34 150.88 38.1 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.255 -0.903 . . . . 0.0 109.491 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.581 ' HD2' ' CE2' ' A' ' 125' ' ' TRP . 1.0 OUTLIER -164.27 121.83 1.72 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.187 -0.946 . . . . 0.0 108.971 179.981 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.69 167.49 9.73 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -0.922 . . . . 0.0 110.053 -179.491 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -58.52 -48.77 79.74 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.265 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.558 ' C ' HG22 ' A' ' 123' ' ' THR . 2.9 mt-30 -118.28 150.97 38.58 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.299 -0.876 . . . . 0.0 109.163 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.724 ' N ' HG22 ' A' ' 123' ' ' THR . 0.6 OUTLIER -66.34 145.13 56.06 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.255 -0.903 . . . . 0.0 109.701 -179.778 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 114.07 35.21 1.53 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.47 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -120.2 139.54 52.49 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.269 -1.136 . . . . 0.0 109.246 179.698 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.468 ' HB ' ' OD1' ' A' ' 152' ' ' ASN . 54.2 t -117.94 157.86 19.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 121.325 -0.859 . . . . 0.0 110.759 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.692 HG22 ' CE1' ' A' ' 147' ' ' PHE . 62.1 t -154.94 162.25 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 179.47 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.525 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 4.8 m -116.78 129.49 56.13 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.085 -1.009 . . . . 0.0 109.392 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.688 ' HD2' HD13 ' A' ' 90' ' ' ILE . 0.2 OUTLIER -123.84 103.92 8.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.145 -0.972 . . . . 0.0 109.734 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.586 HG22 ' HA ' ' A' ' 115' ' ' ARG . 36.1 p -135.35 169.63 17.18 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.972 -1.08 . . . . 0.0 110.233 179.742 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.968 HG23 ' N ' ' A' ' 114' ' ' GLY . 0.0 OUTLIER -131.99 127.66 58.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-O 121.71 0.767 . . . . 0.0 110.41 179.121 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -122.01 165.78 14.8 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.119 -1.992 . . . . 0.0 108.119 178.827 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.595 ' OD1' ' CE1' ' A' ' 113' ' ' TYR . 0.0 OUTLIER -125.97 -170.82 2.26 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.922 -1.34 . . . . 0.0 109.272 -179.714 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 13.0 mt-30 -81.22 -19.86 42.31 Favored 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 118.791 -1.164 . . . . 0.0 109.588 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.505 ' HB2' ' HG2' ' A' ' 111' ' ' GLN . 2.4 m -82.09 8.78 9.89 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.72 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.462 ' HB2' ' O ' ' A' ' 109' ' ' SER . 16.8 m-30 65.3 24.03 12.14 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.313 -0.867 . . . . 0.0 108.674 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.525 ' CA ' ' OE1' ' A' ' 111' ' ' GLN . 0.7 OUTLIER -86.54 161.8 18.37 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.434 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 112' ' ' GLU . . . . . 0.479 ' OE1' ' HG3' ' A' ' 115' ' ' ARG . 0.5 OUTLIER -107.68 101.35 10.67 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.336 -0.852 . . . . 0.0 109.891 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.952 ' OH ' HG13 ' A' ' 134' ' ' VAL . 2.0 m-30 -70.83 -64.43 0.9 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.586 -0.696 . . . . 0.0 109.72 178.607 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.968 ' N ' HG23 ' A' ' 105' ' ' VAL . . . -115.44 166.38 12.22 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 -179.384 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.611 ' NE ' ' CE1' ' A' ' 117' ' ' HIS . 0.0 OUTLIER -157.81 74.61 0.74 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.242 -1.152 . . . . 0.0 110.691 -179.706 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.953 HD21 ' CD2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -131.45 86.47 2.36 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.985 -1.072 . . . . 0.0 108.811 178.495 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 117' ' ' HIS . . . . . 0.611 ' CE1' ' NE ' ' A' ' 115' ' ' ARG . 29.8 p-80 -121.53 163.32 19.04 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -0.862 . . . . 0.0 110.009 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 3.0 tt0 76.89 36.31 0.34 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.42 -0.8 . . . . 0.0 109.373 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 17.3 mm-40 -100.3 135.81 41.15 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.299 -0.876 . . . . 0.0 109.542 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.625 ' O ' HD13 ' A' ' 121' ' ' ILE . 20.5 mt-30 -71.29 156.03 39.99 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.388 -0.82 . . . . 0.0 108.944 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.625 HD13 ' O ' ' A' ' 120' ' ' GLN . 6.1 mm -134.37 133.42 55.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.092 -1.005 . . . . 0.0 110.132 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.87 -179.42 6.81 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.514 -0.741 . . . . 0.0 109.971 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.724 HG22 ' N ' ' A' ' 97' ' ' ASP . 37.9 p -73.96 -2.67 25.02 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.771 -0.772 . . . . 0.0 109.243 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.524 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 0.9 OUTLIER -110.02 175.42 5.45 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.334 -0.854 . . . . 0.0 109.177 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 125' ' ' TRP . . . . . 0.581 ' CE2' ' HD2' ' A' ' 93' ' ' ARG . 95.0 m95 -81.77 122.35 27.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.83 121.02 46.29 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.252 -0.905 . . . . 0.0 108.833 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.596 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.6 Cg_endo -80.17 101.69 1.37 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.412 2.074 . . . . 0.0 111.177 -179.477 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -103.86 132.25 50.3 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 178.553 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.456 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -144.15 176.29 9.43 Favored 'General case' 0 C--N 1.295 -1.776 0 O-C-N 120.875 -1.141 . . . . 0.0 110.723 -179.241 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.953 ' CD2' HD21 ' A' ' 116' ' ' LEU . 25.3 p90 -175.11 152.56 1.47 Allowed 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 114.978 -1.01 . . . . 0.0 109.34 179.651 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -101.96 142.49 33.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.257 -0.902 . . . . 0.0 109.68 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.637 ' CD1' ' CE1' ' A' ' 130' ' ' PHE . 8.1 p90 -153.65 137.54 16.25 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.34 -0.85 . . . . 0.0 109.371 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.445 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.8 OUTLIER -98.72 146.58 25.73 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.256 -0.902 . . . . 0.0 108.836 179.923 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.952 HG13 ' OH ' ' A' ' 113' ' ' TYR . 4.1 t -41.55 108.96 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.443 -0.786 . . . . 0.0 109.171 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -48.17 -35.33 11.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.332 -0.855 . . . . 0.0 109.007 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -138.49 -90.79 0.21 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.452 -0.78 . . . . 0.0 109.293 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -158.35 56.05 0.45 Allowed 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.524 -0.735 . . . . 0.0 109.1 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.604 ' O ' HG23 ' A' ' 80' ' ' VAL . 31.8 mm-40 -92.58 111.06 22.51 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.2 p -79.31 -18.32 52.83 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 40.2 t -131.66 135.79 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.586 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -143.6 171.62 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.926 -1.109 . . . . 0.0 110.751 -179.177 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 142' ' ' ARG . . . . . 0.512 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.7 OUTLIER -133.02 132.22 41.6 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.682 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ALA . . . . . 0.625 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -99.36 107.22 43.81 Favored Pre-proline 0 C--N 1.304 -1.374 0 O-C-N 120.976 -1.077 . . . . 0.0 109.382 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.534 ' HD2' ' HA ' ' A' ' 105' ' ' VAL . 34.9 Cg_endo -77.31 110.94 3.09 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.27 1.98 . . . . 0.0 111.341 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.738 HD12 ' CZ2' ' A' ' 28' ' ' TRP . 1.6 mt -99.57 138.91 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' HIS . . . . . 0.581 ' O ' ' CD2' ' A' ' 147' ' ' PHE . 4.8 m80 -103.81 159.11 15.91 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.53 -1.356 . . . . 0.0 111.732 -177.289 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.692 ' CE1' HG22 ' A' ' 101' ' ' VAL . 17.1 m-85 -161.24 160.0 29.4 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.563 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 105.77 52.22 0.81 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 -179.692 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.569 ' C ' HG11 ' A' ' 64' ' ' VAL . 22.8 m-85 -129.0 158.88 37.63 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.531 -0.982 . . . . 0.0 109.165 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.33 -26.51 67.33 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.466 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -71.64 -15.81 62.25 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.534 -0.729 . . . . 0.0 109.367 179.555 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.503 ' OD1' ' N ' ' A' ' 152' ' ' ASN . 0.2 OUTLIER -112.05 8.8 20.24 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.444 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.3 t -83.87 164.44 2.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 O-C-N 121.423 -0.798 . . . . 0.0 109.747 -179.303 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' GLY . . . . . 0.492 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 55.89 26.29 47.45 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.911 -1.275 . . . . 0.0 109.911 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.464 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.7 t-20 -160.38 143.01 13.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.98 -1.306 . . . . 0.0 110.202 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 156' ' ' THR . . . . . 0.826 HG23 ' O ' ' A' ' 59' ' ' VAL . 46.1 m -89.4 121.48 31.69 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 178.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.647 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.1 mt -98.03 117.7 43.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 120.882 -1.136 . . . . 0.0 110.097 -178.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.719 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.4 m-85 -96.9 130.83 44.14 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.597 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.631 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.1 mt -121.03 142.41 37.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 120.726 -1.234 . . . . 0.0 110.154 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' ASP . . . . . 0.598 ' CB ' HG12 ' A' ' 56' ' ' VAL . 9.0 t0 -174.14 136.24 0.5 Allowed 'General case' 0 N--CA 1.486 1.366 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' GLY . . . . . 0.529 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 124.82 -7.73 8.24 Favored Glycine 0 N--CA 1.486 1.985 0 C-N-CA 119.329 -1.415 . . . . 0.0 110.633 179.403 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.619 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 3.2 tp -60.29 100.0 0.09 Allowed 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.58 -1.541 . . . . 0.0 108.895 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 163' ' ' ALA . . . . . 0.481 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -136.7 145.7 45.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.445 -0.785 . . . . 0.0 109.662 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.866 HD12 HG11 ' A' ' 78' ' ' VAL . 25.5 mt -128.58 108.8 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.239 -0.913 . . . . 0.0 109.431 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.857 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.177 -0.952 . . . . 0.0 109.576 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.911 HG23 ' HB2' ' A' ' 165' ' ' ALA . 4.4 p . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.587 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -75.86 -39.63 56.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.192 -0.943 . . . . 0.0 109.714 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.527 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 5.7 t-20 -92.1 129.45 38.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.706 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.468 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 64.7 mt -113.55 129.96 68.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.243 -0.911 . . . . 0.0 109.346 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.545 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.7 OUTLIER 69.93 28.0 4.31 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.206 -0.934 . . . . 0.0 109.597 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -44.26 -26.95 1.04 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 160' ' ' ASP . . . -142.14 52.03 0.67 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.717 ' CD2' HG11 ' A' ' 25' ' ' VAL . 2.8 m-85 45.27 56.38 5.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.261 -1.14 . . . . 0.0 109.237 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -84.52 -29.64 25.77 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.139 -0.976 . . . . 0.0 110.249 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.6 p -95.0 -47.49 6.38 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.011 -1.056 . . . . 0.0 110.129 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.938 ' OG1' HG13 ' A' ' 25' ' ' VAL . 3.1 m -59.84 135.76 90.04 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.166 -0.959 . . . . 0.0 109.538 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.466 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.9 Cg_endo -77.36 146.14 24.53 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.561 2.174 . . . . 0.0 110.71 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.611 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -44.62 170.76 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 121.299 0.571 . . . . 0.0 109.798 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 140.33 130.56 2.66 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.097 -1.601 . . . . 0.0 109.097 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.568 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.07 139.21 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.224 -1.162 . . . . 0.0 109.166 -179.653 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.566 HG13 ' HA3' ' A' ' 24' ' ' GLY . 60.2 t -90.66 142.95 12.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-O 121.625 0.726 . . . . 0.0 110.442 -179.468 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.5 t -100.7 -29.44 12.29 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.071 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 19.4 m-20 -131.48 93.92 3.44 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 1.075 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -48.86 -29.32 4.53 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.264 -0.897 . . . . 0.0 110.135 -178.626 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.075 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.44 -57.04 14.72 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.495 -0.753 . . . . 0.0 110.119 -179.364 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -119.99 41.82 3.09 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.155 -0.965 . . . . 0.0 109.45 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.566 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -77.07 -39.87 26.36 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.952 -1.259 . . . . 0.0 109.952 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.938 HG13 ' OG1' ' A' ' 13' ' ' THR . 46.3 t -141.74 133.72 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.102 -1.234 . . . . 0.0 109.904 -179.62 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 20.6 tp10 -68.68 141.58 55.29 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -0.857 . . . . 0.0 109.224 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.545 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 106.58 -32.14 7.58 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' TRP . . . . . 0.929 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.1 OUTLIER -135.04 121.0 19.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.152 -1.205 . . . . 0.0 109.109 179.492 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -112.84 109.71 19.34 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.831 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -89.93 173.66 8.11 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.218 -0.926 . . . . 0.0 109.665 -179.139 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.497 ' O ' ' HB3' ' A' ' 72' ' ' GLU . 7.1 m120 -160.93 128.02 4.16 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.181 -0.949 . . . . 0.0 110.807 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.058 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -117.16 130.05 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.209 -0.932 . . . . 0.0 108.993 178.198 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.29 171.7 16.18 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.499 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.4 ' O ' ' C ' ' A' ' 35' ' ' SER . 0.7 OUTLIER -45.6 -29.89 1.34 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.377 -1.073 . . . . 0.0 109.419 179.951 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.505 ' HB2' ' CB ' ' A' ' 70' ' ' ASP . 0.4 OUTLIER -45.88 -53.41 9.85 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.369 -0.832 . . . . 0.0 109.116 179.943 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 1.058 HG21 HG12 ' A' ' 32' ' ' VAL . 34.7 t -47.63 102.57 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 O-C-N 121.251 -0.905 . . . . 0.0 110.084 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 40.8 m -81.63 -26.19 35.02 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 121.894 0.854 . . . . 0.0 108.764 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.682 ' O ' HG12 ' A' ' 36' ' ' VAL . 2.1 m-80 -111.67 147.75 37.43 Favored Pre-proline 0 C--N 1.296 -1.751 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.724 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -77.01 110.85 3.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.485 2.123 . . . . 0.0 110.654 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 38' ' ' ASN . 36.4 Cg_endo -80.05 160.98 23.74 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.475 2.117 . . . . 0.0 109.68 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.537 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 54.8 t -109.95 119.78 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.004 -1.06 . . . . 0.0 110.291 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.455 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 76.7 m-85 -105.9 112.16 25.1 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.369 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.568 ' HG3' HG23 ' A' ' 17' ' ' VAL . 1.3 tm-20 -155.01 147.06 23.64 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.005 -1.059 . . . . 0.0 109.872 -179.437 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.474 ' N ' ' HG2' ' A' ' 43' ' ' GLU . 53.1 t -91.89 148.54 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.493 -0.754 . . . . 0.0 109.193 179.574 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.675 HD21 ' CG2' ' A' ' 47' ' ' THR . 0.4 OUTLIER -131.97 146.9 52.37 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.207 -0.933 . . . . 0.0 108.888 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 0.611 ' HG3' ' HB2' ' A' ' 15' ' ' ALA . 17.4 mt-10 -117.91 115.04 24.13 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.676 -0.64 . . . . 0.0 109.508 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.675 ' CG2' HD21 ' A' ' 45' ' ' LEU . 2.2 p -142.11 172.25 12.94 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.488 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.95 11.7 24.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.248 -0.908 . . . . 0.0 109.484 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -103.33 -15.81 15.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.158 -0.964 . . . . 0.0 109.434 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.64 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -50.33 145.68 9.91 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.234 -0.916 . . . . 0.0 109.403 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.569 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 35.9 Cg_endo -78.38 -41.91 0.25 Allowed 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.577 2.185 . . . . 0.0 110.375 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -110.91 108.34 18.09 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.255 -0.903 . . . . 0.0 109.298 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.16 -117.16 6.64 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.64 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 50.0 p30 -160.06 29.87 0.18 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -1.173 . . . . 0.0 109.524 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.544 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 60.5 mttt -136.89 138.68 40.97 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.215 -0.928 . . . . 0.0 109.678 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.637 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.6 m -150.08 174.41 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.299 -0.876 . . . . 0.0 109.203 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.72 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -103.33 102.15 12.09 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.15 -0.969 . . . . 0.0 108.98 179.643 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.65 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.47 119.91 24.34 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.853 ' O ' HG23 ' A' ' 156' ' ' THR . 40.5 t -113.18 144.51 20.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.106 -0.997 . . . . 0.0 109.024 -179.172 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.537 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 19.9 m -110.7 90.59 3.37 Favored 'General case' 0 C--N 1.283 -2.284 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.519 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 43.9 t -86.48 127.78 40.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.273 -0.892 . . . . 0.0 109.211 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.417 HD22 HG22 ' A' ' 60' ' ' THR . 4.8 p30 -151.07 57.0 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.887 . . . . 0.0 109.844 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.433 ' HA3' ' CG ' ' A' ' 38' ' ' ASN . . . 147.66 103.44 0.33 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.817 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.3 m -79.94 -175.82 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.236 -1.155 . . . . 0.0 109.51 179.787 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -126.61 -178.5 15.34 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.666 -1.373 . . . . 0.0 109.666 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -68.73 -20.27 64.38 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.241 -1.152 . . . . 0.0 109.431 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.592 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.3 m-20 -106.98 152.54 41.02 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.28 -0.887 . . . . 0.0 109.492 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.41 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.2 Cg_endo -78.58 12.64 2.09 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 122.646 2.23 . . . . 0.0 110.973 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.592 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.2 p90 -135.57 54.58 1.91 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.991 -1.068 . . . . 0.0 109.631 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.522 ' HB3' ' N ' ' A' ' 36' ' ' VAL . 0.5 OUTLIER -83.37 -48.08 10.77 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.216 -0.927 . . . . 0.0 109.191 179.872 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.58 HD13 HG22 ' A' ' 36' ' ' VAL . 3.7 mm -98.72 149.09 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.254 -0.904 . . . . 0.0 108.776 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.534 ' HA ' ' HB3' ' A' ' 146' ' ' HIS . 58.0 tt0 -137.71 160.27 39.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.872 -1.143 . . . . 0.0 110.93 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.929 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -162.37 106.48 1.16 Allowed 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 179.462 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.591 HG22 ' N ' ' A' ' 75' ' ' ALA . 49.9 m -120.63 166.33 13.81 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.246 -1.534 . . . . 0.0 110.953 -178.004 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.591 ' N ' HG22 ' A' ' 74' ' ' THR . . . -124.7 137.91 54.32 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.476 -0.765 . . . . 0.0 108.96 179.07 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.547 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER 178.17 162.52 0.62 Allowed Pre-proline 0 N--CA 1.492 1.651 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 -179.728 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.532 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.82 167.14 73.74 Favored 'Cis proline' 0 C--N 1.31 -1.472 0 C-N-CA 123.641 -1.4 . . . . 0.0 110.778 -0.357 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.817 HG11 HD12 ' A' ' 164' ' ' ILE . 76.7 t -126.27 151.5 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.303 -0.873 . . . . 0.0 108.961 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ASN . . . . . 0.476 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 47.3 m-20 -114.75 122.79 47.48 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.045 -1.034 . . . . 0.0 109.812 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 138' ' ' GLU . 3.0 m -129.57 -173.82 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.21 -0.932 . . . . 0.0 109.458 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.625 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -138.74 145.87 47.92 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.364 -0.835 . . . . 0.0 109.306 179.896 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.489 ' HD2' ' HG2' ' A' ' 81' ' ' ARG . 35.3 Cg_endo -77.33 110.28 2.96 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.465 2.11 . . . . 0.0 110.47 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 113.91 -34.99 4.71 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.551 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -85.0 149.71 4.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.241 -1.152 . . . . 0.0 109.39 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.469 ' HA ' ' OG1' ' A' ' 133' ' ' THR . 11.6 t -95.3 145.31 25.18 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 109.354 -0.609 . . . . 0.0 109.354 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' TYR . . . . . 0.564 ' HD2' HG22 ' A' ' 164' ' ' ILE . 8.6 m-85 -123.29 159.07 29.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.297 -0.877 . . . . 0.0 109.627 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.467 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 59.1 m -118.06 148.46 42.25 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.32 -0.862 . . . . 0.0 109.282 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.615 ' N ' ' CD1' ' A' ' 88' ' ' TYR . 0.2 OUTLIER -127.04 104.75 8.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.124 -0.985 . . . . 0.0 109.631 -179.927 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.476 ' O ' ' O ' ' A' ' 161' ' ' GLY . 54.7 m -112.8 148.08 35.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.365 -0.834 . . . . 0.0 108.955 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.676 HD12 ' HB2' ' A' ' 162' ' ' LEU . 19.4 tt -150.08 163.51 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.76 -1.212 . . . . 0.0 109.817 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.574 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 70.3 m95 -125.77 129.55 49.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.156 -0.965 . . . . 0.0 109.281 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.99 145.96 47.62 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.283 -0.886 . . . . 0.0 109.513 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.584 ' HD2' ' CE2' ' A' ' 125' ' ' TRP . 16.4 ttt-85 -157.91 118.23 3.39 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.267 -0.896 . . . . 0.0 109.179 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.3 166.8 10.16 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.357 -0.84 . . . . 0.0 109.839 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -64.18 -52.04 60.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.373 -0.829 . . . . 0.0 109.615 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.428 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -112.03 140.93 46.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 109.52 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.877 ' CG ' HG23 ' A' ' 123' ' ' THR . 1.1 m-20 -60.82 149.61 35.39 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.249 -0.907 . . . . 0.0 109.476 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 106.98 33.82 3.14 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.969 -1.253 . . . . 0.0 109.969 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.546 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -114.09 139.73 49.06 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.066 -1.255 . . . . 0.0 109.165 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.433 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 73.8 t -120.65 149.43 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 110.421 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.587 ' HB ' ' CE1' ' A' ' 103' ' ' PHE . 48.4 t -144.94 166.75 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.471 -0.768 . . . . 0.0 109.029 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.615 ' O ' HG23 ' A' ' 145' ' ' ILE . 5.6 m -124.68 123.47 40.1 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.06 -1.025 . . . . 0.0 109.612 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.63 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.4 m-85 -121.94 103.9 9.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -0.875 . . . . 0.0 109.902 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.523 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 16.5 p -121.38 174.34 6.8 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.098 -1.001 . . . . 0.0 109.88 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.646 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -131.72 154.0 39.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-O 121.492 0.663 . . . . 0.0 110.282 -179.688 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -174.92 158.11 25.7 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.53 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.5 p30 -97.91 -169.32 1.8 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.099 -1.236 . . . . 0.0 109.37 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' GLN . . . . . 0.53 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 4.5 mp0 -73.11 11.66 0.68 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.1 -1.0 . . . . 0.0 111.105 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.445 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 1.4 m -111.02 13.91 22.0 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 120.595 -1.316 . . . . 0.0 109.139 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.512 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 4.0 m-30 71.47 3.96 4.87 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.484 -0.76 . . . . 0.0 109.619 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.528 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 29.4 tt0 -78.0 162.39 26.79 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.236 -0.915 . . . . 0.0 108.564 179.335 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' GLU . . . . . 0.482 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 7.1 tt0 -138.22 143.47 40.17 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.994 -1.066 . . . . 0.0 109.89 -179.443 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.569 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 19.7 m-85 -102.4 -70.11 0.76 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.163 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.582 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -98.47 174.31 28.17 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.062 -1.615 . . . . 0.0 109.062 179.428 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.576 ' C ' HD23 ' A' ' 116' ' ' LEU . 0.0 OUTLIER -175.28 129.45 0.28 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.005 -1.291 . . . . 0.0 110.461 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.666 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -146.9 72.31 1.26 Allowed 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 179.145 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 117' ' ' HIS . . . . . 0.541 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 15.1 p80 -93.31 150.79 20.21 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.321 -0.862 . . . . 0.0 110.181 -179.164 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.541 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.7 tt0 80.0 47.63 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.653 -0.654 . . . . 0.0 109.458 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 12.7 mm100 -107.98 125.45 51.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.387 -0.821 . . . . 0.0 109.333 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.626 ' O ' HD13 ' A' ' 121' ' ' ILE . 25.1 mt-30 -66.95 153.58 43.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.451 -0.781 . . . . 0.0 109.066 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.626 HD13 ' O ' ' A' ' 120' ' ' GLN . 6.6 mm -135.37 134.48 52.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.195 -0.94 . . . . 0.0 109.961 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -86.06 -179.37 6.74 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.425 -0.797 . . . . 0.0 110.075 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.877 HG23 ' CG ' ' A' ' 97' ' ' ASP . 39.6 p -76.96 -3.94 41.45 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.961 -0.696 . . . . 0.0 109.337 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.429 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 1.3 mt-10 -106.27 -173.24 2.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.257 -0.902 . . . . 0.0 109.263 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' TRP . . . . . 0.584 ' CE2' ' HD2' ' A' ' 93' ' ' ARG . 98.2 m95 -91.01 118.04 30.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.571 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -106.86 121.24 45.54 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.176 -0.953 . . . . 0.0 108.953 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.574 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.5 Cg_endo -79.42 105.37 1.87 Allowed 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.311 2.007 . . . . 0.0 111.011 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -112.88 133.43 54.87 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -151.52 177.04 10.72 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 122.435 1.112 . . . . 0.0 110.724 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.666 ' CE1' HD21 ' A' ' 116' ' ' LEU . 3.6 p90 -161.48 -169.67 2.36 Favored 'General case' 0 C--N 1.292 -1.934 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.148 179.429 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' GLU . . . . . 0.567 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 68.9 mt-10 -138.6 144.1 39.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.006 -1.059 . . . . 0.0 109.982 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.582 ' CE2' ' HA2' ' A' ' 114' ' ' GLY . 1.0 OUTLIER -163.63 147.56 10.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.448 -0.783 . . . . 0.0 109.215 179.763 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.469 ' OG1' ' HA ' ' A' ' 85' ' ' THR . 0.5 OUTLIER -116.22 147.93 40.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.879 . . . . 0.0 109.71 -179.537 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.625 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.5 t -40.49 110.42 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.602 -0.686 . . . . 0.0 109.291 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 12.4 t -61.98 -53.34 57.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.274 -0.891 . . . . 0.0 109.295 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -101.77 -91.59 0.33 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.367 -0.833 . . . . 0.0 109.21 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -163.33 50.81 0.16 Allowed 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.469 -0.769 . . . . 0.0 109.087 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.484 ' O ' HG23 ' A' ' 80' ' ' VAL . 61.3 mm-40 -87.92 112.08 22.15 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.242 -0.911 . . . . 0.0 109.738 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.5 p -79.39 -14.95 58.61 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.214 -0.929 . . . . 0.0 108.584 179.356 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 25.8 t -134.29 128.67 52.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.318 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.47 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -139.52 171.83 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.174 -0.954 . . . . 0.0 110.147 -179.629 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 142' ' ' ARG . . . . . 0.511 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.9 ptm180 -141.75 132.82 26.16 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ALA . . . . . 0.662 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -93.4 109.42 40.33 Favored Pre-proline 0 N--CA 1.486 1.365 0 O-C-N 121.228 -0.92 . . . . 0.0 110.202 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.523 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.1 Cg_endo -76.47 110.14 3.0 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.141 1.894 . . . . 0.0 110.9 179.399 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.838 HD11 HD22 ' A' ' 162' ' ' LEU . 3.0 mt -116.66 108.21 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 179.035 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' HIS . . . . . 0.602 ' N ' ' ND1' ' A' ' 146' ' ' HIS . 0.1 OUTLIER -123.74 160.75 26.59 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.299 -1.501 . . . . 0.0 112.111 -177.142 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.774 ' CE2' HD11 ' A' ' 159' ' ' ILE . 0.1 OUTLIER -113.53 -168.37 1.33 Allowed 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.628 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 127.02 32.84 0.66 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.817 ' C ' HG11 ' A' ' 64' ' ' VAL . 28.6 m-85 -121.34 155.27 35.1 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.297 -1.119 . . . . 0.0 109.283 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.476 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -67.06 -26.27 66.66 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -179.829 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.465 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.78 -7.57 46.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.409 -0.807 . . . . 0.0 109.562 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.57 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 2.5 t30 -115.21 14.17 16.89 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.684 HG23 HG13 ' A' ' 64' ' ' VAL . 2.4 t -89.32 159.5 2.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.585 -0.697 . . . . 0.0 109.674 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.55 37.31 49.67 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.428 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 1.9 m-20 -160.31 136.28 8.49 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.074 -1.251 . . . . 0.0 110.175 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 156' ' ' THR . . . . . 0.853 HG23 ' O ' ' A' ' 59' ' ' VAL . 45.2 m -86.25 122.25 29.98 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 179.085 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.57 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.8 OUTLIER -102.93 117.93 49.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.881 -1.137 . . . . 0.0 110.34 -178.873 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.65 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 13.9 m-85 -96.57 144.59 26.49 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 178.569 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.774 HD11 ' CE2' ' A' ' 147' ' ' PHE . 1.3 mt -140.99 139.83 33.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.768 -1.207 . . . . 0.0 110.636 -178.813 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 160' ' ' ASP . . . . . 0.637 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.5 OUTLIER -174.18 135.58 0.46 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.159 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 161' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 128.61 -6.65 6.59 Favored Glycine 0 N--CA 1.486 1.974 0 C-N-CA 119.127 -1.511 . . . . 0.0 111.21 179.183 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.838 HD22 HD11 ' A' ' 145' ' ' ILE . 8.0 tp -59.73 97.78 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.39 -1.653 . . . . 0.0 108.784 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 163' ' ' ALA . . . . . 0.49 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -121.94 145.59 47.96 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.565 -0.709 . . . . 0.0 109.931 -179.211 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.817 HD12 HG11 ' A' ' 78' ' ' VAL . 52.4 mt -125.65 108.85 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.328 -0.858 . . . . 0.0 109.291 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.911 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.144 -0.972 . . . . 0.0 109.661 -179.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.565 HG22 ' H ' ' A' ' 4' ' ' ALA . 4.2 p . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.565 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -68.06 -55.13 13.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.128 -0.982 . . . . 0.0 109.453 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.504 ' HB2' HG12 ' A' ' 164' ' ' ILE . 0.4 OUTLIER -69.56 148.74 49.01 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 109.112 179.949 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.523 HG22 ' ND2' ' A' ' 7' ' ' ASN . 15.4 mm -112.03 148.58 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.383 -0.823 . . . . 0.0 109.207 179.707 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.523 ' ND2' HG22 ' A' ' 6' ' ' ILE . 42.6 m-80 45.02 38.77 3.26 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.254 -0.904 . . . . 0.0 109.649 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.519 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -56.9 -40.77 90.9 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 107.968 -2.053 . . . . 0.0 107.968 179.077 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.525 ' CA ' ' OD2' ' A' ' 160' ' ' ASP . . . -112.9 18.2 22.04 Favored Glycine 0 N--CA 1.488 2.103 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 178.823 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.826 ' CD2' HG21 ' A' ' 25' ' ' VAL . 61.4 m-85 65.66 46.61 2.36 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.478 -1.013 . . . . 0.0 109.683 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -84.66 -28.05 26.67 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.283 -0.885 . . . . 0.0 109.549 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.411 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 0.7 OUTLIER -88.29 -30.78 19.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.592 -179.726 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . 1.025 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.1 m -82.02 124.28 79.08 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.216 -0.928 . . . . 0.0 109.564 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.452 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.6 Cg_endo -78.03 138.21 16.19 Favored 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 122.412 2.075 . . . . 0.0 110.457 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -40.32 161.01 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 CA-C-O 121.233 0.539 . . . . 0.0 109.741 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 140.42 131.08 2.71 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.577 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.07 140.63 15.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.282 -1.129 . . . . 0.0 109.187 -179.689 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.478 HG23 ' HA ' ' A' ' 43' ' ' GLU . 43.7 t -89.91 144.41 9.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.453 -0.779 . . . . 0.0 110.197 -179.744 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.462 HG23 ' OD2' ' A' ' 20' ' ' ASP . 9.0 t -98.24 -27.56 14.1 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.16 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.546 ' HB2' ' CG ' ' A' ' 23' ' ' GLU . 7.0 m-20 -136.41 103.51 5.3 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.272 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 1.095 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -45.84 -30.43 1.69 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.101 -0.999 . . . . 0.0 109.746 -178.781 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.095 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -60.05 -49.51 77.37 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 121.643 -0.66 . . . . 0.0 109.796 -179.636 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.546 ' CG ' ' HB2' ' A' ' 20' ' ' ASP . 1.8 pt-20 -101.13 31.07 3.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.424 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.446 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -67.2 -45.73 78.3 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 1.025 HG13 ' OG1' ' A' ' 13' ' ' THR . 77.0 t -141.91 145.28 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -1.166 . . . . 0.0 109.695 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.77 -46.91 70.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.207 -0.933 . . . . 0.0 109.749 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.466 ' HA3' ' O ' ' A' ' 6' ' ' ILE . . . -81.53 -6.55 89.08 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' TRP . . . . . 1.059 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.2 OUTLIER -133.96 123.71 25.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.155 -1.203 . . . . 0.0 109.091 179.528 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.528 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -126.62 126.98 44.51 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.35 -0.844 . . . . 0.0 108.934 179.586 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.906 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -106.43 170.08 8.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.12 -0.987 . . . . 0.0 109.586 -179.395 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.425 ' HA ' HD21 ' A' ' 21' ' ' LEU . 19.4 m120 -160.53 122.45 3.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 110.241 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.779 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -103.65 137.54 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.257 -0.902 . . . . 0.0 109.354 178.625 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -86.88 169.72 40.83 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -60.6 -14.44 20.25 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.15 -1.206 . . . . 0.0 109.185 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.443 ' HB3' ' OD1' ' A' ' 67' ' ' ASN . 5.7 p -67.46 -33.72 75.72 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.338 -0.851 . . . . 0.0 109.796 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.796 HG12 ' O ' ' A' ' 36' ' ' VAL . 2.2 t -67.03 86.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.016 -1.053 . . . . 0.0 109.385 -179.862 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 17.7 m -65.81 -29.04 69.46 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.086 -1.009 . . . . 0.0 108.3 179.34 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 41.8 t30 -131.57 101.08 15.97 Favored Pre-proline 0 C--N 1.295 -1.765 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.32 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.2 149.87 36.52 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.368 2.045 . . . . 0.0 110.592 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.541 ' CD ' HG12 ' A' ' 71' ' ' ILE . 36.0 Cg_endo -77.38 -165.49 0.33 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.588 2.192 . . . . 0.0 110.191 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 56.0 t -108.52 118.88 57.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.331 -0.856 . . . . 0.0 110.13 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.602 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 2.7 m-85 -97.37 111.61 23.79 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.038 -1.039 . . . . 0.0 108.221 178.505 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.577 ' HG3' HG23 ' A' ' 17' ' ' VAL . 3.3 tm-20 -153.01 148.51 27.15 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.125 -0.984 . . . . 0.0 110.099 -179.446 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.458 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 61.4 t -102.41 148.45 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.388 -0.82 . . . . 0.0 109.048 179.387 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 1.05 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -150.19 164.28 36.07 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.084 -1.01 . . . . 0.0 108.602 -179.938 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 1.05 ' N ' HD22 ' A' ' 45' ' ' LEU . 13.0 mt-10 -110.68 112.81 24.95 Favored 'General case' 0 C--N 1.293 -1.863 0 O-C-N 121.443 -0.785 . . . . 0.0 109.809 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' THR . . . . . 1.022 HG22 HD21 ' A' ' 45' ' ' LEU . 1.9 p -106.48 152.99 22.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.453 -0.78 . . . . 0.0 109.458 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 51.9 p -88.25 18.79 4.12 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.345 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.421 ' O ' ' C ' ' A' ' 50' ' ' ALA . 14.7 t0 -132.97 7.81 4.03 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 109.519 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.421 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -43.93 149.22 0.68 Allowed Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.276 -0.89 . . . . 0.0 109.351 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.596 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 35.2 Cg_endo -78.21 -32.96 2.16 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.697 2.265 . . . . 0.0 110.372 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -139.28 77.49 1.62 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.283 -0.885 . . . . 0.0 109.531 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 118.48 -127.15 7.15 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.489 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 6.9 t30 -157.57 22.51 0.28 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.26 -1.141 . . . . 0.0 109.413 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.551 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 17.8 mttp -136.58 142.76 43.36 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.29 -0.881 . . . . 0.0 109.412 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.572 HG11 ' CZ2' ' A' ' 125' ' ' TRP . 6.1 m -150.64 174.18 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.217 -0.927 . . . . 0.0 109.563 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.667 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -102.88 103.15 13.28 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.575 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.764 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.96 118.55 23.06 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.079 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.838 ' O ' HG23 ' A' ' 156' ' ' THR . 46.9 t -113.29 143.9 22.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.096 -1.003 . . . . 0.0 108.6 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.621 HG22 ' OD1' ' A' ' 62' ' ' ASN . 45.7 m -108.66 94.29 4.97 Favored 'General case' 0 C--N 1.283 -2.316 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.59 HG12 ' HA ' ' A' ' 153' ' ' VAL . 55.5 t -89.03 125.36 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.281 -0.887 . . . . 0.0 108.843 179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.621 ' OD1' HG22 ' A' ' 60' ' ' THR . 0.6 OUTLIER -160.17 61.58 0.34 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.41 -0.806 . . . . 0.0 109.68 -179.511 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 149.24 89.81 0.08 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.7 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.5 m -79.91 -171.93 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.281 -1.129 . . . . 0.0 109.58 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -134.71 -164.43 10.52 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -92.3 19.1 7.39 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -1.139 . . . . 0.0 109.459 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.526 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 30.5 m120 -132.72 148.15 68.37 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.231 -0.918 . . . . 0.0 109.398 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.508 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.3 Cg_endo -78.52 12.52 2.12 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.578 2.186 . . . . 0.0 110.836 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.526 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -136.59 58.83 1.72 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.99 -1.069 . . . . 0.0 109.688 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.51 ' HB3' ' CG2' ' A' ' 36' ' ' VAL . 1.8 m-20 -77.71 -69.61 0.53 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.122 -0.986 . . . . 0.0 108.963 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.573 HD12 ' HA2' ' A' ' 148' ' ' GLY . 3.0 mt -106.26 126.82 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.396 -0.815 . . . . 0.0 108.904 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -121.92 128.79 51.94 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.078 -1.013 . . . . 0.0 110.504 -179.268 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 1.059 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -113.68 108.54 17.26 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.554 HG22 ' N ' ' A' ' 75' ' ' ALA . 40.9 m -115.28 162.48 17.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.513 -1.367 . . . . 0.0 110.137 -178.745 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.554 ' N ' HG22 ' A' ' 74' ' ' THR . . . -123.46 140.1 53.34 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.227 -0.92 . . . . 0.0 109.219 179.337 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.535 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 3.1 p90 178.98 160.56 0.7 Allowed Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.416 -0.802 . . . . 0.0 109.22 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.53 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.9 Cg_endo -81.58 168.64 67.57 Favored 'Cis proline' 0 C--N 1.311 -1.418 0 C-N-CA 123.699 -1.375 . . . . 0.0 110.696 -0.468 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.535 HG11 HD11 ' A' ' 141' ' ' ILE . 33.3 t -121.22 131.58 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.233 -0.917 . . . . 0.0 108.87 179.355 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ASN . . . . . 0.522 ' O ' ' HB2' ' A' ' 4' ' ' ALA . 14.2 m120 -94.03 103.97 16.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.079 -1.013 . . . . 0.0 109.975 -179.518 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.585 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.2 m -113.57 -176.6 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.402 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.709 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -133.42 142.61 44.77 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.302 -0.874 . . . . 0.0 109.346 179.88 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.449 ' HD3' HG22 ' A' ' 139' ' ' THR . 35.5 Cg_endo -77.63 106.47 2.2 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.448 2.099 . . . . 0.0 110.505 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 113.33 -30.68 7.14 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.5 ' HB ' ' HB3' ' A' ' 81' ' ' ARG . 2.5 t -84.51 149.74 4.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.23 -1.159 . . . . 0.0 109.47 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 19.7 m -90.6 123.65 34.41 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' TYR . . . . . 0.585 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 6.3 m-85 -106.37 154.84 20.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.282 -0.886 . . . . 0.0 109.733 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.472 ' HB ' ' O ' ' A' ' 165' ' ' ALA . 59.0 m -118.04 154.36 32.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.433 -0.792 . . . . 0.0 109.238 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.688 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -129.33 127.38 40.97 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.146 -0.971 . . . . 0.0 109.515 -179.84 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.511 ' O ' ' O ' ' A' ' 161' ' ' GLY . 21.6 m -130.5 145.54 51.87 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.266 -0.896 . . . . 0.0 108.78 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.726 HD13 ' HD2' ' A' ' 103' ' ' PHE . 16.9 tt -151.34 161.91 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 120.554 -1.341 . . . . 0.0 109.741 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.596 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 18.1 m95 -132.63 124.88 29.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.154 -0.966 . . . . 0.0 108.982 179.5 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.98 145.91 47.66 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.741 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.623 ' HA ' HG22 ' A' ' 121' ' ' ILE . 8.8 ptt180 -156.73 179.2 9.5 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -154.47 160.62 41.69 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.091 -1.006 . . . . 0.0 109.868 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -54.04 -41.19 67.8 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.383 -0.823 . . . . 0.0 109.452 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.472 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 57.4 mt-30 -130.34 143.38 50.74 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.225 -0.922 . . . . 0.0 109.442 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.79 ' OD1' HG23 ' A' ' 123' ' ' THR . 2.2 m-20 -57.14 149.37 19.7 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.293 -0.879 . . . . 0.0 109.505 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 111.23 36.99 1.71 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.841 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -125.19 141.8 51.88 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.072 -1.252 . . . . 0.0 109.32 179.695 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.52 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 54.0 t -118.56 151.27 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 110.832 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.64 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 40.7 t -150.02 162.11 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.527 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 54.4 m -124.42 128.83 49.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.09 -1.006 . . . . 0.0 109.31 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.726 ' HD2' HD13 ' A' ' 90' ' ' ILE . 0.2 OUTLIER -121.66 103.78 9.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.084 -1.01 . . . . 0.0 109.957 -179.788 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.488 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 20.9 p -128.4 165.02 21.43 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.216 -0.928 . . . . 0.0 109.927 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.655 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -121.62 125.23 73.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.564 0.697 . . . . 0.0 110.167 179.876 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -115.1 179.02 18.14 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.551 ' CB ' ' O ' ' A' ' 111' ' ' GLN . 25.7 t30 -127.83 172.04 11.22 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -1.097 . . . . 0.0 109.077 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' GLN . . . . . 0.455 ' HB2' ' OE2' ' A' ' 138' ' ' GLU . 31.4 mt-30 -59.17 -47.63 84.59 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.007 -1.058 . . . . 0.0 109.608 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.538 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 46.9 t -84.37 19.36 1.92 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.219 -0.926 . . . . 0.0 110.117 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.56 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.1 m-30 80.61 7.79 1.36 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.36 -0.838 . . . . 0.0 110.186 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.551 ' O ' ' CB ' ' A' ' 107' ' ' ASN . 37.0 mm-40 -69.9 123.99 22.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.994 -1.066 . . . . 0.0 108.736 179.249 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' GLU . . . . . 0.492 ' HG3' ' N ' ' A' ' 113' ' ' TYR . 1.2 tt0 -104.93 140.41 38.21 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.925 -1.109 . . . . 0.0 110.122 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.748 ' CE2' HG21 ' A' ' 141' ' ' ILE . 5.8 m-85 -108.37 -68.56 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.453 -0.779 . . . . 0.0 108.915 179.198 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.582 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -99.37 171.61 24.42 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 179.478 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.476 ' CG ' ' O ' ' A' ' 115' ' ' ARG . 0.2 OUTLIER -171.03 110.11 0.33 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.044 -1.268 . . . . 0.0 110.381 -179.867 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.91 HD21 ' CD1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -145.38 77.29 1.51 Allowed 'General case' 0 N--CA 1.494 1.74 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.168 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 117' ' ' HIS . . . . . 0.54 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 41.2 p-80 -104.27 158.04 16.73 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.354 -0.842 . . . . 0.0 110.11 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 30.0 tt0 79.1 78.52 0.06 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.513 -0.742 . . . . 0.0 109.689 179.687 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' GLN . . . . . 0.451 ' OE1' ' O ' ' A' ' 118' ' ' GLU . 19.5 mm100 -144.24 131.74 21.02 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.251 -0.906 . . . . 0.0 109.467 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.793 ' O ' HD13 ' A' ' 121' ' ' ILE . 10.6 mt-30 -66.66 156.04 36.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 109.066 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.793 HD13 ' O ' ' A' ' 120' ' ' GLN . 13.9 mm -133.21 136.76 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 O-C-N 121.066 -1.021 . . . . 0.0 110.005 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -90.48 -179.17 5.52 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.908 0.861 . . . . 0.0 110.636 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.79 HG23 ' OD1' ' A' ' 97' ' ' ASP . 0.8 OUTLIER -68.69 -15.67 63.59 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.416 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.521 ' O ' ' CB ' ' A' ' 93' ' ' ARG . 3.8 mt-10 -100.36 -172.09 2.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.475 -0.766 . . . . 0.0 109.289 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' TRP . . . . . 0.588 ' CE2' ' HD3' ' A' ' 51' ' ' PRO . 98.2 m95 -90.07 135.46 33.64 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.324 -0.86 . . . . 0.0 109.796 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.44 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 0.6 OUTLIER -106.83 121.37 45.16 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.233 -0.917 . . . . 0.0 108.977 179.751 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -79.64 110.1 2.57 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.447 2.098 . . . . 0.0 110.945 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -122.79 133.71 54.44 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 179.189 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.1 t -151.62 176.42 11.37 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 120.625 -1.297 . . . . 0.0 111.057 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.91 ' CD1' HD21 ' A' ' 116' ' ' LEU . 10.5 p90 -171.98 178.01 3.09 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.019 179.437 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' GLU . . . . . 0.474 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 33.5 mt-10 -133.7 153.57 51.6 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.061 -1.025 . . . . 0.0 110.041 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.565 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.14 160.76 19.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.458 -0.776 . . . . 0.0 109.147 179.746 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -119.11 146.2 45.31 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.18 -0.95 . . . . 0.0 109.293 -179.579 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.709 HG21 ' O ' ' A' ' 81' ' ' ARG . 2.5 t -56.72 111.94 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.362 -0.836 . . . . 0.0 109.264 179.611 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 3.8 m -83.61 -42.32 16.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.442 -0.786 . . . . 0.0 109.947 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.576 ' O ' ' CB ' ' A' ' 137' ' ' GLN . 33.1 t70 -85.91 -16.64 37.85 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.401 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' GLN . . . . . 0.691 ' H ' HG12 ' A' ' 134' ' ' VAL . 3.2 mm-40 86.32 28.38 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -178.697 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.523 ' CG ' ' OD1' ' A' ' 107' ' ' ASN . 3.0 mm-40 -74.48 119.4 18.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.606 -0.683 . . . . 0.0 109.795 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.449 HG22 ' HD3' ' A' ' 82' ' ' PRO . 17.3 p -79.34 -3.78 47.83 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.344 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.488 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.9 t -140.13 132.19 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.352 -0.843 . . . . 0.0 109.131 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.748 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.6 OUTLIER -144.53 171.98 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.259 -0.901 . . . . 0.0 109.821 -179.861 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 142' ' ' ARG . . . . . 0.501 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.1 ptm180 -139.61 132.26 28.89 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.528 -0.732 . . . . 0.0 109.419 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ALA . . . . . 0.655 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -96.09 108.78 43.31 Favored Pre-proline 0 N--CA 1.486 1.339 0 O-C-N 121.219 -0.926 . . . . 0.0 110.029 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.501 ' HD3' ' O ' ' A' ' 142' ' ' ARG . 36.2 Cg_endo -77.73 112.51 3.32 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.324 2.016 . . . . 0.0 111.106 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.809 HD11 HD22 ' A' ' 162' ' ' LEU . 2.4 mt -99.14 134.19 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 178.413 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' HIS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 12.8 m80 -97.2 154.83 17.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.34 -1.475 . . . . 0.0 111.607 -177.556 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.64 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 28.1 m-85 -155.1 157.21 37.16 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 179.284 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.573 ' HA2' HD12 ' A' ' 71' ' ' ILE . . . 108.11 53.59 0.65 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.7 ' C ' HG11 ' A' ' 64' ' ' VAL . 22.6 m-85 -129.03 159.47 35.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.245 -1.15 . . . . 0.0 109.39 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.414 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.67 -30.15 70.33 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -71.23 -11.6 61.01 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.369 -0.832 . . . . 0.0 109.049 179.265 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.841 ' OD1' ' HB1' ' A' ' 99' ' ' ALA . 1.8 t30 -116.86 13.07 14.93 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 179.172 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.59 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.2 t -85.15 162.22 2.95 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 O-C-N 121.635 -0.665 . . . . 0.0 109.695 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' GLY . . . . . 0.446 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 54.06 33.19 50.76 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.472 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.0 m-20 -160.47 135.46 7.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.187 -1.184 . . . . 0.0 110.069 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 156' ' ' THR . . . . . 0.838 HG23 ' O ' ' A' ' 59' ' ' VAL . 42.2 m -85.13 122.43 29.33 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.067 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.55 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -101.13 118.72 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.832 -1.167 . . . . 0.0 110.331 -178.811 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.764 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 3.5 m-85 -95.12 130.81 41.68 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.583 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.636 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.4 mt -120.31 142.0 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.915 -1.115 . . . . 0.0 110.078 -178.809 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 160' ' ' ASP . . . . . 0.564 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.8 OUTLIER -174.38 136.37 0.47 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.108 -0.995 . . . . 0.0 109.252 179.535 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 161' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 122.63 -10.4 9.1 Favored Glycine 0 N--CA 1.487 2.069 0 C-N-CA 119.322 -1.418 . . . . 0.0 111.014 179.023 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.809 HD22 HD11 ' A' ' 145' ' ' ILE . 9.9 tp -59.62 97.19 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.53 -1.571 . . . . 0.0 108.903 -179.643 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 163' ' ' ALA . . . . . 0.934 ' C ' HD13 ' A' ' 164' ' ' ILE . . . -134.57 145.55 48.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.537 -0.727 . . . . 0.0 109.985 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.934 HD13 ' C ' ' A' ' 163' ' ' ALA . 2.6 mm -119.65 108.5 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.284 -0.885 . . . . 0.0 109.204 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.525 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.127 -0.983 . . . . 0.0 109.527 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.798 HG22 ' O ' ' A' ' 164' ' ' ILE . 2.9 p . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.636 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -75.3 -46.57 32.63 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.186 -0.946 . . . . 0.0 109.587 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.511 ' HB2' ' CG1' ' A' ' 164' ' ' ILE . 0.9 OUTLIER -89.84 124.65 34.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.293 -0.88 . . . . 0.0 109.603 -179.945 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.492 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 1.8 mp -116.83 138.06 48.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.244 -0.91 . . . . 0.0 109.3 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.509 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.3 OUTLIER 74.99 16.52 2.87 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.219 -0.926 . . . . 0.0 109.627 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.502 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -60.11 -45.98 95.02 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.527 ' CA ' ' OD2' ' A' ' 160' ' ' ASP . . . -94.77 28.44 11.4 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 179.407 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.6 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 8.4 m-85 44.53 52.01 7.73 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.434 -1.039 . . . . 0.0 109.552 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.481 ' OE1' ' HA3' ' A' ' 53' ' ' GLY . 57.3 mm-40 -84.6 -28.24 26.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.298 -0.876 . . . . 0.0 109.639 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.423 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 0.9 OUTLIER -87.31 -37.08 17.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.198 -0.939 . . . . 0.0 109.762 -179.675 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.788 ' OG1' HG13 ' A' ' 25' ' ' VAL . 10.1 m -70.82 117.0 51.79 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.153 -0.967 . . . . 0.0 109.354 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 15' ' ' ALA . 35.2 Cg_endo -76.95 138.82 18.85 Favored 'Trans proline' 0 C--N 1.312 -1.378 0 C-N-CA 122.319 2.013 . . . . 0.0 110.396 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.441 ' C ' ' O ' ' A' ' 14' ' ' PRO . . . -39.31 153.88 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.516 0 CA-C-O 121.279 0.561 . . . . 0.0 109.857 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.49 131.37 2.41 Favored Glycine 0 N--CA 1.485 1.966 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.531 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.84 141.13 14.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.227 -1.16 . . . . 0.0 109.213 -179.602 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.642 HG13 ' HA2' ' A' ' 24' ' ' GLY . 47.8 t -86.58 142.37 13.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 CA-C-O 121.722 0.772 . . . . 0.0 110.365 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.411 ' C ' ' OD1' ' A' ' 20' ' ' ASP . 1.8 t -95.34 -28.53 14.92 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.069 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.426 ' O ' ' C ' ' A' ' 21' ' ' LEU . 1.0 OUTLIER -136.31 100.5 4.4 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.325 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 1.107 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -43.23 -29.02 0.36 Allowed 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.259 -0.9 . . . . 0.0 109.773 -178.868 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.107 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.69 -55.06 39.13 Favored 'General case' 0 C--N 1.294 -1.823 0 O-C-N 121.599 -0.688 . . . . 0.0 109.822 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -101.5 31.6 3.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.135 -0.978 . . . . 0.0 109.349 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.642 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -67.56 -47.18 63.74 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.788 HG13 ' OG1' ' A' ' 13' ' ' THR . 4.3 t -126.61 144.83 35.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.093 -1.24 . . . . 0.0 109.842 -179.638 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -62.49 -65.56 0.67 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.331 -0.855 . . . . 0.0 110.084 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.509 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -76.31 2.5 56.93 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' TRP . . . . . 0.687 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.7 OUTLIER -133.99 122.11 22.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.028 -1.278 . . . . 0.0 109.124 179.549 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.537 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -126.6 128.22 46.46 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.4 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.906 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -104.67 175.98 5.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.972 -1.08 . . . . 0.0 110.236 -178.927 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 -160.2 122.09 3.22 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.47 -0.769 . . . . 0.0 109.629 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.785 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -110.6 136.53 46.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.217 -0.927 . . . . 0.0 109.494 179.417 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.45 -179.87 21.03 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.1 m -58.42 -16.3 14.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -1.165 . . . . 0.0 109.294 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.484 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 37.7 m -60.37 -38.85 85.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.257 -0.902 . . . . 0.0 109.592 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.785 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -62.97 89.29 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.045 -1.034 . . . . 0.0 109.257 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.4 m -59.79 -29.23 68.07 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.242 -0.911 . . . . 0.0 108.69 179.499 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.693 ' O ' HG13 ' A' ' 36' ' ' VAL . 0.5 OUTLIER -129.07 128.79 23.36 Favored Pre-proline 0 C--N 1.296 -1.728 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.448 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.63 122.02 6.23 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.203 1.935 . . . . 0.0 110.523 -179.423 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.515 ' HG3' ' CD1' ' A' ' 71' ' ' ILE . 35.4 Cg_endo -77.3 -165.68 0.34 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.302 2.002 . . . . 0.0 109.905 179.697 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.513 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 70.2 t -117.34 118.72 59.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.034 -1.041 . . . . 0.0 110.775 -179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.453 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 2.3 m-85 -102.33 111.97 24.48 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.163 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.538 ' HA ' HG23 ' A' ' 18' ' ' VAL . 1.3 tm-20 -154.1 151.52 29.39 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.062 -1.024 . . . . 0.0 110.118 -179.116 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.444 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 48.0 t -103.75 148.39 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.488 -0.757 . . . . 0.0 109.188 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 1.071 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -149.13 164.12 35.63 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.77 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 1.071 ' N ' HD22 ' A' ' 45' ' ' LEU . 9.9 pt-20 -125.47 124.89 42.37 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.333 -0.855 . . . . 0.0 109.551 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.92 HG23 HD21 ' A' ' 45' ' ' LEU . 1.3 p -127.24 166.77 17.12 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.388 -0.82 . . . . 0.0 109.461 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 95.6 p -88.24 18.58 4.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.912 . . . . 0.0 109.4 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 50' ' ' ALA . 0.1 OUTLIER -123.96 -0.81 8.39 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.277 -0.889 . . . . 0.0 109.584 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.34 145.84 1.32 Allowed Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.166 -0.959 . . . . 0.0 109.406 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.603 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 36.1 Cg_endo -78.44 -41.94 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.647 2.231 . . . . 0.0 110.396 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -128.26 89.61 2.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.315 -0.865 . . . . 0.0 109.413 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.481 ' HA3' ' OE1' ' A' ' 11' ' ' GLU . . . 105.49 -128.38 9.37 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.484 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 9.2 p-10 -152.63 18.24 0.61 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.201 -1.176 . . . . 0.0 109.704 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.466 ' O ' ' OD2' ' A' ' 160' ' ' ASP . 95.1 mttt -138.73 146.6 41.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.15 -0.969 . . . . 0.0 109.665 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.64 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.4 m -150.1 174.48 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.392 -0.817 . . . . 0.0 109.242 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.672 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -100.43 103.75 15.13 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.12 -0.988 . . . . 0.0 108.964 179.475 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.721 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -82.04 121.9 27.14 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 178.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.789 ' O ' HG23 ' A' ' 156' ' ' THR . 44.0 t -115.46 144.17 23.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.113 -0.992 . . . . 0.0 109.084 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.708 HG22 ' OD1' ' A' ' 62' ' ' ASN . 95.9 m -107.79 88.48 2.74 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.196 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.699 HG21 ' CD1' ' A' ' 157' ' ' ILE . 60.1 t -86.77 120.91 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.419 -0.801 . . . . 0.0 109.291 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.708 ' OD1' HG22 ' A' ' 60' ' ' THR . 1.9 p-10 -160.23 59.3 0.35 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.423 -0.798 . . . . 0.0 109.835 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 154.57 84.65 0.05 OUTLIER Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.719 HG12 ' C ' ' A' ' 148' ' ' GLY . 1.7 m -80.66 -176.54 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.24 -1.153 . . . . 0.0 109.396 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.484 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -126.99 -159.53 10.21 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 22.8 m-20 -89.48 -9.22 50.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.295 -1.121 . . . . 0.0 109.455 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.499 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 18.3 m120 -104.77 148.06 35.46 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.241 -0.912 . . . . 0.0 109.388 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 67' ' ' ASN . 36.2 Cg_endo -78.85 13.54 1.92 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.651 2.234 . . . . 0.0 110.942 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.499 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 1.9 p90 -137.72 53.33 1.85 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.98 -1.075 . . . . 0.0 109.744 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.522 ' CB ' HG23 ' A' ' 36' ' ' VAL . 0.4 OUTLIER -75.48 -65.28 0.91 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.174 -0.953 . . . . 0.0 109.095 179.645 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.546 HG13 ' CG2' ' A' ' 36' ' ' VAL . 4.5 mt -105.05 128.68 58.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.275 -0.89 . . . . 0.0 108.709 179.523 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -130.69 130.44 43.86 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.822 -1.174 . . . . 0.0 110.545 -179.275 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.906 ' HA ' HD23 ' A' ' 30' ' ' LEU . . . -113.66 108.82 17.64 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.548 HG22 ' N ' ' A' ' 75' ' ' ALA . 54.5 m -109.23 162.3 14.42 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.688 -1.257 . . . . 0.0 110.134 -178.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.548 ' N ' HG22 ' A' ' 74' ' ' THR . . . -122.74 138.97 54.47 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.267 -0.895 . . . . 0.0 109.173 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.555 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 4.1 p90 179.36 161.57 0.76 Allowed Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.526 -0.734 . . . . 0.0 109.098 -179.723 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.555 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.7 Cg_endo -81.76 166.32 72.28 Favored 'Cis proline' 0 C--N 1.311 -1.444 0 C-N-CA 123.802 -1.333 . . . . 0.0 110.972 -0.364 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.72 HG11 HD13 ' A' ' 164' ' ' ILE . 86.7 t -127.19 156.64 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ASN . . . . . 0.636 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 69.1 m-20 -122.53 139.52 53.81 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.007 -1.058 . . . . 0.0 109.875 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.45 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 4.0 m -146.04 -174.04 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.226 -0.921 . . . . 0.0 109.758 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.542 ' O ' HG21 ' A' ' 134' ' ' VAL . 3.1 ttt85 -138.07 141.38 32.06 Favored Pre-proline 0 N--CA 1.49 1.534 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.513 ' HD2' ' CG ' ' A' ' 81' ' ' ARG . 34.9 Cg_endo -76.12 117.27 4.6 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.467 2.111 . . . . 0.0 110.778 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 107.72 -33.53 6.26 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.454 ' HB ' ' HB3' ' A' ' 81' ' ' ARG . 2.7 t -88.59 149.72 3.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.221 -1.164 . . . . 0.0 109.584 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.3 t -94.19 147.54 23.07 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' TYR . . . . . 0.573 ' CD2' ' O ' ' A' ' 165' ' ' ALA . 7.6 m-85 -122.2 157.46 31.54 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.102 -0.999 . . . . 0.0 109.937 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 47.7 m -111.21 142.12 43.84 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.375 -0.828 . . . . 0.0 109.05 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.816 ' CD1' HG23 ' A' ' 164' ' ' ILE . 0.2 OUTLIER -134.19 128.25 33.62 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.093 -1.004 . . . . 0.0 109.548 -179.522 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.501 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.5 m -134.83 152.79 52.04 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.716 HD13 ' CD2' ' A' ' 103' ' ' PHE . 18.6 tt -150.9 163.4 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.787 -1.196 . . . . 0.0 109.343 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.603 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 17.2 m95 -130.66 124.87 32.61 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.076 -1.015 . . . . 0.0 109.566 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.465 ' HB3' HG23 ' A' ' 121' ' ' ILE . . . -113.49 146.81 39.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.3 -0.875 . . . . 0.0 109.204 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.494 ' HG3' ' O ' ' A' ' 123' ' ' THR . 6.5 ttp85 -162.34 119.68 2.08 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.144 -0.973 . . . . 0.0 109.228 -179.755 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.418 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.35 160.52 15.31 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.22 -0.925 . . . . 0.0 109.937 -179.61 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.08 -44.83 75.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.425 -0.797 . . . . 0.0 109.176 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.518 ' C ' HG22 ' A' ' 123' ' ' THR . 0.0 OUTLIER -117.68 151.62 36.88 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.872 . . . . 0.0 109.132 179.758 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.872 ' N ' HG22 ' A' ' 123' ' ' THR . 2.3 p-10 -73.59 146.01 45.02 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.139 -0.976 . . . . 0.0 109.566 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 113.56 37.89 1.26 Allowed Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -121.66 140.53 52.17 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.188 -1.184 . . . . 0.0 109.128 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.461 ' HB ' ' OD1' ' A' ' 152' ' ' ASN . 50.7 t -116.23 154.3 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.218 -0.926 . . . . 0.0 110.66 -179.427 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.69 HG22 ' CE1' ' A' ' 147' ' ' PHE . 61.6 t -155.02 166.49 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.688 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.592 ' HB2' ' CD2' ' A' ' 117' ' ' HIS . 30.8 t -136.18 130.81 33.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.027 -1.046 . . . . 0.0 109.643 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.716 ' CD2' HD13 ' A' ' 90' ' ' ILE . 0.3 OUTLIER -122.86 104.51 9.32 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.145 -0.972 . . . . 0.0 109.572 -179.965 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.614 ' O ' ' HB1' ' A' ' 143' ' ' ALA . 16.0 p -117.22 170.78 8.41 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.119 -0.988 . . . . 0.0 110.462 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.649 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -127.32 157.71 38.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.834 -0.541 . . . . 0.0 109.726 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 111' ' ' GLN . . . 172.98 138.33 2.58 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.639 ' CB ' HG22 ' A' ' 141' ' ' ILE . 1.3 p30 -76.98 -169.88 1.46 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.123 -1.222 . . . . 0.0 109.334 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' GLN . . . . . 0.521 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 1.4 mp0 -77.28 14.91 0.83 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.04 -1.037 . . . . 0.0 110.925 -179.156 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.508 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 0.9 OUTLIER -113.63 6.36 16.91 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 120.785 -1.197 . . . . 0.0 109.344 179.598 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.569 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.6 m-30 77.94 14.84 1.55 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.361 -0.837 . . . . 0.0 109.611 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.493 ' HG2' ' HB2' ' A' ' 109' ' ' SER . 7.9 mm-40 -90.0 94.39 9.78 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 108.655 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' GLU . . . . . 0.53 ' CG ' ' O ' ' A' ' 105' ' ' VAL . 2.0 tt0 -81.92 142.08 32.77 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.362 -0.836 . . . . 0.0 110.34 -179.06 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.596 ' HB3' ' CD1' ' A' ' 132' ' ' PHE . 4.8 m-85 -109.69 -69.02 0.88 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.207 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.422 ' N ' HG23 ' A' ' 105' ' ' VAL . . . -89.34 177.67 44.19 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 179.479 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 1.01 ' O ' HD23 ' A' ' 116' ' ' LEU . 0.6 OUTLIER -177.87 135.83 0.17 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.951 -1.323 . . . . 0.0 110.393 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 1.01 HD23 ' O ' ' A' ' 115' ' ' ARG . 0.5 OUTLIER -147.36 69.87 1.16 Allowed 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.304 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 117' ' ' HIS . . . . . 0.592 ' CD2' ' HB2' ' A' ' 102' ' ' SER . 27.2 t-80 -93.77 141.57 28.35 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 110.295 -179.043 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.559 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 4.2 tt0 82.21 36.8 0.06 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.711 -0.618 . . . . 0.0 109.52 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 6.9 mm100 -88.55 120.34 29.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.355 -0.841 . . . . 0.0 109.165 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.71 ' O ' HD13 ' A' ' 121' ' ' ILE . 1.6 mt-30 -65.5 140.99 58.63 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.462 -0.774 . . . . 0.0 108.945 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.71 HD13 ' O ' ' A' ' 120' ' ' GLN . 5.9 mm -125.81 129.68 72.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.109 -0.995 . . . . 0.0 110.126 -179.44 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -89.86 -178.77 5.57 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.618 0.723 . . . . 0.0 110.094 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.872 HG22 ' N ' ' A' ' 97' ' ' ASP . 11.6 p -72.87 -2.08 19.32 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 119.914 -0.714 . . . . 0.0 109.352 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.47 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 0.4 OUTLIER -112.44 -168.73 1.36 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.166 -0.959 . . . . 0.0 108.981 179.727 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 125' ' ' TRP . . . . . 0.534 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 95.3 m95 -91.95 130.26 37.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.145 -0.972 . . . . 0.0 109.613 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.439 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 0.3 OUTLIER -109.51 121.45 42.33 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.156 -0.965 . . . . 0.0 109.109 179.787 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.17 100.41 1.26 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 C-N-CA 122.514 2.143 . . . . 0.0 111.141 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -110.9 137.83 48.05 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.14 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.1 t -144.18 176.21 9.5 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.565 -1.334 . . . . 0.0 111.058 -179.362 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.661 ' CE1' HD11 ' A' ' 116' ' ' LEU . 16.9 p90 -173.9 171.06 3.77 Favored 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 115.036 -0.983 . . . . 0.0 109.034 179.653 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' GLU . . . . . 0.516 ' HA ' ' CE2' ' A' ' 88' ' ' TYR . 34.3 mt-10 -143.64 142.18 30.92 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.089 -1.007 . . . . 0.0 109.904 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.702 ' CE2' ' CZ ' ' A' ' 88' ' ' TYR . 5.2 p90 -151.11 168.07 25.78 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.35 -0.844 . . . . 0.0 109.145 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.407 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -119.37 147.29 44.51 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.907 . . . . 0.0 109.623 -179.719 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.542 HG21 ' O ' ' A' ' 81' ' ' ARG . 3.6 t -43.51 110.43 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.46 -0.775 . . . . 0.0 108.977 179.546 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -58.52 -51.12 71.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.293 -179.741 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -110.65 -91.16 0.47 Allowed 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.399 -0.813 . . . . 0.0 109.209 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -160.94 55.2 0.3 Allowed 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.576 -0.702 . . . . 0.0 109.127 179.737 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.512 ' HG3' ' ND2' ' A' ' 107' ' ' ASN . 7.2 mm-40 -95.01 111.91 23.67 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.213 -0.93 . . . . 0.0 109.851 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.0 p -79.42 -13.46 59.58 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 41.6 t -134.03 136.42 53.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.212 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.639 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -143.36 171.89 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.072 -1.018 . . . . 0.0 110.224 -179.498 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 142' ' ' ARG . . . . . 0.501 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.4 ptm180 -141.37 132.43 26.23 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ALA . . . . . 0.649 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -94.22 109.67 43.78 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.331 -0.856 . . . . 0.0 110.286 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.502 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.9 Cg_endo -77.2 110.68 3.06 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 122.023 1.816 . . . . 0.0 109.664 178.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.687 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 3.3 mt -95.18 124.15 47.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' HIS . . . . . 0.492 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 12.8 m80 -84.5 149.36 25.99 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.926 -1.109 . . . . 0.0 111.638 -177.008 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.694 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 10.4 m-85 -154.55 158.43 39.79 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.063 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.719 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 109.33 38.77 1.74 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.66 ' C ' HG11 ' A' ' 64' ' ' VAL . 20.9 m-85 -113.99 158.08 21.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.444 -1.033 . . . . 0.0 109.207 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.21 -27.58 68.09 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.479 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.43 -14.99 62.77 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.447 -0.783 . . . . 0.0 109.328 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.521 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.2 OUTLIER -109.62 11.25 24.77 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.371 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.529 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.4 t -85.79 163.88 2.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 O-C-N 121.523 -0.735 . . . . 0.0 109.881 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' GLY . . . . . 0.481 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.98 31.83 40.73 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.034 -1.227 . . . . 0.0 110.034 179.671 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.476 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.1 m-20 -160.61 139.36 10.28 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.147 -1.207 . . . . 0.0 110.27 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 156' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 59' ' ' VAL . 80.1 m -87.29 121.2 29.42 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.699 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.2 mt -101.89 118.2 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 120.868 -1.145 . . . . 0.0 110.383 -178.65 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.721 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.6 m-85 -97.24 138.78 34.2 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 178.426 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.694 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -130.35 139.78 50.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 C-N-CA 118.767 -1.173 . . . . 0.0 110.014 -178.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 160' ' ' ASP . . . . . 0.64 ' CB ' HG12 ' A' ' 56' ' ' VAL . 1.0 OUTLIER -173.94 136.1 0.52 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.371 -0.831 . . . . 0.0 109.136 179.687 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 161' ' ' GLY . . . . . 0.501 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 126.58 -8.08 7.39 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.688 179.397 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.565 ' HB2' HD12 ' A' ' 90' ' ' ILE . 10.4 tp -59.61 93.06 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.648 -1.501 . . . . 0.0 108.82 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 163' ' ' ALA . . . . . 0.475 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -118.22 145.75 44.76 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.694 -0.629 . . . . 0.0 109.9 -179.061 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.816 HG23 ' CD1' ' A' ' 88' ' ' TYR . 20.6 mt -132.68 127.28 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.362 -0.836 . . . . 0.0 109.095 179.607 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.573 ' O ' ' CD2' ' A' ' 86' ' ' TYR . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.201 -0.937 . . . . 0.0 109.599 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.679 HG23 ' HB2' ' A' ' 165' ' ' ALA . 4.1 p . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.913 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -77.61 -31.31 52.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 109.51 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.643 ' HB2' HD12 ' A' ' 164' ' ' ILE . 10.2 t-20 -92.19 124.67 36.44 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.24 -0.913 . . . . 0.0 109.689 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.512 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 65.5 mt -110.38 121.63 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.323 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.525 ' OD1' ' CB ' ' A' ' 12' ' ' SER . 0.1 OUTLIER 76.83 43.8 0.12 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.243 -0.911 . . . . 0.0 109.169 -179.436 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.452 ' O ' ' HB3' ' A' ' 162' ' ' LEU . . . -47.76 -22.57 1.96 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.64 ' O ' ' CB ' ' A' ' 10' ' ' PHE . . . 164.2 60.35 0.02 OUTLIER Glycine 0 N--CA 1.487 2.082 0 C-N-CA 119.609 -1.281 . . . . 0.0 109.964 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.64 ' CB ' ' O ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER 118.4 1.06 0.0 OUTLIER 'General case' 0 N--CA 1.518 2.946 0 C-N-CA 122.832 0.453 . . . . 0.0 111.579 179.115 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.569 ' HG2' ' CD1' ' A' ' 10' ' ' PHE . 9.2 mm-40 -75.73 -60.79 2.16 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.418 -1.426 . . . . 0.0 110.831 -177.757 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.525 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.3 OUTLIER -75.11 -3.01 30.26 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.048 -1.032 . . . . 0.0 110.025 -179.201 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.642 ' OG1' HG13 ' A' ' 25' ' ' VAL . 4.4 m -126.1 123.8 24.49 Favored Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.029 -1.045 . . . . 0.0 109.411 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.454 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.4 Cg_endo -77.35 149.11 27.41 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 C-N-CA 122.46 2.107 . . . . 0.0 110.719 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.467 ' HA ' ' HB ' ' A' ' 44' ' ' VAL . . . -39.96 161.15 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.196 0.522 . . . . 0.0 109.676 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.35 134.49 3.42 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.654 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.47 140.87 14.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.392 -1.063 . . . . 0.0 108.969 -179.569 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.429 HG23 ' HA ' ' A' ' 43' ' ' GLU . 47.2 t -87.93 144.34 9.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.427 -0.796 . . . . 0.0 110.169 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.6 p -105.78 -21.2 13.23 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.391 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.403 ' HB3' ' HG3' ' A' ' 23' ' ' GLU . 7.7 m-20 -145.32 130.08 18.12 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.566 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 1.034 HD12 ' N ' ' A' ' 22' ' ' ALA . 1.7 pp -87.13 -38.31 16.57 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.088 -1.008 . . . . 0.0 110.179 -179.486 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.034 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.61 -24.93 64.21 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.155 -0.966 . . . . 0.0 108.87 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.403 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 2.0 pt-20 -138.66 34.63 2.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.452 -0.78 . . . . 0.0 109.215 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.98 -72.78 1.28 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.642 HG13 ' OG1' ' A' ' 13' ' ' THR . 1.6 t -86.08 127.85 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.288 -1.125 . . . . 0.0 109.134 179.73 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.5 ' HB3' ' HB3' ' A' ' 12' ' ' SER . 25.7 tt0 -54.71 -36.45 64.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.351 -0.843 . . . . 0.0 110.1 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.517 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -109.96 8.61 31.57 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.862 -1.161 . . . . 0.0 110.214 -179.367 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' TRP . . . . . 0.749 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.7 OUTLIER -140.57 119.67 12.81 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.089 -1.242 . . . . 0.0 109.125 179.313 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.585 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 7.3 m-20 -124.81 142.17 51.61 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.188 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.922 ' O ' HD13 ' A' ' 21' ' ' LEU . 3.3 mt -109.48 172.13 7.04 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.846 -1.159 . . . . 0.0 109.794 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -159.95 122.41 3.38 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.767 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.688 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.23 137.87 37.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.476 -0.765 . . . . 0.0 109.598 179.302 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -90.73 172.98 37.88 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 72.4 m -62.61 -12.28 22.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.17 -1.194 . . . . 0.0 109.38 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 20.9 p -72.23 -32.64 66.91 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.32 -0.863 . . . . 0.0 109.812 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.787 HG12 ' O ' ' A' ' 36' ' ' VAL . 2.2 t -70.34 87.1 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 O-C-N 121.112 -0.992 . . . . 0.0 109.318 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 22.2 m -63.96 -28.98 70.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.194 -0.941 . . . . 0.0 108.484 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.1 t30 -128.86 114.86 19.05 Favored Pre-proline 0 C--N 1.296 -1.74 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.44 ' HA ' ' HD3' ' A' ' 40' ' ' PRO . 34.8 Cg_endo -76.45 144.56 25.8 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.167 1.911 . . . . 0.0 110.492 -179.501 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.643 ' CG ' HG21 ' A' ' 71' ' ' ILE . 35.3 Cg_endo -77.27 -164.08 0.25 Allowed 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.557 2.171 . . . . 0.0 110.133 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 56.8 t -116.09 120.26 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.127 -0.983 . . . . 0.0 110.667 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.817 ' CD1' HD13 ' A' ' 30' ' ' LEU . 5.5 m-85 -101.78 112.21 24.72 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 178.364 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.654 ' HG3' HG23 ' A' ' 17' ' ' VAL . 0.4 OUTLIER -155.93 140.04 16.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.005 -1.059 . . . . 0.0 110.361 -179.451 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.473 ' N ' ' HG2' ' A' ' 43' ' ' GLU . 36.5 t -92.52 148.79 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.884 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 1.039 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -148.67 165.16 32.17 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.013 -1.055 . . . . 0.0 109.033 -179.558 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLU . . . . . 1.039 ' N ' HD22 ' A' ' 45' ' ' LEU . 13.4 mt-10 -111.19 113.89 26.72 Favored 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.452 -0.78 . . . . 0.0 109.644 -178.739 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.941 ' CG2' HD21 ' A' ' 45' ' ' LEU . 7.7 p -111.71 165.82 11.71 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 41.8 t -94.67 -10.11 32.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.3 m-20 -102.54 -1.79 29.77 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.263 -0.898 . . . . 0.0 109.59 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.482 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -44.1 147.38 0.94 Allowed Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.165 -0.959 . . . . 0.0 109.43 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.613 ' HB3' ' CE3' ' A' ' 91' ' ' TRP . 35.4 Cg_endo -78.34 -40.85 0.31 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.704 2.269 . . . . 0.0 110.325 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.14 107.06 11.73 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.418 ' O ' ' CG ' ' A' ' 54' ' ' ASN . . . 87.5 -120.5 5.56 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ASN . . . . . 0.482 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 27.7 m120 -160.16 36.28 0.17 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -1.169 . . . . 0.0 109.504 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.64 ' CD ' ' CD2' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -158.91 157.27 31.09 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.31 -0.869 . . . . 0.0 109.765 179.824 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.801 HG12 ' HB3' ' A' ' 160' ' ' ASP . 15.3 m -152.27 174.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.372 -0.83 . . . . 0.0 108.897 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' LEU . . . . . 0.493 ' O ' ' HA ' ' A' ' 158' ' ' TYR . 0.2 OUTLIER -91.44 100.67 13.4 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 178.777 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.744 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -80.34 120.05 23.87 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 119.394 -0.922 . . . . 0.0 108.991 -179.812 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.841 ' O ' HG23 ' A' ' 156' ' ' THR . 41.3 t -112.97 144.48 20.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' THR . . . . . 0.691 HG22 ' OD1' ' A' ' 62' ' ' ASN . 59.7 m -109.87 91.14 3.53 Favored 'General case' 0 C--N 1.282 -2.327 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.537 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 52.4 t -89.95 122.82 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.311 -0.868 . . . . 0.0 108.799 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.691 ' OD1' HG22 ' A' ' 60' ' ' THR . 1.1 p-10 -160.09 60.96 0.35 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.284 -0.885 . . . . 0.0 109.935 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 158.51 86.48 0.06 OUTLIER Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.729 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.3 m -82.23 -177.15 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.248 -1.148 . . . . 0.0 109.588 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -136.52 -157.86 7.87 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -96.0 23.73 6.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.326 -1.102 . . . . 0.0 109.566 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.645 ' ND2' ' CZ2' ' A' ' 69' ' ' TRP . 5.2 m120 -136.55 148.19 62.78 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.2 -0.937 . . . . 0.0 109.466 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.414 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.4 Cg_endo -78.24 11.93 2.22 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.662 2.242 . . . . 0.0 110.926 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.645 ' CZ2' ' ND2' ' A' ' 67' ' ' ASN . 1.3 p90 -136.76 59.56 1.69 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.093 -1.004 . . . . 0.0 109.647 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.514 ' HB3' ' CG2' ' A' ' 36' ' ' VAL . 1.4 m-20 -76.6 -67.59 0.68 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.242 -0.911 . . . . 0.0 109.111 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.643 HG21 ' CG ' ' A' ' 40' ' ' PRO . 2.2 mt -116.57 123.37 71.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.433 -0.792 . . . . 0.0 109.12 179.669 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.517 ' CG ' ' O ' ' A' ' 145' ' ' ILE . 20.7 tt0 -129.12 134.33 48.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.972 -1.08 . . . . 0.0 110.335 -179.4 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ALA . . . . . 0.749 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -115.91 107.69 15.31 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 178.855 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.56 HG22 ' N ' ' A' ' 75' ' ' ALA . 99.3 m -103.52 165.06 11.26 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.334 -0.854 . . . . 0.0 109.669 -179.24 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.56 ' N ' HG22 ' A' ' 74' ' ' THR . . . -122.98 137.49 54.94 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.026 -1.046 . . . . 0.0 109.227 179.027 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CZ ' ' HB2' ' A' ' 29' ' ' ASP . 11.2 p90 -176.05 160.32 1.89 Allowed Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.4 -0.812 . . . . 0.0 109.383 -179.766 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.519 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -82.53 170.22 58.1 Favored 'Cis proline' 0 C--N 1.311 -1.395 0 O-C-N 123.652 1.343 . . . . 0.0 111.064 -0.648 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.674 HG11 HD13 ' A' ' 164' ' ' ILE . 96.4 t -131.75 156.9 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.239 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ASN . . . . . 0.913 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 76.1 m-20 -123.24 140.28 53.18 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.922 -1.111 . . . . 0.0 110.289 -179.459 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 138' ' ' GLU . 4.3 m -145.48 -173.51 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.304 -0.873 . . . . 0.0 109.387 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.766 ' O ' HG21 ' A' ' 134' ' ' VAL . 17.6 mmt180 -136.45 144.73 48.69 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.382 -0.824 . . . . 0.0 109.348 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.454 ' HD2' ' HD3' ' A' ' 81' ' ' ARG . 35.1 Cg_endo -77.73 126.87 8.4 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.457 2.105 . . . . 0.0 110.539 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.22 -25.17 21.61 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.424 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -86.32 149.61 4.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.239 -1.154 . . . . 0.0 109.496 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 32.8 m -94.86 131.96 40.18 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' TYR . . . . . 0.502 ' HD2' HG22 ' A' ' 164' ' ' ILE . 14.6 m-85 -113.32 167.31 10.67 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.236 -0.915 . . . . 0.0 109.666 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.47 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 43.8 m -118.38 152.88 34.99 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.338 -0.851 . . . . 0.0 109.418 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.688 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 7.9 t80 -132.81 114.83 14.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.481 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.485 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.2 m -135.11 146.23 48.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.194 -0.941 . . . . 0.0 109.002 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.701 HD13 ' HD2' ' A' ' 103' ' ' PHE . 15.3 tt -150.96 163.78 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.796 -1.19 . . . . 0.0 109.5 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.613 ' CE3' ' HB3' ' A' ' 51' ' ' PRO . 37.3 m95 -128.76 135.41 49.15 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.862 -1.149 . . . . 0.0 109.375 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.425 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -130.0 148.09 51.82 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.213 -0.929 . . . . 0.0 109.747 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.636 ' CB ' ' CD2' ' A' ' 125' ' ' TRP . 11.6 ttt-85 -164.14 121.66 1.74 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.317 -0.864 . . . . 0.0 108.909 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.04 165.68 11.04 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.305 -0.872 . . . . 0.0 110.086 -179.403 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.07 -56.6 12.06 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.425 -0.797 . . . . 0.0 109.117 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.517 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.5 OUTLIER -101.77 134.93 44.17 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.279 -0.888 . . . . 0.0 109.204 179.701 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.581 ' N ' ' CG2' ' A' ' 123' ' ' THR . 1.2 p30 -60.77 144.95 51.37 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.212 -0.93 . . . . 0.0 109.551 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 112.45 37.82 1.41 Allowed Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.536 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -118.78 139.31 51.8 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.204 -1.174 . . . . 0.0 109.224 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.449 HG22 ' HA ' ' A' ' 120' ' ' GLN . 76.0 t -116.46 149.93 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.205 -0.934 . . . . 0.0 110.407 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.813 HG13 ' CE2' ' A' ' 147' ' ' PHE . 43.0 t -146.15 165.77 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.34 -0.85 . . . . 0.0 109.45 179.721 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.556 ' CB ' ' HB2' ' A' ' 117' ' ' HIS . 24.2 m -124.77 133.42 53.16 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.146 -0.971 . . . . 0.0 109.681 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.701 ' HD2' HD13 ' A' ' 90' ' ' ILE . 1.0 OUTLIER -129.1 103.85 7.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.126 -0.984 . . . . 0.0 109.477 179.497 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.647 HG22 ' HA ' ' A' ' 115' ' ' ARG . 29.2 p -128.14 175.63 8.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.133 -0.979 . . . . 0.0 110.323 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.904 HG23 ' H ' ' A' ' 114' ' ' GLY . 0.0 OUTLIER -133.45 106.34 9.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-O 121.575 0.702 . . . . 0.0 110.316 179.175 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.459 ' O ' ' HG2' ' A' ' 142' ' ' ARG . . . -101.54 132.46 10.97 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 108.052 -2.019 . . . . 0.0 108.052 178.554 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.584 ' OD1' ' CE1' ' A' ' 113' ' ' TYR . 0.2 OUTLIER -96.87 -170.62 2.08 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.963 -1.316 . . . . 0.0 109.052 -179.399 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 44.6 mt-30 -81.28 -19.8 42.24 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 118.751 -1.18 . . . . 0.0 109.829 -179.439 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.539 ' HB3' ' CG ' ' A' ' 111' ' ' GLN . 0.6 OUTLIER -81.92 8.82 9.45 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.113 -0.992 . . . . 0.0 108.792 178.979 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 110' ' ' PHE . . . . . 0.44 ' HB2' ' O ' ' A' ' 109' ' ' SER . 18.3 m-30 63.01 21.75 13.08 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.428 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.539 ' CG ' ' HB3' ' A' ' 109' ' ' SER . 0.0 OUTLIER -88.36 161.61 17.01 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.649 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.82 102.12 12.22 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.447 -0.783 . . . . 0.0 109.768 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 1.016 ' OH ' HG13 ' A' ' 134' ' ' VAL . 1.9 m-30 -69.41 -67.14 0.5 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.401 -0.812 . . . . 0.0 108.941 178.553 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.904 ' H ' HG23 ' A' ' 105' ' ' VAL . . . -130.55 171.45 20.72 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.647 ' HA ' HG22 ' A' ' 104' ' ' THR . 0.2 OUTLIER -162.78 117.31 1.75 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.029 -1.277 . . . . 0.0 110.723 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.891 HD21 ' CD2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -150.62 74.31 1.17 Allowed 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 178.997 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 117' ' ' HIS . . . . . 0.556 ' HB2' ' CB ' ' A' ' 102' ' ' SER . 22.4 p80 -118.3 169.15 9.97 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.193 -0.942 . . . . 0.0 110.134 -179.304 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.512 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 0.2 OUTLIER 77.53 41.04 0.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.517 -0.739 . . . . 0.0 109.294 179.925 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 119' ' ' GLN . . . . . 0.452 ' HG3' HD11 ' A' ' 121' ' ' ILE . 0.8 OUTLIER -116.03 138.35 51.3 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.316 -0.865 . . . . 0.0 109.668 -179.836 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 120' ' ' GLN . . . . . 0.486 ' O ' HD13 ' A' ' 121' ' ' ILE . 2.4 mt-30 -74.54 156.49 36.8 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.486 HD13 ' O ' ' A' ' 120' ' ' GLN . 5.2 mm -135.19 134.64 52.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.116 -0.99 . . . . 0.0 110.022 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.0 -179.43 7.25 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.523 -0.735 . . . . 0.0 109.947 179.477 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.581 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 70.2 p -75.98 -0.46 21.67 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 119.829 -0.748 . . . . 0.0 109.23 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.442 ' O ' ' HG3' ' A' ' 93' ' ' ARG . 22.5 mm-40 -102.4 -168.91 1.59 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.246 -0.909 . . . . 0.0 109.21 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' TRP . . . . . 0.679 ' CH2' HG11 ' A' ' 56' ' ' VAL . 88.4 m95 -103.2 115.17 30.07 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 0.0 109.614 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 -106.68 120.75 47.32 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.11 -0.994 . . . . 0.0 108.986 179.65 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.408 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.9 Cg_endo -80.58 116.28 3.22 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 C-N-CA 122.384 2.056 . . . . 0.0 111.175 -179.635 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -112.03 135.6 52.46 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.689 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.435 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -145.71 176.3 9.75 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 120.822 -1.174 . . . . 0.0 110.801 -179.348 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.891 ' CD2' HD21 ' A' ' 116' ' ' LEU . 21.2 p90 -176.89 152.7 0.96 Allowed 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.303 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -105.28 154.91 19.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.752 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 113' ' ' TYR . 0.2 OUTLIER -165.02 160.88 19.43 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.431 -0.793 . . . . 0.0 109.334 179.942 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.7 OUTLIER -124.13 146.42 48.65 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.214 -0.929 . . . . 0.0 108.937 -179.883 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 1.016 HG13 ' OH ' ' A' ' 113' ' ' TYR . 3.5 t -43.57 109.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.294 -0.879 . . . . 0.0 108.955 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -51.41 -40.05 58.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.123 -0.986 . . . . 0.0 109.149 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -129.81 -90.28 0.48 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.38 -0.825 . . . . 0.0 109.369 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -158.58 52.73 0.42 Allowed 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.479 -0.763 . . . . 0.0 109.279 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' GLU . . . . . 0.6 ' O ' HG23 ' A' ' 80' ' ' VAL . 32.5 mm-40 -85.53 110.15 19.01 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.261 -0.9 . . . . 0.0 109.547 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.3 p -79.48 -16.25 56.38 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.249 -0.907 . . . . 0.0 108.71 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.515 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 42.4 t -132.24 134.31 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.06 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.725 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -139.81 172.28 12.69 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.051 -1.031 . . . . 0.0 110.447 -179.447 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 142' ' ' ARG . . . . . 0.502 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.0 OUTLIER -143.73 132.07 22.07 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.895 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ALA . . . . . 0.848 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -99.31 106.58 39.88 Favored Pre-proline 0 N--CA 1.487 1.421 0 O-C-N 121.207 -0.933 . . . . 0.0 109.616 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.586 ' C ' HD13 ' A' ' 145' ' ' ILE . 36.1 Cg_endo -78.04 111.92 3.16 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.206 1.937 . . . . 0.0 110.827 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ILE . . . . . 0.705 ' N ' HD13 ' A' ' 145' ' ' ILE . 2.0 mm -94.31 139.56 18.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 178.343 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' HIS . . . . . 0.539 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 4.5 m80 -107.22 159.75 16.11 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.299 -1.501 . . . . 0.0 112.165 -177.007 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.813 ' CE2' HG13 ' A' ' 101' ' ' VAL . 39.0 m-85 -160.72 165.25 30.77 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.639 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 104.52 46.51 1.3 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.729 ' C ' HG11 ' A' ' 64' ' ' VAL . 23.9 m-85 -125.03 161.27 27.1 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.477 -1.013 . . . . 0.0 109.115 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.418 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.72 -28.47 68.45 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -75.78 -11.54 60.0 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.434 -0.791 . . . . 0.0 109.065 179.031 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.613 ' ND2' HD13 ' A' ' 157' ' ' ILE . 1.5 t30 -114.61 11.0 16.88 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.403 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.535 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.4 t -88.02 162.81 2.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.495 -0.753 . . . . 0.0 109.868 -179.223 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 154' ' ' GLY . . . . . 0.466 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.42 34.04 41.07 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 3.5 m-20 -160.39 138.71 10.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.177 -1.19 . . . . 0.0 110.013 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' THR . . . . . 0.841 HG23 ' O ' ' A' ' 59' ' ' VAL . 53.5 m -89.37 120.44 30.72 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.613 HD13 ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -100.37 117.44 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.902 -1.124 . . . . 0.0 110.222 -178.894 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.744 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 13.1 m-85 -92.52 143.63 26.16 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 178.381 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.656 ' CD1' ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -142.04 136.22 29.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.604 -1.31 . . . . 0.0 111.025 -178.014 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 160' ' ' ASP . . . . . 0.801 ' HB3' HG12 ' A' ' 56' ' ' VAL . 4.7 t0 -173.23 136.24 0.62 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.245 -0.909 . . . . 0.0 108.586 179.144 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 133.35 -7.29 5.01 Favored Glycine 0 N--CA 1.484 1.896 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.422 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.848 HD21 ' HB3' ' A' ' 143' ' ' ALA . 7.3 tp -59.33 93.14 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.626 -1.514 . . . . 0.0 108.596 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 163' ' ' ALA . . . . . 0.444 ' N ' ' O ' ' A' ' 161' ' ' GLY . . . -123.62 145.98 48.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.594 -0.691 . . . . 0.0 109.965 -178.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 164' ' ' ILE . . . . . 0.674 HD13 HG11 ' A' ' 78' ' ' VAL . 8.0 mt -132.41 119.58 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.325 -0.86 . . . . 0.0 109.258 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.679 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.772 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.1 tmm? . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -57.09 101.3 0.06 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 0.0 109.427 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.629 HG22 ' O ' ' A' ' 164' ' ' ILE . 4.1 p -87.98 173.5 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.239 -0.913 . . . . 0.0 109.405 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.76 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -71.74 -46.61 57.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.173 -0.955 . . . . 0.0 109.487 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.852 ' HB2' HD12 ' A' ' 164' ' ' ILE . 38.7 t-20 -82.56 125.83 31.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.207 -0.933 . . . . 0.0 109.496 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.472 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 2.0 mp -112.2 123.35 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.292 -0.88 . . . . 0.0 109.265 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.483 ' HB3' ' HA3' ' A' ' 27' ' ' GLY . 0.8 OUTLIER 69.05 12.9 8.7 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.266 -0.896 . . . . 0.0 109.504 179.973 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -59.14 -24.96 59.29 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.458 ' O ' ' OD2' ' A' ' 160' ' ' ASP . . . -110.99 36.56 4.16 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.214 -1.555 . . . . 0.0 109.214 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.733 ' HD2' HG21 ' A' ' 25' ' ' VAL . 0.7 OUTLIER 43.64 53.21 6.02 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.368 -1.078 . . . . 0.0 109.422 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.483 ' OE2' ' CG ' ' A' ' 52' ' ' GLU . 7.7 mm-40 -84.04 -49.62 8.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -0.926 . . . . 0.0 109.728 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.451 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 7.3 m -79.58 -16.49 55.8 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.677 -179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . 1.048 ' OG1' HG13 ' A' ' 25' ' ' VAL . 0.5 OUTLIER -74.51 114.74 36.89 Favored Pre-proline 0 C--N 1.304 -1.389 0 O-C-N 121.185 -0.947 . . . . 0.0 109.422 -179.802 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.2 Cg_endo -77.09 136.9 16.75 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.424 2.082 . . . . 0.0 110.474 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.47 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -40.02 155.51 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.393 0.616 . . . . 0.0 109.717 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.3 132.6 3.0 Favored Glycine 0 N--CA 1.485 1.961 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.531 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.71 142.45 12.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.252 -1.146 . . . . 0.0 109.011 -179.528 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.6 t -88.42 144.14 9.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-O 121.778 0.799 . . . . 0.0 110.277 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.3 t -105.03 -26.69 12.04 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 179.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.48 ' CB ' ' HG3' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -138.18 101.37 4.38 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 179.453 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.969 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.7 OUTLIER -55.56 -34.91 65.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.204 -0.935 . . . . 0.0 110.384 -179.004 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.946 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.69 -33.79 72.03 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.061 -1.024 . . . . 0.0 109.334 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.48 ' HG3' ' CB ' ' A' ' 20' ' ' ASP . 1.4 pt-20 -122.15 37.67 4.32 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.303 -0.873 . . . . 0.0 109.369 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -89.2 -73.1 1.28 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 1.048 HG13 ' OG1' ' A' ' 13' ' ' THR . 14.6 t -99.72 127.43 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.307 -1.113 . . . . 0.0 109.259 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 31.6 tp10 -56.76 -35.69 68.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.417 -0.802 . . . . 0.0 109.783 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.483 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -99.14 -2.4 56.91 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 -179.503 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 0.614 ' CZ3' ' CB ' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -138.79 123.21 18.32 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.088 -1.242 . . . . 0.0 109.845 179.941 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.744 ' C ' HD23 ' A' ' 30' ' ' LEU . 3.9 m-20 -123.47 144.23 49.66 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.969 ' O ' HD13 ' A' ' 21' ' ' LEU . 0.7 OUTLIER -113.5 166.98 10.98 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.714 -1.242 . . . . 0.0 109.461 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.458 ' OD1' ' O ' ' A' ' 30' ' ' LEU . 8.5 m120 -157.02 124.67 5.39 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.45 -0.781 . . . . 0.0 109.687 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.045 ' CG1' HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.04 136.56 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.383 -0.823 . . . . 0.0 109.457 179.539 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.43 -170.6 23.81 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.4 t -66.74 -9.09 33.01 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.195 -1.18 . . . . 0.0 109.438 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.473 ' HB2' ' HA ' ' A' ' 70' ' ' ASP . 0.6 OUTLIER -73.12 -31.39 64.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.204 -0.935 . . . . 0.0 109.593 -179.964 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 1.045 HG21 ' CG1' ' A' ' 32' ' ' VAL . 2.1 t -64.64 87.86 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 O-C-N 121.176 -0.952 . . . . 0.0 109.339 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 16.4 m -72.58 -29.0 63.15 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.624 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.2 t-20 -114.57 144.98 32.88 Favored Pre-proline 0 C--N 1.296 -1.746 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.607 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.446 ' HD2' ' CG ' ' A' ' 38' ' ' ASN . 34.8 Cg_endo -76.38 111.8 3.34 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 122.359 2.039 . . . . 0.0 110.591 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.55 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.2 Cg_endo -77.57 166.13 26.16 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.371 2.048 . . . . 0.0 109.593 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.532 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 49.0 t -108.16 121.59 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.966 -1.084 . . . . 0.0 110.559 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.629 ' CE2' HD23 ' A' ' 21' ' ' LEU . 27.4 m-85 -110.12 112.47 24.48 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.464 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.531 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 0.9 OUTLIER -153.56 151.32 29.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.1 -1.0 . . . . 0.0 109.801 -179.422 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.459 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 62.3 t -98.78 148.57 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -0.885 . . . . 0.0 109.255 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.758 HD21 ' CG2' ' A' ' 47' ' ' THR . 0.4 OUTLIER -131.9 147.01 52.44 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.185 -0.947 . . . . 0.0 108.776 179.978 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.56 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 18.1 mt-10 -115.08 113.69 24.37 Favored 'General case' 0 C--N 1.295 -1.8 0 O-C-N 121.576 -0.702 . . . . 0.0 109.548 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.758 ' CG2' HD21 ' A' ' 45' ' ' LEU . 1.7 p -141.5 164.66 29.62 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.31 -0.869 . . . . 0.0 109.41 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.448 ' HA ' ' OD1' ' A' ' 54' ' ' ASN . 0.1 OUTLIER -86.9 15.59 5.73 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.9 . . . . 0.0 109.51 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -102.89 -18.51 15.03 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.242 -0.911 . . . . 0.0 109.436 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.721 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -55.55 144.68 52.97 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.2 -0.938 . . . . 0.0 109.329 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.515 ' HG3' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.29 -42.12 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.571 2.181 . . . . 0.0 110.365 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.483 ' CG ' ' OE2' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -101.42 92.8 5.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.901 . . . . 0.0 109.407 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.93 -115.97 4.35 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.721 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 15.2 m-20 -160.02 37.77 0.18 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -1.147 . . . . 0.0 109.412 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.52 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 62.1 mttt -138.54 134.24 33.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.198 -0.938 . . . . 0.0 109.6 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.659 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.9 m -146.53 174.62 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.313 -0.867 . . . . 0.0 109.229 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.789 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -107.46 103.09 12.34 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.101 -1.0 . . . . 0.0 109.181 179.731 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.684 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.17 120.71 25.21 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.034 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.824 ' O ' HG23 ' A' ' 156' ' ' THR . 41.5 t -115.79 144.89 22.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.15 -0.969 . . . . 0.0 109.331 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.601 HG22 ' OD1' ' A' ' 62' ' ' ASN . 19.6 m -108.99 92.75 4.18 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.563 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 52.5 t -90.54 115.73 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.236 -0.915 . . . . 0.0 109.272 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.601 ' OD1' HG22 ' A' ' 60' ' ' THR . 0.8 OUTLIER -149.51 56.41 0.98 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.248 -0.908 . . . . 0.0 109.828 -179.767 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 160.9 90.09 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.779 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.5 m -80.14 -171.32 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.176 -1.19 . . . . 0.0 109.451 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -139.95 -168.44 11.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -86.21 1.41 50.86 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.233 -1.157 . . . . 0.0 109.569 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.603 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 1.2 m120 -116.33 145.02 34.16 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.241 -0.912 . . . . 0.0 109.284 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.584 ' HG2' ' CZ3' ' A' ' 69' ' ' TRP . 36.4 Cg_endo -79.52 38.88 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.607 2.204 . . . . 0.0 111.197 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.603 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 8.2 p90 -162.58 50.05 0.18 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.968 -1.082 . . . . 0.0 109.807 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.649 ' HB2' HD12 ' A' ' 71' ' ' ILE . 0.4 OUTLIER -70.94 -64.64 0.86 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.126 -0.984 . . . . 0.0 108.924 179.536 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.649 HD12 ' HB2' ' A' ' 70' ' ' ASP . 4.1 mp -106.4 128.73 60.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 108.996 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.452 ' OE2' ' HB2' ' A' ' 144' ' ' PRO . 71.3 tt0 -138.26 122.68 18.35 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.843 -1.16 . . . . 0.0 110.195 -179.551 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.635 ' CB ' HD22 ' A' ' 30' ' ' LEU . . . -113.76 107.41 15.7 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.069 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.55 HG22 ' N ' ' A' ' 75' ' ' ALA . 96.7 m -94.4 165.44 12.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.57 -0.706 . . . . 0.0 110.17 -179.107 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.55 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.12 137.78 53.36 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.175 -0.953 . . . . 0.0 108.726 178.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.536 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 0.2 OUTLIER -179.12 161.49 1.0 Allowed Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.561 -0.712 . . . . 0.0 109.165 -179.387 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.536 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.2 Cg_endo -82.46 163.32 74.97 Favored 'Cis proline' 0 C--N 1.311 -1.437 0 C-N-CA 123.81 -1.329 . . . . 0.0 110.893 -0.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.761 HG11 HD13 ' A' ' 164' ' ' ILE . 96.8 t -123.99 156.45 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.4 -0.813 . . . . 0.0 108.913 179.206 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.76 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 52.1 m-20 -121.21 139.8 52.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.115 -0.991 . . . . 0.0 109.854 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.565 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 2.5 m -146.3 -174.0 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.138 -0.976 . . . . 0.0 109.478 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.691 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -137.3 146.09 52.52 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.233 -0.917 . . . . 0.0 109.429 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.45 106.14 2.16 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.474 2.116 . . . . 0.0 110.494 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 112.35 -29.7 8.12 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.475 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.43 149.71 4.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.158 -1.201 . . . . 0.0 109.474 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.471 ' HA ' ' OG1' ' A' ' 133' ' ' THR . 10.8 m -95.47 143.07 27.11 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.565 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 12.0 m-85 -120.61 168.49 11.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.171 -0.956 . . . . 0.0 109.604 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.478 ' CB ' ' O ' ' A' ' 165' ' ' ALA . 5.2 m -118.15 154.47 32.1 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.26 -0.9 . . . . 0.0 109.561 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.682 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 5.1 t80 -130.56 118.96 21.81 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.298 -0.876 . . . . 0.0 109.319 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.474 ' O ' ' O ' ' A' ' 161' ' ' GLY . 31.8 m -134.31 144.04 48.07 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.215 -0.928 . . . . 0.0 109.333 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.552 HD13 ' CD2' ' A' ' 103' ' ' PHE . 14.9 tt -150.62 163.54 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 120.703 -1.248 . . . . 0.0 109.506 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.515 ' HB2' ' HG3' ' A' ' 51' ' ' PRO . 20.1 m95 -132.73 124.98 29.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.974 -1.079 . . . . 0.0 109.342 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.88 150.42 37.08 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.288 -0.883 . . . . 0.0 109.459 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.552 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 1.1 ttt85 -164.4 119.12 1.44 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.309 -0.869 . . . . 0.0 109.027 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.39 170.1 8.12 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 110.065 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -66.12 -55.94 13.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.443 -0.785 . . . . 0.0 109.41 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.514 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -104.43 137.3 42.5 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.222 -0.924 . . . . 0.0 109.463 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.585 ' N ' ' CG2' ' A' ' 123' ' ' THR . 19.2 p-10 -61.64 148.35 42.82 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.308 -0.87 . . . . 0.0 109.562 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 108.9 39.43 1.71 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.506 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -119.55 141.15 49.5 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.14 -1.212 . . . . 0.0 108.98 179.657 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.401 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 52.0 t -115.94 148.25 18.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 110.712 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.634 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 25.1 t -150.01 164.96 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.457 -0.777 . . . . 0.0 109.203 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.539 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 16.4 t -136.47 144.33 44.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.011 -1.056 . . . . 0.0 109.457 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.629 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.1 OUTLIER -135.99 104.67 5.78 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.224 -0.923 . . . . 0.0 109.924 -179.726 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.507 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 14.0 p -112.77 168.75 9.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.093 -1.005 . . . . 0.0 110.058 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -127.83 141.45 46.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 CA-C-O 121.386 0.612 . . . . 0.0 109.837 -179.879 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -167.49 143.9 8.58 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.4 p30 -84.66 -169.79 2.8 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.197 -1.179 . . . . 0.0 109.632 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.52 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 11.2 mp0 -77.84 16.95 0.62 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.196 -0.94 . . . . 0.0 110.683 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.463 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 0.8 OUTLIER -113.23 15.46 19.36 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 120.831 -1.168 . . . . 0.0 108.801 179.447 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.463 ' HB2' ' O ' ' A' ' 109' ' ' SER . 9.8 m-30 67.63 16.86 9.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.504 -0.748 . . . . 0.0 109.599 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.528 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 12.8 mm-40 -93.5 157.66 16.1 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.177 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.471 ' OE2' ' HB2' ' A' ' 115' ' ' ARG . 8.0 tt0 -137.83 147.15 44.29 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.034 -1.041 . . . . 0.0 109.99 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.509 ' CE2' HG21 ' A' ' 141' ' ' ILE . 4.0 m-85 -112.3 -67.4 1.0 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.237 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.587 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -92.35 173.42 35.73 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.471 ' HB2' ' OE2' ' A' ' 112' ' ' GLU . 6.8 ttt-85 -178.78 119.46 0.08 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.08 -1.247 . . . . 0.0 110.217 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.646 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -141.91 70.03 1.33 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.396 -0.815 . . . . 0.0 108.803 179.241 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.54 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 0.2 OUTLIER -86.64 148.07 25.63 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 110.346 -179.265 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 1.2 mt-10 79.42 66.32 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.466 -0.771 . . . . 0.0 109.557 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLN . . . . . 0.472 ' HA ' ' NE2' ' A' ' 119' ' ' GLN . 7.8 mm100 -118.79 123.73 45.51 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.315 -0.866 . . . . 0.0 109.259 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.553 ' O ' HD13 ' A' ' 121' ' ' ILE . 0.0 OUTLIER -64.23 139.14 58.73 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.429 -0.794 . . . . 0.0 108.972 179.78 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 120' ' ' GLN . 5.6 mm -125.95 130.17 72.32 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.08 -1.012 . . . . 0.0 110.14 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.04 -179.28 6.17 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.604 0.716 . . . . 0.0 109.949 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.585 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 74.9 p -75.85 -4.19 39.36 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.793 -0.763 . . . . 0.0 109.183 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 2.8 mt-10 -106.65 -168.78 1.46 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.327 -0.858 . . . . 0.0 109.311 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.552 ' CE2' ' HD3' ' A' ' 93' ' ' ARG . 93.8 m95 -94.38 118.64 31.92 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.208 -0.933 . . . . 0.0 109.691 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -106.88 121.44 44.88 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.289 -0.882 . . . . 0.0 108.985 179.723 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -79.54 117.05 3.64 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.341 2.027 . . . . 0.0 111.075 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -121.25 138.29 54.3 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.7 t -151.27 175.81 11.84 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.608 -1.308 . . . . 0.0 111.149 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.682 ' CE2' ' CD1' ' A' ' 88' ' ' TYR . 36.3 p90 -173.22 -172.69 0.84 Allowed 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.095 179.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' GLU . . . . . 0.412 ' N ' ' CD1' ' A' ' 130' ' ' PHE . 21.7 mt-10 -129.01 155.78 44.86 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.098 -1.001 . . . . 0.0 110.051 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -164.98 139.18 4.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.422 -0.799 . . . . 0.0 109.065 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.471 ' OG1' ' HA ' ' A' ' 85' ' ' THR . 0.8 OUTLIER -117.85 146.19 44.05 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.216 -0.927 . . . . 0.0 109.377 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.691 HG21 ' O ' ' A' ' 81' ' ' ARG . 4.4 t -44.57 110.49 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.396 -0.815 . . . . 0.0 109.203 179.426 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 65.5 m -61.8 -53.08 60.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.207 -0.933 . . . . 0.0 109.258 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 -102.91 -91.74 0.34 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.359 -0.838 . . . . 0.0 109.218 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -162.27 50.59 0.2 Allowed 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.458 -0.776 . . . . 0.0 109.314 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.51 ' O ' HG23 ' A' ' 80' ' ' VAL . 23.1 mm-40 -88.18 114.63 25.0 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.209 -0.932 . . . . 0.0 109.604 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.6 p -79.19 -12.38 59.97 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.294 -0.879 . . . . 0.0 108.759 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.492 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 40.8 t -135.73 134.77 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.391 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.509 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -139.58 172.52 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.194 -0.941 . . . . 0.0 110.057 -179.725 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.493 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.4 ptm180 -145.54 132.54 20.28 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.556 -0.715 . . . . 0.0 109.614 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.596 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -100.24 106.58 42.87 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.292 -0.88 . . . . 0.0 109.655 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.507 ' HD2' ' O ' ' A' ' 104' ' ' THR . 33.7 Cg_endo -76.64 110.56 3.07 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.061 1.841 . . . . 0.0 110.291 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.633 ' N ' HD13 ' A' ' 145' ' ' ILE . 3.2 mm -85.71 124.74 40.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.499 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 6.7 m80 -84.57 150.15 25.41 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.972 -1.08 . . . . 0.0 110.984 -178.158 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.66 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 12.1 m-85 -154.91 157.36 37.66 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.125 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.599 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 108.44 50.67 0.74 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.779 ' C ' HG11 ' A' ' 64' ' ' VAL . 27.5 m-85 -121.17 159.77 25.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.378 -1.072 . . . . 0.0 109.227 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.487 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -65.78 -30.39 71.03 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.611 -0.681 . . . . 0.0 109.168 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.467 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -77.0 -11.0 59.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.394 -0.816 . . . . 0.0 109.108 179.273 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.577 ' ND2' HD13 ' A' ' 157' ' ' ILE . 3.8 t30 -109.81 11.62 24.28 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.55 HG23 HG13 ' A' ' 64' ' ' VAL . 2.4 t -90.06 164.76 2.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 O-C-N 121.519 -0.738 . . . . 0.0 109.763 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.493 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 53.29 32.7 44.72 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.864 -1.295 . . . . 0.0 109.864 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.7 m-20 -160.53 136.78 8.59 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.137 -1.214 . . . . 0.0 110.04 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.824 HG23 ' O ' ' A' ' 59' ' ' VAL . 53.6 m -86.83 121.13 28.9 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.01 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.577 HD13 ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -100.86 118.73 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 120.967 -1.083 . . . . 0.0 110.291 -178.775 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.684 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.6 m-85 -97.09 129.42 44.51 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 178.613 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.66 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -120.37 141.99 38.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 120.749 -1.219 . . . . 0.0 110.091 -178.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.659 ' CB ' HG12 ' A' ' 56' ' ' VAL . 4.5 t70 -173.89 136.41 0.54 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.299 -0.876 . . . . 0.0 108.901 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 124.78 -6.93 8.34 Favored Glycine 0 N--CA 1.486 2.033 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.157 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.601 HD11 ' CE2' ' A' ' 88' ' ' TYR . 0.6 OUTLIER -60.01 94.04 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 O-C-N 120.768 -1.43 . . . . 0.0 108.491 179.899 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 163' ' ' ALA . . . . . 0.494 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -132.93 145.85 51.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.633 -0.667 . . . . 0.0 109.815 -179.068 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.852 HD12 ' HB2' ' A' ' 5' ' ' ASN . 3.2 mt -123.08 115.65 46.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.235 -0.915 . . . . 0.0 109.202 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.5 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . -142.02 146.69 35.81 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.171 -0.956 . . . . 0.0 109.626 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 4.0 p -84.42 176.58 8.58 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.279 -0.888 . . . . 0.0 109.533 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.435 ' HB2' ' HD2' ' A' ' 168' ' ' PRO . 2.3 pt20 -76.66 159.45 79.21 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.27 -0.894 . . . . 0.0 109.543 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 167' ' ' GLN . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.576 0 C-N-CA 122.674 2.25 . . . . 0.0 110.449 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.634 ' O ' HG12 ' A' ' 3' ' ' VAL . 1.0 OUTLIER -77.38 -23.39 50.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.183 -0.948 . . . . 0.0 109.451 179.992 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.874 ' CG2' ' HB2' ' A' ' 165' ' ' ALA . 1.4 p 43.85 -169.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.359 -0.838 . . . . 0.0 109.553 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.713 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -70.79 -61.19 1.86 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.058 -1.027 . . . . 0.0 109.324 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.599 ' HB3' HD13 ' A' ' 164' ' ' ILE . 13.0 p-10 -74.92 176.92 6.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.367 -0.833 . . . . 0.0 109.405 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.669 HG22 ' ND2' ' A' ' 7' ' ' ASN . 2.6 mp -128.3 136.83 59.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.286 -0.884 . . . . 0.0 109.717 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.669 ' ND2' HG22 ' A' ' 6' ' ' ILE . 0.3 OUTLIER 44.92 57.71 4.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.678 179.908 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.497 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -56.96 -42.79 92.92 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.504 ' HA2' ' HA ' ' A' ' 160' ' ' ASP . . . -107.74 35.62 4.89 Favored Glycine 0 N--CA 1.487 2.088 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.994 ' CE2' HG21 ' A' ' 25' ' ' VAL . 4.1 m-85 63.52 54.73 1.87 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.468 -1.019 . . . . 0.0 109.386 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -82.35 -50.53 8.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.897 . . . . 0.0 109.737 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.532 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 41.3 t -69.9 -42.14 73.77 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.105 -0.997 . . . . 0.0 109.693 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.956 ' OG1' HG13 ' A' ' 25' ' ' VAL . 0.6 OUTLIER -68.53 125.71 91.99 Favored Pre-proline 0 C--N 1.305 -1.351 0 O-C-N 121.217 -0.927 . . . . 0.0 109.199 -179.882 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.47 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.2 Cg_endo -76.98 146.1 25.53 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 122.462 2.108 . . . . 0.0 111.071 -179.493 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.804 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -42.05 165.48 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.564 0 CA-C-O 121.214 0.53 . . . . 0.0 109.663 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 130.96 135.27 3.76 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.531 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.57 140.14 15.14 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.34 -1.094 . . . . 0.0 109.029 -179.596 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -84.77 143.67 11.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 CA-C-O 121.763 0.792 . . . . 0.0 110.196 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.4 p -113.56 -27.1 7.99 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.553 ' CB ' ' HG3' ' A' ' 23' ' ' GLU . 20.5 m-20 -133.42 77.83 1.75 Allowed 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.923 HD12 ' N ' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -44.63 -32.25 1.41 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.323 -0.861 . . . . 0.0 109.708 -179.365 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.923 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -71.11 -47.03 60.44 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.283 -0.885 . . . . 0.0 109.548 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.553 ' HG3' ' CB ' ' A' ' 20' ' ' ASP . 9.1 pt-20 -115.49 38.12 3.36 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.257 -0.902 . . . . 0.0 109.569 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 20' ' ' ASP . . . -106.9 -77.69 1.09 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.994 HG21 ' CE2' ' A' ' 10' ' ' PHE . 5.8 t -92.8 111.0 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.283 -1.128 . . . . 0.0 109.264 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -59.98 -39.86 87.15 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.299 -0.876 . . . . 0.0 109.867 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.461 ' HA3' ' HB2' ' A' ' 7' ' ' ASN . . . -67.56 -35.12 85.86 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.454 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 0.535 ' CE3' ' HB1' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -129.64 126.26 37.98 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.153 -1.204 . . . . 0.0 109.67 -179.797 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.727 ' C ' HD23 ' A' ' 30' ' ' LEU . 6.3 m-20 -115.54 141.25 48.31 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.902 ' O ' HD13 ' A' ' 21' ' ' LEU . 0.9 OUTLIER -116.29 163.13 16.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.716 -1.24 . . . . 0.0 109.53 -179.548 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 71.8 m-80 -156.18 123.15 5.29 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.518 -0.738 . . . . 0.0 109.402 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.005 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -102.97 133.84 45.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.342 -0.849 . . . . 0.0 109.514 179.571 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.14 167.34 16.89 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -44.86 -26.16 0.38 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -1.142 . . . . 0.0 109.411 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.491 ' CB ' ' HB2' ' A' ' 67' ' ' ASN . 6.8 m -53.08 -53.12 55.0 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.19 -0.944 . . . . 0.0 109.455 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 1.005 HG21 HG12 ' A' ' 32' ' ' VAL . 42.2 t -46.18 94.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.2 -0.938 . . . . 0.0 110.196 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.484 ' N ' ' O ' ' A' ' 35' ' ' SER . 82.9 m -78.25 -27.53 47.6 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.336 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.512 ' O ' HG12 ' A' ' 36' ' ' VAL . 20.1 m-20 -114.9 147.36 38.1 Favored Pre-proline 0 C--N 1.297 -1.696 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.32 111.08 3.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.496 2.131 . . . . 0.0 110.768 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.538 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 36.0 Cg_endo -78.69 167.33 22.63 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.495 2.13 . . . . 0.0 109.684 179.551 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.524 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 51.1 t -110.38 121.89 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.953 -1.092 . . . . 0.0 110.47 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.634 ' CD2' HD23 ' A' ' 21' ' ' LEU . 28.2 m-85 -111.01 112.8 24.87 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 178.503 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.531 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 29.3 tt0 -151.08 160.8 43.68 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.109 -0.994 . . . . 0.0 109.702 -179.383 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.476 HG13 ' O ' ' A' ' 56' ' ' VAL . 49.2 t -102.26 133.48 45.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.434 -0.791 . . . . 0.0 109.133 179.555 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.508 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -111.28 118.7 36.62 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.349 -0.845 . . . . 0.0 109.415 -179.606 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.804 ' HG3' ' HB2' ' A' ' 15' ' ' ALA . 6.1 mt-10 -91.65 109.84 21.16 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 4.8 p -141.67 153.89 44.99 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.544 -0.723 . . . . 0.0 109.41 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 89.3 p -78.85 -10.15 59.7 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.228 -0.92 . . . . 0.0 109.484 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.401 ' O ' ' C ' ' A' ' 50' ' ' ALA . 5.4 m-20 -79.81 -18.17 51.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.191 -0.943 . . . . 0.0 109.536 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.405 ' HA ' ' HD3' ' A' ' 51' ' ' PRO . . . -45.02 147.65 1.13 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.895 . . . . 0.0 109.544 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.512 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.16 -40.59 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.629 2.219 . . . . 0.0 110.355 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.27 115.57 26.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.52 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.05 -124.54 23.35 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -152.74 22.85 0.59 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.164 -1.198 . . . . 0.0 109.499 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.521 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 8.6 mttt -129.37 143.61 50.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.436 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.627 HG12 ' CB ' ' A' ' 160' ' ' ASP . 11.9 m -150.24 175.59 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.347 -0.846 . . . . 0.0 109.004 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.685 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -108.43 99.64 9.01 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.057 -1.027 . . . . 0.0 109.033 179.508 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.614 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.23 119.2 23.32 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.818 ' O ' HG23 ' A' ' 156' ' ' THR . 43.7 t -115.68 144.85 22.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.134 -0.979 . . . . 0.0 109.212 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.524 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 9.3 m -108.96 91.69 3.74 Favored 'General case' 0 C--N 1.283 -2.313 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.546 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 48.2 t -89.58 117.41 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.395 -0.815 . . . . 0.0 109.091 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -154.4 58.55 0.7 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.305 -0.872 . . . . 0.0 109.935 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 157.02 84.2 0.05 OUTLIER Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.706 HG12 ' C ' ' A' ' 148' ' ' GLY . 1.8 m -80.07 -175.85 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.21 -1.171 . . . . 0.0 109.513 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -129.31 -148.52 6.59 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -94.74 -5.89 44.33 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.325 -1.103 . . . . 0.0 109.576 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.568 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 27.8 m-20 -112.74 146.75 35.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.077 -1.014 . . . . 0.0 109.45 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.414 ' O ' ' CE1' ' A' ' 149' ' ' TYR . 36.3 Cg_endo -78.7 12.99 2.02 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.602 2.202 . . . . 0.0 110.931 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.568 ' CZ2' ' OD1' ' A' ' 67' ' ' ASN . 4.2 p90 -133.5 51.86 2.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.035 -1.041 . . . . 0.0 109.659 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.484 ' O ' ' CG2' ' A' ' 36' ' ' VAL . 2.6 m-20 -74.24 -64.17 1.08 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.3 -0.875 . . . . 0.0 109.193 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.581 HG22 ' HB2' ' A' ' 147' ' ' PHE . 2.9 mp -100.22 118.3 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 109.043 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -121.4 127.49 51.23 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.138 -0.976 . . . . 0.0 110.15 -179.565 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.888 ' HB3' ' CE1' ' A' ' 147' ' ' PHE . . . -123.72 108.26 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.26 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.561 HG22 ' N ' ' A' ' 75' ' ' ALA . 86.0 m -104.95 165.76 10.85 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.418 -0.801 . . . . 0.0 109.95 -179.008 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.561 ' N ' HG22 ' A' ' 74' ' ' THR . . . -120.92 140.13 52.27 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.071 -1.018 . . . . 0.0 108.875 178.753 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.568 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.3 p90 179.53 162.86 0.79 Allowed Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.496 -0.752 . . . . 0.0 109.2 -179.551 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.568 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.8 Cg_endo -82.14 169.31 62.94 Favored 'Cis proline' 0 C--N 1.311 -1.416 0 C-N-CA 123.885 -1.298 . . . . 0.0 110.856 -0.534 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 85.1 t -127.65 156.22 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.388 -0.82 . . . . 0.0 108.891 179.292 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.541 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 16.5 m-80 -123.44 118.66 27.95 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.16 -0.962 . . . . 0.0 109.94 -179.567 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.556 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 3.0 m -124.63 -173.83 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.27 -0.894 . . . . 0.0 109.541 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.664 ' O ' HG21 ' A' ' 134' ' ' VAL . 15.3 mmt180 -136.63 144.93 49.14 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.332 -0.855 . . . . 0.0 109.269 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.19 120.57 5.4 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 122.545 2.163 . . . . 0.0 110.618 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 98.21 -27.76 17.81 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.417 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.06 149.7 4.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.21 -1.171 . . . . 0.0 109.501 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 28.5 m -95.86 133.03 40.49 Favored 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.556 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 7.4 m-85 -111.68 166.76 10.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.896 . . . . 0.0 109.692 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.479 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 32.4 m -118.38 154.31 32.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.358 -0.839 . . . . 0.0 109.335 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.69 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 7.6 t80 -129.72 117.98 21.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.159 -0.963 . . . . 0.0 109.548 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.476 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.7 m -135.0 144.26 47.26 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.24 -0.912 . . . . 0.0 109.186 179.794 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.756 HD12 ' HB2' ' A' ' 162' ' ' LEU . 14.4 tt -150.49 163.78 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 120.817 -1.177 . . . . 0.0 109.562 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.512 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 19.8 m95 -132.73 125.99 31.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.062 -1.024 . . . . 0.0 109.303 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -117.08 151.81 36.01 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.359 -0.838 . . . . 0.0 109.487 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.56 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 8.5 ttp85 -164.14 118.49 1.47 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.188 -0.945 . . . . 0.0 109.188 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -105.37 160.93 14.74 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.301 -0.874 . . . . 0.0 109.951 -179.522 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -58.95 -48.56 81.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.417 -0.802 . . . . 0.0 109.289 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.517 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 2.0 mt-30 -113.91 142.16 46.47 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.273 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.582 ' N ' HG22 ' A' ' 123' ' ' THR . 28.4 p-10 -65.14 146.16 55.34 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.23 -0.919 . . . . 0.0 109.485 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 110.91 38.3 1.57 Allowed Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.494 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -120.45 140.66 51.07 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.257 -1.143 . . . . 0.0 109.082 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.422 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 55.5 t -116.14 145.27 22.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.224 -0.922 . . . . 0.0 110.766 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.7 HG13 ' CE2' ' A' ' 147' ' ' PHE . 39.0 t -143.05 165.86 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.569 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.536 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 4.1 m -123.25 126.22 46.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.069 -1.019 . . . . 0.0 109.9 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.537 ' CD1' HD13 ' A' ' 90' ' ' ILE . 66.8 m-85 -116.79 103.45 10.34 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.028 -1.045 . . . . 0.0 109.322 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.504 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 17.8 p -128.11 164.73 21.8 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.011 -1.055 . . . . 0.0 110.691 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.653 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -129.7 155.95 41.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-O 121.213 0.53 . . . . 0.0 109.964 -179.934 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.521 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -174.11 -173.81 40.47 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.2 p30 -131.24 -169.56 2.2 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.152 -1.205 . . . . 0.0 109.45 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.52 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 3.5 mp0 -68.34 3.81 1.58 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.098 -1.002 . . . . 0.0 111.336 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.462 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 1.4 m -107.1 14.87 25.83 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 120.661 -1.274 . . . . 0.0 109.239 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.462 ' HB2' ' O ' ' A' ' 109' ' ' SER . 13.7 m-30 67.04 7.84 5.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.447 -0.783 . . . . 0.0 109.609 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.521 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 6.0 tt0 -80.07 158.32 26.47 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.49 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 4.2 tt0 -136.15 136.5 40.09 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.028 -1.045 . . . . 0.0 110.012 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.573 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 7.3 m-85 -96.17 -70.74 0.7 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.412 -0.805 . . . . 0.0 108.875 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.58 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -81.92 156.48 36.3 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 179.5 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.7 ttt180 -153.36 106.94 3.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.057 -1.261 . . . . 0.0 110.258 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.716 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -146.12 70.0 1.22 Allowed 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.146 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.536 ' CB ' ' HB3' ' A' ' 102' ' ' SER . 4.1 p80 -107.85 160.71 15.53 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.252 -0.905 . . . . 0.0 110.048 -179.449 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 16.5 tt0 77.28 58.56 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.361 -0.837 . . . . 0.0 109.469 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 4.0 mm-40 -130.14 136.98 49.88 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.315 -0.866 . . . . 0.0 109.501 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.447 ' O ' HD13 ' A' ' 121' ' ' ILE . 47.9 mt-30 -70.88 156.28 39.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.472 -0.768 . . . . 0.0 109.065 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 99' ' ' ALA . 6.0 mm -133.49 135.67 55.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.148 -0.97 . . . . 0.0 109.873 -179.455 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -82.74 -179.34 7.4 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.672 0.749 . . . . 0.0 110.001 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.582 HG22 ' N ' ' A' ' 97' ' ' ASP . 63.7 p -78.45 -1.59 34.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.511 -0.743 . . . . 0.0 109.307 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.411 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 2.5 mt-10 -108.42 -168.87 1.41 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.184 -0.947 . . . . 0.0 109.397 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.56 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 95.5 m95 -95.26 121.15 36.61 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.206 -0.934 . . . . 0.0 109.688 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -106.84 121.02 46.3 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.261 -0.899 . . . . 0.0 108.935 179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.407 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.8 Cg_endo -80.25 107.39 2.03 Favored 'Trans proline' 0 C--N 1.311 -1.416 0 C-N-CA 122.456 2.104 . . . . 0.0 111.064 -179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -111.0 135.5 51.41 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 178.731 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.8 t -151.13 175.74 11.85 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 120.701 -1.25 . . . . 0.0 111.078 -179.187 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.716 ' CE2' HD21 ' A' ' 116' ' ' LEU . 33.8 p90 -171.89 -177.64 1.99 Allowed 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.192 179.285 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -127.92 151.11 49.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.191 -0.943 . . . . 0.0 109.757 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.573 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.07 168.15 17.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.44 -0.788 . . . . 0.0 109.255 179.841 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -138.69 147.74 43.13 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.5 -179.663 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.664 HG21 ' O ' ' A' ' 81' ' ' ARG . 6.0 t -40.43 110.33 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.607 -0.683 . . . . 0.0 109.367 179.663 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 27.8 m -59.95 -51.58 69.05 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.283 -0.885 . . . . 0.0 109.255 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -106.74 -90.87 0.42 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.384 -0.823 . . . . 0.0 109.213 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -163.98 53.97 0.15 Allowed 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.478 -0.764 . . . . 0.0 109.058 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.55 ' O ' HG23 ' A' ' 80' ' ' VAL . 31.6 mm-40 -91.67 113.22 25.43 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.188 -0.945 . . . . 0.0 109.791 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.5 p -79.44 -14.07 59.17 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.275 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.3 t -134.01 132.07 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.128 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.509 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -141.59 171.92 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.164 -0.96 . . . . 0.0 110.051 -179.608 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.519 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 2.9 ptm180 -143.76 133.12 23.28 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.624 -0.673 . . . . 0.0 109.263 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.759 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -94.44 108.62 37.82 Favored Pre-proline 0 N--CA 1.487 1.384 0 O-C-N 121.302 -0.874 . . . . 0.0 109.897 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.658 ' C ' HD13 ' A' ' 145' ' ' ILE . 35.4 Cg_endo -76.74 113.49 3.66 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.16 1.907 . . . . 0.0 110.847 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.723 ' N ' HD13 ' A' ' 145' ' ' ILE . 1.7 mm -97.26 141.66 15.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 178.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 147' ' ' PHE . 6.2 m80 -105.28 158.32 16.69 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.55 -1.344 . . . . 0.0 111.691 -177.634 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.888 ' CE1' ' HB3' ' A' ' 73' ' ' ALA . 20.9 m-85 -160.81 158.2 28.05 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.132 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.706 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 108.13 43.8 1.25 Allowed Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.686 ' C ' HG11 ' A' ' 64' ' ' VAL . 61.5 m-85 -117.06 161.42 19.44 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.421 -1.047 . . . . 0.0 109.111 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.52 -29.4 69.48 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.472 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -76.61 -10.52 59.45 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 109.179 179.269 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.624 ' ND2' HD13 ' A' ' 157' ' ' ILE . 1.5 t30 -109.74 12.3 24.15 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.365 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -89.15 164.22 2.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 O-C-N 121.551 -0.718 . . . . 0.0 109.784 -179.173 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.492 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.39 32.61 37.98 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.7 m-20 -160.49 136.82 8.65 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.139 -1.212 . . . . 0.0 110.111 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.818 HG23 ' O ' ' A' ' 59' ' ' VAL . 55.3 m -87.59 120.94 29.41 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.624 HD13 ' ND2' ' A' ' 152' ' ' ASN . 0.8 OUTLIER -99.63 117.58 44.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 120.75 -1.219 . . . . 0.0 110.327 -178.781 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.614 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 12.2 m-85 -98.01 135.78 39.21 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 178.447 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.644 ' CD1' ' CE2' ' A' ' 147' ' ' PHE . 1.3 mt -128.16 141.15 47.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 120.768 -1.207 . . . . 0.0 110.44 -178.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.627 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.7 OUTLIER -173.8 136.34 0.55 Allowed 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.348 -0.845 . . . . 0.0 108.837 179.633 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 125.19 -8.23 8.0 Favored Glycine 0 N--CA 1.487 2.066 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.366 179.577 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.759 HD21 ' HB3' ' A' ' 143' ' ' ALA . 4.4 tp -60.2 100.64 0.1 Allowed 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.742 -1.446 . . . . 0.0 108.944 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 163' ' ' ALA . . . . . 0.543 ' C ' HD12 ' A' ' 164' ' ' ILE . . . -133.24 145.75 50.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.455 -0.778 . . . . 0.0 109.778 -179.145 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.702 HD12 ' N ' ' A' ' 164' ' ' ILE . 4.4 mp -126.8 109.07 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.288 -0.882 . . . . 0.0 109.425 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.874 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . -156.1 150.49 25.69 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.171 -0.956 . . . . 0.0 109.637 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 8.5 t -74.78 -43.68 53.52 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.513 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -135.46 92.06 17.89 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.219 -0.926 . . . . 0.0 109.516 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo . . . . . 0 C--N 1.309 -1.545 0 C-N-CA 122.627 2.218 . . . . 0.0 110.403 179.995 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.433 ' HA ' HD23 ' A' ' 2' ' ' LEU . 57.4 mt -109.94 157.15 19.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.243 -0.911 . . . . 0.0 109.516 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.846 HG23 ' HB2' ' A' ' 165' ' ' ALA . 4.2 p -104.06 173.06 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.262 -0.899 . . . . 0.0 109.386 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.922 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -71.64 -59.41 2.77 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.187 -0.945 . . . . 0.0 109.453 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 162' ' ' LEU . 47.4 t-20 -71.26 128.93 37.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.481 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.464 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 2.2 mp -107.7 138.53 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.273 -0.892 . . . . 0.0 109.518 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.523 ' OD1' ' CB ' ' A' ' 12' ' ' SER . 1.0 OUTLIER 66.97 17.31 10.5 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.242 -0.911 . . . . 0.0 109.638 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.5 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -61.52 -35.56 91.28 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.524 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -103.59 28.01 17.33 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.681 ' CD2' HG11 ' A' ' 25' ' ' VAL . 6.5 m-85 50.65 48.03 23.35 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.365 -1.079 . . . . 0.0 109.412 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.438 ' OE1' ' O ' ' A' ' 52' ' ' GLU . 5.6 mm-40 -83.68 -35.81 24.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.236 -0.915 . . . . 0.0 109.67 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.523 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.6 OUTLIER -84.8 -24.81 28.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.234 -0.916 . . . . 0.0 109.663 -179.759 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.9 ' OG1' HG13 ' A' ' 25' ' ' VAL . 0.7 OUTLIER -78.48 121.57 83.87 Favored Pre-proline 0 N--CA 1.486 1.352 0 O-C-N 121.185 -0.947 . . . . 0.0 109.292 -179.896 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 15' ' ' ALA . 36.1 Cg_endo -77.61 138.95 17.64 Favored 'Trans proline' 0 C--N 1.312 -1.36 0 C-N-CA 122.469 2.112 . . . . 0.0 110.754 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.522 ' HA ' ' CG1' ' A' ' 44' ' ' VAL . . . -41.59 163.53 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.71 137.38 4.45 Favored Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.529 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.23 141.52 12.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.325 -1.103 . . . . 0.0 109.079 -179.688 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.479 HG23 ' HA ' ' A' ' 43' ' ' GLU . 46.1 t -85.69 145.65 7.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 CA-C-O 121.695 0.759 . . . . 0.0 109.921 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 4.1 p -106.36 -22.3 12.85 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.411 ' HB3' ' HG3' ' A' ' 23' ' ' GLU . 0.4 OUTLIER -143.94 92.63 2.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.439 -0.788 . . . . 0.0 109.085 179.692 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.969 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -49.41 -33.19 13.26 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.293 -0.88 . . . . 0.0 109.899 -179.339 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.919 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.66 -43.6 93.89 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.165 -0.959 . . . . 0.0 109.514 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.411 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 3.3 pt-20 -118.12 35.74 4.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.252 -0.905 . . . . 0.0 109.336 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.18 -71.8 1.29 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.9 HG13 ' OG1' ' A' ' 13' ' ' THR . 2.0 t -95.96 123.63 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -1.173 . . . . 0.0 109.209 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -56.38 -32.28 64.63 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.421 -0.8 . . . . 0.0 109.854 -179.623 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.492 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -102.33 -3.45 50.7 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.94 -1.124 . . . . 0.0 110.305 -179.35 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 0.585 ' CE3' ' HB1' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -139.77 121.65 15.53 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.932 -1.334 . . . . 0.0 109.877 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.717 ' C ' HD23 ' A' ' 30' ' ' LEU . 1.2 m-20 -121.38 143.12 49.39 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.813 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.969 ' O ' HD13 ' A' ' 21' ' ' LEU . 0.9 OUTLIER -113.25 162.46 15.99 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.781 -1.199 . . . . 0.0 109.439 -179.601 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -152.84 121.17 6.28 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.424 -0.797 . . . . 0.0 109.522 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.868 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.05 135.2 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.4 -0.812 . . . . 0.0 109.675 179.638 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.49 -170.99 25.75 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.04 -4.58 25.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.249 -1.148 . . . . 0.0 109.505 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.484 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 16.0 m -74.11 -31.87 62.96 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.942 . . . . 0.0 109.625 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.868 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -67.68 89.46 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 O-C-N 121.132 -0.98 . . . . 0.0 109.364 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 30.4 m -59.74 -28.69 67.58 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.199 -0.938 . . . . 0.0 108.713 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.687 ' O ' HG13 ' A' ' 36' ' ' VAL . 6.5 m-20 -130.88 130.4 22.83 Favored Pre-proline 0 C--N 1.296 -1.753 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.21 123.11 6.46 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.189 1.926 . . . . 0.0 110.55 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.586 ' HG2' ' CZ ' ' A' ' 42' ' ' PHE . 35.4 Cg_endo -77.46 -165.74 0.35 Allowed 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.366 2.044 . . . . 0.0 110.013 179.695 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.55 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 53.7 t -116.73 121.43 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.116 -0.99 . . . . 0.0 110.458 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.631 ' CE2' HD23 ' A' ' 21' ' ' LEU . 28.0 m-85 -105.11 112.38 25.49 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.529 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 29.2 tt0 -154.56 159.32 40.83 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.194 -0.941 . . . . 0.0 109.857 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.522 ' CG1' ' HA ' ' A' ' 15' ' ' ALA . 89.1 t -95.2 140.59 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.476 -0.765 . . . . 0.0 109.017 179.277 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.435 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.4 OUTLIER -119.38 120.51 37.12 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.327 -0.858 . . . . 0.0 109.793 -179.32 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -77.35 109.83 11.58 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 121.54 0.686 . . . . 0.0 109.152 179.737 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.7 p -128.64 129.89 46.49 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.606 -0.684 . . . . 0.0 109.527 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.2 m -72.41 -12.56 61.16 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.239 -0.913 . . . . 0.0 109.397 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.41 ' O ' ' C ' ' A' ' 50' ' ' ALA . 49.7 m-20 -98.4 2.08 47.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.214 -0.929 . . . . 0.0 109.612 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.529 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -44.31 155.18 0.37 Allowed Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.103 -0.998 . . . . 0.0 109.443 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.533 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.9 Cg_endo -77.91 -35.97 1.25 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.599 2.199 . . . . 0.0 110.335 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.438 ' O ' ' OE1' ' A' ' 11' ' ' GLU . 4.9 tt0 -121.28 97.01 5.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.268 -0.895 . . . . 0.0 109.35 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.8 -115.16 4.07 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.529 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 2.6 m120 -156.63 35.64 0.31 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.226 -1.161 . . . . 0.0 109.405 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.487 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 33.0 mttm -145.5 131.1 18.85 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -0.899 . . . . 0.0 109.505 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.662 HG12 ' OD2' ' A' ' 160' ' ' ASP . 3.9 m -139.72 175.36 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.381 -0.825 . . . . 0.0 109.326 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.723 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -101.79 100.46 10.81 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.063 -1.023 . . . . 0.0 108.776 179.306 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.584 ' HB1' ' CE2' ' A' ' 158' ' ' TYR . . . -81.33 118.21 22.46 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.068 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.837 ' O ' HG23 ' A' ' 156' ' ' THR . 49.3 t -114.9 144.61 22.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.113 -0.992 . . . . 0.0 109.17 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.519 HG22 ' OD1' ' A' ' 62' ' ' ASN . 31.9 m -107.12 93.64 4.66 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.706 HG21 ' CD1' ' A' ' 157' ' ' ILE . 59.9 t -87.93 123.47 40.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.253 -0.905 . . . . 0.0 109.334 -179.69 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.519 ' OD1' HG22 ' A' ' 60' ' ' THR . 0.8 OUTLIER -160.11 60.34 0.35 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.379 -0.825 . . . . 0.0 109.77 -179.89 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 156.38 89.24 0.07 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.798 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.4 m -81.06 -177.14 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.218 -1.166 . . . . 0.0 109.674 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.484 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -130.99 -161.61 10.34 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -95.99 12.54 30.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -1.119 . . . . 0.0 109.545 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.514 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 8.1 m120 -128.33 148.35 67.52 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.194 -0.941 . . . . 0.0 109.508 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.495 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.2 Cg_endo -78.25 11.88 2.24 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.63 2.22 . . . . 0.0 110.963 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.514 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -136.36 58.33 1.74 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.113 -0.992 . . . . 0.0 109.623 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.484 ' CB ' HG23 ' A' ' 36' ' ' VAL . 0.7 OUTLIER -83.11 -69.18 0.65 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.204 -0.935 . . . . 0.0 109.248 179.825 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.541 HG13 ' CG2' ' A' ' 36' ' ' VAL . 4.1 mt -105.94 121.76 58.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.277 -0.89 . . . . 0.0 108.979 179.795 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -130.17 132.89 46.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.098 -1.001 . . . . 0.0 110.224 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.592 ' CB ' HD22 ' A' ' 30' ' ' LEU . . . -121.82 108.47 13.51 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.559 HG22 ' N ' ' A' ' 75' ' ' ALA . 98.3 m -100.2 165.0 11.71 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.386 -0.821 . . . . 0.0 110.006 -179.029 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.559 ' N ' HG22 ' A' ' 74' ' ' THR . . . -118.92 136.42 54.08 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.022 -1.049 . . . . 0.0 108.768 178.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.556 ' CE2' ' OD1' ' A' ' 29' ' ' ASP . 10.1 p90 179.44 160.44 0.76 Allowed Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.585 -0.697 . . . . 0.0 109.276 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.532 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.9 Cg_endo -81.67 164.96 74.89 Favored 'Cis proline' 0 C--N 1.31 -1.465 0 C-N-CA 123.782 -1.341 . . . . 0.0 110.801 -0.495 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 89.1 t -126.81 156.14 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.344 -0.848 . . . . 0.0 109.107 179.269 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.922 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 4.3 m-80 -112.43 145.79 39.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.075 -1.016 . . . . 0.0 109.666 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.581 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 1.1 m -153.32 -173.85 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.174 -0.954 . . . . 0.0 109.467 179.749 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.763 ' O ' HG21 ' A' ' 134' ' ' VAL . 20.5 mtt180 -136.21 146.01 54.5 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.288 -0.883 . . . . 0.0 109.352 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.492 ' HB3' ' HB3' ' A' ' 137' ' ' GLN . 35.6 Cg_endo -77.82 112.09 3.23 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.511 2.141 . . . . 0.0 110.463 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 100.44 -22.97 37.59 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.601 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -84.12 149.65 4.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.191 -1.182 . . . . 0.0 109.482 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.3 m -92.42 140.48 29.53 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.601 ' CE1' HG12 ' A' ' 84' ' ' VAL . 18.3 m-85 -123.05 164.88 17.75 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.25 -0.906 . . . . 0.0 109.578 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.47 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 6.1 m -118.35 154.31 32.57 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.398 -0.814 . . . . 0.0 109.51 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.692 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.7 t80 -126.87 120.1 28.4 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.145 -0.972 . . . . 0.0 109.38 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.487 ' O ' ' O ' ' A' ' 161' ' ' GLY . 32.3 m -134.53 142.79 47.11 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.244 -0.91 . . . . 0.0 109.11 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.796 HD13 ' CD2' ' A' ' 103' ' ' PHE . 19.8 tt -150.9 163.45 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.603 -1.311 . . . . 0.0 109.628 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.533 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 20.3 m95 -132.14 128.62 38.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.976 -1.078 . . . . 0.0 109.385 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -119.53 148.13 43.65 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.222 -0.924 . . . . 0.0 109.582 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.586 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 8.3 ttp180 -161.02 120.22 2.58 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.162 -0.961 . . . . 0.0 109.15 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.481 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -107.07 161.7 14.52 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 110.02 -179.591 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -61.06 -51.18 70.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.377 -0.827 . . . . 0.0 109.319 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.485 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -108.45 137.74 45.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.339 -0.85 . . . . 0.0 109.355 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.582 ' N ' ' CG2' ' A' ' 123' ' ' THR . 5.1 p30 -63.08 146.85 52.36 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.273 -0.892 . . . . 0.0 109.559 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 109.06 38.66 1.8 Allowed Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -119.15 141.36 48.9 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.234 -1.157 . . . . 0.0 109.063 179.601 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.427 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 54.9 t -116.78 149.88 18.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.277 -0.889 . . . . 0.0 110.636 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.722 HG13 ' CE2' ' A' ' 147' ' ' PHE . 51.9 t -151.14 164.71 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.538 -0.726 . . . . 0.0 109.051 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.526 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 3.8 t -127.92 138.05 52.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.989 -1.07 . . . . 0.0 109.687 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.796 ' CD2' HD13 ' A' ' 90' ' ' ILE . 1.0 OUTLIER -130.6 103.86 6.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.086 -1.009 . . . . 0.0 109.807 -179.969 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.509 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 11.6 p -119.43 164.86 15.11 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.091 -1.005 . . . . 0.0 110.064 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.623 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -125.67 152.55 32.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.69 -0.631 . . . . 0.0 109.998 -179.734 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.469 ' O ' ' HG2' ' A' ' 142' ' ' ARG . . . 176.46 147.71 6.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.214 -1.555 . . . . 0.0 109.214 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.3 p30 -90.3 -169.59 2.46 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.018 -1.283 . . . . 0.0 109.51 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.518 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 4.1 mp0 -71.1 8.0 1.08 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.184 -0.947 . . . . 0.0 111.245 -179.123 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.455 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 3.7 t -110.52 10.27 23.14 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.712 -1.243 . . . . 0.0 109.215 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.538 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 3.2 m-30 71.87 6.08 5.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.412 -0.805 . . . . 0.0 109.689 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -78.89 95.12 5.34 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 108.672 179.399 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.524 ' CG ' ' O ' ' A' ' 105' ' ' VAL . 1.3 tt0 -83.47 139.69 32.78 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.278 -0.889 . . . . 0.0 110.259 -179.099 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.523 ' CE2' HG21 ' A' ' 141' ' ' ILE . 3.9 m-85 -102.78 -69.88 0.78 Allowed 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.601 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -85.77 166.17 39.11 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.021 -1.632 . . . . 0.0 109.021 179.401 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.473 ' C ' HD23 ' A' ' 116' ' ' LEU . 1.2 tpp180 -164.42 109.65 0.99 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.948 -1.325 . . . . 0.0 110.326 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.771 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -142.53 69.88 1.32 Allowed 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.061 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.542 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 0.0 OUTLIER -99.11 152.56 19.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.335 -0.853 . . . . 0.0 110.149 -179.31 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.542 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.3 tt0 79.33 68.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -0.787 . . . . 0.0 109.706 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLN . . . . . 0.431 ' HG2' ' C ' ' A' ' 118' ' ' GLU . 1.1 mm-40 -133.42 130.96 39.4 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.293 -0.879 . . . . 0.0 109.475 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.724 ' O ' HD13 ' A' ' 121' ' ' ILE . 4.8 mt-30 -67.66 153.81 42.88 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.327 -0.858 . . . . 0.0 109.006 179.702 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.724 HD13 ' O ' ' A' ' 120' ' ' GLN . 8.1 mm -134.8 135.73 52.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.094 -1.003 . . . . 0.0 110.089 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.32 -179.16 6.91 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.637 0.732 . . . . 0.0 110.067 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.582 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 47.2 p -76.37 -2.48 32.01 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.416 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.412 ' C ' ' HG3' ' A' ' 93' ' ' ARG . 3.9 mm-40 -107.67 -169.0 1.45 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.361 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.586 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 97.1 m95 -95.83 122.6 38.79 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.201 -0.937 . . . . 0.0 109.604 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -106.93 121.39 45.03 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.272 -0.892 . . . . 0.0 108.941 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -80.1 109.48 2.37 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.451 2.1 . . . . 0.0 110.895 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -114.34 136.64 52.76 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.7 t -151.27 175.85 11.8 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 120.685 -1.259 . . . . 0.0 111.152 -179.252 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.771 ' CE2' HD21 ' A' ' 116' ' ' LEU . 37.7 p90 -173.41 -172.61 0.81 Allowed 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.819 -1.082 . . . . 0.0 109.221 179.22 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -127.95 156.96 41.83 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.075 -1.016 . . . . 0.0 110.009 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.596 ' CZ ' ' HB2' ' A' ' 86' ' ' TYR . 11.1 p90 -161.23 168.06 24.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.391 -0.818 . . . . 0.0 109.191 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.92 146.2 38.91 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.145 -0.972 . . . . 0.0 109.224 -179.761 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.763 HG21 ' O ' ' A' ' 81' ' ' ARG . 2.2 t -62.38 112.95 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.257 -0.902 . . . . 0.0 109.392 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 5.8 t -86.51 -40.48 15.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.401 -0.812 . . . . 0.0 109.85 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.56 ' O ' ' CB ' ' A' ' 137' ' ' GLN . 17.5 t70 -87.63 -16.22 35.06 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.445 -0.784 . . . . 0.0 109.432 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' GLN . . . . . 0.674 ' H ' HG12 ' A' ' 134' ' ' VAL . 2.3 mt-30 86.97 27.28 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -178.621 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.513 ' HG3' ' ND2' ' A' ' 107' ' ' ASN . 12.5 mm-40 -68.94 122.44 18.65 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.609 -0.682 . . . . 0.0 109.732 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 5.8 p -79.12 -6.97 57.74 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.174 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 42.4 t -138.14 138.38 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.364 -0.835 . . . . 0.0 108.824 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.564 HD11 HD13 ' A' ' 164' ' ' ILE . 0.6 OUTLIER -143.27 172.23 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.121 -0.987 . . . . 0.0 109.904 -179.705 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.49 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.2 ptm180 -146.76 132.52 18.95 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.463 -0.773 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.748 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -99.66 106.95 43.29 Favored Pre-proline 0 C--N 1.303 -1.421 0 O-C-N 121.21 -0.931 . . . . 0.0 109.879 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.54 ' C ' HD13 ' A' ' 145' ' ' ILE . 34.9 Cg_endo -76.79 110.74 3.1 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.113 1.875 . . . . 0.0 110.688 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.72 ' N ' HD13 ' A' ' 145' ' ' ILE . 2.0 mm -91.25 140.15 16.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 178.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.648 ' N ' ' CD2' ' A' ' 146' ' ' HIS . 9.0 m-70 -107.7 157.86 17.76 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.542 -1.349 . . . . 0.0 111.897 -177.46 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.722 ' CE2' HG13 ' A' ' 101' ' ' VAL . 30.6 m-85 -158.12 160.98 37.88 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 179.013 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.496 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 116.77 40.79 0.75 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.798 ' C ' HG11 ' A' ' 64' ' ' VAL . 15.1 m-85 -122.08 159.37 27.23 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.381 -1.07 . . . . 0.0 109.311 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.527 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.21 -26.71 67.51 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -69.91 -15.28 63.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.436 -0.79 . . . . 0.0 109.269 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.52 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.3 OUTLIER -110.85 8.31 22.22 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 179.366 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.626 HG23 HG13 ' A' ' 64' ' ' VAL . 2.3 t -83.33 162.57 3.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 121.424 -0.797 . . . . 0.0 109.7 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.455 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 50.63 33.47 26.37 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 1.8 m-20 -160.18 139.44 10.88 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.258 -1.143 . . . . 0.0 109.976 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.837 HG23 ' O ' ' A' ' 59' ' ' VAL . 97.7 m -89.32 128.04 35.85 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.205 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.706 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.4 mt -108.96 118.83 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.873 -1.142 . . . . 0.0 109.969 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.584 ' CE2' ' HB1' ' A' ' 58' ' ' ALA . 8.7 m-85 -100.55 137.77 38.51 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 178.561 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.669 HD11 ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -129.34 141.64 46.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 120.777 -1.202 . . . . 0.0 110.381 -178.656 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.662 ' OD2' HG12 ' A' ' 56' ' ' VAL . 49.7 t0 -173.82 136.01 0.53 Allowed 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.5 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.533 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 127.13 -9.02 7.08 Favored Glycine 0 N--CA 1.485 1.915 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.258 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.748 HD21 ' HB3' ' A' ' 143' ' ' ALA . 1.2 tp -59.43 91.29 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.811 -1.405 . . . . 0.0 108.583 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 163' ' ' ALA . . . . . 0.459 ' N ' ' O ' ' A' ' 161' ' ' GLY . . . -131.06 146.03 52.23 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.605 -0.685 . . . . 0.0 109.86 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.716 ' O ' HG22 ' A' ' 3' ' ' VAL . 23.4 mt -126.16 131.47 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.325 -0.86 . . . . 0.0 109.217 179.471 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.846 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -158.55 147.53 18.93 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.202 -0.936 . . . . 0.0 109.677 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 3.1 p -73.68 166.5 23.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.295 -0.878 . . . . 0.0 109.528 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.407 ' CD ' ' O ' ' A' ' 167' ' ' GLN . 0.6 OUTLIER -145.47 89.87 6.18 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.277 -0.889 . . . . 0.0 109.402 179.893 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.555 0 C-N-CA 122.652 2.235 . . . . 0.0 110.422 179.985 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.2 tmt? . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 1.6 mp -121.99 131.84 54.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -0.907 . . . . 0.0 109.581 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.652 HG22 ' O ' ' A' ' 164' ' ' ILE . 4.6 p -109.86 174.58 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.288 -0.882 . . . . 0.0 109.307 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.597 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -63.09 -53.78 48.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.107 -0.996 . . . . 0.0 109.732 -179.633 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.532 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 3.9 t-20 -84.09 149.86 25.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.293 -0.879 . . . . 0.0 109.7 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.476 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 3.7 mt -128.13 129.79 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.358 -0.839 . . . . 0.0 109.157 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.565 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 1.5 m120 65.84 35.1 6.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.203 -0.936 . . . . 0.0 109.59 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -44.99 -25.73 1.04 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.454 ' HA3' ' OD2' ' A' ' 160' ' ' ASP . . . -145.82 44.93 0.83 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.902 ' CD2' HG11 ' A' ' 25' ' ' VAL . 4.2 m-85 61.32 51.65 4.16 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.167 -1.196 . . . . 0.0 109.443 179.581 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.445 ' OE2' ' OD2' ' A' ' 160' ' ' ASP . 62.0 mm-40 -84.34 -27.61 27.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.136 -0.977 . . . . 0.0 109.79 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.504 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 7.9 t -99.75 -13.65 19.19 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.178 -0.951 . . . . 0.0 110.149 -179.361 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . 1.048 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.2 m -100.25 133.39 21.49 Favored Pre-proline 0 N--CA 1.489 1.475 0 O-C-N 121.052 -1.03 . . . . 0.0 109.423 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.476 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.5 Cg_endo -77.3 148.37 26.82 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 122.522 2.148 . . . . 0.0 110.84 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.476 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -42.11 166.0 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 121.317 0.579 . . . . 0.0 109.773 179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.09 132.54 3.01 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.526 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -56.55 144.63 8.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.268 -1.136 . . . . 0.0 109.218 -179.367 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.515 HG13 ' HA3' ' A' ' 24' ' ' GLY . 47.7 t -85.12 144.51 9.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.687 0.756 . . . . 0.0 110.043 -179.773 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.9 p -106.59 -23.77 12.36 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.458 ' O ' ' N ' ' A' ' 24' ' ' GLY . 0.4 OUTLIER -145.99 88.21 1.8 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.478 -0.764 . . . . 0.0 108.966 179.759 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.911 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -43.46 -32.08 0.82 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 109.624 -179.464 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.906 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -65.42 -49.09 70.49 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.351 -0.843 . . . . 0.0 109.456 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -125.51 43.78 2.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.434 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.515 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -91.86 -66.7 1.13 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 1.048 HG13 ' OG1' ' A' ' 13' ' ' THR . 41.3 t -120.63 128.66 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.207 -1.172 . . . . 0.0 109.618 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.451 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 13.7 tt0 -67.25 139.38 57.33 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.879 . . . . 0.0 109.606 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.565 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 109.29 -33.78 5.91 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 0.67 ' CZ3' HD12 ' A' ' 159' ' ' ILE . 1.2 m95 -140.5 119.98 13.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.191 -1.182 . . . . 0.0 109.454 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.522 ' C ' HD23 ' A' ' 30' ' ' LEU . 11.0 m-20 -115.98 144.17 44.45 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.133 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.911 ' O ' HD13 ' A' ' 21' ' ' LEU . 2.1 mt -118.95 168.03 11.18 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.723 -1.235 . . . . 0.0 109.603 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 70.5 m-20 -160.09 123.75 3.61 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.382 -0.824 . . . . 0.0 109.575 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.801 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -106.47 136.56 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.337 -0.852 . . . . 0.0 109.743 179.678 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.69 176.16 24.86 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.4 t -58.98 -15.65 14.14 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.18 -1.188 . . . . 0.0 109.418 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.466 ' HB2' ' OD1' ' A' ' 70' ' ' ASP . 7.9 p -63.81 -37.17 86.39 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.243 -0.91 . . . . 0.0 109.636 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.823 HG23 ' HB3' ' A' ' 70' ' ' ASP . 2.1 t -67.35 88.55 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 O-C-N 121.144 -0.973 . . . . 0.0 109.194 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 50.1 m -63.41 -28.64 70.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.326 -0.859 . . . . 0.0 108.997 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.673 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.3 m-80 -120.92 130.1 25.0 Favored Pre-proline 0 C--N 1.296 -1.721 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -76.51 121.83 6.19 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.188 1.926 . . . . 0.0 110.524 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.593 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.4 Cg_endo -77.44 -169.93 0.84 Allowed 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.443 2.096 . . . . 0.0 109.865 179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.521 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 53.2 t -114.53 119.4 61.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.092 -1.005 . . . . 0.0 110.586 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.593 ' CE1' ' HG2' ' A' ' 40' ' ' PRO . 2.9 m-85 -104.35 112.34 25.34 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 178.251 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.526 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 0.0 OUTLIER -157.9 148.58 20.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.052 -1.03 . . . . 0.0 109.962 -179.354 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.584 HG22 ' CE2' ' A' ' 10' ' ' PHE . 2.0 t -92.55 148.68 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.379 -0.825 . . . . 0.0 109.398 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.555 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -133.43 147.45 51.72 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.284 -0.885 . . . . 0.0 108.713 179.931 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.555 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 15.3 pt-20 -121.17 120.41 35.16 Favored 'General case' 0 C--N 1.296 -1.758 0 O-C-N 121.526 -0.734 . . . . 0.0 109.296 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.487 ' CG2' HD21 ' A' ' 45' ' ' LEU . 1.5 p -144.0 -175.97 4.81 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.44 -0.787 . . . . 0.0 109.483 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -101.02 22.4 12.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.908 . . . . 0.0 109.433 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.7 -14.33 12.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.913 . . . . 0.0 109.481 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.721 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -56.45 144.53 62.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.18 -0.95 . . . . 0.0 109.327 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.555 ' HG3' ' CB ' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -78.44 -42.1 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.617 2.211 . . . . 0.0 110.388 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.406 ' O ' ' OE1' ' A' ' 11' ' ' GLU . 40.6 mm-40 -105.43 97.22 7.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.246 -0.909 . . . . 0.0 109.382 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.48 -117.75 4.71 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.721 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 13.5 p30 -160.09 38.62 0.18 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.226 -1.161 . . . . 0.0 109.542 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.482 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 92.0 mttt -144.84 139.04 27.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.143 -0.973 . . . . 0.0 109.655 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.636 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.3 m -150.13 174.54 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.3 -0.875 . . . . 0.0 109.372 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.616 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -99.92 102.22 13.55 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.161 -0.962 . . . . 0.0 108.943 179.61 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.649 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -82.04 122.85 28.34 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 178.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.833 ' O ' HG23 ' A' ' 156' ' ' THR . 47.0 t -117.4 144.18 25.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.135 -0.978 . . . . 0.0 109.304 -179.101 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.672 HG22 ' OD1' ' A' ' 62' ' ' ASN . 55.3 m -108.6 87.87 2.59 Favored 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.304 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.657 HG21 ' CD1' ' A' ' 157' ' ' ILE . 72.6 t -85.85 125.43 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.23 -0.919 . . . . 0.0 109.308 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.672 ' OD1' HG22 ' A' ' 60' ' ' THR . 0.6 OUTLIER -160.08 55.42 0.35 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.383 -0.823 . . . . 0.0 109.733 -179.694 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 162.7 89.91 0.07 OUTLIER Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.892 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.8 m -81.84 -171.32 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -1.14 . . . . 0.0 109.642 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -138.81 -163.27 9.46 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -78.29 -10.65 59.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -1.135 . . . . 0.0 109.499 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.553 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 1.3 m120 -111.08 145.33 32.23 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.171 -0.956 . . . . 0.0 109.426 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.505 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.5 Cg_endo -78.99 13.6 1.93 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.599 2.199 . . . . 0.0 110.997 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.553 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 3.5 p90 -136.33 51.76 2.0 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.031 -1.043 . . . . 0.0 109.759 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.823 ' HB3' HG23 ' A' ' 36' ' ' VAL . 0.6 OUTLIER -75.89 -50.24 15.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 109.215 179.685 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.686 HD12 ' HB2' ' A' ' 70' ' ' ASP . 4.6 mp -102.2 119.95 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.399 -0.813 . . . . 0.0 109.174 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.45 128.96 50.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.06 -1.025 . . . . 0.0 109.882 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.61 ' HB3' ' CE1' ' A' ' 147' ' ' PHE . . . -130.11 108.3 9.96 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.338 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.566 HG22 ' N ' ' A' ' 75' ' ' ALA . 75.5 m -103.93 165.26 11.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.545 -0.722 . . . . 0.0 110.018 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.566 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.01 137.14 53.73 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.055 -1.028 . . . . 0.0 108.882 178.767 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.561 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.7 p90 -174.46 163.57 2.65 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.497 -0.752 . . . . 0.0 109.256 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.561 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.4 Cg_endo -83.97 170.6 50.85 Favored 'Cis proline' 0 C--N 1.312 -1.372 0 C-N-CA 124.002 -1.249 . . . . 0.0 110.907 -0.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.953 HG11 HD13 ' A' ' 164' ' ' ILE . 85.2 t -130.25 156.27 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.526 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 1.9 m120 -121.21 132.02 54.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.09 -1.006 . . . . 0.0 109.929 -179.636 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.555 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.9 m -140.71 -174.07 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.169 -0.957 . . . . 0.0 109.644 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.745 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.3 OUTLIER -136.85 144.74 47.93 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 109.266 179.872 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.472 ' HD2' ' HG2' ' A' ' 81' ' ' ARG . 35.6 Cg_endo -77.12 110.48 3.03 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.426 2.084 . . . . 0.0 110.581 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 111.2 -34.98 5.01 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.551 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -84.75 149.78 4.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.146 -1.208 . . . . 0.0 109.433 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.441 ' O ' ' HB2' ' A' ' 166' ' ' SER . 17.8 m -94.58 141.65 28.36 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.555 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 8.5 m-85 -119.89 170.91 8.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 4.1 m -118.07 153.9 32.96 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.274 -0.891 . . . . 0.0 109.29 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.763 ' CE1' HD11 ' A' ' 116' ' ' LEU . 5.3 t80 -134.13 120.3 19.95 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.222 -0.924 . . . . 0.0 109.532 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.487 ' O ' ' O ' ' A' ' 161' ' ' GLY . 15.7 m -135.66 147.37 48.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.233 -0.917 . . . . 0.0 109.03 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.662 HD12 ' CA ' ' A' ' 162' ' ' LEU . 2.2 tt -151.21 163.61 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.966 -1.084 . . . . 0.0 109.219 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.555 ' CB ' ' HG3' ' A' ' 51' ' ' PRO . 19.3 m95 -131.02 125.17 32.56 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.894 -1.129 . . . . 0.0 109.574 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.581 ' HB2' ' CZ ' ' A' ' 103' ' ' PHE . . . -115.06 150.46 35.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.303 -0.873 . . . . 0.0 109.367 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.595 ' HB3' ' CZ3' ' A' ' 125' ' ' TRP . 5.3 ttp85 -164.57 121.86 1.64 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.111 -0.993 . . . . 0.0 109.51 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -102.84 170.1 8.2 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.158 -0.964 . . . . 0.0 109.764 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLU . . . . . 0.571 ' OE1' ' CE1' ' A' ' 158' ' ' TYR . 0.4 OUTLIER -67.16 -59.16 3.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.417 -0.802 . . . . 0.0 109.378 -179.939 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.482 ' C ' HG22 ' A' ' 123' ' ' THR . 0.8 OUTLIER -109.97 141.9 42.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.358 -0.839 . . . . 0.0 109.29 179.945 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.654 ' N ' HG22 ' A' ' 123' ' ' THR . 0.3 OUTLIER -58.16 144.79 39.33 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.206 -0.934 . . . . 0.0 109.206 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 118.17 31.94 1.47 Allowed Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -123.07 136.95 55.02 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.17 -1.194 . . . . 0.0 108.962 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.526 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 53.0 t -111.61 146.63 16.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 O-C-N 121.184 -0.947 . . . . 0.0 110.624 -179.342 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.904 HG21 HG21 ' A' ' 157' ' ' ILE . 89.0 t -155.83 149.88 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.481 -0.762 . . . . 0.0 109.5 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.518 ' CB ' ' HG2' ' A' ' 118' ' ' GLU . 19.5 m -125.29 138.6 54.09 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.202 -0.936 . . . . 0.0 109.69 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.625 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.7 m-85 -120.25 103.22 9.06 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.966 -1.084 . . . . 0.0 109.088 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.504 HG22 ' HA ' ' A' ' 115' ' ' ARG . 11.4 p -117.04 171.05 8.17 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.235 -0.916 . . . . 0.0 110.02 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.729 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -120.94 164.16 17.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.623 -0.673 . . . . 0.0 110.428 -179.51 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.529 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -176.16 148.59 9.3 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.52 ' HB3' ' OH ' ' A' ' 113' ' ' TYR . 1.5 p30 -89.59 -169.64 2.55 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.208 -1.172 . . . . 0.0 109.112 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.519 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 59.2 mt-30 -78.7 18.36 0.6 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.122 -0.986 . . . . 0.0 110.628 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 0.2 OUTLIER -113.4 11.61 18.55 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 120.828 -1.17 . . . . 0.0 109.182 179.624 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.505 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.8 m-30 74.22 11.83 4.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.38 -0.825 . . . . 0.0 109.461 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.529 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 54.3 mm-40 -92.23 164.04 13.69 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.181 -0.949 . . . . 0.0 109.027 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.491 ' HA ' ' HA2' ' A' ' 106' ' ' GLY . 9.8 tt0 -127.96 142.77 51.15 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.204 -0.935 . . . . 0.0 109.572 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.52 ' OH ' ' HB3' ' A' ' 107' ' ' ASN . 79.1 m-85 -93.82 -75.88 0.49 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.25 -0.906 . . . . 0.0 108.883 179.484 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.573 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -113.99 170.6 13.38 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.504 ' HA ' HG22 ' A' ' 104' ' ' THR . 3.1 ptm180 -144.14 142.31 30.5 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -1.101 . . . . 0.0 109.012 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.763 HD11 ' CE1' ' A' ' 88' ' ' TYR . 0.0 OUTLIER -151.26 162.5 40.79 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.993 -1.067 . . . . 0.0 110.624 -179.169 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.622 ' ND1' ' CE1' ' A' ' 103' ' ' PHE . 0.0 OUTLIER 69.96 -153.73 0.13 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.635 -0.666 . . . . 0.0 110.598 178.439 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.601 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.8 mt-10 97.95 28.36 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLN . . . . . 0.489 ' O ' HG13 ' A' ' 100' ' ' VAL . 5.5 mt-30 -134.44 -164.05 1.46 Allowed 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.463 -0.773 . . . . 0.0 109.731 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.442 ' HA ' HG22 ' A' ' 100' ' ' VAL . 21.1 mt-30 -67.94 157.69 34.43 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.349 0.595 . . . . 0.0 110.018 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.585 ' CD1' ' NE2' ' A' ' 117' ' ' HIS . 4.9 mm -132.73 140.69 46.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.402 -0.811 . . . . 0.0 109.407 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -82.19 -179.53 7.44 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.439 -0.788 . . . . 0.0 110.412 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.654 HG22 ' N ' ' A' ' 97' ' ' ASP . 18.0 p -84.93 1.04 49.09 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 120.081 -0.648 . . . . 0.0 109.419 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.482 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 3.2 mt-10 -104.17 -169.79 1.68 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.242 -0.911 . . . . 0.0 109.428 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.595 ' CZ3' ' HB3' ' A' ' 93' ' ' ARG . 92.0 m95 -98.12 122.77 41.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.304 -0.873 . . . . 0.0 109.533 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.89 121.11 45.94 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.18 -0.95 . . . . 0.0 109.045 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.32 110.45 2.48 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.466 2.111 . . . . 0.0 110.753 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.407 ' CD2' ' CE1' ' A' ' 117' ' ' HIS . 1.0 OUTLIER -115.99 134.69 54.7 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 179.235 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.443 ' OG1' ' OG1' ' A' ' 89' ' ' THR . 14.5 t -151.36 176.59 11.11 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 120.716 -1.24 . . . . 0.0 110.956 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.626 ' CE1' HD21 ' A' ' 116' ' ' LEU . 6.9 p90 -178.37 165.39 1.79 Allowed 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.004 -0.998 . . . . 0.0 108.987 179.498 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -102.91 138.92 39.16 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.123 -0.986 . . . . 0.0 109.965 -179.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.597 ' HB3' ' CE2' ' A' ' 130' ' ' PHE . 22.2 p90 -138.49 155.95 47.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.395 -0.815 . . . . 0.0 109.218 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -131.34 144.12 51.01 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.209 -0.932 . . . . 0.0 109.131 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.745 HG21 ' O ' ' A' ' 81' ' ' ARG . 3.7 t -47.69 110.27 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.364 -0.835 . . . . 0.0 109.177 179.658 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -60.56 -51.79 67.93 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.245 -0.91 . . . . 0.0 109.21 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 43.7 m-20 -108.09 -92.35 0.42 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.413 -0.804 . . . . 0.0 109.153 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -160.66 55.51 0.32 Allowed 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.468 -0.77 . . . . 0.0 109.041 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.508 ' O ' HG23 ' A' ' 80' ' ' VAL . 18.8 mm-40 -93.2 113.71 26.0 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.303 -0.873 . . . . 0.0 109.75 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.43 -15.7 57.38 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.2 t -134.57 130.25 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.145 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.479 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -140.48 172.33 11.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.27 -0.894 . . . . 0.0 110.116 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.523 ' HB2' ' HB3' ' A' ' 76' ' ' PHE . 1.4 ptm180 -143.66 133.59 24.06 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.729 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.09 110.03 41.44 Favored Pre-proline 0 N--CA 1.486 1.369 0 O-C-N 121.319 -0.863 . . . . 0.0 109.76 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.516 ' HD2' ' HA ' ' A' ' 105' ' ' VAL . 36.0 Cg_endo -77.22 111.24 3.16 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.168 1.912 . . . . 0.0 111.169 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.689 ' N ' HD13 ' A' ' 145' ' ' ILE . 2.0 mm -90.68 139.34 17.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.622 ' N ' ' CD2' ' A' ' 146' ' ' HIS . 14.1 m-70 -109.37 149.51 29.4 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.696 -1.253 . . . . 0.0 112.337 -177.102 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.648 ' CE2' HG13 ' A' ' 101' ' ' VAL . 2.6 m-85 -153.68 153.8 32.93 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 131.6 38.23 0.27 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.892 ' C ' HG11 ' A' ' 64' ' ' VAL . 77.2 m-85 -116.68 163.69 15.75 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.409 -1.054 . . . . 0.0 109.104 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.01 -27.25 67.27 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -73.02 -7.18 50.04 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.444 -0.785 . . . . 0.0 109.621 179.707 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.581 ' HB3' HD11 ' A' ' 157' ' ' ILE . 1.5 m-20 -107.08 9.06 30.55 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 179.254 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.413 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.5 t -87.98 158.69 3.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 O-C-N 121.418 -0.801 . . . . 0.0 109.618 -179.383 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.413 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 53.13 35.78 50.31 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.461 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.2 m-20 -160.29 139.22 10.57 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.111 -1.229 . . . . 0.0 110.087 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.833 HG23 ' O ' ' A' ' 59' ' ' VAL . 73.6 m -92.09 122.39 34.55 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.123 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.904 HG21 HG21 ' A' ' 101' ' ' VAL . 1.4 mt -102.51 119.92 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.726 -1.234 . . . . 0.0 110.005 -178.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.713 ' CE1' HG22 ' A' ' 156' ' ' THR . 2.1 m-85 -100.11 142.17 31.96 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 178.701 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.67 HD12 ' CZ3' ' A' ' 28' ' ' TRP . 1.2 mt -133.22 138.29 51.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.788 -1.195 . . . . 0.0 110.162 -178.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.636 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.8 OUTLIER -173.67 136.4 0.57 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.216 -0.928 . . . . 0.0 108.926 179.592 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 131.0 -3.85 5.64 Favored Glycine 0 N--CA 1.485 1.958 0 C-N-CA 119.407 -1.378 . . . . 0.0 110.324 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.662 ' CA ' HD12 ' A' ' 90' ' ' ILE . 0.1 OUTLIER -59.27 97.15 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.754 -1.439 . . . . 0.0 108.614 -179.928 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 163' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -131.54 145.44 51.73 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.348 -0.845 . . . . 0.0 109.778 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.953 HD13 HG11 ' A' ' 78' ' ' VAL . 7.5 mt -133.81 124.57 47.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.318 -0.864 . . . . 0.0 109.285 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.527 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . -157.18 147.07 20.68 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.129 -0.982 . . . . 0.0 109.583 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.454 ' HB2' ' HA ' ' A' ' 86' ' ' TYR . 11.1 t -109.0 161.95 14.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.299 -0.875 . . . . 0.0 109.461 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -87.95 151.36 49.45 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.307 -0.87 . . . . 0.0 109.372 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo . . . . . 0 C--N 1.309 -1.551 0 C-N-CA 122.575 2.183 . . . . 0.0 110.414 -179.979 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 23.8 mt -75.25 123.83 26.0 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.441 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.569 HG22 ' H ' ' A' ' 4' ' ' ALA . 4.2 p -108.06 173.29 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -0.944 . . . . 0.0 109.368 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.735 ' HB3' ' O ' ' A' ' 164' ' ' ILE . . . -70.3 -57.9 4.35 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.234 -0.916 . . . . 0.0 109.539 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.471 ' HB3' ' HA ' ' A' ' 163' ' ' ALA . 4.0 t-20 -75.3 116.99 16.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.239 -0.913 . . . . 0.0 109.66 -179.753 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.625 HD12 ' O ' ' A' ' 4' ' ' ALA . 3.0 mp -103.89 140.88 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.35 -0.844 . . . . 0.0 109.068 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.508 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.7 OUTLIER 61.89 19.17 10.46 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.221 -0.924 . . . . 0.0 109.425 -179.804 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.488 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -61.54 -29.48 71.92 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.527 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -107.83 32.51 7.03 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 179.436 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.648 ' CD2' HG11 ' A' ' 25' ' ' VAL . 3.0 m-85 43.8 54.55 5.6 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.395 -1.062 . . . . 0.0 109.534 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -84.22 -36.89 22.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.16 -0.963 . . . . 0.0 109.68 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.465 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 18.6 m -84.01 -26.24 29.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.215 -0.928 . . . . 0.0 109.608 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.92 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.3 m -78.82 114.36 43.18 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.172 -0.955 . . . . 0.0 109.43 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.465 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.5 Cg_endo -77.86 142.68 20.19 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 C-N-CA 122.414 2.076 . . . . 0.0 110.61 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.71 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -40.11 161.43 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.885 -0.509 . . . . 0.0 109.709 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.82 132.99 3.23 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.024 -1.63 . . . . 0.0 109.024 -179.622 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.586 HG23 ' CD ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.94 138.45 17.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.3 -1.117 . . . . 0.0 109.325 -179.543 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.696 HG23 ' HA ' ' A' ' 43' ' ' GLU . 48.2 t -83.78 143.73 11.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-O 121.681 0.753 . . . . 0.0 110.096 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.9 p -94.84 -27.02 15.96 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.536 ' HB3' ' CG ' ' A' ' 23' ' ' GLU . 2.7 t0 -141.19 101.7 4.08 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 1.106 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -44.78 -30.13 0.91 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.178 -0.951 . . . . 0.0 109.751 -178.966 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.106 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -60.35 -53.34 58.77 Favored 'General case' 0 C--N 1.294 -1.842 0 O-C-N 121.6 -0.688 . . . . 0.0 109.678 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.536 ' CG ' ' HB3' ' A' ' 20' ' ' ASP . 1.8 pt-20 -102.15 31.52 3.92 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.249 -0.907 . . . . 0.0 109.409 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.52 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -71.14 -55.05 8.23 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.781 -1.327 . . . . 0.0 109.781 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.92 HG13 ' OG1' ' A' ' 13' ' ' THR . 2.8 t -121.53 143.1 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.16 -1.2 . . . . 0.0 109.663 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -67.49 -56.02 11.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.264 -0.897 . . . . 0.0 109.726 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.508 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -77.15 0.86 66.06 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 0.658 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.7 OUTLIER -137.5 121.54 17.83 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.116 -1.226 . . . . 0.0 109.274 179.653 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.534 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -123.44 118.89 28.46 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.363 -0.836 . . . . 0.0 109.034 179.589 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.72 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -97.85 174.5 6.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.185 -0.947 . . . . 0.0 109.842 -179.477 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -160.39 122.92 3.29 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.364 -0.835 . . . . 0.0 109.567 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.856 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -110.73 135.03 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.168 -0.958 . . . . 0.0 109.651 179.418 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.49 178.38 21.74 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.3 t -58.6 -15.81 13.15 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.199 -1.177 . . . . 0.0 109.39 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.487 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 1.4 p -60.94 -38.1 84.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.648 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.856 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -59.9 89.41 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 O-C-N 121.084 -1.01 . . . . 0.0 109.414 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.409 ' N ' ' O ' ' A' ' 35' ' ' SER . 25.4 m -62.73 -28.97 70.32 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.264 -0.898 . . . . 0.0 108.674 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.706 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.8 t-20 -122.91 128.81 25.22 Favored Pre-proline 0 C--N 1.297 -1.688 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.453 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.1 Cg_endo -75.84 116.55 4.46 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.261 1.974 . . . . 0.0 110.729 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.509 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.3 Cg_endo -77.44 -176.26 3.11 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 C-N-CA 122.421 2.081 . . . . 0.0 109.77 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 55.5 t -113.26 119.68 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.046 -1.034 . . . . 0.0 110.682 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.591 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 3.7 m-85 -101.07 112.38 24.83 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.184 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.696 ' HA ' HG23 ' A' ' 18' ' ' VAL . 31.6 tt0 -154.08 158.8 41.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.069 -1.02 . . . . 0.0 110.038 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.441 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 58.9 t -99.5 148.21 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.506 -0.747 . . . . 0.0 109.106 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.502 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -123.35 122.1 37.47 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.295 -0.878 . . . . 0.0 109.787 -179.427 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.71 ' HG3' ' HB2' ' A' ' 15' ' ' ALA . 8.5 mt-10 -98.29 110.01 22.67 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.46 ' O ' ' HB3' ' A' ' 54' ' ' ASN . 3.1 p -142.53 -177.89 5.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.466 -0.771 . . . . 0.0 109.488 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.1 m -104.59 -5.24 21.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.306 -0.871 . . . . 0.0 109.558 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.403 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.9 m-20 -87.01 -16.56 35.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.174 -0.954 . . . . 0.0 109.444 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.403 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.33 149.74 0.71 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.234 -0.916 . . . . 0.0 109.376 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.459 ' HG3' ' HB2' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -77.93 -38.96 0.54 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.592 2.195 . . . . 0.0 110.409 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -121.23 121.28 37.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.295 -0.878 . . . . 0.0 109.397 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 63.93 -120.81 21.44 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.46 ' HB3' ' O ' ' A' ' 47' ' ' THR . 4.8 m120 -158.14 34.48 0.25 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -1.14 . . . . 0.0 109.503 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.524 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 5.4 mttp -140.2 142.17 35.89 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.298 -0.876 . . . . 0.0 109.584 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.54 HG12 ' OD2' ' A' ' 160' ' ' ASP . 4.6 m -149.22 174.85 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -0.899 . . . . 0.0 109.259 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.632 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -105.46 99.39 9.0 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.059 -1.026 . . . . 0.0 108.525 179.057 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.636 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.06 118.91 22.91 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.115 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.801 ' O ' HG23 ' A' ' 156' ' ' THR . 40.9 t -112.85 144.2 21.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.188 -0.945 . . . . 0.0 108.99 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.68 HG22 ' OD1' ' A' ' 62' ' ' ASN . 80.2 m -109.12 90.53 3.32 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.658 HG21 ' CD1' ' A' ' 157' ' ' ILE . 53.1 t -88.33 125.54 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.284 -0.885 . . . . 0.0 108.987 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.68 ' OD1' HG22 ' A' ' 60' ' ' THR . 0.6 OUTLIER -159.23 61.15 0.4 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.34 -0.85 . . . . 0.0 109.802 -179.674 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 144.36 93.9 0.17 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.727 HG12 ' C ' ' A' ' 148' ' ' GLY . 1.6 m -83.19 178.53 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.259 -1.142 . . . . 0.0 109.596 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.487 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -113.93 -154.47 11.21 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.4 m-20 -96.1 -10.12 29.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.317 -1.107 . . . . 0.0 109.491 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.597 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 4.8 m120 -109.8 151.47 42.36 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.309 -0.869 . . . . 0.0 109.381 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.43 12.53 2.09 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.693 2.262 . . . . 0.0 111.075 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.597 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.1 p90 -132.95 53.58 2.01 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.035 -1.041 . . . . 0.0 109.721 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.612 ' C ' HG23 ' A' ' 36' ' ' VAL . 0.3 OUTLIER -82.48 -69.32 0.63 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.21 -0.931 . . . . 0.0 109.057 179.763 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.491 ' HB ' ' HB3' ' A' ' 147' ' ' PHE . 6.1 mt -98.47 126.32 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.265 -0.897 . . . . 0.0 108.775 179.491 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -129.32 139.26 51.81 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.961 -1.087 . . . . 0.0 110.44 -179.358 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.72 ' HA ' HD23 ' A' ' 30' ' ' LEU . . . -122.49 143.12 49.91 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 178.593 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.521 HG22 ' N ' ' A' ' 75' ' ' ALA . 12.8 m -143.9 162.23 36.67 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.544 -1.348 . . . . 0.0 110.322 -178.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.521 ' N ' HG22 ' A' ' 74' ' ' THR . . . -123.93 136.18 54.17 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.48 -0.762 . . . . 0.0 109.142 179.191 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.539 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 1.3 p90 178.21 161.94 0.63 Allowed Pre-proline 0 N--CA 1.491 1.617 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.535 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -81.5 167.62 70.42 Favored 'Cis proline' 0 C--N 1.31 -1.491 0 C-N-CA 123.672 -1.387 . . . . 0.0 110.837 -0.678 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.654 HG11 HD12 ' A' ' 164' ' ' ILE . 62.2 t -124.07 150.04 28.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.263 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.522 ' O ' ' HB2' ' A' ' 4' ' ' ALA . 98.1 m-20 -117.29 108.85 16.12 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.0 -1.063 . . . . 0.0 110.075 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.572 HG23 ' O ' ' A' ' 138' ' ' GLU . 3.1 m -114.33 -173.85 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.209 -0.932 . . . . 0.0 109.479 179.478 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.704 ' O ' HG21 ' A' ' 134' ' ' VAL . 21.5 mmt180 -137.01 144.81 47.86 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.38 -0.825 . . . . 0.0 109.229 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -76.95 111.24 3.19 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.523 2.149 . . . . 0.0 110.47 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 109.13 -30.88 8.16 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.495 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -84.79 149.68 4.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.235 -1.156 . . . . 0.0 109.452 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.407 ' CG2' ' HA ' ' A' ' 168' ' ' PRO . 8.5 t -92.81 136.43 33.25 Favored 'General case' 0 C--N 1.292 -1.922 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.558 ' CZ ' ' HB3' ' A' ' 166' ' ' SER . 20.3 m-85 -119.39 148.98 42.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.688 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.474 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 17.5 m -113.79 151.77 31.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.312 -0.867 . . . . 0.0 108.985 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.618 ' N ' ' CD1' ' A' ' 88' ' ' TYR . 0.1 OUTLIER -128.81 114.45 16.56 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.178 -0.952 . . . . 0.0 109.628 -179.775 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.484 ' O ' ' O ' ' A' ' 161' ' ' GLY . 41.2 m -118.87 149.29 41.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.351 -0.843 . . . . 0.0 108.971 179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.789 HD13 ' CD2' ' A' ' 103' ' ' PHE . 19.2 tt -150.75 163.51 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 120.821 -1.174 . . . . 0.0 109.755 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.498 ' CD1' ' C ' ' A' ' 90' ' ' ILE . 20.5 m95 -132.27 125.87 32.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.11 -0.994 . . . . 0.0 109.271 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -115.55 148.11 39.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.24 -0.913 . . . . 0.0 109.562 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.484 ' HD2' ' HA ' ' A' ' 124' ' ' GLU . 5.0 ttp180 -160.68 118.02 2.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.197 -0.939 . . . . 0.0 109.007 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.478 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -104.41 150.12 24.81 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.405 -0.809 . . . . 0.0 109.889 -179.596 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLU . . . . . 0.489 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 3.0 mt-10 -52.75 -38.98 61.75 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.451 -0.781 . . . . 0.0 109.263 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.493 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -119.57 137.48 53.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.342 -0.848 . . . . 0.0 109.378 179.978 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.577 ' N ' ' CG2' ' A' ' 123' ' ' THR . 0.5 OUTLIER -63.4 147.59 50.79 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.482 -179.847 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 106.97 38.28 2.19 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.773 -1.331 . . . . 0.0 109.773 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.468 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -121.64 140.11 52.68 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.175 -1.191 . . . . 0.0 109.101 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.461 ' HB ' ' OD1' ' A' ' 152' ' ' ASN . 51.3 t -116.75 158.23 17.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.318 -0.864 . . . . 0.0 110.759 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.784 HG22 ' CE1' ' A' ' 147' ' ' PHE . 59.3 t -154.56 163.36 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.536 ' HB3' ' HB2' ' A' ' 146' ' ' HIS . 34.2 t -118.8 123.06 43.85 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.921 -1.112 . . . . 0.0 109.797 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.789 ' CD2' HD13 ' A' ' 90' ' ' ILE . 2.3 m-85 -119.25 103.45 9.51 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.173 -0.955 . . . . 0.0 109.633 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.487 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 19.0 p -128.97 167.87 16.83 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.195 -0.941 . . . . 0.0 110.185 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.688 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -128.44 155.67 40.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.732 -0.605 . . . . 0.0 110.341 -179.726 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.53 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -175.68 160.81 29.32 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.548 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 0.9 OUTLIER -99.3 -170.26 1.88 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.125 -1.221 . . . . 0.0 109.418 -179.88 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.548 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 22.1 mt-30 -71.87 8.73 1.1 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.06 -1.025 . . . . 0.0 111.185 -179.18 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.545 ' HB2' ' NE2' ' A' ' 111' ' ' GLN . 2.0 m -108.93 13.52 24.71 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 120.667 -1.271 . . . . 0.0 109.219 179.729 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.5 m-30 73.88 1.69 3.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.454 -0.779 . . . . 0.0 109.641 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.545 ' NE2' ' HB2' ' A' ' 109' ' ' SER . 0.7 OUTLIER -73.11 161.33 30.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.198 -0.939 . . . . 0.0 108.69 179.283 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.491 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 3.6 tt0 -138.45 134.78 34.47 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.0 -1.063 . . . . 0.0 109.882 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.572 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 18.9 m-85 -94.8 -71.61 0.66 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.272 -0.893 . . . . 0.0 108.67 179.016 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.592 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -87.67 165.81 35.45 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 108.979 -1.648 . . . . 0.0 108.979 179.369 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.485 ' HA ' HG22 ' A' ' 104' ' ' THR . 50.9 ttt180 -160.94 110.55 1.67 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.997 -1.296 . . . . 0.0 110.474 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.832 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -144.97 69.97 1.26 Allowed 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 108.698 -0.852 . . . . 0.0 108.698 179.077 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.534 ' CB ' ' OG ' ' A' ' 102' ' ' SER . 56.6 p-80 -102.71 157.7 16.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 110.02 -179.337 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 1.3 tp10 77.98 44.34 0.08 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.388 -0.82 . . . . 0.0 109.403 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLN . . . . . 0.463 ' OE1' ' HB2' ' A' ' 116' ' ' LEU . 0.9 OUTLIER -109.35 136.67 48.42 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.286 -0.884 . . . . 0.0 109.473 179.912 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.984 ' O ' HD13 ' A' ' 121' ' ' ILE . 18.9 mm-40 -73.85 155.92 38.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.445 -0.784 . . . . 0.0 109.029 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.984 HD13 ' O ' ' A' ' 120' ' ' GLN . 13.6 mm -134.38 135.81 53.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.081 -1.012 . . . . 0.0 110.071 -179.631 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.61 -179.06 6.25 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 121.638 0.732 . . . . 0.0 110.254 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.577 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 39.2 p -75.22 -0.63 20.1 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.386 179.562 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.484 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 6.4 mt-10 -110.91 -168.94 1.37 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.922 . . . . 0.0 109.238 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.463 ' HA ' ' O ' ' A' ' 92' ' ' ALA . 94.1 m95 -94.39 124.89 38.69 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.159 -0.963 . . . . 0.0 109.565 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.418 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 2.1 tt0 -106.95 121.2 45.61 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.223 -0.923 . . . . 0.0 109.078 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.09 100.57 1.28 Allowed 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.4 2.067 . . . . 0.0 110.923 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -111.62 133.93 53.54 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.44 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.3 t -151.16 176.78 10.86 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 120.793 -1.192 . . . . 0.0 110.794 -179.445 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.832 ' CE1' HD21 ' A' ' 116' ' ' LEU . 6.3 p90 -166.74 165.8 16.19 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.123 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -118.85 138.89 52.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.129 -0.982 . . . . 0.0 109.891 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.572 ' CE2' ' O ' ' A' ' 113' ' ' TYR . 0.5 OUTLIER -154.77 157.73 38.41 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.375 -0.828 . . . . 0.0 109.128 179.729 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.447 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -121.09 147.66 45.23 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.232 -0.917 . . . . 0.0 109.551 -179.66 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.704 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.2 t -41.44 110.05 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.511 -0.743 . . . . 0.0 109.214 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 33.7 t -59.39 -50.64 73.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -0.872 . . . . 0.0 109.205 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -108.23 -91.7 0.43 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.382 -0.824 . . . . 0.0 109.189 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -163.23 54.74 0.18 Allowed 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.572 ' O ' HG23 ' A' ' 80' ' ' VAL . 40.4 mm-40 -91.33 111.55 23.09 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.293 -0.879 . . . . 0.0 109.944 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.35 -17.53 54.3 Favored 'General case' 0 N--CA 1.487 1.42 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.233 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.4 t -131.64 132.2 62.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.513 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -142.65 171.73 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.082 -1.011 . . . . 0.0 110.385 -179.416 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.471 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.8 OUTLIER -141.9 132.77 25.83 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.806 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.688 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.15 111.45 50.22 Favored Pre-proline 0 C--N 1.304 -1.396 0 O-C-N 121.162 -0.961 . . . . 0.0 109.4 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.487 ' HD2' ' O ' ' A' ' 104' ' ' THR . 33.2 Cg_endo -74.69 111.95 3.44 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 C-N-CA 122.199 1.933 . . . . 0.0 110.764 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.658 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 2.1 mt -100.17 136.81 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 179.135 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.536 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 5.9 m80 -105.72 160.37 15.27 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.525 -1.359 . . . . 0.0 111.105 -178.343 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.795 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 11.1 m-85 -159.74 162.2 34.88 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.727 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 107.01 38.91 2.07 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.641 ' C ' HG11 ' A' ' 64' ' ' VAL . 20.5 m-85 -113.42 158.09 21.09 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.489 -1.007 . . . . 0.0 109.287 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.38 -27.29 67.74 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.646 -0.659 . . . . 0.0 109.265 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.57 -15.13 62.74 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.45 -0.781 . . . . 0.0 109.187 179.469 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.525 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.2 OUTLIER -109.78 11.88 24.24 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.338 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.541 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.3 t -84.87 161.48 3.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.492 -0.755 . . . . 0.0 109.821 -179.296 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.441 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 51.37 33.88 32.75 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.1 m-20 -160.4 141.84 12.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.22 -1.165 . . . . 0.0 110.226 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.801 HG23 ' O ' ' A' ' 59' ' ' VAL . 85.2 m -89.55 124.45 34.54 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.658 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.2 mt -105.02 116.32 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.855 -1.153 . . . . 0.0 110.055 -178.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.636 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 5.8 m-85 -98.91 139.85 33.96 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 178.518 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.795 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -132.16 139.34 50.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.739 -1.225 . . . . 0.0 110.228 -178.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' A' ' 161' ' ' GLY . 39.9 t0 -173.9 135.95 0.52 Allowed 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.368 -0.832 . . . . 0.0 108.876 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.543 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 127.28 -9.77 6.96 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.41 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.488 ' O ' ' HA3' ' A' ' 8' ' ' GLY . 12.4 tp -59.81 109.13 0.86 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.712 -1.464 . . . . 0.0 108.642 -179.818 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 163' ' ' ALA . . . . . 0.479 ' O ' ' HA ' ' A' ' 88' ' ' TYR . . . -138.87 145.55 40.09 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.457 -0.777 . . . . 0.0 109.985 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.735 ' O ' ' HB3' ' A' ' 4' ' ' ALA . 16.5 mt -130.97 109.0 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.37 -0.831 . . . . 0.0 109.18 179.472 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.509 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -119.38 171.17 8.51 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.164 -0.96 . . . . 0.0 109.621 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.558 ' HB3' ' CZ ' ' A' ' 86' ' ' TYR . 1.3 p -99.71 93.4 5.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -112.99 92.23 20.55 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.904 . . . . 0.0 109.468 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' PRO . . . . . 0.481 ' HD3' ' O ' ' A' ' 166' ' ' SER . 35.4 Cg_endo . . . . . 0 C--N 1.309 -1.522 0 C-N-CA 122.653 2.235 . . . . 0.0 110.455 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.464 ' O ' ' HB ' ' A' ' 3' ' ' VAL . 4.3 mm? -83.75 167.66 16.94 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.354 -0.841 . . . . 0.0 109.477 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.616 HG22 ' O ' ' A' ' 164' ' ' ILE . 4.4 p 179.75 173.87 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.253 -0.905 . . . . 0.0 109.311 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.759 ' HB3' ' O ' ' A' ' 164' ' ' ILE . . . -65.46 -43.75 89.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.092 -1.005 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.644 ' HB2' HD12 ' A' ' 164' ' ' ILE . 21.4 t-20 -85.87 130.94 34.41 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.278 -0.889 . . . . 0.0 109.338 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.42 ' O ' ' HB3' ' A' ' 7' ' ' ASN . 1.7 mp -127.62 126.61 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.223 -0.923 . . . . 0.0 109.613 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.527 ' HB3' ' CA ' ' A' ' 27' ' ' GLY . 0.6 OUTLIER 65.32 10.7 6.71 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.333 -0.854 . . . . 0.0 109.546 179.591 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.426 ' HA3' ' OD1' ' A' ' 5' ' ' ASN . . . -66.06 -33.24 84.86 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 179.412 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.529 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -91.32 16.14 59.58 Favored Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.628 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.604 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 13.2 m-85 61.28 40.27 14.62 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.337 -1.096 . . . . 0.0 109.439 179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -84.65 -43.38 14.44 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.838 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -78.71 -42.29 28.75 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.212 -0.93 . . . . 0.0 109.875 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.87 ' OG1' HG13 ' A' ' 25' ' ' VAL . 12.8 m -59.81 123.67 72.8 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.33 -0.856 . . . . 0.0 109.586 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.8 Cg_endo -77.87 137.42 15.83 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 122.439 2.092 . . . . 0.0 110.569 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.463 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -41.97 164.63 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.715 -0.616 . . . . 0.0 109.707 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 132.71 131.18 3.17 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 108.999 -1.64 . . . . 0.0 108.999 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.542 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -56.96 142.94 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.167 -1.196 . . . . 0.0 108.943 -179.71 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.468 HG13 ' HA2' ' A' ' 24' ' ' GLY . 54.1 t -90.64 142.47 12.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.456 -0.778 . . . . 0.0 110.386 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 33.3 p -93.03 -30.14 15.46 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 178.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.41 ' O ' ' C ' ' A' ' 21' ' ' LEU . 4.9 m-20 -133.39 99.53 4.55 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 1.098 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -44.13 -29.57 0.64 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.207 -0.933 . . . . 0.0 109.764 -178.567 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.098 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.8 -51.7 68.62 Favored 'General case' 0 C--N 1.294 -1.823 0 O-C-N 121.588 -0.695 . . . . 0.0 109.706 -179.673 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -101.86 31.05 4.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.2 -0.937 . . . . 0.0 109.384 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.468 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -74.1 -59.91 3.78 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.87 HG13 ' OG1' ' A' ' 13' ' ' THR . 3.5 t -120.56 137.91 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -1.135 . . . . 0.0 109.555 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -69.44 -42.31 75.14 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.305 -0.872 . . . . 0.0 109.587 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.527 ' CA ' ' HB3' ' A' ' 7' ' ' ASN . . . -76.91 -12.67 84.39 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 1.049 ' CZ2' HD13 ' A' ' 145' ' ' ILE . 1.0 OUTLIER -132.44 123.73 27.23 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.19 -1.182 . . . . 0.0 109.754 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.461 ' OD1' ' CE2' ' A' ' 76' ' ' PHE . 1.8 m-20 -113.83 115.82 28.36 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 178.836 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.914 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -98.81 168.0 10.41 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.946 -1.096 . . . . 0.0 110.16 -178.581 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 72' ' ' GLU . 19.5 m120 -160.53 123.43 3.34 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.532 -0.73 . . . . 0.0 109.633 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.005 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -101.12 131.88 47.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.097 -1.002 . . . . 0.0 109.447 179.263 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.29 178.65 26.74 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.5 m -57.99 -16.75 13.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -1.133 . . . . 0.0 109.345 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.471 ' HB3' ' HB2' ' A' ' 67' ' ' ASN . 1.3 p -61.99 -38.55 89.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.442 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 1.005 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -63.78 89.67 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 O-C-N 121.221 -0.925 . . . . 0.0 109.455 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 45.2 m -71.23 -28.4 64.16 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.846 0.832 . . . . 0.0 108.84 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.656 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.3 m-20 -115.0 139.77 24.71 Favored Pre-proline 0 C--N 1.297 -1.702 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.655 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.484 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.4 Cg_endo -76.01 111.76 3.35 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.389 2.059 . . . . 0.0 110.816 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 38' ' ' ASN . 34.9 Cg_endo -77.57 179.61 6.35 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.46 2.106 . . . . 0.0 109.552 179.537 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.54 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 61.9 t -117.18 120.74 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.999 -1.063 . . . . 0.0 110.769 -179.576 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.485 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 90.6 m-85 -106.83 112.24 25.12 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 178.086 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.542 ' HG3' HG23 ' A' ' 17' ' ' VAL . 0.4 OUTLIER -150.28 148.26 28.65 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.976 -1.078 . . . . 0.0 110.237 -179.261 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.0 t -101.77 148.19 7.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.519 -0.738 . . . . 0.0 109.117 179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 1.077 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -150.54 164.32 36.27 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 179.85 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 1.077 ' N ' HD22 ' A' ' 45' ' ' LEU . 19.4 pt-20 -120.04 123.84 44.42 Favored 'General case' 0 C--N 1.291 -1.945 0 O-C-N 121.391 -0.818 . . . . 0.0 109.388 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.985 HG23 HD21 ' A' ' 45' ' ' LEU . 6.7 p -117.42 178.98 4.18 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 109.459 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -101.97 8.76 40.94 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.219 -0.926 . . . . 0.0 109.524 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.413 ' O ' ' C ' ' A' ' 50' ' ' ALA . 7.7 m-20 -125.25 8.72 7.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.178 -0.952 . . . . 0.0 109.572 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -43.9 148.78 0.72 Allowed Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.234 -0.916 . . . . 0.0 109.437 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.601 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -77.97 -40.16 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 122.642 2.228 . . . . 0.0 110.384 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -131.71 94.04 3.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.43 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 99.19 -124.29 8.18 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.493 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 76.6 m-20 -155.06 20.33 0.43 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.241 -1.153 . . . . 0.0 109.556 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 51.9 mttp -137.62 145.33 42.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.237 -0.914 . . . . 0.0 109.638 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.644 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.1 m -150.14 174.69 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.32 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.732 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -101.35 102.95 13.87 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 109.016 179.618 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.709 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.92 117.7 22.36 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.779 ' O ' HG23 ' A' ' 156' ' ' THR . 39.6 t -111.86 144.64 19.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.052 -1.03 . . . . 0.0 109.076 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.54 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 16.0 m -109.2 89.27 2.95 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.534 HG21 ' CD1' ' A' ' 157' ' ' ILE . 41.5 t -85.25 128.7 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.334 -0.854 . . . . 0.0 109.16 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -159.93 61.56 0.36 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.427 -0.795 . . . . 0.0 109.835 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 150.56 93.55 0.11 Allowed Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.69 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.4 m -79.86 -173.41 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.181 -1.188 . . . . 0.0 109.497 179.776 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -135.46 -162.02 9.52 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASN . . . . . 0.418 ' C ' ' OD1' ' A' ' 67' ' ' ASN . 23.0 t30 -89.82 10.28 24.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.213 -1.169 . . . . 0.0 109.453 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.594 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.0 m-20 -131.82 148.26 69.21 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.188 -0.945 . . . . 0.0 109.391 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.43 12.99 1.94 Allowed 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.568 2.179 . . . . 0.0 111.022 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.594 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.2 p90 -133.44 55.66 1.89 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.95 -1.094 . . . . 0.0 109.916 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.52 ' C ' HG23 ' A' ' 36' ' ' VAL . 0.3 OUTLIER -78.68 -68.31 0.66 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 108.862 179.535 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.412 ' HB ' ' HB2' ' A' ' 147' ' ' PHE . 2.8 mp -90.19 124.63 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.472 ' HB3' ' O ' ' A' ' 31' ' ' ASN . 1.6 tt0 -114.7 128.76 56.49 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.031 -1.043 . . . . 0.0 110.729 -179.137 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 1.083 ' HB3' ' CE1' ' A' ' 147' ' ' PHE . . . -131.43 107.67 9.07 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.471 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.558 HG22 ' N ' ' A' ' 75' ' ' ALA . 52.0 m -117.92 163.87 15.91 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.894 -1.129 . . . . 0.0 110.255 -178.252 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.558 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.19 137.26 53.75 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.234 -0.916 . . . . 0.0 109.214 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.54 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 0.6 OUTLIER 177.42 162.95 0.55 Allowed Pre-proline 0 N--CA 1.492 1.67 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -179.888 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.511 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.11 167.45 74.52 Favored 'Cis proline' 0 C--N 1.309 -1.52 0 C-N-CA 123.722 -1.366 . . . . 0.0 110.699 -0.242 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.541 ' CG1' ' HB1' ' A' ' 4' ' ' ALA . 69.5 t -125.37 151.04 30.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.396 -0.815 . . . . 0.0 108.819 179.361 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.593 ' O ' ' HB2' ' A' ' 4' ' ' ALA . 8.5 m-80 -117.15 113.24 21.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.077 -1.014 . . . . 0.0 109.933 -179.51 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.587 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.8 m -117.83 -176.24 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.192 -0.943 . . . . 0.0 109.449 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.722 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -134.91 144.97 52.7 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.319 -0.863 . . . . 0.0 109.236 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.474 ' HD2' ' HG3' ' A' ' 81' ' ' ARG . 34.8 Cg_endo -76.19 113.26 3.66 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.49 2.127 . . . . 0.0 110.553 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.6 -31.6 8.1 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.533 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -85.09 149.79 4.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.256 -1.144 . . . . 0.0 109.466 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 4.3 m -95.37 138.23 33.35 Favored 'General case' 0 C--N 1.292 -1.906 0 CA-C-O 121.296 0.57 . . . . 0.0 109.473 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.587 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 12.2 m-85 -117.93 157.4 26.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -0.936 . . . . 0.0 109.616 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 40.1 m -118.1 149.48 40.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -0.879 . . . . 0.0 109.29 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.69 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 0.2 OUTLIER -125.97 107.98 10.97 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -0.891 . . . . 0.0 109.507 -179.884 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 161' ' ' GLY . 48.6 m -115.15 146.64 41.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.29 -0.882 . . . . 0.0 109.098 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.816 HD13 ' CD2' ' A' ' 103' ' ' PHE . 18.9 tt -150.48 163.32 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 120.884 -1.135 . . . . 0.0 109.465 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.601 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 21.0 m95 -131.37 127.1 36.87 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.971 -1.081 . . . . 0.0 109.526 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.47 146.96 41.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.364 -0.835 . . . . 0.0 109.316 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.501 ' HG3' ' CA ' ' A' ' 124' ' ' GLU . 28.2 ttt-85 -162.16 118.06 1.98 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.125 -0.985 . . . . 0.0 109.182 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.71 166.12 10.69 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.878 -179.527 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.0 mm-40 -59.46 -49.82 76.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.426 -0.796 . . . . 0.0 109.363 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.575 ' C ' HG22 ' A' ' 123' ' ' THR . 0.6 OUTLIER -112.35 148.38 34.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.335 -0.853 . . . . 0.0 109.252 179.879 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.778 ' N ' HG22 ' A' ' 123' ' ' THR . 2.1 t70 -68.81 163.14 24.87 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.205 -0.935 . . . . 0.0 109.487 -179.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.505 ' N ' ' OD1' ' A' ' 97' ' ' ASP . . . 93.42 39.5 5.03 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.905 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -119.02 142.59 47.68 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.278 -1.131 . . . . 0.0 109.044 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.443 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 54.3 t -118.87 149.69 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.205 -0.934 . . . . 0.0 110.909 -179.235 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.702 HG13 ' CE2' ' A' ' 147' ' ' PHE . 47.7 t -149.42 165.26 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.521 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 66.5 m -130.54 125.47 34.33 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.976 -1.077 . . . . 0.0 109.392 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.816 ' CD2' HD13 ' A' ' 90' ' ' ILE . 1.2 m-85 -122.38 104.18 9.23 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.235 -0.915 . . . . 0.0 110.095 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.541 HG22 ' CA ' ' A' ' 115' ' ' ARG . 17.4 p -121.67 163.49 18.92 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.113 -0.992 . . . . 0.0 109.87 179.437 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -112.62 118.0 56.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 C-N-CA 119.948 -0.701 . . . . 0.0 110.007 179.701 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -109.46 172.61 16.25 Favored Glycine 0 N--CA 1.487 2.086 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.552 ' CB ' ' O ' ' A' ' 111' ' ' GLN . 17.1 t30 -123.57 171.78 9.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.369 -1.077 . . . . 0.0 109.133 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.411 ' N ' ' CG ' ' A' ' 107' ' ' ASN . 19.1 mt-30 -59.06 -48.17 82.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.972 -1.08 . . . . 0.0 109.675 -179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 2.8 m -83.36 17.96 1.95 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.239 -0.913 . . . . 0.0 110.12 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.548 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.8 m-30 81.14 8.58 1.08 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.479 -0.763 . . . . 0.0 110.189 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.552 ' O ' ' CB ' ' A' ' 107' ' ' ASN . 5.4 mm-40 -71.02 121.82 18.9 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.955 -1.091 . . . . 0.0 108.807 179.257 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -106.17 139.5 40.59 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.817 -1.177 . . . . 0.0 109.949 -179.328 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.574 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 4.6 m-85 -107.3 -65.53 1.09 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.589 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -104.74 179.29 24.25 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.052 -1.619 . . . . 0.0 109.052 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.541 ' CA ' HG22 ' A' ' 104' ' ' THR . 0.0 OUTLIER 175.35 119.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.917 -1.343 . . . . 0.0 110.398 179.959 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.897 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -140.84 70.01 1.35 Allowed 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.25 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.544 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 17.7 p-80 -89.28 152.7 21.41 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.893 . . . . 0.0 110.129 -179.364 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 4.0 tt0 79.66 72.74 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.402 -0.811 . . . . 0.0 109.598 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLN . . . . . 0.434 ' HG2' ' C ' ' A' ' 118' ' ' GLU . 14.0 mm-40 -134.67 130.18 35.94 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.357 -0.839 . . . . 0.0 109.45 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.696 ' O ' HD13 ' A' ' 121' ' ' ILE . 1.1 mp0 -66.41 152.66 44.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.269 -0.895 . . . . 0.0 109.013 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.696 HD13 ' O ' ' A' ' 120' ' ' GLN . 9.1 mm -136.08 136.07 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 O-C-N 121.068 -1.02 . . . . 0.0 110.099 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.427 HG22 ' OD2' ' A' ' 97' ' ' ASP . 0.6 OUTLIER -87.4 -179.04 6.31 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 121.651 0.738 . . . . 0.0 110.125 179.641 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.778 HG22 ' N ' ' A' ' 97' ' ' ASP . 30.5 p -76.45 1.15 17.3 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.35 179.519 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.501 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 8.6 mt-10 -111.64 -168.95 1.37 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 0.0 109.177 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.529 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 97.6 m95 -94.22 123.36 37.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.657 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.407 ' OE1' ' HD2' ' A' ' 127' ' ' PRO . 12.2 mm-40 -106.93 121.36 45.11 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.301 -0.875 . . . . 0.0 108.992 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.591 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.6 Cg_endo -80.02 104.51 1.68 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.396 2.064 . . . . 0.0 110.947 -179.755 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -116.98 131.67 56.9 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.559 ' HG1' ' C ' ' A' ' 88' ' ' TYR . 14.4 t -151.76 177.09 10.75 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.936 -1.102 . . . . 0.0 110.745 -179.489 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.897 ' CE1' HD21 ' A' ' 116' ' ' LEU . 12.2 p90 -163.36 178.21 8.31 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.08 179.533 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 82.4 mt-10 -130.48 138.92 50.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.117 -0.989 . . . . 0.0 109.975 -179.658 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.589 ' CE2' ' HA2' ' A' ' 114' ' ' GLY . 0.3 OUTLIER -151.06 168.13 25.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.372 -0.83 . . . . 0.0 109.163 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.7 OUTLIER -127.82 146.57 50.56 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.115 -0.991 . . . . 0.0 109.409 -179.507 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.722 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.9 t -41.28 110.43 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.618 -0.676 . . . . 0.0 109.266 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -56.1 -46.94 78.92 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.318 -0.864 . . . . 0.0 109.043 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.472 ' O ' ' HG3' ' A' ' 137' ' ' GLN . 2.8 m-20 -118.49 -91.71 0.55 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.429 -0.794 . . . . 0.0 109.173 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' GLN . . . . . 0.472 ' HG3' ' O ' ' A' ' 136' ' ' ASP . 71.9 mt-30 -159.7 57.37 0.38 Allowed 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.47 -0.769 . . . . 0.0 108.929 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.565 ' O ' HG23 ' A' ' 80' ' ' VAL . 16.6 mm-40 -95.7 111.49 23.43 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.293 -0.88 . . . . 0.0 109.765 -179.662 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.38 -13.79 59.39 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.324 -0.86 . . . . 0.0 108.73 179.492 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 39.2 t -132.17 130.6 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.367 -0.833 . . . . 0.0 109.009 179.463 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.545 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -144.36 171.8 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.254 -0.903 . . . . 0.0 109.824 -179.812 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.507 ' HB2' ' HB3' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -146.47 131.83 18.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.489 -0.757 . . . . 0.0 109.522 179.86 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.613 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -93.34 110.54 47.27 Favored Pre-proline 0 N--CA 1.486 1.372 0 O-C-N 121.259 -0.9 . . . . 0.0 110.168 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.486 ' HD2' ' O ' ' A' ' 104' ' ' THR . 36.0 Cg_endo -77.46 111.06 3.09 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.297 1.998 . . . . 0.0 110.735 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 1.049 HD13 ' CZ2' ' A' ' 28' ' ' TRP . 1.2 mt -97.8 120.71 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 179.162 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.538 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 7.1 m80 -85.83 159.36 19.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.777 -1.202 . . . . 0.0 112.202 -176.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 1.083 ' CE1' ' HB3' ' A' ' 73' ' ' ALA . 61.6 m-85 -157.57 158.43 35.59 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 179.001 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.556 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 112.19 52.53 0.52 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.69 ' C ' HG11 ' A' ' 64' ' ' VAL . 41.8 m-85 -125.73 158.17 35.54 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.428 -1.042 . . . . 0.0 109.195 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.474 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.98 -29.51 69.38 Favored 'General case' 0 C--N 1.296 -1.734 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.86 -9.59 57.94 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 121.738 0.78 . . . . 0.0 109.327 179.299 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.905 ' OD1' ' HB1' ' A' ' 99' ' ' ALA . 2.1 t-20 -120.59 12.18 11.45 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.521 ' CG2' HG13 ' A' ' 64' ' ' VAL . 2.2 t -82.92 161.69 3.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 O-C-N 121.628 -0.67 . . . . 0.0 109.631 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.44 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.7 37.42 51.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.428 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.1 m-20 -160.32 138.37 9.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.128 -1.219 . . . . 0.0 110.17 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 59' ' ' VAL . 98.0 m -86.26 121.2 28.5 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.039 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.573 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 1.0 OUTLIER -101.87 117.27 46.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.865 -1.147 . . . . 0.0 110.224 -178.874 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.709 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.9 m-85 -95.96 135.77 37.28 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 178.598 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.634 HD13 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -129.16 137.66 56.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 120.819 -1.176 . . . . 0.0 110.12 -178.601 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.644 ' CB ' HG12 ' A' ' 56' ' ' VAL . 9.0 t0 -174.08 136.26 0.5 Allowed 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.307 -0.871 . . . . 0.0 109.018 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 128.0 -11.11 6.58 Favored Glycine 0 N--CA 1.485 1.958 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.334 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.522 HD23 ' HB2' ' A' ' 75' ' ' ALA . 11.4 tp -59.63 110.19 1.08 Allowed 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.694 -1.474 . . . . 0.0 108.486 -179.721 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 163' ' ' ALA . . . . . 0.506 ' HA ' ' CB ' ' A' ' 5' ' ' ASN . . . -139.6 145.65 38.82 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.474 -0.766 . . . . 0.0 110.265 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.759 ' O ' ' HB3' ' A' ' 4' ' ' ALA . 2.3 mp -126.86 109.02 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.422 -0.799 . . . . 0.0 109.047 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.494 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . -126.87 146.94 50.1 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.083 -1.011 . . . . 0.0 109.826 -179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.586 ' HB2' ' CZ ' ' A' ' 86' ' ' TYR . 5.2 t -76.17 138.46 40.7 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.201 -0.937 . . . . 0.0 109.571 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.409 ' HB2' ' HD2' ' A' ' 168' ' ' PRO . 1.8 pt20 -136.06 158.24 74.18 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.257 -0.902 . . . . 0.0 109.48 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 168' ' ' PRO . . . . . 0.409 ' HD2' ' HB2' ' A' ' 167' ' ' GLN . 35.8 Cg_endo . . . . . 0 C--N 1.308 -1.565 0 C-N-CA 122.622 2.214 . . . . 0.0 110.45 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.2 ttt . . . . . 0 N--CA 1.492 1.634 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 26.1 mt -96.53 -162.5 0.96 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.453 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.992 HG23 ' HB2' ' A' ' 165' ' ' ALA . 3.2 p -162.99 178.15 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.226 -0.921 . . . . 0.0 109.363 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.632 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -68.79 -57.92 4.92 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.188 -0.945 . . . . 0.0 109.854 -179.741 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.875 ' HB3' HG22 ' A' ' 78' ' ' VAL . 8.5 p-10 -102.07 141.83 34.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.238 -0.914 . . . . 0.0 109.79 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.5 ' O ' ' HA3' ' A' ' 27' ' ' GLY . 1.8 mp -102.78 150.17 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 0.0 109.555 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.541 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.9 OUTLIER 66.63 17.98 10.69 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.254 -0.904 . . . . 0.0 110.0 179.464 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -59.02 -26.97 61.68 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.855 -1.698 . . . . 0.0 108.855 179.571 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.445 ' O ' ' OD1' ' A' ' 160' ' ' ASP . . . -115.38 37.57 3.42 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.605 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 1.1 m-85 43.58 46.09 5.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.328 -1.101 . . . . 0.0 109.417 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -77.08 -36.14 56.04 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.19 -0.944 . . . . 0.0 109.659 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.519 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 4.5 t -88.3 -21.68 24.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.227 -0.921 . . . . 0.0 109.499 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . 1.03 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.2 m -70.81 113.92 22.65 Favored Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.7 Cg_endo -77.48 136.16 15.42 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.392 2.061 . . . . 0.0 110.502 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.6 ' HB2' ' HB2' ' A' ' 46' ' ' GLU . . . -40.21 154.46 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.897 -0.502 . . . . 0.0 109.65 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.52 131.1 2.96 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 -179.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.527 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.2 139.0 17.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.273 -1.134 . . . . 0.0 109.494 -179.591 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.438 HG13 ' HA2' ' A' ' 24' ' ' GLY . 53.7 t -86.52 142.86 12.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 CA-C-O 121.568 0.699 . . . . 0.0 110.122 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 19.6 p -93.75 -28.43 15.93 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.99 101.05 5.08 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 1.102 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -47.29 -30.21 2.96 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.247 -0.908 . . . . 0.0 109.873 -178.842 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.102 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.72 -47.74 84.46 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.559 -0.713 . . . . 0.0 109.857 -179.642 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -107.58 34.59 3.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.123 -0.985 . . . . 0.0 109.432 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.438 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -74.55 -50.02 10.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 1.03 HG13 ' OG1' ' A' ' 13' ' ' THR . 4.9 t -119.84 141.49 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.24 -1.153 . . . . 0.0 109.738 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -67.18 -47.18 71.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.345 -0.847 . . . . 0.0 109.433 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.541 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -89.29 0.66 81.49 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 0.696 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -135.64 121.75 20.17 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.198 -1.177 . . . . 0.0 109.215 179.659 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.539 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -121.65 122.79 40.41 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.366 -0.834 . . . . 0.0 108.912 179.452 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.828 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -99.32 173.5 6.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.756 -179.308 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 62.7 m-80 -160.37 123.45 3.42 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.369 -0.832 . . . . 0.0 109.842 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.958 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.54 136.25 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.205 -0.935 . . . . 0.0 109.415 179.219 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.01 -178.91 26.5 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 70.2 m -58.79 -16.99 19.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -1.127 . . . . 0.0 109.538 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.492 ' HB3' ' HB2' ' A' ' 67' ' ' ASN . 2.8 p -60.99 -37.0 80.94 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.242 -0.911 . . . . 0.0 109.367 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.958 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -62.41 89.39 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 O-C-N 121.27 -0.894 . . . . 0.0 109.334 179.631 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 88.7 m -73.14 -28.07 62.03 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.362 -0.836 . . . . 0.0 108.864 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.638 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.5 p-10 -112.72 142.99 28.13 Favored Pre-proline 0 C--N 1.297 -1.703 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -76.41 111.38 3.25 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.384 2.056 . . . . 0.0 110.801 -179.599 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.542 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.8 Cg_endo -78.05 177.11 9.18 Favored 'Trans proline' 0 C--N 1.312 -1.365 0 C-N-CA 122.521 2.147 . . . . 0.0 109.391 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.543 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 63.2 t -118.03 120.87 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 120.873 -1.142 . . . . 0.0 110.829 -179.602 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.591 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 96.3 m-85 -110.01 112.89 25.17 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 178.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.527 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 22.8 tt0 -150.93 155.55 39.35 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.006 -1.059 . . . . 0.0 109.845 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.67 HG21 HG22 ' A' ' 13' ' ' THR . 85.2 t -94.49 141.52 14.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.203 179.491 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.507 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -117.88 118.85 33.12 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.512 -0.743 . . . . 0.0 109.347 -179.663 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.6 ' HB2' ' HB2' ' A' ' 15' ' ' ALA . 6.3 mt-10 -103.55 109.85 21.67 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.61 -0.681 . . . . 0.0 109.394 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.483 ' O ' ' HB2' ' A' ' 54' ' ' ASN . 2.4 p -144.5 -179.54 6.62 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.46 -0.775 . . . . 0.0 109.386 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -102.13 29.71 4.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 109.367 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -119.5 -14.31 9.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 0.0 109.541 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.465 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -45.91 154.62 0.56 Allowed Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.147 -0.971 . . . . 0.0 109.521 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.542 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 36.0 Cg_endo -78.04 -34.01 1.86 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.596 2.198 . . . . 0.0 110.419 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -129.1 91.68 3.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.266 -0.896 . . . . 0.0 109.351 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.62 -120.98 6.31 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.544 -1.423 . . . . 0.0 109.544 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.483 ' HB2' ' O ' ' A' ' 47' ' ' THR . 11.9 p30 -160.02 30.16 0.18 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.239 -1.154 . . . . 0.0 109.472 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.528 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 8.2 mttp -135.09 130.74 36.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.305 -0.872 . . . . 0.0 109.547 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.678 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.0 m -149.05 175.62 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.372 -0.83 . . . . 0.0 109.145 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.731 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -105.81 100.91 10.44 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.032 -1.043 . . . . 0.0 108.998 179.441 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.618 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.62 117.87 22.33 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 178.735 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.767 ' O ' HG23 ' A' ' 156' ' ' THR . 40.9 t -115.15 144.92 21.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.069 -1.02 . . . . 0.0 109.168 -179.042 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.543 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 9.9 m -107.19 94.18 4.95 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.652 HG21 ' CD1' ' A' ' 157' ' ' ILE . 50.8 t -90.27 118.1 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.384 -0.823 . . . . 0.0 109.194 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -153.91 58.66 0.73 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.866 . . . . 0.0 109.941 -179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.422 ' HA3' ' CG ' ' A' ' 38' ' ' ASN . . . 158.47 92.49 0.09 OUTLIER Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.692 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.744 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.7 m -84.36 -172.38 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.282 -1.128 . . . . 0.0 109.599 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -138.23 -157.17 7.36 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.4 m120 -96.06 10.03 38.88 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -1.121 . . . . 0.0 109.491 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.578 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 17.5 m-80 -127.35 146.46 58.3 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.212 -0.93 . . . . 0.0 109.42 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.586 ' HG2' ' CZ3' ' A' ' 69' ' ' TRP . 35.8 Cg_endo -78.47 12.54 2.09 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.579 2.186 . . . . 0.0 110.957 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.586 ' CZ3' ' HG2' ' A' ' 68' ' ' PRO . 1.1 p90 -133.56 54.5 1.95 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.987 -1.07 . . . . 0.0 109.853 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.476 ' HA ' ' OG ' ' A' ' 35' ' ' SER . 0.8 OUTLIER -78.4 -69.0 0.59 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.185 -0.947 . . . . 0.0 108.838 179.464 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.542 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 3.2 mp -106.05 128.02 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.155 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.61 138.24 52.1 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.903 -1.123 . . . . 0.0 110.467 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.828 ' HA ' HD23 ' A' ' 30' ' ' LEU . . . -120.35 132.15 55.16 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 178.716 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.531 HG22 ' N ' ' A' ' 75' ' ' ALA . 16.4 m -135.52 163.1 30.86 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.721 -1.237 . . . . 0.0 110.379 -178.618 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.56 ' HB2' ' NE1' ' A' ' 28' ' ' TRP . . . -122.66 137.56 54.87 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.433 -0.792 . . . . 0.0 109.145 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.539 ' CE2' ' CG ' ' A' ' 29' ' ' ASP . 1.6 p90 179.03 161.31 0.71 Allowed Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.516 -0.74 . . . . 0.0 109.103 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.531 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.3 Cg_endo -80.03 165.41 78.82 Favored 'Cis proline' 0 C--N 1.309 -1.514 0 C-N-CA 123.63 -1.404 . . . . 0.0 110.775 -0.147 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.875 HG22 ' HB3' ' A' ' 5' ' ' ASN . 92.6 t -120.34 156.47 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.381 -0.824 . . . . 0.0 108.918 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.571 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 4.5 m-80 -124.13 122.05 36.8 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.17 -0.956 . . . . 0.0 109.961 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.57 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 3.3 m -129.96 -174.01 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.153 -0.967 . . . . 0.0 109.54 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.652 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -137.12 143.88 43.79 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.394 -0.816 . . . . 0.0 109.148 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -76.14 115.46 4.14 Favored 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.475 2.117 . . . . 0.0 110.452 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.67 -27.36 20.61 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.512 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.86 149.81 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.186 -1.185 . . . . 0.0 109.549 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.434 ' O ' ' CB ' ' A' ' 166' ' ' SER . 39.0 m -97.14 132.99 42.37 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.57 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 12.9 m-85 -111.88 164.83 12.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.582 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.467 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 12.1 m -115.33 154.1 29.77 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.3 -0.875 . . . . 0.0 109.445 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.671 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 6.2 t80 -131.12 118.56 20.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.258 -0.901 . . . . 0.0 109.236 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.481 ' O ' ' O ' ' A' ' 161' ' ' GLY . 16.6 m -135.74 143.55 45.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.174 -0.954 . . . . 0.0 109.187 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.734 HD12 ' HB2' ' A' ' 162' ' ' LEU . 17.5 tt -150.51 163.71 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.868 -1.145 . . . . 0.0 109.588 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.542 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 18.2 m95 -130.4 126.34 36.8 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.037 -1.039 . . . . 0.0 109.247 179.626 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -115.79 149.22 38.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.275 -0.891 . . . . 0.0 109.541 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.576 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 4.9 ttp85 -164.02 120.61 1.66 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.196 -0.94 . . . . 0.0 109.145 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.479 ' HB1' ' O ' ' A' ' 156' ' ' THR . . . -105.4 160.56 15.04 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.324 -0.86 . . . . 0.0 110.012 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLU . . . . . 0.476 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 0.0 OUTLIER -57.26 -48.96 77.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.436 -0.79 . . . . 0.0 109.172 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.529 ' C ' HG22 ' A' ' 123' ' ' THR . 16.3 mt-30 -116.44 146.19 42.72 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.336 -0.852 . . . . 0.0 109.166 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.639 ' N ' HG22 ' A' ' 123' ' ' THR . 8.5 p30 -65.17 146.29 55.16 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.204 -0.935 . . . . 0.0 109.517 -179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 112.12 30.87 2.81 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.477 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -118.13 138.18 52.45 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.117 -1.226 . . . . 0.0 109.112 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.641 HG22 ' HA ' ' A' ' 120' ' ' GLN . 52.1 t -116.9 158.36 17.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 O-C-N 121.256 -0.902 . . . . 0.0 110.747 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.877 HG22 ' CE1' ' A' ' 147' ' ' PHE . 72.6 t -153.68 163.04 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.547 ' CB ' ' HB2' ' A' ' 117' ' ' HIS . 74.9 m -121.72 125.24 46.13 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.916 -1.115 . . . . 0.0 109.907 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.613 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.2 OUTLIER -119.76 103.56 9.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.062 -1.024 . . . . 0.0 109.737 179.72 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.503 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 18.5 p -127.3 167.95 15.45 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.168 -0.958 . . . . 0.0 110.151 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.688 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -128.16 156.86 40.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.715 -0.615 . . . . 0.0 110.247 -179.793 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.503 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -173.92 -173.17 39.85 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.608 ' CB ' HG22 ' A' ' 141' ' ' ILE . 1.4 p30 -126.52 -169.37 2.01 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.18 -1.188 . . . . 0.0 109.049 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.531 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 5.6 mp0 -73.66 11.9 0.74 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.049 -1.032 . . . . 0.0 110.971 -179.4 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.499 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 1.0 OUTLIER -113.19 7.89 18.03 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 120.722 -1.236 . . . . 0.0 109.288 179.658 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.6 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.6 m-30 78.87 1.95 2.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.355 -0.841 . . . . 0.0 109.815 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.503 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 4.9 mm100 -76.04 159.47 30.77 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.106 -0.996 . . . . 0.0 108.729 179.466 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.495 ' HA ' ' HA2' ' A' ' 106' ' ' GLY . 5.2 tt0 -138.09 135.3 35.67 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.968 -1.083 . . . . 0.0 110.005 -179.415 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.568 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 6.5 m-85 -95.95 -70.62 0.71 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.06 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.586 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -81.72 162.0 42.79 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.358 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.466 ' HA ' HG22 ' A' ' 104' ' ' THR . 7.7 ttm180 -158.05 103.95 1.87 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.974 -1.309 . . . . 0.0 110.337 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.72 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -144.1 72.85 1.36 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.335 -0.853 . . . . 0.0 108.784 179.087 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.547 ' HB2' ' CB ' ' A' ' 102' ' ' SER . 32.1 p-80 -115.82 162.79 16.81 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.121 -0.987 . . . . 0.0 110.049 -179.412 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.531 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 3.2 tt0 77.22 53.31 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.399 -0.813 . . . . 0.0 109.256 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLN . . . . . 0.407 ' O ' HG13 ' A' ' 100' ' ' VAL . 53.2 mm-40 -126.4 141.69 51.8 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.378 -0.826 . . . . 0.0 109.599 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.641 ' HA ' HG22 ' A' ' 100' ' ' VAL . 46.9 mm-40 -73.64 156.55 37.88 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.62 HD13 ' O ' ' A' ' 120' ' ' GLN . 10.8 mm -133.5 136.9 53.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.025 -1.047 . . . . 0.0 110.129 -179.469 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.64 -179.31 7.1 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.541 -0.724 . . . . 0.0 110.121 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.639 HG22 ' N ' ' A' ' 97' ' ' ASP . 61.9 p -78.06 0.49 24.42 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.877 -0.729 . . . . 0.0 109.36 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.436 ' O ' ' HB2' ' A' ' 93' ' ' ARG . 2.8 mt-10 -110.06 -168.83 1.37 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -0.883 . . . . 0.0 109.327 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.576 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 85.6 m95 -98.01 121.91 40.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 109.562 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -106.83 121.35 45.22 Favored Pre-proline 0 N--CA 1.488 1.475 0 O-C-N 121.204 -0.935 . . . . 0.0 108.966 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.77 108.22 2.23 Favored 'Trans proline' 0 C--N 1.312 -1.381 0 C-N-CA 122.292 1.994 . . . . 0.0 110.96 -179.61 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -112.51 136.02 52.53 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.462 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.5 t -151.07 175.94 11.63 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.651 -1.28 . . . . 0.0 111.05 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.72 ' CE2' HD21 ' A' ' 116' ' ' LEU . 29.1 p90 -173.87 -178.29 1.53 Allowed 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.346 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -131.14 155.2 47.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.237 -0.914 . . . . 0.0 109.698 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.568 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.02 168.31 17.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.341 -0.849 . . . . 0.0 109.41 179.783 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -133.78 147.68 51.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.187 -0.946 . . . . 0.0 109.516 -179.745 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.652 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.2 t -42.01 110.3 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.511 -0.743 . . . . 0.0 109.272 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 67.5 m -58.7 -50.35 74.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 0.0 109.203 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -110.51 -90.79 0.47 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.436 -0.79 . . . . 0.0 109.202 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -163.31 56.31 0.18 Allowed 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.55 -0.719 . . . . 0.0 109.11 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.498 ' O ' HG23 ' A' ' 80' ' ' VAL . 50.0 mm-40 -95.66 112.9 24.52 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.271 -0.893 . . . . 0.0 109.809 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.37 -14.9 58.66 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.29 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.6 t -133.72 132.91 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.608 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.6 OUTLIER -143.52 172.22 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.184 -0.948 . . . . 0.0 110.285 -179.58 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.498 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.6 OUTLIER -140.79 133.22 28.42 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.57 -0.706 . . . . 0.0 109.111 179.978 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.688 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.48 110.48 45.18 Favored Pre-proline 0 C--N 1.305 -1.339 0 O-C-N 121.135 -0.978 . . . . 0.0 109.625 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.503 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.3 Cg_endo -76.49 110.96 3.16 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 C-N-CA 122.293 1.995 . . . . 0.0 111.089 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.531 ' HB ' ' O ' ' A' ' 73' ' ' ALA . 2.3 mm -97.45 135.3 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 178.523 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.513 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 8.8 m80 -102.24 158.55 16.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.438 -1.414 . . . . 0.0 111.335 -178.102 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.877 ' CE1' HG22 ' A' ' 101' ' ' VAL . 11.1 m-85 -159.1 160.2 35.42 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.327 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.537 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 106.71 48.11 0.99 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.744 ' C ' HG11 ' A' ' 64' ' ' VAL . 17.4 m-85 -125.35 159.35 32.01 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.435 -1.038 . . . . 0.0 109.166 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.499 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -64.83 -27.24 68.74 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.469 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.4 -19.42 63.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.367 -0.833 . . . . 0.0 109.199 179.522 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.494 ' OD1' ' N ' ' A' ' 152' ' ' ASN . 0.3 OUTLIER -107.96 10.17 28.45 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.42 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.538 HG23 HG13 ' A' ' 64' ' ' VAL . 2.2 t -84.65 163.98 2.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 121.437 -0.789 . . . . 0.0 109.686 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.477 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 49.88 31.57 17.23 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.441 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 2.2 t-20 -160.14 144.85 14.72 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.149 -1.207 . . . . 0.0 110.113 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.767 HG23 ' O ' ' A' ' 59' ' ' VAL . 52.6 m -92.55 128.83 38.55 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.733 HG21 ' CG2' ' A' ' 101' ' ' VAL . 1.2 mt -107.7 118.75 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.853 -1.154 . . . . 0.0 109.759 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.618 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 3.4 m-85 -102.96 133.14 48.56 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 178.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.86 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -124.55 142.86 40.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.308 -178.694 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.678 ' CB ' HG12 ' A' ' 56' ' ' VAL . 19.4 t70 -174.23 136.38 0.49 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.418 -0.801 . . . . 0.0 109.064 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 124.32 -7.76 8.52 Favored Glycine 0 N--CA 1.486 1.988 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.537 179.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.734 ' HB2' HD12 ' A' ' 90' ' ' ILE . 3.7 tp -59.9 103.97 0.26 Allowed 'General case' 0 N--CA 1.487 1.406 0 O-C-N 120.741 -1.446 . . . . 0.0 108.901 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -136.08 145.65 46.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.514 -0.741 . . . . 0.0 109.86 -179.226 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.629 HD13 HG11 ' A' ' 78' ' ' VAL . 8.4 mt -128.69 109.07 18.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.392 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.992 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -153.52 152.38 30.88 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.119 -0.988 . . . . 0.0 109.637 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.477 ' HB3' ' HA ' ' A' ' 86' ' ' TYR . 80.5 p -110.91 162.15 15.12 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.888 . . . . 0.0 109.425 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.468 ' HB3' ' HD2' ' A' ' 168' ' ' PRO . 2.4 mt-30 -95.63 158.67 34.05 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.431 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 168' ' ' PRO . . . . . 0.468 ' HD2' ' HB3' ' A' ' 167' ' ' GLN . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.56 0 C-N-CA 122.622 2.215 . . . . 0.0 110.419 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.452 -0.574 . . . . 0.0 109.452 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mp -85.09 109.81 18.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.241 -0.912 . . . . 0.0 109.425 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.857 HG23 ' HB2' ' A' ' 165' ' ' ALA . 3.9 p -100.98 173.17 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.9 . . . . 0.0 109.546 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.573 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -69.89 -58.85 3.38 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -0.893 . . . . 0.0 109.569 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.614 ' HA ' HG22 ' A' ' 78' ' ' VAL . 7.7 t30 -77.46 134.49 38.35 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.145 -0.972 . . . . 0.0 109.558 -179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.513 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 62.3 mt -111.72 138.86 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.262 -0.899 . . . . 0.0 109.536 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.58 ' ND2' ' HA ' ' A' ' 10' ' ' PHE . 1.5 t30 76.17 26.48 0.96 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.309 -0.869 . . . . 0.0 109.83 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.41 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -57.27 -34.93 68.64 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 179.284 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.52 ' HA3' ' OD1' ' A' ' 160' ' ' ASP . . . -119.76 34.44 4.22 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 108.85 -1.7 . . . . 0.0 108.85 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.697 ' HD2' HG11 ' A' ' 25' ' ' VAL . 8.4 m-85 43.84 53.76 6.02 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.375 -1.074 . . . . 0.0 109.358 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.422 ' HA ' ' HD3' ' A' ' 55' ' ' LYS . 31.7 mm-40 -83.96 -28.56 27.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.471 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.9 t -86.67 -41.98 13.77 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -0.879 . . . . 0.0 109.541 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.966 HG21 HG22 ' A' ' 25' ' ' VAL . 90.8 m -71.97 127.73 90.22 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.9 Cg_endo -77.63 141.13 19.41 Favored 'Trans proline' 0 C--N 1.312 -1.383 0 C-N-CA 122.481 2.121 . . . . 0.0 110.568 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.468 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -41.7 164.35 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.742 -0.599 . . . . 0.0 109.582 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.66 133.7 3.32 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 108.931 -1.668 . . . . 0.0 108.931 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.466 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.89 140.2 15.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.277 -1.131 . . . . 0.0 109.207 -179.637 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.768 HG13 ' HA3' ' A' ' 24' ' ' GLY . 62.1 t -86.61 142.4 13.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 CA-C-O 121.638 0.732 . . . . 0.0 110.439 -179.416 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.35 -28.81 12.76 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -131.38 86.73 2.38 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 1.101 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -45.33 -29.85 1.14 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.268 -0.895 . . . . 0.0 110.006 -178.953 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.101 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -60.22 -49.0 79.34 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.494 -0.754 . . . . 0.0 110.232 -179.53 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -133.67 48.77 2.33 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.961 -1.087 . . . . 0.0 109.732 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.768 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -97.44 -12.37 48.42 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.966 HG22 HG21 ' A' ' 13' ' ' THR . 90.8 t -141.24 133.95 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.186 -1.185 . . . . 0.0 109.636 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.472 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 17.7 tt0 -78.36 126.69 31.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.384 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.549 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 101.76 -16.17 56.37 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 1.015 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.2 OUTLIER -137.6 120.24 16.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -1.117 . . . . 0.0 108.426 179.164 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.529 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -121.94 110.66 16.12 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.32 -0.863 . . . . 0.0 109.209 179.935 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.837 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -91.7 173.6 7.79 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.286 -0.884 . . . . 0.0 109.339 -179.73 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.457 ' HA ' HD21 ' A' ' 21' ' ' LEU . 77.7 m-20 -160.62 123.45 3.31 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.205 -0.934 . . . . 0.0 110.366 -179.675 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.981 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -109.36 131.32 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.291 -0.88 . . . . 0.0 109.286 178.861 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.79 -172.54 22.76 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -56.67 -31.65 64.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.334 -1.098 . . . . 0.0 109.559 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.48 ' HB2' ' HA ' ' A' ' 70' ' ' ASP . 0.7 OUTLIER -45.98 -42.42 13.05 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.196 -0.94 . . . . 0.0 109.279 -179.869 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.981 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -60.77 89.84 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 121.188 -0.945 . . . . 0.0 109.529 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 94.7 m -74.05 -28.13 61.25 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.854 0.835 . . . . 0.0 108.789 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.649 ' O ' HG13 ' A' ' 36' ' ' VAL . 8.2 t30 -114.01 144.48 31.66 Favored Pre-proline 0 C--N 1.297 -1.681 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.405 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.2 Cg_endo -75.83 111.07 3.21 Favored 'Trans proline' 0 C--N 1.307 -1.627 0 C-N-CA 122.443 2.095 . . . . 0.0 111.011 -179.374 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.538 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 36.2 Cg_endo -78.97 174.41 12.22 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.558 2.172 . . . . 0.0 109.607 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.549 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 73.8 t -116.9 120.5 65.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.998 -1.064 . . . . 0.0 110.659 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.752 ' HZ ' HG23 ' A' ' 71' ' ' ILE . 60.6 m-85 -109.04 112.55 24.79 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 178.044 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.466 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 28.7 tt0 -150.59 146.96 26.87 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.11 -0.994 . . . . 0.0 109.904 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.7 t -95.49 148.61 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.392 -0.817 . . . . 0.0 109.232 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.867 HD21 ' CG2' ' A' ' 47' ' ' THR . 0.4 OUTLIER -132.64 147.23 52.33 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.175 -0.953 . . . . 0.0 108.895 -179.79 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.577 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 16.9 mt-10 -117.06 114.09 23.26 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.53 -0.731 . . . . 0.0 109.63 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.867 ' CG2' HD21 ' A' ' 45' ' ' LEU . 12.9 p -139.8 174.14 10.82 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.473 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.521 ' HA ' ' ND2' ' A' ' 54' ' ' ASN . 16.9 m -100.06 21.67 12.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.462 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.413 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.0 OUTLIER -111.82 -15.33 13.4 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.182 -0.949 . . . . 0.0 109.534 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.437 ' HB3' ' O ' ' A' ' 53' ' ' GLY . . . -44.17 147.19 0.99 Allowed Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.549 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.06 -40.54 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.548 2.165 . . . . 0.0 110.389 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.4 ' O ' ' OE2' ' A' ' 11' ' ' GLU . 2.5 tp10 -117.87 79.71 1.4 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 109.432 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.449 ' O ' ' OD1' ' A' ' 54' ' ' ASN . . . 102.81 -139.41 14.42 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.521 ' ND2' ' HA ' ' A' ' 48' ' ' SER . 3.0 m120 -142.28 35.35 1.5 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -1.111 . . . . 0.0 109.463 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.537 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 8.9 mttt -144.64 138.3 27.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.279 -0.888 . . . . 0.0 109.555 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.598 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.8 m -150.32 174.39 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.344 -0.847 . . . . 0.0 109.281 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.791 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -108.13 103.51 12.73 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.072 -1.018 . . . . 0.0 108.893 179.45 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.719 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.59 119.17 23.45 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.826 ' O ' HG23 ' A' ' 156' ' ' THR . 41.3 t -114.66 144.83 21.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.092 -1.005 . . . . 0.0 109.075 -179.212 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.631 HG22 ' OD1' ' A' ' 62' ' ' ASN . 24.0 m -106.4 91.52 3.74 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 179.281 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.647 HG21 ' CD1' ' A' ' 157' ' ' ILE . 53.8 t -90.86 113.01 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.385 -0.822 . . . . 0.0 109.11 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.631 ' OD1' HG22 ' A' ' 60' ' ' THR . 3.1 p-10 -153.46 58.02 0.76 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.312 -0.868 . . . . 0.0 109.831 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 162.09 85.09 0.05 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.569 HG11 ' C ' ' A' ' 149' ' ' TYR . 1.3 m -79.89 175.82 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.211 -1.17 . . . . 0.0 109.46 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -124.45 -149.91 7.76 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -95.15 -4.54 45.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.302 -1.116 . . . . 0.0 109.609 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.582 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 0.8 OUTLIER -114.78 147.89 39.2 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 109.283 179.991 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -79.02 14.25 1.78 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.717 2.278 . . . . 0.0 111.008 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.582 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.3 p90 -135.34 52.53 2.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.99 -1.069 . . . . 0.0 109.921 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.511 ' C ' HG23 ' A' ' 36' ' ' VAL . 0.4 OUTLIER -75.22 -66.45 0.76 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.046 -1.034 . . . . 0.0 108.966 179.552 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.752 HG23 ' HZ ' ' A' ' 42' ' ' PHE . 2.5 mt -101.23 127.79 54.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.305 -0.872 . . . . 0.0 108.659 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.465 ' O ' ' HB3' ' A' ' 30' ' ' LEU . 7.2 mt-10 -126.58 137.71 53.37 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.05 -1.031 . . . . 0.0 110.363 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 1.015 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -118.31 123.32 45.07 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 106.998 -1.482 . . . . 0.0 106.998 178.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.541 HG22 ' N ' ' A' ' 75' ' ' ALA . 18.0 m -128.61 163.31 25.31 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 120.441 -1.412 . . . . 0.0 110.459 -178.578 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.541 ' N ' HG22 ' A' ' 74' ' ' THR . . . -129.7 138.32 51.09 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.472 -0.768 . . . . 0.0 109.238 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.546 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 2.2 p90 177.99 160.48 0.59 Allowed Pre-proline 0 N--CA 1.492 1.647 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.526 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -81.65 166.75 71.9 Favored 'Cis proline' 0 C--N 1.31 -1.476 0 C-N-CA 123.686 -1.381 . . . . 0.0 110.799 -0.568 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.866 HG11 HD12 ' A' ' 164' ' ' ILE . 76.5 t -124.69 156.34 32.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.219 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.518 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 3.6 m120 -123.77 123.05 39.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.915 -1.116 . . . . 0.0 110.417 -179.301 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.685 HG12 ' CD2' ' A' ' 86' ' ' TYR . 3.0 m -128.19 -173.88 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.115 179.244 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.832 ' O ' HG21 ' A' ' 134' ' ' VAL . 1.7 mtt180 -126.96 145.16 52.86 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.246 -0.908 . . . . 0.0 109.438 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.41 120.78 5.38 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.437 2.091 . . . . 0.0 110.493 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.35 -27.43 17.18 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.6 t -85.94 149.72 4.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.271 -1.135 . . . . 0.0 109.439 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 20.8 m -97.74 122.4 40.78 Favored 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.685 ' CD2' HG12 ' A' ' 80' ' ' VAL . 3.6 m-85 -99.77 170.28 8.66 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.922 . . . . 0.0 109.619 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.477 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 6.5 m -118.23 154.09 32.82 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.404 -0.81 . . . . 0.0 109.431 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.627 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.8 t80 -128.11 121.23 29.1 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.256 -0.903 . . . . 0.0 109.266 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.468 ' O ' ' O ' ' A' ' 161' ' ' GLY . 19.6 m -135.54 145.97 47.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.191 -0.943 . . . . 0.0 109.317 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.688 HD13 ' HD2' ' A' ' 103' ' ' PHE . 16.7 tt -150.74 163.68 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 120.765 -1.209 . . . . 0.0 109.531 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.596 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 19.7 m95 -133.92 124.73 26.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.884 -1.135 . . . . 0.0 109.057 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -117.34 150.88 38.1 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.255 -0.903 . . . . 0.0 109.491 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.581 ' HD2' ' CE2' ' A' ' 125' ' ' TRP . 1.0 OUTLIER -164.27 121.83 1.72 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.187 -0.946 . . . . 0.0 108.971 179.981 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.69 167.49 9.73 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -0.922 . . . . 0.0 110.053 -179.491 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -58.52 -48.77 79.74 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.265 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.558 ' C ' HG22 ' A' ' 123' ' ' THR . 2.9 mt-30 -118.28 150.97 38.58 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.299 -0.876 . . . . 0.0 109.163 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.724 ' N ' HG22 ' A' ' 123' ' ' THR . 0.6 OUTLIER -66.34 145.13 56.06 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.255 -0.903 . . . . 0.0 109.701 -179.778 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 114.07 35.21 1.53 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.47 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -120.2 139.54 52.49 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.269 -1.136 . . . . 0.0 109.246 179.698 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.468 ' HB ' ' OD1' ' A' ' 152' ' ' ASN . 54.2 t -117.94 157.86 19.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 121.325 -0.859 . . . . 0.0 110.759 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.692 HG22 ' CE1' ' A' ' 147' ' ' PHE . 62.1 t -154.94 162.25 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 179.47 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.525 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 4.8 m -116.78 129.49 56.13 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.085 -1.009 . . . . 0.0 109.392 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.688 ' HD2' HD13 ' A' ' 90' ' ' ILE . 0.2 OUTLIER -123.84 103.92 8.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.145 -0.972 . . . . 0.0 109.734 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.586 HG22 ' HA ' ' A' ' 115' ' ' ARG . 36.1 p -135.35 169.63 17.18 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.972 -1.08 . . . . 0.0 110.233 179.742 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.968 HG23 ' N ' ' A' ' 114' ' ' GLY . 0.0 OUTLIER -131.99 127.66 58.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-O 121.71 0.767 . . . . 0.0 110.41 179.121 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -122.01 165.78 14.8 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.119 -1.992 . . . . 0.0 108.119 178.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.595 ' OD1' ' CE1' ' A' ' 113' ' ' TYR . 0.0 OUTLIER -125.97 -170.82 2.26 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.922 -1.34 . . . . 0.0 109.272 -179.714 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 13.0 mt-30 -81.22 -19.86 42.31 Favored 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 118.791 -1.164 . . . . 0.0 109.588 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.505 ' HB2' ' HG2' ' A' ' 111' ' ' GLN . 2.4 m -82.09 8.78 9.89 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.462 ' HB2' ' O ' ' A' ' 109' ' ' SER . 16.8 m-30 65.3 24.03 12.14 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.313 -0.867 . . . . 0.0 108.674 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.525 ' CA ' ' OE1' ' A' ' 111' ' ' GLN . 0.7 OUTLIER -86.54 161.8 18.37 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.434 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.479 ' OE1' ' HG3' ' A' ' 115' ' ' ARG . 0.5 OUTLIER -107.68 101.35 10.67 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.336 -0.852 . . . . 0.0 109.891 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.952 ' OH ' HG13 ' A' ' 134' ' ' VAL . 2.0 m-30 -70.83 -64.43 0.9 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.586 -0.696 . . . . 0.0 109.72 178.607 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.968 ' N ' HG23 ' A' ' 105' ' ' VAL . . . -115.44 166.38 12.22 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 -179.384 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.611 ' NE ' ' CE1' ' A' ' 117' ' ' HIS . 0.0 OUTLIER -157.81 74.61 0.74 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.242 -1.152 . . . . 0.0 110.691 -179.706 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.953 HD21 ' CD2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -131.45 86.47 2.36 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.985 -1.072 . . . . 0.0 108.811 178.495 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.611 ' CE1' ' NE ' ' A' ' 115' ' ' ARG . 29.8 p-80 -121.53 163.32 19.04 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -0.862 . . . . 0.0 110.009 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 3.0 tt0 76.89 36.31 0.34 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.42 -0.8 . . . . 0.0 109.373 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 17.3 mm-40 -100.3 135.81 41.15 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.299 -0.876 . . . . 0.0 109.542 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.625 ' O ' HD13 ' A' ' 121' ' ' ILE . 20.5 mt-30 -71.29 156.03 39.99 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.388 -0.82 . . . . 0.0 108.944 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.625 HD13 ' O ' ' A' ' 120' ' ' GLN . 6.1 mm -134.37 133.42 55.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.092 -1.005 . . . . 0.0 110.132 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.87 -179.42 6.81 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.514 -0.741 . . . . 0.0 109.971 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.724 HG22 ' N ' ' A' ' 97' ' ' ASP . 37.9 p -73.96 -2.67 25.02 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.771 -0.772 . . . . 0.0 109.243 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.524 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 0.9 OUTLIER -110.02 175.42 5.45 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.334 -0.854 . . . . 0.0 109.177 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.581 ' CE2' ' HD2' ' A' ' 93' ' ' ARG . 95.0 m95 -81.77 122.35 27.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.83 121.02 46.29 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.252 -0.905 . . . . 0.0 108.833 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.596 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.6 Cg_endo -80.17 101.69 1.37 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.412 2.074 . . . . 0.0 111.177 -179.477 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -103.86 132.25 50.3 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 178.553 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.456 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -144.15 176.29 9.43 Favored 'General case' 0 C--N 1.295 -1.776 0 O-C-N 120.875 -1.141 . . . . 0.0 110.723 -179.241 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.953 ' CD2' HD21 ' A' ' 116' ' ' LEU . 25.3 p90 -175.11 152.56 1.47 Allowed 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 114.978 -1.01 . . . . 0.0 109.34 179.651 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -101.96 142.49 33.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.257 -0.902 . . . . 0.0 109.68 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.637 ' CD1' ' CE1' ' A' ' 130' ' ' PHE . 8.1 p90 -153.65 137.54 16.25 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.34 -0.85 . . . . 0.0 109.371 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.445 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.8 OUTLIER -98.72 146.58 25.73 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.256 -0.902 . . . . 0.0 108.836 179.923 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.952 HG13 ' OH ' ' A' ' 113' ' ' TYR . 4.1 t -41.55 108.96 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.443 -0.786 . . . . 0.0 109.171 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -48.17 -35.33 11.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.332 -0.855 . . . . 0.0 109.007 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -138.49 -90.79 0.21 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.452 -0.78 . . . . 0.0 109.293 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -158.35 56.05 0.45 Allowed 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.524 -0.735 . . . . 0.0 109.1 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.604 ' O ' HG23 ' A' ' 80' ' ' VAL . 31.8 mm-40 -92.58 111.06 22.51 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.2 p -79.31 -18.32 52.83 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 40.2 t -131.66 135.79 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.586 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -143.6 171.62 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.926 -1.109 . . . . 0.0 110.751 -179.177 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.512 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.7 OUTLIER -133.02 132.22 41.6 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.682 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.625 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -99.36 107.22 43.81 Favored Pre-proline 0 C--N 1.304 -1.374 0 O-C-N 120.976 -1.077 . . . . 0.0 109.382 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.534 ' HD2' ' HA ' ' A' ' 105' ' ' VAL . 34.9 Cg_endo -77.31 110.94 3.09 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.27 1.98 . . . . 0.0 111.341 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.738 HD12 ' CZ2' ' A' ' 28' ' ' TRP . 1.6 mt -99.57 138.91 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.581 ' O ' ' CD2' ' A' ' 147' ' ' PHE . 4.8 m80 -103.81 159.11 15.91 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.53 -1.356 . . . . 0.0 111.732 -177.289 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.692 ' CE1' HG22 ' A' ' 101' ' ' VAL . 17.1 m-85 -161.24 160.0 29.4 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.563 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 105.77 52.22 0.81 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 -179.692 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.569 ' C ' HG11 ' A' ' 64' ' ' VAL . 22.8 m-85 -129.0 158.88 37.63 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.531 -0.982 . . . . 0.0 109.165 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.33 -26.51 67.33 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.466 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -71.64 -15.81 62.25 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.534 -0.729 . . . . 0.0 109.367 179.555 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.503 ' OD1' ' N ' ' A' ' 152' ' ' ASN . 0.2 OUTLIER -112.05 8.8 20.24 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.444 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.3 t -83.87 164.44 2.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 O-C-N 121.423 -0.798 . . . . 0.0 109.747 -179.303 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.492 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 55.89 26.29 47.45 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.911 -1.275 . . . . 0.0 109.911 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.464 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.7 t-20 -160.38 143.01 13.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.98 -1.306 . . . . 0.0 110.202 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.826 HG23 ' O ' ' A' ' 59' ' ' VAL . 46.1 m -89.4 121.48 31.69 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 178.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.647 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.1 mt -98.03 117.7 43.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 120.882 -1.136 . . . . 0.0 110.097 -178.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.719 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.4 m-85 -96.9 130.83 44.14 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.597 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.631 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.1 mt -121.03 142.41 37.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 120.726 -1.234 . . . . 0.0 110.154 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.598 ' CB ' HG12 ' A' ' 56' ' ' VAL . 9.0 t0 -174.14 136.24 0.5 Allowed 'General case' 0 N--CA 1.486 1.366 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.529 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 124.82 -7.73 8.24 Favored Glycine 0 N--CA 1.486 1.985 0 C-N-CA 119.329 -1.415 . . . . 0.0 110.633 179.403 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.619 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 3.2 tp -60.29 100.0 0.09 Allowed 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.58 -1.541 . . . . 0.0 108.895 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 163' ' ' ALA . . . . . 0.481 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -136.7 145.7 45.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.445 -0.785 . . . . 0.0 109.662 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.866 HD12 HG11 ' A' ' 78' ' ' VAL . 25.5 mt -128.58 108.8 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.239 -0.913 . . . . 0.0 109.431 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.857 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -146.47 147.36 31.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.177 -0.952 . . . . 0.0 109.576 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.7 p -67.11 -174.8 0.39 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.378 -0.826 . . . . 0.0 109.538 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.42 ' HB3' ' HD2' ' A' ' 168' ' ' PRO . 0.0 OUTLIER -72.77 168.48 23.94 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.322 -0.861 . . . . 0.0 109.44 -179.97 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 168' ' ' PRO . . . . . 0.42 ' HD2' ' HB3' ' A' ' 167' ' ' GLN . 35.8 Cg_endo . . . . . 0 C--N 1.309 -1.516 0 C-N-CA 122.623 2.216 . . . . 0.0 110.457 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.52 ' C ' HD22 ' A' ' 2' ' ' LEU . 6.4 ttt . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.666 HD22 ' N ' ' A' ' 2' ' ' LEU . 3.9 mm? -101.92 169.73 8.59 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.31 -0.869 . . . . 0.0 109.413 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.911 HG23 ' HB2' ' A' ' 165' ' ' ALA . 4.4 p -153.93 173.73 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.38 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.587 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -75.86 -39.63 56.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.192 -0.943 . . . . 0.0 109.714 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.527 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 5.7 t-20 -92.1 129.45 38.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.706 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.468 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 64.7 mt -113.55 129.96 68.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.243 -0.911 . . . . 0.0 109.346 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.545 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.7 OUTLIER 69.93 28.0 4.31 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.206 -0.934 . . . . 0.0 109.597 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -44.26 -26.95 1.04 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 160' ' ' ASP . . . -142.14 52.03 0.67 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.717 ' CD2' HG11 ' A' ' 25' ' ' VAL . 2.8 m-85 45.27 56.38 5.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.261 -1.14 . . . . 0.0 109.237 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -84.52 -29.64 25.77 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.139 -0.976 . . . . 0.0 110.249 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.6 p -95.0 -47.49 6.38 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.011 -1.056 . . . . 0.0 110.129 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.938 ' OG1' HG13 ' A' ' 25' ' ' VAL . 3.1 m -59.84 135.76 90.04 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.166 -0.959 . . . . 0.0 109.538 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.466 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.9 Cg_endo -77.36 146.14 24.53 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.561 2.174 . . . . 0.0 110.71 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.611 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -44.62 170.76 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 121.299 0.571 . . . . 0.0 109.798 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 140.33 130.56 2.66 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.097 -1.601 . . . . 0.0 109.097 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.568 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.07 139.21 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.224 -1.162 . . . . 0.0 109.166 -179.653 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.566 HG13 ' HA3' ' A' ' 24' ' ' GLY . 60.2 t -90.66 142.95 12.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-O 121.625 0.726 . . . . 0.0 110.442 -179.468 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.5 t -100.7 -29.44 12.29 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.071 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 19.4 m-20 -131.48 93.92 3.44 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 1.075 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -48.86 -29.32 4.53 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.264 -0.897 . . . . 0.0 110.135 -178.626 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.075 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.44 -57.04 14.72 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.495 -0.753 . . . . 0.0 110.119 -179.364 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -119.99 41.82 3.09 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.155 -0.965 . . . . 0.0 109.45 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.566 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -77.07 -39.87 26.36 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.952 -1.259 . . . . 0.0 109.952 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.938 HG13 ' OG1' ' A' ' 13' ' ' THR . 46.3 t -141.74 133.72 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.102 -1.234 . . . . 0.0 109.904 -179.62 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 20.6 tp10 -68.68 141.58 55.29 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -0.857 . . . . 0.0 109.224 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.545 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 106.58 -32.14 7.58 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 0.929 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.1 OUTLIER -135.04 121.0 19.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.152 -1.205 . . . . 0.0 109.109 179.492 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -112.84 109.71 19.34 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.831 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -89.93 173.66 8.11 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.218 -0.926 . . . . 0.0 109.665 -179.139 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.497 ' O ' ' HB3' ' A' ' 72' ' ' GLU . 7.1 m120 -160.93 128.02 4.16 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.181 -0.949 . . . . 0.0 110.807 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.058 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -117.16 130.05 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.209 -0.932 . . . . 0.0 108.993 178.198 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.29 171.7 16.18 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.499 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.4 ' O ' ' C ' ' A' ' 35' ' ' SER . 0.7 OUTLIER -45.6 -29.89 1.34 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.377 -1.073 . . . . 0.0 109.419 179.951 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.505 ' HB2' ' CB ' ' A' ' 70' ' ' ASP . 0.4 OUTLIER -45.88 -53.41 9.85 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.369 -0.832 . . . . 0.0 109.116 179.943 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 1.058 HG21 HG12 ' A' ' 32' ' ' VAL . 34.7 t -47.63 102.57 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 O-C-N 121.251 -0.905 . . . . 0.0 110.084 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 40.8 m -81.63 -26.19 35.02 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 121.894 0.854 . . . . 0.0 108.764 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.682 ' O ' HG12 ' A' ' 36' ' ' VAL . 2.1 m-80 -111.67 147.75 37.43 Favored Pre-proline 0 C--N 1.296 -1.751 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.724 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -77.01 110.85 3.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.485 2.123 . . . . 0.0 110.654 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 38' ' ' ASN . 36.4 Cg_endo -80.05 160.98 23.74 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.475 2.117 . . . . 0.0 109.68 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.537 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 54.8 t -109.95 119.78 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.004 -1.06 . . . . 0.0 110.291 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.455 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 76.7 m-85 -105.9 112.16 25.1 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.369 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.568 ' HG3' HG23 ' A' ' 17' ' ' VAL . 1.3 tm-20 -155.01 147.06 23.64 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.005 -1.059 . . . . 0.0 109.872 -179.437 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.474 ' N ' ' HG2' ' A' ' 43' ' ' GLU . 53.1 t -91.89 148.54 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.493 -0.754 . . . . 0.0 109.193 179.574 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.675 HD21 ' CG2' ' A' ' 47' ' ' THR . 0.4 OUTLIER -131.97 146.9 52.37 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.207 -0.933 . . . . 0.0 108.888 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.611 ' HG3' ' HB2' ' A' ' 15' ' ' ALA . 17.4 mt-10 -117.91 115.04 24.13 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.676 -0.64 . . . . 0.0 109.508 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.675 ' CG2' HD21 ' A' ' 45' ' ' LEU . 2.2 p -142.11 172.25 12.94 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.488 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.95 11.7 24.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.248 -0.908 . . . . 0.0 109.484 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -103.33 -15.81 15.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.158 -0.964 . . . . 0.0 109.434 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.64 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -50.33 145.68 9.91 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.234 -0.916 . . . . 0.0 109.403 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.569 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 35.9 Cg_endo -78.38 -41.91 0.25 Allowed 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.577 2.185 . . . . 0.0 110.375 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -110.91 108.34 18.09 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.255 -0.903 . . . . 0.0 109.298 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.16 -117.16 6.64 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.64 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 50.0 p30 -160.06 29.87 0.18 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -1.173 . . . . 0.0 109.524 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.544 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 60.5 mttt -136.89 138.68 40.97 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.215 -0.928 . . . . 0.0 109.678 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.637 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.6 m -150.08 174.41 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.299 -0.876 . . . . 0.0 109.203 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.72 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -103.33 102.15 12.09 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.15 -0.969 . . . . 0.0 108.98 179.643 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.65 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.47 119.91 24.34 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.853 ' O ' HG23 ' A' ' 156' ' ' THR . 40.5 t -113.18 144.51 20.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.106 -0.997 . . . . 0.0 109.024 -179.172 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.537 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 19.9 m -110.7 90.59 3.37 Favored 'General case' 0 C--N 1.283 -2.284 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.519 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 43.9 t -86.48 127.78 40.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.273 -0.892 . . . . 0.0 109.211 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.417 HD22 HG22 ' A' ' 60' ' ' THR . 4.8 p30 -151.07 57.0 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.887 . . . . 0.0 109.844 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.433 ' HA3' ' CG ' ' A' ' 38' ' ' ASN . . . 147.66 103.44 0.33 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.817 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.3 m -79.94 -175.82 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.236 -1.155 . . . . 0.0 109.51 179.787 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -126.61 -178.5 15.34 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.666 -1.373 . . . . 0.0 109.666 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -68.73 -20.27 64.38 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.241 -1.152 . . . . 0.0 109.431 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.592 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.3 m-20 -106.98 152.54 41.02 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.28 -0.887 . . . . 0.0 109.492 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.41 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.2 Cg_endo -78.58 12.64 2.09 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 122.646 2.23 . . . . 0.0 110.973 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.592 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.2 p90 -135.57 54.58 1.91 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.991 -1.068 . . . . 0.0 109.631 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.522 ' HB3' ' N ' ' A' ' 36' ' ' VAL . 0.5 OUTLIER -83.37 -48.08 10.77 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.216 -0.927 . . . . 0.0 109.191 179.872 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.58 HD13 HG22 ' A' ' 36' ' ' VAL . 3.7 mm -98.72 149.09 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.254 -0.904 . . . . 0.0 108.776 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.534 ' HA ' ' HB3' ' A' ' 146' ' ' HIS . 58.0 tt0 -137.71 160.27 39.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.872 -1.143 . . . . 0.0 110.93 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.929 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -162.37 106.48 1.16 Allowed 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 179.462 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.591 HG22 ' N ' ' A' ' 75' ' ' ALA . 49.9 m -120.63 166.33 13.81 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.246 -1.534 . . . . 0.0 110.953 -178.004 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.591 ' N ' HG22 ' A' ' 74' ' ' THR . . . -124.7 137.91 54.32 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.476 -0.765 . . . . 0.0 108.96 179.07 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.547 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER 178.17 162.52 0.62 Allowed Pre-proline 0 N--CA 1.492 1.651 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 -179.728 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.532 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.82 167.14 73.74 Favored 'Cis proline' 0 C--N 1.31 -1.472 0 C-N-CA 123.641 -1.4 . . . . 0.0 110.778 -0.357 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.817 HG11 HD12 ' A' ' 164' ' ' ILE . 76.7 t -126.27 151.5 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.303 -0.873 . . . . 0.0 108.961 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.476 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 47.3 m-20 -114.75 122.79 47.48 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.045 -1.034 . . . . 0.0 109.812 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 138' ' ' GLU . 3.0 m -129.57 -173.82 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.21 -0.932 . . . . 0.0 109.458 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.625 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -138.74 145.87 47.92 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.364 -0.835 . . . . 0.0 109.306 179.896 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.489 ' HD2' ' HG2' ' A' ' 81' ' ' ARG . 35.3 Cg_endo -77.33 110.28 2.96 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.465 2.11 . . . . 0.0 110.47 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 113.91 -34.99 4.71 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.551 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -85.0 149.71 4.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.241 -1.152 . . . . 0.0 109.39 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.469 ' HA ' ' OG1' ' A' ' 133' ' ' THR . 11.6 t -95.3 145.31 25.18 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 109.354 -0.609 . . . . 0.0 109.354 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.564 ' HD2' HG22 ' A' ' 164' ' ' ILE . 8.6 m-85 -123.29 159.07 29.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.297 -0.877 . . . . 0.0 109.627 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.467 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 59.1 m -118.06 148.46 42.25 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.32 -0.862 . . . . 0.0 109.282 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.615 ' N ' ' CD1' ' A' ' 88' ' ' TYR . 0.2 OUTLIER -127.04 104.75 8.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.124 -0.985 . . . . 0.0 109.631 -179.927 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.476 ' O ' ' O ' ' A' ' 161' ' ' GLY . 54.7 m -112.8 148.08 35.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.365 -0.834 . . . . 0.0 108.955 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.676 HD12 ' HB2' ' A' ' 162' ' ' LEU . 19.4 tt -150.08 163.51 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.76 -1.212 . . . . 0.0 109.817 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.574 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 70.3 m95 -125.77 129.55 49.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.156 -0.965 . . . . 0.0 109.281 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.99 145.96 47.62 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.283 -0.886 . . . . 0.0 109.513 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.584 ' HD2' ' CE2' ' A' ' 125' ' ' TRP . 16.4 ttt-85 -157.91 118.23 3.39 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.267 -0.896 . . . . 0.0 109.179 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.3 166.8 10.16 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.357 -0.84 . . . . 0.0 109.839 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -64.18 -52.04 60.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.373 -0.829 . . . . 0.0 109.615 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.428 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -112.03 140.93 46.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 109.52 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.877 ' CG ' HG23 ' A' ' 123' ' ' THR . 1.1 m-20 -60.82 149.61 35.39 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.249 -0.907 . . . . 0.0 109.476 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 106.98 33.82 3.14 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.969 -1.253 . . . . 0.0 109.969 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.546 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -114.09 139.73 49.06 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.066 -1.255 . . . . 0.0 109.165 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.433 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 73.8 t -120.65 149.43 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 110.421 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.587 ' HB ' ' CE1' ' A' ' 103' ' ' PHE . 48.4 t -144.94 166.75 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.471 -0.768 . . . . 0.0 109.029 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.615 ' O ' HG23 ' A' ' 145' ' ' ILE . 5.6 m -124.68 123.47 40.1 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.06 -1.025 . . . . 0.0 109.612 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.63 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 1.4 m-85 -121.94 103.9 9.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -0.875 . . . . 0.0 109.902 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.523 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 16.5 p -121.38 174.34 6.8 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.098 -1.001 . . . . 0.0 109.88 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.646 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -131.72 154.0 39.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-O 121.492 0.663 . . . . 0.0 110.282 -179.688 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -174.92 158.11 25.7 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.53 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.5 p30 -97.91 -169.32 1.8 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.099 -1.236 . . . . 0.0 109.37 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.53 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 4.5 mp0 -73.11 11.66 0.68 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.1 -1.0 . . . . 0.0 111.105 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.445 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 1.4 m -111.02 13.91 22.0 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 120.595 -1.316 . . . . 0.0 109.139 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.512 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 4.0 m-30 71.47 3.96 4.87 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.484 -0.76 . . . . 0.0 109.619 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.528 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 29.4 tt0 -78.0 162.39 26.79 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.236 -0.915 . . . . 0.0 108.564 179.335 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.482 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 7.1 tt0 -138.22 143.47 40.17 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.994 -1.066 . . . . 0.0 109.89 -179.443 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.569 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 19.7 m-85 -102.4 -70.11 0.76 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.163 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.582 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -98.47 174.31 28.17 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.062 -1.615 . . . . 0.0 109.062 179.428 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.576 ' C ' HD23 ' A' ' 116' ' ' LEU . 0.0 OUTLIER -175.28 129.45 0.28 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.005 -1.291 . . . . 0.0 110.461 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.666 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -146.9 72.31 1.26 Allowed 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 179.145 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.541 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 15.1 p80 -93.31 150.79 20.21 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.321 -0.862 . . . . 0.0 110.181 -179.164 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.541 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.7 tt0 80.0 47.63 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.653 -0.654 . . . . 0.0 109.458 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 12.7 mm100 -107.98 125.45 51.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.387 -0.821 . . . . 0.0 109.333 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.626 ' O ' HD13 ' A' ' 121' ' ' ILE . 25.1 mt-30 -66.95 153.58 43.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.451 -0.781 . . . . 0.0 109.066 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.626 HD13 ' O ' ' A' ' 120' ' ' GLN . 6.6 mm -135.37 134.48 52.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.195 -0.94 . . . . 0.0 109.961 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -86.06 -179.37 6.74 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.425 -0.797 . . . . 0.0 110.075 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.877 HG23 ' CG ' ' A' ' 97' ' ' ASP . 39.6 p -76.96 -3.94 41.45 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.961 -0.696 . . . . 0.0 109.337 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.429 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 1.3 mt-10 -106.27 -173.24 2.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.257 -0.902 . . . . 0.0 109.263 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.584 ' CE2' ' HD2' ' A' ' 93' ' ' ARG . 98.2 m95 -91.01 118.04 30.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.571 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -106.86 121.24 45.54 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.176 -0.953 . . . . 0.0 108.953 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.574 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.5 Cg_endo -79.42 105.37 1.87 Allowed 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.311 2.007 . . . . 0.0 111.011 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -112.88 133.43 54.87 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -151.52 177.04 10.72 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 122.435 1.112 . . . . 0.0 110.724 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.666 ' CE1' HD21 ' A' ' 116' ' ' LEU . 3.6 p90 -161.48 -169.67 2.36 Favored 'General case' 0 C--N 1.292 -1.934 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.148 179.429 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' GLU . . . . . 0.567 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 68.9 mt-10 -138.6 144.1 39.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.006 -1.059 . . . . 0.0 109.982 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.582 ' CE2' ' HA2' ' A' ' 114' ' ' GLY . 1.0 OUTLIER -163.63 147.56 10.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.448 -0.783 . . . . 0.0 109.215 179.763 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.469 ' OG1' ' HA ' ' A' ' 85' ' ' THR . 0.5 OUTLIER -116.22 147.93 40.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.879 . . . . 0.0 109.71 -179.537 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.625 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.5 t -40.49 110.42 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.602 -0.686 . . . . 0.0 109.291 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 12.4 t -61.98 -53.34 57.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.274 -0.891 . . . . 0.0 109.295 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -101.77 -91.59 0.33 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.367 -0.833 . . . . 0.0 109.21 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -163.33 50.81 0.16 Allowed 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.469 -0.769 . . . . 0.0 109.087 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.484 ' O ' HG23 ' A' ' 80' ' ' VAL . 61.3 mm-40 -87.92 112.08 22.15 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.242 -0.911 . . . . 0.0 109.738 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.5 p -79.39 -14.95 58.61 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.214 -0.929 . . . . 0.0 108.584 179.356 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 25.8 t -134.29 128.67 52.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.318 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.47 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -139.52 171.83 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.174 -0.954 . . . . 0.0 110.147 -179.629 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.511 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.9 ptm180 -141.75 132.82 26.16 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.662 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -93.4 109.42 40.33 Favored Pre-proline 0 N--CA 1.486 1.365 0 O-C-N 121.228 -0.92 . . . . 0.0 110.202 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.523 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.1 Cg_endo -76.47 110.14 3.0 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.141 1.894 . . . . 0.0 110.9 179.399 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.838 HD11 HD22 ' A' ' 162' ' ' LEU . 3.0 mt -116.66 108.21 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 179.035 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.602 ' N ' ' ND1' ' A' ' 146' ' ' HIS . 0.1 OUTLIER -123.74 160.75 26.59 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.299 -1.501 . . . . 0.0 112.111 -177.142 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.774 ' CE2' HD11 ' A' ' 159' ' ' ILE . 0.1 OUTLIER -113.53 -168.37 1.33 Allowed 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.628 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 127.02 32.84 0.66 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.817 ' C ' HG11 ' A' ' 64' ' ' VAL . 28.6 m-85 -121.34 155.27 35.1 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.297 -1.119 . . . . 0.0 109.283 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.476 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -67.06 -26.27 66.66 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -179.829 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.465 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.78 -7.57 46.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.409 -0.807 . . . . 0.0 109.562 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.57 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 2.5 t30 -115.21 14.17 16.89 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.684 HG23 HG13 ' A' ' 64' ' ' VAL . 2.4 t -89.32 159.5 2.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.585 -0.697 . . . . 0.0 109.674 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.55 37.31 49.67 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.428 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 1.9 m-20 -160.31 136.28 8.49 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.074 -1.251 . . . . 0.0 110.175 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.853 HG23 ' O ' ' A' ' 59' ' ' VAL . 45.2 m -86.25 122.25 29.98 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 179.085 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.57 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.8 OUTLIER -102.93 117.93 49.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.881 -1.137 . . . . 0.0 110.34 -178.873 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.65 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 13.9 m-85 -96.57 144.59 26.49 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 178.569 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.774 HD11 ' CE2' ' A' ' 147' ' ' PHE . 1.3 mt -140.99 139.83 33.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.768 -1.207 . . . . 0.0 110.636 -178.813 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.637 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.5 OUTLIER -174.18 135.58 0.46 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.159 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 128.61 -6.65 6.59 Favored Glycine 0 N--CA 1.486 1.974 0 C-N-CA 119.127 -1.511 . . . . 0.0 111.21 179.183 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.838 HD22 HD11 ' A' ' 145' ' ' ILE . 8.0 tp -59.73 97.78 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.39 -1.653 . . . . 0.0 108.784 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 163' ' ' ALA . . . . . 0.49 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -121.94 145.59 47.96 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.565 -0.709 . . . . 0.0 109.931 -179.211 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.817 HD12 HG11 ' A' ' 78' ' ' VAL . 52.4 mt -125.65 108.85 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.328 -0.858 . . . . 0.0 109.291 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.911 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -152.36 149.84 29.07 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.144 -0.972 . . . . 0.0 109.661 -179.738 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.453 ' HB3' ' O ' ' A' ' 85' ' ' THR . 0.3 OUTLIER -87.67 159.5 18.5 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.285 -0.884 . . . . 0.0 109.47 179.92 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.448 ' HB2' ' HD2' ' A' ' 168' ' ' PRO . 17.7 pt20 -71.53 159.01 86.75 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.451 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 167' ' ' GLN . 35.7 Cg_endo . . . . . 0 C--N 1.309 -1.529 0 C-N-CA 122.631 2.221 . . . . 0.0 110.445 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.6 ttt . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.315 0.579 . . . . 0.0 109.459 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mp -87.45 178.83 6.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.23 -0.919 . . . . 0.0 109.506 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.565 HG22 ' H ' ' A' ' 4' ' ' ALA . 4.2 p -162.8 173.31 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.236 -0.915 . . . . 0.0 109.385 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.565 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -68.06 -55.13 13.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.128 -0.982 . . . . 0.0 109.453 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.504 ' HB2' HG12 ' A' ' 164' ' ' ILE . 0.4 OUTLIER -69.56 148.74 49.01 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 109.112 179.949 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.523 HG22 ' ND2' ' A' ' 7' ' ' ASN . 15.4 mm -112.03 148.58 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.383 -0.823 . . . . 0.0 109.207 179.707 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.523 ' ND2' HG22 ' A' ' 6' ' ' ILE . 42.6 m-80 45.02 38.77 3.26 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.254 -0.904 . . . . 0.0 109.649 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.519 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -56.9 -40.77 90.9 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 107.968 -2.053 . . . . 0.0 107.968 179.077 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.525 ' CA ' ' OD2' ' A' ' 160' ' ' ASP . . . -112.9 18.2 22.04 Favored Glycine 0 N--CA 1.488 2.103 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 178.823 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.826 ' CD2' HG21 ' A' ' 25' ' ' VAL . 61.4 m-85 65.66 46.61 2.36 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.478 -1.013 . . . . 0.0 109.683 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -84.66 -28.05 26.67 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.283 -0.885 . . . . 0.0 109.549 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.411 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 0.7 OUTLIER -88.29 -30.78 19.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.592 -179.726 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . 1.025 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.1 m -82.02 124.28 79.08 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.216 -0.928 . . . . 0.0 109.564 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.452 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.6 Cg_endo -78.03 138.21 16.19 Favored 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 122.412 2.075 . . . . 0.0 110.457 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -40.32 161.01 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 CA-C-O 121.233 0.539 . . . . 0.0 109.741 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 140.42 131.08 2.71 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.577 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.07 140.63 15.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.282 -1.129 . . . . 0.0 109.187 -179.689 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.478 HG23 ' HA ' ' A' ' 43' ' ' GLU . 43.7 t -89.91 144.41 9.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.453 -0.779 . . . . 0.0 110.197 -179.744 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.462 HG23 ' OD2' ' A' ' 20' ' ' ASP . 9.0 t -98.24 -27.56 14.1 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.16 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.546 ' HB2' ' CG ' ' A' ' 23' ' ' GLU . 7.0 m-20 -136.41 103.51 5.3 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.272 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 1.095 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -45.84 -30.43 1.69 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.101 -0.999 . . . . 0.0 109.746 -178.781 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.095 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -60.05 -49.51 77.37 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 121.643 -0.66 . . . . 0.0 109.796 -179.636 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.546 ' CG ' ' HB2' ' A' ' 20' ' ' ASP . 1.8 pt-20 -101.13 31.07 3.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.424 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.446 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -67.2 -45.73 78.3 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 1.025 HG13 ' OG1' ' A' ' 13' ' ' THR . 77.0 t -141.91 145.28 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -1.166 . . . . 0.0 109.695 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.77 -46.91 70.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.207 -0.933 . . . . 0.0 109.749 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.466 ' HA3' ' O ' ' A' ' 6' ' ' ILE . . . -81.53 -6.55 89.08 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 1.059 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.2 OUTLIER -133.96 123.71 25.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.155 -1.203 . . . . 0.0 109.091 179.528 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.528 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -126.62 126.98 44.51 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.35 -0.844 . . . . 0.0 108.934 179.586 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.906 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -106.43 170.08 8.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.12 -0.987 . . . . 0.0 109.586 -179.395 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.425 ' HA ' HD21 ' A' ' 21' ' ' LEU . 19.4 m120 -160.53 122.45 3.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 110.241 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.779 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -103.65 137.54 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.257 -0.902 . . . . 0.0 109.354 178.625 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -86.88 169.72 40.83 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -60.6 -14.44 20.25 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.15 -1.206 . . . . 0.0 109.185 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.443 ' HB3' ' OD1' ' A' ' 67' ' ' ASN . 5.7 p -67.46 -33.72 75.72 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.338 -0.851 . . . . 0.0 109.796 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.796 HG12 ' O ' ' A' ' 36' ' ' VAL . 2.2 t -67.03 86.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.016 -1.053 . . . . 0.0 109.385 -179.862 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 17.7 m -65.81 -29.04 69.46 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.086 -1.009 . . . . 0.0 108.3 179.34 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 41.8 t30 -131.57 101.08 15.97 Favored Pre-proline 0 C--N 1.295 -1.765 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.32 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.2 149.87 36.52 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.368 2.045 . . . . 0.0 110.592 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.541 ' CD ' HG12 ' A' ' 71' ' ' ILE . 36.0 Cg_endo -77.38 -165.49 0.33 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.588 2.192 . . . . 0.0 110.191 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 56.0 t -108.52 118.88 57.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.331 -0.856 . . . . 0.0 110.13 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.602 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 2.7 m-85 -97.37 111.61 23.79 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.038 -1.039 . . . . 0.0 108.221 178.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.577 ' HG3' HG23 ' A' ' 17' ' ' VAL . 3.3 tm-20 -153.01 148.51 27.15 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.125 -0.984 . . . . 0.0 110.099 -179.446 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.458 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 61.4 t -102.41 148.45 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.388 -0.82 . . . . 0.0 109.048 179.387 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 1.05 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -150.19 164.28 36.07 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.084 -1.01 . . . . 0.0 108.602 -179.938 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 1.05 ' N ' HD22 ' A' ' 45' ' ' LEU . 13.0 mt-10 -110.68 112.81 24.95 Favored 'General case' 0 C--N 1.293 -1.863 0 O-C-N 121.443 -0.785 . . . . 0.0 109.809 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' THR . . . . . 1.022 HG22 HD21 ' A' ' 45' ' ' LEU . 1.9 p -106.48 152.99 22.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.453 -0.78 . . . . 0.0 109.458 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 51.9 p -88.25 18.79 4.12 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.345 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.421 ' O ' ' C ' ' A' ' 50' ' ' ALA . 14.7 t0 -132.97 7.81 4.03 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 109.519 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.421 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -43.93 149.22 0.68 Allowed Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.276 -0.89 . . . . 0.0 109.351 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.596 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 35.2 Cg_endo -78.21 -32.96 2.16 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.697 2.265 . . . . 0.0 110.372 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -139.28 77.49 1.62 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.283 -0.885 . . . . 0.0 109.531 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 118.48 -127.15 7.15 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.489 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 6.9 t30 -157.57 22.51 0.28 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.26 -1.141 . . . . 0.0 109.413 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.551 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 17.8 mttp -136.58 142.76 43.36 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.29 -0.881 . . . . 0.0 109.412 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.572 HG11 ' CZ2' ' A' ' 125' ' ' TRP . 6.1 m -150.64 174.18 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.217 -0.927 . . . . 0.0 109.563 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.667 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -102.88 103.15 13.28 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.575 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.764 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.96 118.55 23.06 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.079 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.838 ' O ' HG23 ' A' ' 156' ' ' THR . 46.9 t -113.29 143.9 22.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.096 -1.003 . . . . 0.0 108.6 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.621 HG22 ' OD1' ' A' ' 62' ' ' ASN . 45.7 m -108.66 94.29 4.97 Favored 'General case' 0 C--N 1.283 -2.316 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.59 HG12 ' HA ' ' A' ' 153' ' ' VAL . 55.5 t -89.03 125.36 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.281 -0.887 . . . . 0.0 108.843 179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.621 ' OD1' HG22 ' A' ' 60' ' ' THR . 0.6 OUTLIER -160.17 61.58 0.34 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.41 -0.806 . . . . 0.0 109.68 -179.511 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 149.24 89.81 0.08 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.7 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.5 m -79.91 -171.93 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.281 -1.129 . . . . 0.0 109.58 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -134.71 -164.43 10.52 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -92.3 19.1 7.39 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -1.139 . . . . 0.0 109.459 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.526 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 30.5 m120 -132.72 148.15 68.37 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.231 -0.918 . . . . 0.0 109.398 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.508 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.3 Cg_endo -78.52 12.52 2.12 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.578 2.186 . . . . 0.0 110.836 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.526 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -136.59 58.83 1.72 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.99 -1.069 . . . . 0.0 109.688 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.51 ' HB3' ' CG2' ' A' ' 36' ' ' VAL . 1.8 m-20 -77.71 -69.61 0.53 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.122 -0.986 . . . . 0.0 108.963 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.573 HD12 ' HA2' ' A' ' 148' ' ' GLY . 3.0 mt -106.26 126.82 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.396 -0.815 . . . . 0.0 108.904 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -121.92 128.79 51.94 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.078 -1.013 . . . . 0.0 110.504 -179.268 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 1.059 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -113.68 108.54 17.26 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.554 HG22 ' N ' ' A' ' 75' ' ' ALA . 40.9 m -115.28 162.48 17.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.513 -1.367 . . . . 0.0 110.137 -178.745 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.554 ' N ' HG22 ' A' ' 74' ' ' THR . . . -123.46 140.1 53.34 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.227 -0.92 . . . . 0.0 109.219 179.337 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.535 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 3.1 p90 178.98 160.56 0.7 Allowed Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.416 -0.802 . . . . 0.0 109.22 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.53 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.9 Cg_endo -81.58 168.64 67.57 Favored 'Cis proline' 0 C--N 1.311 -1.418 0 C-N-CA 123.699 -1.375 . . . . 0.0 110.696 -0.468 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.535 HG11 HD11 ' A' ' 141' ' ' ILE . 33.3 t -121.22 131.58 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.233 -0.917 . . . . 0.0 108.87 179.355 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.522 ' O ' ' HB2' ' A' ' 4' ' ' ALA . 14.2 m120 -94.03 103.97 16.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.079 -1.013 . . . . 0.0 109.975 -179.518 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.585 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.2 m -113.57 -176.6 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.402 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.709 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -133.42 142.61 44.77 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.302 -0.874 . . . . 0.0 109.346 179.88 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.449 ' HD3' HG22 ' A' ' 139' ' ' THR . 35.5 Cg_endo -77.63 106.47 2.2 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.448 2.099 . . . . 0.0 110.505 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 113.33 -30.68 7.14 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.5 ' HB ' ' HB3' ' A' ' 81' ' ' ARG . 2.5 t -84.51 149.74 4.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.23 -1.159 . . . . 0.0 109.47 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 19.7 m -90.6 123.65 34.41 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.585 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 6.3 m-85 -106.37 154.84 20.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.282 -0.886 . . . . 0.0 109.733 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.472 ' HB ' ' O ' ' A' ' 165' ' ' ALA . 59.0 m -118.04 154.36 32.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.433 -0.792 . . . . 0.0 109.238 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.688 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -129.33 127.38 40.97 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.146 -0.971 . . . . 0.0 109.515 -179.84 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.511 ' O ' ' O ' ' A' ' 161' ' ' GLY . 21.6 m -130.5 145.54 51.87 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.266 -0.896 . . . . 0.0 108.78 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.726 HD13 ' HD2' ' A' ' 103' ' ' PHE . 16.9 tt -151.34 161.91 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 120.554 -1.341 . . . . 0.0 109.741 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.596 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 18.1 m95 -132.63 124.88 29.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.154 -0.966 . . . . 0.0 108.982 179.5 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.98 145.91 47.66 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.741 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.623 ' HA ' HG22 ' A' ' 121' ' ' ILE . 8.8 ptt180 -156.73 179.2 9.5 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -154.47 160.62 41.69 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.091 -1.006 . . . . 0.0 109.868 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -54.04 -41.19 67.8 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.383 -0.823 . . . . 0.0 109.452 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.472 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 57.4 mt-30 -130.34 143.38 50.74 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.225 -0.922 . . . . 0.0 109.442 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.79 ' OD1' HG23 ' A' ' 123' ' ' THR . 2.2 m-20 -57.14 149.37 19.7 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.293 -0.879 . . . . 0.0 109.505 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 111.23 36.99 1.71 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.841 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -125.19 141.8 51.88 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.072 -1.252 . . . . 0.0 109.32 179.695 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.52 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 54.0 t -118.56 151.27 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 110.832 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.64 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 40.7 t -150.02 162.11 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.527 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 54.4 m -124.42 128.83 49.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.09 -1.006 . . . . 0.0 109.31 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.726 ' HD2' HD13 ' A' ' 90' ' ' ILE . 0.2 OUTLIER -121.66 103.78 9.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.084 -1.01 . . . . 0.0 109.957 -179.788 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.488 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 20.9 p -128.4 165.02 21.43 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.216 -0.928 . . . . 0.0 109.927 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.655 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -121.62 125.23 73.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.564 0.697 . . . . 0.0 110.167 179.876 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -115.1 179.02 18.14 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.551 ' CB ' ' O ' ' A' ' 111' ' ' GLN . 25.7 t30 -127.83 172.04 11.22 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -1.097 . . . . 0.0 109.077 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.455 ' HB2' ' OE2' ' A' ' 138' ' ' GLU . 31.4 mt-30 -59.17 -47.63 84.59 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.007 -1.058 . . . . 0.0 109.608 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.538 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 46.9 t -84.37 19.36 1.92 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.219 -0.926 . . . . 0.0 110.117 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.56 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.1 m-30 80.61 7.79 1.36 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.36 -0.838 . . . . 0.0 110.186 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.551 ' O ' ' CB ' ' A' ' 107' ' ' ASN . 37.0 mm-40 -69.9 123.99 22.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.994 -1.066 . . . . 0.0 108.736 179.249 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.492 ' HG3' ' N ' ' A' ' 113' ' ' TYR . 1.2 tt0 -104.93 140.41 38.21 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.925 -1.109 . . . . 0.0 110.122 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.748 ' CE2' HG21 ' A' ' 141' ' ' ILE . 5.8 m-85 -108.37 -68.56 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.453 -0.779 . . . . 0.0 108.915 179.198 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.582 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -99.37 171.61 24.42 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 179.478 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.476 ' CG ' ' O ' ' A' ' 115' ' ' ARG . 0.2 OUTLIER -171.03 110.11 0.33 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.044 -1.268 . . . . 0.0 110.381 -179.867 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.91 HD21 ' CD1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -145.38 77.29 1.51 Allowed 'General case' 0 N--CA 1.494 1.74 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.168 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.54 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 41.2 p-80 -104.27 158.04 16.73 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.354 -0.842 . . . . 0.0 110.11 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 30.0 tt0 79.1 78.52 0.06 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.513 -0.742 . . . . 0.0 109.689 179.687 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLN . . . . . 0.451 ' OE1' ' O ' ' A' ' 118' ' ' GLU . 19.5 mm100 -144.24 131.74 21.02 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.251 -0.906 . . . . 0.0 109.467 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.793 ' O ' HD13 ' A' ' 121' ' ' ILE . 10.6 mt-30 -66.66 156.04 36.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 109.066 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.793 HD13 ' O ' ' A' ' 120' ' ' GLN . 13.9 mm -133.21 136.76 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 O-C-N 121.066 -1.021 . . . . 0.0 110.005 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -90.48 -179.17 5.52 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.908 0.861 . . . . 0.0 110.636 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.79 HG23 ' OD1' ' A' ' 97' ' ' ASP . 0.8 OUTLIER -68.69 -15.67 63.59 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.416 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.521 ' O ' ' CB ' ' A' ' 93' ' ' ARG . 3.8 mt-10 -100.36 -172.09 2.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.475 -0.766 . . . . 0.0 109.289 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.588 ' CE2' ' HD3' ' A' ' 51' ' ' PRO . 98.2 m95 -90.07 135.46 33.64 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.324 -0.86 . . . . 0.0 109.796 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.44 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 0.6 OUTLIER -106.83 121.37 45.16 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.233 -0.917 . . . . 0.0 108.977 179.751 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -79.64 110.1 2.57 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.447 2.098 . . . . 0.0 110.945 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -122.79 133.71 54.44 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 179.189 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.1 t -151.62 176.42 11.37 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 120.625 -1.297 . . . . 0.0 111.057 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.91 ' CD1' HD21 ' A' ' 116' ' ' LEU . 10.5 p90 -171.98 178.01 3.09 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.019 179.437 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' GLU . . . . . 0.474 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 33.5 mt-10 -133.7 153.57 51.6 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.061 -1.025 . . . . 0.0 110.041 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.565 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.14 160.76 19.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.458 -0.776 . . . . 0.0 109.147 179.746 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -119.11 146.2 45.31 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.18 -0.95 . . . . 0.0 109.293 -179.579 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.709 HG21 ' O ' ' A' ' 81' ' ' ARG . 2.5 t -56.72 111.94 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.362 -0.836 . . . . 0.0 109.264 179.611 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 3.8 m -83.61 -42.32 16.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.442 -0.786 . . . . 0.0 109.947 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.576 ' O ' ' CB ' ' A' ' 137' ' ' GLN . 33.1 t70 -85.91 -16.64 37.85 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.401 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' GLN . . . . . 0.691 ' H ' HG12 ' A' ' 134' ' ' VAL . 3.2 mm-40 86.32 28.38 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -178.697 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.523 ' CG ' ' OD1' ' A' ' 107' ' ' ASN . 3.0 mm-40 -74.48 119.4 18.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.606 -0.683 . . . . 0.0 109.795 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.449 HG22 ' HD3' ' A' ' 82' ' ' PRO . 17.3 p -79.34 -3.78 47.83 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.344 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.488 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.9 t -140.13 132.19 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.352 -0.843 . . . . 0.0 109.131 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.748 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.6 OUTLIER -144.53 171.98 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.259 -0.901 . . . . 0.0 109.821 -179.861 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.501 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.1 ptm180 -139.61 132.26 28.89 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.528 -0.732 . . . . 0.0 109.419 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.655 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -96.09 108.78 43.31 Favored Pre-proline 0 N--CA 1.486 1.339 0 O-C-N 121.219 -0.926 . . . . 0.0 110.029 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.501 ' HD3' ' O ' ' A' ' 142' ' ' ARG . 36.2 Cg_endo -77.73 112.51 3.32 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.324 2.016 . . . . 0.0 111.106 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.809 HD11 HD22 ' A' ' 162' ' ' LEU . 2.4 mt -99.14 134.19 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 178.413 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 12.8 m80 -97.2 154.83 17.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.34 -1.475 . . . . 0.0 111.607 -177.556 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.64 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 28.1 m-85 -155.1 157.21 37.16 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 179.284 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.573 ' HA2' HD12 ' A' ' 71' ' ' ILE . . . 108.11 53.59 0.65 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.7 ' C ' HG11 ' A' ' 64' ' ' VAL . 22.6 m-85 -129.03 159.47 35.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.245 -1.15 . . . . 0.0 109.39 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.414 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.67 -30.15 70.33 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -71.23 -11.6 61.01 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.369 -0.832 . . . . 0.0 109.049 179.265 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.841 ' OD1' ' HB1' ' A' ' 99' ' ' ALA . 1.8 t30 -116.86 13.07 14.93 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 179.172 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.59 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.2 t -85.15 162.22 2.95 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 O-C-N 121.635 -0.665 . . . . 0.0 109.695 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.446 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 54.06 33.19 50.76 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.472 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.0 m-20 -160.47 135.46 7.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.187 -1.184 . . . . 0.0 110.069 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.838 HG23 ' O ' ' A' ' 59' ' ' VAL . 42.2 m -85.13 122.43 29.33 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.067 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.55 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -101.13 118.72 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.832 -1.167 . . . . 0.0 110.331 -178.811 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.764 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 3.5 m-85 -95.12 130.81 41.68 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.583 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.636 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.4 mt -120.31 142.0 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.915 -1.115 . . . . 0.0 110.078 -178.809 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.564 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.8 OUTLIER -174.38 136.37 0.47 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.108 -0.995 . . . . 0.0 109.252 179.535 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 122.63 -10.4 9.1 Favored Glycine 0 N--CA 1.487 2.069 0 C-N-CA 119.322 -1.418 . . . . 0.0 111.014 179.023 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.809 HD22 HD11 ' A' ' 145' ' ' ILE . 9.9 tp -59.62 97.19 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.53 -1.571 . . . . 0.0 108.903 -179.643 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 163' ' ' ALA . . . . . 0.934 ' C ' HD13 ' A' ' 164' ' ' ILE . . . -134.57 145.55 48.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.537 -0.727 . . . . 0.0 109.985 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.934 HD13 ' C ' ' A' ' 163' ' ' ALA . 2.6 mm -119.65 108.5 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.284 -0.885 . . . . 0.0 109.204 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.525 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -140.78 145.01 35.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.127 -0.983 . . . . 0.0 109.527 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 4.2 p -74.37 176.67 6.53 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.294 -0.879 . . . . 0.0 109.559 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -154.71 150.63 21.96 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.241 -0.912 . . . . 0.0 109.376 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo . . . . . 0 C--N 1.309 -1.542 0 C-N-CA 122.638 2.226 . . . . 0.0 110.389 -179.98 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.7 ttt . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mt -102.36 105.92 16.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.32 -0.863 . . . . 0.0 109.396 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.798 HG22 ' O ' ' A' ' 164' ' ' ILE . 2.9 p -102.12 171.27 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.2 -0.937 . . . . 0.0 109.403 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.636 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -75.3 -46.57 32.63 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.186 -0.946 . . . . 0.0 109.587 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.511 ' HB2' ' CG1' ' A' ' 164' ' ' ILE . 0.9 OUTLIER -89.84 124.65 34.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.293 -0.88 . . . . 0.0 109.603 -179.945 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.492 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 1.8 mp -116.83 138.06 48.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.244 -0.91 . . . . 0.0 109.3 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.509 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.3 OUTLIER 74.99 16.52 2.87 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.219 -0.926 . . . . 0.0 109.627 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.502 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -60.11 -45.98 95.02 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.527 ' CA ' ' OD2' ' A' ' 160' ' ' ASP . . . -94.77 28.44 11.4 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 179.407 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.6 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 8.4 m-85 44.53 52.01 7.73 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.434 -1.039 . . . . 0.0 109.552 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.481 ' OE1' ' HA3' ' A' ' 53' ' ' GLY . 57.3 mm-40 -84.6 -28.24 26.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.298 -0.876 . . . . 0.0 109.639 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.423 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 0.9 OUTLIER -87.31 -37.08 17.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.198 -0.939 . . . . 0.0 109.762 -179.675 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.788 ' OG1' HG13 ' A' ' 25' ' ' VAL . 10.1 m -70.82 117.0 51.79 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.153 -0.967 . . . . 0.0 109.354 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 15' ' ' ALA . 35.2 Cg_endo -76.95 138.82 18.85 Favored 'Trans proline' 0 C--N 1.312 -1.378 0 C-N-CA 122.319 2.013 . . . . 0.0 110.396 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.441 ' C ' ' O ' ' A' ' 14' ' ' PRO . . . -39.31 153.88 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.516 0 CA-C-O 121.279 0.561 . . . . 0.0 109.857 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.49 131.37 2.41 Favored Glycine 0 N--CA 1.485 1.966 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.531 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.84 141.13 14.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.227 -1.16 . . . . 0.0 109.213 -179.602 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.642 HG13 ' HA2' ' A' ' 24' ' ' GLY . 47.8 t -86.58 142.37 13.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 CA-C-O 121.722 0.772 . . . . 0.0 110.365 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.411 ' C ' ' OD1' ' A' ' 20' ' ' ASP . 1.8 t -95.34 -28.53 14.92 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.069 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.426 ' O ' ' C ' ' A' ' 21' ' ' LEU . 1.0 OUTLIER -136.31 100.5 4.4 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.325 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 1.107 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -43.23 -29.02 0.36 Allowed 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.259 -0.9 . . . . 0.0 109.773 -178.868 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.107 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.69 -55.06 39.13 Favored 'General case' 0 C--N 1.294 -1.823 0 O-C-N 121.599 -0.688 . . . . 0.0 109.822 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -101.5 31.6 3.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.135 -0.978 . . . . 0.0 109.349 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.642 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -67.56 -47.18 63.74 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.788 HG13 ' OG1' ' A' ' 13' ' ' THR . 4.3 t -126.61 144.83 35.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.093 -1.24 . . . . 0.0 109.842 -179.638 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -62.49 -65.56 0.67 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.331 -0.855 . . . . 0.0 110.084 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.509 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -76.31 2.5 56.93 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 0.687 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.7 OUTLIER -133.99 122.11 22.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.028 -1.278 . . . . 0.0 109.124 179.549 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.537 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -126.6 128.22 46.46 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.4 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.906 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -104.67 175.98 5.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.972 -1.08 . . . . 0.0 110.236 -178.927 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 73.1 m-20 -160.2 122.09 3.22 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.47 -0.769 . . . . 0.0 109.629 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.785 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -110.6 136.53 46.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.217 -0.927 . . . . 0.0 109.494 179.417 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.45 -179.87 21.03 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.1 m -58.42 -16.3 14.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -1.165 . . . . 0.0 109.294 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.484 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 37.7 m -60.37 -38.85 85.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.257 -0.902 . . . . 0.0 109.592 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.785 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -62.97 89.29 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.045 -1.034 . . . . 0.0 109.257 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.4 m -59.79 -29.23 68.07 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.242 -0.911 . . . . 0.0 108.69 179.499 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.693 ' O ' HG13 ' A' ' 36' ' ' VAL . 0.5 OUTLIER -129.07 128.79 23.36 Favored Pre-proline 0 C--N 1.296 -1.728 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.448 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.63 122.02 6.23 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.203 1.935 . . . . 0.0 110.523 -179.423 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.515 ' HG3' ' CD1' ' A' ' 71' ' ' ILE . 35.4 Cg_endo -77.3 -165.68 0.34 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.302 2.002 . . . . 0.0 109.905 179.697 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.513 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 70.2 t -117.34 118.72 59.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.034 -1.041 . . . . 0.0 110.775 -179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.453 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 2.3 m-85 -102.33 111.97 24.48 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.163 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.538 ' HA ' HG23 ' A' ' 18' ' ' VAL . 1.3 tm-20 -154.1 151.52 29.39 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.062 -1.024 . . . . 0.0 110.118 -179.116 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.444 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 48.0 t -103.75 148.39 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.488 -0.757 . . . . 0.0 109.188 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 1.071 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -149.13 164.12 35.63 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.77 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 1.071 ' N ' HD22 ' A' ' 45' ' ' LEU . 9.9 pt-20 -125.47 124.89 42.37 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.333 -0.855 . . . . 0.0 109.551 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.92 HG23 HD21 ' A' ' 45' ' ' LEU . 1.3 p -127.24 166.77 17.12 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.388 -0.82 . . . . 0.0 109.461 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 95.6 p -88.24 18.58 4.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.912 . . . . 0.0 109.4 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 50' ' ' ALA . 0.1 OUTLIER -123.96 -0.81 8.39 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.277 -0.889 . . . . 0.0 109.584 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.34 145.84 1.32 Allowed Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.166 -0.959 . . . . 0.0 109.406 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.603 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 36.1 Cg_endo -78.44 -41.94 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.647 2.231 . . . . 0.0 110.396 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -128.26 89.61 2.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.315 -0.865 . . . . 0.0 109.413 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.481 ' HA3' ' OE1' ' A' ' 11' ' ' GLU . . . 105.49 -128.38 9.37 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.484 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 9.2 p-10 -152.63 18.24 0.61 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.201 -1.176 . . . . 0.0 109.704 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.466 ' O ' ' OD2' ' A' ' 160' ' ' ASP . 95.1 mttt -138.73 146.6 41.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.15 -0.969 . . . . 0.0 109.665 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.64 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.4 m -150.1 174.48 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.392 -0.817 . . . . 0.0 109.242 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.672 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -100.43 103.75 15.13 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.12 -0.988 . . . . 0.0 108.964 179.475 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.721 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -82.04 121.9 27.14 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 178.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.789 ' O ' HG23 ' A' ' 156' ' ' THR . 44.0 t -115.46 144.17 23.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.113 -0.992 . . . . 0.0 109.084 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.708 HG22 ' OD1' ' A' ' 62' ' ' ASN . 95.9 m -107.79 88.48 2.74 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.196 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.699 HG21 ' CD1' ' A' ' 157' ' ' ILE . 60.1 t -86.77 120.91 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.419 -0.801 . . . . 0.0 109.291 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.708 ' OD1' HG22 ' A' ' 60' ' ' THR . 1.9 p-10 -160.23 59.3 0.35 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.423 -0.798 . . . . 0.0 109.835 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 154.57 84.65 0.05 OUTLIER Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.719 HG12 ' C ' ' A' ' 148' ' ' GLY . 1.7 m -80.66 -176.54 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.24 -1.153 . . . . 0.0 109.396 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.484 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -126.99 -159.53 10.21 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 22.8 m-20 -89.48 -9.22 50.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.295 -1.121 . . . . 0.0 109.455 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.499 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 18.3 m120 -104.77 148.06 35.46 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.241 -0.912 . . . . 0.0 109.388 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 67' ' ' ASN . 36.2 Cg_endo -78.85 13.54 1.92 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.651 2.234 . . . . 0.0 110.942 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.499 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 1.9 p90 -137.72 53.33 1.85 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.98 -1.075 . . . . 0.0 109.744 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.522 ' CB ' HG23 ' A' ' 36' ' ' VAL . 0.4 OUTLIER -75.48 -65.28 0.91 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.174 -0.953 . . . . 0.0 109.095 179.645 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.546 HG13 ' CG2' ' A' ' 36' ' ' VAL . 4.5 mt -105.05 128.68 58.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.275 -0.89 . . . . 0.0 108.709 179.523 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -130.69 130.44 43.86 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.822 -1.174 . . . . 0.0 110.545 -179.275 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.906 ' HA ' HD23 ' A' ' 30' ' ' LEU . . . -113.66 108.82 17.64 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.548 HG22 ' N ' ' A' ' 75' ' ' ALA . 54.5 m -109.23 162.3 14.42 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.688 -1.257 . . . . 0.0 110.134 -178.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.548 ' N ' HG22 ' A' ' 74' ' ' THR . . . -122.74 138.97 54.47 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.267 -0.895 . . . . 0.0 109.173 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.555 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 4.1 p90 179.36 161.57 0.76 Allowed Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.526 -0.734 . . . . 0.0 109.098 -179.723 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.555 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.7 Cg_endo -81.76 166.32 72.28 Favored 'Cis proline' 0 C--N 1.311 -1.444 0 C-N-CA 123.802 -1.333 . . . . 0.0 110.972 -0.364 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.72 HG11 HD13 ' A' ' 164' ' ' ILE . 86.7 t -127.19 156.64 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.636 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 69.1 m-20 -122.53 139.52 53.81 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.007 -1.058 . . . . 0.0 109.875 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.45 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 4.0 m -146.04 -174.04 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.226 -0.921 . . . . 0.0 109.758 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.542 ' O ' HG21 ' A' ' 134' ' ' VAL . 3.1 ttt85 -138.07 141.38 32.06 Favored Pre-proline 0 N--CA 1.49 1.534 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.513 ' HD2' ' CG ' ' A' ' 81' ' ' ARG . 34.9 Cg_endo -76.12 117.27 4.6 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.467 2.111 . . . . 0.0 110.778 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 107.72 -33.53 6.26 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.454 ' HB ' ' HB3' ' A' ' 81' ' ' ARG . 2.7 t -88.59 149.72 3.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.221 -1.164 . . . . 0.0 109.584 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.3 t -94.19 147.54 23.07 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.631 ' CZ ' ' CB ' ' A' ' 166' ' ' SER . 7.6 m-85 -122.2 157.46 31.54 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.102 -0.999 . . . . 0.0 109.937 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 47.7 m -111.21 142.12 43.84 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.375 -0.828 . . . . 0.0 109.05 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.816 ' CD1' HG23 ' A' ' 164' ' ' ILE . 0.2 OUTLIER -134.19 128.25 33.62 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.093 -1.004 . . . . 0.0 109.548 -179.522 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.501 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.5 m -134.83 152.79 52.04 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.716 HD13 ' CD2' ' A' ' 103' ' ' PHE . 18.6 tt -150.9 163.4 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.787 -1.196 . . . . 0.0 109.343 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.603 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 17.2 m95 -130.66 124.87 32.61 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.076 -1.015 . . . . 0.0 109.566 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.465 ' HB3' HG23 ' A' ' 121' ' ' ILE . . . -113.49 146.81 39.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.3 -0.875 . . . . 0.0 109.204 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.494 ' HG3' ' O ' ' A' ' 123' ' ' THR . 6.5 ttp85 -162.34 119.68 2.08 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.144 -0.973 . . . . 0.0 109.228 -179.755 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.418 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.35 160.52 15.31 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.22 -0.925 . . . . 0.0 109.937 -179.61 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.08 -44.83 75.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.425 -0.797 . . . . 0.0 109.176 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.518 ' C ' HG22 ' A' ' 123' ' ' THR . 0.0 OUTLIER -117.68 151.62 36.88 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.872 . . . . 0.0 109.132 179.758 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.872 ' N ' HG22 ' A' ' 123' ' ' THR . 2.3 p-10 -73.59 146.01 45.02 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.139 -0.976 . . . . 0.0 109.566 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 113.56 37.89 1.26 Allowed Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -121.66 140.53 52.17 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.188 -1.184 . . . . 0.0 109.128 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.461 ' HB ' ' OD1' ' A' ' 152' ' ' ASN . 50.7 t -116.23 154.3 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.218 -0.926 . . . . 0.0 110.66 -179.427 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.69 HG22 ' CE1' ' A' ' 147' ' ' PHE . 61.6 t -155.02 166.49 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.688 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.592 ' HB2' ' CD2' ' A' ' 117' ' ' HIS . 30.8 t -136.18 130.81 33.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.027 -1.046 . . . . 0.0 109.643 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.716 ' CD2' HD13 ' A' ' 90' ' ' ILE . 0.3 OUTLIER -122.86 104.51 9.32 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.145 -0.972 . . . . 0.0 109.572 -179.965 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.614 ' O ' ' HB1' ' A' ' 143' ' ' ALA . 16.0 p -117.22 170.78 8.41 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.119 -0.988 . . . . 0.0 110.462 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.649 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -127.32 157.71 38.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.834 -0.541 . . . . 0.0 109.726 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 111' ' ' GLN . . . 172.98 138.33 2.58 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.639 ' CB ' HG22 ' A' ' 141' ' ' ILE . 1.3 p30 -76.98 -169.88 1.46 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.123 -1.222 . . . . 0.0 109.334 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.521 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 1.4 mp0 -77.28 14.91 0.83 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.04 -1.037 . . . . 0.0 110.925 -179.156 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.508 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 0.9 OUTLIER -113.63 6.36 16.91 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 120.785 -1.197 . . . . 0.0 109.344 179.598 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.569 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.6 m-30 77.94 14.84 1.55 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.361 -0.837 . . . . 0.0 109.611 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.493 ' HG2' ' HB2' ' A' ' 109' ' ' SER . 7.9 mm-40 -90.0 94.39 9.78 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 108.655 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.53 ' CG ' ' O ' ' A' ' 105' ' ' VAL . 2.0 tt0 -81.92 142.08 32.77 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.362 -0.836 . . . . 0.0 110.34 -179.06 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.596 ' HB3' ' CD1' ' A' ' 132' ' ' PHE . 4.8 m-85 -109.69 -69.02 0.88 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.207 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.422 ' N ' HG23 ' A' ' 105' ' ' VAL . . . -89.34 177.67 44.19 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 179.479 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 1.01 ' O ' HD23 ' A' ' 116' ' ' LEU . 0.6 OUTLIER -177.87 135.83 0.17 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.951 -1.323 . . . . 0.0 110.393 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 1.01 HD23 ' O ' ' A' ' 115' ' ' ARG . 0.5 OUTLIER -147.36 69.87 1.16 Allowed 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.304 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.592 ' CD2' ' HB2' ' A' ' 102' ' ' SER . 27.2 t-80 -93.77 141.57 28.35 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 110.295 -179.043 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.559 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 4.2 tt0 82.21 36.8 0.06 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.711 -0.618 . . . . 0.0 109.52 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 6.9 mm100 -88.55 120.34 29.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.355 -0.841 . . . . 0.0 109.165 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.71 ' O ' HD13 ' A' ' 121' ' ' ILE . 1.6 mt-30 -65.5 140.99 58.63 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.462 -0.774 . . . . 0.0 108.945 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.71 HD13 ' O ' ' A' ' 120' ' ' GLN . 5.9 mm -125.81 129.68 72.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.109 -0.995 . . . . 0.0 110.126 -179.44 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -89.86 -178.77 5.57 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.618 0.723 . . . . 0.0 110.094 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.872 HG22 ' N ' ' A' ' 97' ' ' ASP . 11.6 p -72.87 -2.08 19.32 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 119.914 -0.714 . . . . 0.0 109.352 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.47 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 0.4 OUTLIER -112.44 -168.73 1.36 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.166 -0.959 . . . . 0.0 108.981 179.727 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.534 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 95.3 m95 -91.95 130.26 37.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.145 -0.972 . . . . 0.0 109.613 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.439 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 0.3 OUTLIER -109.51 121.45 42.33 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.156 -0.965 . . . . 0.0 109.109 179.787 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.17 100.41 1.26 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 C-N-CA 122.514 2.143 . . . . 0.0 111.141 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -110.9 137.83 48.05 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.14 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.1 t -144.18 176.21 9.5 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.565 -1.334 . . . . 0.0 111.058 -179.362 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.661 ' CE1' HD11 ' A' ' 116' ' ' LEU . 16.9 p90 -173.9 171.06 3.77 Favored 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 115.036 -0.983 . . . . 0.0 109.034 179.653 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' GLU . . . . . 0.516 ' HA ' ' CE2' ' A' ' 88' ' ' TYR . 34.3 mt-10 -143.64 142.18 30.92 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.089 -1.007 . . . . 0.0 109.904 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.702 ' CE2' ' CZ ' ' A' ' 88' ' ' TYR . 5.2 p90 -151.11 168.07 25.78 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.35 -0.844 . . . . 0.0 109.145 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.407 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -119.37 147.29 44.51 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.907 . . . . 0.0 109.623 -179.719 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.542 HG21 ' O ' ' A' ' 81' ' ' ARG . 3.6 t -43.51 110.43 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.46 -0.775 . . . . 0.0 108.977 179.546 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -58.52 -51.12 71.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.293 -179.741 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -110.65 -91.16 0.47 Allowed 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.399 -0.813 . . . . 0.0 109.209 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -160.94 55.2 0.3 Allowed 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.576 -0.702 . . . . 0.0 109.127 179.737 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.512 ' HG3' ' ND2' ' A' ' 107' ' ' ASN . 7.2 mm-40 -95.01 111.91 23.67 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.213 -0.93 . . . . 0.0 109.851 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.0 p -79.42 -13.46 59.58 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 41.6 t -134.03 136.42 53.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.212 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.639 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -143.36 171.89 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.072 -1.018 . . . . 0.0 110.224 -179.498 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.501 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.4 ptm180 -141.37 132.43 26.23 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.649 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -94.22 109.67 43.78 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.331 -0.856 . . . . 0.0 110.286 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.502 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.9 Cg_endo -77.2 110.68 3.06 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 122.023 1.816 . . . . 0.0 109.664 178.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.687 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 3.3 mt -95.18 124.15 47.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.492 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 12.8 m80 -84.5 149.36 25.99 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.926 -1.109 . . . . 0.0 111.638 -177.008 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.694 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 10.4 m-85 -154.55 158.43 39.79 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.063 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.719 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 109.33 38.77 1.74 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.66 ' C ' HG11 ' A' ' 64' ' ' VAL . 20.9 m-85 -113.99 158.08 21.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.444 -1.033 . . . . 0.0 109.207 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.21 -27.58 68.09 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.479 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.43 -14.99 62.77 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.447 -0.783 . . . . 0.0 109.328 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.521 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.2 OUTLIER -109.62 11.25 24.77 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.371 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.529 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.4 t -85.79 163.88 2.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 O-C-N 121.523 -0.735 . . . . 0.0 109.881 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.481 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.98 31.83 40.73 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.034 -1.227 . . . . 0.0 110.034 179.671 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.476 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.1 m-20 -160.61 139.36 10.28 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.147 -1.207 . . . . 0.0 110.27 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 59' ' ' VAL . 80.1 m -87.29 121.2 29.42 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.699 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.2 mt -101.89 118.2 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 120.868 -1.145 . . . . 0.0 110.383 -178.65 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.721 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.6 m-85 -97.24 138.78 34.2 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 178.426 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.694 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -130.35 139.78 50.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 C-N-CA 118.767 -1.173 . . . . 0.0 110.014 -178.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.64 ' CB ' HG12 ' A' ' 56' ' ' VAL . 1.0 OUTLIER -173.94 136.1 0.52 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.371 -0.831 . . . . 0.0 109.136 179.687 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.501 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 126.58 -8.08 7.39 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.688 179.397 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.565 ' HB2' HD12 ' A' ' 90' ' ' ILE . 10.4 tp -59.61 93.06 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.648 -1.501 . . . . 0.0 108.82 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 163' ' ' ALA . . . . . 0.475 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -118.22 145.75 44.76 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.694 -0.629 . . . . 0.0 109.9 -179.061 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.816 HG23 ' CD1' ' A' ' 88' ' ' TYR . 20.6 mt -132.68 127.28 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.362 -0.836 . . . . 0.0 109.095 179.607 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.573 ' O ' ' CD2' ' A' ' 86' ' ' TYR . . . -133.04 171.22 14.28 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -0.937 . . . . 0.0 109.599 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.631 ' CB ' ' CZ ' ' A' ' 86' ' ' TYR . 4.0 p -107.42 -15.63 14.57 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.183 -0.948 . . . . 0.0 109.464 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.431 ' HB3' ' HD2' ' A' ' 168' ' ' PRO . 13.0 mm-40 -134.06 163.12 53.44 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 109.568 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 168' ' ' PRO . . . . . 0.431 ' HD2' ' HB3' ' A' ' 167' ' ' GLN . 35.5 Cg_endo . . . . . 0 C--N 1.31 -1.489 0 C-N-CA 122.638 2.226 . . . . 0.0 110.344 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.4 ttt . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.8 mt -67.11 91.18 0.21 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.284 -0.885 . . . . 0.0 109.473 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.679 HG23 ' HB2' ' A' ' 165' ' ' ALA . 4.1 p -56.68 173.53 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.292 -0.88 . . . . 0.0 109.336 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.913 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -77.61 -31.31 52.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 109.51 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.643 ' HB2' HD12 ' A' ' 164' ' ' ILE . 10.2 t-20 -92.19 124.67 36.44 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.24 -0.913 . . . . 0.0 109.689 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.512 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 65.5 mt -110.38 121.63 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.323 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.525 ' OD1' ' CB ' ' A' ' 12' ' ' SER . 0.1 OUTLIER 76.83 43.8 0.12 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.243 -0.911 . . . . 0.0 109.169 -179.436 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.452 ' O ' ' HB3' ' A' ' 162' ' ' LEU . . . -47.76 -22.57 1.96 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.64 ' O ' ' CB ' ' A' ' 10' ' ' PHE . . . 164.2 60.35 0.02 OUTLIER Glycine 0 N--CA 1.487 2.082 0 C-N-CA 119.609 -1.281 . . . . 0.0 109.964 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.64 ' CB ' ' O ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER 118.4 1.06 0.0 OUTLIER 'General case' 0 N--CA 1.518 2.946 0 C-N-CA 122.832 0.453 . . . . 0.0 111.579 179.115 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.569 ' HG2' ' CD1' ' A' ' 10' ' ' PHE . 9.2 mm-40 -75.73 -60.79 2.16 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.418 -1.426 . . . . 0.0 110.831 -177.757 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.525 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.3 OUTLIER -75.11 -3.01 30.26 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.048 -1.032 . . . . 0.0 110.025 -179.201 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.642 ' OG1' HG13 ' A' ' 25' ' ' VAL . 4.4 m -126.1 123.8 24.49 Favored Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.029 -1.045 . . . . 0.0 109.411 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.454 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.4 Cg_endo -77.35 149.11 27.41 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 C-N-CA 122.46 2.107 . . . . 0.0 110.719 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.467 ' HA ' ' HB ' ' A' ' 44' ' ' VAL . . . -39.96 161.15 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.196 0.522 . . . . 0.0 109.676 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.35 134.49 3.42 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.654 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.47 140.87 14.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.392 -1.063 . . . . 0.0 108.969 -179.569 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.429 HG23 ' HA ' ' A' ' 43' ' ' GLU . 47.2 t -87.93 144.34 9.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.427 -0.796 . . . . 0.0 110.169 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.6 p -105.78 -21.2 13.23 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.391 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.403 ' HB3' ' HG3' ' A' ' 23' ' ' GLU . 7.7 m-20 -145.32 130.08 18.12 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.566 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 1.034 HD12 ' N ' ' A' ' 22' ' ' ALA . 1.7 pp -87.13 -38.31 16.57 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.088 -1.008 . . . . 0.0 110.179 -179.486 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.034 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.61 -24.93 64.21 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.155 -0.966 . . . . 0.0 108.87 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.403 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 2.0 pt-20 -138.66 34.63 2.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.452 -0.78 . . . . 0.0 109.215 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.98 -72.78 1.28 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.642 HG13 ' OG1' ' A' ' 13' ' ' THR . 1.6 t -86.08 127.85 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.288 -1.125 . . . . 0.0 109.134 179.73 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.5 ' HB3' ' HB3' ' A' ' 12' ' ' SER . 25.7 tt0 -54.71 -36.45 64.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.351 -0.843 . . . . 0.0 110.1 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.517 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -109.96 8.61 31.57 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.862 -1.161 . . . . 0.0 110.214 -179.367 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 0.749 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.7 OUTLIER -140.57 119.67 12.81 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.089 -1.242 . . . . 0.0 109.125 179.313 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.585 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 7.3 m-20 -124.81 142.17 51.61 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.188 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.922 ' O ' HD13 ' A' ' 21' ' ' LEU . 3.3 mt -109.48 172.13 7.04 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.846 -1.159 . . . . 0.0 109.794 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -159.95 122.41 3.38 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.767 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.688 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.23 137.87 37.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.476 -0.765 . . . . 0.0 109.598 179.302 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -90.73 172.98 37.88 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 72.4 m -62.61 -12.28 22.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.17 -1.194 . . . . 0.0 109.38 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 20.9 p -72.23 -32.64 66.91 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.32 -0.863 . . . . 0.0 109.812 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.787 HG12 ' O ' ' A' ' 36' ' ' VAL . 2.2 t -70.34 87.1 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 O-C-N 121.112 -0.992 . . . . 0.0 109.318 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 22.2 m -63.96 -28.98 70.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.194 -0.941 . . . . 0.0 108.484 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.1 t30 -128.86 114.86 19.05 Favored Pre-proline 0 C--N 1.296 -1.74 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.44 ' HA ' ' HD3' ' A' ' 40' ' ' PRO . 34.8 Cg_endo -76.45 144.56 25.8 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.167 1.911 . . . . 0.0 110.492 -179.501 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.643 ' CG ' HG21 ' A' ' 71' ' ' ILE . 35.3 Cg_endo -77.27 -164.08 0.25 Allowed 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.557 2.171 . . . . 0.0 110.133 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 56.8 t -116.09 120.26 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.127 -0.983 . . . . 0.0 110.667 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.817 ' CD1' HD13 ' A' ' 30' ' ' LEU . 5.5 m-85 -101.78 112.21 24.72 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 178.364 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.654 ' HG3' HG23 ' A' ' 17' ' ' VAL . 0.4 OUTLIER -155.93 140.04 16.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.005 -1.059 . . . . 0.0 110.361 -179.451 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.473 ' N ' ' HG2' ' A' ' 43' ' ' GLU . 36.5 t -92.52 148.79 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.884 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 1.039 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -148.67 165.16 32.17 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.013 -1.055 . . . . 0.0 109.033 -179.558 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 1.039 ' N ' HD22 ' A' ' 45' ' ' LEU . 13.4 mt-10 -111.19 113.89 26.72 Favored 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.452 -0.78 . . . . 0.0 109.644 -178.739 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.941 ' CG2' HD21 ' A' ' 45' ' ' LEU . 7.7 p -111.71 165.82 11.71 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 41.8 t -94.67 -10.11 32.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.3 m-20 -102.54 -1.79 29.77 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.263 -0.898 . . . . 0.0 109.59 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.482 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -44.1 147.38 0.94 Allowed Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.165 -0.959 . . . . 0.0 109.43 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.613 ' HB3' ' CE3' ' A' ' 91' ' ' TRP . 35.4 Cg_endo -78.34 -40.85 0.31 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.704 2.269 . . . . 0.0 110.325 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.14 107.06 11.73 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.418 ' O ' ' CG ' ' A' ' 54' ' ' ASN . . . 87.5 -120.5 5.56 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.482 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 27.7 m120 -160.16 36.28 0.17 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -1.169 . . . . 0.0 109.504 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.64 ' CD ' ' CD2' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -158.91 157.27 31.09 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.31 -0.869 . . . . 0.0 109.765 179.824 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.801 HG12 ' HB3' ' A' ' 160' ' ' ASP . 15.3 m -152.27 174.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.372 -0.83 . . . . 0.0 108.897 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.493 ' O ' ' HA ' ' A' ' 158' ' ' TYR . 0.2 OUTLIER -91.44 100.67 13.4 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 178.777 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.744 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -80.34 120.05 23.87 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 119.394 -0.922 . . . . 0.0 108.991 -179.812 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.841 ' O ' HG23 ' A' ' 156' ' ' THR . 41.3 t -112.97 144.48 20.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.691 HG22 ' OD1' ' A' ' 62' ' ' ASN . 59.7 m -109.87 91.14 3.53 Favored 'General case' 0 C--N 1.282 -2.327 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.537 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 52.4 t -89.95 122.82 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.311 -0.868 . . . . 0.0 108.799 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.691 ' OD1' HG22 ' A' ' 60' ' ' THR . 1.1 p-10 -160.09 60.96 0.35 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.284 -0.885 . . . . 0.0 109.935 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 158.51 86.48 0.06 OUTLIER Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.729 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.3 m -82.23 -177.15 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.248 -1.148 . . . . 0.0 109.588 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -136.52 -157.86 7.87 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -96.0 23.73 6.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.326 -1.102 . . . . 0.0 109.566 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.645 ' ND2' ' CZ2' ' A' ' 69' ' ' TRP . 5.2 m120 -136.55 148.19 62.78 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.2 -0.937 . . . . 0.0 109.466 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.414 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.4 Cg_endo -78.24 11.93 2.22 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.662 2.242 . . . . 0.0 110.926 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.645 ' CZ2' ' ND2' ' A' ' 67' ' ' ASN . 1.3 p90 -136.76 59.56 1.69 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.093 -1.004 . . . . 0.0 109.647 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.514 ' HB3' ' CG2' ' A' ' 36' ' ' VAL . 1.4 m-20 -76.6 -67.59 0.68 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.242 -0.911 . . . . 0.0 109.111 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.643 HG21 ' CG ' ' A' ' 40' ' ' PRO . 2.2 mt -116.57 123.37 71.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.433 -0.792 . . . . 0.0 109.12 179.669 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.517 ' CG ' ' O ' ' A' ' 145' ' ' ILE . 20.7 tt0 -129.12 134.33 48.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.972 -1.08 . . . . 0.0 110.335 -179.4 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.749 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -115.91 107.69 15.31 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 178.855 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.56 HG22 ' N ' ' A' ' 75' ' ' ALA . 99.3 m -103.52 165.06 11.26 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.334 -0.854 . . . . 0.0 109.669 -179.24 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.56 ' N ' HG22 ' A' ' 74' ' ' THR . . . -122.98 137.49 54.94 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.026 -1.046 . . . . 0.0 109.227 179.027 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CZ ' ' HB2' ' A' ' 29' ' ' ASP . 11.2 p90 -176.05 160.32 1.89 Allowed Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.4 -0.812 . . . . 0.0 109.383 -179.766 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.519 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -82.53 170.22 58.1 Favored 'Cis proline' 0 C--N 1.311 -1.395 0 O-C-N 123.652 1.343 . . . . 0.0 111.064 -0.648 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.674 HG11 HD13 ' A' ' 164' ' ' ILE . 96.4 t -131.75 156.9 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.239 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.913 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 76.1 m-20 -123.24 140.28 53.18 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.922 -1.111 . . . . 0.0 110.289 -179.459 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 138' ' ' GLU . 4.3 m -145.48 -173.51 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.304 -0.873 . . . . 0.0 109.387 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.766 ' O ' HG21 ' A' ' 134' ' ' VAL . 17.6 mmt180 -136.45 144.73 48.69 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.382 -0.824 . . . . 0.0 109.348 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.454 ' HD2' ' HD3' ' A' ' 81' ' ' ARG . 35.1 Cg_endo -77.73 126.87 8.4 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.457 2.105 . . . . 0.0 110.539 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.22 -25.17 21.61 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.424 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -86.32 149.61 4.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.239 -1.154 . . . . 0.0 109.496 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 32.8 m -94.86 131.96 40.18 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.502 ' HD2' HG22 ' A' ' 164' ' ' ILE . 14.6 m-85 -113.32 167.31 10.67 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.236 -0.915 . . . . 0.0 109.666 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.47 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 43.8 m -118.38 152.88 34.99 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.338 -0.851 . . . . 0.0 109.418 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.688 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 7.9 t80 -132.81 114.83 14.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.481 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.485 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.2 m -135.11 146.23 48.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.194 -0.941 . . . . 0.0 109.002 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.701 HD13 ' HD2' ' A' ' 103' ' ' PHE . 15.3 tt -150.96 163.78 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.796 -1.19 . . . . 0.0 109.5 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.613 ' CE3' ' HB3' ' A' ' 51' ' ' PRO . 37.3 m95 -128.76 135.41 49.15 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.862 -1.149 . . . . 0.0 109.375 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.425 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -130.0 148.09 51.82 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.213 -0.929 . . . . 0.0 109.747 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.636 ' CB ' ' CD2' ' A' ' 125' ' ' TRP . 11.6 ttt-85 -164.14 121.66 1.74 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.317 -0.864 . . . . 0.0 108.909 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.04 165.68 11.04 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.305 -0.872 . . . . 0.0 110.086 -179.403 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.07 -56.6 12.06 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.425 -0.797 . . . . 0.0 109.117 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.517 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.5 OUTLIER -101.77 134.93 44.17 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.279 -0.888 . . . . 0.0 109.204 179.701 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.581 ' N ' ' CG2' ' A' ' 123' ' ' THR . 1.2 p30 -60.77 144.95 51.37 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.212 -0.93 . . . . 0.0 109.551 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 112.45 37.82 1.41 Allowed Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.536 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -118.78 139.31 51.8 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.204 -1.174 . . . . 0.0 109.224 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.449 HG22 ' HA ' ' A' ' 120' ' ' GLN . 76.0 t -116.46 149.93 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.205 -0.934 . . . . 0.0 110.407 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.813 HG13 ' CE2' ' A' ' 147' ' ' PHE . 43.0 t -146.15 165.77 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.34 -0.85 . . . . 0.0 109.45 179.721 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.556 ' CB ' ' HB2' ' A' ' 117' ' ' HIS . 24.2 m -124.77 133.42 53.16 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.146 -0.971 . . . . 0.0 109.681 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.701 ' HD2' HD13 ' A' ' 90' ' ' ILE . 1.0 OUTLIER -129.1 103.85 7.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.126 -0.984 . . . . 0.0 109.477 179.497 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.647 HG22 ' HA ' ' A' ' 115' ' ' ARG . 29.2 p -128.14 175.63 8.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.133 -0.979 . . . . 0.0 110.323 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.904 HG23 ' H ' ' A' ' 114' ' ' GLY . 0.0 OUTLIER -133.45 106.34 9.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-O 121.575 0.702 . . . . 0.0 110.316 179.175 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.459 ' O ' ' HG2' ' A' ' 142' ' ' ARG . . . -101.54 132.46 10.97 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 108.052 -2.019 . . . . 0.0 108.052 178.554 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.584 ' OD1' ' CE1' ' A' ' 113' ' ' TYR . 0.2 OUTLIER -96.87 -170.62 2.08 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.963 -1.316 . . . . 0.0 109.052 -179.399 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 44.6 mt-30 -81.28 -19.8 42.24 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 118.751 -1.18 . . . . 0.0 109.829 -179.439 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.539 ' HB3' ' CG ' ' A' ' 111' ' ' GLN . 0.6 OUTLIER -81.92 8.82 9.45 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.113 -0.992 . . . . 0.0 108.792 178.979 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.44 ' HB2' ' O ' ' A' ' 109' ' ' SER . 18.3 m-30 63.01 21.75 13.08 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.428 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.539 ' CG ' ' HB3' ' A' ' 109' ' ' SER . 0.0 OUTLIER -88.36 161.61 17.01 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.649 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.82 102.12 12.22 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.447 -0.783 . . . . 0.0 109.768 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 1.016 ' OH ' HG13 ' A' ' 134' ' ' VAL . 1.9 m-30 -69.41 -67.14 0.5 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.401 -0.812 . . . . 0.0 108.941 178.553 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.904 ' H ' HG23 ' A' ' 105' ' ' VAL . . . -130.55 171.45 20.72 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.647 ' HA ' HG22 ' A' ' 104' ' ' THR . 0.2 OUTLIER -162.78 117.31 1.75 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.029 -1.277 . . . . 0.0 110.723 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.891 HD21 ' CD2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -150.62 74.31 1.17 Allowed 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 178.997 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.556 ' HB2' ' CB ' ' A' ' 102' ' ' SER . 22.4 p80 -118.3 169.15 9.97 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.193 -0.942 . . . . 0.0 110.134 -179.304 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.512 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 0.2 OUTLIER 77.53 41.04 0.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.517 -0.739 . . . . 0.0 109.294 179.925 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLN . . . . . 0.452 ' HG3' HD11 ' A' ' 121' ' ' ILE . 0.8 OUTLIER -116.03 138.35 51.3 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.316 -0.865 . . . . 0.0 109.668 -179.836 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.486 ' O ' HD13 ' A' ' 121' ' ' ILE . 2.4 mt-30 -74.54 156.49 36.8 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.486 HD13 ' O ' ' A' ' 120' ' ' GLN . 5.2 mm -135.19 134.64 52.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.116 -0.99 . . . . 0.0 110.022 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.0 -179.43 7.25 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.523 -0.735 . . . . 0.0 109.947 179.477 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.581 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 70.2 p -75.98 -0.46 21.67 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 119.829 -0.748 . . . . 0.0 109.23 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.442 ' O ' ' HG3' ' A' ' 93' ' ' ARG . 22.5 mm-40 -102.4 -168.91 1.59 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.246 -0.909 . . . . 0.0 109.21 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.679 ' CH2' HG11 ' A' ' 56' ' ' VAL . 88.4 m95 -103.2 115.17 30.07 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 0.0 109.614 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 -106.68 120.75 47.32 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.11 -0.994 . . . . 0.0 108.986 179.65 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.408 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.9 Cg_endo -80.58 116.28 3.22 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 C-N-CA 122.384 2.056 . . . . 0.0 111.175 -179.635 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -112.03 135.6 52.46 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.689 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.435 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -145.71 176.3 9.75 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 120.822 -1.174 . . . . 0.0 110.801 -179.348 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.891 ' CD2' HD21 ' A' ' 116' ' ' LEU . 21.2 p90 -176.89 152.7 0.96 Allowed 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.303 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -105.28 154.91 19.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.752 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 113' ' ' TYR . 0.2 OUTLIER -165.02 160.88 19.43 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.431 -0.793 . . . . 0.0 109.334 179.942 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.7 OUTLIER -124.13 146.42 48.65 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.214 -0.929 . . . . 0.0 108.937 -179.883 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 1.016 HG13 ' OH ' ' A' ' 113' ' ' TYR . 3.5 t -43.57 109.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.294 -0.879 . . . . 0.0 108.955 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -51.41 -40.05 58.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.123 -0.986 . . . . 0.0 109.149 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -129.81 -90.28 0.48 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.38 -0.825 . . . . 0.0 109.369 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -158.58 52.73 0.42 Allowed 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.479 -0.763 . . . . 0.0 109.279 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.6 ' O ' HG23 ' A' ' 80' ' ' VAL . 32.5 mm-40 -85.53 110.15 19.01 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.261 -0.9 . . . . 0.0 109.547 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.3 p -79.48 -16.25 56.38 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.249 -0.907 . . . . 0.0 108.71 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.515 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 42.4 t -132.24 134.31 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.06 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.725 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -139.81 172.28 12.69 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.051 -1.031 . . . . 0.0 110.447 -179.447 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.502 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.0 OUTLIER -143.73 132.07 22.07 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.895 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.848 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -99.31 106.58 39.88 Favored Pre-proline 0 N--CA 1.487 1.421 0 O-C-N 121.207 -0.933 . . . . 0.0 109.616 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.586 ' C ' HD13 ' A' ' 145' ' ' ILE . 36.1 Cg_endo -78.04 111.92 3.16 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.206 1.937 . . . . 0.0 110.827 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.705 ' N ' HD13 ' A' ' 145' ' ' ILE . 2.0 mm -94.31 139.56 18.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 178.343 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.539 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 4.5 m80 -107.22 159.75 16.11 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.299 -1.501 . . . . 0.0 112.165 -177.007 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.813 ' CE2' HG13 ' A' ' 101' ' ' VAL . 39.0 m-85 -160.72 165.25 30.77 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.639 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 104.52 46.51 1.3 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.729 ' C ' HG11 ' A' ' 64' ' ' VAL . 23.9 m-85 -125.03 161.27 27.1 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.477 -1.013 . . . . 0.0 109.115 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.418 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.72 -28.47 68.45 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -75.78 -11.54 60.0 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.434 -0.791 . . . . 0.0 109.065 179.031 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.613 ' ND2' HD13 ' A' ' 157' ' ' ILE . 1.5 t30 -114.61 11.0 16.88 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.403 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.535 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.4 t -88.02 162.81 2.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.495 -0.753 . . . . 0.0 109.868 -179.223 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.466 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.42 34.04 41.07 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 3.5 m-20 -160.39 138.71 10.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.177 -1.19 . . . . 0.0 110.013 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.841 HG23 ' O ' ' A' ' 59' ' ' VAL . 53.5 m -89.37 120.44 30.72 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.613 HD13 ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -100.37 117.44 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.902 -1.124 . . . . 0.0 110.222 -178.894 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.744 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 13.1 m-85 -92.52 143.63 26.16 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 178.381 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.656 ' CD1' ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -142.04 136.22 29.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.604 -1.31 . . . . 0.0 111.025 -178.014 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.801 ' HB3' HG12 ' A' ' 56' ' ' VAL . 4.7 t0 -173.23 136.24 0.62 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.245 -0.909 . . . . 0.0 108.586 179.144 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 133.35 -7.29 5.01 Favored Glycine 0 N--CA 1.484 1.896 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.422 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.848 HD21 ' HB3' ' A' ' 143' ' ' ALA . 7.3 tp -59.33 93.14 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.626 -1.514 . . . . 0.0 108.596 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 163' ' ' ALA . . . . . 0.444 ' N ' ' O ' ' A' ' 161' ' ' GLY . . . -123.62 145.98 48.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.594 -0.691 . . . . 0.0 109.965 -178.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.674 HD13 HG11 ' A' ' 78' ' ' VAL . 8.0 mt -132.41 119.58 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.325 -0.86 . . . . 0.0 109.258 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.679 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -153.01 144.55 23.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.772 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 166' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 86' ' ' TYR . 0.7 OUTLIER -43.71 -64.76 0.6 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.354 -0.841 . . . . 0.0 109.535 179.837 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.18 168.27 18.54 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.279 -0.888 . . . . 0.0 109.494 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo . . . . . 0 C--N 1.309 -1.528 0 C-N-CA 122.63 2.22 . . . . 0.0 110.401 -179.984 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.629 HG22 ' O ' ' A' ' 164' ' ' ILE . 4.1 p . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.76 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -71.74 -46.61 57.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.173 -0.955 . . . . 0.0 109.487 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.852 ' HB2' HD12 ' A' ' 164' ' ' ILE . 38.7 t-20 -82.56 125.83 31.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.207 -0.933 . . . . 0.0 109.496 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.472 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 2.0 mp -112.2 123.35 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.292 -0.88 . . . . 0.0 109.265 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.483 ' HB3' ' HA3' ' A' ' 27' ' ' GLY . 0.8 OUTLIER 69.05 12.9 8.7 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.266 -0.896 . . . . 0.0 109.504 179.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -59.14 -24.96 59.29 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.458 ' O ' ' OD2' ' A' ' 160' ' ' ASP . . . -110.99 36.56 4.16 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.214 -1.555 . . . . 0.0 109.214 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.733 ' HD2' HG21 ' A' ' 25' ' ' VAL . 0.7 OUTLIER 43.64 53.21 6.02 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.368 -1.078 . . . . 0.0 109.422 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.483 ' OE2' ' CG ' ' A' ' 52' ' ' GLU . 7.7 mm-40 -84.04 -49.62 8.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -0.926 . . . . 0.0 109.728 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.451 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 7.3 m -79.58 -16.49 55.8 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.677 -179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 1.048 ' OG1' HG13 ' A' ' 25' ' ' VAL . 0.5 OUTLIER -74.51 114.74 36.89 Favored Pre-proline 0 C--N 1.304 -1.389 0 O-C-N 121.185 -0.947 . . . . 0.0 109.422 -179.802 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.2 Cg_endo -77.09 136.9 16.75 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.424 2.082 . . . . 0.0 110.474 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.47 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -40.02 155.51 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.393 0.616 . . . . 0.0 109.717 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.3 132.6 3.0 Favored Glycine 0 N--CA 1.485 1.961 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.531 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.71 142.45 12.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.252 -1.146 . . . . 0.0 109.011 -179.528 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.6 t -88.42 144.14 9.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-O 121.778 0.799 . . . . 0.0 110.277 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.3 t -105.03 -26.69 12.04 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 179.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.48 ' CB ' ' HG3' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -138.18 101.37 4.38 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 179.453 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.969 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.7 OUTLIER -55.56 -34.91 65.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.204 -0.935 . . . . 0.0 110.384 -179.004 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.946 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.69 -33.79 72.03 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.061 -1.024 . . . . 0.0 109.334 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.48 ' HG3' ' CB ' ' A' ' 20' ' ' ASP . 1.4 pt-20 -122.15 37.67 4.32 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.303 -0.873 . . . . 0.0 109.369 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -89.2 -73.1 1.28 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 1.048 HG13 ' OG1' ' A' ' 13' ' ' THR . 14.6 t -99.72 127.43 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.307 -1.113 . . . . 0.0 109.259 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 31.6 tp10 -56.76 -35.69 68.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.417 -0.802 . . . . 0.0 109.783 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.483 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -99.14 -2.4 56.91 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 -179.503 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' TRP . . . . . 0.614 ' CZ3' ' CB ' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -138.79 123.21 18.32 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.088 -1.242 . . . . 0.0 109.845 179.941 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.744 ' C ' HD23 ' A' ' 30' ' ' LEU . 3.9 m-20 -123.47 144.23 49.66 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.969 ' O ' HD13 ' A' ' 21' ' ' LEU . 0.7 OUTLIER -113.5 166.98 10.98 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.714 -1.242 . . . . 0.0 109.461 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.458 ' OD1' ' O ' ' A' ' 30' ' ' LEU . 8.5 m120 -157.02 124.67 5.39 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.45 -0.781 . . . . 0.0 109.687 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.045 ' CG1' HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.04 136.56 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.383 -0.823 . . . . 0.0 109.457 179.539 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.43 -170.6 23.81 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.4 t -66.74 -9.09 33.01 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.195 -1.18 . . . . 0.0 109.438 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.473 ' HB2' ' HA ' ' A' ' 70' ' ' ASP . 0.6 OUTLIER -73.12 -31.39 64.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.204 -0.935 . . . . 0.0 109.593 -179.964 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 1.045 HG21 ' CG1' ' A' ' 32' ' ' VAL . 2.1 t -64.64 87.86 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 O-C-N 121.176 -0.952 . . . . 0.0 109.339 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 16.4 m -72.58 -29.0 63.15 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.624 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.2 t-20 -114.57 144.98 32.88 Favored Pre-proline 0 C--N 1.296 -1.746 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.446 ' HD2' ' CG ' ' A' ' 38' ' ' ASN . 34.8 Cg_endo -76.38 111.8 3.34 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 122.359 2.039 . . . . 0.0 110.591 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.55 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.2 Cg_endo -77.57 166.13 26.16 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.371 2.048 . . . . 0.0 109.593 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.532 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 49.0 t -108.16 121.59 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.966 -1.084 . . . . 0.0 110.559 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.629 ' CE2' HD23 ' A' ' 21' ' ' LEU . 27.4 m-85 -110.12 112.47 24.48 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.531 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 0.9 OUTLIER -153.56 151.32 29.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.1 -1.0 . . . . 0.0 109.801 -179.422 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.459 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 62.3 t -98.78 148.57 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -0.885 . . . . 0.0 109.255 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.758 HD21 ' CG2' ' A' ' 47' ' ' THR . 0.4 OUTLIER -131.9 147.01 52.44 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.185 -0.947 . . . . 0.0 108.776 179.978 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.56 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 18.1 mt-10 -115.08 113.69 24.37 Favored 'General case' 0 C--N 1.295 -1.8 0 O-C-N 121.576 -0.702 . . . . 0.0 109.548 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.758 ' CG2' HD21 ' A' ' 45' ' ' LEU . 1.7 p -141.5 164.66 29.62 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.31 -0.869 . . . . 0.0 109.41 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.448 ' HA ' ' OD1' ' A' ' 54' ' ' ASN . 0.1 OUTLIER -86.9 15.59 5.73 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.9 . . . . 0.0 109.51 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -102.89 -18.51 15.03 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.242 -0.911 . . . . 0.0 109.436 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.721 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -55.55 144.68 52.97 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.2 -0.938 . . . . 0.0 109.329 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.515 ' HG3' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.29 -42.12 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.571 2.181 . . . . 0.0 110.365 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.483 ' CG ' ' OE2' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -101.42 92.8 5.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.901 . . . . 0.0 109.407 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.93 -115.97 4.35 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.721 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 15.2 m-20 -160.02 37.77 0.18 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -1.147 . . . . 0.0 109.412 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.52 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 62.1 mttt -138.54 134.24 33.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.198 -0.938 . . . . 0.0 109.6 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.659 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.9 m -146.53 174.62 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.313 -0.867 . . . . 0.0 109.229 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.789 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -107.46 103.09 12.34 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.101 -1.0 . . . . 0.0 109.181 179.731 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.684 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.17 120.71 25.21 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.034 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.824 ' O ' HG23 ' A' ' 156' ' ' THR . 41.5 t -115.79 144.89 22.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.15 -0.969 . . . . 0.0 109.331 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.816 HG22 HD22 ' A' ' 62' ' ' ASN . 19.6 m -108.99 92.75 4.18 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.563 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 52.5 t -90.54 115.73 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.236 -0.915 . . . . 0.0 109.272 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.816 HD22 HG22 ' A' ' 60' ' ' THR . 2.0 p30 -149.51 56.41 0.98 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.248 -0.908 . . . . 0.0 109.828 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 160.9 90.09 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.779 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.5 m -80.14 -171.32 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.176 -1.19 . . . . 0.0 109.451 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -139.95 -168.44 11.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -86.21 1.41 50.86 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.233 -1.157 . . . . 0.0 109.569 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.603 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 1.2 m120 -116.33 145.02 34.16 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.241 -0.912 . . . . 0.0 109.284 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.584 ' HG2' ' CZ3' ' A' ' 69' ' ' TRP . 36.4 Cg_endo -79.52 38.88 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.607 2.204 . . . . 0.0 111.197 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.603 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 8.2 p90 -162.58 50.05 0.18 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.968 -1.082 . . . . 0.0 109.807 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.649 ' HB2' HD12 ' A' ' 71' ' ' ILE . 0.4 OUTLIER -70.94 -64.64 0.86 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.126 -0.984 . . . . 0.0 108.924 179.536 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.649 HD12 ' HB2' ' A' ' 70' ' ' ASP . 4.1 mp -106.4 128.73 60.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 108.996 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.452 ' OE2' ' HB2' ' A' ' 144' ' ' PRO . 71.3 tt0 -138.26 122.68 18.35 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.843 -1.16 . . . . 0.0 110.195 -179.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.635 ' CB ' HD22 ' A' ' 30' ' ' LEU . . . -113.76 107.41 15.7 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.069 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.55 HG22 ' N ' ' A' ' 75' ' ' ALA . 96.7 m -94.4 165.44 12.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.57 -0.706 . . . . 0.0 110.17 -179.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.55 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.12 137.78 53.36 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.175 -0.953 . . . . 0.0 108.726 178.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.536 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 0.2 OUTLIER -179.12 161.49 1.0 Allowed Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.561 -0.712 . . . . 0.0 109.165 -179.387 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.536 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.2 Cg_endo -82.46 163.32 74.97 Favored 'Cis proline' 0 C--N 1.311 -1.437 0 C-N-CA 123.81 -1.329 . . . . 0.0 110.893 -0.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.761 HG11 HD13 ' A' ' 164' ' ' ILE . 96.8 t -123.99 156.45 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.4 -0.813 . . . . 0.0 108.913 179.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ASN . . . . . 0.76 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 52.1 m-20 -121.21 139.8 52.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.115 -0.991 . . . . 0.0 109.854 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.565 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 2.5 m -146.3 -174.0 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.138 -0.976 . . . . 0.0 109.478 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.691 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -137.3 146.09 52.52 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.233 -0.917 . . . . 0.0 109.429 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.45 106.14 2.16 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.474 2.116 . . . . 0.0 110.494 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 112.35 -29.7 8.12 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.475 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.43 149.71 4.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.158 -1.201 . . . . 0.0 109.474 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.471 ' HA ' ' OG1' ' A' ' 133' ' ' THR . 10.8 m -95.47 143.07 27.11 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' TYR . . . . . 0.565 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 12.0 m-85 -120.61 168.49 11.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.171 -0.956 . . . . 0.0 109.604 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.478 ' CB ' ' O ' ' A' ' 165' ' ' ALA . 5.2 m -118.15 154.47 32.1 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.26 -0.9 . . . . 0.0 109.561 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.682 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 5.1 t80 -130.56 118.96 21.81 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.298 -0.876 . . . . 0.0 109.319 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.474 ' O ' ' O ' ' A' ' 161' ' ' GLY . 31.8 m -134.31 144.04 48.07 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.215 -0.928 . . . . 0.0 109.333 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.552 HD13 ' CD2' ' A' ' 103' ' ' PHE . 14.9 tt -150.62 163.54 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 120.703 -1.248 . . . . 0.0 109.506 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.515 ' HB2' ' HG3' ' A' ' 51' ' ' PRO . 20.1 m95 -132.73 124.98 29.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.974 -1.079 . . . . 0.0 109.342 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.88 150.42 37.08 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.288 -0.883 . . . . 0.0 109.459 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.552 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 1.1 ttt85 -164.4 119.12 1.44 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.309 -0.869 . . . . 0.0 109.027 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.39 170.1 8.12 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 110.065 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -66.12 -55.94 13.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.443 -0.785 . . . . 0.0 109.41 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.514 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -104.43 137.3 42.5 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.222 -0.924 . . . . 0.0 109.463 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.585 ' N ' ' CG2' ' A' ' 123' ' ' THR . 19.2 p-10 -61.64 148.35 42.82 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.308 -0.87 . . . . 0.0 109.562 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 108.9 39.43 1.71 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.506 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -119.55 141.15 49.5 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.14 -1.212 . . . . 0.0 108.98 179.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.401 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 52.0 t -115.94 148.25 18.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 110.712 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.634 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 25.1 t -150.01 164.96 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.457 -0.777 . . . . 0.0 109.203 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.539 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 16.4 t -136.47 144.33 44.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.011 -1.056 . . . . 0.0 109.457 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.629 ' N ' ' CD1' ' A' ' 103' ' ' PHE . 0.1 OUTLIER -135.99 104.67 5.78 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.224 -0.923 . . . . 0.0 109.924 -179.726 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.507 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 14.0 p -112.77 168.75 9.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.093 -1.005 . . . . 0.0 110.058 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -127.83 141.45 46.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 CA-C-O 121.386 0.612 . . . . 0.0 109.837 -179.879 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -167.49 143.9 8.58 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.4 p30 -84.66 -169.79 2.8 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.197 -1.179 . . . . 0.0 109.632 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . 0.52 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 11.2 mp0 -77.84 16.95 0.62 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.196 -0.94 . . . . 0.0 110.683 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.463 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 0.8 OUTLIER -113.23 15.46 19.36 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 120.831 -1.168 . . . . 0.0 108.801 179.447 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.463 ' HB2' ' O ' ' A' ' 109' ' ' SER . 9.8 m-30 67.63 16.86 9.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.504 -0.748 . . . . 0.0 109.599 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.528 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 12.8 mm-40 -93.5 157.66 16.1 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.177 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . 0.471 ' OE2' ' HB2' ' A' ' 115' ' ' ARG . 8.0 tt0 -137.83 147.15 44.29 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.034 -1.041 . . . . 0.0 109.99 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.509 ' CE2' HG21 ' A' ' 141' ' ' ILE . 4.0 m-85 -112.3 -67.4 1.0 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.587 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -92.35 173.42 35.73 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.471 ' HB2' ' OE2' ' A' ' 112' ' ' GLU . 6.8 ttt-85 -178.78 119.46 0.08 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.08 -1.247 . . . . 0.0 110.217 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.646 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -141.91 70.03 1.33 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.396 -0.815 . . . . 0.0 108.803 179.241 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' HIS . . . . . 0.54 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 0.2 OUTLIER -86.64 148.07 25.63 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 110.346 -179.265 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 1.2 mt-10 79.42 66.32 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.466 -0.771 . . . . 0.0 109.557 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.472 ' NE2' ' HA ' ' A' ' 119' ' ' GLN . 7.8 mm100 -118.79 123.73 45.51 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.315 -0.866 . . . . 0.0 109.259 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.553 ' O ' HD13 ' A' ' 121' ' ' ILE . 0.0 OUTLIER -64.23 139.14 58.73 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.429 -0.794 . . . . 0.0 108.972 179.78 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 120' ' ' GLN . 5.6 mm -125.95 130.17 72.32 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.08 -1.012 . . . . 0.0 110.14 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.04 -179.28 6.17 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.604 0.716 . . . . 0.0 109.949 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.585 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 74.9 p -75.85 -4.19 39.36 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.793 -0.763 . . . . 0.0 109.183 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 2.8 mt-10 -106.65 -168.78 1.46 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.327 -0.858 . . . . 0.0 109.311 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' TRP . . . . . 0.552 ' CE2' ' HD3' ' A' ' 93' ' ' ARG . 93.8 m95 -94.38 118.64 31.92 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.208 -0.933 . . . . 0.0 109.691 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -106.88 121.44 44.88 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.289 -0.882 . . . . 0.0 108.985 179.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -79.54 117.05 3.64 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.341 2.027 . . . . 0.0 111.075 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -121.25 138.29 54.3 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.7 t -151.27 175.81 11.84 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.608 -1.308 . . . . 0.0 111.149 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.682 ' CE2' ' CD1' ' A' ' 88' ' ' TYR . 36.3 p90 -173.22 -172.69 0.84 Allowed 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.095 179.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . 0.412 ' N ' ' CD1' ' A' ' 130' ' ' PHE . 21.7 mt-10 -129.01 155.78 44.86 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.098 -1.001 . . . . 0.0 110.051 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -164.98 139.18 4.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.422 -0.799 . . . . 0.0 109.065 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.471 ' OG1' ' HA ' ' A' ' 85' ' ' THR . 0.8 OUTLIER -117.85 146.19 44.05 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.216 -0.927 . . . . 0.0 109.377 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.691 HG21 ' O ' ' A' ' 81' ' ' ARG . 4.4 t -44.57 110.49 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.396 -0.815 . . . . 0.0 109.203 179.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 65.5 m -61.8 -53.08 60.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.207 -0.933 . . . . 0.0 109.258 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 -102.91 -91.74 0.34 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.359 -0.838 . . . . 0.0 109.218 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -162.27 50.59 0.2 Allowed 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.458 -0.776 . . . . 0.0 109.314 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.51 ' O ' HG23 ' A' ' 80' ' ' VAL . 23.1 mm-40 -88.18 114.63 25.0 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.209 -0.932 . . . . 0.0 109.604 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.6 p -79.19 -12.38 59.97 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.294 -0.879 . . . . 0.0 108.759 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.492 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 40.8 t -135.73 134.77 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.391 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.509 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -139.58 172.52 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.194 -0.941 . . . . 0.0 110.057 -179.725 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' ARG . . . . . 0.493 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.4 ptm180 -145.54 132.54 20.28 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.556 -0.715 . . . . 0.0 109.614 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ALA . . . . . 0.596 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -100.24 106.58 42.87 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.292 -0.88 . . . . 0.0 109.655 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.507 ' HD2' ' O ' ' A' ' 104' ' ' THR . 33.7 Cg_endo -76.64 110.56 3.07 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.061 1.841 . . . . 0.0 110.291 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.633 HD13 ' N ' ' A' ' 145' ' ' ILE . 3.2 mm -85.71 124.74 40.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' HIS . . . . . 0.499 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 6.7 m80 -84.57 150.15 25.41 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.972 -1.08 . . . . 0.0 110.984 -178.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.66 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 12.1 m-85 -154.91 157.36 37.66 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.125 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.599 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 108.44 50.67 0.74 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.779 ' C ' HG11 ' A' ' 64' ' ' VAL . 27.5 m-85 -121.17 159.77 25.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.378 -1.072 . . . . 0.0 109.227 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.487 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -65.78 -30.39 71.03 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.611 -0.681 . . . . 0.0 109.168 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.467 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -77.0 -11.0 59.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.394 -0.816 . . . . 0.0 109.108 179.273 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.577 ' ND2' HD13 ' A' ' 157' ' ' ILE . 3.8 t30 -109.81 11.62 24.28 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.55 HG23 HG13 ' A' ' 64' ' ' VAL . 2.4 t -90.06 164.76 2.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 O-C-N 121.519 -0.738 . . . . 0.0 109.763 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' GLY . . . . . 0.493 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 53.29 32.7 44.72 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.864 -1.295 . . . . 0.0 109.864 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.7 m-20 -160.53 136.78 8.59 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.137 -1.214 . . . . 0.0 110.04 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' THR . . . . . 0.824 HG23 ' O ' ' A' ' 59' ' ' VAL . 53.6 m -86.83 121.13 28.9 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.01 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.577 HD13 ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -100.86 118.73 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 120.967 -1.083 . . . . 0.0 110.291 -178.775 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.684 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.6 m-85 -97.09 129.42 44.51 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 178.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.66 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -120.37 141.99 38.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 120.749 -1.219 . . . . 0.0 110.091 -178.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' ASP . . . . . 0.659 ' CB ' HG12 ' A' ' 56' ' ' VAL . 4.5 t70 -173.89 136.41 0.54 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.299 -0.876 . . . . 0.0 108.901 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 124.78 -6.93 8.34 Favored Glycine 0 N--CA 1.486 2.033 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.157 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.601 HD11 ' CE2' ' A' ' 88' ' ' TYR . 0.6 OUTLIER -60.01 94.04 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 O-C-N 120.768 -1.43 . . . . 0.0 108.491 179.899 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . 0.494 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -132.93 145.85 51.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.633 -0.667 . . . . 0.0 109.815 -179.068 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.852 HD12 ' HB2' ' A' ' 5' ' ' ASN . 3.2 mt -123.08 115.65 46.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.235 -0.915 . . . . 0.0 109.202 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.5 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.621 0 O-C-N 121.171 -0.956 . . . . 0.0 109.626 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.874 ' CG2' ' HB2' ' A' ' 165' ' ' ALA . 1.4 p . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.236 0.541 . . . . 0.0 109.553 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.713 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -70.79 -61.19 1.86 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.058 -1.027 . . . . 0.0 109.324 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.599 ' HB3' HD13 ' A' ' 164' ' ' ILE . 13.0 p-10 -74.92 176.92 6.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.367 -0.833 . . . . 0.0 109.405 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.669 HG22 ' ND2' ' A' ' 7' ' ' ASN . 2.6 mp -128.3 136.83 59.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.286 -0.884 . . . . 0.0 109.717 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.669 ' ND2' HG22 ' A' ' 6' ' ' ILE . 0.3 OUTLIER 44.92 57.71 4.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.678 179.908 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.497 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -56.96 -42.79 92.92 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.504 ' HA2' ' HA ' ' A' ' 160' ' ' ASP . . . -107.74 35.62 4.89 Favored Glycine 0 N--CA 1.487 2.088 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.994 ' CE2' HG21 ' A' ' 25' ' ' VAL . 4.1 m-85 63.52 54.73 1.87 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.468 -1.019 . . . . 0.0 109.386 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -82.35 -50.53 8.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.897 . . . . 0.0 109.737 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.532 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 41.3 t -69.9 -42.14 73.77 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.105 -0.997 . . . . 0.0 109.693 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.956 ' OG1' HG13 ' A' ' 25' ' ' VAL . 0.6 OUTLIER -68.53 125.71 91.99 Favored Pre-proline 0 C--N 1.305 -1.351 0 O-C-N 121.217 -0.927 . . . . 0.0 109.199 -179.882 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.47 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.2 Cg_endo -76.98 146.1 25.53 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 122.462 2.108 . . . . 0.0 111.071 -179.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.804 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -42.05 165.48 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.564 0 CA-C-O 121.214 0.53 . . . . 0.0 109.663 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 130.96 135.27 3.76 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.531 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.57 140.14 15.14 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.34 -1.094 . . . . 0.0 109.029 -179.596 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -84.77 143.67 11.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 CA-C-O 121.763 0.792 . . . . 0.0 110.196 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.4 p -113.56 -27.1 7.99 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.553 ' CB ' ' HG3' ' A' ' 23' ' ' GLU . 20.5 m-20 -133.42 77.83 1.75 Allowed 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.923 HD12 ' N ' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -44.63 -32.25 1.41 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.323 -0.861 . . . . 0.0 109.708 -179.365 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.923 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -71.11 -47.03 60.44 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.283 -0.885 . . . . 0.0 109.548 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.553 ' HG3' ' CB ' ' A' ' 20' ' ' ASP . 9.1 pt-20 -115.49 38.12 3.36 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.257 -0.902 . . . . 0.0 109.569 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 20' ' ' ASP . . . -106.9 -77.69 1.09 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.994 HG21 ' CE2' ' A' ' 10' ' ' PHE . 5.8 t -92.8 111.0 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.283 -1.128 . . . . 0.0 109.264 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -59.98 -39.86 87.15 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.299 -0.876 . . . . 0.0 109.867 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.461 ' HA3' ' HB2' ' A' ' 7' ' ' ASN . . . -67.56 -35.12 85.86 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' TRP . . . . . 0.535 ' CE3' ' HB1' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -129.64 126.26 37.98 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.153 -1.204 . . . . 0.0 109.67 -179.797 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.727 ' C ' HD23 ' A' ' 30' ' ' LEU . 6.3 m-20 -115.54 141.25 48.31 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.902 ' O ' HD13 ' A' ' 21' ' ' LEU . 0.9 OUTLIER -116.29 163.13 16.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.716 -1.24 . . . . 0.0 109.53 -179.548 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 71.8 m-80 -156.18 123.15 5.29 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.518 -0.738 . . . . 0.0 109.402 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.005 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -102.97 133.84 45.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.342 -0.849 . . . . 0.0 109.514 179.571 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.14 167.34 16.89 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -44.86 -26.16 0.38 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -1.142 . . . . 0.0 109.411 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.491 ' CB ' ' HB2' ' A' ' 67' ' ' ASN . 6.8 m -53.08 -53.12 55.0 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.19 -0.944 . . . . 0.0 109.455 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 1.005 HG21 HG12 ' A' ' 32' ' ' VAL . 42.2 t -46.18 94.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.2 -0.938 . . . . 0.0 110.196 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.484 ' N ' ' O ' ' A' ' 35' ' ' SER . 82.9 m -78.25 -27.53 47.6 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.336 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.512 ' O ' HG12 ' A' ' 36' ' ' VAL . 20.1 m-20 -114.9 147.36 38.1 Favored Pre-proline 0 C--N 1.297 -1.696 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.32 111.08 3.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.496 2.131 . . . . 0.0 110.768 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.538 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 36.0 Cg_endo -78.69 167.33 22.63 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.495 2.13 . . . . 0.0 109.684 179.551 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.524 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 51.1 t -110.38 121.89 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.953 -1.092 . . . . 0.0 110.47 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.634 ' CD2' HD23 ' A' ' 21' ' ' LEU . 28.2 m-85 -111.01 112.8 24.87 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 178.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.531 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 29.3 tt0 -151.08 160.8 43.68 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.109 -0.994 . . . . 0.0 109.702 -179.383 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.476 HG13 ' O ' ' A' ' 56' ' ' VAL . 49.2 t -102.26 133.48 45.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.434 -0.791 . . . . 0.0 109.133 179.555 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.508 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -111.28 118.7 36.62 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.349 -0.845 . . . . 0.0 109.415 -179.606 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.804 ' HG3' ' HB2' ' A' ' 15' ' ' ALA . 6.1 mt-10 -91.65 109.84 21.16 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 4.8 p -141.67 153.89 44.99 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.544 -0.723 . . . . 0.0 109.41 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 89.3 p -78.85 -10.15 59.7 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.228 -0.92 . . . . 0.0 109.484 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.401 ' O ' ' C ' ' A' ' 50' ' ' ALA . 5.4 m-20 -79.81 -18.17 51.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.191 -0.943 . . . . 0.0 109.536 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.405 ' HA ' ' HD3' ' A' ' 51' ' ' PRO . . . -45.02 147.65 1.13 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.895 . . . . 0.0 109.544 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.512 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.16 -40.59 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.629 2.219 . . . . 0.0 110.355 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.27 115.57 26.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.52 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.05 -124.54 23.35 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -152.74 22.85 0.59 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.164 -1.198 . . . . 0.0 109.499 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.521 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 8.6 mttt -129.37 143.61 50.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.436 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.627 HG12 ' CB ' ' A' ' 160' ' ' ASP . 11.9 m -150.24 175.59 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.347 -0.846 . . . . 0.0 109.004 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.685 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -108.43 99.64 9.01 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.057 -1.027 . . . . 0.0 109.033 179.508 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.614 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.23 119.2 23.32 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.818 ' O ' HG23 ' A' ' 156' ' ' THR . 43.7 t -115.68 144.85 22.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.134 -0.979 . . . . 0.0 109.212 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.524 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 9.3 m -108.96 91.69 3.74 Favored 'General case' 0 C--N 1.283 -2.313 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.546 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 48.2 t -89.58 117.41 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.395 -0.815 . . . . 0.0 109.091 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.423 HD22 HG22 ' A' ' 60' ' ' THR . 3.1 p30 -154.4 58.55 0.7 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.305 -0.872 . . . . 0.0 109.935 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 157.02 84.2 0.05 OUTLIER Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.706 HG12 ' C ' ' A' ' 148' ' ' GLY . 1.8 m -80.07 -175.85 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.21 -1.171 . . . . 0.0 109.513 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -129.31 -148.52 6.59 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -94.74 -5.89 44.33 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.325 -1.103 . . . . 0.0 109.576 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.568 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 27.8 m-20 -112.74 146.75 35.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.077 -1.014 . . . . 0.0 109.45 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.414 ' O ' ' CE1' ' A' ' 149' ' ' TYR . 36.3 Cg_endo -78.7 12.99 2.02 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.602 2.202 . . . . 0.0 110.931 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.568 ' CZ2' ' OD1' ' A' ' 67' ' ' ASN . 4.2 p90 -133.5 51.86 2.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.035 -1.041 . . . . 0.0 109.659 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.484 ' O ' ' CG2' ' A' ' 36' ' ' VAL . 2.6 m-20 -74.24 -64.17 1.08 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.3 -0.875 . . . . 0.0 109.193 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.581 HG22 ' HB2' ' A' ' 147' ' ' PHE . 2.9 mp -100.22 118.3 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 109.043 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -121.4 127.49 51.23 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.138 -0.976 . . . . 0.0 110.15 -179.565 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.888 ' HB3' ' CE1' ' A' ' 147' ' ' PHE . . . -123.72 108.26 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.561 HG22 ' N ' ' A' ' 75' ' ' ALA . 86.0 m -104.95 165.76 10.85 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.418 -0.801 . . . . 0.0 109.95 -179.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.561 ' N ' HG22 ' A' ' 74' ' ' THR . . . -120.92 140.13 52.27 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.071 -1.018 . . . . 0.0 108.875 178.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.568 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.3 p90 179.53 162.86 0.79 Allowed Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.496 -0.752 . . . . 0.0 109.2 -179.551 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.568 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.8 Cg_endo -82.14 169.31 62.94 Favored 'Cis proline' 0 C--N 1.311 -1.416 0 C-N-CA 123.885 -1.298 . . . . 0.0 110.856 -0.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 85.1 t -127.65 156.22 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.388 -0.82 . . . . 0.0 108.891 179.292 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ASN . . . . . 0.541 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 16.5 m-80 -123.44 118.66 27.95 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.16 -0.962 . . . . 0.0 109.94 -179.567 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.556 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 3.0 m -124.63 -173.83 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.27 -0.894 . . . . 0.0 109.541 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.664 ' O ' HG21 ' A' ' 134' ' ' VAL . 15.3 mmt180 -136.63 144.93 49.14 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.332 -0.855 . . . . 0.0 109.269 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.19 120.57 5.4 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 122.545 2.163 . . . . 0.0 110.618 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 98.21 -27.76 17.81 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.417 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.06 149.7 4.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.21 -1.171 . . . . 0.0 109.501 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 28.5 m -95.86 133.03 40.49 Favored 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' TYR . . . . . 0.556 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 7.4 m-85 -111.68 166.76 10.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.896 . . . . 0.0 109.692 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.479 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 32.4 m -118.38 154.31 32.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.358 -0.839 . . . . 0.0 109.335 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.69 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 7.6 t80 -129.72 117.98 21.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.159 -0.963 . . . . 0.0 109.548 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.476 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.7 m -135.0 144.26 47.26 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.24 -0.912 . . . . 0.0 109.186 179.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.756 HD12 ' HB2' ' A' ' 162' ' ' LEU . 14.4 tt -150.49 163.78 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 120.817 -1.177 . . . . 0.0 109.562 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.512 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 19.8 m95 -132.73 125.99 31.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.062 -1.024 . . . . 0.0 109.303 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -117.08 151.81 36.01 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.359 -0.838 . . . . 0.0 109.487 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.56 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 8.5 ttp85 -164.14 118.49 1.47 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.188 -0.945 . . . . 0.0 109.188 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -105.37 160.93 14.74 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.301 -0.874 . . . . 0.0 109.951 -179.522 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -58.95 -48.56 81.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.417 -0.802 . . . . 0.0 109.289 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.517 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 2.0 mt-30 -113.91 142.16 46.47 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.273 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.582 ' N ' HG22 ' A' ' 123' ' ' THR . 28.4 p-10 -65.14 146.16 55.34 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.23 -0.919 . . . . 0.0 109.485 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 110.91 38.3 1.57 Allowed Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.494 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -120.45 140.66 51.07 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.257 -1.143 . . . . 0.0 109.082 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.422 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 55.5 t -116.14 145.27 22.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.224 -0.922 . . . . 0.0 110.766 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.7 HG13 ' CE2' ' A' ' 147' ' ' PHE . 39.0 t -143.05 165.86 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.569 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.536 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 4.1 m -123.25 126.22 46.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.069 -1.019 . . . . 0.0 109.9 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.537 ' CD1' HD13 ' A' ' 90' ' ' ILE . 66.8 m-85 -116.79 103.45 10.34 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.028 -1.045 . . . . 0.0 109.322 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.504 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 17.8 p -128.11 164.73 21.8 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.011 -1.055 . . . . 0.0 110.691 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.653 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -129.7 155.95 41.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-O 121.213 0.53 . . . . 0.0 109.964 -179.934 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.521 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -174.11 -173.81 40.47 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.2 p30 -131.24 -169.56 2.2 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.152 -1.205 . . . . 0.0 109.45 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . 0.52 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 3.5 mp0 -68.34 3.81 1.58 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.098 -1.002 . . . . 0.0 111.336 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.462 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 1.4 m -107.1 14.87 25.83 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 120.661 -1.274 . . . . 0.0 109.239 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.462 ' HB2' ' O ' ' A' ' 109' ' ' SER . 13.7 m-30 67.04 7.84 5.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.447 -0.783 . . . . 0.0 109.609 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.521 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 24.4 tt0 -80.07 158.32 26.47 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . 0.49 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 4.2 tt0 -136.15 136.5 40.09 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.028 -1.045 . . . . 0.0 110.012 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.573 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 7.3 m-85 -96.17 -70.74 0.7 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.412 -0.805 . . . . 0.0 108.875 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.58 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -81.92 156.48 36.3 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 179.5 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.7 ttt180 -153.36 106.94 3.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.057 -1.261 . . . . 0.0 110.258 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.716 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -146.12 70.0 1.22 Allowed 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.146 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' HIS . . . . . 0.536 ' CB ' ' HB3' ' A' ' 102' ' ' SER . 2.1 p-80 -107.85 160.71 15.53 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.252 -0.905 . . . . 0.0 110.048 -179.449 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 16.5 tt0 77.28 58.56 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.361 -0.837 . . . . 0.0 109.469 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 4.0 mm-40 -130.14 136.98 49.88 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.315 -0.866 . . . . 0.0 109.501 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.447 ' O ' HD13 ' A' ' 121' ' ' ILE . 47.9 mt-30 -70.88 156.28 39.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.472 -0.768 . . . . 0.0 109.065 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 99' ' ' ALA . 6.0 mm -133.49 135.67 55.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.148 -0.97 . . . . 0.0 109.873 -179.455 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -82.74 -179.34 7.4 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.672 0.749 . . . . 0.0 110.001 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.582 HG22 ' N ' ' A' ' 97' ' ' ASP . 63.7 p -78.45 -1.59 34.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.511 -0.743 . . . . 0.0 109.307 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.411 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 2.5 mt-10 -108.42 -168.87 1.41 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.184 -0.947 . . . . 0.0 109.397 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' TRP . . . . . 0.56 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 95.5 m95 -95.26 121.15 36.61 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.206 -0.934 . . . . 0.0 109.688 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -106.84 121.02 46.3 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.261 -0.899 . . . . 0.0 108.935 179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.407 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.8 Cg_endo -80.25 107.39 2.03 Favored 'Trans proline' 0 C--N 1.311 -1.416 0 C-N-CA 122.456 2.104 . . . . 0.0 111.064 -179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -111.0 135.5 51.41 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 178.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.8 t -151.13 175.74 11.85 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 120.701 -1.25 . . . . 0.0 111.078 -179.187 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.716 ' CE2' HD21 ' A' ' 116' ' ' LEU . 33.8 p90 -171.89 -177.64 1.99 Allowed 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.192 179.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -127.92 151.11 49.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.191 -0.943 . . . . 0.0 109.757 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.573 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.07 168.15 17.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.44 -0.788 . . . . 0.0 109.255 179.841 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -138.69 147.74 43.13 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.5 -179.663 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.664 HG21 ' O ' ' A' ' 81' ' ' ARG . 6.0 t -40.43 110.33 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.607 -0.683 . . . . 0.0 109.367 179.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 27.8 m -59.95 -51.58 69.05 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.283 -0.885 . . . . 0.0 109.255 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -106.74 -90.87 0.42 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.384 -0.823 . . . . 0.0 109.213 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -163.98 53.97 0.15 Allowed 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.478 -0.764 . . . . 0.0 109.058 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.55 ' O ' HG23 ' A' ' 80' ' ' VAL . 31.6 mm-40 -91.67 113.22 25.43 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.188 -0.945 . . . . 0.0 109.791 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.5 p -79.44 -14.07 59.17 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.275 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.3 t -134.01 132.07 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.509 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -141.59 171.92 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.164 -0.96 . . . . 0.0 110.051 -179.608 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' ARG . . . . . 0.519 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 2.9 ptm180 -143.76 133.12 23.28 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.624 -0.673 . . . . 0.0 109.263 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ALA . . . . . 0.759 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -94.44 108.62 37.82 Favored Pre-proline 0 N--CA 1.487 1.384 0 O-C-N 121.302 -0.874 . . . . 0.0 109.897 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.658 ' C ' HD13 ' A' ' 145' ' ' ILE . 35.4 Cg_endo -76.74 113.49 3.66 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.16 1.907 . . . . 0.0 110.847 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.723 HD13 ' N ' ' A' ' 145' ' ' ILE . 1.7 mm -97.26 141.66 15.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 178.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 147' ' ' PHE . 6.2 m80 -105.28 158.32 16.69 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.55 -1.344 . . . . 0.0 111.691 -177.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.888 ' CE1' ' HB3' ' A' ' 73' ' ' ALA . 20.9 m-85 -160.81 158.2 28.05 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.132 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.706 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 108.13 43.8 1.25 Allowed Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.686 ' C ' HG11 ' A' ' 64' ' ' VAL . 61.5 m-85 -117.06 161.42 19.44 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.421 -1.047 . . . . 0.0 109.111 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.52 -29.4 69.48 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.472 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -76.61 -10.52 59.45 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 109.179 179.269 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.624 ' ND2' HD13 ' A' ' 157' ' ' ILE . 1.5 t30 -109.74 12.3 24.15 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.365 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -89.15 164.22 2.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 O-C-N 121.551 -0.718 . . . . 0.0 109.784 -179.173 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' GLY . . . . . 0.492 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.39 32.61 37.98 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.7 m-20 -160.49 136.82 8.65 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.139 -1.212 . . . . 0.0 110.111 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' THR . . . . . 0.818 HG23 ' O ' ' A' ' 59' ' ' VAL . 55.3 m -87.59 120.94 29.41 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.624 HD13 ' ND2' ' A' ' 152' ' ' ASN . 0.8 OUTLIER -99.63 117.58 44.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 120.75 -1.219 . . . . 0.0 110.327 -178.781 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.614 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 12.2 m-85 -98.01 135.78 39.21 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 178.447 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.644 ' CD1' ' CE2' ' A' ' 147' ' ' PHE . 1.3 mt -128.16 141.15 47.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 120.768 -1.207 . . . . 0.0 110.44 -178.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' ASP . . . . . 0.627 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.7 OUTLIER -173.8 136.34 0.55 Allowed 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.348 -0.845 . . . . 0.0 108.837 179.633 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 125.19 -8.23 8.0 Favored Glycine 0 N--CA 1.487 2.066 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.366 179.577 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.759 HD21 ' HB3' ' A' ' 143' ' ' ALA . 4.4 tp -60.2 100.64 0.1 Allowed 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.742 -1.446 . . . . 0.0 108.944 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . 0.543 ' C ' HD12 ' A' ' 164' ' ' ILE . . . -133.24 145.75 50.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.455 -0.778 . . . . 0.0 109.778 -179.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.702 HD12 ' N ' ' A' ' 164' ' ' ILE . 4.4 mp -126.8 109.07 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.288 -0.882 . . . . 0.0 109.425 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.874 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.171 -0.956 . . . . 0.0 109.637 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.846 HG23 ' HB2' ' A' ' 165' ' ' ALA . 4.2 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.922 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -71.64 -59.41 2.77 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.187 -0.945 . . . . 0.0 109.453 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 162' ' ' LEU . 47.4 t-20 -71.26 128.93 37.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.481 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.464 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 2.2 mp -107.7 138.53 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.273 -0.892 . . . . 0.0 109.518 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.523 ' OD1' ' CB ' ' A' ' 12' ' ' SER . 1.0 OUTLIER 66.97 17.31 10.5 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.242 -0.911 . . . . 0.0 109.638 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.5 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -61.52 -35.56 91.28 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.524 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -103.59 28.01 17.33 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.681 ' CD2' HG11 ' A' ' 25' ' ' VAL . 6.5 m-85 50.65 48.03 23.35 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.365 -1.079 . . . . 0.0 109.412 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.438 ' OE1' ' O ' ' A' ' 52' ' ' GLU . 5.6 mm-40 -83.68 -35.81 24.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.236 -0.915 . . . . 0.0 109.67 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.523 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.6 OUTLIER -84.8 -24.81 28.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.234 -0.916 . . . . 0.0 109.663 -179.759 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.9 ' OG1' HG13 ' A' ' 25' ' ' VAL . 0.7 OUTLIER -78.48 121.57 83.87 Favored Pre-proline 0 N--CA 1.486 1.352 0 O-C-N 121.185 -0.947 . . . . 0.0 109.292 -179.896 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 15' ' ' ALA . 36.1 Cg_endo -77.61 138.95 17.64 Favored 'Trans proline' 0 C--N 1.312 -1.36 0 C-N-CA 122.469 2.112 . . . . 0.0 110.754 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.522 ' HA ' ' CG1' ' A' ' 44' ' ' VAL . . . -41.59 163.53 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.71 137.38 4.45 Favored Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.529 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.23 141.52 12.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.325 -1.103 . . . . 0.0 109.079 -179.688 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.479 HG23 ' HA ' ' A' ' 43' ' ' GLU . 46.1 t -85.69 145.65 7.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 CA-C-O 121.695 0.759 . . . . 0.0 109.921 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 4.1 p -106.36 -22.3 12.85 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.411 ' HB3' ' HG3' ' A' ' 23' ' ' GLU . 0.4 OUTLIER -143.94 92.63 2.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.439 -0.788 . . . . 0.0 109.085 179.692 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.969 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -49.41 -33.19 13.26 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.293 -0.88 . . . . 0.0 109.899 -179.339 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.919 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.66 -43.6 93.89 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.165 -0.959 . . . . 0.0 109.514 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.411 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 3.3 pt-20 -118.12 35.74 4.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.252 -0.905 . . . . 0.0 109.336 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.18 -71.8 1.29 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.9 HG13 ' OG1' ' A' ' 13' ' ' THR . 2.0 t -95.96 123.63 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -1.173 . . . . 0.0 109.209 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -56.38 -32.28 64.63 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.421 -0.8 . . . . 0.0 109.854 -179.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.492 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -102.33 -3.45 50.7 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.94 -1.124 . . . . 0.0 110.305 -179.35 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' TRP . . . . . 0.585 ' CE3' ' HB1' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -139.77 121.65 15.53 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.932 -1.334 . . . . 0.0 109.877 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.717 ' C ' HD23 ' A' ' 30' ' ' LEU . 1.2 m-20 -121.38 143.12 49.39 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.969 ' O ' HD13 ' A' ' 21' ' ' LEU . 0.9 OUTLIER -113.25 162.46 15.99 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.781 -1.199 . . . . 0.0 109.439 -179.601 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -152.84 121.17 6.28 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.424 -0.797 . . . . 0.0 109.522 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.868 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.05 135.2 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.4 -0.812 . . . . 0.0 109.675 179.638 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.49 -170.99 25.75 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.04 -4.58 25.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.249 -1.148 . . . . 0.0 109.505 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.484 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 16.0 m -74.11 -31.87 62.96 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.942 . . . . 0.0 109.625 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.868 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -67.68 89.46 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 O-C-N 121.132 -0.98 . . . . 0.0 109.364 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 30.4 m -59.74 -28.69 67.58 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.199 -0.938 . . . . 0.0 108.713 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.687 ' O ' HG13 ' A' ' 36' ' ' VAL . 6.5 m-20 -130.88 130.4 22.83 Favored Pre-proline 0 C--N 1.296 -1.753 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.21 123.11 6.46 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.189 1.926 . . . . 0.0 110.55 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.586 ' HG2' ' CZ ' ' A' ' 42' ' ' PHE . 35.4 Cg_endo -77.46 -165.74 0.35 Allowed 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.366 2.044 . . . . 0.0 110.013 179.695 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.55 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 53.7 t -116.73 121.43 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.116 -0.99 . . . . 0.0 110.458 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.631 ' CE2' HD23 ' A' ' 21' ' ' LEU . 28.0 m-85 -105.11 112.38 25.49 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.529 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 29.2 tt0 -154.56 159.32 40.83 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.194 -0.941 . . . . 0.0 109.857 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.522 ' CG1' ' HA ' ' A' ' 15' ' ' ALA . 89.1 t -95.2 140.59 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.476 -0.765 . . . . 0.0 109.017 179.277 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.435 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.4 OUTLIER -119.38 120.51 37.12 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.327 -0.858 . . . . 0.0 109.793 -179.32 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -77.35 109.83 11.58 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 121.54 0.686 . . . . 0.0 109.152 179.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.7 p -128.64 129.89 46.49 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.606 -0.684 . . . . 0.0 109.527 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.2 m -72.41 -12.56 61.16 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.239 -0.913 . . . . 0.0 109.397 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.41 ' O ' ' C ' ' A' ' 50' ' ' ALA . 49.7 m-20 -98.4 2.08 47.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.214 -0.929 . . . . 0.0 109.612 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.529 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -44.31 155.18 0.37 Allowed Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.103 -0.998 . . . . 0.0 109.443 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.533 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.9 Cg_endo -77.91 -35.97 1.25 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.599 2.199 . . . . 0.0 110.335 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.438 ' O ' ' OE1' ' A' ' 11' ' ' GLU . 4.9 tt0 -121.28 97.01 5.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.268 -0.895 . . . . 0.0 109.35 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.8 -115.16 4.07 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.529 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 2.6 m120 -156.63 35.64 0.31 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.226 -1.161 . . . . 0.0 109.405 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.487 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 33.0 mttm -145.5 131.1 18.85 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -0.899 . . . . 0.0 109.505 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.662 HG12 ' OD2' ' A' ' 160' ' ' ASP . 3.9 m -139.72 175.36 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.381 -0.825 . . . . 0.0 109.326 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.723 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -101.79 100.46 10.81 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.063 -1.023 . . . . 0.0 108.776 179.306 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.584 ' HB1' ' CE2' ' A' ' 158' ' ' TYR . . . -81.33 118.21 22.46 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.068 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.837 ' O ' HG23 ' A' ' 156' ' ' THR . 49.3 t -114.9 144.61 22.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.113 -0.992 . . . . 0.0 109.17 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.818 HG22 HD22 ' A' ' 62' ' ' ASN . 31.9 m -107.12 93.64 4.66 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.706 HG21 ' CD1' ' A' ' 157' ' ' ILE . 59.9 t -87.93 123.47 40.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.253 -0.905 . . . . 0.0 109.334 -179.69 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.818 HD22 HG22 ' A' ' 60' ' ' THR . 6.3 p30 -160.11 60.34 0.35 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.379 -0.825 . . . . 0.0 109.77 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 156.38 89.24 0.07 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.798 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.4 m -81.06 -177.14 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.218 -1.166 . . . . 0.0 109.674 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.484 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -130.99 -161.61 10.34 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -95.99 12.54 30.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -1.119 . . . . 0.0 109.545 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.514 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.9 m-80 -128.33 148.35 67.52 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.194 -0.941 . . . . 0.0 109.508 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.495 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.2 Cg_endo -78.25 11.88 2.24 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.63 2.22 . . . . 0.0 110.963 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.514 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -136.36 58.33 1.74 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.113 -0.992 . . . . 0.0 109.623 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.484 ' CB ' HG23 ' A' ' 36' ' ' VAL . 0.7 OUTLIER -83.11 -69.18 0.65 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.204 -0.935 . . . . 0.0 109.248 179.825 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.541 HG13 ' CG2' ' A' ' 36' ' ' VAL . 4.1 mt -105.94 121.76 58.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.277 -0.89 . . . . 0.0 108.979 179.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -130.17 132.89 46.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.098 -1.001 . . . . 0.0 110.224 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.592 ' CB ' HD22 ' A' ' 30' ' ' LEU . . . -121.82 108.47 13.51 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.559 HG22 ' N ' ' A' ' 75' ' ' ALA . 98.3 m -100.2 165.0 11.71 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.386 -0.821 . . . . 0.0 110.006 -179.029 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.559 ' N ' HG22 ' A' ' 74' ' ' THR . . . -118.92 136.42 54.08 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.022 -1.049 . . . . 0.0 108.768 178.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.556 ' CE2' ' OD1' ' A' ' 29' ' ' ASP . 10.1 p90 179.44 160.44 0.76 Allowed Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.585 -0.697 . . . . 0.0 109.276 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.532 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.9 Cg_endo -81.67 164.96 74.89 Favored 'Cis proline' 0 C--N 1.31 -1.465 0 C-N-CA 123.782 -1.341 . . . . 0.0 110.801 -0.495 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 89.1 t -126.81 156.14 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.344 -0.848 . . . . 0.0 109.107 179.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ASN . . . . . 0.922 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 4.3 m-80 -112.43 145.79 39.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.075 -1.016 . . . . 0.0 109.666 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.581 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 1.1 m -153.32 -173.85 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.174 -0.954 . . . . 0.0 109.467 179.749 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.763 ' O ' HG21 ' A' ' 134' ' ' VAL . 20.5 mtt180 -136.21 146.01 54.5 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.288 -0.883 . . . . 0.0 109.352 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.492 ' HB3' ' HB3' ' A' ' 137' ' ' GLN . 35.6 Cg_endo -77.82 112.09 3.23 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.511 2.141 . . . . 0.0 110.463 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 100.44 -22.97 37.59 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.601 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -84.12 149.65 4.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.191 -1.182 . . . . 0.0 109.482 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.3 m -92.42 140.48 29.53 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' TYR . . . . . 0.601 ' CE1' HG12 ' A' ' 84' ' ' VAL . 18.3 m-85 -123.05 164.88 17.75 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.25 -0.906 . . . . 0.0 109.578 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.47 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 6.1 m -118.35 154.31 32.57 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.398 -0.814 . . . . 0.0 109.51 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.692 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.7 t80 -126.87 120.1 28.4 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.145 -0.972 . . . . 0.0 109.38 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.487 ' O ' ' O ' ' A' ' 161' ' ' GLY . 32.3 m -134.53 142.79 47.11 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.244 -0.91 . . . . 0.0 109.11 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.796 HD13 ' CD2' ' A' ' 103' ' ' PHE . 19.8 tt -150.9 163.45 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.603 -1.311 . . . . 0.0 109.628 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.533 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 20.3 m95 -132.14 128.62 38.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.976 -1.078 . . . . 0.0 109.385 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -119.53 148.13 43.65 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.222 -0.924 . . . . 0.0 109.582 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.586 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 8.3 ttp180 -161.02 120.22 2.58 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.162 -0.961 . . . . 0.0 109.15 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.481 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -107.07 161.7 14.52 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 110.02 -179.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -61.06 -51.18 70.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.377 -0.827 . . . . 0.0 109.319 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.485 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -108.45 137.74 45.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.339 -0.85 . . . . 0.0 109.355 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.582 ' N ' ' CG2' ' A' ' 123' ' ' THR . 5.1 p30 -63.08 146.85 52.36 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.273 -0.892 . . . . 0.0 109.559 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 109.06 38.66 1.8 Allowed Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -119.15 141.36 48.9 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.234 -1.157 . . . . 0.0 109.063 179.601 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.427 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 54.9 t -116.78 149.88 18.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.277 -0.889 . . . . 0.0 110.636 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.722 HG13 ' CE2' ' A' ' 147' ' ' PHE . 51.9 t -151.14 164.71 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.538 -0.726 . . . . 0.0 109.051 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.526 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 3.8 t -127.92 138.05 52.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.989 -1.07 . . . . 0.0 109.687 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.796 ' CD2' HD13 ' A' ' 90' ' ' ILE . 1.0 OUTLIER -130.6 103.86 6.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.086 -1.009 . . . . 0.0 109.807 -179.969 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.509 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 11.6 p -119.43 164.86 15.11 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.091 -1.005 . . . . 0.0 110.064 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.623 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -125.67 152.55 32.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.69 -0.631 . . . . 0.0 109.998 -179.734 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.469 ' O ' ' HG2' ' A' ' 142' ' ' ARG . . . 176.46 147.71 6.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.214 -1.555 . . . . 0.0 109.214 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.3 p30 -90.3 -169.59 2.46 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.018 -1.283 . . . . 0.0 109.51 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . 0.518 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 4.1 mp0 -71.1 8.0 1.08 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.184 -0.947 . . . . 0.0 111.245 -179.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.455 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 3.7 t -110.52 10.27 23.14 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.712 -1.243 . . . . 0.0 109.215 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.538 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 3.2 m-30 71.87 6.08 5.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.412 -0.805 . . . . 0.0 109.689 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -78.89 95.12 5.34 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 108.672 179.399 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . 0.524 ' CG ' ' O ' ' A' ' 105' ' ' VAL . 1.3 tt0 -83.47 139.69 32.78 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.278 -0.889 . . . . 0.0 110.259 -179.099 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.523 ' CE2' HG21 ' A' ' 141' ' ' ILE . 3.9 m-85 -102.78 -69.88 0.78 Allowed 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.601 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -85.77 166.17 39.11 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.021 -1.632 . . . . 0.0 109.021 179.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.473 ' C ' HD23 ' A' ' 116' ' ' LEU . 1.2 tpp180 -164.42 109.65 0.99 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.948 -1.325 . . . . 0.0 110.326 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.771 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -142.53 69.88 1.32 Allowed 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.061 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' HIS . . . . . 0.546 ' O ' ' CD2' ' A' ' 117' ' ' HIS . 0.5 OUTLIER -99.11 152.56 19.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.335 -0.853 . . . . 0.0 110.149 -179.31 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.542 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.3 tt0 79.33 68.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -0.787 . . . . 0.0 109.706 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.431 ' HG2' ' C ' ' A' ' 118' ' ' GLU . 1.1 mm-40 -133.42 130.96 39.4 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.293 -0.879 . . . . 0.0 109.475 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.724 ' O ' HD13 ' A' ' 121' ' ' ILE . 4.8 mt-30 -67.66 153.81 42.88 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.327 -0.858 . . . . 0.0 109.006 179.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.724 HD13 ' O ' ' A' ' 120' ' ' GLN . 8.1 mm -134.8 135.73 52.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.094 -1.003 . . . . 0.0 110.089 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.32 -179.16 6.91 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.637 0.732 . . . . 0.0 110.067 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.582 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 47.2 p -76.37 -2.48 32.01 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.416 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.412 ' C ' ' HG3' ' A' ' 93' ' ' ARG . 3.9 mm-40 -107.67 -169.0 1.45 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.361 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' TRP . . . . . 0.586 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 97.1 m95 -95.83 122.6 38.79 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.201 -0.937 . . . . 0.0 109.604 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -106.93 121.39 45.03 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.272 -0.892 . . . . 0.0 108.941 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -80.1 109.48 2.37 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.451 2.1 . . . . 0.0 110.895 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -114.34 136.64 52.76 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.7 t -151.27 175.85 11.8 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 120.685 -1.259 . . . . 0.0 111.152 -179.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.771 ' CE2' HD21 ' A' ' 116' ' ' LEU . 37.7 p90 -173.41 -172.61 0.81 Allowed 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.819 -1.082 . . . . 0.0 109.221 179.22 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -127.95 156.96 41.83 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.075 -1.016 . . . . 0.0 110.009 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.596 ' CZ ' ' HB2' ' A' ' 86' ' ' TYR . 11.1 p90 -161.23 168.06 24.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.391 -0.818 . . . . 0.0 109.191 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.92 146.2 38.91 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.145 -0.972 . . . . 0.0 109.224 -179.761 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.763 HG21 ' O ' ' A' ' 81' ' ' ARG . 2.2 t -62.38 112.95 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.257 -0.902 . . . . 0.0 109.392 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 5.8 t -86.51 -40.48 15.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.401 -0.812 . . . . 0.0 109.85 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.56 ' O ' ' CB ' ' A' ' 137' ' ' GLN . 17.5 t70 -87.63 -16.22 35.06 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.445 -0.784 . . . . 0.0 109.432 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . 0.674 ' H ' HG12 ' A' ' 134' ' ' VAL . 2.3 mt-30 86.97 27.28 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -178.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.513 ' HG3' ' ND2' ' A' ' 107' ' ' ASN . 12.5 mm-40 -68.94 122.44 18.65 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.609 -0.682 . . . . 0.0 109.732 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 5.8 p -79.12 -6.97 57.74 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 42.4 t -138.14 138.38 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.364 -0.835 . . . . 0.0 108.824 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.564 HD11 HD13 ' A' ' 164' ' ' ILE . 0.6 OUTLIER -143.27 172.23 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.121 -0.987 . . . . 0.0 109.904 -179.705 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' ARG . . . . . 0.49 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.2 ptm180 -146.76 132.52 18.95 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.463 -0.773 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ALA . . . . . 0.748 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -99.66 106.95 43.29 Favored Pre-proline 0 C--N 1.303 -1.421 0 O-C-N 121.21 -0.931 . . . . 0.0 109.879 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.54 ' C ' HD13 ' A' ' 145' ' ' ILE . 34.9 Cg_endo -76.79 110.74 3.1 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.113 1.875 . . . . 0.0 110.688 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.72 HD13 ' N ' ' A' ' 145' ' ' ILE . 2.0 mm -91.25 140.15 16.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 178.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' HIS . . . . . 0.54 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 5.9 m80 -107.7 157.86 17.76 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.542 -1.349 . . . . 0.0 111.897 -177.46 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.722 ' CE2' HG13 ' A' ' 101' ' ' VAL . 30.6 m-85 -158.12 160.98 37.88 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 179.013 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.496 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 116.77 40.79 0.75 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.798 ' C ' HG11 ' A' ' 64' ' ' VAL . 15.1 m-85 -122.08 159.37 27.23 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.381 -1.07 . . . . 0.0 109.311 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.527 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.21 -26.71 67.51 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -69.91 -15.28 63.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.436 -0.79 . . . . 0.0 109.269 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.52 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.3 OUTLIER -110.85 8.31 22.22 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 179.366 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.626 HG23 HG13 ' A' ' 64' ' ' VAL . 2.3 t -83.33 162.57 3.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 121.424 -0.797 . . . . 0.0 109.7 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' GLY . . . . . 0.455 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 50.63 33.47 26.37 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 1.8 m-20 -160.18 139.44 10.88 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.258 -1.143 . . . . 0.0 109.976 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' THR . . . . . 0.837 HG23 ' O ' ' A' ' 59' ' ' VAL . 97.7 m -89.32 128.04 35.85 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.205 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.706 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.4 mt -108.96 118.83 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.873 -1.142 . . . . 0.0 109.969 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.584 ' CE2' ' HB1' ' A' ' 58' ' ' ALA . 8.7 m-85 -100.55 137.77 38.51 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 178.561 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.669 HD11 ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -129.34 141.64 46.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 120.777 -1.202 . . . . 0.0 110.381 -178.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' ASP . . . . . 0.662 ' OD2' HG12 ' A' ' 56' ' ' VAL . 49.7 t0 -173.82 136.01 0.53 Allowed 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . 0.533 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 127.13 -9.02 7.08 Favored Glycine 0 N--CA 1.485 1.915 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.258 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.748 HD21 ' HB3' ' A' ' 143' ' ' ALA . 1.2 tp -59.43 91.29 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.811 -1.405 . . . . 0.0 108.583 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . 0.459 ' N ' ' O ' ' A' ' 161' ' ' GLY . . . -131.06 146.03 52.23 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.605 -0.685 . . . . 0.0 109.86 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.716 ' O ' HG22 ' A' ' 3' ' ' VAL . 23.4 mt -126.16 131.47 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.325 -0.86 . . . . 0.0 109.217 179.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.846 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.202 -0.936 . . . . 0.0 109.677 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.652 HG22 ' O ' ' A' ' 164' ' ' ILE . 4.6 p . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.597 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -63.09 -53.78 48.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.107 -0.996 . . . . 0.0 109.732 -179.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.532 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 3.9 t-20 -84.09 149.86 25.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.293 -0.879 . . . . 0.0 109.7 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.476 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 3.7 mt -128.13 129.79 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.358 -0.839 . . . . 0.0 109.157 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.565 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 1.5 m120 65.84 35.1 6.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.203 -0.936 . . . . 0.0 109.59 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -44.99 -25.73 1.04 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.454 ' HA3' ' OD2' ' A' ' 160' ' ' ASP . . . -145.82 44.93 0.83 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.902 ' CD2' HG11 ' A' ' 25' ' ' VAL . 4.2 m-85 61.32 51.65 4.16 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.167 -1.196 . . . . 0.0 109.443 179.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.445 ' OE2' ' OD2' ' A' ' 160' ' ' ASP . 62.0 mm-40 -84.34 -27.61 27.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.136 -0.977 . . . . 0.0 109.79 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.504 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 7.9 t -99.75 -13.65 19.19 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.178 -0.951 . . . . 0.0 110.149 -179.361 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 1.048 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.2 m -100.25 133.39 21.49 Favored Pre-proline 0 N--CA 1.489 1.475 0 O-C-N 121.052 -1.03 . . . . 0.0 109.423 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.476 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.5 Cg_endo -77.3 148.37 26.82 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 122.522 2.148 . . . . 0.0 110.84 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.476 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -42.11 166.0 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 121.317 0.579 . . . . 0.0 109.773 179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.09 132.54 3.01 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.526 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -56.55 144.63 8.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.268 -1.136 . . . . 0.0 109.218 -179.367 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.515 HG13 ' HA3' ' A' ' 24' ' ' GLY . 47.7 t -85.12 144.51 9.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.687 0.756 . . . . 0.0 110.043 -179.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.9 p -106.59 -23.77 12.36 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.458 ' O ' ' N ' ' A' ' 24' ' ' GLY . 0.4 OUTLIER -145.99 88.21 1.8 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.478 -0.764 . . . . 0.0 108.966 179.759 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.911 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -43.46 -32.08 0.82 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 109.624 -179.464 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.906 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -65.42 -49.09 70.49 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.351 -0.843 . . . . 0.0 109.456 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -125.51 43.78 2.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.434 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.515 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -91.86 -66.7 1.13 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 1.048 HG13 ' OG1' ' A' ' 13' ' ' THR . 41.3 t -120.63 128.66 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.207 -1.172 . . . . 0.0 109.618 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.451 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 13.7 tt0 -67.25 139.38 57.33 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.879 . . . . 0.0 109.606 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.565 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 109.29 -33.78 5.91 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' TRP . . . . . 0.67 ' CZ3' HD12 ' A' ' 159' ' ' ILE . 1.2 m95 -140.5 119.98 13.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.191 -1.182 . . . . 0.0 109.454 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.522 ' C ' HD23 ' A' ' 30' ' ' LEU . 11.0 m-20 -115.98 144.17 44.45 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.133 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.911 ' O ' HD13 ' A' ' 21' ' ' LEU . 2.1 mt -118.95 168.03 11.18 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.723 -1.235 . . . . 0.0 109.603 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 70.5 m-20 -160.09 123.75 3.61 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.382 -0.824 . . . . 0.0 109.575 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.801 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -106.47 136.56 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.337 -0.852 . . . . 0.0 109.743 179.678 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.69 176.16 24.86 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.4 t -58.98 -15.65 14.14 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.18 -1.188 . . . . 0.0 109.418 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.466 ' HB2' ' OD1' ' A' ' 70' ' ' ASP . 7.9 p -63.81 -37.17 86.39 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.243 -0.91 . . . . 0.0 109.636 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.823 HG23 ' HB3' ' A' ' 70' ' ' ASP . 2.1 t -67.35 88.55 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 O-C-N 121.144 -0.973 . . . . 0.0 109.194 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 50.1 m -63.41 -28.64 70.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.326 -0.859 . . . . 0.0 108.997 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.673 ' O ' HG13 ' A' ' 36' ' ' VAL . 0.5 OUTLIER -120.92 130.1 25.0 Favored Pre-proline 0 C--N 1.296 -1.721 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.755 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -76.51 121.83 6.19 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.188 1.926 . . . . 0.0 110.524 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.593 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.4 Cg_endo -77.44 -169.93 0.84 Allowed 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.443 2.096 . . . . 0.0 109.865 179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.521 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 53.2 t -114.53 119.4 61.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.092 -1.005 . . . . 0.0 110.586 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.593 ' CE1' ' HG2' ' A' ' 40' ' ' PRO . 2.9 m-85 -104.35 112.34 25.34 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 178.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.526 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 0.0 OUTLIER -157.9 148.58 20.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.052 -1.03 . . . . 0.0 109.962 -179.354 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.584 HG22 ' CE2' ' A' ' 10' ' ' PHE . 2.0 t -92.55 148.68 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.379 -0.825 . . . . 0.0 109.398 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.555 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -133.43 147.45 51.72 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.284 -0.885 . . . . 0.0 108.713 179.931 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.555 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 15.3 pt-20 -121.17 120.41 35.16 Favored 'General case' 0 C--N 1.296 -1.758 0 O-C-N 121.526 -0.734 . . . . 0.0 109.296 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.487 ' CG2' HD21 ' A' ' 45' ' ' LEU . 1.5 p -144.0 -175.97 4.81 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.44 -0.787 . . . . 0.0 109.483 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -101.02 22.4 12.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.908 . . . . 0.0 109.433 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.7 -14.33 12.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.913 . . . . 0.0 109.481 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.721 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -56.45 144.53 62.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.18 -0.95 . . . . 0.0 109.327 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.555 ' HG3' ' CB ' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -78.44 -42.1 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.617 2.211 . . . . 0.0 110.388 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.406 ' O ' ' OE1' ' A' ' 11' ' ' GLU . 40.6 mm-40 -105.43 97.22 7.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.246 -0.909 . . . . 0.0 109.382 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.48 -117.75 4.71 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.721 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 13.5 p30 -160.09 38.62 0.18 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.226 -1.161 . . . . 0.0 109.542 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.482 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 92.0 mttt -144.84 139.04 27.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.143 -0.973 . . . . 0.0 109.655 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.636 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.3 m -150.13 174.54 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.3 -0.875 . . . . 0.0 109.372 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.616 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -99.92 102.22 13.55 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.161 -0.962 . . . . 0.0 108.943 179.61 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.649 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -82.04 122.85 28.34 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 178.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.833 ' O ' HG23 ' A' ' 156' ' ' THR . 47.0 t -117.4 144.18 25.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.135 -0.978 . . . . 0.0 109.304 -179.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.822 HG22 ' ND2' ' A' ' 62' ' ' ASN . 55.3 m -108.6 87.87 2.59 Favored 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.304 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.657 HG21 ' CD1' ' A' ' 157' ' ' ILE . 72.6 t -85.85 125.43 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.23 -0.919 . . . . 0.0 109.308 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.822 ' ND2' HG22 ' A' ' 60' ' ' THR . 3.8 p30 -160.08 55.42 0.35 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.383 -0.823 . . . . 0.0 109.733 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 162.7 89.91 0.07 OUTLIER Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.892 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.8 m -81.84 -171.32 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -1.14 . . . . 0.0 109.642 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -138.81 -163.27 9.46 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -78.29 -10.65 59.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -1.135 . . . . 0.0 109.499 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.553 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 1.3 m120 -111.08 145.33 32.23 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.171 -0.956 . . . . 0.0 109.426 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.505 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.5 Cg_endo -78.99 13.6 1.93 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.599 2.199 . . . . 0.0 110.997 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.553 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 3.5 p90 -136.33 51.76 2.0 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.031 -1.043 . . . . 0.0 109.759 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.823 ' HB3' HG23 ' A' ' 36' ' ' VAL . 0.6 OUTLIER -75.89 -50.24 15.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 109.215 179.685 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.686 HD12 ' HB2' ' A' ' 70' ' ' ASP . 4.6 mp -102.2 119.95 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.399 -0.813 . . . . 0.0 109.174 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.45 128.96 50.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.06 -1.025 . . . . 0.0 109.882 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.61 ' HB3' ' CE1' ' A' ' 147' ' ' PHE . . . -130.11 108.3 9.96 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.338 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.566 HG22 ' N ' ' A' ' 75' ' ' ALA . 75.5 m -103.93 165.26 11.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.545 -0.722 . . . . 0.0 110.018 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.566 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.01 137.14 53.73 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.055 -1.028 . . . . 0.0 108.882 178.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.561 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.7 p90 -174.46 163.57 2.65 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.497 -0.752 . . . . 0.0 109.256 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.561 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.4 Cg_endo -83.97 170.6 50.85 Favored 'Cis proline' 0 C--N 1.312 -1.372 0 C-N-CA 124.002 -1.249 . . . . 0.0 110.907 -0.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.953 HG11 HD13 ' A' ' 164' ' ' ILE . 85.2 t -130.25 156.27 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ASN . . . . . 0.526 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 1.9 m120 -121.21 132.02 54.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.09 -1.006 . . . . 0.0 109.929 -179.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.555 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.9 m -140.71 -174.07 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.169 -0.957 . . . . 0.0 109.644 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.745 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.3 OUTLIER -136.85 144.74 47.93 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 109.266 179.872 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.472 ' HD2' ' HG2' ' A' ' 81' ' ' ARG . 35.6 Cg_endo -77.12 110.48 3.03 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.426 2.084 . . . . 0.0 110.581 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 111.2 -34.98 5.01 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.551 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -84.75 149.78 4.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.146 -1.208 . . . . 0.0 109.433 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 17.8 m -94.58 141.65 28.36 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' TYR . . . . . 0.555 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 8.5 m-85 -119.89 170.91 8.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 4.1 m -118.07 153.9 32.96 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.274 -0.891 . . . . 0.0 109.29 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.763 ' CE1' HD11 ' A' ' 116' ' ' LEU . 5.3 t80 -134.13 120.3 19.95 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.222 -0.924 . . . . 0.0 109.532 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.487 ' O ' ' O ' ' A' ' 161' ' ' GLY . 15.7 m -135.66 147.37 48.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.233 -0.917 . . . . 0.0 109.03 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.662 HD12 ' CA ' ' A' ' 162' ' ' LEU . 2.2 tt -151.21 163.61 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.966 -1.084 . . . . 0.0 109.219 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.555 ' CB ' ' HG3' ' A' ' 51' ' ' PRO . 19.3 m95 -131.02 125.17 32.56 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.894 -1.129 . . . . 0.0 109.574 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.581 ' HB2' ' CZ ' ' A' ' 103' ' ' PHE . . . -115.06 150.46 35.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.303 -0.873 . . . . 0.0 109.367 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.595 ' HB3' ' CZ3' ' A' ' 125' ' ' TRP . 5.3 ttp85 -164.57 121.86 1.64 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.111 -0.993 . . . . 0.0 109.51 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -102.84 170.1 8.2 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.158 -0.964 . . . . 0.0 109.764 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . 0.571 ' OE1' ' CE1' ' A' ' 158' ' ' TYR . 0.4 OUTLIER -67.16 -59.16 3.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.417 -0.802 . . . . 0.0 109.378 -179.939 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.482 ' C ' HG22 ' A' ' 123' ' ' THR . 0.8 OUTLIER -109.97 141.9 42.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.358 -0.839 . . . . 0.0 109.29 179.945 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.654 ' N ' HG22 ' A' ' 123' ' ' THR . 0.3 OUTLIER -58.16 144.79 39.33 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.206 -0.934 . . . . 0.0 109.206 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 118.17 31.94 1.47 Allowed Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -123.07 136.95 55.02 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.17 -1.194 . . . . 0.0 108.962 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.526 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 53.0 t -111.61 146.63 16.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 O-C-N 121.184 -0.947 . . . . 0.0 110.624 -179.342 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.904 HG21 HG21 ' A' ' 157' ' ' ILE . 89.0 t -155.83 149.88 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.481 -0.762 . . . . 0.0 109.5 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.518 ' CB ' ' HG2' ' A' ' 118' ' ' GLU . 19.5 m -125.29 138.6 54.09 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.202 -0.936 . . . . 0.0 109.69 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.625 ' N ' ' CD1' ' A' ' 103' ' ' PHE . 1.7 m-85 -120.25 103.22 9.06 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.966 -1.084 . . . . 0.0 109.088 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.504 HG22 ' HA ' ' A' ' 115' ' ' ARG . 11.4 p -117.04 171.05 8.17 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.235 -0.916 . . . . 0.0 110.02 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.729 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -120.94 164.16 17.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.623 -0.673 . . . . 0.0 110.428 -179.51 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.529 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -176.16 148.59 9.3 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.52 ' HB3' ' OH ' ' A' ' 113' ' ' TYR . 1.5 p30 -89.59 -169.64 2.55 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.208 -1.172 . . . . 0.0 109.112 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . 0.519 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 59.2 mt-30 -78.7 18.36 0.6 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.122 -0.986 . . . . 0.0 110.628 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 0.2 OUTLIER -113.4 11.61 18.55 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 120.828 -1.17 . . . . 0.0 109.182 179.624 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.505 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.8 m-30 74.22 11.83 4.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.38 -0.825 . . . . 0.0 109.461 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.529 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 54.3 mm-40 -92.23 164.04 13.69 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.181 -0.949 . . . . 0.0 109.027 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . 0.491 ' HA ' ' HA2' ' A' ' 106' ' ' GLY . 9.8 tt0 -127.96 142.77 51.15 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.204 -0.935 . . . . 0.0 109.572 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.52 ' OH ' ' HB3' ' A' ' 107' ' ' ASN . 79.1 m-85 -93.82 -75.88 0.49 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.25 -0.906 . . . . 0.0 108.883 179.484 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.573 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -113.99 170.6 13.38 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.504 ' HA ' HG22 ' A' ' 104' ' ' THR . 3.1 ptm180 -144.14 142.31 30.5 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -1.101 . . . . 0.0 109.012 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.763 HD11 ' CE1' ' A' ' 88' ' ' TYR . 0.0 OUTLIER -151.26 162.5 40.79 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.993 -1.067 . . . . 0.0 110.624 -179.169 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' HIS . . . . . 0.622 ' ND1' ' CE1' ' A' ' 103' ' ' PHE . 0.0 OUTLIER 69.96 -153.73 0.13 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.635 -0.666 . . . . 0.0 110.598 178.439 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.601 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.8 mt-10 97.95 28.36 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.489 ' O ' HG13 ' A' ' 100' ' ' VAL . 0.9 OUTLIER -134.44 -164.05 1.46 Allowed 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.463 -0.773 . . . . 0.0 109.731 -179.94 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.442 ' HA ' HG22 ' A' ' 100' ' ' VAL . 21.1 mt-30 -67.94 157.69 34.43 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.349 0.595 . . . . 0.0 110.018 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.585 ' CD1' ' NE2' ' A' ' 117' ' ' HIS . 4.9 mm -132.73 140.69 46.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.402 -0.811 . . . . 0.0 109.407 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -82.19 -179.53 7.44 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.439 -0.788 . . . . 0.0 110.412 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.654 HG22 ' N ' ' A' ' 97' ' ' ASP . 18.0 p -84.93 1.04 49.09 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 120.081 -0.648 . . . . 0.0 109.419 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.482 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 3.2 mt-10 -104.17 -169.79 1.68 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.242 -0.911 . . . . 0.0 109.428 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' TRP . . . . . 0.595 ' CZ3' ' HB3' ' A' ' 93' ' ' ARG . 92.0 m95 -98.12 122.77 41.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.304 -0.873 . . . . 0.0 109.533 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.89 121.11 45.94 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.18 -0.95 . . . . 0.0 109.045 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.32 110.45 2.48 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.466 2.111 . . . . 0.0 110.753 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.407 ' CD2' ' CE1' ' A' ' 117' ' ' HIS . 1.0 OUTLIER -115.99 134.69 54.7 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 179.235 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.443 ' OG1' ' OG1' ' A' ' 89' ' ' THR . 14.5 t -151.36 176.59 11.11 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 120.716 -1.24 . . . . 0.0 110.956 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.626 ' CE1' HD21 ' A' ' 116' ' ' LEU . 6.9 p90 -178.37 165.39 1.79 Allowed 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.004 -0.998 . . . . 0.0 108.987 179.498 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -102.91 138.92 39.16 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.123 -0.986 . . . . 0.0 109.965 -179.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.597 ' HB3' ' CE2' ' A' ' 130' ' ' PHE . 22.2 p90 -138.49 155.95 47.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.395 -0.815 . . . . 0.0 109.218 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -131.34 144.12 51.01 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.209 -0.932 . . . . 0.0 109.131 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.745 HG21 ' O ' ' A' ' 81' ' ' ARG . 3.7 t -47.69 110.27 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.364 -0.835 . . . . 0.0 109.177 179.658 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -60.56 -51.79 67.93 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.245 -0.91 . . . . 0.0 109.21 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 43.7 m-20 -108.09 -92.35 0.42 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.413 -0.804 . . . . 0.0 109.153 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -160.66 55.51 0.32 Allowed 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.468 -0.77 . . . . 0.0 109.041 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.508 ' O ' HG23 ' A' ' 80' ' ' VAL . 18.8 mm-40 -93.2 113.71 26.0 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.303 -0.873 . . . . 0.0 109.75 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.43 -15.7 57.38 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.2 t -134.57 130.25 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.479 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -140.48 172.33 11.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.27 -0.894 . . . . 0.0 110.116 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' ARG . . . . . 0.523 ' HB2' ' HB3' ' A' ' 76' ' ' PHE . 1.4 ptm180 -143.66 133.59 24.06 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ALA . . . . . 0.729 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.09 110.03 41.44 Favored Pre-proline 0 N--CA 1.486 1.369 0 O-C-N 121.319 -0.863 . . . . 0.0 109.76 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.516 ' HD2' ' HA ' ' A' ' 105' ' ' VAL . 36.0 Cg_endo -77.22 111.24 3.16 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.168 1.912 . . . . 0.0 111.169 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.689 HD13 ' N ' ' A' ' 145' ' ' ILE . 2.0 mm -90.68 139.34 17.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' HIS . . . . . 0.545 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 10.7 m80 -109.37 149.51 29.4 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.696 -1.253 . . . . 0.0 112.337 -177.102 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.648 ' CE2' HG13 ' A' ' 101' ' ' VAL . 2.6 m-85 -153.68 153.8 32.93 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 131.6 38.23 0.27 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.892 ' C ' HG11 ' A' ' 64' ' ' VAL . 77.2 m-85 -116.68 163.69 15.75 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.409 -1.054 . . . . 0.0 109.104 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.01 -27.25 67.27 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -73.02 -7.18 50.04 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.444 -0.785 . . . . 0.0 109.621 179.707 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.581 ' HB3' HD11 ' A' ' 157' ' ' ILE . 1.5 m-20 -107.08 9.06 30.55 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 179.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.413 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.5 t -87.98 158.69 3.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 O-C-N 121.418 -0.801 . . . . 0.0 109.618 -179.383 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' GLY . . . . . 0.413 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 53.13 35.78 50.31 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.461 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.2 m-20 -160.29 139.22 10.57 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.111 -1.229 . . . . 0.0 110.087 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' THR . . . . . 0.833 HG23 ' O ' ' A' ' 59' ' ' VAL . 73.6 m -92.09 122.39 34.55 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.123 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.904 HG21 HG21 ' A' ' 101' ' ' VAL . 1.4 mt -102.51 119.92 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.726 -1.234 . . . . 0.0 110.005 -178.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.713 ' CE1' HG22 ' A' ' 156' ' ' THR . 2.1 m-85 -100.11 142.17 31.96 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 178.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.67 HD12 ' CZ3' ' A' ' 28' ' ' TRP . 1.2 mt -133.22 138.29 51.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.788 -1.195 . . . . 0.0 110.162 -178.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' ASP . . . . . 0.636 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.8 OUTLIER -173.67 136.4 0.57 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.216 -0.928 . . . . 0.0 108.926 179.592 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 131.0 -3.85 5.64 Favored Glycine 0 N--CA 1.485 1.958 0 C-N-CA 119.407 -1.378 . . . . 0.0 110.324 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.662 ' CA ' HD12 ' A' ' 90' ' ' ILE . 0.1 OUTLIER -59.27 97.15 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.754 -1.439 . . . . 0.0 108.614 -179.928 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -131.54 145.44 51.73 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.348 -0.845 . . . . 0.0 109.778 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.953 HD13 HG11 ' A' ' 78' ' ' VAL . 7.5 mt -133.81 124.57 47.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.318 -0.864 . . . . 0.0 109.285 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.527 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.129 -0.982 . . . . 0.0 109.583 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.569 HG22 ' H ' ' A' ' 4' ' ' ALA . 4.2 p . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.735 ' HB3' ' O ' ' A' ' 164' ' ' ILE . . . -70.3 -57.9 4.35 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.234 -0.916 . . . . 0.0 109.539 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.471 ' HB3' ' HA ' ' A' ' 163' ' ' ALA . 0.7 OUTLIER -75.3 116.99 16.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.239 -0.913 . . . . 0.0 109.66 -179.753 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.625 HD12 ' O ' ' A' ' 4' ' ' ALA . 3.0 mp -103.89 140.88 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.35 -0.844 . . . . 0.0 109.068 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.508 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.7 OUTLIER 61.89 19.17 10.46 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.221 -0.924 . . . . 0.0 109.425 -179.804 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.488 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -61.54 -29.48 71.92 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.527 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -107.83 32.51 7.03 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 179.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.648 ' CD2' HG11 ' A' ' 25' ' ' VAL . 3.0 m-85 43.8 54.55 5.6 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.395 -1.062 . . . . 0.0 109.534 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -84.22 -36.89 22.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.16 -0.963 . . . . 0.0 109.68 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.465 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 18.6 m -84.01 -26.24 29.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.215 -0.928 . . . . 0.0 109.608 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.92 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.3 m -78.82 114.36 43.18 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.172 -0.955 . . . . 0.0 109.43 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.465 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.5 Cg_endo -77.86 142.68 20.19 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 C-N-CA 122.414 2.076 . . . . 0.0 110.61 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.71 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -40.11 161.43 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.885 -0.509 . . . . 0.0 109.709 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.82 132.99 3.23 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.024 -1.63 . . . . 0.0 109.024 -179.622 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.586 HG23 ' CD ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.94 138.45 17.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.3 -1.117 . . . . 0.0 109.325 -179.543 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.696 HG23 ' HA ' ' A' ' 43' ' ' GLU . 48.2 t -83.78 143.73 11.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-O 121.681 0.753 . . . . 0.0 110.096 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.9 p -94.84 -27.02 15.96 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.536 ' HB3' ' CG ' ' A' ' 23' ' ' GLU . 2.7 t0 -141.19 101.7 4.08 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 1.106 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -44.78 -30.13 0.91 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.178 -0.951 . . . . 0.0 109.751 -178.966 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.106 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -60.35 -53.34 58.77 Favored 'General case' 0 C--N 1.294 -1.842 0 O-C-N 121.6 -0.688 . . . . 0.0 109.678 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.536 ' CG ' ' HB3' ' A' ' 20' ' ' ASP . 1.8 pt-20 -102.15 31.52 3.92 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.249 -0.907 . . . . 0.0 109.409 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.52 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -71.14 -55.05 8.23 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.781 -1.327 . . . . 0.0 109.781 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.92 HG13 ' OG1' ' A' ' 13' ' ' THR . 2.8 t -121.53 143.1 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.16 -1.2 . . . . 0.0 109.663 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -67.49 -56.02 11.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.264 -0.897 . . . . 0.0 109.726 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.508 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -77.15 0.86 66.06 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' TRP . . . . . 0.658 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.7 OUTLIER -137.5 121.54 17.83 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.116 -1.226 . . . . 0.0 109.274 179.653 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.534 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -123.44 118.89 28.46 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.363 -0.836 . . . . 0.0 109.034 179.589 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.72 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -97.85 174.5 6.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.185 -0.947 . . . . 0.0 109.842 -179.477 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -160.39 122.92 3.29 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.364 -0.835 . . . . 0.0 109.567 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.856 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -110.73 135.03 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.168 -0.958 . . . . 0.0 109.651 179.418 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.49 178.38 21.74 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.3 t -58.6 -15.81 13.15 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.199 -1.177 . . . . 0.0 109.39 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.487 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 1.4 p -60.94 -38.1 84.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.648 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.856 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -59.9 89.41 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 O-C-N 121.084 -1.01 . . . . 0.0 109.414 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.409 ' N ' ' O ' ' A' ' 35' ' ' SER . 25.4 m -62.73 -28.97 70.32 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.264 -0.898 . . . . 0.0 108.674 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.706 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.8 t-20 -122.91 128.81 25.22 Favored Pre-proline 0 C--N 1.297 -1.688 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.453 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.1 Cg_endo -75.84 116.55 4.46 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.261 1.974 . . . . 0.0 110.729 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.509 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.3 Cg_endo -77.44 -176.26 3.11 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 C-N-CA 122.421 2.081 . . . . 0.0 109.77 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 55.5 t -113.26 119.68 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.046 -1.034 . . . . 0.0 110.682 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.591 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 3.7 m-85 -101.07 112.38 24.83 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.184 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.696 ' HA ' HG23 ' A' ' 18' ' ' VAL . 31.6 tt0 -154.08 158.8 41.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.069 -1.02 . . . . 0.0 110.038 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.441 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 58.9 t -99.5 148.21 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.506 -0.747 . . . . 0.0 109.106 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.502 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -123.35 122.1 37.47 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.295 -0.878 . . . . 0.0 109.787 -179.427 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.71 ' HG3' ' HB2' ' A' ' 15' ' ' ALA . 8.5 mt-10 -98.29 110.01 22.67 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.46 ' O ' ' HB3' ' A' ' 54' ' ' ASN . 3.1 p -142.53 -177.89 5.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.466 -0.771 . . . . 0.0 109.488 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.1 m -104.59 -5.24 21.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.306 -0.871 . . . . 0.0 109.558 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.403 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.9 m-20 -87.01 -16.56 35.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.174 -0.954 . . . . 0.0 109.444 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.403 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.33 149.74 0.71 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.234 -0.916 . . . . 0.0 109.376 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.459 ' HG3' ' HB2' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -77.93 -38.96 0.54 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.592 2.195 . . . . 0.0 110.409 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -121.23 121.28 37.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.295 -0.878 . . . . 0.0 109.397 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 63.93 -120.81 21.44 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.46 ' HB3' ' O ' ' A' ' 47' ' ' THR . 4.8 m120 -158.14 34.48 0.25 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -1.14 . . . . 0.0 109.503 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.524 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 5.4 mttp -140.2 142.17 35.89 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.298 -0.876 . . . . 0.0 109.584 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.54 HG12 ' OD2' ' A' ' 160' ' ' ASP . 4.6 m -149.22 174.85 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -0.899 . . . . 0.0 109.259 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.632 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -105.46 99.39 9.0 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.059 -1.026 . . . . 0.0 108.525 179.057 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.636 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.06 118.91 22.91 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.801 ' O ' HG23 ' A' ' 156' ' ' THR . 40.9 t -112.85 144.2 21.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.188 -0.945 . . . . 0.0 108.99 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.83 HG22 ' ND2' ' A' ' 62' ' ' ASN . 80.2 m -109.12 90.53 3.32 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.658 HG21 ' CD1' ' A' ' 157' ' ' ILE . 53.1 t -88.33 125.54 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.284 -0.885 . . . . 0.0 108.987 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.83 ' ND2' HG22 ' A' ' 60' ' ' THR . 3.6 p30 -159.23 61.15 0.4 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.34 -0.85 . . . . 0.0 109.802 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 144.36 93.9 0.17 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.727 HG12 ' C ' ' A' ' 148' ' ' GLY . 1.6 m -83.19 178.53 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.259 -1.142 . . . . 0.0 109.596 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.487 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -113.93 -154.47 11.21 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.4 m-20 -96.1 -10.12 29.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.317 -1.107 . . . . 0.0 109.491 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.597 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 4.8 m120 -109.8 151.47 42.36 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.309 -0.869 . . . . 0.0 109.381 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.43 12.53 2.09 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.693 2.262 . . . . 0.0 111.075 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.597 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.1 p90 -132.95 53.58 2.01 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.035 -1.041 . . . . 0.0 109.721 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.612 ' C ' HG23 ' A' ' 36' ' ' VAL . 0.3 OUTLIER -82.48 -69.32 0.63 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.21 -0.931 . . . . 0.0 109.057 179.763 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.491 ' HB ' ' HB3' ' A' ' 147' ' ' PHE . 6.1 mt -98.47 126.32 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.265 -0.897 . . . . 0.0 108.775 179.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -129.32 139.26 51.81 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.961 -1.087 . . . . 0.0 110.44 -179.358 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.72 ' HA ' HD23 ' A' ' 30' ' ' LEU . . . -122.49 143.12 49.91 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 178.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.521 HG22 ' N ' ' A' ' 75' ' ' ALA . 12.8 m -143.9 162.23 36.67 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.544 -1.348 . . . . 0.0 110.322 -178.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.521 ' N ' HG22 ' A' ' 74' ' ' THR . . . -123.93 136.18 54.17 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.48 -0.762 . . . . 0.0 109.142 179.191 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.539 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 1.3 p90 178.21 161.94 0.63 Allowed Pre-proline 0 N--CA 1.491 1.617 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.535 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -81.5 167.62 70.42 Favored 'Cis proline' 0 C--N 1.31 -1.491 0 C-N-CA 123.672 -1.387 . . . . 0.0 110.837 -0.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.654 HG11 HD12 ' A' ' 164' ' ' ILE . 62.2 t -124.07 150.04 28.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.263 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ASN . . . . . 0.522 ' O ' ' HB2' ' A' ' 4' ' ' ALA . 98.1 m-20 -117.29 108.85 16.12 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.0 -1.063 . . . . 0.0 110.075 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.572 HG23 ' O ' ' A' ' 138' ' ' GLU . 3.1 m -114.33 -173.85 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.209 -0.932 . . . . 0.0 109.479 179.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.704 ' O ' HG21 ' A' ' 134' ' ' VAL . 21.5 mmt180 -137.01 144.81 47.86 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.38 -0.825 . . . . 0.0 109.229 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -76.95 111.24 3.19 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.523 2.149 . . . . 0.0 110.47 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 109.13 -30.88 8.16 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.495 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -84.79 149.68 4.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.235 -1.156 . . . . 0.0 109.452 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.5 t -92.81 136.43 33.25 Favored 'General case' 0 C--N 1.292 -1.922 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' TYR . . . . . 0.495 ' CE1' HG12 ' A' ' 84' ' ' VAL . 20.3 m-85 -119.39 148.98 42.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.688 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.474 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 17.5 m -113.79 151.77 31.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.312 -0.867 . . . . 0.0 108.985 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.618 ' CD1' ' N ' ' A' ' 88' ' ' TYR . 0.1 OUTLIER -128.81 114.45 16.56 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.178 -0.952 . . . . 0.0 109.628 -179.775 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.484 ' O ' ' O ' ' A' ' 161' ' ' GLY . 41.2 m -118.87 149.29 41.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.351 -0.843 . . . . 0.0 108.971 179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.789 HD13 ' CD2' ' A' ' 103' ' ' PHE . 19.2 tt -150.75 163.51 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 120.821 -1.174 . . . . 0.0 109.755 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.498 ' CD1' ' C ' ' A' ' 90' ' ' ILE . 20.5 m95 -132.27 125.87 32.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.11 -0.994 . . . . 0.0 109.271 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -115.55 148.11 39.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.24 -0.913 . . . . 0.0 109.562 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.484 ' HD2' ' HA ' ' A' ' 124' ' ' GLU . 5.0 ttp180 -160.68 118.02 2.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.197 -0.939 . . . . 0.0 109.007 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.478 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -104.41 150.12 24.81 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.405 -0.809 . . . . 0.0 109.889 -179.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . 0.489 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 3.0 mt-10 -52.75 -38.98 61.75 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.451 -0.781 . . . . 0.0 109.263 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.493 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -119.57 137.48 53.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.342 -0.848 . . . . 0.0 109.378 179.978 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.577 ' N ' ' CG2' ' A' ' 123' ' ' THR . 0.5 OUTLIER -63.4 147.59 50.79 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.482 -179.847 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 106.97 38.28 2.19 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.773 -1.331 . . . . 0.0 109.773 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.468 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -121.64 140.11 52.68 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.175 -1.191 . . . . 0.0 109.101 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.461 ' HB ' ' OD1' ' A' ' 152' ' ' ASN . 51.3 t -116.75 158.23 17.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.318 -0.864 . . . . 0.0 110.759 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.784 HG22 ' CE1' ' A' ' 147' ' ' PHE . 59.3 t -154.56 163.36 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.536 ' HB3' ' HB2' ' A' ' 146' ' ' HIS . 34.2 t -118.8 123.06 43.85 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.921 -1.112 . . . . 0.0 109.797 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.789 ' CD2' HD13 ' A' ' 90' ' ' ILE . 2.3 m-85 -119.25 103.45 9.51 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.173 -0.955 . . . . 0.0 109.633 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.487 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 19.0 p -128.97 167.87 16.83 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.195 -0.941 . . . . 0.0 110.185 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.688 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -128.44 155.67 40.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.732 -0.605 . . . . 0.0 110.341 -179.726 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.53 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -175.68 160.81 29.32 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.548 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 0.9 OUTLIER -99.3 -170.26 1.88 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.125 -1.221 . . . . 0.0 109.418 -179.88 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . 0.548 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 22.1 mt-30 -71.87 8.73 1.1 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.06 -1.025 . . . . 0.0 111.185 -179.18 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.545 ' HB2' ' NE2' ' A' ' 111' ' ' GLN . 2.0 m -108.93 13.52 24.71 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 120.667 -1.271 . . . . 0.0 109.219 179.729 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.5 m-30 73.88 1.69 3.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.454 -0.779 . . . . 0.0 109.641 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.545 ' NE2' ' HB2' ' A' ' 109' ' ' SER . 0.7 OUTLIER -73.11 161.33 30.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.198 -0.939 . . . . 0.0 108.69 179.283 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . 0.491 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 3.6 tt0 -138.45 134.78 34.47 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.0 -1.063 . . . . 0.0 109.882 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.572 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 18.9 m-85 -94.8 -71.61 0.66 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.272 -0.893 . . . . 0.0 108.67 179.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.592 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -87.67 165.81 35.45 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 108.979 -1.648 . . . . 0.0 108.979 179.369 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.485 ' HA ' HG22 ' A' ' 104' ' ' THR . 50.9 ttt180 -160.94 110.55 1.67 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.997 -1.296 . . . . 0.0 110.474 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.832 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -144.97 69.97 1.26 Allowed 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 108.698 -0.852 . . . . 0.0 108.698 179.077 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' HIS . . . . . 0.534 ' CB ' ' OG ' ' A' ' 102' ' ' SER . 19.2 p80 -102.71 157.7 16.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 110.02 -179.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 1.3 tp10 77.98 44.34 0.08 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.388 -0.82 . . . . 0.0 109.403 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.463 ' OE1' ' HB2' ' A' ' 116' ' ' LEU . 0.9 OUTLIER -109.35 136.67 48.42 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.286 -0.884 . . . . 0.0 109.473 179.912 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.984 ' O ' HD13 ' A' ' 121' ' ' ILE . 18.9 mm-40 -73.85 155.92 38.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.445 -0.784 . . . . 0.0 109.029 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.984 HD13 ' O ' ' A' ' 120' ' ' GLN . 13.6 mm -134.38 135.81 53.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.081 -1.012 . . . . 0.0 110.071 -179.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.61 -179.06 6.25 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 121.638 0.732 . . . . 0.0 110.254 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.577 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 39.2 p -75.22 -0.63 20.1 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.386 179.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.484 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 6.4 mt-10 -110.91 -168.94 1.37 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.922 . . . . 0.0 109.238 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' TRP . . . . . 0.463 ' HA ' ' O ' ' A' ' 92' ' ' ALA . 94.1 m95 -94.39 124.89 38.69 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.159 -0.963 . . . . 0.0 109.565 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.418 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 2.1 tt0 -106.95 121.2 45.61 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.223 -0.923 . . . . 0.0 109.078 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.09 100.57 1.28 Allowed 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.4 2.067 . . . . 0.0 110.923 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -111.62 133.93 53.54 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.44 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.3 t -151.16 176.78 10.86 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 120.793 -1.192 . . . . 0.0 110.794 -179.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.832 ' CE1' HD21 ' A' ' 116' ' ' LEU . 6.3 p90 -166.74 165.8 16.19 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.123 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -118.85 138.89 52.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.129 -0.982 . . . . 0.0 109.891 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.572 ' CE2' ' O ' ' A' ' 113' ' ' TYR . 0.5 OUTLIER -154.77 157.73 38.41 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.375 -0.828 . . . . 0.0 109.128 179.729 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.447 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -121.09 147.66 45.23 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.232 -0.917 . . . . 0.0 109.551 -179.66 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.704 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.2 t -41.44 110.05 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.511 -0.743 . . . . 0.0 109.214 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 33.7 t -59.39 -50.64 73.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -0.872 . . . . 0.0 109.205 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -108.23 -91.7 0.43 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.382 -0.824 . . . . 0.0 109.189 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -163.23 54.74 0.18 Allowed 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.572 ' O ' HG23 ' A' ' 80' ' ' VAL . 40.4 mm-40 -91.33 111.55 23.09 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.293 -0.879 . . . . 0.0 109.944 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.35 -17.53 54.3 Favored 'General case' 0 N--CA 1.487 1.42 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.233 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.4 t -131.64 132.2 62.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.513 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -142.65 171.73 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.082 -1.011 . . . . 0.0 110.385 -179.416 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' ARG . . . . . 0.471 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.8 OUTLIER -141.9 132.77 25.83 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.806 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ALA . . . . . 0.688 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.15 111.45 50.22 Favored Pre-proline 0 C--N 1.304 -1.396 0 O-C-N 121.162 -0.961 . . . . 0.0 109.4 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.487 ' HD2' ' O ' ' A' ' 104' ' ' THR . 33.2 Cg_endo -74.69 111.95 3.44 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 C-N-CA 122.199 1.933 . . . . 0.0 110.764 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.658 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 2.1 mt -100.17 136.81 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 179.135 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' HIS . . . . . 0.536 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 5.9 m80 -105.72 160.37 15.27 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.525 -1.359 . . . . 0.0 111.105 -178.343 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.795 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 11.1 m-85 -159.74 162.2 34.88 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.727 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 107.01 38.91 2.07 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.641 ' C ' HG11 ' A' ' 64' ' ' VAL . 20.5 m-85 -113.42 158.09 21.09 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.489 -1.007 . . . . 0.0 109.287 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.38 -27.29 67.74 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.646 -0.659 . . . . 0.0 109.265 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.57 -15.13 62.74 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.45 -0.781 . . . . 0.0 109.187 179.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.525 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.2 OUTLIER -109.78 11.88 24.24 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.338 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.541 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.3 t -84.87 161.48 3.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.492 -0.755 . . . . 0.0 109.821 -179.296 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' GLY . . . . . 0.441 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 51.37 33.88 32.75 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.1 m-20 -160.4 141.84 12.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.22 -1.165 . . . . 0.0 110.226 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' THR . . . . . 0.801 HG23 ' O ' ' A' ' 59' ' ' VAL . 85.2 m -89.55 124.45 34.54 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.658 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.2 mt -105.02 116.32 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.855 -1.153 . . . . 0.0 110.055 -178.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.636 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 5.8 m-85 -98.91 139.85 33.96 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 178.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.795 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -132.16 139.34 50.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.739 -1.225 . . . . 0.0 110.228 -178.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' A' ' 161' ' ' GLY . 39.9 t0 -173.9 135.95 0.52 Allowed 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.368 -0.832 . . . . 0.0 108.876 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . 0.543 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 127.28 -9.77 6.96 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.41 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.488 ' O ' ' HA3' ' A' ' 8' ' ' GLY . 12.4 tp -59.81 109.13 0.86 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.712 -1.464 . . . . 0.0 108.642 -179.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . 0.479 ' O ' ' HA ' ' A' ' 88' ' ' TYR . . . -138.87 145.55 40.09 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.457 -0.777 . . . . 0.0 109.985 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.735 ' O ' ' HB3' ' A' ' 4' ' ' ALA . 16.5 mt -130.97 109.0 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.37 -0.831 . . . . 0.0 109.18 179.472 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.509 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.164 -0.96 . . . . 0.0 109.621 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.616 HG22 ' O ' ' A' ' 164' ' ' ILE . 4.4 p . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.311 -0.625 . . . . 0.0 109.311 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.759 ' HB3' ' O ' ' A' ' 164' ' ' ILE . . . -65.46 -43.75 89.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.092 -1.005 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.644 ' HB2' HD12 ' A' ' 164' ' ' ILE . 21.4 t-20 -85.87 130.94 34.41 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.278 -0.889 . . . . 0.0 109.338 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.42 ' O ' ' HB3' ' A' ' 7' ' ' ASN . 1.7 mp -127.62 126.61 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.223 -0.923 . . . . 0.0 109.613 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.527 ' HB3' ' CA ' ' A' ' 27' ' ' GLY . 0.6 OUTLIER 65.32 10.7 6.71 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.333 -0.854 . . . . 0.0 109.546 179.591 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.426 ' HA3' ' OD1' ' A' ' 5' ' ' ASN . . . -66.06 -33.24 84.86 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 179.412 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.529 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -91.32 16.14 59.58 Favored Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.604 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 13.2 m-85 61.28 40.27 14.62 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.337 -1.096 . . . . 0.0 109.439 179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -84.65 -43.38 14.44 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.838 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -78.71 -42.29 28.75 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.212 -0.93 . . . . 0.0 109.875 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.87 ' OG1' HG13 ' A' ' 25' ' ' VAL . 12.8 m -59.81 123.67 72.8 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.33 -0.856 . . . . 0.0 109.586 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.8 Cg_endo -77.87 137.42 15.83 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 122.439 2.092 . . . . 0.0 110.569 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.463 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -41.97 164.63 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.715 -0.616 . . . . 0.0 109.707 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 132.71 131.18 3.17 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 108.999 -1.64 . . . . 0.0 108.999 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.542 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -56.96 142.94 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.167 -1.196 . . . . 0.0 108.943 -179.71 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.468 HG13 ' HA2' ' A' ' 24' ' ' GLY . 54.1 t -90.64 142.47 12.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.456 -0.778 . . . . 0.0 110.386 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 33.3 p -93.03 -30.14 15.46 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 178.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.41 ' O ' ' C ' ' A' ' 21' ' ' LEU . 4.9 m-20 -133.39 99.53 4.55 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 1.098 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -44.13 -29.57 0.64 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.207 -0.933 . . . . 0.0 109.764 -178.567 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.098 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.8 -51.7 68.62 Favored 'General case' 0 C--N 1.294 -1.823 0 O-C-N 121.588 -0.695 . . . . 0.0 109.706 -179.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -101.86 31.05 4.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.2 -0.937 . . . . 0.0 109.384 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.468 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -74.1 -59.91 3.78 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.87 HG13 ' OG1' ' A' ' 13' ' ' THR . 3.5 t -120.56 137.91 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -1.135 . . . . 0.0 109.555 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -69.44 -42.31 75.14 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.305 -0.872 . . . . 0.0 109.587 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.527 ' CA ' ' HB3' ' A' ' 7' ' ' ASN . . . -76.91 -12.67 84.39 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' TRP . . . . . 1.049 ' CZ2' HD13 ' A' ' 145' ' ' ILE . 1.0 OUTLIER -132.44 123.73 27.23 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.19 -1.182 . . . . 0.0 109.754 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.461 ' OD1' ' CE2' ' A' ' 76' ' ' PHE . 1.8 m-20 -113.83 115.82 28.36 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 178.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.914 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -98.81 168.0 10.41 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.946 -1.096 . . . . 0.0 110.16 -178.581 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 72' ' ' GLU . 19.5 m120 -160.53 123.43 3.34 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.532 -0.73 . . . . 0.0 109.633 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.005 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -101.12 131.88 47.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.097 -1.002 . . . . 0.0 109.447 179.263 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.29 178.65 26.74 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.5 m -57.99 -16.75 13.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -1.133 . . . . 0.0 109.345 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.471 ' HB3' ' HB2' ' A' ' 67' ' ' ASN . 1.3 p -61.99 -38.55 89.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.442 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 1.005 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -63.78 89.67 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 O-C-N 121.221 -0.925 . . . . 0.0 109.455 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 45.2 m -71.23 -28.4 64.16 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.846 0.832 . . . . 0.0 108.84 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.656 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.3 m-20 -115.0 139.77 24.71 Favored Pre-proline 0 C--N 1.297 -1.702 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.484 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.4 Cg_endo -76.01 111.76 3.35 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.389 2.059 . . . . 0.0 110.816 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 38' ' ' ASN . 34.9 Cg_endo -77.57 179.61 6.35 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.46 2.106 . . . . 0.0 109.552 179.537 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.54 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 61.9 t -117.18 120.74 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.999 -1.063 . . . . 0.0 110.769 -179.576 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.485 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 90.6 m-85 -106.83 112.24 25.12 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 178.086 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.542 ' HG3' HG23 ' A' ' 17' ' ' VAL . 0.4 OUTLIER -150.28 148.26 28.65 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.976 -1.078 . . . . 0.0 110.237 -179.261 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.0 t -101.77 148.19 7.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.519 -0.738 . . . . 0.0 109.117 179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 1.077 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -150.54 164.32 36.27 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 179.85 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 1.077 ' N ' HD22 ' A' ' 45' ' ' LEU . 19.4 pt-20 -120.04 123.84 44.42 Favored 'General case' 0 C--N 1.291 -1.945 0 O-C-N 121.391 -0.818 . . . . 0.0 109.388 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.985 HG23 HD21 ' A' ' 45' ' ' LEU . 6.7 p -117.42 178.98 4.18 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 109.459 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -101.97 8.76 40.94 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.219 -0.926 . . . . 0.0 109.524 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.413 ' O ' ' C ' ' A' ' 50' ' ' ALA . 7.7 m-20 -125.25 8.72 7.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.178 -0.952 . . . . 0.0 109.572 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -43.9 148.78 0.72 Allowed Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.234 -0.916 . . . . 0.0 109.437 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.601 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -77.97 -40.16 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 122.642 2.228 . . . . 0.0 110.384 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -131.71 94.04 3.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.43 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 99.19 -124.29 8.18 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.493 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 76.6 m-20 -155.06 20.33 0.43 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.241 -1.153 . . . . 0.0 109.556 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 51.9 mttp -137.62 145.33 42.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.237 -0.914 . . . . 0.0 109.638 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.644 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.1 m -150.14 174.69 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.32 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.732 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -101.35 102.95 13.87 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 109.016 179.618 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.709 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.92 117.7 22.36 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.779 ' O ' HG23 ' A' ' 156' ' ' THR . 39.6 t -111.86 144.64 19.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.052 -1.03 . . . . 0.0 109.076 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.54 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 16.0 m -109.2 89.27 2.95 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.534 HG21 ' CD1' ' A' ' 157' ' ' ILE . 41.5 t -85.25 128.7 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.334 -0.854 . . . . 0.0 109.16 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -159.93 61.56 0.36 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.427 -0.795 . . . . 0.0 109.835 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 150.56 93.55 0.11 Allowed Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.69 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.4 m -79.86 -173.41 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.181 -1.188 . . . . 0.0 109.497 179.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -135.46 -162.02 9.52 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . 0.418 ' C ' ' OD1' ' A' ' 67' ' ' ASN . 23.0 t30 -89.82 10.28 24.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.213 -1.169 . . . . 0.0 109.453 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.594 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.0 m-20 -131.82 148.26 69.21 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.188 -0.945 . . . . 0.0 109.391 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.43 12.99 1.94 Allowed 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.568 2.179 . . . . 0.0 111.022 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.594 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.2 p90 -133.44 55.66 1.89 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.95 -1.094 . . . . 0.0 109.916 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.52 ' C ' HG23 ' A' ' 36' ' ' VAL . 0.3 OUTLIER -78.68 -68.31 0.66 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 108.862 179.535 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.412 ' HB ' ' HB2' ' A' ' 147' ' ' PHE . 2.8 mp -90.19 124.63 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.472 ' HB3' ' O ' ' A' ' 31' ' ' ASN . 1.6 tt0 -114.7 128.76 56.49 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.031 -1.043 . . . . 0.0 110.729 -179.137 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 1.083 ' HB3' ' CE1' ' A' ' 147' ' ' PHE . . . -131.43 107.67 9.07 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.558 HG22 ' N ' ' A' ' 75' ' ' ALA . 52.0 m -117.92 163.87 15.91 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.894 -1.129 . . . . 0.0 110.255 -178.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.558 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.19 137.26 53.75 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.234 -0.916 . . . . 0.0 109.214 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.54 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 0.6 OUTLIER 177.42 162.95 0.55 Allowed Pre-proline 0 N--CA 1.492 1.67 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -179.888 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.511 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.11 167.45 74.52 Favored 'Cis proline' 0 C--N 1.309 -1.52 0 C-N-CA 123.722 -1.366 . . . . 0.0 110.699 -0.242 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.541 ' CG1' ' HB1' ' A' ' 4' ' ' ALA . 69.5 t -125.37 151.04 30.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.396 -0.815 . . . . 0.0 108.819 179.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ASN . . . . . 0.593 ' O ' ' HB2' ' A' ' 4' ' ' ALA . 8.5 m-80 -117.15 113.24 21.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.077 -1.014 . . . . 0.0 109.933 -179.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.587 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.8 m -117.83 -176.24 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.192 -0.943 . . . . 0.0 109.449 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.722 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -134.91 144.97 52.7 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.319 -0.863 . . . . 0.0 109.236 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.474 ' HD2' ' HG3' ' A' ' 81' ' ' ARG . 34.8 Cg_endo -76.19 113.26 3.66 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.49 2.127 . . . . 0.0 110.553 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.6 -31.6 8.1 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.533 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -85.09 149.79 4.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.256 -1.144 . . . . 0.0 109.466 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 4.3 m -95.37 138.23 33.35 Favored 'General case' 0 C--N 1.292 -1.906 0 CA-C-O 121.296 0.57 . . . . 0.0 109.473 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' TYR . . . . . 0.587 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 12.2 m-85 -117.93 157.4 26.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -0.936 . . . . 0.0 109.616 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 40.1 m -118.1 149.48 40.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -0.879 . . . . 0.0 109.29 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.69 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 0.2 OUTLIER -125.97 107.98 10.97 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -0.891 . . . . 0.0 109.507 -179.884 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 161' ' ' GLY . 48.6 m -115.15 146.64 41.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.29 -0.882 . . . . 0.0 109.098 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.816 HD13 ' CD2' ' A' ' 103' ' ' PHE . 18.9 tt -150.48 163.32 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 120.884 -1.135 . . . . 0.0 109.465 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.601 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 21.0 m95 -131.37 127.1 36.87 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.971 -1.081 . . . . 0.0 109.526 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.47 146.96 41.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.364 -0.835 . . . . 0.0 109.316 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.501 ' HG3' ' CA ' ' A' ' 124' ' ' GLU . 28.2 ttt-85 -162.16 118.06 1.98 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.125 -0.985 . . . . 0.0 109.182 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.71 166.12 10.69 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.878 -179.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.0 mm-40 -59.46 -49.82 76.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.426 -0.796 . . . . 0.0 109.363 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.575 ' C ' HG22 ' A' ' 123' ' ' THR . 0.6 OUTLIER -112.35 148.38 34.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.335 -0.853 . . . . 0.0 109.252 179.879 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.778 ' N ' HG22 ' A' ' 123' ' ' THR . 2.1 t70 -68.81 163.14 24.87 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.205 -0.935 . . . . 0.0 109.487 -179.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.505 ' N ' ' OD1' ' A' ' 97' ' ' ASP . . . 93.42 39.5 5.03 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.905 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -119.02 142.59 47.68 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.278 -1.131 . . . . 0.0 109.044 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.443 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 54.3 t -118.87 149.69 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.205 -0.934 . . . . 0.0 110.909 -179.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.702 HG13 ' CE2' ' A' ' 147' ' ' PHE . 47.7 t -149.42 165.26 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.521 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 66.5 m -130.54 125.47 34.33 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.976 -1.077 . . . . 0.0 109.392 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.816 ' CD2' HD13 ' A' ' 90' ' ' ILE . 1.2 m-85 -122.38 104.18 9.23 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.235 -0.915 . . . . 0.0 110.095 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.541 HG22 ' CA ' ' A' ' 115' ' ' ARG . 17.4 p -121.67 163.49 18.92 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.113 -0.992 . . . . 0.0 109.87 179.437 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -112.62 118.0 56.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 C-N-CA 119.948 -0.701 . . . . 0.0 110.007 179.701 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -109.46 172.61 16.25 Favored Glycine 0 N--CA 1.487 2.086 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.552 ' CB ' ' O ' ' A' ' 111' ' ' GLN . 17.1 t30 -123.57 171.78 9.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.369 -1.077 . . . . 0.0 109.133 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . 0.411 ' N ' ' CG ' ' A' ' 107' ' ' ASN . 19.1 mt-30 -59.06 -48.17 82.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.972 -1.08 . . . . 0.0 109.675 -179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 2.8 m -83.36 17.96 1.95 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.239 -0.913 . . . . 0.0 110.12 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.548 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.8 m-30 81.14 8.58 1.08 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.479 -0.763 . . . . 0.0 110.189 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.552 ' O ' ' CB ' ' A' ' 107' ' ' ASN . 5.4 mm-40 -71.02 121.82 18.9 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.955 -1.091 . . . . 0.0 108.807 179.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -106.17 139.5 40.59 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.817 -1.177 . . . . 0.0 109.949 -179.328 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.574 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 4.6 m-85 -107.3 -65.53 1.09 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.589 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -104.74 179.29 24.25 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.052 -1.619 . . . . 0.0 109.052 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.541 ' CA ' HG22 ' A' ' 104' ' ' THR . 0.0 OUTLIER 175.35 119.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.917 -1.343 . . . . 0.0 110.398 179.959 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.897 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -140.84 70.01 1.35 Allowed 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.25 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' HIS . . . . . 0.544 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 17.7 p-80 -89.28 152.7 21.41 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.893 . . . . 0.0 110.129 -179.364 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 4.0 tt0 79.66 72.74 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.402 -0.811 . . . . 0.0 109.598 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.434 ' HG2' ' C ' ' A' ' 118' ' ' GLU . 14.0 mm-40 -134.67 130.18 35.94 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.357 -0.839 . . . . 0.0 109.45 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.696 ' O ' HD13 ' A' ' 121' ' ' ILE . 1.1 mp0 -66.41 152.66 44.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.269 -0.895 . . . . 0.0 109.013 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.696 HD13 ' O ' ' A' ' 120' ' ' GLN . 9.1 mm -136.08 136.07 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 O-C-N 121.068 -1.02 . . . . 0.0 110.099 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.427 HG22 ' OD2' ' A' ' 97' ' ' ASP . 0.6 OUTLIER -87.4 -179.04 6.31 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 121.651 0.738 . . . . 0.0 110.125 179.641 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.778 HG22 ' N ' ' A' ' 97' ' ' ASP . 30.5 p -76.45 1.15 17.3 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.35 179.519 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.501 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 8.6 mt-10 -111.64 -168.95 1.37 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 0.0 109.177 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' TRP . . . . . 0.529 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 97.6 m95 -94.22 123.36 37.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.657 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.407 ' OE1' ' HD2' ' A' ' 127' ' ' PRO . 12.2 mm-40 -106.93 121.36 45.11 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.301 -0.875 . . . . 0.0 108.992 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.591 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.6 Cg_endo -80.02 104.51 1.68 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.396 2.064 . . . . 0.0 110.947 -179.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -116.98 131.67 56.9 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.559 ' HG1' ' C ' ' A' ' 88' ' ' TYR . 14.4 t -151.76 177.09 10.75 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.936 -1.102 . . . . 0.0 110.745 -179.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.897 ' CE1' HD21 ' A' ' 116' ' ' LEU . 12.2 p90 -163.36 178.21 8.31 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.08 179.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 82.4 mt-10 -130.48 138.92 50.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.117 -0.989 . . . . 0.0 109.975 -179.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.589 ' CE2' ' HA2' ' A' ' 114' ' ' GLY . 0.3 OUTLIER -151.06 168.13 25.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.372 -0.83 . . . . 0.0 109.163 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.7 OUTLIER -127.82 146.57 50.56 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.115 -0.991 . . . . 0.0 109.409 -179.507 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.722 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.9 t -41.28 110.43 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.618 -0.676 . . . . 0.0 109.266 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -56.1 -46.94 78.92 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.318 -0.864 . . . . 0.0 109.043 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.472 ' O ' ' HG3' ' A' ' 137' ' ' GLN . 2.8 m-20 -118.49 -91.71 0.55 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.429 -0.794 . . . . 0.0 109.173 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . 0.472 ' HG3' ' O ' ' A' ' 136' ' ' ASP . 71.9 mt-30 -159.7 57.37 0.38 Allowed 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.47 -0.769 . . . . 0.0 108.929 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.565 ' O ' HG23 ' A' ' 80' ' ' VAL . 16.6 mm-40 -95.7 111.49 23.43 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.293 -0.88 . . . . 0.0 109.765 -179.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.38 -13.79 59.39 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.324 -0.86 . . . . 0.0 108.73 179.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 39.2 t -132.17 130.6 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.367 -0.833 . . . . 0.0 109.009 179.463 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.545 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -144.36 171.8 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.254 -0.903 . . . . 0.0 109.824 -179.812 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' ARG . . . . . 0.507 ' HB2' ' HB3' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -146.47 131.83 18.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.489 -0.757 . . . . 0.0 109.522 179.86 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ALA . . . . . 0.613 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -93.34 110.54 47.27 Favored Pre-proline 0 N--CA 1.486 1.372 0 O-C-N 121.259 -0.9 . . . . 0.0 110.168 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.486 ' HD2' ' O ' ' A' ' 104' ' ' THR . 36.0 Cg_endo -77.46 111.06 3.09 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.297 1.998 . . . . 0.0 110.735 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 1.049 HD13 ' CZ2' ' A' ' 28' ' ' TRP . 1.2 mt -97.8 120.71 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 179.162 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' HIS . . . . . 0.538 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 7.1 m80 -85.83 159.36 19.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.777 -1.202 . . . . 0.0 112.202 -176.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 1.083 ' CE1' ' HB3' ' A' ' 73' ' ' ALA . 61.6 m-85 -157.57 158.43 35.59 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 179.001 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.556 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 112.19 52.53 0.52 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.69 ' C ' HG11 ' A' ' 64' ' ' VAL . 41.8 m-85 -125.73 158.17 35.54 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.428 -1.042 . . . . 0.0 109.195 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.474 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.98 -29.51 69.38 Favored 'General case' 0 C--N 1.296 -1.734 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.86 -9.59 57.94 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 121.738 0.78 . . . . 0.0 109.327 179.299 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.905 ' OD1' ' HB1' ' A' ' 99' ' ' ALA . 2.1 t-20 -120.59 12.18 11.45 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.521 ' CG2' HG13 ' A' ' 64' ' ' VAL . 2.2 t -82.92 161.69 3.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 O-C-N 121.628 -0.67 . . . . 0.0 109.631 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' GLY . . . . . 0.44 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.7 37.42 51.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.428 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.1 m-20 -160.32 138.37 9.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.128 -1.219 . . . . 0.0 110.17 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 59' ' ' VAL . 98.0 m -86.26 121.2 28.5 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.573 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 1.0 OUTLIER -101.87 117.27 46.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.865 -1.147 . . . . 0.0 110.224 -178.874 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.709 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.9 m-85 -95.96 135.77 37.28 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 178.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.634 HD13 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -129.16 137.66 56.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 120.819 -1.176 . . . . 0.0 110.12 -178.601 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' ASP . . . . . 0.644 ' CB ' HG12 ' A' ' 56' ' ' VAL . 9.0 t0 -174.08 136.26 0.5 Allowed 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.307 -0.871 . . . . 0.0 109.018 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 128.0 -11.11 6.58 Favored Glycine 0 N--CA 1.485 1.958 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.334 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.522 HD23 ' HB2' ' A' ' 75' ' ' ALA . 11.4 tp -59.63 110.19 1.08 Allowed 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.694 -1.474 . . . . 0.0 108.486 -179.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . 0.506 ' HA ' ' CB ' ' A' ' 5' ' ' ASN . . . -139.6 145.65 38.82 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.474 -0.766 . . . . 0.0 110.265 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.759 ' O ' ' HB3' ' A' ' 4' ' ' ALA . 2.3 mp -126.86 109.02 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.422 -0.799 . . . . 0.0 109.047 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.494 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.616 0 O-C-N 121.083 -1.011 . . . . 0.0 109.826 -179.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.992 HG23 ' HB2' ' A' ' 165' ' ' ALA . 3.2 p . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.632 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -68.79 -57.92 4.92 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.188 -0.945 . . . . 0.0 109.854 -179.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.875 ' HB3' HG22 ' A' ' 78' ' ' VAL . 8.5 p-10 -102.07 141.83 34.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.238 -0.914 . . . . 0.0 109.79 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.5 ' O ' ' HA3' ' A' ' 27' ' ' GLY . 1.8 mp -102.78 150.17 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 0.0 109.555 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.541 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.9 OUTLIER 66.63 17.98 10.69 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.254 -0.904 . . . . 0.0 110.0 179.464 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -59.02 -26.97 61.68 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.855 -1.698 . . . . 0.0 108.855 179.571 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.445 ' O ' ' OD1' ' A' ' 160' ' ' ASP . . . -115.38 37.57 3.42 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.605 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 1.1 m-85 43.58 46.09 5.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.328 -1.101 . . . . 0.0 109.417 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -77.08 -36.14 56.04 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.19 -0.944 . . . . 0.0 109.659 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.519 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 4.5 t -88.3 -21.68 24.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.227 -0.921 . . . . 0.0 109.499 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 1.03 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.2 m -70.81 113.92 22.65 Favored Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.7 Cg_endo -77.48 136.16 15.42 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.392 2.061 . . . . 0.0 110.502 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.6 ' HB2' ' HB2' ' A' ' 46' ' ' GLU . . . -40.21 154.46 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.897 -0.502 . . . . 0.0 109.65 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.52 131.1 2.96 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 -179.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.527 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.2 139.0 17.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.273 -1.134 . . . . 0.0 109.494 -179.591 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.438 HG13 ' HA2' ' A' ' 24' ' ' GLY . 53.7 t -86.52 142.86 12.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 CA-C-O 121.568 0.699 . . . . 0.0 110.122 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 19.6 p -93.75 -28.43 15.93 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.99 101.05 5.08 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 1.102 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -47.29 -30.21 2.96 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.247 -0.908 . . . . 0.0 109.873 -178.842 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.102 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.72 -47.74 84.46 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.559 -0.713 . . . . 0.0 109.857 -179.642 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -107.58 34.59 3.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.123 -0.985 . . . . 0.0 109.432 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.438 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -74.55 -50.02 10.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 1.03 HG13 ' OG1' ' A' ' 13' ' ' THR . 4.9 t -119.84 141.49 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.24 -1.153 . . . . 0.0 109.738 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -67.18 -47.18 71.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.345 -0.847 . . . . 0.0 109.433 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.541 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -89.29 0.66 81.49 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' TRP . . . . . 0.696 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -135.64 121.75 20.17 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.198 -1.177 . . . . 0.0 109.215 179.659 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.539 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -121.65 122.79 40.41 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.366 -0.834 . . . . 0.0 108.912 179.452 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.828 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -99.32 173.5 6.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.756 -179.308 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 62.7 m-80 -160.37 123.45 3.42 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.369 -0.832 . . . . 0.0 109.842 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.958 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.54 136.25 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.205 -0.935 . . . . 0.0 109.415 179.219 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.01 -178.91 26.5 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 70.2 m -58.79 -16.99 19.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -1.127 . . . . 0.0 109.538 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.492 ' HB3' ' HB2' ' A' ' 67' ' ' ASN . 2.8 p -60.99 -37.0 80.94 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.242 -0.911 . . . . 0.0 109.367 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.958 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -62.41 89.39 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 O-C-N 121.27 -0.894 . . . . 0.0 109.334 179.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 88.7 m -73.14 -28.07 62.03 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.362 -0.836 . . . . 0.0 108.864 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.638 ' O ' HG13 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -112.72 142.99 28.13 Favored Pre-proline 0 C--N 1.297 -1.703 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.584 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -76.41 111.38 3.25 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.384 2.056 . . . . 0.0 110.801 -179.599 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.542 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.8 Cg_endo -78.05 177.11 9.18 Favored 'Trans proline' 0 C--N 1.312 -1.365 0 C-N-CA 122.521 2.147 . . . . 0.0 109.391 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.543 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 63.2 t -118.03 120.87 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 120.873 -1.142 . . . . 0.0 110.829 -179.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.591 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 96.3 m-85 -110.01 112.89 25.17 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 178.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.527 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 22.8 tt0 -150.93 155.55 39.35 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.006 -1.059 . . . . 0.0 109.845 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.67 HG21 HG22 ' A' ' 13' ' ' THR . 85.2 t -94.49 141.52 14.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.203 179.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.507 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -117.88 118.85 33.12 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.512 -0.743 . . . . 0.0 109.347 -179.663 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.6 ' HB2' ' HB2' ' A' ' 15' ' ' ALA . 6.3 mt-10 -103.55 109.85 21.67 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.61 -0.681 . . . . 0.0 109.394 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.483 ' O ' ' HB2' ' A' ' 54' ' ' ASN . 2.4 p -144.5 -179.54 6.62 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.46 -0.775 . . . . 0.0 109.386 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -102.13 29.71 4.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 109.367 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -119.5 -14.31 9.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 0.0 109.541 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.465 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -45.91 154.62 0.56 Allowed Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.147 -0.971 . . . . 0.0 109.521 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.542 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 36.0 Cg_endo -78.04 -34.01 1.86 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.596 2.198 . . . . 0.0 110.419 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -129.1 91.68 3.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.266 -0.896 . . . . 0.0 109.351 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.62 -120.98 6.31 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.544 -1.423 . . . . 0.0 109.544 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.483 ' HB2' ' O ' ' A' ' 47' ' ' THR . 11.9 p30 -160.02 30.16 0.18 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.239 -1.154 . . . . 0.0 109.472 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.528 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 8.2 mttp -135.09 130.74 36.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.305 -0.872 . . . . 0.0 109.547 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.678 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.0 m -149.05 175.62 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.372 -0.83 . . . . 0.0 109.145 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.731 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -105.81 100.91 10.44 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.032 -1.043 . . . . 0.0 108.998 179.441 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.618 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.62 117.87 22.33 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 178.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.767 ' O ' HG23 ' A' ' 156' ' ' THR . 40.9 t -115.15 144.92 21.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.069 -1.02 . . . . 0.0 109.168 -179.042 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.543 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 9.9 m -107.19 94.18 4.95 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.652 HG21 ' CD1' ' A' ' 157' ' ' ILE . 50.8 t -90.27 118.1 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.384 -0.823 . . . . 0.0 109.194 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -153.91 58.66 0.73 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.866 . . . . 0.0 109.941 -179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.51 ' O ' ' ND2' ' A' ' 38' ' ' ASN . . . 158.47 92.49 0.09 OUTLIER Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.744 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.7 m -84.36 -172.38 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.282 -1.128 . . . . 0.0 109.599 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -138.23 -157.17 7.36 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.4 m120 -96.06 10.03 38.88 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -1.121 . . . . 0.0 109.491 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.578 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 17.5 m-80 -127.35 146.46 58.3 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.212 -0.93 . . . . 0.0 109.42 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.586 ' HG2' ' CZ3' ' A' ' 69' ' ' TRP . 35.8 Cg_endo -78.47 12.54 2.09 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.579 2.186 . . . . 0.0 110.957 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.586 ' CZ3' ' HG2' ' A' ' 68' ' ' PRO . 1.1 p90 -133.56 54.5 1.95 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.987 -1.07 . . . . 0.0 109.853 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.476 ' HA ' ' OG ' ' A' ' 35' ' ' SER . 0.8 OUTLIER -78.4 -69.0 0.59 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.185 -0.947 . . . . 0.0 108.838 179.464 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.542 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 3.2 mp -106.05 128.02 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.155 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.61 138.24 52.1 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.903 -1.123 . . . . 0.0 110.467 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.828 ' HA ' HD23 ' A' ' 30' ' ' LEU . . . -120.35 132.15 55.16 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 178.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.531 HG22 ' N ' ' A' ' 75' ' ' ALA . 16.4 m -135.52 163.1 30.86 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.721 -1.237 . . . . 0.0 110.379 -178.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.56 ' HB2' ' NE1' ' A' ' 28' ' ' TRP . . . -122.66 137.56 54.87 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.433 -0.792 . . . . 0.0 109.145 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.539 ' CE2' ' CG ' ' A' ' 29' ' ' ASP . 1.6 p90 179.03 161.31 0.71 Allowed Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.516 -0.74 . . . . 0.0 109.103 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.531 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.3 Cg_endo -80.03 165.41 78.82 Favored 'Cis proline' 0 C--N 1.309 -1.514 0 C-N-CA 123.63 -1.404 . . . . 0.0 110.775 -0.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.875 HG22 ' HB3' ' A' ' 5' ' ' ASN . 92.6 t -120.34 156.47 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.381 -0.824 . . . . 0.0 108.918 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ASN . . . . . 0.571 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 4.5 m-80 -124.13 122.05 36.8 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.17 -0.956 . . . . 0.0 109.961 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.57 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 3.3 m -129.96 -174.01 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.153 -0.967 . . . . 0.0 109.54 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.652 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -137.12 143.88 43.79 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.394 -0.816 . . . . 0.0 109.148 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -76.14 115.46 4.14 Favored 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.475 2.117 . . . . 0.0 110.452 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.67 -27.36 20.61 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.512 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.86 149.81 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.186 -1.185 . . . . 0.0 109.549 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 39.0 m -97.14 132.99 42.37 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' TYR . . . . . 0.57 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 12.9 m-85 -111.88 164.83 12.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.582 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.467 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 12.1 m -115.33 154.1 29.77 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.3 -0.875 . . . . 0.0 109.445 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.671 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 6.2 t80 -131.12 118.56 20.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.258 -0.901 . . . . 0.0 109.236 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.481 ' O ' ' O ' ' A' ' 161' ' ' GLY . 16.6 m -135.74 143.55 45.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.174 -0.954 . . . . 0.0 109.187 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.734 HD12 ' HB2' ' A' ' 162' ' ' LEU . 17.5 tt -150.51 163.71 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.868 -1.145 . . . . 0.0 109.588 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.542 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 18.2 m95 -130.4 126.34 36.8 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.037 -1.039 . . . . 0.0 109.247 179.626 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -115.79 149.22 38.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.275 -0.891 . . . . 0.0 109.541 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.576 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 4.9 ttp85 -164.02 120.61 1.66 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.196 -0.94 . . . . 0.0 109.145 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.479 ' HB1' ' O ' ' A' ' 156' ' ' THR . . . -105.4 160.56 15.04 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.324 -0.86 . . . . 0.0 110.012 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . 0.476 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 0.0 OUTLIER -57.26 -48.96 77.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.436 -0.79 . . . . 0.0 109.172 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.529 ' C ' HG22 ' A' ' 123' ' ' THR . 16.3 mt-30 -116.44 146.19 42.72 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.336 -0.852 . . . . 0.0 109.166 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.639 ' N ' HG22 ' A' ' 123' ' ' THR . 8.5 p30 -65.17 146.29 55.16 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.204 -0.935 . . . . 0.0 109.517 -179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 112.12 30.87 2.81 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.477 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -118.13 138.18 52.45 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.117 -1.226 . . . . 0.0 109.112 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.641 HG22 ' HA ' ' A' ' 120' ' ' GLN . 52.1 t -116.9 158.36 17.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 O-C-N 121.256 -0.902 . . . . 0.0 110.747 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.877 HG22 ' CE1' ' A' ' 147' ' ' PHE . 72.6 t -153.68 163.04 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.547 ' CB ' ' HB2' ' A' ' 117' ' ' HIS . 74.9 m -121.72 125.24 46.13 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.916 -1.115 . . . . 0.0 109.907 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.613 ' N ' ' CD1' ' A' ' 103' ' ' PHE . 0.2 OUTLIER -119.76 103.56 9.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.062 -1.024 . . . . 0.0 109.737 179.72 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.503 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 18.5 p -127.3 167.95 15.45 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.168 -0.958 . . . . 0.0 110.151 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.688 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -128.16 156.86 40.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.715 -0.615 . . . . 0.0 110.247 -179.793 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.503 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -173.92 -173.17 39.85 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.608 ' CB ' HG22 ' A' ' 141' ' ' ILE . 1.4 p30 -126.52 -169.37 2.01 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.18 -1.188 . . . . 0.0 109.049 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . 0.531 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 5.6 mp0 -73.66 11.9 0.74 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.049 -1.032 . . . . 0.0 110.971 -179.4 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.499 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 1.0 OUTLIER -113.19 7.89 18.03 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 120.722 -1.236 . . . . 0.0 109.288 179.658 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.6 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.6 m-30 78.87 1.95 2.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.355 -0.841 . . . . 0.0 109.815 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.503 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 4.9 mm100 -76.04 159.47 30.77 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.106 -0.996 . . . . 0.0 108.729 179.466 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . 0.495 ' HA ' ' HA2' ' A' ' 106' ' ' GLY . 5.2 tt0 -138.09 135.3 35.67 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.968 -1.083 . . . . 0.0 110.005 -179.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.568 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 6.5 m-85 -95.95 -70.62 0.71 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.06 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.586 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -81.72 162.0 42.79 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.466 ' HA ' HG22 ' A' ' 104' ' ' THR . 7.7 ttm180 -158.05 103.95 1.87 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.974 -1.309 . . . . 0.0 110.337 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.72 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -144.1 72.85 1.36 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.335 -0.853 . . . . 0.0 108.784 179.087 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' HIS . . . . . 0.547 ' HB2' ' CB ' ' A' ' 102' ' ' SER . 32.1 p-80 -115.82 162.79 16.81 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.121 -0.987 . . . . 0.0 110.049 -179.412 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.531 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 3.2 tt0 77.22 53.31 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.399 -0.813 . . . . 0.0 109.256 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.407 ' O ' HG13 ' A' ' 100' ' ' VAL . 53.2 mm-40 -126.4 141.69 51.8 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.378 -0.826 . . . . 0.0 109.599 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.641 ' HA ' HG22 ' A' ' 100' ' ' VAL . 46.9 mm-40 -73.64 156.55 37.88 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.62 HD13 ' O ' ' A' ' 120' ' ' GLN . 10.8 mm -133.5 136.9 53.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.025 -1.047 . . . . 0.0 110.129 -179.469 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.64 -179.31 7.1 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.541 -0.724 . . . . 0.0 110.121 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.639 HG22 ' N ' ' A' ' 97' ' ' ASP . 61.9 p -78.06 0.49 24.42 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.877 -0.729 . . . . 0.0 109.36 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.436 ' O ' ' HB2' ' A' ' 93' ' ' ARG . 2.8 mt-10 -110.06 -168.83 1.37 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -0.883 . . . . 0.0 109.327 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' TRP . . . . . 0.576 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 85.6 m95 -98.01 121.91 40.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 109.562 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -106.83 121.35 45.22 Favored Pre-proline 0 N--CA 1.488 1.475 0 O-C-N 121.204 -0.935 . . . . 0.0 108.966 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.77 108.22 2.23 Favored 'Trans proline' 0 C--N 1.312 -1.381 0 C-N-CA 122.292 1.994 . . . . 0.0 110.96 -179.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -112.51 136.02 52.53 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.462 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.5 t -151.07 175.94 11.63 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.651 -1.28 . . . . 0.0 111.05 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.72 ' CE2' HD21 ' A' ' 116' ' ' LEU . 29.1 p90 -173.87 -178.29 1.53 Allowed 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.346 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -131.14 155.2 47.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.237 -0.914 . . . . 0.0 109.698 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.568 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.02 168.31 17.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.341 -0.849 . . . . 0.0 109.41 179.783 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -133.78 147.68 51.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.187 -0.946 . . . . 0.0 109.516 -179.745 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.652 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.2 t -42.01 110.3 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.511 -0.743 . . . . 0.0 109.272 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 67.5 m -58.7 -50.35 74.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 0.0 109.203 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -110.51 -90.79 0.47 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.436 -0.79 . . . . 0.0 109.202 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -163.31 56.31 0.18 Allowed 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.55 -0.719 . . . . 0.0 109.11 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.498 ' O ' HG23 ' A' ' 80' ' ' VAL . 50.0 mm-40 -95.66 112.9 24.52 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.271 -0.893 . . . . 0.0 109.809 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.37 -14.9 58.66 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.29 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.6 t -133.72 132.91 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.608 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.6 OUTLIER -143.52 172.22 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.184 -0.948 . . . . 0.0 110.285 -179.58 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' ARG . . . . . 0.498 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.6 OUTLIER -140.79 133.22 28.42 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.57 -0.706 . . . . 0.0 109.111 179.978 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ALA . . . . . 0.688 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.48 110.48 45.18 Favored Pre-proline 0 C--N 1.305 -1.339 0 O-C-N 121.135 -0.978 . . . . 0.0 109.625 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.503 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.3 Cg_endo -76.49 110.96 3.16 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 C-N-CA 122.293 1.995 . . . . 0.0 111.089 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.531 ' HB ' ' O ' ' A' ' 73' ' ' ALA . 2.3 mm -97.45 135.3 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 178.523 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' HIS . . . . . 0.513 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 8.8 m80 -102.24 158.55 16.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.438 -1.414 . . . . 0.0 111.335 -178.102 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.877 ' CE1' HG22 ' A' ' 101' ' ' VAL . 11.1 m-85 -159.1 160.2 35.42 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.327 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.537 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 106.71 48.11 0.99 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.744 ' C ' HG11 ' A' ' 64' ' ' VAL . 17.4 m-85 -125.35 159.35 32.01 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.435 -1.038 . . . . 0.0 109.166 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.499 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -64.83 -27.24 68.74 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.469 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.4 -19.42 63.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.367 -0.833 . . . . 0.0 109.199 179.522 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.494 ' N ' ' OD1' ' A' ' 152' ' ' ASN . 0.3 OUTLIER -107.96 10.17 28.45 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.42 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.538 HG23 HG13 ' A' ' 64' ' ' VAL . 2.2 t -84.65 163.98 2.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 121.437 -0.789 . . . . 0.0 109.686 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' GLY . . . . . 0.477 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 49.88 31.57 17.23 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.441 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 2.2 t-20 -160.14 144.85 14.72 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.149 -1.207 . . . . 0.0 110.113 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' THR . . . . . 0.767 HG23 ' O ' ' A' ' 59' ' ' VAL . 52.6 m -92.55 128.83 38.55 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.733 HG21 ' CG2' ' A' ' 101' ' ' VAL . 1.2 mt -107.7 118.75 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.853 -1.154 . . . . 0.0 109.759 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.618 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 3.4 m-85 -102.96 133.14 48.56 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 178.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.86 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -124.55 142.86 40.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.308 -178.694 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' ASP . . . . . 0.678 ' CB ' HG12 ' A' ' 56' ' ' VAL . 19.4 t70 -174.23 136.38 0.49 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.418 -0.801 . . . . 0.0 109.064 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 124.32 -7.76 8.52 Favored Glycine 0 N--CA 1.486 1.988 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.537 179.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.734 ' HB2' HD12 ' A' ' 90' ' ' ILE . 3.7 tp -59.9 103.97 0.26 Allowed 'General case' 0 N--CA 1.487 1.406 0 O-C-N 120.741 -1.446 . . . . 0.0 108.901 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -136.08 145.65 46.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.514 -0.741 . . . . 0.0 109.86 -179.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.629 HD13 HG11 ' A' ' 78' ' ' VAL . 8.4 mt -128.69 109.07 18.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.392 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.992 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.119 -0.988 . . . . 0.0 109.637 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.857 HG23 ' HB2' ' A' ' 165' ' ' ALA . 3.9 p . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.573 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -69.89 -58.85 3.38 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -0.893 . . . . 0.0 109.569 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.614 ' HA ' HG22 ' A' ' 78' ' ' VAL . 7.7 t30 -77.46 134.49 38.35 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.145 -0.972 . . . . 0.0 109.558 -179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.513 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 62.3 mt -111.72 138.86 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.262 -0.899 . . . . 0.0 109.536 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.549 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 10.2 t-20 76.17 26.48 0.96 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.309 -0.869 . . . . 0.0 109.83 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.41 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -57.27 -34.93 68.64 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 179.284 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.52 ' HA3' ' OD1' ' A' ' 160' ' ' ASP . . . -119.76 34.44 4.22 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 108.85 -1.7 . . . . 0.0 108.85 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.697 ' HD2' HG11 ' A' ' 25' ' ' VAL . 8.4 m-85 43.84 53.76 6.02 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.375 -1.074 . . . . 0.0 109.358 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.422 ' HA ' ' HD3' ' A' ' 55' ' ' LYS . 31.7 mm-40 -83.96 -28.56 27.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.471 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.9 t -86.67 -41.98 13.77 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -0.879 . . . . 0.0 109.541 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.966 HG21 HG22 ' A' ' 25' ' ' VAL . 90.8 m -71.97 127.73 90.22 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.9 Cg_endo -77.63 141.13 19.41 Favored 'Trans proline' 0 C--N 1.312 -1.383 0 C-N-CA 122.481 2.121 . . . . 0.0 110.568 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.468 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -41.7 164.35 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.742 -0.599 . . . . 0.0 109.582 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.66 133.7 3.32 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 108.931 -1.668 . . . . 0.0 108.931 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.466 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.89 140.2 15.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.277 -1.131 . . . . 0.0 109.207 -179.637 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.768 HG13 ' HA3' ' A' ' 24' ' ' GLY . 62.1 t -86.61 142.4 13.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 CA-C-O 121.638 0.732 . . . . 0.0 110.439 -179.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.35 -28.81 12.76 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -131.38 86.73 2.38 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 1.101 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -45.33 -29.85 1.14 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.268 -0.895 . . . . 0.0 110.006 -178.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.101 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -60.22 -49.0 79.34 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.494 -0.754 . . . . 0.0 110.232 -179.53 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -133.67 48.77 2.33 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.961 -1.087 . . . . 0.0 109.732 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.768 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -97.44 -12.37 48.42 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.966 HG22 HG21 ' A' ' 13' ' ' THR . 90.8 t -141.24 133.95 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.186 -1.185 . . . . 0.0 109.636 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.509 ' O ' ' ND2' ' A' ' 7' ' ' ASN . 17.7 tt0 -78.36 126.69 31.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.384 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.549 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 101.76 -16.17 56.37 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' TRP . . . . . 1.015 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.2 OUTLIER -137.6 120.24 16.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -1.117 . . . . 0.0 108.426 179.164 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.529 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -121.94 110.66 16.12 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.32 -0.863 . . . . 0.0 109.209 179.935 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.837 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -91.7 173.6 7.79 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.286 -0.884 . . . . 0.0 109.339 -179.73 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.457 ' HA ' HD21 ' A' ' 21' ' ' LEU . 77.7 m-20 -160.62 123.45 3.31 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.205 -0.934 . . . . 0.0 110.366 -179.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.981 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -109.36 131.32 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.291 -0.88 . . . . 0.0 109.286 178.861 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.79 -172.54 22.76 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -56.67 -31.65 64.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.334 -1.098 . . . . 0.0 109.559 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.48 ' HB2' ' HA ' ' A' ' 70' ' ' ASP . 0.7 OUTLIER -45.98 -42.42 13.05 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.196 -0.94 . . . . 0.0 109.279 -179.869 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.981 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -60.77 89.84 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 121.188 -0.945 . . . . 0.0 109.529 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 94.7 m -74.05 -28.13 61.25 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.854 0.835 . . . . 0.0 108.789 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.649 ' O ' HG13 ' A' ' 36' ' ' VAL . 8.2 t30 -114.01 144.48 31.66 Favored Pre-proline 0 C--N 1.297 -1.681 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.405 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.2 Cg_endo -75.83 111.07 3.21 Favored 'Trans proline' 0 C--N 1.307 -1.627 0 C-N-CA 122.443 2.095 . . . . 0.0 111.011 -179.374 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.538 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 36.2 Cg_endo -78.97 174.41 12.22 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.558 2.172 . . . . 0.0 109.607 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.549 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 73.8 t -116.9 120.5 65.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.998 -1.064 . . . . 0.0 110.659 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.752 ' HZ ' HG23 ' A' ' 71' ' ' ILE . 60.6 m-85 -109.04 112.55 24.79 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 178.044 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.466 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 28.7 tt0 -150.59 146.96 26.87 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.11 -0.994 . . . . 0.0 109.904 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.7 t -95.49 148.61 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.392 -0.817 . . . . 0.0 109.232 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.867 HD21 ' CG2' ' A' ' 47' ' ' THR . 0.4 OUTLIER -132.64 147.23 52.33 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.175 -0.953 . . . . 0.0 108.895 -179.79 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.577 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 16.9 mt-10 -117.06 114.09 23.26 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.53 -0.731 . . . . 0.0 109.63 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.867 ' CG2' HD21 ' A' ' 45' ' ' LEU . 12.9 p -139.8 174.14 10.82 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.473 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.521 ' HA ' ' ND2' ' A' ' 54' ' ' ASN . 16.9 m -100.06 21.67 12.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.462 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.413 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.0 OUTLIER -111.82 -15.33 13.4 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.182 -0.949 . . . . 0.0 109.534 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.437 ' HB3' ' O ' ' A' ' 53' ' ' GLY . . . -44.17 147.19 0.99 Allowed Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.549 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.06 -40.54 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.548 2.165 . . . . 0.0 110.389 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.4 ' O ' ' OE2' ' A' ' 11' ' ' GLU . 2.5 tp10 -117.87 79.71 1.4 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 109.432 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.449 ' O ' ' OD1' ' A' ' 54' ' ' ASN . . . 102.81 -139.41 14.42 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.521 ' ND2' ' HA ' ' A' ' 48' ' ' SER . 3.0 m120 -142.28 35.35 1.5 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -1.111 . . . . 0.0 109.463 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.537 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 8.9 mttt -144.64 138.3 27.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.279 -0.888 . . . . 0.0 109.555 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.598 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.8 m -150.32 174.39 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.344 -0.847 . . . . 0.0 109.281 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.791 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -108.13 103.51 12.73 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.072 -1.018 . . . . 0.0 108.893 179.45 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.719 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.59 119.17 23.45 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.826 ' O ' HG23 ' A' ' 156' ' ' THR . 41.3 t -114.66 144.83 21.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.092 -1.005 . . . . 0.0 109.075 -179.212 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.781 HG22 ' ND2' ' A' ' 62' ' ' ASN . 24.0 m -106.4 91.52 3.74 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 179.281 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.647 HG21 ' CD1' ' A' ' 157' ' ' ILE . 53.8 t -90.86 113.01 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.385 -0.822 . . . . 0.0 109.11 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.781 ' ND2' HG22 ' A' ' 60' ' ' THR . 2.5 p30 -153.46 58.02 0.76 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.312 -0.868 . . . . 0.0 109.831 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 162.09 85.09 0.05 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.569 HG11 ' C ' ' A' ' 149' ' ' TYR . 1.3 m -79.89 175.82 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.211 -1.17 . . . . 0.0 109.46 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -124.45 -149.91 7.76 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -95.15 -4.54 45.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.302 -1.116 . . . . 0.0 109.609 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.582 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 0.8 OUTLIER -114.78 147.89 39.2 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 109.283 179.991 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -79.02 14.25 1.78 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.717 2.278 . . . . 0.0 111.008 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.582 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.3 p90 -135.34 52.53 2.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.99 -1.069 . . . . 0.0 109.921 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.511 ' C ' HG23 ' A' ' 36' ' ' VAL . 0.4 OUTLIER -75.22 -66.45 0.76 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.046 -1.034 . . . . 0.0 108.966 179.552 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.752 HG23 ' HZ ' ' A' ' 42' ' ' PHE . 2.5 mt -101.23 127.79 54.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.305 -0.872 . . . . 0.0 108.659 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.465 ' O ' ' HB3' ' A' ' 30' ' ' LEU . 7.2 mt-10 -126.58 137.71 53.37 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.05 -1.031 . . . . 0.0 110.363 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 1.015 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -118.31 123.32 45.07 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 106.998 -1.482 . . . . 0.0 106.998 178.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.541 HG22 ' N ' ' A' ' 75' ' ' ALA . 18.0 m -128.61 163.31 25.31 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 120.441 -1.412 . . . . 0.0 110.459 -178.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.541 ' N ' HG22 ' A' ' 74' ' ' THR . . . -129.7 138.32 51.09 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.472 -0.768 . . . . 0.0 109.238 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.546 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 2.2 p90 177.99 160.48 0.59 Allowed Pre-proline 0 N--CA 1.492 1.647 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.526 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -81.65 166.75 71.9 Favored 'Cis proline' 0 C--N 1.31 -1.476 0 C-N-CA 123.686 -1.381 . . . . 0.0 110.799 -0.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.866 HG11 HD12 ' A' ' 164' ' ' ILE . 76.5 t -124.69 156.34 32.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.219 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ASN . . . . . 0.518 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 3.6 m120 -123.77 123.05 39.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.915 -1.116 . . . . 0.0 110.417 -179.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.685 HG12 ' CD2' ' A' ' 86' ' ' TYR . 3.0 m -128.19 -173.88 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.115 179.244 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.832 ' O ' HG21 ' A' ' 134' ' ' VAL . 1.7 mtt180 -126.96 145.16 52.86 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.246 -0.908 . . . . 0.0 109.438 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.41 120.78 5.38 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.437 2.091 . . . . 0.0 110.493 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.35 -27.43 17.18 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.6 t -85.94 149.72 4.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.271 -1.135 . . . . 0.0 109.439 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 20.8 m -97.74 122.4 40.78 Favored 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' TYR . . . . . 0.685 ' CD2' HG12 ' A' ' 80' ' ' VAL . 3.6 m-85 -99.77 170.28 8.66 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.922 . . . . 0.0 109.619 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.477 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 6.5 m -118.23 154.09 32.82 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.404 -0.81 . . . . 0.0 109.431 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.627 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.8 t80 -128.11 121.23 29.1 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.256 -0.903 . . . . 0.0 109.266 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.468 ' O ' ' O ' ' A' ' 161' ' ' GLY . 19.6 m -135.54 145.97 47.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.191 -0.943 . . . . 0.0 109.317 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.688 HD13 ' HD2' ' A' ' 103' ' ' PHE . 16.7 tt -150.74 163.68 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 120.765 -1.209 . . . . 0.0 109.531 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.596 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 19.7 m95 -133.92 124.73 26.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.884 -1.135 . . . . 0.0 109.057 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -117.34 150.88 38.1 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.255 -0.903 . . . . 0.0 109.491 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.581 ' HD2' ' CE2' ' A' ' 125' ' ' TRP . 1.0 OUTLIER -164.27 121.83 1.72 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.187 -0.946 . . . . 0.0 108.971 179.981 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.69 167.49 9.73 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -0.922 . . . . 0.0 110.053 -179.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -58.52 -48.77 79.74 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.265 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.558 ' C ' HG22 ' A' ' 123' ' ' THR . 2.9 mt-30 -118.28 150.97 38.58 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.299 -0.876 . . . . 0.0 109.163 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.724 ' N ' HG22 ' A' ' 123' ' ' THR . 0.6 OUTLIER -66.34 145.13 56.06 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.255 -0.903 . . . . 0.0 109.701 -179.778 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 114.07 35.21 1.53 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.47 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -120.2 139.54 52.49 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.269 -1.136 . . . . 0.0 109.246 179.698 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.468 ' HB ' ' OD1' ' A' ' 152' ' ' ASN . 54.2 t -117.94 157.86 19.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 121.325 -0.859 . . . . 0.0 110.759 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.692 HG22 ' CE1' ' A' ' 147' ' ' PHE . 62.1 t -154.94 162.25 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 179.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.525 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 4.8 m -116.78 129.49 56.13 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.085 -1.009 . . . . 0.0 109.392 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.688 ' HD2' HD13 ' A' ' 90' ' ' ILE . 0.2 OUTLIER -123.84 103.92 8.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.145 -0.972 . . . . 0.0 109.734 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.586 HG22 ' HA ' ' A' ' 115' ' ' ARG . 36.1 p -135.35 169.63 17.18 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.972 -1.08 . . . . 0.0 110.233 179.742 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.968 HG23 ' N ' ' A' ' 114' ' ' GLY . 0.0 OUTLIER -131.99 127.66 58.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-O 121.71 0.767 . . . . 0.0 110.41 179.121 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -122.01 165.78 14.8 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.119 -1.992 . . . . 0.0 108.119 178.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.595 ' OD1' ' CE1' ' A' ' 113' ' ' TYR . 0.0 OUTLIER -125.97 -170.82 2.26 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.922 -1.34 . . . . 0.0 109.272 -179.714 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 13.0 mt-30 -81.22 -19.86 42.31 Favored 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 118.791 -1.164 . . . . 0.0 109.588 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.505 ' HB2' ' HG2' ' A' ' 111' ' ' GLN . 2.4 m -82.09 8.78 9.89 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.462 ' HB2' ' O ' ' A' ' 109' ' ' SER . 16.8 m-30 65.3 24.03 12.14 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.313 -0.867 . . . . 0.0 108.674 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.525 ' OE1' ' CA ' ' A' ' 111' ' ' GLN . 0.7 OUTLIER -86.54 161.8 18.37 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.434 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . 0.479 ' OE1' ' HG3' ' A' ' 115' ' ' ARG . 0.5 OUTLIER -107.68 101.35 10.67 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.336 -0.852 . . . . 0.0 109.891 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.952 ' OH ' HG13 ' A' ' 134' ' ' VAL . 2.0 m-30 -70.83 -64.43 0.9 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.586 -0.696 . . . . 0.0 109.72 178.607 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.968 ' N ' HG23 ' A' ' 105' ' ' VAL . . . -115.44 166.38 12.22 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 -179.384 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.611 ' NE ' ' CE1' ' A' ' 117' ' ' HIS . 0.0 OUTLIER -157.81 74.61 0.74 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.242 -1.152 . . . . 0.0 110.691 -179.706 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.953 HD21 ' CD2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -131.45 86.47 2.36 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.985 -1.072 . . . . 0.0 108.811 178.495 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' HIS . . . . . 0.611 ' CE1' ' NE ' ' A' ' 115' ' ' ARG . 29.8 p-80 -121.53 163.32 19.04 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -0.862 . . . . 0.0 110.009 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 3.0 tt0 76.89 36.31 0.34 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.42 -0.8 . . . . 0.0 109.373 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 17.3 mm-40 -100.3 135.81 41.15 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.299 -0.876 . . . . 0.0 109.542 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.625 ' O ' HD13 ' A' ' 121' ' ' ILE . 20.5 mt-30 -71.29 156.03 39.99 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.388 -0.82 . . . . 0.0 108.944 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.625 HD13 ' O ' ' A' ' 120' ' ' GLN . 6.1 mm -134.37 133.42 55.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.092 -1.005 . . . . 0.0 110.132 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.87 -179.42 6.81 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.514 -0.741 . . . . 0.0 109.971 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.724 HG22 ' N ' ' A' ' 97' ' ' ASP . 37.9 p -73.96 -2.67 25.02 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.771 -0.772 . . . . 0.0 109.243 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.524 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 0.9 OUTLIER -110.02 175.42 5.45 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.334 -0.854 . . . . 0.0 109.177 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' TRP . . . . . 0.581 ' CE2' ' HD2' ' A' ' 93' ' ' ARG . 95.0 m95 -81.77 122.35 27.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.83 121.02 46.29 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.252 -0.905 . . . . 0.0 108.833 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.596 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.6 Cg_endo -80.17 101.69 1.37 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.412 2.074 . . . . 0.0 111.177 -179.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -103.86 132.25 50.3 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 178.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.456 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -144.15 176.29 9.43 Favored 'General case' 0 C--N 1.295 -1.776 0 O-C-N 120.875 -1.141 . . . . 0.0 110.723 -179.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.953 ' CD2' HD21 ' A' ' 116' ' ' LEU . 25.3 p90 -175.11 152.56 1.47 Allowed 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 114.978 -1.01 . . . . 0.0 109.34 179.651 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -101.96 142.49 33.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.257 -0.902 . . . . 0.0 109.68 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.637 ' CD1' ' CE1' ' A' ' 130' ' ' PHE . 8.1 p90 -153.65 137.54 16.25 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.34 -0.85 . . . . 0.0 109.371 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.445 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.8 OUTLIER -98.72 146.58 25.73 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.256 -0.902 . . . . 0.0 108.836 179.923 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.952 HG13 ' OH ' ' A' ' 113' ' ' TYR . 4.1 t -41.55 108.96 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.443 -0.786 . . . . 0.0 109.171 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -48.17 -35.33 11.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.332 -0.855 . . . . 0.0 109.007 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -138.49 -90.79 0.21 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.452 -0.78 . . . . 0.0 109.293 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -158.35 56.05 0.45 Allowed 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.524 -0.735 . . . . 0.0 109.1 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.604 ' O ' HG23 ' A' ' 80' ' ' VAL . 31.8 mm-40 -92.58 111.06 22.51 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.2 p -79.31 -18.32 52.83 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 40.2 t -131.66 135.79 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.586 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -143.6 171.62 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.926 -1.109 . . . . 0.0 110.751 -179.177 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' ARG . . . . . 0.512 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.7 OUTLIER -133.02 132.22 41.6 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.682 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ALA . . . . . 0.625 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -99.36 107.22 43.81 Favored Pre-proline 0 C--N 1.304 -1.374 0 O-C-N 120.976 -1.077 . . . . 0.0 109.382 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.534 ' HD2' ' HA ' ' A' ' 105' ' ' VAL . 34.9 Cg_endo -77.31 110.94 3.09 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.27 1.98 . . . . 0.0 111.341 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.738 HD12 ' CZ2' ' A' ' 28' ' ' TRP . 1.6 mt -99.57 138.91 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' HIS . . . . . 0.581 ' O ' ' CD2' ' A' ' 147' ' ' PHE . 4.8 m80 -103.81 159.11 15.91 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.53 -1.356 . . . . 0.0 111.732 -177.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.692 ' CE1' HG22 ' A' ' 101' ' ' VAL . 17.1 m-85 -161.24 160.0 29.4 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.563 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 105.77 52.22 0.81 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 -179.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.569 ' C ' HG11 ' A' ' 64' ' ' VAL . 22.8 m-85 -129.0 158.88 37.63 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.531 -0.982 . . . . 0.0 109.165 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.33 -26.51 67.33 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.466 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -71.64 -15.81 62.25 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.534 -0.729 . . . . 0.0 109.367 179.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' A' ' 152' ' ' ASN . 0.2 OUTLIER -112.05 8.8 20.24 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.444 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.3 t -83.87 164.44 2.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 O-C-N 121.423 -0.798 . . . . 0.0 109.747 -179.303 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' GLY . . . . . 0.492 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 55.89 26.29 47.45 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.911 -1.275 . . . . 0.0 109.911 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.464 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.7 t-20 -160.38 143.01 13.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.98 -1.306 . . . . 0.0 110.202 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' THR . . . . . 0.826 HG23 ' O ' ' A' ' 59' ' ' VAL . 46.1 m -89.4 121.48 31.69 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 178.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.647 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.1 mt -98.03 117.7 43.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 120.882 -1.136 . . . . 0.0 110.097 -178.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.719 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.4 m-85 -96.9 130.83 44.14 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.631 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.1 mt -121.03 142.41 37.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 120.726 -1.234 . . . . 0.0 110.154 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' ASP . . . . . 0.598 ' CB ' HG12 ' A' ' 56' ' ' VAL . 9.0 t0 -174.14 136.24 0.5 Allowed 'General case' 0 N--CA 1.486 1.366 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . 0.529 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 124.82 -7.73 8.24 Favored Glycine 0 N--CA 1.486 1.985 0 C-N-CA 119.329 -1.415 . . . . 0.0 110.633 179.403 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.619 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 3.2 tp -60.29 100.0 0.09 Allowed 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.58 -1.541 . . . . 0.0 108.895 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . 0.481 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -136.7 145.7 45.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.445 -0.785 . . . . 0.0 109.662 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.866 HD12 HG11 ' A' ' 78' ' ' VAL . 25.5 mt -128.58 108.8 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.239 -0.913 . . . . 0.0 109.431 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.857 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.177 -0.952 . . . . 0.0 109.576 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.911 HG23 ' HB2' ' A' ' 165' ' ' ALA . 4.4 p . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.587 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -75.86 -39.63 56.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.192 -0.943 . . . . 0.0 109.714 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.527 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 1.2 t30 -92.1 129.45 38.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.706 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.468 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 64.7 mt -113.55 129.96 68.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.243 -0.911 . . . . 0.0 109.346 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.545 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.7 OUTLIER 69.93 28.0 4.31 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.206 -0.934 . . . . 0.0 109.597 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -44.26 -26.95 1.04 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 160' ' ' ASP . . . -142.14 52.03 0.67 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.717 ' CD2' HG11 ' A' ' 25' ' ' VAL . 2.8 m-85 45.27 56.38 5.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.261 -1.14 . . . . 0.0 109.237 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -84.52 -29.64 25.77 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.139 -0.976 . . . . 0.0 110.249 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.6 p -95.0 -47.49 6.38 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.011 -1.056 . . . . 0.0 110.129 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.938 ' OG1' HG13 ' A' ' 25' ' ' VAL . 3.1 m -59.84 135.76 90.04 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.166 -0.959 . . . . 0.0 109.538 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.466 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.9 Cg_endo -77.36 146.14 24.53 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.561 2.174 . . . . 0.0 110.71 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.611 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -44.62 170.76 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 121.299 0.571 . . . . 0.0 109.798 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 140.33 130.56 2.66 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.097 -1.601 . . . . 0.0 109.097 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.568 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.07 139.21 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.224 -1.162 . . . . 0.0 109.166 -179.653 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.566 HG13 ' HA3' ' A' ' 24' ' ' GLY . 60.2 t -90.66 142.95 12.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-O 121.625 0.726 . . . . 0.0 110.442 -179.468 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.5 t -100.7 -29.44 12.29 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.071 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 19.4 m-20 -131.48 93.92 3.44 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 1.075 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -48.86 -29.32 4.53 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.264 -0.897 . . . . 0.0 110.135 -178.626 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.075 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.44 -57.04 14.72 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.495 -0.753 . . . . 0.0 110.119 -179.364 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -119.99 41.82 3.09 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.155 -0.965 . . . . 0.0 109.45 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.566 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -77.07 -39.87 26.36 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.952 -1.259 . . . . 0.0 109.952 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.938 HG13 ' OG1' ' A' ' 13' ' ' THR . 46.3 t -141.74 133.72 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.102 -1.234 . . . . 0.0 109.904 -179.62 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 20.6 tp10 -68.68 141.58 55.29 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -0.857 . . . . 0.0 109.224 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.545 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 106.58 -32.14 7.58 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' TRP . . . . . 0.929 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.1 OUTLIER -135.04 121.0 19.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.152 -1.205 . . . . 0.0 109.109 179.492 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -112.84 109.71 19.34 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.831 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -89.93 173.66 8.11 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.218 -0.926 . . . . 0.0 109.665 -179.139 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.497 ' O ' ' HB3' ' A' ' 72' ' ' GLU . 7.1 m120 -160.93 128.02 4.16 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.181 -0.949 . . . . 0.0 110.807 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.058 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -117.16 130.05 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.209 -0.932 . . . . 0.0 108.993 178.198 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.29 171.7 16.18 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.499 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.4 ' O ' ' C ' ' A' ' 35' ' ' SER . 0.7 OUTLIER -45.6 -29.89 1.34 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.377 -1.073 . . . . 0.0 109.419 179.951 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.505 ' HB2' ' CB ' ' A' ' 70' ' ' ASP . 0.4 OUTLIER -45.88 -53.41 9.85 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.369 -0.832 . . . . 0.0 109.116 179.943 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 1.058 HG21 HG12 ' A' ' 32' ' ' VAL . 34.7 t -47.63 102.57 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 O-C-N 121.251 -0.905 . . . . 0.0 110.084 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 40.8 m -81.63 -26.19 35.02 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 121.894 0.854 . . . . 0.0 108.764 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.682 ' O ' HG12 ' A' ' 36' ' ' VAL . 2.1 m-80 -111.67 147.75 37.43 Favored Pre-proline 0 C--N 1.296 -1.751 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.724 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -77.01 110.85 3.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.485 2.123 . . . . 0.0 110.654 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 38' ' ' ASN . 36.4 Cg_endo -80.05 160.98 23.74 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.475 2.117 . . . . 0.0 109.68 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.537 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 54.8 t -109.95 119.78 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.004 -1.06 . . . . 0.0 110.291 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.455 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 76.7 m-85 -105.9 112.16 25.1 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.568 ' HG3' HG23 ' A' ' 17' ' ' VAL . 1.3 tm-20 -155.01 147.06 23.64 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.005 -1.059 . . . . 0.0 109.872 -179.437 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.474 ' N ' ' HG2' ' A' ' 43' ' ' GLU . 53.1 t -91.89 148.54 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.493 -0.754 . . . . 0.0 109.193 179.574 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.675 HD21 ' CG2' ' A' ' 47' ' ' THR . 0.4 OUTLIER -131.97 146.9 52.37 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.207 -0.933 . . . . 0.0 108.888 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 0.611 ' HG3' ' HB2' ' A' ' 15' ' ' ALA . 17.4 mt-10 -117.91 115.04 24.13 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.676 -0.64 . . . . 0.0 109.508 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.675 ' CG2' HD21 ' A' ' 45' ' ' LEU . 2.2 p -142.11 172.25 12.94 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.488 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.95 11.7 24.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.248 -0.908 . . . . 0.0 109.484 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -103.33 -15.81 15.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.158 -0.964 . . . . 0.0 109.434 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.64 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -50.33 145.68 9.91 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.234 -0.916 . . . . 0.0 109.403 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.569 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 35.9 Cg_endo -78.38 -41.91 0.25 Allowed 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.577 2.185 . . . . 0.0 110.375 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -110.91 108.34 18.09 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.255 -0.903 . . . . 0.0 109.298 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.16 -117.16 6.64 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.64 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 50.0 p30 -160.06 29.87 0.18 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -1.173 . . . . 0.0 109.524 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.544 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 60.5 mttt -136.89 138.68 40.97 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.215 -0.928 . . . . 0.0 109.678 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.637 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.6 m -150.08 174.41 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.299 -0.876 . . . . 0.0 109.203 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.72 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -103.33 102.15 12.09 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.15 -0.969 . . . . 0.0 108.98 179.643 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.65 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.47 119.91 24.34 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.853 ' O ' HG23 ' A' ' 156' ' ' THR . 40.5 t -113.18 144.51 20.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.106 -0.997 . . . . 0.0 109.024 -179.172 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.537 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 19.9 m -110.7 90.59 3.37 Favored 'General case' 0 C--N 1.283 -2.284 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.519 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 43.9 t -86.48 127.78 40.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.273 -0.892 . . . . 0.0 109.211 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.417 HD22 HG22 ' A' ' 60' ' ' THR . 4.8 p30 -151.07 57.0 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.887 . . . . 0.0 109.844 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.433 ' HA3' ' CG ' ' A' ' 38' ' ' ASN . . . 147.66 103.44 0.33 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.817 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.3 m -79.94 -175.82 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.236 -1.155 . . . . 0.0 109.51 179.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -126.61 -178.5 15.34 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.666 -1.373 . . . . 0.0 109.666 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -68.73 -20.27 64.38 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.241 -1.152 . . . . 0.0 109.431 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.592 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.3 m-20 -106.98 152.54 41.02 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.28 -0.887 . . . . 0.0 109.492 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.41 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.2 Cg_endo -78.58 12.64 2.09 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 122.646 2.23 . . . . 0.0 110.973 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.592 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.2 p90 -135.57 54.58 1.91 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.991 -1.068 . . . . 0.0 109.631 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.522 ' HB3' ' N ' ' A' ' 36' ' ' VAL . 0.5 OUTLIER -83.37 -48.08 10.77 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.216 -0.927 . . . . 0.0 109.191 179.872 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.58 HD13 HG22 ' A' ' 36' ' ' VAL . 3.7 mm -98.72 149.09 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.254 -0.904 . . . . 0.0 108.776 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.534 ' HA ' ' HB3' ' A' ' 146' ' ' HIS . 58.0 tt0 -137.71 160.27 39.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.872 -1.143 . . . . 0.0 110.93 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.929 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -162.37 106.48 1.16 Allowed 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 179.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.591 HG22 ' N ' ' A' ' 75' ' ' ALA . 49.9 m -120.63 166.33 13.81 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.246 -1.534 . . . . 0.0 110.953 -178.004 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.591 ' N ' HG22 ' A' ' 74' ' ' THR . . . -124.7 137.91 54.32 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.476 -0.765 . . . . 0.0 108.96 179.07 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.547 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER 178.17 162.52 0.62 Allowed Pre-proline 0 N--CA 1.492 1.651 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 -179.728 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.532 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.82 167.14 73.74 Favored 'Cis proline' 0 C--N 1.31 -1.472 0 C-N-CA 123.641 -1.4 . . . . 0.0 110.778 -0.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.817 HG11 HD12 ' A' ' 164' ' ' ILE . 76.7 t -126.27 151.5 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.303 -0.873 . . . . 0.0 108.961 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ASN . . . . . 0.476 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 47.3 m-20 -114.75 122.79 47.48 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.045 -1.034 . . . . 0.0 109.812 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 138' ' ' GLU . 3.0 m -129.57 -173.82 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.21 -0.932 . . . . 0.0 109.458 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.625 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -138.74 145.87 47.92 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.364 -0.835 . . . . 0.0 109.306 179.896 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.489 ' HD2' ' HG2' ' A' ' 81' ' ' ARG . 35.3 Cg_endo -77.33 110.28 2.96 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.465 2.11 . . . . 0.0 110.47 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 113.91 -34.99 4.71 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.551 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -85.0 149.71 4.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.241 -1.152 . . . . 0.0 109.39 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.469 ' HA ' ' OG1' ' A' ' 133' ' ' THR . 11.6 t -95.3 145.31 25.18 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 109.354 -0.609 . . . . 0.0 109.354 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' TYR . . . . . 0.564 ' HD2' HG22 ' A' ' 164' ' ' ILE . 8.6 m-85 -123.29 159.07 29.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.297 -0.877 . . . . 0.0 109.627 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.467 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 59.1 m -118.06 148.46 42.25 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.32 -0.862 . . . . 0.0 109.282 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.615 ' CD1' ' N ' ' A' ' 88' ' ' TYR . 0.2 OUTLIER -127.04 104.75 8.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.124 -0.985 . . . . 0.0 109.631 -179.927 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.476 ' O ' ' O ' ' A' ' 161' ' ' GLY . 54.7 m -112.8 148.08 35.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.365 -0.834 . . . . 0.0 108.955 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.676 HD12 ' HB2' ' A' ' 162' ' ' LEU . 19.4 tt -150.08 163.51 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.76 -1.212 . . . . 0.0 109.817 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.574 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 70.3 m95 -125.77 129.55 49.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.156 -0.965 . . . . 0.0 109.281 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.99 145.96 47.62 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.283 -0.886 . . . . 0.0 109.513 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.584 ' HD2' ' CE2' ' A' ' 125' ' ' TRP . 16.4 ttt-85 -157.91 118.23 3.39 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.267 -0.896 . . . . 0.0 109.179 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.3 166.8 10.16 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.357 -0.84 . . . . 0.0 109.839 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -64.18 -52.04 60.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.373 -0.829 . . . . 0.0 109.615 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.428 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -112.03 140.93 46.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 109.52 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.877 ' CG ' HG23 ' A' ' 123' ' ' THR . 1.1 m-20 -60.82 149.61 35.39 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.249 -0.907 . . . . 0.0 109.476 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 106.98 33.82 3.14 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.969 -1.253 . . . . 0.0 109.969 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.546 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -114.09 139.73 49.06 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.066 -1.255 . . . . 0.0 109.165 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.433 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 73.8 t -120.65 149.43 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 110.421 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.587 ' HB ' ' CE1' ' A' ' 103' ' ' PHE . 48.4 t -144.94 166.75 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.471 -0.768 . . . . 0.0 109.029 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.615 ' O ' HG23 ' A' ' 145' ' ' ILE . 5.6 m -124.68 123.47 40.1 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.06 -1.025 . . . . 0.0 109.612 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.63 ' N ' ' CD1' ' A' ' 103' ' ' PHE . 1.4 m-85 -121.94 103.9 9.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -0.875 . . . . 0.0 109.902 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.523 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 16.5 p -121.38 174.34 6.8 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.098 -1.001 . . . . 0.0 109.88 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.646 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -131.72 154.0 39.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-O 121.492 0.663 . . . . 0.0 110.282 -179.688 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -174.92 158.11 25.7 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.53 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.5 p30 -97.91 -169.32 1.8 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.099 -1.236 . . . . 0.0 109.37 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . 0.53 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 4.5 mp0 -73.11 11.66 0.68 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.1 -1.0 . . . . 0.0 111.105 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.445 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 1.4 m -111.02 13.91 22.0 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 120.595 -1.316 . . . . 0.0 109.139 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.512 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 4.0 m-30 71.47 3.96 4.87 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.484 -0.76 . . . . 0.0 109.619 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.528 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 29.4 tt0 -78.0 162.39 26.79 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.236 -0.915 . . . . 0.0 108.564 179.335 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . 0.482 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 7.1 tt0 -138.22 143.47 40.17 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.994 -1.066 . . . . 0.0 109.89 -179.443 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.569 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 19.7 m-85 -102.4 -70.11 0.76 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.163 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.582 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -98.47 174.31 28.17 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.062 -1.615 . . . . 0.0 109.062 179.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.576 ' C ' HD23 ' A' ' 116' ' ' LEU . 0.0 OUTLIER -175.28 129.45 0.28 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.005 -1.291 . . . . 0.0 110.461 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.666 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -146.9 72.31 1.26 Allowed 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 179.145 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' HIS . . . . . 0.541 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 15.1 p80 -93.31 150.79 20.21 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.321 -0.862 . . . . 0.0 110.181 -179.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.541 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.7 tt0 80.0 47.63 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.653 -0.654 . . . . 0.0 109.458 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 12.7 mm100 -107.98 125.45 51.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.387 -0.821 . . . . 0.0 109.333 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.626 ' O ' HD13 ' A' ' 121' ' ' ILE . 25.1 mt-30 -66.95 153.58 43.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.451 -0.781 . . . . 0.0 109.066 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.626 HD13 ' O ' ' A' ' 120' ' ' GLN . 6.6 mm -135.37 134.48 52.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.195 -0.94 . . . . 0.0 109.961 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -86.06 -179.37 6.74 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.425 -0.797 . . . . 0.0 110.075 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.877 HG23 ' CG ' ' A' ' 97' ' ' ASP . 39.6 p -76.96 -3.94 41.45 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.961 -0.696 . . . . 0.0 109.337 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.429 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 1.3 mt-10 -106.27 -173.24 2.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.257 -0.902 . . . . 0.0 109.263 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' TRP . . . . . 0.584 ' CE2' ' HD2' ' A' ' 93' ' ' ARG . 98.2 m95 -91.01 118.04 30.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.571 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -106.86 121.24 45.54 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.176 -0.953 . . . . 0.0 108.953 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.574 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.5 Cg_endo -79.42 105.37 1.87 Allowed 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.311 2.007 . . . . 0.0 111.011 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -112.88 133.43 54.87 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -151.52 177.04 10.72 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 122.435 1.112 . . . . 0.0 110.724 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.666 ' CE1' HD21 ' A' ' 116' ' ' LEU . 3.6 p90 -161.48 -169.67 2.36 Favored 'General case' 0 C--N 1.292 -1.934 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.148 179.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . 0.567 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 68.9 mt-10 -138.6 144.1 39.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.006 -1.059 . . . . 0.0 109.982 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.582 ' CE2' ' HA2' ' A' ' 114' ' ' GLY . 1.0 OUTLIER -163.63 147.56 10.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.448 -0.783 . . . . 0.0 109.215 179.763 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.469 ' OG1' ' HA ' ' A' ' 85' ' ' THR . 0.5 OUTLIER -116.22 147.93 40.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.879 . . . . 0.0 109.71 -179.537 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.625 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.5 t -40.49 110.42 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.602 -0.686 . . . . 0.0 109.291 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 12.4 t -61.98 -53.34 57.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.274 -0.891 . . . . 0.0 109.295 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -101.77 -91.59 0.33 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.367 -0.833 . . . . 0.0 109.21 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -163.33 50.81 0.16 Allowed 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.469 -0.769 . . . . 0.0 109.087 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.484 ' O ' HG23 ' A' ' 80' ' ' VAL . 61.3 mm-40 -87.92 112.08 22.15 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.242 -0.911 . . . . 0.0 109.738 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.5 p -79.39 -14.95 58.61 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.214 -0.929 . . . . 0.0 108.584 179.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 25.8 t -134.29 128.67 52.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.47 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -139.52 171.83 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.174 -0.954 . . . . 0.0 110.147 -179.629 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' ARG . . . . . 0.511 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.9 ptm180 -141.75 132.82 26.16 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ALA . . . . . 0.662 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -93.4 109.42 40.33 Favored Pre-proline 0 N--CA 1.486 1.365 0 O-C-N 121.228 -0.92 . . . . 0.0 110.202 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.523 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.1 Cg_endo -76.47 110.14 3.0 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.141 1.894 . . . . 0.0 110.9 179.399 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.838 HD11 HD22 ' A' ' 162' ' ' LEU . 3.0 mt -116.66 108.21 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 179.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' HIS . . . . . 0.602 ' N ' ' ND1' ' A' ' 146' ' ' HIS . 0.1 OUTLIER -123.74 160.75 26.59 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.299 -1.501 . . . . 0.0 112.111 -177.142 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.774 ' CE2' HD11 ' A' ' 159' ' ' ILE . 0.1 OUTLIER -113.53 -168.37 1.33 Allowed 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.628 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 127.02 32.84 0.66 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.817 ' C ' HG11 ' A' ' 64' ' ' VAL . 28.6 m-85 -121.34 155.27 35.1 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.297 -1.119 . . . . 0.0 109.283 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.476 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -67.06 -26.27 66.66 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -179.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.465 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.78 -7.57 46.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.409 -0.807 . . . . 0.0 109.562 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.57 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 2.5 t30 -115.21 14.17 16.89 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.684 HG23 HG13 ' A' ' 64' ' ' VAL . 2.4 t -89.32 159.5 2.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.585 -0.697 . . . . 0.0 109.674 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.55 37.31 49.67 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.428 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 1.9 m-20 -160.31 136.28 8.49 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.074 -1.251 . . . . 0.0 110.175 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' THR . . . . . 0.853 HG23 ' O ' ' A' ' 59' ' ' VAL . 45.2 m -86.25 122.25 29.98 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 179.085 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.57 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.8 OUTLIER -102.93 117.93 49.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.881 -1.137 . . . . 0.0 110.34 -178.873 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.65 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 13.9 m-85 -96.57 144.59 26.49 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 178.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.774 HD11 ' CE2' ' A' ' 147' ' ' PHE . 1.3 mt -140.99 139.83 33.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.768 -1.207 . . . . 0.0 110.636 -178.813 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' ASP . . . . . 0.637 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.5 OUTLIER -174.18 135.58 0.46 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.159 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 128.61 -6.65 6.59 Favored Glycine 0 N--CA 1.486 1.974 0 C-N-CA 119.127 -1.511 . . . . 0.0 111.21 179.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.838 HD22 HD11 ' A' ' 145' ' ' ILE . 8.0 tp -59.73 97.78 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.39 -1.653 . . . . 0.0 108.784 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . 0.49 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -121.94 145.59 47.96 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.565 -0.709 . . . . 0.0 109.931 -179.211 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.817 HD12 HG11 ' A' ' 78' ' ' VAL . 52.4 mt -125.65 108.85 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.328 -0.858 . . . . 0.0 109.291 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.911 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.144 -0.972 . . . . 0.0 109.661 -179.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.565 HG22 ' H ' ' A' ' 4' ' ' ALA . 4.2 p . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.565 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -68.06 -55.13 13.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.128 -0.982 . . . . 0.0 109.453 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.504 ' HB2' HG12 ' A' ' 164' ' ' ILE . 0.4 OUTLIER -69.56 148.74 49.01 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 109.112 179.949 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.523 HG22 ' ND2' ' A' ' 7' ' ' ASN . 15.4 mm -112.03 148.58 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.383 -0.823 . . . . 0.0 109.207 179.707 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.523 ' ND2' HG22 ' A' ' 6' ' ' ILE . 42.6 m-80 45.02 38.77 3.26 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.254 -0.904 . . . . 0.0 109.649 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.519 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -56.9 -40.77 90.9 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 107.968 -2.053 . . . . 0.0 107.968 179.077 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.525 ' CA ' ' OD2' ' A' ' 160' ' ' ASP . . . -112.9 18.2 22.04 Favored Glycine 0 N--CA 1.488 2.103 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 178.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.826 ' CD2' HG21 ' A' ' 25' ' ' VAL . 61.4 m-85 65.66 46.61 2.36 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.478 -1.013 . . . . 0.0 109.683 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -84.66 -28.05 26.67 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.283 -0.885 . . . . 0.0 109.549 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.411 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 0.7 OUTLIER -88.29 -30.78 19.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.592 -179.726 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 1.025 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.1 m -82.02 124.28 79.08 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.216 -0.928 . . . . 0.0 109.564 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.452 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.6 Cg_endo -78.03 138.21 16.19 Favored 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 122.412 2.075 . . . . 0.0 110.457 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -40.32 161.01 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 CA-C-O 121.233 0.539 . . . . 0.0 109.741 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 140.42 131.08 2.71 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.577 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.07 140.63 15.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.282 -1.129 . . . . 0.0 109.187 -179.689 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.478 HG23 ' HA ' ' A' ' 43' ' ' GLU . 43.7 t -89.91 144.41 9.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.453 -0.779 . . . . 0.0 110.197 -179.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.462 HG23 ' OD2' ' A' ' 20' ' ' ASP . 9.0 t -98.24 -27.56 14.1 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.16 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.546 ' HB2' ' CG ' ' A' ' 23' ' ' GLU . 7.0 m-20 -136.41 103.51 5.3 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.272 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 1.095 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -45.84 -30.43 1.69 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.101 -0.999 . . . . 0.0 109.746 -178.781 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.095 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -60.05 -49.51 77.37 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 121.643 -0.66 . . . . 0.0 109.796 -179.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.546 ' CG ' ' HB2' ' A' ' 20' ' ' ASP . 1.8 pt-20 -101.13 31.07 3.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.424 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.446 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -67.2 -45.73 78.3 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 1.025 HG13 ' OG1' ' A' ' 13' ' ' THR . 77.0 t -141.91 145.28 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -1.166 . . . . 0.0 109.695 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.77 -46.91 70.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.207 -0.933 . . . . 0.0 109.749 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.466 ' HA3' ' O ' ' A' ' 6' ' ' ILE . . . -81.53 -6.55 89.08 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' TRP . . . . . 1.059 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.2 OUTLIER -133.96 123.71 25.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.155 -1.203 . . . . 0.0 109.091 179.528 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.528 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -126.62 126.98 44.51 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.35 -0.844 . . . . 0.0 108.934 179.586 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.906 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -106.43 170.08 8.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.12 -0.987 . . . . 0.0 109.586 -179.395 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.425 ' HA ' HD21 ' A' ' 21' ' ' LEU . 19.4 m120 -160.53 122.45 3.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 110.241 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.779 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -103.65 137.54 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.257 -0.902 . . . . 0.0 109.354 178.625 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -86.88 169.72 40.83 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -60.6 -14.44 20.25 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.15 -1.206 . . . . 0.0 109.185 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.443 ' HB3' ' OD1' ' A' ' 67' ' ' ASN . 5.7 p -67.46 -33.72 75.72 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.338 -0.851 . . . . 0.0 109.796 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.796 HG12 ' O ' ' A' ' 36' ' ' VAL . 2.2 t -67.03 86.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.016 -1.053 . . . . 0.0 109.385 -179.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 17.7 m -65.81 -29.04 69.46 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.086 -1.009 . . . . 0.0 108.3 179.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 41.8 t30 -131.57 101.08 15.97 Favored Pre-proline 0 C--N 1.295 -1.765 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.32 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.2 149.87 36.52 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.368 2.045 . . . . 0.0 110.592 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.541 ' CD ' HG12 ' A' ' 71' ' ' ILE . 36.0 Cg_endo -77.38 -165.49 0.33 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.588 2.192 . . . . 0.0 110.191 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 56.0 t -108.52 118.88 57.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.331 -0.856 . . . . 0.0 110.13 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.602 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 2.7 m-85 -97.37 111.61 23.79 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.038 -1.039 . . . . 0.0 108.221 178.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.577 ' HG3' HG23 ' A' ' 17' ' ' VAL . 3.3 tm-20 -153.01 148.51 27.15 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.125 -0.984 . . . . 0.0 110.099 -179.446 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.458 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 61.4 t -102.41 148.45 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.388 -0.82 . . . . 0.0 109.048 179.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 1.05 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -150.19 164.28 36.07 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.084 -1.01 . . . . 0.0 108.602 -179.938 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 1.05 ' N ' HD22 ' A' ' 45' ' ' LEU . 13.0 mt-10 -110.68 112.81 24.95 Favored 'General case' 0 C--N 1.293 -1.863 0 O-C-N 121.443 -0.785 . . . . 0.0 109.809 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 1.022 HG22 HD21 ' A' ' 45' ' ' LEU . 1.9 p -106.48 152.99 22.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.453 -0.78 . . . . 0.0 109.458 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 51.9 p -88.25 18.79 4.12 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.345 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.421 ' O ' ' C ' ' A' ' 50' ' ' ALA . 14.7 t0 -132.97 7.81 4.03 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 109.519 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.421 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -43.93 149.22 0.68 Allowed Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.276 -0.89 . . . . 0.0 109.351 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.596 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 35.2 Cg_endo -78.21 -32.96 2.16 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.697 2.265 . . . . 0.0 110.372 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -139.28 77.49 1.62 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.283 -0.885 . . . . 0.0 109.531 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 118.48 -127.15 7.15 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.489 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 6.9 t30 -157.57 22.51 0.28 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.26 -1.141 . . . . 0.0 109.413 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.551 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 17.8 mttp -136.58 142.76 43.36 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.29 -0.881 . . . . 0.0 109.412 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.572 HG11 ' CZ2' ' A' ' 125' ' ' TRP . 6.1 m -150.64 174.18 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.217 -0.927 . . . . 0.0 109.563 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.667 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -102.88 103.15 13.28 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.575 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.764 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.96 118.55 23.06 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.838 ' O ' HG23 ' A' ' 156' ' ' THR . 46.9 t -113.29 143.9 22.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.096 -1.003 . . . . 0.0 108.6 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.845 HG22 HD22 ' A' ' 62' ' ' ASN . 45.7 m -108.66 94.29 4.97 Favored 'General case' 0 C--N 1.283 -2.316 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.59 HG12 ' HA ' ' A' ' 153' ' ' VAL . 55.5 t -89.03 125.36 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.281 -0.887 . . . . 0.0 108.843 179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.845 HD22 HG22 ' A' ' 60' ' ' THR . 5.7 p30 -160.17 61.58 0.34 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.41 -0.806 . . . . 0.0 109.68 -179.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 149.24 89.81 0.08 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.7 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.5 m -79.91 -171.93 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.281 -1.129 . . . . 0.0 109.58 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -134.71 -164.43 10.52 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -92.3 19.1 7.39 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -1.139 . . . . 0.0 109.459 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.526 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 30.5 m120 -132.72 148.15 68.37 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.231 -0.918 . . . . 0.0 109.398 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.508 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.3 Cg_endo -78.52 12.52 2.12 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.578 2.186 . . . . 0.0 110.836 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.526 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -136.59 58.83 1.72 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.99 -1.069 . . . . 0.0 109.688 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.51 ' HB3' ' CG2' ' A' ' 36' ' ' VAL . 1.8 m-20 -77.71 -69.61 0.53 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.122 -0.986 . . . . 0.0 108.963 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.573 HD12 ' HA2' ' A' ' 148' ' ' GLY . 3.0 mt -106.26 126.82 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.396 -0.815 . . . . 0.0 108.904 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -121.92 128.79 51.94 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.078 -1.013 . . . . 0.0 110.504 -179.268 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 1.059 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -113.68 108.54 17.26 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.554 HG22 ' N ' ' A' ' 75' ' ' ALA . 40.9 m -115.28 162.48 17.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.513 -1.367 . . . . 0.0 110.137 -178.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.554 ' N ' HG22 ' A' ' 74' ' ' THR . . . -123.46 140.1 53.34 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.227 -0.92 . . . . 0.0 109.219 179.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.535 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 3.1 p90 178.98 160.56 0.7 Allowed Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.416 -0.802 . . . . 0.0 109.22 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.53 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.9 Cg_endo -81.58 168.64 67.57 Favored 'Cis proline' 0 C--N 1.311 -1.418 0 C-N-CA 123.699 -1.375 . . . . 0.0 110.696 -0.468 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.535 HG11 HD11 ' A' ' 141' ' ' ILE . 33.3 t -121.22 131.58 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.233 -0.917 . . . . 0.0 108.87 179.355 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ASN . . . . . 0.522 ' O ' ' HB2' ' A' ' 4' ' ' ALA . 26.7 m-80 -94.03 103.97 16.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.079 -1.013 . . . . 0.0 109.975 -179.518 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.585 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.2 m -113.57 -176.6 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.402 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.709 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -133.42 142.61 44.77 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.302 -0.874 . . . . 0.0 109.346 179.88 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.449 ' HD3' HG22 ' A' ' 139' ' ' THR . 35.5 Cg_endo -77.63 106.47 2.2 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.448 2.099 . . . . 0.0 110.505 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 113.33 -30.68 7.14 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.5 ' HB ' ' HB3' ' A' ' 81' ' ' ARG . 2.5 t -84.51 149.74 4.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.23 -1.159 . . . . 0.0 109.47 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 19.7 m -90.6 123.65 34.41 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' TYR . . . . . 0.585 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 6.3 m-85 -106.37 154.84 20.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.282 -0.886 . . . . 0.0 109.733 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.472 ' HB ' ' O ' ' A' ' 165' ' ' ALA . 59.0 m -118.04 154.36 32.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.433 -0.792 . . . . 0.0 109.238 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.688 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -129.33 127.38 40.97 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.146 -0.971 . . . . 0.0 109.515 -179.84 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.511 ' O ' ' O ' ' A' ' 161' ' ' GLY . 21.6 m -130.5 145.54 51.87 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.266 -0.896 . . . . 0.0 108.78 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.726 HD13 ' HD2' ' A' ' 103' ' ' PHE . 16.9 tt -151.34 161.91 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 120.554 -1.341 . . . . 0.0 109.741 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.596 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 18.1 m95 -132.63 124.88 29.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.154 -0.966 . . . . 0.0 108.982 179.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.98 145.91 47.66 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.741 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.623 ' HA ' HG22 ' A' ' 121' ' ' ILE . 8.8 ptt180 -156.73 179.2 9.5 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -154.47 160.62 41.69 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.091 -1.006 . . . . 0.0 109.868 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -54.04 -41.19 67.8 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.383 -0.823 . . . . 0.0 109.452 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.472 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 57.4 mt-30 -130.34 143.38 50.74 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.225 -0.922 . . . . 0.0 109.442 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.79 ' OD1' HG23 ' A' ' 123' ' ' THR . 2.2 m-20 -57.14 149.37 19.7 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.293 -0.879 . . . . 0.0 109.505 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 111.23 36.99 1.71 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.841 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -125.19 141.8 51.88 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.072 -1.252 . . . . 0.0 109.32 179.695 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.52 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 54.0 t -118.56 151.27 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 110.832 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.64 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 40.7 t -150.02 162.11 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.527 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 54.4 m -124.42 128.83 49.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.09 -1.006 . . . . 0.0 109.31 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.726 ' HD2' HD13 ' A' ' 90' ' ' ILE . 0.2 OUTLIER -121.66 103.78 9.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.084 -1.01 . . . . 0.0 109.957 -179.788 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.488 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 20.9 p -128.4 165.02 21.43 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.216 -0.928 . . . . 0.0 109.927 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.655 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -121.62 125.23 73.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.564 0.697 . . . . 0.0 110.167 179.876 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -115.1 179.02 18.14 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.551 ' CB ' ' O ' ' A' ' 111' ' ' GLN . 25.7 t30 -127.83 172.04 11.22 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -1.097 . . . . 0.0 109.077 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . 0.455 ' HB2' ' OE2' ' A' ' 138' ' ' GLU . 31.4 mt-30 -59.17 -47.63 84.59 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.007 -1.058 . . . . 0.0 109.608 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.538 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 46.9 t -84.37 19.36 1.92 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.219 -0.926 . . . . 0.0 110.117 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.56 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.1 m-30 80.61 7.79 1.36 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.36 -0.838 . . . . 0.0 110.186 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.551 ' O ' ' CB ' ' A' ' 107' ' ' ASN . 37.0 mm-40 -69.9 123.99 22.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.994 -1.066 . . . . 0.0 108.736 179.249 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . 0.492 ' HG3' ' N ' ' A' ' 113' ' ' TYR . 1.2 tt0 -104.93 140.41 38.21 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.925 -1.109 . . . . 0.0 110.122 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.748 ' CE2' HG21 ' A' ' 141' ' ' ILE . 5.8 m-85 -108.37 -68.56 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.453 -0.779 . . . . 0.0 108.915 179.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.582 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -99.37 171.61 24.42 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 179.478 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.476 ' CG ' ' O ' ' A' ' 115' ' ' ARG . 0.2 OUTLIER -171.03 110.11 0.33 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.044 -1.268 . . . . 0.0 110.381 -179.867 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.91 HD21 ' CD1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -145.38 77.29 1.51 Allowed 'General case' 0 N--CA 1.494 1.74 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.168 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' HIS . . . . . 0.54 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 18.5 p80 -104.27 158.04 16.73 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.354 -0.842 . . . . 0.0 110.11 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 30.0 tt0 79.1 78.52 0.06 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.513 -0.742 . . . . 0.0 109.689 179.687 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.451 ' OE1' ' O ' ' A' ' 118' ' ' GLU . 19.5 mm100 -144.24 131.74 21.02 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.251 -0.906 . . . . 0.0 109.467 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.793 ' O ' HD13 ' A' ' 121' ' ' ILE . 10.6 mt-30 -66.66 156.04 36.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 109.066 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.793 HD13 ' O ' ' A' ' 120' ' ' GLN . 13.9 mm -133.21 136.76 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 O-C-N 121.066 -1.021 . . . . 0.0 110.005 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -90.48 -179.17 5.52 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.908 0.861 . . . . 0.0 110.636 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.79 HG23 ' OD1' ' A' ' 97' ' ' ASP . 0.8 OUTLIER -68.69 -15.67 63.59 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.416 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.521 ' O ' ' CB ' ' A' ' 93' ' ' ARG . 3.8 mt-10 -100.36 -172.09 2.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.475 -0.766 . . . . 0.0 109.289 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' TRP . . . . . 0.588 ' CE2' ' HD3' ' A' ' 51' ' ' PRO . 98.2 m95 -90.07 135.46 33.64 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.324 -0.86 . . . . 0.0 109.796 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.44 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 0.6 OUTLIER -106.83 121.37 45.16 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.233 -0.917 . . . . 0.0 108.977 179.751 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -79.64 110.1 2.57 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.447 2.098 . . . . 0.0 110.945 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -122.79 133.71 54.44 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 179.189 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.1 t -151.62 176.42 11.37 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 120.625 -1.297 . . . . 0.0 111.057 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.91 ' CD1' HD21 ' A' ' 116' ' ' LEU . 10.5 p90 -171.98 178.01 3.09 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.019 179.437 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . 0.474 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 33.5 mt-10 -133.7 153.57 51.6 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.061 -1.025 . . . . 0.0 110.041 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.565 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.14 160.76 19.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.458 -0.776 . . . . 0.0 109.147 179.746 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -119.11 146.2 45.31 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.18 -0.95 . . . . 0.0 109.293 -179.579 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.709 HG21 ' O ' ' A' ' 81' ' ' ARG . 2.5 t -56.72 111.94 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.362 -0.836 . . . . 0.0 109.264 179.611 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 3.8 m -83.61 -42.32 16.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.442 -0.786 . . . . 0.0 109.947 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.576 ' O ' ' CB ' ' A' ' 137' ' ' GLN . 33.1 t70 -85.91 -16.64 37.85 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.401 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . 0.691 ' H ' HG12 ' A' ' 134' ' ' VAL . 3.2 mm-40 86.32 28.38 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -178.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.523 ' CG ' ' OD1' ' A' ' 107' ' ' ASN . 3.0 mm-40 -74.48 119.4 18.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.606 -0.683 . . . . 0.0 109.795 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.449 HG22 ' HD3' ' A' ' 82' ' ' PRO . 17.3 p -79.34 -3.78 47.83 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.488 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.9 t -140.13 132.19 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.352 -0.843 . . . . 0.0 109.131 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.748 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.6 OUTLIER -144.53 171.98 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.259 -0.901 . . . . 0.0 109.821 -179.861 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' ARG . . . . . 0.501 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.1 ptm180 -139.61 132.26 28.89 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.528 -0.732 . . . . 0.0 109.419 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ALA . . . . . 0.655 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -96.09 108.78 43.31 Favored Pre-proline 0 N--CA 1.486 1.339 0 O-C-N 121.219 -0.926 . . . . 0.0 110.029 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.501 ' HD3' ' O ' ' A' ' 142' ' ' ARG . 36.2 Cg_endo -77.73 112.51 3.32 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.324 2.016 . . . . 0.0 111.106 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.809 HD11 HD22 ' A' ' 162' ' ' LEU . 2.4 mt -99.14 134.19 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 178.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' HIS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 12.8 m80 -97.2 154.83 17.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.34 -1.475 . . . . 0.0 111.607 -177.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.64 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 28.1 m-85 -155.1 157.21 37.16 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 179.284 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.573 ' HA2' HD12 ' A' ' 71' ' ' ILE . . . 108.11 53.59 0.65 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.7 ' C ' HG11 ' A' ' 64' ' ' VAL . 22.6 m-85 -129.03 159.47 35.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.245 -1.15 . . . . 0.0 109.39 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.414 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.67 -30.15 70.33 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -71.23 -11.6 61.01 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.369 -0.832 . . . . 0.0 109.049 179.265 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.841 ' OD1' ' HB1' ' A' ' 99' ' ' ALA . 1.8 t30 -116.86 13.07 14.93 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 179.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.59 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.2 t -85.15 162.22 2.95 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 O-C-N 121.635 -0.665 . . . . 0.0 109.695 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' GLY . . . . . 0.446 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 54.06 33.19 50.76 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.472 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.0 m-20 -160.47 135.46 7.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.187 -1.184 . . . . 0.0 110.069 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' THR . . . . . 0.838 HG23 ' O ' ' A' ' 59' ' ' VAL . 42.2 m -85.13 122.43 29.33 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.067 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.55 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -101.13 118.72 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.832 -1.167 . . . . 0.0 110.331 -178.811 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.764 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 3.5 m-85 -95.12 130.81 41.68 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.636 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.4 mt -120.31 142.0 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.915 -1.115 . . . . 0.0 110.078 -178.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' ASP . . . . . 0.564 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.8 OUTLIER -174.38 136.37 0.47 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.108 -0.995 . . . . 0.0 109.252 179.535 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 122.63 -10.4 9.1 Favored Glycine 0 N--CA 1.487 2.069 0 C-N-CA 119.322 -1.418 . . . . 0.0 111.014 179.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.809 HD22 HD11 ' A' ' 145' ' ' ILE . 9.9 tp -59.62 97.19 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.53 -1.571 . . . . 0.0 108.903 -179.643 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . 0.934 ' C ' HD13 ' A' ' 164' ' ' ILE . . . -134.57 145.55 48.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.537 -0.727 . . . . 0.0 109.985 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.934 HD13 ' C ' ' A' ' 163' ' ' ALA . 2.6 mm -119.65 108.5 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.284 -0.885 . . . . 0.0 109.204 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.525 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.127 -0.983 . . . . 0.0 109.527 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.798 HG22 ' O ' ' A' ' 164' ' ' ILE . 2.9 p . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.636 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -75.3 -46.57 32.63 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.186 -0.946 . . . . 0.0 109.587 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.511 ' HB2' ' CG1' ' A' ' 164' ' ' ILE . 0.9 OUTLIER -89.84 124.65 34.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.293 -0.88 . . . . 0.0 109.603 -179.945 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.492 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 1.8 mp -116.83 138.06 48.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.244 -0.91 . . . . 0.0 109.3 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.509 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.3 OUTLIER 74.99 16.52 2.87 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.219 -0.926 . . . . 0.0 109.627 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.502 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -60.11 -45.98 95.02 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.527 ' CA ' ' OD2' ' A' ' 160' ' ' ASP . . . -94.77 28.44 11.4 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 179.407 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.6 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 8.4 m-85 44.53 52.01 7.73 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.434 -1.039 . . . . 0.0 109.552 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.481 ' OE1' ' HA3' ' A' ' 53' ' ' GLY . 57.3 mm-40 -84.6 -28.24 26.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.298 -0.876 . . . . 0.0 109.639 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.423 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 0.9 OUTLIER -87.31 -37.08 17.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.198 -0.939 . . . . 0.0 109.762 -179.675 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.788 ' OG1' HG13 ' A' ' 25' ' ' VAL . 10.1 m -70.82 117.0 51.79 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.153 -0.967 . . . . 0.0 109.354 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 15' ' ' ALA . 35.2 Cg_endo -76.95 138.82 18.85 Favored 'Trans proline' 0 C--N 1.312 -1.378 0 C-N-CA 122.319 2.013 . . . . 0.0 110.396 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.441 ' C ' ' O ' ' A' ' 14' ' ' PRO . . . -39.31 153.88 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.516 0 CA-C-O 121.279 0.561 . . . . 0.0 109.857 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.49 131.37 2.41 Favored Glycine 0 N--CA 1.485 1.966 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.531 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.84 141.13 14.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.227 -1.16 . . . . 0.0 109.213 -179.602 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.642 HG13 ' HA2' ' A' ' 24' ' ' GLY . 47.8 t -86.58 142.37 13.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 CA-C-O 121.722 0.772 . . . . 0.0 110.365 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.411 ' C ' ' OD1' ' A' ' 20' ' ' ASP . 1.8 t -95.34 -28.53 14.92 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.069 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.426 ' O ' ' C ' ' A' ' 21' ' ' LEU . 1.0 OUTLIER -136.31 100.5 4.4 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.325 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 1.107 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -43.23 -29.02 0.36 Allowed 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.259 -0.9 . . . . 0.0 109.773 -178.868 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.107 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.69 -55.06 39.13 Favored 'General case' 0 C--N 1.294 -1.823 0 O-C-N 121.599 -0.688 . . . . 0.0 109.822 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -101.5 31.6 3.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.135 -0.978 . . . . 0.0 109.349 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.642 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -67.56 -47.18 63.74 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.788 HG13 ' OG1' ' A' ' 13' ' ' THR . 4.3 t -126.61 144.83 35.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.093 -1.24 . . . . 0.0 109.842 -179.638 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -62.49 -65.56 0.67 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.331 -0.855 . . . . 0.0 110.084 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.509 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -76.31 2.5 56.93 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' TRP . . . . . 0.687 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.7 OUTLIER -133.99 122.11 22.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.028 -1.278 . . . . 0.0 109.124 179.549 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.537 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -126.6 128.22 46.46 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.4 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.906 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -104.67 175.98 5.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.972 -1.08 . . . . 0.0 110.236 -178.927 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.409 ' ND2' ' O ' ' A' ' 30' ' ' LEU . 16.8 m120 -160.2 122.09 3.22 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.47 -0.769 . . . . 0.0 109.629 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.785 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -110.6 136.53 46.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.217 -0.927 . . . . 0.0 109.494 179.417 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.45 -179.87 21.03 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.1 m -58.42 -16.3 14.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -1.165 . . . . 0.0 109.294 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.484 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 37.7 m -60.37 -38.85 85.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.257 -0.902 . . . . 0.0 109.592 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.785 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -62.97 89.29 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.045 -1.034 . . . . 0.0 109.257 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.4 m -59.79 -29.23 68.07 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.242 -0.911 . . . . 0.0 108.69 179.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.693 ' O ' HG13 ' A' ' 36' ' ' VAL . 0.5 OUTLIER -129.07 128.79 23.36 Favored Pre-proline 0 C--N 1.296 -1.728 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.448 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.63 122.02 6.23 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.203 1.935 . . . . 0.0 110.523 -179.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.515 ' HG3' ' CD1' ' A' ' 71' ' ' ILE . 35.4 Cg_endo -77.3 -165.68 0.34 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.302 2.002 . . . . 0.0 109.905 179.697 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.513 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 70.2 t -117.34 118.72 59.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.034 -1.041 . . . . 0.0 110.775 -179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.453 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 2.3 m-85 -102.33 111.97 24.48 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.163 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.538 ' HA ' HG23 ' A' ' 18' ' ' VAL . 1.3 tm-20 -154.1 151.52 29.39 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.062 -1.024 . . . . 0.0 110.118 -179.116 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.444 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 48.0 t -103.75 148.39 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.488 -0.757 . . . . 0.0 109.188 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 1.071 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -149.13 164.12 35.63 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.77 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 1.071 ' N ' HD22 ' A' ' 45' ' ' LEU . 9.9 pt-20 -125.47 124.89 42.37 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.333 -0.855 . . . . 0.0 109.551 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.92 HG23 HD21 ' A' ' 45' ' ' LEU . 1.3 p -127.24 166.77 17.12 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.388 -0.82 . . . . 0.0 109.461 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 95.6 p -88.24 18.58 4.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.912 . . . . 0.0 109.4 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 50' ' ' ALA . 0.1 OUTLIER -123.96 -0.81 8.39 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.277 -0.889 . . . . 0.0 109.584 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.34 145.84 1.32 Allowed Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.166 -0.959 . . . . 0.0 109.406 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.603 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 36.1 Cg_endo -78.44 -41.94 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.647 2.231 . . . . 0.0 110.396 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -128.26 89.61 2.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.315 -0.865 . . . . 0.0 109.413 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.481 ' HA3' ' OE1' ' A' ' 11' ' ' GLU . . . 105.49 -128.38 9.37 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.484 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 9.2 p-10 -152.63 18.24 0.61 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.201 -1.176 . . . . 0.0 109.704 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.466 ' O ' ' OD2' ' A' ' 160' ' ' ASP . 95.1 mttt -138.73 146.6 41.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.15 -0.969 . . . . 0.0 109.665 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.64 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.4 m -150.1 174.48 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.392 -0.817 . . . . 0.0 109.242 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.672 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -100.43 103.75 15.13 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.12 -0.988 . . . . 0.0 108.964 179.475 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.721 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -82.04 121.9 27.14 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 178.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.789 ' O ' HG23 ' A' ' 156' ' ' THR . 44.0 t -115.46 144.17 23.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.113 -0.992 . . . . 0.0 109.084 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.858 HG22 ' ND2' ' A' ' 62' ' ' ASN . 95.9 m -107.79 88.48 2.74 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.196 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.699 HG21 ' CD1' ' A' ' 157' ' ' ILE . 60.1 t -86.77 120.91 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.419 -0.801 . . . . 0.0 109.291 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.858 ' ND2' HG22 ' A' ' 60' ' ' THR . 5.4 p30 -160.23 59.3 0.35 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.423 -0.798 . . . . 0.0 109.835 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 154.57 84.65 0.05 OUTLIER Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.719 HG12 ' C ' ' A' ' 148' ' ' GLY . 1.7 m -80.66 -176.54 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.24 -1.153 . . . . 0.0 109.396 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.484 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -126.99 -159.53 10.21 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 22.8 m-20 -89.48 -9.22 50.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.295 -1.121 . . . . 0.0 109.455 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.499 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 39.6 m-80 -104.77 148.06 35.46 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.241 -0.912 . . . . 0.0 109.388 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 67' ' ' ASN . 36.2 Cg_endo -78.85 13.54 1.92 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.651 2.234 . . . . 0.0 110.942 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.499 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 1.9 p90 -137.72 53.33 1.85 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.98 -1.075 . . . . 0.0 109.744 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.522 ' CB ' HG23 ' A' ' 36' ' ' VAL . 0.4 OUTLIER -75.48 -65.28 0.91 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.174 -0.953 . . . . 0.0 109.095 179.645 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.546 HG13 ' CG2' ' A' ' 36' ' ' VAL . 4.5 mt -105.05 128.68 58.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.275 -0.89 . . . . 0.0 108.709 179.523 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -130.69 130.44 43.86 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.822 -1.174 . . . . 0.0 110.545 -179.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.906 ' HA ' HD23 ' A' ' 30' ' ' LEU . . . -113.66 108.82 17.64 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.548 HG22 ' N ' ' A' ' 75' ' ' ALA . 54.5 m -109.23 162.3 14.42 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.688 -1.257 . . . . 0.0 110.134 -178.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.548 ' N ' HG22 ' A' ' 74' ' ' THR . . . -122.74 138.97 54.47 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.267 -0.895 . . . . 0.0 109.173 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.555 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 4.1 p90 179.36 161.57 0.76 Allowed Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.526 -0.734 . . . . 0.0 109.098 -179.723 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.555 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.7 Cg_endo -81.76 166.32 72.28 Favored 'Cis proline' 0 C--N 1.311 -1.444 0 C-N-CA 123.802 -1.333 . . . . 0.0 110.972 -0.364 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.72 HG11 HD13 ' A' ' 164' ' ' ILE . 86.7 t -127.19 156.64 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ASN . . . . . 0.636 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 69.1 m-20 -122.53 139.52 53.81 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.007 -1.058 . . . . 0.0 109.875 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.45 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 4.0 m -146.04 -174.04 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.226 -0.921 . . . . 0.0 109.758 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.542 ' O ' HG21 ' A' ' 134' ' ' VAL . 3.1 ttt85 -138.07 141.38 32.06 Favored Pre-proline 0 N--CA 1.49 1.534 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.513 ' HD2' ' CG ' ' A' ' 81' ' ' ARG . 34.9 Cg_endo -76.12 117.27 4.6 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.467 2.111 . . . . 0.0 110.778 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 107.72 -33.53 6.26 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.454 ' HB ' ' HB3' ' A' ' 81' ' ' ARG . 2.7 t -88.59 149.72 3.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.221 -1.164 . . . . 0.0 109.584 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.3 t -94.19 147.54 23.07 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' TYR . . . . . 0.573 ' CD2' ' O ' ' A' ' 165' ' ' ALA . 7.6 m-85 -122.2 157.46 31.54 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.102 -0.999 . . . . 0.0 109.937 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 47.7 m -111.21 142.12 43.84 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.375 -0.828 . . . . 0.0 109.05 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.816 ' CD1' HG23 ' A' ' 164' ' ' ILE . 0.2 OUTLIER -134.19 128.25 33.62 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.093 -1.004 . . . . 0.0 109.548 -179.522 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.501 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.5 m -134.83 152.79 52.04 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.716 HD13 ' CD2' ' A' ' 103' ' ' PHE . 18.6 tt -150.9 163.4 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.787 -1.196 . . . . 0.0 109.343 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.603 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 17.2 m95 -130.66 124.87 32.61 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.076 -1.015 . . . . 0.0 109.566 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.465 ' HB3' HG23 ' A' ' 121' ' ' ILE . . . -113.49 146.81 39.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.3 -0.875 . . . . 0.0 109.204 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.494 ' HG3' ' O ' ' A' ' 123' ' ' THR . 6.5 ttp85 -162.34 119.68 2.08 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.144 -0.973 . . . . 0.0 109.228 -179.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.418 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.35 160.52 15.31 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.22 -0.925 . . . . 0.0 109.937 -179.61 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.08 -44.83 75.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.425 -0.797 . . . . 0.0 109.176 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.518 ' C ' HG22 ' A' ' 123' ' ' THR . 0.0 OUTLIER -117.68 151.62 36.88 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.872 . . . . 0.0 109.132 179.758 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.872 ' N ' HG22 ' A' ' 123' ' ' THR . 2.3 p-10 -73.59 146.01 45.02 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.139 -0.976 . . . . 0.0 109.566 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 113.56 37.89 1.26 Allowed Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -121.66 140.53 52.17 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.188 -1.184 . . . . 0.0 109.128 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.461 ' HB ' ' OD1' ' A' ' 152' ' ' ASN . 50.7 t -116.23 154.3 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.218 -0.926 . . . . 0.0 110.66 -179.427 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.69 HG22 ' CE1' ' A' ' 147' ' ' PHE . 61.6 t -155.02 166.49 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.592 ' HB2' ' CD2' ' A' ' 117' ' ' HIS . 30.8 t -136.18 130.81 33.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.027 -1.046 . . . . 0.0 109.643 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.716 ' CD2' HD13 ' A' ' 90' ' ' ILE . 0.3 OUTLIER -122.86 104.51 9.32 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.145 -0.972 . . . . 0.0 109.572 -179.965 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.614 ' O ' ' HB1' ' A' ' 143' ' ' ALA . 16.0 p -117.22 170.78 8.41 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.119 -0.988 . . . . 0.0 110.462 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.649 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -127.32 157.71 38.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.834 -0.541 . . . . 0.0 109.726 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 111' ' ' GLN . . . 172.98 138.33 2.58 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.639 ' CB ' HG22 ' A' ' 141' ' ' ILE . 1.3 p30 -76.98 -169.88 1.46 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.123 -1.222 . . . . 0.0 109.334 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . 0.521 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 1.4 mp0 -77.28 14.91 0.83 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.04 -1.037 . . . . 0.0 110.925 -179.156 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.508 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 0.9 OUTLIER -113.63 6.36 16.91 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 120.785 -1.197 . . . . 0.0 109.344 179.598 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.569 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.6 m-30 77.94 14.84 1.55 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.361 -0.837 . . . . 0.0 109.611 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.493 ' HG2' ' HB2' ' A' ' 109' ' ' SER . 7.9 mm-40 -90.0 94.39 9.78 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 108.655 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . 0.53 ' CG ' ' O ' ' A' ' 105' ' ' VAL . 2.0 tt0 -81.92 142.08 32.77 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.362 -0.836 . . . . 0.0 110.34 -179.06 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.596 ' HB3' ' CD1' ' A' ' 132' ' ' PHE . 4.8 m-85 -109.69 -69.02 0.88 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.207 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.422 ' N ' HG23 ' A' ' 105' ' ' VAL . . . -89.34 177.67 44.19 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 179.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 1.01 ' O ' HD23 ' A' ' 116' ' ' LEU . 0.6 OUTLIER -177.87 135.83 0.17 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.951 -1.323 . . . . 0.0 110.393 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 1.01 HD23 ' O ' ' A' ' 115' ' ' ARG . 0.5 OUTLIER -147.36 69.87 1.16 Allowed 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.304 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' HIS . . . . . 0.592 ' CD2' ' HB2' ' A' ' 102' ' ' SER . 27.2 t-80 -93.77 141.57 28.35 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 110.295 -179.043 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.559 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 4.2 tt0 82.21 36.8 0.06 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.711 -0.618 . . . . 0.0 109.52 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 6.9 mm100 -88.55 120.34 29.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.355 -0.841 . . . . 0.0 109.165 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.71 ' O ' HD13 ' A' ' 121' ' ' ILE . 1.6 mt-30 -65.5 140.99 58.63 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.462 -0.774 . . . . 0.0 108.945 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.71 HD13 ' O ' ' A' ' 120' ' ' GLN . 5.9 mm -125.81 129.68 72.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.109 -0.995 . . . . 0.0 110.126 -179.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -89.86 -178.77 5.57 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.618 0.723 . . . . 0.0 110.094 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.872 HG22 ' N ' ' A' ' 97' ' ' ASP . 11.6 p -72.87 -2.08 19.32 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 119.914 -0.714 . . . . 0.0 109.352 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.47 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 0.4 OUTLIER -112.44 -168.73 1.36 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.166 -0.959 . . . . 0.0 108.981 179.727 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' TRP . . . . . 0.534 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 95.3 m95 -91.95 130.26 37.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.145 -0.972 . . . . 0.0 109.613 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.439 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 12.1 mm-40 -109.51 121.45 42.33 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.156 -0.965 . . . . 0.0 109.109 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.17 100.41 1.26 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 C-N-CA 122.514 2.143 . . . . 0.0 111.141 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -110.9 137.83 48.05 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.14 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.1 t -144.18 176.21 9.5 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.565 -1.334 . . . . 0.0 111.058 -179.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.661 ' CE1' HD11 ' A' ' 116' ' ' LEU . 16.9 p90 -173.9 171.06 3.77 Favored 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 115.036 -0.983 . . . . 0.0 109.034 179.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . 0.516 ' HA ' ' CE2' ' A' ' 88' ' ' TYR . 34.3 mt-10 -143.64 142.18 30.92 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.089 -1.007 . . . . 0.0 109.904 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.702 ' CE2' ' CZ ' ' A' ' 88' ' ' TYR . 5.2 p90 -151.11 168.07 25.78 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.35 -0.844 . . . . 0.0 109.145 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.407 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -119.37 147.29 44.51 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.907 . . . . 0.0 109.623 -179.719 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.542 HG21 ' O ' ' A' ' 81' ' ' ARG . 3.6 t -43.51 110.43 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.46 -0.775 . . . . 0.0 108.977 179.546 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -58.52 -51.12 71.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.293 -179.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -110.65 -91.16 0.47 Allowed 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.399 -0.813 . . . . 0.0 109.209 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -160.94 55.2 0.3 Allowed 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.576 -0.702 . . . . 0.0 109.127 179.737 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.512 ' HG3' ' ND2' ' A' ' 107' ' ' ASN . 7.2 mm-40 -95.01 111.91 23.67 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.213 -0.93 . . . . 0.0 109.851 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.0 p -79.42 -13.46 59.58 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 41.6 t -134.03 136.42 53.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.212 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.639 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -143.36 171.89 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.072 -1.018 . . . . 0.0 110.224 -179.498 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' ARG . . . . . 0.501 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.4 ptm180 -141.37 132.43 26.23 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ALA . . . . . 0.649 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -94.22 109.67 43.78 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.331 -0.856 . . . . 0.0 110.286 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.502 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.9 Cg_endo -77.2 110.68 3.06 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 122.023 1.816 . . . . 0.0 109.664 178.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.687 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 3.3 mt -95.18 124.15 47.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' HIS . . . . . 0.492 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 12.8 m80 -84.5 149.36 25.99 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.926 -1.109 . . . . 0.0 111.638 -177.008 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.694 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 10.4 m-85 -154.55 158.43 39.79 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.063 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.719 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 109.33 38.77 1.74 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.66 ' C ' HG11 ' A' ' 64' ' ' VAL . 20.9 m-85 -113.99 158.08 21.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.444 -1.033 . . . . 0.0 109.207 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.21 -27.58 68.09 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.479 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.43 -14.99 62.77 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.447 -0.783 . . . . 0.0 109.328 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.521 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.2 OUTLIER -109.62 11.25 24.77 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.371 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.529 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.4 t -85.79 163.88 2.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 O-C-N 121.523 -0.735 . . . . 0.0 109.881 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' GLY . . . . . 0.481 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.98 31.83 40.73 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.034 -1.227 . . . . 0.0 110.034 179.671 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.476 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.1 m-20 -160.61 139.36 10.28 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.147 -1.207 . . . . 0.0 110.27 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 59' ' ' VAL . 80.1 m -87.29 121.2 29.42 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.699 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.2 mt -101.89 118.2 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 120.868 -1.145 . . . . 0.0 110.383 -178.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.721 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.6 m-85 -97.24 138.78 34.2 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 178.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.694 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -130.35 139.78 50.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 C-N-CA 118.767 -1.173 . . . . 0.0 110.014 -178.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' ASP . . . . . 0.64 ' CB ' HG12 ' A' ' 56' ' ' VAL . 1.0 OUTLIER -173.94 136.1 0.52 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.371 -0.831 . . . . 0.0 109.136 179.687 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . 0.501 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 126.58 -8.08 7.39 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.688 179.397 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.565 ' HB2' HD12 ' A' ' 90' ' ' ILE . 10.4 tp -59.61 93.06 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.648 -1.501 . . . . 0.0 108.82 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . 0.475 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -118.22 145.75 44.76 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.694 -0.629 . . . . 0.0 109.9 -179.061 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.816 HG23 ' CD1' ' A' ' 88' ' ' TYR . 20.6 mt -132.68 127.28 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.362 -0.836 . . . . 0.0 109.095 179.607 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.573 ' O ' ' CD2' ' A' ' 86' ' ' TYR . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.201 -0.937 . . . . 0.0 109.599 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.679 HG23 ' HB2' ' A' ' 165' ' ' ALA . 4.1 p . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.913 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -77.61 -31.31 52.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 109.51 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.643 ' HB2' HD12 ' A' ' 164' ' ' ILE . 10.2 t-20 -92.19 124.67 36.44 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.24 -0.913 . . . . 0.0 109.689 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.512 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 65.5 mt -110.38 121.63 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.323 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.525 ' OD1' ' CB ' ' A' ' 12' ' ' SER . 0.1 OUTLIER 76.83 43.8 0.12 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.243 -0.911 . . . . 0.0 109.169 -179.436 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.452 ' O ' ' HB3' ' A' ' 162' ' ' LEU . . . -47.76 -22.57 1.96 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.64 ' O ' ' CB ' ' A' ' 10' ' ' PHE . . . 164.2 60.35 0.02 OUTLIER Glycine 0 N--CA 1.487 2.082 0 C-N-CA 119.609 -1.281 . . . . 0.0 109.964 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.64 ' CB ' ' O ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER 118.4 1.06 0.0 OUTLIER 'General case' 0 N--CA 1.518 2.946 0 C-N-CA 122.832 0.453 . . . . 0.0 111.579 179.115 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.569 ' HG2' ' CD1' ' A' ' 10' ' ' PHE . 9.2 mm-40 -75.73 -60.79 2.16 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.418 -1.426 . . . . 0.0 110.831 -177.757 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.525 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.3 OUTLIER -75.11 -3.01 30.26 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.048 -1.032 . . . . 0.0 110.025 -179.201 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.642 ' OG1' HG13 ' A' ' 25' ' ' VAL . 4.4 m -126.1 123.8 24.49 Favored Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.029 -1.045 . . . . 0.0 109.411 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.454 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.4 Cg_endo -77.35 149.11 27.41 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 C-N-CA 122.46 2.107 . . . . 0.0 110.719 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.467 ' HA ' ' HB ' ' A' ' 44' ' ' VAL . . . -39.96 161.15 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.196 0.522 . . . . 0.0 109.676 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.35 134.49 3.42 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.654 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.47 140.87 14.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.392 -1.063 . . . . 0.0 108.969 -179.569 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.429 HG23 ' HA ' ' A' ' 43' ' ' GLU . 47.2 t -87.93 144.34 9.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.427 -0.796 . . . . 0.0 110.169 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.6 p -105.78 -21.2 13.23 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.391 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.403 ' HB3' ' HG3' ' A' ' 23' ' ' GLU . 7.7 m-20 -145.32 130.08 18.12 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.566 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 1.034 HD12 ' N ' ' A' ' 22' ' ' ALA . 1.7 pp -87.13 -38.31 16.57 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.088 -1.008 . . . . 0.0 110.179 -179.486 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.034 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.61 -24.93 64.21 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.155 -0.966 . . . . 0.0 108.87 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.403 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 2.0 pt-20 -138.66 34.63 2.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.452 -0.78 . . . . 0.0 109.215 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.98 -72.78 1.28 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.642 HG13 ' OG1' ' A' ' 13' ' ' THR . 1.6 t -86.08 127.85 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.288 -1.125 . . . . 0.0 109.134 179.73 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.5 ' HB3' ' HB3' ' A' ' 12' ' ' SER . 25.7 tt0 -54.71 -36.45 64.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.351 -0.843 . . . . 0.0 110.1 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.517 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -109.96 8.61 31.57 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.862 -1.161 . . . . 0.0 110.214 -179.367 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' TRP . . . . . 0.749 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.7 OUTLIER -140.57 119.67 12.81 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.089 -1.242 . . . . 0.0 109.125 179.313 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.585 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 7.3 m-20 -124.81 142.17 51.61 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.188 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.922 ' O ' HD13 ' A' ' 21' ' ' LEU . 3.3 mt -109.48 172.13 7.04 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.846 -1.159 . . . . 0.0 109.794 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -159.95 122.41 3.38 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.767 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.688 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.23 137.87 37.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.476 -0.765 . . . . 0.0 109.598 179.302 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -90.73 172.98 37.88 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 72.4 m -62.61 -12.28 22.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.17 -1.194 . . . . 0.0 109.38 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 20.9 p -72.23 -32.64 66.91 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.32 -0.863 . . . . 0.0 109.812 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.787 HG12 ' O ' ' A' ' 36' ' ' VAL . 2.2 t -70.34 87.1 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 O-C-N 121.112 -0.992 . . . . 0.0 109.318 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 22.2 m -63.96 -28.98 70.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.194 -0.941 . . . . 0.0 108.484 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.1 t30 -128.86 114.86 19.05 Favored Pre-proline 0 C--N 1.296 -1.74 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.44 ' HA ' ' HD3' ' A' ' 40' ' ' PRO . 34.8 Cg_endo -76.45 144.56 25.8 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.167 1.911 . . . . 0.0 110.492 -179.501 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.643 ' CG ' HG21 ' A' ' 71' ' ' ILE . 35.3 Cg_endo -77.27 -164.08 0.25 Allowed 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.557 2.171 . . . . 0.0 110.133 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 56.8 t -116.09 120.26 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.127 -0.983 . . . . 0.0 110.667 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.817 ' CD1' HD13 ' A' ' 30' ' ' LEU . 5.5 m-85 -101.78 112.21 24.72 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 178.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.654 ' HG3' HG23 ' A' ' 17' ' ' VAL . 0.4 OUTLIER -155.93 140.04 16.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.005 -1.059 . . . . 0.0 110.361 -179.451 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.473 ' N ' ' HG2' ' A' ' 43' ' ' GLU . 36.5 t -92.52 148.79 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 1.039 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -148.67 165.16 32.17 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.013 -1.055 . . . . 0.0 109.033 -179.558 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . 1.039 ' N ' HD22 ' A' ' 45' ' ' LEU . 13.4 mt-10 -111.19 113.89 26.72 Favored 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.452 -0.78 . . . . 0.0 109.644 -178.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.941 ' CG2' HD21 ' A' ' 45' ' ' LEU . 7.7 p -111.71 165.82 11.71 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 41.8 t -94.67 -10.11 32.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.3 m-20 -102.54 -1.79 29.77 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.263 -0.898 . . . . 0.0 109.59 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.482 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -44.1 147.38 0.94 Allowed Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.165 -0.959 . . . . 0.0 109.43 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.613 ' HB3' ' CE3' ' A' ' 91' ' ' TRP . 35.4 Cg_endo -78.34 -40.85 0.31 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.704 2.269 . . . . 0.0 110.325 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.14 107.06 11.73 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.418 ' O ' ' CG ' ' A' ' 54' ' ' ASN . . . 87.5 -120.5 5.56 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ASN . . . . . 0.482 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 27.7 m120 -160.16 36.28 0.17 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -1.169 . . . . 0.0 109.504 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.64 ' CD ' ' CD2' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -158.91 157.27 31.09 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.31 -0.869 . . . . 0.0 109.765 179.824 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.801 HG12 ' HB3' ' A' ' 160' ' ' ASP . 15.3 m -152.27 174.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.372 -0.83 . . . . 0.0 108.897 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' LEU . . . . . 0.493 ' O ' ' HA ' ' A' ' 158' ' ' TYR . 0.2 OUTLIER -91.44 100.67 13.4 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 178.777 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.744 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -80.34 120.05 23.87 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 119.394 -0.922 . . . . 0.0 108.991 -179.812 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.841 ' O ' HG23 ' A' ' 156' ' ' THR . 41.3 t -112.97 144.48 20.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . 0.841 HG22 ' ND2' ' A' ' 62' ' ' ASN . 59.7 m -109.87 91.14 3.53 Favored 'General case' 0 C--N 1.282 -2.327 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.537 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 52.4 t -89.95 122.82 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.311 -0.868 . . . . 0.0 108.799 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.841 ' ND2' HG22 ' A' ' 60' ' ' THR . 5.0 p30 -160.09 60.96 0.35 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.284 -0.885 . . . . 0.0 109.935 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 158.51 86.48 0.06 OUTLIER Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.729 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.3 m -82.23 -177.15 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.248 -1.148 . . . . 0.0 109.588 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -136.52 -157.86 7.87 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -96.0 23.73 6.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.326 -1.102 . . . . 0.0 109.566 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.502 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 7.0 m-80 -136.55 148.19 62.78 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.2 -0.937 . . . . 0.0 109.466 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.414 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.4 Cg_endo -78.24 11.93 2.22 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.662 2.242 . . . . 0.0 110.926 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.502 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 1.3 p90 -136.76 59.56 1.69 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.093 -1.004 . . . . 0.0 109.647 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.514 ' HB3' ' CG2' ' A' ' 36' ' ' VAL . 1.4 m-20 -76.6 -67.59 0.68 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.242 -0.911 . . . . 0.0 109.111 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.643 HG21 ' CG ' ' A' ' 40' ' ' PRO . 2.2 mt -116.57 123.37 71.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.433 -0.792 . . . . 0.0 109.12 179.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.517 ' CG ' ' O ' ' A' ' 145' ' ' ILE . 20.7 tt0 -129.12 134.33 48.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.972 -1.08 . . . . 0.0 110.335 -179.4 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . 0.749 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -115.91 107.69 15.31 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 178.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.56 HG22 ' N ' ' A' ' 75' ' ' ALA . 99.3 m -103.52 165.06 11.26 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.334 -0.854 . . . . 0.0 109.669 -179.24 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.56 ' N ' HG22 ' A' ' 74' ' ' THR . . . -122.98 137.49 54.94 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.026 -1.046 . . . . 0.0 109.227 179.027 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CZ ' ' HB2' ' A' ' 29' ' ' ASP . 11.2 p90 -176.05 160.32 1.89 Allowed Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.4 -0.812 . . . . 0.0 109.383 -179.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.519 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -82.53 170.22 58.1 Favored 'Cis proline' 0 C--N 1.311 -1.395 0 O-C-N 123.652 1.343 . . . . 0.0 111.064 -0.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.674 HG11 HD13 ' A' ' 164' ' ' ILE . 96.4 t -131.75 156.9 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.239 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ASN . . . . . 0.913 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 76.1 m-20 -123.24 140.28 53.18 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.922 -1.111 . . . . 0.0 110.289 -179.459 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 138' ' ' GLU . 4.3 m -145.48 -173.51 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.304 -0.873 . . . . 0.0 109.387 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.766 ' O ' HG21 ' A' ' 134' ' ' VAL . 17.6 mmt180 -136.45 144.73 48.69 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.382 -0.824 . . . . 0.0 109.348 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.454 ' HD2' ' HD3' ' A' ' 81' ' ' ARG . 35.1 Cg_endo -77.73 126.87 8.4 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.457 2.105 . . . . 0.0 110.539 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.22 -25.17 21.61 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.424 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -86.32 149.61 4.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.239 -1.154 . . . . 0.0 109.496 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 32.8 m -94.86 131.96 40.18 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' TYR . . . . . 0.502 ' HD2' HG22 ' A' ' 164' ' ' ILE . 14.6 m-85 -113.32 167.31 10.67 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.236 -0.915 . . . . 0.0 109.666 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.47 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 43.8 m -118.38 152.88 34.99 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.338 -0.851 . . . . 0.0 109.418 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.688 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 7.9 t80 -132.81 114.83 14.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.481 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.485 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.2 m -135.11 146.23 48.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.194 -0.941 . . . . 0.0 109.002 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.701 HD13 ' HD2' ' A' ' 103' ' ' PHE . 15.3 tt -150.96 163.78 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.796 -1.19 . . . . 0.0 109.5 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.613 ' CE3' ' HB3' ' A' ' 51' ' ' PRO . 37.3 m95 -128.76 135.41 49.15 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.862 -1.149 . . . . 0.0 109.375 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.425 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -130.0 148.09 51.82 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.213 -0.929 . . . . 0.0 109.747 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.636 ' CB ' ' CD2' ' A' ' 125' ' ' TRP . 11.6 ttt-85 -164.14 121.66 1.74 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.317 -0.864 . . . . 0.0 108.909 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.04 165.68 11.04 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.305 -0.872 . . . . 0.0 110.086 -179.403 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.07 -56.6 12.06 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.425 -0.797 . . . . 0.0 109.117 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.517 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.5 OUTLIER -101.77 134.93 44.17 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.279 -0.888 . . . . 0.0 109.204 179.701 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.581 ' N ' ' CG2' ' A' ' 123' ' ' THR . 1.2 p30 -60.77 144.95 51.37 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.212 -0.93 . . . . 0.0 109.551 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 112.45 37.82 1.41 Allowed Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.536 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -118.78 139.31 51.8 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.204 -1.174 . . . . 0.0 109.224 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.449 HG22 ' HA ' ' A' ' 120' ' ' GLN . 76.0 t -116.46 149.93 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.205 -0.934 . . . . 0.0 110.407 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.813 HG13 ' CE2' ' A' ' 147' ' ' PHE . 43.0 t -146.15 165.77 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.34 -0.85 . . . . 0.0 109.45 179.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.556 ' CB ' ' HB2' ' A' ' 117' ' ' HIS . 24.2 m -124.77 133.42 53.16 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.146 -0.971 . . . . 0.0 109.681 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.701 ' HD2' HD13 ' A' ' 90' ' ' ILE . 1.0 OUTLIER -129.1 103.85 7.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.126 -0.984 . . . . 0.0 109.477 179.497 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.647 HG22 ' HA ' ' A' ' 115' ' ' ARG . 29.2 p -128.14 175.63 8.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.133 -0.979 . . . . 0.0 110.323 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.904 HG23 ' H ' ' A' ' 114' ' ' GLY . 0.0 OUTLIER -133.45 106.34 9.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-O 121.575 0.702 . . . . 0.0 110.316 179.175 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.459 ' O ' ' HG2' ' A' ' 142' ' ' ARG . . . -101.54 132.46 10.97 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 108.052 -2.019 . . . . 0.0 108.052 178.554 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.584 ' OD1' ' CE1' ' A' ' 113' ' ' TYR . 0.2 OUTLIER -96.87 -170.62 2.08 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.963 -1.316 . . . . 0.0 109.052 -179.399 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 62.1 mt-30 -81.28 -19.8 42.24 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 118.751 -1.18 . . . . 0.0 109.829 -179.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.539 ' HB3' ' CG ' ' A' ' 111' ' ' GLN . 0.6 OUTLIER -81.92 8.82 9.45 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.113 -0.992 . . . . 0.0 108.792 178.979 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' PHE . . . . . 0.44 ' HB2' ' O ' ' A' ' 109' ' ' SER . 18.3 m-30 63.01 21.75 13.08 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.428 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.539 ' CG ' ' HB3' ' A' ' 109' ' ' SER . 2.0 mt-30 -88.36 161.61 17.01 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.649 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.82 102.12 12.22 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.447 -0.783 . . . . 0.0 109.768 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 1.016 ' OH ' HG13 ' A' ' 134' ' ' VAL . 1.9 m-30 -69.41 -67.14 0.5 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.401 -0.812 . . . . 0.0 108.941 178.553 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.904 ' H ' HG23 ' A' ' 105' ' ' VAL . . . -130.55 171.45 20.72 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.647 ' HA ' HG22 ' A' ' 104' ' ' THR . 0.2 OUTLIER -162.78 117.31 1.75 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.029 -1.277 . . . . 0.0 110.723 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.891 HD21 ' CD2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -150.62 74.31 1.17 Allowed 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 178.997 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' HIS . . . . . 0.556 ' HB2' ' CB ' ' A' ' 102' ' ' SER . 22.4 p80 -118.3 169.15 9.97 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.193 -0.942 . . . . 0.0 110.134 -179.304 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.512 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 0.2 OUTLIER 77.53 41.04 0.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.517 -0.739 . . . . 0.0 109.294 179.925 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.452 ' HG3' HD11 ' A' ' 121' ' ' ILE . 0.8 OUTLIER -116.03 138.35 51.3 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.316 -0.865 . . . . 0.0 109.668 -179.836 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' GLN . . . . . 0.486 ' O ' HD13 ' A' ' 121' ' ' ILE . 2.4 mt-30 -74.54 156.49 36.8 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.486 HD13 ' O ' ' A' ' 120' ' ' GLN . 5.2 mm -135.19 134.64 52.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.116 -0.99 . . . . 0.0 110.022 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.0 -179.43 7.25 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.523 -0.735 . . . . 0.0 109.947 179.477 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.581 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 70.2 p -75.98 -0.46 21.67 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 119.829 -0.748 . . . . 0.0 109.23 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.442 ' O ' ' HG3' ' A' ' 93' ' ' ARG . 22.5 mm-40 -102.4 -168.91 1.59 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.246 -0.909 . . . . 0.0 109.21 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' TRP . . . . . 0.679 ' CH2' HG11 ' A' ' 56' ' ' VAL . 88.4 m95 -103.2 115.17 30.07 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 0.0 109.614 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 -106.68 120.75 47.32 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.11 -0.994 . . . . 0.0 108.986 179.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.408 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.9 Cg_endo -80.58 116.28 3.22 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 C-N-CA 122.384 2.056 . . . . 0.0 111.175 -179.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -112.03 135.6 52.46 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.435 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -145.71 176.3 9.75 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 120.822 -1.174 . . . . 0.0 110.801 -179.348 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.891 ' CD2' HD21 ' A' ' 116' ' ' LEU . 21.2 p90 -176.89 152.7 0.96 Allowed 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.303 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -105.28 154.91 19.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.752 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 113' ' ' TYR . 0.2 OUTLIER -165.02 160.88 19.43 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.431 -0.793 . . . . 0.0 109.334 179.942 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.7 OUTLIER -124.13 146.42 48.65 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.214 -0.929 . . . . 0.0 108.937 -179.883 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 1.016 HG13 ' OH ' ' A' ' 113' ' ' TYR . 3.5 t -43.57 109.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.294 -0.879 . . . . 0.0 108.955 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -51.41 -40.05 58.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.123 -0.986 . . . . 0.0 109.149 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -129.81 -90.28 0.48 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.38 -0.825 . . . . 0.0 109.369 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -158.58 52.73 0.42 Allowed 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.479 -0.763 . . . . 0.0 109.279 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . 0.6 ' O ' HG23 ' A' ' 80' ' ' VAL . 32.5 mm-40 -85.53 110.15 19.01 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.261 -0.9 . . . . 0.0 109.547 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.3 p -79.48 -16.25 56.38 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.249 -0.907 . . . . 0.0 108.71 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.515 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 42.4 t -132.24 134.31 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.725 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -139.81 172.28 12.69 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.051 -1.031 . . . . 0.0 110.447 -179.447 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' ARG . . . . . 0.502 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.0 OUTLIER -143.73 132.07 22.07 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.895 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ALA . . . . . 0.848 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -99.31 106.58 39.88 Favored Pre-proline 0 N--CA 1.487 1.421 0 O-C-N 121.207 -0.933 . . . . 0.0 109.616 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.586 ' C ' HD13 ' A' ' 145' ' ' ILE . 36.1 Cg_endo -78.04 111.92 3.16 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.206 1.937 . . . . 0.0 110.827 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ILE . . . . . 0.705 HD13 ' N ' ' A' ' 145' ' ' ILE . 2.0 mm -94.31 139.56 18.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 178.343 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' HIS . . . . . 0.539 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 4.5 m80 -107.22 159.75 16.11 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.299 -1.501 . . . . 0.0 112.165 -177.007 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.813 ' CE2' HG13 ' A' ' 101' ' ' VAL . 39.0 m-85 -160.72 165.25 30.77 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.639 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 104.52 46.51 1.3 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.729 ' C ' HG11 ' A' ' 64' ' ' VAL . 23.9 m-85 -125.03 161.27 27.1 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.477 -1.013 . . . . 0.0 109.115 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.418 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.72 -28.47 68.45 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -75.78 -11.54 60.0 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.434 -0.791 . . . . 0.0 109.065 179.031 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.613 ' ND2' HD13 ' A' ' 157' ' ' ILE . 1.5 t30 -114.61 11.0 16.88 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.403 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.535 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.4 t -88.02 162.81 2.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.495 -0.753 . . . . 0.0 109.868 -179.223 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' GLY . . . . . 0.466 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.42 34.04 41.07 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 3.5 m-20 -160.39 138.71 10.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.177 -1.19 . . . . 0.0 110.013 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' THR . . . . . 0.841 HG23 ' O ' ' A' ' 59' ' ' VAL . 53.5 m -89.37 120.44 30.72 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.613 HD13 ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -100.37 117.44 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.902 -1.124 . . . . 0.0 110.222 -178.894 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.744 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 13.1 m-85 -92.52 143.63 26.16 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 178.381 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.656 ' CD1' ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -142.04 136.22 29.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.604 -1.31 . . . . 0.0 111.025 -178.014 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' ASP . . . . . 0.801 ' HB3' HG12 ' A' ' 56' ' ' VAL . 4.7 t0 -173.23 136.24 0.62 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.245 -0.909 . . . . 0.0 108.586 179.144 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 133.35 -7.29 5.01 Favored Glycine 0 N--CA 1.484 1.896 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.422 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.848 HD21 ' HB3' ' A' ' 143' ' ' ALA . 7.3 tp -59.33 93.14 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.626 -1.514 . . . . 0.0 108.596 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . 0.444 ' N ' ' O ' ' A' ' 161' ' ' GLY . . . -123.62 145.98 48.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.594 -0.691 . . . . 0.0 109.965 -178.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' ILE . . . . . 0.674 HD13 HG11 ' A' ' 78' ' ' VAL . 8.0 mt -132.41 119.58 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.325 -0.86 . . . . 0.0 109.258 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.679 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.772 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.1 tmm? . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -57.09 101.3 0.06 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 0.0 109.427 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.629 HG22 ' O ' ' A' ' 164' ' ' ILE . 4.1 p -87.98 173.5 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.239 -0.913 . . . . 0.0 109.405 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.76 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -71.74 -46.61 57.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.173 -0.955 . . . . 0.0 109.487 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.852 ' HB2' HD12 ' A' ' 164' ' ' ILE . 38.7 t-20 -82.56 125.83 31.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.207 -0.933 . . . . 0.0 109.496 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.472 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 2.0 mp -112.2 123.35 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.292 -0.88 . . . . 0.0 109.265 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.483 ' HB3' ' HA3' ' A' ' 27' ' ' GLY . 0.8 OUTLIER 69.05 12.9 8.7 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.266 -0.896 . . . . 0.0 109.504 179.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.465 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -59.14 -24.96 59.29 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.458 ' O ' ' OD2' ' A' ' 160' ' ' ASP . . . -110.99 36.56 4.16 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.214 -1.555 . . . . 0.0 109.214 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.733 ' HD2' HG21 ' A' ' 25' ' ' VAL . 0.7 OUTLIER 43.64 53.21 6.02 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.368 -1.078 . . . . 0.0 109.422 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.483 ' OE2' ' CG ' ' A' ' 52' ' ' GLU . 7.7 mm-40 -84.04 -49.62 8.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -0.926 . . . . 0.0 109.728 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.451 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 7.3 m -79.58 -16.49 55.8 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.677 -179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 1.048 ' OG1' HG13 ' A' ' 25' ' ' VAL . 0.5 OUTLIER -74.51 114.74 36.89 Favored Pre-proline 0 C--N 1.304 -1.389 0 O-C-N 121.185 -0.947 . . . . 0.0 109.422 -179.802 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.2 Cg_endo -77.09 136.9 16.75 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.424 2.082 . . . . 0.0 110.474 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.47 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -40.02 155.51 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.393 0.616 . . . . 0.0 109.717 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.3 132.6 3.0 Favored Glycine 0 N--CA 1.485 1.961 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.531 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.71 142.45 12.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.252 -1.146 . . . . 0.0 109.011 -179.528 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.6 t -88.42 144.14 9.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-O 121.778 0.799 . . . . 0.0 110.277 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.3 t -105.03 -26.69 12.04 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 179.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.48 ' CB ' ' HG3' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -138.18 101.37 4.38 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 179.453 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.969 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.7 OUTLIER -55.56 -34.91 65.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.204 -0.935 . . . . 0.0 110.384 -179.004 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.946 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.69 -33.79 72.03 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.061 -1.024 . . . . 0.0 109.334 -179.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.48 ' HG3' ' CB ' ' A' ' 20' ' ' ASP . 1.4 pt-20 -122.15 37.67 4.32 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.303 -0.873 . . . . 0.0 109.369 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -89.2 -73.1 1.28 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 1.048 HG13 ' OG1' ' A' ' 13' ' ' THR . 14.6 t -99.72 127.43 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.307 -1.113 . . . . 0.0 109.259 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 31.6 tp10 -56.76 -35.69 68.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.417 -0.802 . . . . 0.0 109.783 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.483 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -99.14 -2.4 56.91 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 -179.503 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 0.614 ' CZ3' ' CB ' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -138.79 123.21 18.32 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.088 -1.242 . . . . 0.0 109.845 179.941 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.744 ' C ' HD23 ' A' ' 30' ' ' LEU . 3.9 m-20 -123.47 144.23 49.66 Favored 'General case' 0 N--CA 1.492 1.625 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.969 ' O ' HD13 ' A' ' 21' ' ' LEU . 0.7 OUTLIER -113.5 166.98 10.98 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.714 -1.242 . . . . 0.0 109.461 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.458 ' OD1' ' O ' ' A' ' 30' ' ' LEU . 8.5 m120 -157.02 124.67 5.39 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.45 -0.781 . . . . 0.0 109.687 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.045 ' CG1' HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.04 136.56 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.383 -0.823 . . . . 0.0 109.457 179.539 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.43 -170.6 23.81 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.4 t -66.74 -9.09 33.01 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.195 -1.18 . . . . 0.0 109.438 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.473 ' HB2' ' HA ' ' A' ' 70' ' ' ASP . 0.6 OUTLIER -73.12 -31.39 64.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.204 -0.935 . . . . 0.0 109.593 -179.964 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 1.045 HG21 ' CG1' ' A' ' 32' ' ' VAL . 2.1 t -64.64 87.86 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 O-C-N 121.176 -0.952 . . . . 0.0 109.339 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 16.4 m -72.58 -29.0 63.15 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.624 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.2 t-20 -114.57 144.98 32.88 Favored Pre-proline 0 C--N 1.296 -1.746 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.446 ' HD2' ' CG ' ' A' ' 38' ' ' ASN . 34.8 Cg_endo -76.38 111.8 3.34 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 122.359 2.039 . . . . 0.0 110.591 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.55 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.2 Cg_endo -77.57 166.13 26.16 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.371 2.048 . . . . 0.0 109.593 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.532 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 49.0 t -108.16 121.59 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.966 -1.084 . . . . 0.0 110.559 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.629 ' CE2' HD23 ' A' ' 21' ' ' LEU . 27.4 m-85 -110.12 112.47 24.48 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.531 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 0.9 OUTLIER -153.56 151.32 29.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.1 -1.0 . . . . 0.0 109.801 -179.422 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.459 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 62.3 t -98.78 148.57 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -0.885 . . . . 0.0 109.255 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.758 HD21 ' CG2' ' A' ' 47' ' ' THR . 0.4 OUTLIER -131.9 147.01 52.44 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.185 -0.947 . . . . 0.0 108.776 179.978 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.56 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 18.1 mt-10 -115.08 113.69 24.37 Favored 'General case' 0 C--N 1.295 -1.8 0 O-C-N 121.576 -0.702 . . . . 0.0 109.548 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.758 ' CG2' HD21 ' A' ' 45' ' ' LEU . 1.7 p -141.5 164.66 29.62 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.31 -0.869 . . . . 0.0 109.41 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.448 ' HA ' ' OD1' ' A' ' 54' ' ' ASN . 0.1 OUTLIER -86.9 15.59 5.73 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -0.9 . . . . 0.0 109.51 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -102.89 -18.51 15.03 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.242 -0.911 . . . . 0.0 109.436 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.721 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -55.55 144.68 52.97 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.2 -0.938 . . . . 0.0 109.329 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.515 ' HG3' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.29 -42.12 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.571 2.181 . . . . 0.0 110.365 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.483 ' CG ' ' OE2' ' A' ' 11' ' ' GLU . 0.1 OUTLIER -101.42 92.8 5.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.901 . . . . 0.0 109.407 179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.93 -115.97 4.35 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.721 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 15.2 m-20 -160.02 37.77 0.18 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -1.147 . . . . 0.0 109.412 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.52 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 62.1 mttt -138.54 134.24 33.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.198 -0.938 . . . . 0.0 109.6 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.659 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.9 m -146.53 174.62 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.313 -0.867 . . . . 0.0 109.229 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.789 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -107.46 103.09 12.34 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.101 -1.0 . . . . 0.0 109.181 179.731 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.684 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.17 120.71 25.21 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.034 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.824 ' O ' HG23 ' A' ' 156' ' ' THR . 41.5 t -115.79 144.89 22.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.15 -0.969 . . . . 0.0 109.331 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.816 HG22 HD22 ' A' ' 62' ' ' ASN . 19.6 m -108.99 92.75 4.18 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.563 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 52.5 t -90.54 115.73 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.236 -0.915 . . . . 0.0 109.272 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.816 HD22 HG22 ' A' ' 60' ' ' THR . 2.0 p30 -149.51 56.41 0.98 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.248 -0.908 . . . . 0.0 109.828 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 160.9 90.09 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.779 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.5 m -80.14 -171.32 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.176 -1.19 . . . . 0.0 109.451 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -139.95 -168.44 11.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -86.21 1.41 50.86 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.233 -1.157 . . . . 0.0 109.569 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.603 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 1.2 m120 -116.33 145.02 34.16 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.241 -0.912 . . . . 0.0 109.284 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.584 ' HG2' ' CZ3' ' A' ' 69' ' ' TRP . 36.4 Cg_endo -79.52 38.88 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.607 2.204 . . . . 0.0 111.197 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.603 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 8.2 p90 -162.58 50.05 0.18 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.968 -1.082 . . . . 0.0 109.807 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.649 ' HB2' HD12 ' A' ' 71' ' ' ILE . 0.4 OUTLIER -70.94 -64.64 0.86 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.126 -0.984 . . . . 0.0 108.924 179.536 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.649 HD12 ' HB2' ' A' ' 70' ' ' ASP . 4.1 mp -106.4 128.73 60.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 108.996 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.452 ' OE2' ' HB2' ' A' ' 144' ' ' PRO . 71.3 tt0 -138.26 122.68 18.35 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.843 -1.16 . . . . 0.0 110.195 -179.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.635 ' CB ' HD22 ' A' ' 30' ' ' LEU . . . -113.76 107.41 15.7 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.069 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.55 HG22 ' N ' ' A' ' 75' ' ' ALA . 96.7 m -94.4 165.44 12.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.57 -0.706 . . . . 0.0 110.17 -179.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.55 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.12 137.78 53.36 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.175 -0.953 . . . . 0.0 108.726 178.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.536 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 0.2 OUTLIER -179.12 161.49 1.0 Allowed Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.561 -0.712 . . . . 0.0 109.165 -179.387 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.536 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.2 Cg_endo -82.46 163.32 74.97 Favored 'Cis proline' 0 C--N 1.311 -1.437 0 C-N-CA 123.81 -1.329 . . . . 0.0 110.893 -0.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.761 HG11 HD13 ' A' ' 164' ' ' ILE . 96.8 t -123.99 156.45 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.4 -0.813 . . . . 0.0 108.913 179.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.76 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 52.1 m-20 -121.21 139.8 52.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.115 -0.991 . . . . 0.0 109.854 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.565 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 2.5 m -146.3 -174.0 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.138 -0.976 . . . . 0.0 109.478 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.691 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -137.3 146.09 52.52 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.233 -0.917 . . . . 0.0 109.429 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.45 106.14 2.16 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.474 2.116 . . . . 0.0 110.494 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 112.35 -29.7 8.12 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.475 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.43 149.71 4.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.158 -1.201 . . . . 0.0 109.474 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.471 ' HA ' ' OG1' ' A' ' 133' ' ' THR . 10.8 m -95.47 143.07 27.11 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.565 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 12.0 m-85 -120.61 168.49 11.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.171 -0.956 . . . . 0.0 109.604 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.478 ' CB ' ' O ' ' A' ' 165' ' ' ALA . 5.2 m -118.15 154.47 32.1 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.26 -0.9 . . . . 0.0 109.561 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.682 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 5.1 t80 -130.56 118.96 21.81 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.298 -0.876 . . . . 0.0 109.319 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.474 ' O ' ' O ' ' A' ' 161' ' ' GLY . 31.8 m -134.31 144.04 48.07 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.215 -0.928 . . . . 0.0 109.333 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.552 HD13 ' CD2' ' A' ' 103' ' ' PHE . 14.9 tt -150.62 163.54 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 120.703 -1.248 . . . . 0.0 109.506 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.515 ' HB2' ' HG3' ' A' ' 51' ' ' PRO . 20.1 m95 -132.73 124.98 29.17 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.974 -1.079 . . . . 0.0 109.342 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.88 150.42 37.08 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.288 -0.883 . . . . 0.0 109.459 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.552 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 1.1 ttt85 -164.4 119.12 1.44 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.309 -0.869 . . . . 0.0 109.027 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.39 170.1 8.12 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 110.065 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -66.12 -55.94 13.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.443 -0.785 . . . . 0.0 109.41 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.514 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -104.43 137.3 42.5 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.222 -0.924 . . . . 0.0 109.463 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.585 ' N ' ' CG2' ' A' ' 123' ' ' THR . 19.2 p-10 -61.64 148.35 42.82 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.308 -0.87 . . . . 0.0 109.562 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 108.9 39.43 1.71 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.506 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -119.55 141.15 49.5 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.14 -1.212 . . . . 0.0 108.98 179.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.401 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 52.0 t -115.94 148.25 18.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 110.712 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.634 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 25.1 t -150.01 164.96 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.457 -0.777 . . . . 0.0 109.203 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.539 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 16.4 t -136.47 144.33 44.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.011 -1.056 . . . . 0.0 109.457 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.629 ' N ' ' CD1' ' A' ' 103' ' ' PHE . 0.1 OUTLIER -135.99 104.67 5.78 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.224 -0.923 . . . . 0.0 109.924 -179.726 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.507 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 14.0 p -112.77 168.75 9.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.093 -1.005 . . . . 0.0 110.058 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.596 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -127.83 141.45 46.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 CA-C-O 121.386 0.612 . . . . 0.0 109.837 -179.879 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -167.49 143.9 8.58 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.4 p30 -84.66 -169.79 2.8 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.197 -1.179 . . . . 0.0 109.632 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.52 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 11.2 mp0 -77.84 16.95 0.62 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.196 -0.94 . . . . 0.0 110.683 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.463 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 0.8 OUTLIER -113.23 15.46 19.36 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 120.831 -1.168 . . . . 0.0 108.801 179.447 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.463 ' HB2' ' O ' ' A' ' 109' ' ' SER . 9.8 m-30 67.63 16.86 9.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.504 -0.748 . . . . 0.0 109.599 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.528 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 12.8 mm-40 -93.5 157.66 16.1 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.177 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.471 ' OE2' ' HB2' ' A' ' 115' ' ' ARG . 8.0 tt0 -137.83 147.15 44.29 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.034 -1.041 . . . . 0.0 109.99 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.509 ' CE2' HG21 ' A' ' 141' ' ' ILE . 4.0 m-85 -112.3 -67.4 1.0 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.587 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -92.35 173.42 35.73 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.471 ' HB2' ' OE2' ' A' ' 112' ' ' GLU . 6.8 ttt-85 -178.78 119.46 0.08 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.08 -1.247 . . . . 0.0 110.217 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.646 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -141.91 70.03 1.33 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.396 -0.815 . . . . 0.0 108.803 179.241 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.54 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 0.2 OUTLIER -86.64 148.07 25.63 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 110.346 -179.265 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 1.2 mt-10 79.42 66.32 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.466 -0.771 . . . . 0.0 109.557 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.472 ' NE2' ' HA ' ' A' ' 119' ' ' GLN . 7.8 mm100 -118.79 123.73 45.51 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.315 -0.866 . . . . 0.0 109.259 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.553 ' O ' HD13 ' A' ' 121' ' ' ILE . 0.0 OUTLIER -64.23 139.14 58.73 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.429 -0.794 . . . . 0.0 108.972 179.78 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 120' ' ' GLN . 5.6 mm -125.95 130.17 72.32 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.08 -1.012 . . . . 0.0 110.14 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.04 -179.28 6.17 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.604 0.716 . . . . 0.0 109.949 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.585 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 74.9 p -75.85 -4.19 39.36 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.793 -0.763 . . . . 0.0 109.183 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 2.8 mt-10 -106.65 -168.78 1.46 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.327 -0.858 . . . . 0.0 109.311 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.552 ' CE2' ' HD3' ' A' ' 93' ' ' ARG . 93.8 m95 -94.38 118.64 31.92 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.208 -0.933 . . . . 0.0 109.691 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -106.88 121.44 44.88 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.289 -0.882 . . . . 0.0 108.985 179.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -79.54 117.05 3.64 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 C-N-CA 122.341 2.027 . . . . 0.0 111.075 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -121.25 138.29 54.3 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.7 t -151.27 175.81 11.84 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.608 -1.308 . . . . 0.0 111.149 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.682 ' CE2' ' CD1' ' A' ' 88' ' ' TYR . 36.3 p90 -173.22 -172.69 0.84 Allowed 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.095 179.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . 0.412 ' N ' ' CD1' ' A' ' 130' ' ' PHE . 21.7 mt-10 -129.01 155.78 44.86 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.098 -1.001 . . . . 0.0 110.051 -179.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -164.98 139.18 4.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.422 -0.799 . . . . 0.0 109.065 179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.471 ' OG1' ' HA ' ' A' ' 85' ' ' THR . 0.8 OUTLIER -117.85 146.19 44.05 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.216 -0.927 . . . . 0.0 109.377 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.691 HG21 ' O ' ' A' ' 81' ' ' ARG . 4.4 t -44.57 110.49 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.396 -0.815 . . . . 0.0 109.203 179.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 65.5 m -61.8 -53.08 60.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.207 -0.933 . . . . 0.0 109.258 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 -102.91 -91.74 0.34 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.359 -0.838 . . . . 0.0 109.218 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -162.27 50.59 0.2 Allowed 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.458 -0.776 . . . . 0.0 109.314 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.51 ' O ' HG23 ' A' ' 80' ' ' VAL . 23.1 mm-40 -88.18 114.63 25.0 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.209 -0.932 . . . . 0.0 109.604 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.6 p -79.19 -12.38 59.97 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.294 -0.879 . . . . 0.0 108.759 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.492 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 40.8 t -135.73 134.77 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.391 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.509 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -139.58 172.52 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.194 -0.941 . . . . 0.0 110.057 -179.725 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.493 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.4 ptm180 -145.54 132.54 20.28 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.556 -0.715 . . . . 0.0 109.614 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.596 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -100.24 106.58 42.87 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.292 -0.88 . . . . 0.0 109.655 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.507 ' HD2' ' O ' ' A' ' 104' ' ' THR . 33.7 Cg_endo -76.64 110.56 3.07 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.061 1.841 . . . . 0.0 110.291 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.633 HD13 ' N ' ' A' ' 145' ' ' ILE . 3.2 mm -85.71 124.74 40.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.499 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 6.7 m80 -84.57 150.15 25.41 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.972 -1.08 . . . . 0.0 110.984 -178.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.66 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 12.1 m-85 -154.91 157.36 37.66 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.125 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.599 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 108.44 50.67 0.74 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.779 ' C ' HG11 ' A' ' 64' ' ' VAL . 27.5 m-85 -121.17 159.77 25.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.378 -1.072 . . . . 0.0 109.227 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.487 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -65.78 -30.39 71.03 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.611 -0.681 . . . . 0.0 109.168 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.467 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -77.0 -11.0 59.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.394 -0.816 . . . . 0.0 109.108 179.273 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.577 ' ND2' HD13 ' A' ' 157' ' ' ILE . 3.8 t30 -109.81 11.62 24.28 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.55 HG23 HG13 ' A' ' 64' ' ' VAL . 2.4 t -90.06 164.76 2.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 O-C-N 121.519 -0.738 . . . . 0.0 109.763 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.493 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 53.29 32.7 44.72 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.864 -1.295 . . . . 0.0 109.864 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.7 m-20 -160.53 136.78 8.59 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.137 -1.214 . . . . 0.0 110.04 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.824 HG23 ' O ' ' A' ' 59' ' ' VAL . 53.6 m -86.83 121.13 28.9 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.01 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.577 HD13 ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -100.86 118.73 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 120.967 -1.083 . . . . 0.0 110.291 -178.775 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.684 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.6 m-85 -97.09 129.42 44.51 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 178.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.66 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -120.37 141.99 38.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 120.749 -1.219 . . . . 0.0 110.091 -178.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.659 ' CB ' HG12 ' A' ' 56' ' ' VAL . 4.5 t70 -173.89 136.41 0.54 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.299 -0.876 . . . . 0.0 108.901 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 124.78 -6.93 8.34 Favored Glycine 0 N--CA 1.486 2.033 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.157 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.601 HD11 ' CE2' ' A' ' 88' ' ' TYR . 0.6 OUTLIER -60.01 94.04 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 O-C-N 120.768 -1.43 . . . . 0.0 108.491 179.899 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . 0.494 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -132.93 145.85 51.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.633 -0.667 . . . . 0.0 109.815 -179.068 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.852 HD12 ' HB2' ' A' ' 5' ' ' ASN . 3.2 mt -123.08 115.65 46.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.235 -0.915 . . . . 0.0 109.202 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.5 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . -142.02 146.69 35.81 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.171 -0.956 . . . . 0.0 109.626 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 4.0 p -84.42 176.58 8.58 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.279 -0.888 . . . . 0.0 109.533 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.435 ' HB2' ' HD2' ' A' ' 168' ' ' PRO . 2.3 pt20 -76.66 159.45 79.21 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.27 -0.894 . . . . 0.0 109.543 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 167' ' ' GLN . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.576 0 C-N-CA 122.674 2.25 . . . . 0.0 110.449 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.634 ' O ' HG12 ' A' ' 3' ' ' VAL . 1.0 OUTLIER -77.38 -23.39 50.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.183 -0.948 . . . . 0.0 109.451 179.992 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.874 ' CG2' ' HB2' ' A' ' 165' ' ' ALA . 1.4 p 43.85 -169.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.359 -0.838 . . . . 0.0 109.553 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.713 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -70.79 -61.19 1.86 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.058 -1.027 . . . . 0.0 109.324 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.599 ' HB3' HD13 ' A' ' 164' ' ' ILE . 13.0 p-10 -74.92 176.92 6.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.367 -0.833 . . . . 0.0 109.405 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.669 HG22 ' ND2' ' A' ' 7' ' ' ASN . 2.6 mp -128.3 136.83 59.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.286 -0.884 . . . . 0.0 109.717 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.669 ' ND2' HG22 ' A' ' 6' ' ' ILE . 0.3 OUTLIER 44.92 57.71 4.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.678 179.908 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.497 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -56.96 -42.79 92.92 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.504 ' HA2' ' HA ' ' A' ' 160' ' ' ASP . . . -107.74 35.62 4.89 Favored Glycine 0 N--CA 1.487 2.088 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.994 ' CE2' HG21 ' A' ' 25' ' ' VAL . 4.1 m-85 63.52 54.73 1.87 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.468 -1.019 . . . . 0.0 109.386 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -82.35 -50.53 8.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.897 . . . . 0.0 109.737 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.532 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 41.3 t -69.9 -42.14 73.77 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.105 -0.997 . . . . 0.0 109.693 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.956 ' OG1' HG13 ' A' ' 25' ' ' VAL . 0.6 OUTLIER -68.53 125.71 91.99 Favored Pre-proline 0 C--N 1.305 -1.351 0 O-C-N 121.217 -0.927 . . . . 0.0 109.199 -179.882 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.47 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.2 Cg_endo -76.98 146.1 25.53 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 122.462 2.108 . . . . 0.0 111.071 -179.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.804 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -42.05 165.48 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.564 0 CA-C-O 121.214 0.53 . . . . 0.0 109.663 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 130.96 135.27 3.76 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.531 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.57 140.14 15.14 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.34 -1.094 . . . . 0.0 109.029 -179.596 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -84.77 143.67 11.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 CA-C-O 121.763 0.792 . . . . 0.0 110.196 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.4 p -113.56 -27.1 7.99 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.553 ' CB ' ' HG3' ' A' ' 23' ' ' GLU . 20.5 m-20 -133.42 77.83 1.75 Allowed 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.923 HD12 ' N ' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -44.63 -32.25 1.41 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.323 -0.861 . . . . 0.0 109.708 -179.365 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.923 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -71.11 -47.03 60.44 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.283 -0.885 . . . . 0.0 109.548 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.553 ' HG3' ' CB ' ' A' ' 20' ' ' ASP . 9.1 pt-20 -115.49 38.12 3.36 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.257 -0.902 . . . . 0.0 109.569 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 20' ' ' ASP . . . -106.9 -77.69 1.09 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.994 HG21 ' CE2' ' A' ' 10' ' ' PHE . 5.8 t -92.8 111.0 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.283 -1.128 . . . . 0.0 109.264 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -59.98 -39.86 87.15 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.299 -0.876 . . . . 0.0 109.867 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.461 ' HA3' ' HB2' ' A' ' 7' ' ' ASN . . . -67.56 -35.12 85.86 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 0.535 ' CE3' ' HB1' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -129.64 126.26 37.98 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.153 -1.204 . . . . 0.0 109.67 -179.797 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.727 ' C ' HD23 ' A' ' 30' ' ' LEU . 6.3 m-20 -115.54 141.25 48.31 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.902 ' O ' HD13 ' A' ' 21' ' ' LEU . 0.9 OUTLIER -116.29 163.13 16.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.716 -1.24 . . . . 0.0 109.53 -179.548 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 71.8 m-80 -156.18 123.15 5.29 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.518 -0.738 . . . . 0.0 109.402 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.005 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -102.97 133.84 45.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.342 -0.849 . . . . 0.0 109.514 179.571 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.14 167.34 16.89 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -44.86 -26.16 0.38 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -1.142 . . . . 0.0 109.411 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.491 ' CB ' ' HB2' ' A' ' 67' ' ' ASN . 6.8 m -53.08 -53.12 55.0 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.19 -0.944 . . . . 0.0 109.455 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 1.005 HG21 HG12 ' A' ' 32' ' ' VAL . 42.2 t -46.18 94.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.2 -0.938 . . . . 0.0 110.196 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.484 ' N ' ' O ' ' A' ' 35' ' ' SER . 82.9 m -78.25 -27.53 47.6 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.336 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.512 ' O ' HG12 ' A' ' 36' ' ' VAL . 20.1 m-20 -114.9 147.36 38.1 Favored Pre-proline 0 C--N 1.297 -1.696 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.32 111.08 3.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.496 2.131 . . . . 0.0 110.768 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.538 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 36.0 Cg_endo -78.69 167.33 22.63 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.495 2.13 . . . . 0.0 109.684 179.551 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.524 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 51.1 t -110.38 121.89 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.953 -1.092 . . . . 0.0 110.47 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.634 ' CD2' HD23 ' A' ' 21' ' ' LEU . 28.2 m-85 -111.01 112.8 24.87 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 178.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.531 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 29.3 tt0 -151.08 160.8 43.68 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.109 -0.994 . . . . 0.0 109.702 -179.383 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.476 HG13 ' O ' ' A' ' 56' ' ' VAL . 49.2 t -102.26 133.48 45.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.434 -0.791 . . . . 0.0 109.133 179.555 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.508 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -111.28 118.7 36.62 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.349 -0.845 . . . . 0.0 109.415 -179.606 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.804 ' HG3' ' HB2' ' A' ' 15' ' ' ALA . 6.1 mt-10 -91.65 109.84 21.16 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 4.8 p -141.67 153.89 44.99 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.544 -0.723 . . . . 0.0 109.41 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 89.3 p -78.85 -10.15 59.7 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.228 -0.92 . . . . 0.0 109.484 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.401 ' O ' ' C ' ' A' ' 50' ' ' ALA . 5.4 m-20 -79.81 -18.17 51.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.191 -0.943 . . . . 0.0 109.536 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.405 ' HA ' ' HD3' ' A' ' 51' ' ' PRO . . . -45.02 147.65 1.13 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.895 . . . . 0.0 109.544 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.512 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.16 -40.59 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.629 2.219 . . . . 0.0 110.355 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -115.27 115.57 26.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.52 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.05 -124.54 23.35 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -152.74 22.85 0.59 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.164 -1.198 . . . . 0.0 109.499 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.521 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 8.6 mttt -129.37 143.61 50.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 109.436 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.627 HG12 ' CB ' ' A' ' 160' ' ' ASP . 11.9 m -150.24 175.59 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.347 -0.846 . . . . 0.0 109.004 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.685 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -108.43 99.64 9.01 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.057 -1.027 . . . . 0.0 109.033 179.508 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.614 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.23 119.2 23.32 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.818 ' O ' HG23 ' A' ' 156' ' ' THR . 43.7 t -115.68 144.85 22.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.134 -0.979 . . . . 0.0 109.212 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.524 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 9.3 m -108.96 91.69 3.74 Favored 'General case' 0 C--N 1.283 -2.313 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.546 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 48.2 t -89.58 117.41 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.395 -0.815 . . . . 0.0 109.091 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.423 HD22 HG22 ' A' ' 60' ' ' THR . 3.1 p30 -154.4 58.55 0.7 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.305 -0.872 . . . . 0.0 109.935 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 157.02 84.2 0.05 OUTLIER Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.706 HG12 ' C ' ' A' ' 148' ' ' GLY . 1.8 m -80.07 -175.85 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.21 -1.171 . . . . 0.0 109.513 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -129.31 -148.52 6.59 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -94.74 -5.89 44.33 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.325 -1.103 . . . . 0.0 109.576 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.568 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 27.8 m-20 -112.74 146.75 35.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.077 -1.014 . . . . 0.0 109.45 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.414 ' O ' ' CE1' ' A' ' 149' ' ' TYR . 36.3 Cg_endo -78.7 12.99 2.02 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.602 2.202 . . . . 0.0 110.931 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.568 ' CZ2' ' OD1' ' A' ' 67' ' ' ASN . 4.2 p90 -133.5 51.86 2.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.035 -1.041 . . . . 0.0 109.659 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.484 ' O ' ' CG2' ' A' ' 36' ' ' VAL . 2.6 m-20 -74.24 -64.17 1.08 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.3 -0.875 . . . . 0.0 109.193 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.581 HG22 ' HB2' ' A' ' 147' ' ' PHE . 2.9 mp -100.22 118.3 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.272 -0.892 . . . . 0.0 109.043 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -121.4 127.49 51.23 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.138 -0.976 . . . . 0.0 110.15 -179.565 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.888 ' HB3' ' CE1' ' A' ' 147' ' ' PHE . . . -123.72 108.26 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.561 HG22 ' N ' ' A' ' 75' ' ' ALA . 86.0 m -104.95 165.76 10.85 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.418 -0.801 . . . . 0.0 109.95 -179.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.561 ' N ' HG22 ' A' ' 74' ' ' THR . . . -120.92 140.13 52.27 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.071 -1.018 . . . . 0.0 108.875 178.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.568 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.3 p90 179.53 162.86 0.79 Allowed Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.496 -0.752 . . . . 0.0 109.2 -179.551 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.568 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.8 Cg_endo -82.14 169.31 62.94 Favored 'Cis proline' 0 C--N 1.311 -1.416 0 C-N-CA 123.885 -1.298 . . . . 0.0 110.856 -0.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 85.1 t -127.65 156.22 39.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.388 -0.82 . . . . 0.0 108.891 179.292 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.541 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 16.5 m-80 -123.44 118.66 27.95 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.16 -0.962 . . . . 0.0 109.94 -179.567 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.556 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 3.0 m -124.63 -173.83 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.27 -0.894 . . . . 0.0 109.541 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.664 ' O ' HG21 ' A' ' 134' ' ' VAL . 15.3 mmt180 -136.63 144.93 49.14 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.332 -0.855 . . . . 0.0 109.269 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.19 120.57 5.4 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 122.545 2.163 . . . . 0.0 110.618 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 98.21 -27.76 17.81 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.417 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.06 149.7 4.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.21 -1.171 . . . . 0.0 109.501 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 28.5 m -95.86 133.03 40.49 Favored 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.556 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 7.4 m-85 -111.68 166.76 10.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.266 -0.896 . . . . 0.0 109.692 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.479 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 32.4 m -118.38 154.31 32.61 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.358 -0.839 . . . . 0.0 109.335 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.69 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 7.6 t80 -129.72 117.98 21.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.159 -0.963 . . . . 0.0 109.548 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.476 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.7 m -135.0 144.26 47.26 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.24 -0.912 . . . . 0.0 109.186 179.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.756 HD12 ' HB2' ' A' ' 162' ' ' LEU . 14.4 tt -150.49 163.78 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 120.817 -1.177 . . . . 0.0 109.562 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.512 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 19.8 m95 -132.73 125.99 31.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.062 -1.024 . . . . 0.0 109.303 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -117.08 151.81 36.01 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.359 -0.838 . . . . 0.0 109.487 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.56 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 8.5 ttp85 -164.14 118.49 1.47 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.188 -0.945 . . . . 0.0 109.188 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -105.37 160.93 14.74 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.301 -0.874 . . . . 0.0 109.951 -179.522 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -58.95 -48.56 81.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.417 -0.802 . . . . 0.0 109.289 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.517 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 2.0 mt-30 -113.91 142.16 46.47 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.273 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.582 ' N ' HG22 ' A' ' 123' ' ' THR . 28.4 p-10 -65.14 146.16 55.34 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.23 -0.919 . . . . 0.0 109.485 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 110.91 38.3 1.57 Allowed Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.494 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -120.45 140.66 51.07 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.257 -1.143 . . . . 0.0 109.082 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.422 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 55.5 t -116.14 145.27 22.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.224 -0.922 . . . . 0.0 110.766 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.7 HG13 ' CE2' ' A' ' 147' ' ' PHE . 39.0 t -143.05 165.86 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.569 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.536 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 4.1 m -123.25 126.22 46.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.069 -1.019 . . . . 0.0 109.9 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.537 ' CD1' HD13 ' A' ' 90' ' ' ILE . 66.8 m-85 -116.79 103.45 10.34 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.028 -1.045 . . . . 0.0 109.322 179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.504 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 17.8 p -128.11 164.73 21.8 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.011 -1.055 . . . . 0.0 110.691 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.653 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -129.7 155.95 41.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 CA-C-O 121.213 0.53 . . . . 0.0 109.964 -179.934 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.521 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -174.11 -173.81 40.47 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.2 p30 -131.24 -169.56 2.2 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.152 -1.205 . . . . 0.0 109.45 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.52 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 3.5 mp0 -68.34 3.81 1.58 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.098 -1.002 . . . . 0.0 111.336 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.462 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 1.4 m -107.1 14.87 25.83 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 120.661 -1.274 . . . . 0.0 109.239 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.462 ' HB2' ' O ' ' A' ' 109' ' ' SER . 13.7 m-30 67.04 7.84 5.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.447 -0.783 . . . . 0.0 109.609 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.521 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 24.4 tt0 -80.07 158.32 26.47 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.49 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 4.2 tt0 -136.15 136.5 40.09 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.028 -1.045 . . . . 0.0 110.012 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.573 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 7.3 m-85 -96.17 -70.74 0.7 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.412 -0.805 . . . . 0.0 108.875 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.58 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -81.92 156.48 36.3 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 179.5 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 2.7 ttt180 -153.36 106.94 3.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.057 -1.261 . . . . 0.0 110.258 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.716 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -146.12 70.0 1.22 Allowed 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.146 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.536 ' CB ' ' HB3' ' A' ' 102' ' ' SER . 2.1 p-80 -107.85 160.71 15.53 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.252 -0.905 . . . . 0.0 110.048 -179.449 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 16.5 tt0 77.28 58.56 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.361 -0.837 . . . . 0.0 109.469 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 4.0 mm-40 -130.14 136.98 49.88 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.315 -0.866 . . . . 0.0 109.501 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.447 ' O ' HD13 ' A' ' 121' ' ' ILE . 47.9 mt-30 -70.88 156.28 39.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.472 -0.768 . . . . 0.0 109.065 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 99' ' ' ALA . 6.0 mm -133.49 135.67 55.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.148 -0.97 . . . . 0.0 109.873 -179.455 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -82.74 -179.34 7.4 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.672 0.749 . . . . 0.0 110.001 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.582 HG22 ' N ' ' A' ' 97' ' ' ASP . 63.7 p -78.45 -1.59 34.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.511 -0.743 . . . . 0.0 109.307 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.411 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 2.5 mt-10 -108.42 -168.87 1.41 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.184 -0.947 . . . . 0.0 109.397 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.56 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 95.5 m95 -95.26 121.15 36.61 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.206 -0.934 . . . . 0.0 109.688 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -106.84 121.02 46.3 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.261 -0.899 . . . . 0.0 108.935 179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.407 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.8 Cg_endo -80.25 107.39 2.03 Favored 'Trans proline' 0 C--N 1.311 -1.416 0 C-N-CA 122.456 2.104 . . . . 0.0 111.064 -179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -111.0 135.5 51.41 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 178.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.8 t -151.13 175.74 11.85 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 120.701 -1.25 . . . . 0.0 111.078 -179.187 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.716 ' CE2' HD21 ' A' ' 116' ' ' LEU . 33.8 p90 -171.89 -177.64 1.99 Allowed 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 114.734 -1.121 . . . . 0.0 109.192 179.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -127.92 151.11 49.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.191 -0.943 . . . . 0.0 109.757 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.573 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.07 168.15 17.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.44 -0.788 . . . . 0.0 109.255 179.841 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -138.69 147.74 43.13 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.5 -179.663 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.664 HG21 ' O ' ' A' ' 81' ' ' ARG . 6.0 t -40.43 110.33 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.607 -0.683 . . . . 0.0 109.367 179.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 27.8 m -59.95 -51.58 69.05 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.283 -0.885 . . . . 0.0 109.255 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -106.74 -90.87 0.42 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.384 -0.823 . . . . 0.0 109.213 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -163.98 53.97 0.15 Allowed 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.478 -0.764 . . . . 0.0 109.058 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.55 ' O ' HG23 ' A' ' 80' ' ' VAL . 31.6 mm-40 -91.67 113.22 25.43 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.188 -0.945 . . . . 0.0 109.791 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.5 p -79.44 -14.07 59.17 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.275 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.3 t -134.01 132.07 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.509 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -141.59 171.92 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.164 -0.96 . . . . 0.0 110.051 -179.608 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.519 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 2.9 ptm180 -143.76 133.12 23.28 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.624 -0.673 . . . . 0.0 109.263 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.759 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -94.44 108.62 37.82 Favored Pre-proline 0 N--CA 1.487 1.384 0 O-C-N 121.302 -0.874 . . . . 0.0 109.897 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.658 ' C ' HD13 ' A' ' 145' ' ' ILE . 35.4 Cg_endo -76.74 113.49 3.66 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.16 1.907 . . . . 0.0 110.847 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.723 HD13 ' N ' ' A' ' 145' ' ' ILE . 1.7 mm -97.26 141.66 15.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 178.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 147' ' ' PHE . 6.2 m80 -105.28 158.32 16.69 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.55 -1.344 . . . . 0.0 111.691 -177.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.888 ' CE1' ' HB3' ' A' ' 73' ' ' ALA . 20.9 m-85 -160.81 158.2 28.05 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.132 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.706 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 108.13 43.8 1.25 Allowed Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.686 ' C ' HG11 ' A' ' 64' ' ' VAL . 61.5 m-85 -117.06 161.42 19.44 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.421 -1.047 . . . . 0.0 109.111 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.52 -29.4 69.48 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.472 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -76.61 -10.52 59.45 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 109.179 179.269 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.624 ' ND2' HD13 ' A' ' 157' ' ' ILE . 1.5 t30 -109.74 12.3 24.15 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.365 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.4 t -89.15 164.22 2.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 O-C-N 121.551 -0.718 . . . . 0.0 109.784 -179.173 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.492 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.39 32.61 37.98 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.7 m-20 -160.49 136.82 8.65 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.139 -1.212 . . . . 0.0 110.111 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.818 HG23 ' O ' ' A' ' 59' ' ' VAL . 55.3 m -87.59 120.94 29.41 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.624 HD13 ' ND2' ' A' ' 152' ' ' ASN . 0.8 OUTLIER -99.63 117.58 44.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 120.75 -1.219 . . . . 0.0 110.327 -178.781 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.614 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 12.2 m-85 -98.01 135.78 39.21 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 178.447 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.644 ' CD1' ' CE2' ' A' ' 147' ' ' PHE . 1.3 mt -128.16 141.15 47.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 120.768 -1.207 . . . . 0.0 110.44 -178.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.627 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.7 OUTLIER -173.8 136.34 0.55 Allowed 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.348 -0.845 . . . . 0.0 108.837 179.633 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 125.19 -8.23 8.0 Favored Glycine 0 N--CA 1.487 2.066 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.366 179.577 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.759 HD21 ' HB3' ' A' ' 143' ' ' ALA . 4.4 tp -60.2 100.64 0.1 Allowed 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.742 -1.446 . . . . 0.0 108.944 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . 0.543 ' C ' HD12 ' A' ' 164' ' ' ILE . . . -133.24 145.75 50.82 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.455 -0.778 . . . . 0.0 109.778 -179.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.702 HD12 ' N ' ' A' ' 164' ' ' ILE . 4.4 mp -126.8 109.07 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.288 -0.882 . . . . 0.0 109.425 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.874 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . -156.1 150.49 25.69 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.171 -0.956 . . . . 0.0 109.637 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 8.5 t -74.78 -43.68 53.52 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.513 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -135.46 92.06 17.89 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.219 -0.926 . . . . 0.0 109.516 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo . . . . . 0 C--N 1.309 -1.545 0 C-N-CA 122.627 2.218 . . . . 0.0 110.403 179.995 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.433 HD23 ' HA ' ' A' ' 2' ' ' LEU . 57.4 mt -109.94 157.15 19.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.243 -0.911 . . . . 0.0 109.516 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.846 HG23 ' HB2' ' A' ' 165' ' ' ALA . 4.2 p -104.06 173.06 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.262 -0.899 . . . . 0.0 109.386 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.922 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -71.64 -59.41 2.77 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.187 -0.945 . . . . 0.0 109.453 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 162' ' ' LEU . 47.4 t-20 -71.26 128.93 37.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.481 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.464 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 2.2 mp -107.7 138.53 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.273 -0.892 . . . . 0.0 109.518 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.523 ' OD1' ' CB ' ' A' ' 12' ' ' SER . 1.0 OUTLIER 66.97 17.31 10.5 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.242 -0.911 . . . . 0.0 109.638 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.5 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -61.52 -35.56 91.28 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.524 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -103.59 28.01 17.33 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.681 ' CD2' HG11 ' A' ' 25' ' ' VAL . 6.5 m-85 50.65 48.03 23.35 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.365 -1.079 . . . . 0.0 109.412 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.438 ' OE1' ' O ' ' A' ' 52' ' ' GLU . 5.6 mm-40 -83.68 -35.81 24.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.236 -0.915 . . . . 0.0 109.67 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.523 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.6 OUTLIER -84.8 -24.81 28.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.234 -0.916 . . . . 0.0 109.663 -179.759 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.9 ' OG1' HG13 ' A' ' 25' ' ' VAL . 0.7 OUTLIER -78.48 121.57 83.87 Favored Pre-proline 0 N--CA 1.486 1.352 0 O-C-N 121.185 -0.947 . . . . 0.0 109.292 -179.896 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 15' ' ' ALA . 36.1 Cg_endo -77.61 138.95 17.64 Favored 'Trans proline' 0 C--N 1.312 -1.36 0 C-N-CA 122.469 2.112 . . . . 0.0 110.754 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.522 ' HA ' ' CG1' ' A' ' 44' ' ' VAL . . . -41.59 163.53 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 127.71 137.38 4.45 Favored Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.529 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.23 141.52 12.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.325 -1.103 . . . . 0.0 109.079 -179.688 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.479 HG23 ' HA ' ' A' ' 43' ' ' GLU . 46.1 t -85.69 145.65 7.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 CA-C-O 121.695 0.759 . . . . 0.0 109.921 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 4.1 p -106.36 -22.3 12.85 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.411 ' HB3' ' HG3' ' A' ' 23' ' ' GLU . 0.4 OUTLIER -143.94 92.63 2.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.439 -0.788 . . . . 0.0 109.085 179.692 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.969 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -49.41 -33.19 13.26 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.293 -0.88 . . . . 0.0 109.899 -179.339 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.919 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.66 -43.6 93.89 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.165 -0.959 . . . . 0.0 109.514 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.411 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 3.3 pt-20 -118.12 35.74 4.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.252 -0.905 . . . . 0.0 109.336 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.18 -71.8 1.29 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.9 HG13 ' OG1' ' A' ' 13' ' ' THR . 2.0 t -95.96 123.63 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -1.173 . . . . 0.0 109.209 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -56.38 -32.28 64.63 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.421 -0.8 . . . . 0.0 109.854 -179.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.492 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -102.33 -3.45 50.7 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.94 -1.124 . . . . 0.0 110.305 -179.35 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 0.585 ' CE3' ' HB1' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -139.77 121.65 15.53 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.932 -1.334 . . . . 0.0 109.877 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.717 ' C ' HD23 ' A' ' 30' ' ' LEU . 1.2 m-20 -121.38 143.12 49.39 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.969 ' O ' HD13 ' A' ' 21' ' ' LEU . 0.9 OUTLIER -113.25 162.46 15.99 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.781 -1.199 . . . . 0.0 109.439 -179.601 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -152.84 121.17 6.28 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.424 -0.797 . . . . 0.0 109.522 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.868 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.05 135.2 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.4 -0.812 . . . . 0.0 109.675 179.638 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.49 -170.99 25.75 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.04 -4.58 25.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.249 -1.148 . . . . 0.0 109.505 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.484 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 16.0 m -74.11 -31.87 62.96 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.942 . . . . 0.0 109.625 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.868 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -67.68 89.46 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 O-C-N 121.132 -0.98 . . . . 0.0 109.364 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 30.4 m -59.74 -28.69 67.58 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.199 -0.938 . . . . 0.0 108.713 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.687 ' O ' HG13 ' A' ' 36' ' ' VAL . 6.5 m-20 -130.88 130.4 22.83 Favored Pre-proline 0 C--N 1.296 -1.753 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.21 123.11 6.46 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.189 1.926 . . . . 0.0 110.55 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.586 ' HG2' ' CZ ' ' A' ' 42' ' ' PHE . 35.4 Cg_endo -77.46 -165.74 0.35 Allowed 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.366 2.044 . . . . 0.0 110.013 179.695 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.55 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 53.7 t -116.73 121.43 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.116 -0.99 . . . . 0.0 110.458 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.631 ' CE2' HD23 ' A' ' 21' ' ' LEU . 28.0 m-85 -105.11 112.38 25.49 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.529 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 29.2 tt0 -154.56 159.32 40.83 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.194 -0.941 . . . . 0.0 109.857 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.522 ' CG1' ' HA ' ' A' ' 15' ' ' ALA . 89.1 t -95.2 140.59 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.476 -0.765 . . . . 0.0 109.017 179.277 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.435 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.4 OUTLIER -119.38 120.51 37.12 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.327 -0.858 . . . . 0.0 109.793 -179.32 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -77.35 109.83 11.58 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 121.54 0.686 . . . . 0.0 109.152 179.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.7 p -128.64 129.89 46.49 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.606 -0.684 . . . . 0.0 109.527 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.2 m -72.41 -12.56 61.16 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.239 -0.913 . . . . 0.0 109.397 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.41 ' O ' ' C ' ' A' ' 50' ' ' ALA . 49.7 m-20 -98.4 2.08 47.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.214 -0.929 . . . . 0.0 109.612 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.529 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -44.31 155.18 0.37 Allowed Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.103 -0.998 . . . . 0.0 109.443 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.533 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.9 Cg_endo -77.91 -35.97 1.25 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.599 2.199 . . . . 0.0 110.335 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.438 ' O ' ' OE1' ' A' ' 11' ' ' GLU . 4.9 tt0 -121.28 97.01 5.32 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.268 -0.895 . . . . 0.0 109.35 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.8 -115.16 4.07 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.529 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 2.6 m120 -156.63 35.64 0.31 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.226 -1.161 . . . . 0.0 109.405 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.487 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 33.0 mttm -145.5 131.1 18.85 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.262 -0.899 . . . . 0.0 109.505 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.662 HG12 ' OD2' ' A' ' 160' ' ' ASP . 3.9 m -139.72 175.36 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.381 -0.825 . . . . 0.0 109.326 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.723 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -101.79 100.46 10.81 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.063 -1.023 . . . . 0.0 108.776 179.306 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.584 ' HB1' ' CE2' ' A' ' 158' ' ' TYR . . . -81.33 118.21 22.46 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.068 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.837 ' O ' HG23 ' A' ' 156' ' ' THR . 49.3 t -114.9 144.61 22.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.113 -0.992 . . . . 0.0 109.17 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.818 HG22 HD22 ' A' ' 62' ' ' ASN . 31.9 m -107.12 93.64 4.66 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.706 HG21 ' CD1' ' A' ' 157' ' ' ILE . 59.9 t -87.93 123.47 40.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.253 -0.905 . . . . 0.0 109.334 -179.69 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.818 HD22 HG22 ' A' ' 60' ' ' THR . 6.3 p30 -160.11 60.34 0.35 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.379 -0.825 . . . . 0.0 109.77 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 156.38 89.24 0.07 OUTLIER Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.798 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.4 m -81.06 -177.14 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.218 -1.166 . . . . 0.0 109.674 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.484 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -130.99 -161.61 10.34 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -95.99 12.54 30.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -1.119 . . . . 0.0 109.545 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.514 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.9 m-80 -128.33 148.35 67.52 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.194 -0.941 . . . . 0.0 109.508 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.495 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.2 Cg_endo -78.25 11.88 2.24 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.63 2.22 . . . . 0.0 110.963 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.514 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -136.36 58.33 1.74 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.113 -0.992 . . . . 0.0 109.623 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.484 ' CB ' HG23 ' A' ' 36' ' ' VAL . 0.7 OUTLIER -83.11 -69.18 0.65 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.204 -0.935 . . . . 0.0 109.248 179.825 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.541 HG13 ' CG2' ' A' ' 36' ' ' VAL . 4.1 mt -105.94 121.76 58.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.277 -0.89 . . . . 0.0 108.979 179.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -130.17 132.89 46.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.098 -1.001 . . . . 0.0 110.224 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.592 ' CB ' HD22 ' A' ' 30' ' ' LEU . . . -121.82 108.47 13.51 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.559 HG22 ' N ' ' A' ' 75' ' ' ALA . 98.3 m -100.2 165.0 11.71 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.386 -0.821 . . . . 0.0 110.006 -179.029 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.559 ' N ' HG22 ' A' ' 74' ' ' THR . . . -118.92 136.42 54.08 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.022 -1.049 . . . . 0.0 108.768 178.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.556 ' CE2' ' OD1' ' A' ' 29' ' ' ASP . 10.1 p90 179.44 160.44 0.76 Allowed Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.585 -0.697 . . . . 0.0 109.276 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.532 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.9 Cg_endo -81.67 164.96 74.89 Favored 'Cis proline' 0 C--N 1.31 -1.465 0 C-N-CA 123.782 -1.341 . . . . 0.0 110.801 -0.495 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 140' ' ' VAL . 89.1 t -126.81 156.14 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.344 -0.848 . . . . 0.0 109.107 179.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.922 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 4.3 m-80 -112.43 145.79 39.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.075 -1.016 . . . . 0.0 109.666 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.581 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 1.1 m -153.32 -173.85 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.174 -0.954 . . . . 0.0 109.467 179.749 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.763 ' O ' HG21 ' A' ' 134' ' ' VAL . 20.5 mtt180 -136.21 146.01 54.5 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.288 -0.883 . . . . 0.0 109.352 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.492 ' HB3' ' HB3' ' A' ' 137' ' ' GLN . 35.6 Cg_endo -77.82 112.09 3.23 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.511 2.141 . . . . 0.0 110.463 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 100.44 -22.97 37.59 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.601 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -84.12 149.65 4.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.191 -1.182 . . . . 0.0 109.482 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.3 m -92.42 140.48 29.53 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.601 ' CE1' HG12 ' A' ' 84' ' ' VAL . 18.3 m-85 -123.05 164.88 17.75 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.25 -0.906 . . . . 0.0 109.578 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.47 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 6.1 m -118.35 154.31 32.57 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.398 -0.814 . . . . 0.0 109.51 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.692 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.7 t80 -126.87 120.1 28.4 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.145 -0.972 . . . . 0.0 109.38 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.487 ' O ' ' O ' ' A' ' 161' ' ' GLY . 32.3 m -134.53 142.79 47.11 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.244 -0.91 . . . . 0.0 109.11 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.796 HD13 ' CD2' ' A' ' 103' ' ' PHE . 19.8 tt -150.9 163.45 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.603 -1.311 . . . . 0.0 109.628 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.533 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 20.3 m95 -132.14 128.62 38.47 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.976 -1.078 . . . . 0.0 109.385 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -119.53 148.13 43.65 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.222 -0.924 . . . . 0.0 109.582 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.586 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 8.3 ttp180 -161.02 120.22 2.58 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.162 -0.961 . . . . 0.0 109.15 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.481 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -107.07 161.7 14.52 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 110.02 -179.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -61.06 -51.18 70.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.377 -0.827 . . . . 0.0 109.319 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.485 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -108.45 137.74 45.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.339 -0.85 . . . . 0.0 109.355 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.582 ' N ' ' CG2' ' A' ' 123' ' ' THR . 5.1 p30 -63.08 146.85 52.36 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.273 -0.892 . . . . 0.0 109.559 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 109.06 38.66 1.8 Allowed Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -119.15 141.36 48.9 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.234 -1.157 . . . . 0.0 109.063 179.601 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.427 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 54.9 t -116.78 149.88 18.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.277 -0.889 . . . . 0.0 110.636 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.722 HG13 ' CE2' ' A' ' 147' ' ' PHE . 51.9 t -151.14 164.71 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.538 -0.726 . . . . 0.0 109.051 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.526 ' OG ' ' CB ' ' A' ' 117' ' ' HIS . 3.8 t -127.92 138.05 52.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.989 -1.07 . . . . 0.0 109.687 -179.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.796 ' CD2' HD13 ' A' ' 90' ' ' ILE . 1.0 OUTLIER -130.6 103.86 6.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.086 -1.009 . . . . 0.0 109.807 -179.969 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.509 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 11.6 p -119.43 164.86 15.11 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.091 -1.005 . . . . 0.0 110.064 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.623 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -125.67 152.55 32.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.69 -0.631 . . . . 0.0 109.998 -179.734 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.469 ' O ' ' HG2' ' A' ' 142' ' ' ARG . . . 176.46 147.71 6.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.214 -1.555 . . . . 0.0 109.214 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.3 p30 -90.3 -169.59 2.46 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.018 -1.283 . . . . 0.0 109.51 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.518 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 4.1 mp0 -71.1 8.0 1.08 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.184 -0.947 . . . . 0.0 111.245 -179.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.455 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 3.7 t -110.52 10.27 23.14 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.712 -1.243 . . . . 0.0 109.215 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.538 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 3.2 m-30 71.87 6.08 5.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.412 -0.805 . . . . 0.0 109.689 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -78.89 95.12 5.34 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 108.672 179.399 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.524 ' CG ' ' O ' ' A' ' 105' ' ' VAL . 1.3 tt0 -83.47 139.69 32.78 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.278 -0.889 . . . . 0.0 110.259 -179.099 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.523 ' CE2' HG21 ' A' ' 141' ' ' ILE . 3.9 m-85 -102.78 -69.88 0.78 Allowed 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.601 ' HA3' ' CE1' ' A' ' 130' ' ' PHE . . . -85.77 166.17 39.11 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.021 -1.632 . . . . 0.0 109.021 179.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.473 ' C ' HD23 ' A' ' 116' ' ' LEU . 1.2 tpp180 -164.42 109.65 0.99 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.948 -1.325 . . . . 0.0 110.326 -179.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.771 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -142.53 69.88 1.32 Allowed 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.061 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.546 ' O ' ' CD2' ' A' ' 117' ' ' HIS . 0.5 OUTLIER -99.11 152.56 19.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.335 -0.853 . . . . 0.0 110.149 -179.31 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.542 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.3 tt0 79.33 68.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -0.787 . . . . 0.0 109.706 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.431 ' HG2' ' C ' ' A' ' 118' ' ' GLU . 1.1 mm-40 -133.42 130.96 39.4 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.293 -0.879 . . . . 0.0 109.475 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.724 ' O ' HD13 ' A' ' 121' ' ' ILE . 4.8 mt-30 -67.66 153.81 42.88 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.327 -0.858 . . . . 0.0 109.006 179.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.724 HD13 ' O ' ' A' ' 120' ' ' GLN . 8.1 mm -134.8 135.73 52.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.094 -1.003 . . . . 0.0 110.089 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.32 -179.16 6.91 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.637 0.732 . . . . 0.0 110.067 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.582 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 47.2 p -76.37 -2.48 32.01 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.416 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.412 ' C ' ' HG3' ' A' ' 93' ' ' ARG . 3.9 mm-40 -107.67 -169.0 1.45 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.361 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.586 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 97.1 m95 -95.83 122.6 38.79 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.201 -0.937 . . . . 0.0 109.604 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -106.93 121.39 45.03 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.272 -0.892 . . . . 0.0 108.941 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -80.1 109.48 2.37 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.451 2.1 . . . . 0.0 110.895 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -114.34 136.64 52.76 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.7 t -151.27 175.85 11.8 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 120.685 -1.259 . . . . 0.0 111.152 -179.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.771 ' CE2' HD21 ' A' ' 116' ' ' LEU . 37.7 p90 -173.41 -172.61 0.81 Allowed 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.819 -1.082 . . . . 0.0 109.221 179.22 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -127.95 156.96 41.83 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.075 -1.016 . . . . 0.0 110.009 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.596 ' CZ ' ' HB2' ' A' ' 86' ' ' TYR . 11.1 p90 -161.23 168.06 24.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.391 -0.818 . . . . 0.0 109.191 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.92 146.2 38.91 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.145 -0.972 . . . . 0.0 109.224 -179.761 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.763 HG21 ' O ' ' A' ' 81' ' ' ARG . 2.2 t -62.38 112.95 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.257 -0.902 . . . . 0.0 109.392 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 5.8 t -86.51 -40.48 15.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.401 -0.812 . . . . 0.0 109.85 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.56 ' O ' ' CB ' ' A' ' 137' ' ' GLN . 17.5 t70 -87.63 -16.22 35.06 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.445 -0.784 . . . . 0.0 109.432 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . 0.674 ' H ' HG12 ' A' ' 134' ' ' VAL . 2.3 mt-30 86.97 27.28 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -178.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.513 ' HG3' ' ND2' ' A' ' 107' ' ' ASN . 12.5 mm-40 -68.94 122.44 18.65 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.609 -0.682 . . . . 0.0 109.732 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 5.8 p -79.12 -6.97 57.74 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 42.4 t -138.14 138.38 43.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.364 -0.835 . . . . 0.0 108.824 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.564 HD11 HD13 ' A' ' 164' ' ' ILE . 0.6 OUTLIER -143.27 172.23 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.121 -0.987 . . . . 0.0 109.904 -179.705 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.49 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.2 ptm180 -146.76 132.52 18.95 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.463 -0.773 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.748 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -99.66 106.95 43.29 Favored Pre-proline 0 C--N 1.303 -1.421 0 O-C-N 121.21 -0.931 . . . . 0.0 109.879 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.54 ' C ' HD13 ' A' ' 145' ' ' ILE . 34.9 Cg_endo -76.79 110.74 3.1 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.113 1.875 . . . . 0.0 110.688 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.72 HD13 ' N ' ' A' ' 145' ' ' ILE . 2.0 mm -91.25 140.15 16.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 178.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.54 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 5.9 m80 -107.7 157.86 17.76 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.542 -1.349 . . . . 0.0 111.897 -177.46 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.722 ' CE2' HG13 ' A' ' 101' ' ' VAL . 30.6 m-85 -158.12 160.98 37.88 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 179.013 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.496 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 116.77 40.79 0.75 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.798 ' C ' HG11 ' A' ' 64' ' ' VAL . 15.1 m-85 -122.08 159.37 27.23 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.381 -1.07 . . . . 0.0 109.311 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.527 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.21 -26.71 67.51 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -69.91 -15.28 63.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.436 -0.79 . . . . 0.0 109.269 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.52 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.3 OUTLIER -110.85 8.31 22.22 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 179.366 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.626 HG23 HG13 ' A' ' 64' ' ' VAL . 2.3 t -83.33 162.57 3.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 121.424 -0.797 . . . . 0.0 109.7 -179.464 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.455 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 50.63 33.47 26.37 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 1.8 m-20 -160.18 139.44 10.88 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.258 -1.143 . . . . 0.0 109.976 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.837 HG23 ' O ' ' A' ' 59' ' ' VAL . 97.7 m -89.32 128.04 35.85 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.205 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.706 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.4 mt -108.96 118.83 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.873 -1.142 . . . . 0.0 109.969 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.584 ' CE2' ' HB1' ' A' ' 58' ' ' ALA . 8.7 m-85 -100.55 137.77 38.51 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 178.561 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.669 HD11 ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -129.34 141.64 46.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 120.777 -1.202 . . . . 0.0 110.381 -178.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.662 ' OD2' HG12 ' A' ' 56' ' ' VAL . 49.7 t0 -173.82 136.01 0.53 Allowed 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.533 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 127.13 -9.02 7.08 Favored Glycine 0 N--CA 1.485 1.915 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.258 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.748 HD21 ' HB3' ' A' ' 143' ' ' ALA . 1.2 tp -59.43 91.29 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.811 -1.405 . . . . 0.0 108.583 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . 0.459 ' N ' ' O ' ' A' ' 161' ' ' GLY . . . -131.06 146.03 52.23 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.605 -0.685 . . . . 0.0 109.86 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.716 ' O ' HG22 ' A' ' 3' ' ' VAL . 23.4 mt -126.16 131.47 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.325 -0.86 . . . . 0.0 109.217 179.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.846 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -158.55 147.53 18.93 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.202 -0.936 . . . . 0.0 109.677 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 3.1 p -73.68 166.5 23.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.295 -0.878 . . . . 0.0 109.528 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.407 ' O ' ' CD ' ' A' ' 167' ' ' GLN . 0.6 OUTLIER -145.47 89.87 6.18 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.277 -0.889 . . . . 0.0 109.402 179.893 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.555 0 C-N-CA 122.652 2.235 . . . . 0.0 110.422 179.985 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.2 tmt? . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 1.6 mp -121.99 131.84 54.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -0.907 . . . . 0.0 109.581 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.652 HG22 ' O ' ' A' ' 164' ' ' ILE . 4.6 p -109.86 174.58 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.288 -0.882 . . . . 0.0 109.307 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.597 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -63.09 -53.78 48.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.107 -0.996 . . . . 0.0 109.732 -179.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.532 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 3.9 t-20 -84.09 149.86 25.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.293 -0.879 . . . . 0.0 109.7 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.476 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 3.7 mt -128.13 129.79 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.358 -0.839 . . . . 0.0 109.157 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.565 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 1.5 m120 65.84 35.1 6.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.203 -0.936 . . . . 0.0 109.59 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -44.99 -25.73 1.04 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.454 ' HA3' ' OD2' ' A' ' 160' ' ' ASP . . . -145.82 44.93 0.83 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.902 ' CD2' HG11 ' A' ' 25' ' ' VAL . 4.2 m-85 61.32 51.65 4.16 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.167 -1.196 . . . . 0.0 109.443 179.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.445 ' OE2' ' OD2' ' A' ' 160' ' ' ASP . 62.0 mm-40 -84.34 -27.61 27.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.136 -0.977 . . . . 0.0 109.79 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.504 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 7.9 t -99.75 -13.65 19.19 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.178 -0.951 . . . . 0.0 110.149 -179.361 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 1.048 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.2 m -100.25 133.39 21.49 Favored Pre-proline 0 N--CA 1.489 1.475 0 O-C-N 121.052 -1.03 . . . . 0.0 109.423 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.476 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.5 Cg_endo -77.3 148.37 26.82 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 122.522 2.148 . . . . 0.0 110.84 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.476 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -42.11 166.0 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 121.317 0.579 . . . . 0.0 109.773 179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 138.09 132.54 3.01 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.526 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -56.55 144.63 8.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.268 -1.136 . . . . 0.0 109.218 -179.367 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.515 HG13 ' HA3' ' A' ' 24' ' ' GLY . 47.7 t -85.12 144.51 9.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.687 0.756 . . . . 0.0 110.043 -179.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.9 p -106.59 -23.77 12.36 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.458 ' O ' ' N ' ' A' ' 24' ' ' GLY . 0.4 OUTLIER -145.99 88.21 1.8 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.478 -0.764 . . . . 0.0 108.966 179.759 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.911 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -43.46 -32.08 0.82 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 109.624 -179.464 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.906 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -65.42 -49.09 70.49 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.351 -0.843 . . . . 0.0 109.456 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -125.51 43.78 2.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.434 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.515 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -91.86 -66.7 1.13 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 1.048 HG13 ' OG1' ' A' ' 13' ' ' THR . 41.3 t -120.63 128.66 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.207 -1.172 . . . . 0.0 109.618 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.451 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 13.7 tt0 -67.25 139.38 57.33 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.879 . . . . 0.0 109.606 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.565 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 109.29 -33.78 5.91 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 0.67 ' CZ3' HD12 ' A' ' 159' ' ' ILE . 1.2 m95 -140.5 119.98 13.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.191 -1.182 . . . . 0.0 109.454 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.522 ' C ' HD23 ' A' ' 30' ' ' LEU . 11.0 m-20 -115.98 144.17 44.45 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.133 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.911 ' O ' HD13 ' A' ' 21' ' ' LEU . 2.1 mt -118.95 168.03 11.18 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.723 -1.235 . . . . 0.0 109.603 -179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 70.5 m-20 -160.09 123.75 3.61 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.382 -0.824 . . . . 0.0 109.575 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.801 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -106.47 136.56 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.337 -0.852 . . . . 0.0 109.743 179.678 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.69 176.16 24.86 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.4 t -58.98 -15.65 14.14 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.18 -1.188 . . . . 0.0 109.418 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.466 ' HB2' ' OD1' ' A' ' 70' ' ' ASP . 7.9 p -63.81 -37.17 86.39 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.243 -0.91 . . . . 0.0 109.636 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.823 HG23 ' HB3' ' A' ' 70' ' ' ASP . 2.1 t -67.35 88.55 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 O-C-N 121.144 -0.973 . . . . 0.0 109.194 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 50.1 m -63.41 -28.64 70.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.326 -0.859 . . . . 0.0 108.997 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.673 ' O ' HG13 ' A' ' 36' ' ' VAL . 0.5 OUTLIER -120.92 130.1 25.0 Favored Pre-proline 0 C--N 1.296 -1.721 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.755 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -76.51 121.83 6.19 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.188 1.926 . . . . 0.0 110.524 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.593 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.4 Cg_endo -77.44 -169.93 0.84 Allowed 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.443 2.096 . . . . 0.0 109.865 179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.521 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 53.2 t -114.53 119.4 61.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.092 -1.005 . . . . 0.0 110.586 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.593 ' CE1' ' HG2' ' A' ' 40' ' ' PRO . 2.9 m-85 -104.35 112.34 25.34 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 178.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.526 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 0.0 OUTLIER -157.9 148.58 20.83 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.052 -1.03 . . . . 0.0 109.962 -179.354 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.584 HG22 ' CE2' ' A' ' 10' ' ' PHE . 2.0 t -92.55 148.68 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.379 -0.825 . . . . 0.0 109.398 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.555 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -133.43 147.45 51.72 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.284 -0.885 . . . . 0.0 108.713 179.931 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.555 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 15.3 pt-20 -121.17 120.41 35.16 Favored 'General case' 0 C--N 1.296 -1.758 0 O-C-N 121.526 -0.734 . . . . 0.0 109.296 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.487 ' CG2' HD21 ' A' ' 45' ' ' LEU . 1.5 p -144.0 -175.97 4.81 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.44 -0.787 . . . . 0.0 109.483 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -101.02 22.4 12.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.908 . . . . 0.0 109.433 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.7 -14.33 12.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.913 . . . . 0.0 109.481 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.721 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -56.45 144.53 62.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.18 -0.95 . . . . 0.0 109.327 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.555 ' HG3' ' CB ' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -78.44 -42.1 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.617 2.211 . . . . 0.0 110.388 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.406 ' O ' ' OE1' ' A' ' 11' ' ' GLU . 40.6 mm-40 -105.43 97.22 7.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.246 -0.909 . . . . 0.0 109.382 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.48 -117.75 4.71 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.721 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 13.5 p30 -160.09 38.62 0.18 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.226 -1.161 . . . . 0.0 109.542 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.482 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 92.0 mttt -144.84 139.04 27.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.143 -0.973 . . . . 0.0 109.655 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.636 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.3 m -150.13 174.54 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.3 -0.875 . . . . 0.0 109.372 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.616 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -99.92 102.22 13.55 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.161 -0.962 . . . . 0.0 108.943 179.61 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.649 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -82.04 122.85 28.34 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 178.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.833 ' O ' HG23 ' A' ' 156' ' ' THR . 47.0 t -117.4 144.18 25.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.135 -0.978 . . . . 0.0 109.304 -179.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.822 HG22 ' ND2' ' A' ' 62' ' ' ASN . 55.3 m -108.6 87.87 2.59 Favored 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.304 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.657 HG21 ' CD1' ' A' ' 157' ' ' ILE . 72.6 t -85.85 125.43 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.23 -0.919 . . . . 0.0 109.308 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.822 ' ND2' HG22 ' A' ' 60' ' ' THR . 3.8 p30 -160.08 55.42 0.35 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.383 -0.823 . . . . 0.0 109.733 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 162.7 89.91 0.07 OUTLIER Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.892 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.8 m -81.84 -171.32 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -1.14 . . . . 0.0 109.642 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -138.81 -163.27 9.46 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -78.29 -10.65 59.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -1.135 . . . . 0.0 109.499 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.553 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 1.3 m120 -111.08 145.33 32.23 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.171 -0.956 . . . . 0.0 109.426 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.505 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.5 Cg_endo -78.99 13.6 1.93 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.599 2.199 . . . . 0.0 110.997 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.553 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 3.5 p90 -136.33 51.76 2.0 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.031 -1.043 . . . . 0.0 109.759 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.823 ' HB3' HG23 ' A' ' 36' ' ' VAL . 0.6 OUTLIER -75.89 -50.24 15.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 109.215 179.685 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.686 HD12 ' HB2' ' A' ' 70' ' ' ASP . 4.6 mp -102.2 119.95 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.399 -0.813 . . . . 0.0 109.174 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.45 128.96 50.57 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.06 -1.025 . . . . 0.0 109.882 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.61 ' HB3' ' CE1' ' A' ' 147' ' ' PHE . . . -130.11 108.3 9.96 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.338 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.566 HG22 ' N ' ' A' ' 75' ' ' ALA . 75.5 m -103.93 165.26 11.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.545 -0.722 . . . . 0.0 110.018 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.566 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.01 137.14 53.73 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.055 -1.028 . . . . 0.0 108.882 178.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.561 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.7 p90 -174.46 163.57 2.65 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.497 -0.752 . . . . 0.0 109.256 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.561 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.4 Cg_endo -83.97 170.6 50.85 Favored 'Cis proline' 0 C--N 1.312 -1.372 0 C-N-CA 124.002 -1.249 . . . . 0.0 110.907 -0.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.953 HG11 HD13 ' A' ' 164' ' ' ILE . 85.2 t -130.25 156.27 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.526 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 1.9 m120 -121.21 132.02 54.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.09 -1.006 . . . . 0.0 109.929 -179.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.555 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.9 m -140.71 -174.07 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.169 -0.957 . . . . 0.0 109.644 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.745 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.3 OUTLIER -136.85 144.74 47.93 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 109.266 179.872 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.472 ' HD2' ' HG2' ' A' ' 81' ' ' ARG . 35.6 Cg_endo -77.12 110.48 3.03 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.426 2.084 . . . . 0.0 110.581 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 111.2 -34.98 5.01 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.551 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -84.75 149.78 4.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.146 -1.208 . . . . 0.0 109.433 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.441 ' O ' ' HB2' ' A' ' 166' ' ' SER . 17.8 m -94.58 141.65 28.36 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.555 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 8.5 m-85 -119.89 170.91 8.82 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 4.1 m -118.07 153.9 32.96 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.274 -0.891 . . . . 0.0 109.29 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.763 ' CE1' HD11 ' A' ' 116' ' ' LEU . 5.3 t80 -134.13 120.3 19.95 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.222 -0.924 . . . . 0.0 109.532 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.487 ' O ' ' O ' ' A' ' 161' ' ' GLY . 15.7 m -135.66 147.37 48.54 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.233 -0.917 . . . . 0.0 109.03 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.662 HD12 ' CA ' ' A' ' 162' ' ' LEU . 2.2 tt -151.21 163.61 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.966 -1.084 . . . . 0.0 109.219 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.555 ' CB ' ' HG3' ' A' ' 51' ' ' PRO . 19.3 m95 -131.02 125.17 32.56 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.894 -1.129 . . . . 0.0 109.574 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.581 ' HB2' ' CZ ' ' A' ' 103' ' ' PHE . . . -115.06 150.46 35.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.303 -0.873 . . . . 0.0 109.367 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.595 ' HB3' ' CZ3' ' A' ' 125' ' ' TRP . 5.3 ttp85 -164.57 121.86 1.64 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.111 -0.993 . . . . 0.0 109.51 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -102.84 170.1 8.2 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.158 -0.964 . . . . 0.0 109.764 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . 0.571 ' OE1' ' CE1' ' A' ' 158' ' ' TYR . 0.4 OUTLIER -67.16 -59.16 3.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.417 -0.802 . . . . 0.0 109.378 -179.939 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.482 ' C ' HG22 ' A' ' 123' ' ' THR . 0.8 OUTLIER -109.97 141.9 42.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.358 -0.839 . . . . 0.0 109.29 179.945 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.654 ' N ' HG22 ' A' ' 123' ' ' THR . 0.3 OUTLIER -58.16 144.79 39.33 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.206 -0.934 . . . . 0.0 109.206 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 118.17 31.94 1.47 Allowed Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -123.07 136.95 55.02 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.17 -1.194 . . . . 0.0 108.962 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.526 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 53.0 t -111.61 146.63 16.29 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 O-C-N 121.184 -0.947 . . . . 0.0 110.624 -179.342 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.904 HG21 HG21 ' A' ' 157' ' ' ILE . 89.0 t -155.83 149.88 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.481 -0.762 . . . . 0.0 109.5 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.518 ' CB ' ' HG2' ' A' ' 118' ' ' GLU . 19.5 m -125.29 138.6 54.09 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.202 -0.936 . . . . 0.0 109.69 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.625 ' N ' ' CD1' ' A' ' 103' ' ' PHE . 1.7 m-85 -120.25 103.22 9.06 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.966 -1.084 . . . . 0.0 109.088 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.504 HG22 ' HA ' ' A' ' 115' ' ' ARG . 11.4 p -117.04 171.05 8.17 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.235 -0.916 . . . . 0.0 110.02 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.729 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -120.94 164.16 17.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.623 -0.673 . . . . 0.0 110.428 -179.51 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.529 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -176.16 148.59 9.3 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.52 ' HB3' ' OH ' ' A' ' 113' ' ' TYR . 1.5 p30 -89.59 -169.64 2.55 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.208 -1.172 . . . . 0.0 109.112 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.519 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 59.2 mt-30 -78.7 18.36 0.6 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.122 -0.986 . . . . 0.0 110.628 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.465 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 0.2 OUTLIER -113.4 11.61 18.55 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 120.828 -1.17 . . . . 0.0 109.182 179.624 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.505 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.8 m-30 74.22 11.83 4.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.38 -0.825 . . . . 0.0 109.461 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.529 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 54.3 mm-40 -92.23 164.04 13.69 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.181 -0.949 . . . . 0.0 109.027 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.491 ' HA ' ' HA2' ' A' ' 106' ' ' GLY . 9.8 tt0 -127.96 142.77 51.15 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.204 -0.935 . . . . 0.0 109.572 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.52 ' OH ' ' HB3' ' A' ' 107' ' ' ASN . 79.1 m-85 -93.82 -75.88 0.49 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.25 -0.906 . . . . 0.0 108.883 179.484 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.573 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -113.99 170.6 13.38 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.504 ' HA ' HG22 ' A' ' 104' ' ' THR . 3.1 ptm180 -144.14 142.31 30.5 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -1.101 . . . . 0.0 109.012 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.763 HD11 ' CE1' ' A' ' 88' ' ' TYR . 0.0 OUTLIER -151.26 162.5 40.79 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.993 -1.067 . . . . 0.0 110.624 -179.169 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.622 ' ND1' ' CE1' ' A' ' 103' ' ' PHE . 0.0 OUTLIER 69.96 -153.73 0.13 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.635 -0.666 . . . . 0.0 110.598 178.439 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.601 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.8 mt-10 97.95 28.36 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.489 ' O ' HG13 ' A' ' 100' ' ' VAL . 0.9 OUTLIER -134.44 -164.05 1.46 Allowed 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.463 -0.773 . . . . 0.0 109.731 -179.94 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.442 ' HA ' HG22 ' A' ' 100' ' ' VAL . 21.1 mt-30 -67.94 157.69 34.43 Favored 'General case' 0 N--CA 1.492 1.631 0 CA-C-O 121.349 0.595 . . . . 0.0 110.018 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.585 ' CD1' ' NE2' ' A' ' 117' ' ' HIS . 4.9 mm -132.73 140.69 46.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.402 -0.811 . . . . 0.0 109.407 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -82.19 -179.53 7.44 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.439 -0.788 . . . . 0.0 110.412 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.654 HG22 ' N ' ' A' ' 97' ' ' ASP . 18.0 p -84.93 1.04 49.09 Favored 'General case' 0 N--CA 1.491 1.589 0 C-N-CA 120.081 -0.648 . . . . 0.0 109.419 179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.482 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 3.2 mt-10 -104.17 -169.79 1.68 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.242 -0.911 . . . . 0.0 109.428 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.595 ' CZ3' ' HB3' ' A' ' 93' ' ' ARG . 92.0 m95 -98.12 122.77 41.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.304 -0.873 . . . . 0.0 109.533 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.89 121.11 45.94 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.18 -0.95 . . . . 0.0 109.045 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.32 110.45 2.48 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.466 2.111 . . . . 0.0 110.753 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.407 ' CD2' ' CE1' ' A' ' 117' ' ' HIS . 1.0 OUTLIER -115.99 134.69 54.7 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 179.235 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.443 ' OG1' ' OG1' ' A' ' 89' ' ' THR . 14.5 t -151.36 176.59 11.11 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 120.716 -1.24 . . . . 0.0 110.956 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.626 ' CE1' HD21 ' A' ' 116' ' ' LEU . 6.9 p90 -178.37 165.39 1.79 Allowed 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.004 -0.998 . . . . 0.0 108.987 179.498 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -102.91 138.92 39.16 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.123 -0.986 . . . . 0.0 109.965 -179.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.597 ' HB3' ' CE2' ' A' ' 130' ' ' PHE . 22.2 p90 -138.49 155.95 47.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.395 -0.815 . . . . 0.0 109.218 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -131.34 144.12 51.01 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.209 -0.932 . . . . 0.0 109.131 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.745 HG21 ' O ' ' A' ' 81' ' ' ARG . 3.7 t -47.69 110.27 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.364 -0.835 . . . . 0.0 109.177 179.658 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -60.56 -51.79 67.93 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.245 -0.91 . . . . 0.0 109.21 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 43.7 m-20 -108.09 -92.35 0.42 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.413 -0.804 . . . . 0.0 109.153 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -160.66 55.51 0.32 Allowed 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.468 -0.77 . . . . 0.0 109.041 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.508 ' O ' HG23 ' A' ' 80' ' ' VAL . 18.8 mm-40 -93.2 113.71 26.0 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.303 -0.873 . . . . 0.0 109.75 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.43 -15.7 57.38 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.2 t -134.57 130.25 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.479 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -140.48 172.33 11.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.27 -0.894 . . . . 0.0 110.116 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.523 ' HB2' ' HB3' ' A' ' 76' ' ' PHE . 1.4 ptm180 -143.66 133.59 24.06 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.729 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.09 110.03 41.44 Favored Pre-proline 0 N--CA 1.486 1.369 0 O-C-N 121.319 -0.863 . . . . 0.0 109.76 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.516 ' HD2' ' HA ' ' A' ' 105' ' ' VAL . 36.0 Cg_endo -77.22 111.24 3.16 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.168 1.912 . . . . 0.0 111.169 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.689 HD13 ' N ' ' A' ' 145' ' ' ILE . 2.0 mm -90.68 139.34 17.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.545 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 10.7 m80 -109.37 149.51 29.4 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.696 -1.253 . . . . 0.0 112.337 -177.102 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.648 ' CE2' HG13 ' A' ' 101' ' ' VAL . 2.6 m-85 -153.68 153.8 32.93 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 131.6 38.23 0.27 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.892 ' C ' HG11 ' A' ' 64' ' ' VAL . 77.2 m-85 -116.68 163.69 15.75 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.409 -1.054 . . . . 0.0 109.104 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.01 -27.25 67.27 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -73.02 -7.18 50.04 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.444 -0.785 . . . . 0.0 109.621 179.707 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.581 ' HB3' HD11 ' A' ' 157' ' ' ILE . 1.5 m-20 -107.08 9.06 30.55 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 179.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.413 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.5 t -87.98 158.69 3.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 O-C-N 121.418 -0.801 . . . . 0.0 109.618 -179.383 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.413 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 53.13 35.78 50.31 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.461 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.2 m-20 -160.29 139.22 10.57 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.111 -1.229 . . . . 0.0 110.087 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.833 HG23 ' O ' ' A' ' 59' ' ' VAL . 73.6 m -92.09 122.39 34.55 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.123 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.904 HG21 HG21 ' A' ' 101' ' ' VAL . 1.4 mt -102.51 119.92 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.726 -1.234 . . . . 0.0 110.005 -178.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.713 ' CE1' HG22 ' A' ' 156' ' ' THR . 2.1 m-85 -100.11 142.17 31.96 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 178.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.67 HD12 ' CZ3' ' A' ' 28' ' ' TRP . 1.2 mt -133.22 138.29 51.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 120.788 -1.195 . . . . 0.0 110.162 -178.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.636 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.8 OUTLIER -173.67 136.4 0.57 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.216 -0.928 . . . . 0.0 108.926 179.592 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 131.0 -3.85 5.64 Favored Glycine 0 N--CA 1.485 1.958 0 C-N-CA 119.407 -1.378 . . . . 0.0 110.324 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.662 ' CA ' HD12 ' A' ' 90' ' ' ILE . 0.1 OUTLIER -59.27 97.15 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.754 -1.439 . . . . 0.0 108.614 -179.928 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -131.54 145.44 51.73 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.348 -0.845 . . . . 0.0 109.778 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.953 HD13 HG11 ' A' ' 78' ' ' VAL . 7.5 mt -133.81 124.57 47.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.318 -0.864 . . . . 0.0 109.285 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.527 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . -157.18 147.07 20.68 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.129 -0.982 . . . . 0.0 109.583 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.454 ' HB2' ' HA ' ' A' ' 86' ' ' TYR . 11.1 t -109.0 161.95 14.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.299 -0.875 . . . . 0.0 109.461 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -87.95 151.36 49.45 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.307 -0.87 . . . . 0.0 109.372 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo . . . . . 0 C--N 1.309 -1.551 0 C-N-CA 122.575 2.183 . . . . 0.0 110.414 -179.979 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 23.8 mt -75.25 123.83 26.0 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.441 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.569 HG22 ' H ' ' A' ' 4' ' ' ALA . 4.2 p -108.06 173.29 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -0.944 . . . . 0.0 109.368 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.735 ' HB3' ' O ' ' A' ' 164' ' ' ILE . . . -70.3 -57.9 4.35 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.234 -0.916 . . . . 0.0 109.539 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.471 ' HB3' ' HA ' ' A' ' 163' ' ' ALA . 0.7 OUTLIER -75.3 116.99 16.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.239 -0.913 . . . . 0.0 109.66 -179.753 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.625 HD12 ' O ' ' A' ' 4' ' ' ALA . 3.0 mp -103.89 140.88 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.35 -0.844 . . . . 0.0 109.068 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.508 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.7 OUTLIER 61.89 19.17 10.46 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.221 -0.924 . . . . 0.0 109.425 -179.804 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.488 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -61.54 -29.48 71.92 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 179.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.527 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -107.83 32.51 7.03 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 179.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.648 ' CD2' HG11 ' A' ' 25' ' ' VAL . 3.0 m-85 43.8 54.55 5.6 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.395 -1.062 . . . . 0.0 109.534 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -84.22 -36.89 22.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.16 -0.963 . . . . 0.0 109.68 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.465 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 18.6 m -84.01 -26.24 29.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.215 -0.928 . . . . 0.0 109.608 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.92 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.3 m -78.82 114.36 43.18 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.172 -0.955 . . . . 0.0 109.43 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.465 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.5 Cg_endo -77.86 142.68 20.19 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 C-N-CA 122.414 2.076 . . . . 0.0 110.61 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.71 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -40.11 161.43 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.885 -0.509 . . . . 0.0 109.709 179.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.82 132.99 3.23 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.024 -1.63 . . . . 0.0 109.024 -179.622 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.586 HG23 ' CD ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.94 138.45 17.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.3 -1.117 . . . . 0.0 109.325 -179.543 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.696 HG23 ' HA ' ' A' ' 43' ' ' GLU . 48.2 t -83.78 143.73 11.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-O 121.681 0.753 . . . . 0.0 110.096 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 27.9 p -94.84 -27.02 15.96 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.536 ' HB3' ' CG ' ' A' ' 23' ' ' GLU . 2.7 t0 -141.19 101.7 4.08 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 1.106 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -44.78 -30.13 0.91 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.178 -0.951 . . . . 0.0 109.751 -178.966 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.106 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -60.35 -53.34 58.77 Favored 'General case' 0 C--N 1.294 -1.842 0 O-C-N 121.6 -0.688 . . . . 0.0 109.678 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.536 ' CG ' ' HB3' ' A' ' 20' ' ' ASP . 1.8 pt-20 -102.15 31.52 3.92 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.249 -0.907 . . . . 0.0 109.409 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.52 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -71.14 -55.05 8.23 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.781 -1.327 . . . . 0.0 109.781 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.92 HG13 ' OG1' ' A' ' 13' ' ' THR . 2.8 t -121.53 143.1 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.16 -1.2 . . . . 0.0 109.663 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -67.49 -56.02 11.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.264 -0.897 . . . . 0.0 109.726 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.508 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -77.15 0.86 66.06 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 0.658 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.7 OUTLIER -137.5 121.54 17.83 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.116 -1.226 . . . . 0.0 109.274 179.653 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.534 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -123.44 118.89 28.46 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.363 -0.836 . . . . 0.0 109.034 179.589 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.72 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -97.85 174.5 6.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.185 -0.947 . . . . 0.0 109.842 -179.477 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -160.39 122.92 3.29 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.364 -0.835 . . . . 0.0 109.567 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.856 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -110.73 135.03 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.168 -0.958 . . . . 0.0 109.651 179.418 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.49 178.38 21.74 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 1.3 t -58.6 -15.81 13.15 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.199 -1.177 . . . . 0.0 109.39 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.487 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 1.4 p -60.94 -38.1 84.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.648 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.856 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -59.9 89.41 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 O-C-N 121.084 -1.01 . . . . 0.0 109.414 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.409 ' N ' ' O ' ' A' ' 35' ' ' SER . 25.4 m -62.73 -28.97 70.32 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.264 -0.898 . . . . 0.0 108.674 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.706 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.8 t-20 -122.91 128.81 25.22 Favored Pre-proline 0 C--N 1.297 -1.688 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.453 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.1 Cg_endo -75.84 116.55 4.46 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.261 1.974 . . . . 0.0 110.729 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.509 ' HG2' ' CE1' ' A' ' 42' ' ' PHE . 35.3 Cg_endo -77.44 -176.26 3.11 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 C-N-CA 122.421 2.081 . . . . 0.0 109.77 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 55.5 t -113.26 119.68 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.046 -1.034 . . . . 0.0 110.682 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.591 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 3.7 m-85 -101.07 112.38 24.83 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.184 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.696 ' HA ' HG23 ' A' ' 18' ' ' VAL . 31.6 tt0 -154.08 158.8 41.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.069 -1.02 . . . . 0.0 110.038 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.441 ' N ' ' CG ' ' A' ' 43' ' ' GLU . 58.9 t -99.5 148.21 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.506 -0.747 . . . . 0.0 109.106 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.502 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -123.35 122.1 37.47 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.295 -0.878 . . . . 0.0 109.787 -179.427 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.71 ' HG3' ' HB2' ' A' ' 15' ' ' ALA . 8.5 mt-10 -98.29 110.01 22.67 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.46 ' O ' ' HB3' ' A' ' 54' ' ' ASN . 3.1 p -142.53 -177.89 5.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.466 -0.771 . . . . 0.0 109.488 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.1 m -104.59 -5.24 21.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.306 -0.871 . . . . 0.0 109.558 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.403 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.9 m-20 -87.01 -16.56 35.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.174 -0.954 . . . . 0.0 109.444 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.403 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.33 149.74 0.71 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.234 -0.916 . . . . 0.0 109.376 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.459 ' HG3' ' HB2' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -77.93 -38.96 0.54 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.592 2.195 . . . . 0.0 110.409 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -121.23 121.28 37.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.295 -0.878 . . . . 0.0 109.397 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 63.93 -120.81 21.44 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.46 ' HB3' ' O ' ' A' ' 47' ' ' THR . 4.8 m120 -158.14 34.48 0.25 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -1.14 . . . . 0.0 109.503 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.524 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 5.4 mttp -140.2 142.17 35.89 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.298 -0.876 . . . . 0.0 109.584 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.54 HG12 ' OD2' ' A' ' 160' ' ' ASP . 4.6 m -149.22 174.85 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -0.899 . . . . 0.0 109.259 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.632 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -105.46 99.39 9.0 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.059 -1.026 . . . . 0.0 108.525 179.057 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.636 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.06 118.91 22.91 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.801 ' O ' HG23 ' A' ' 156' ' ' THR . 40.9 t -112.85 144.2 21.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.188 -0.945 . . . . 0.0 108.99 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.83 HG22 ' ND2' ' A' ' 62' ' ' ASN . 80.2 m -109.12 90.53 3.32 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.658 HG21 ' CD1' ' A' ' 157' ' ' ILE . 53.1 t -88.33 125.54 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.284 -0.885 . . . . 0.0 108.987 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.83 ' ND2' HG22 ' A' ' 60' ' ' THR . 3.6 p30 -159.23 61.15 0.4 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.34 -0.85 . . . . 0.0 109.802 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 144.36 93.9 0.17 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.727 HG12 ' C ' ' A' ' 148' ' ' GLY . 1.6 m -83.19 178.53 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.259 -1.142 . . . . 0.0 109.596 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.487 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -113.93 -154.47 11.21 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.4 m-20 -96.1 -10.12 29.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.317 -1.107 . . . . 0.0 109.491 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.597 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 4.8 m120 -109.8 151.47 42.36 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.309 -0.869 . . . . 0.0 109.381 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.43 12.53 2.09 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.693 2.262 . . . . 0.0 111.075 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.597 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.1 p90 -132.95 53.58 2.01 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.035 -1.041 . . . . 0.0 109.721 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.612 ' C ' HG23 ' A' ' 36' ' ' VAL . 0.3 OUTLIER -82.48 -69.32 0.63 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.21 -0.931 . . . . 0.0 109.057 179.763 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.491 ' HB ' ' HB3' ' A' ' 147' ' ' PHE . 6.1 mt -98.47 126.32 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.265 -0.897 . . . . 0.0 108.775 179.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -129.32 139.26 51.81 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.961 -1.087 . . . . 0.0 110.44 -179.358 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.72 ' HA ' HD23 ' A' ' 30' ' ' LEU . . . -122.49 143.12 49.91 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 178.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.521 HG22 ' N ' ' A' ' 75' ' ' ALA . 12.8 m -143.9 162.23 36.67 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.544 -1.348 . . . . 0.0 110.322 -178.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.521 ' N ' HG22 ' A' ' 74' ' ' THR . . . -123.93 136.18 54.17 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.48 -0.762 . . . . 0.0 109.142 179.191 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.539 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 1.3 p90 178.21 161.94 0.63 Allowed Pre-proline 0 N--CA 1.491 1.617 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.535 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -81.5 167.62 70.42 Favored 'Cis proline' 0 C--N 1.31 -1.491 0 C-N-CA 123.672 -1.387 . . . . 0.0 110.837 -0.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.654 HG11 HD12 ' A' ' 164' ' ' ILE . 62.2 t -124.07 150.04 28.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.263 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.522 ' O ' ' HB2' ' A' ' 4' ' ' ALA . 98.1 m-20 -117.29 108.85 16.12 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.0 -1.063 . . . . 0.0 110.075 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.572 HG23 ' O ' ' A' ' 138' ' ' GLU . 3.1 m -114.33 -173.85 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.209 -0.932 . . . . 0.0 109.479 179.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.704 ' O ' HG21 ' A' ' 134' ' ' VAL . 21.5 mmt180 -137.01 144.81 47.86 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.38 -0.825 . . . . 0.0 109.229 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -76.95 111.24 3.19 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.523 2.149 . . . . 0.0 110.47 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 109.13 -30.88 8.16 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.495 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -84.79 149.68 4.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.235 -1.156 . . . . 0.0 109.452 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.407 ' CG2' ' HA ' ' A' ' 168' ' ' PRO . 8.5 t -92.81 136.43 33.25 Favored 'General case' 0 C--N 1.292 -1.922 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.558 ' CZ ' ' HB3' ' A' ' 166' ' ' SER . 20.3 m-85 -119.39 148.98 42.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.193 -0.942 . . . . 0.0 109.688 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.474 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 17.5 m -113.79 151.77 31.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.312 -0.867 . . . . 0.0 108.985 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.618 ' CD1' ' N ' ' A' ' 88' ' ' TYR . 0.1 OUTLIER -128.81 114.45 16.56 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.178 -0.952 . . . . 0.0 109.628 -179.775 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.484 ' O ' ' O ' ' A' ' 161' ' ' GLY . 41.2 m -118.87 149.29 41.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.351 -0.843 . . . . 0.0 108.971 179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.789 HD13 ' CD2' ' A' ' 103' ' ' PHE . 19.2 tt -150.75 163.51 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 120.821 -1.174 . . . . 0.0 109.755 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.498 ' CD1' ' C ' ' A' ' 90' ' ' ILE . 20.5 m95 -132.27 125.87 32.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.11 -0.994 . . . . 0.0 109.271 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -115.55 148.11 39.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.24 -0.913 . . . . 0.0 109.562 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.484 ' HD2' ' HA ' ' A' ' 124' ' ' GLU . 5.0 ttp180 -160.68 118.02 2.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.197 -0.939 . . . . 0.0 109.007 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.478 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -104.41 150.12 24.81 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.405 -0.809 . . . . 0.0 109.889 -179.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . 0.489 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 3.0 mt-10 -52.75 -38.98 61.75 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.451 -0.781 . . . . 0.0 109.263 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.493 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -119.57 137.48 53.82 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.342 -0.848 . . . . 0.0 109.378 179.978 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.577 ' N ' ' CG2' ' A' ' 123' ' ' THR . 0.5 OUTLIER -63.4 147.59 50.79 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.482 -179.847 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 106.97 38.28 2.19 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.773 -1.331 . . . . 0.0 109.773 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.468 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -121.64 140.11 52.68 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.175 -1.191 . . . . 0.0 109.101 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.461 ' HB ' ' OD1' ' A' ' 152' ' ' ASN . 51.3 t -116.75 158.23 17.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.318 -0.864 . . . . 0.0 110.759 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.784 HG22 ' CE1' ' A' ' 147' ' ' PHE . 59.3 t -154.56 163.36 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.536 ' HB3' ' HB2' ' A' ' 146' ' ' HIS . 34.2 t -118.8 123.06 43.85 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.921 -1.112 . . . . 0.0 109.797 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.789 ' CD2' HD13 ' A' ' 90' ' ' ILE . 2.3 m-85 -119.25 103.45 9.51 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.173 -0.955 . . . . 0.0 109.633 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.487 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 19.0 p -128.97 167.87 16.83 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.195 -0.941 . . . . 0.0 110.185 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.688 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -128.44 155.67 40.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.732 -0.605 . . . . 0.0 110.341 -179.726 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.53 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -175.68 160.81 29.32 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.548 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 0.9 OUTLIER -99.3 -170.26 1.88 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.125 -1.221 . . . . 0.0 109.418 -179.88 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.548 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 22.1 mt-30 -71.87 8.73 1.1 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.06 -1.025 . . . . 0.0 111.185 -179.18 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.545 ' HB2' ' NE2' ' A' ' 111' ' ' GLN . 2.0 m -108.93 13.52 24.71 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 120.667 -1.271 . . . . 0.0 109.219 179.729 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.5 m-30 73.88 1.69 3.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.454 -0.779 . . . . 0.0 109.641 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.545 ' NE2' ' HB2' ' A' ' 109' ' ' SER . 0.7 OUTLIER -73.11 161.33 30.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.198 -0.939 . . . . 0.0 108.69 179.283 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.491 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 3.6 tt0 -138.45 134.78 34.47 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.0 -1.063 . . . . 0.0 109.882 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.572 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 18.9 m-85 -94.8 -71.61 0.66 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.272 -0.893 . . . . 0.0 108.67 179.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.592 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -87.67 165.81 35.45 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 108.979 -1.648 . . . . 0.0 108.979 179.369 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.485 ' HA ' HG22 ' A' ' 104' ' ' THR . 50.9 ttt180 -160.94 110.55 1.67 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.997 -1.296 . . . . 0.0 110.474 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.832 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -144.97 69.97 1.26 Allowed 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 108.698 -0.852 . . . . 0.0 108.698 179.077 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.534 ' CB ' ' OG ' ' A' ' 102' ' ' SER . 19.2 p80 -102.71 157.7 16.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 110.02 -179.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 1.3 tp10 77.98 44.34 0.08 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.388 -0.82 . . . . 0.0 109.403 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.463 ' OE1' ' HB2' ' A' ' 116' ' ' LEU . 0.9 OUTLIER -109.35 136.67 48.42 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.286 -0.884 . . . . 0.0 109.473 179.912 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.984 ' O ' HD13 ' A' ' 121' ' ' ILE . 18.9 mm-40 -73.85 155.92 38.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.445 -0.784 . . . . 0.0 109.029 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.984 HD13 ' O ' ' A' ' 120' ' ' GLN . 13.6 mm -134.38 135.81 53.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.081 -1.012 . . . . 0.0 110.071 -179.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.61 -179.06 6.25 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 121.638 0.732 . . . . 0.0 110.254 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.577 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 39.2 p -75.22 -0.63 20.1 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.386 179.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.484 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 6.4 mt-10 -110.91 -168.94 1.37 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.226 -0.922 . . . . 0.0 109.238 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.463 ' HA ' ' O ' ' A' ' 92' ' ' ALA . 94.1 m95 -94.39 124.89 38.69 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.159 -0.963 . . . . 0.0 109.565 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.418 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 2.1 tt0 -106.95 121.2 45.61 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.223 -0.923 . . . . 0.0 109.078 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.09 100.57 1.28 Allowed 'Trans proline' 0 C--N 1.311 -1.444 0 C-N-CA 122.4 2.067 . . . . 0.0 110.923 -179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -111.62 133.93 53.54 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.44 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.3 t -151.16 176.78 10.86 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 120.793 -1.192 . . . . 0.0 110.794 -179.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.832 ' CE1' HD21 ' A' ' 116' ' ' LEU . 6.3 p90 -166.74 165.8 16.19 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.123 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -118.85 138.89 52.41 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.129 -0.982 . . . . 0.0 109.891 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.572 ' CE2' ' O ' ' A' ' 113' ' ' TYR . 0.5 OUTLIER -154.77 157.73 38.41 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.375 -0.828 . . . . 0.0 109.128 179.729 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.447 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -121.09 147.66 45.23 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.232 -0.917 . . . . 0.0 109.551 -179.66 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.704 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.2 t -41.44 110.05 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.511 -0.743 . . . . 0.0 109.214 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 33.7 t -59.39 -50.64 73.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -0.872 . . . . 0.0 109.205 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -108.23 -91.7 0.43 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.382 -0.824 . . . . 0.0 109.189 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -163.23 54.74 0.18 Allowed 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.572 ' O ' HG23 ' A' ' 80' ' ' VAL . 40.4 mm-40 -91.33 111.55 23.09 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.293 -0.879 . . . . 0.0 109.944 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.35 -17.53 54.3 Favored 'General case' 0 N--CA 1.487 1.42 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.233 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.4 t -131.64 132.2 62.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.513 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -142.65 171.73 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.082 -1.011 . . . . 0.0 110.385 -179.416 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.471 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.8 OUTLIER -141.9 132.77 25.83 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.806 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.688 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.15 111.45 50.22 Favored Pre-proline 0 C--N 1.304 -1.396 0 O-C-N 121.162 -0.961 . . . . 0.0 109.4 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.487 ' HD2' ' O ' ' A' ' 104' ' ' THR . 33.2 Cg_endo -74.69 111.95 3.44 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 C-N-CA 122.199 1.933 . . . . 0.0 110.764 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.658 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 2.1 mt -100.17 136.81 29.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 179.135 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.536 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 5.9 m80 -105.72 160.37 15.27 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.525 -1.359 . . . . 0.0 111.105 -178.343 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.795 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 11.1 m-85 -159.74 162.2 34.88 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.727 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 107.01 38.91 2.07 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.641 ' C ' HG11 ' A' ' 64' ' ' VAL . 20.5 m-85 -113.42 158.09 21.09 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.489 -1.007 . . . . 0.0 109.287 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.38 -27.29 67.74 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.646 -0.659 . . . . 0.0 109.265 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.57 -15.13 62.74 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.45 -0.781 . . . . 0.0 109.187 179.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.525 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.2 OUTLIER -109.78 11.88 24.24 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.338 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.541 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.3 t -84.87 161.48 3.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.492 -0.755 . . . . 0.0 109.821 -179.296 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.441 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 51.37 33.88 32.75 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.1 m-20 -160.4 141.84 12.34 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.22 -1.165 . . . . 0.0 110.226 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.801 HG23 ' O ' ' A' ' 59' ' ' VAL . 85.2 m -89.55 124.45 34.54 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.658 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.2 mt -105.02 116.32 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.855 -1.153 . . . . 0.0 110.055 -178.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.636 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 5.8 m-85 -98.91 139.85 33.96 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 178.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.795 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -132.16 139.34 50.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.739 -1.225 . . . . 0.0 110.228 -178.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' A' ' 161' ' ' GLY . 39.9 t0 -173.9 135.95 0.52 Allowed 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.368 -0.832 . . . . 0.0 108.876 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.543 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 127.28 -9.77 6.96 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.41 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.488 ' O ' ' HA3' ' A' ' 8' ' ' GLY . 12.4 tp -59.81 109.13 0.86 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.712 -1.464 . . . . 0.0 108.642 -179.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . 0.479 ' O ' ' HA ' ' A' ' 88' ' ' TYR . . . -138.87 145.55 40.09 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.457 -0.777 . . . . 0.0 109.985 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.735 ' O ' ' HB3' ' A' ' 4' ' ' ALA . 16.5 mt -130.97 109.0 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.37 -0.831 . . . . 0.0 109.18 179.472 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.509 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -119.38 171.17 8.51 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.164 -0.96 . . . . 0.0 109.621 -179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.558 ' HB3' ' CZ ' ' A' ' 86' ' ' TYR . 1.3 p -99.71 93.4 5.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.482 ' NE2' ' HB3' ' A' ' 165' ' ' ALA . 0.9 OUTLIER -112.99 92.23 20.55 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.904 . . . . 0.0 109.468 -179.981 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . 0.481 ' HD3' ' O ' ' A' ' 166' ' ' SER . 35.4 Cg_endo . . . . . 0 C--N 1.309 -1.522 0 C-N-CA 122.653 2.235 . . . . 0.0 110.455 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.464 ' O ' ' HB ' ' A' ' 3' ' ' VAL . 4.3 mm? -83.75 167.66 16.94 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.354 -0.841 . . . . 0.0 109.477 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.616 HG22 ' O ' ' A' ' 164' ' ' ILE . 4.4 p 179.75 173.87 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.253 -0.905 . . . . 0.0 109.311 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.759 ' HB3' ' O ' ' A' ' 164' ' ' ILE . . . -65.46 -43.75 89.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.092 -1.005 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.644 ' HB2' HD12 ' A' ' 164' ' ' ILE . 21.4 t-20 -85.87 130.94 34.41 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.278 -0.889 . . . . 0.0 109.338 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.42 ' O ' ' HB3' ' A' ' 7' ' ' ASN . 1.7 mp -127.62 126.61 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.223 -0.923 . . . . 0.0 109.613 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.527 ' HB3' ' CA ' ' A' ' 27' ' ' GLY . 0.6 OUTLIER 65.32 10.7 6.71 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.333 -0.854 . . . . 0.0 109.546 179.591 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.426 ' HA3' ' OD1' ' A' ' 5' ' ' ASN . . . -66.06 -33.24 84.86 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 179.412 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.529 ' CA ' ' OD1' ' A' ' 160' ' ' ASP . . . -91.32 16.14 59.58 Favored Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.604 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 13.2 m-85 61.28 40.27 14.62 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.337 -1.096 . . . . 0.0 109.439 179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -84.65 -43.38 14.44 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.838 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -78.71 -42.29 28.75 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.212 -0.93 . . . . 0.0 109.875 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.87 ' OG1' HG13 ' A' ' 25' ' ' VAL . 12.8 m -59.81 123.67 72.8 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.33 -0.856 . . . . 0.0 109.586 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.8 Cg_endo -77.87 137.42 15.83 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 122.439 2.092 . . . . 0.0 110.569 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.463 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -41.97 164.63 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.715 -0.616 . . . . 0.0 109.707 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 132.71 131.18 3.17 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 108.999 -1.64 . . . . 0.0 108.999 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.542 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -56.96 142.94 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.167 -1.196 . . . . 0.0 108.943 -179.71 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.468 HG13 ' HA2' ' A' ' 24' ' ' GLY . 54.1 t -90.64 142.47 12.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.456 -0.778 . . . . 0.0 110.386 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 33.3 p -93.03 -30.14 15.46 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 178.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.41 ' O ' ' C ' ' A' ' 21' ' ' LEU . 4.9 m-20 -133.39 99.53 4.55 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 1.098 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -44.13 -29.57 0.64 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.207 -0.933 . . . . 0.0 109.764 -178.567 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.098 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.8 -51.7 68.62 Favored 'General case' 0 C--N 1.294 -1.823 0 O-C-N 121.588 -0.695 . . . . 0.0 109.706 -179.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -101.86 31.05 4.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.2 -0.937 . . . . 0.0 109.384 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.468 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -74.1 -59.91 3.78 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.87 HG13 ' OG1' ' A' ' 13' ' ' THR . 3.5 t -120.56 137.91 52.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -1.135 . . . . 0.0 109.555 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -69.44 -42.31 75.14 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.305 -0.872 . . . . 0.0 109.587 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.527 ' CA ' ' HB3' ' A' ' 7' ' ' ASN . . . -76.91 -12.67 84.39 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 1.049 ' CZ2' HD13 ' A' ' 145' ' ' ILE . 1.0 OUTLIER -132.44 123.73 27.23 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.19 -1.182 . . . . 0.0 109.754 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.461 ' OD1' ' CE2' ' A' ' 76' ' ' PHE . 1.8 m-20 -113.83 115.82 28.36 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 178.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.914 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -98.81 168.0 10.41 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.946 -1.096 . . . . 0.0 110.16 -178.581 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 72' ' ' GLU . 19.5 m120 -160.53 123.43 3.34 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.532 -0.73 . . . . 0.0 109.633 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.005 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -101.12 131.88 47.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.097 -1.002 . . . . 0.0 109.447 179.263 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.29 178.65 26.74 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 -179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.5 m -57.99 -16.75 13.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -1.133 . . . . 0.0 109.345 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.471 ' HB3' ' HB2' ' A' ' 67' ' ' ASN . 1.3 p -61.99 -38.55 89.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.442 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 1.005 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -63.78 89.67 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 O-C-N 121.221 -0.925 . . . . 0.0 109.455 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 45.2 m -71.23 -28.4 64.16 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.846 0.832 . . . . 0.0 108.84 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.656 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.3 m-20 -115.0 139.77 24.71 Favored Pre-proline 0 C--N 1.297 -1.702 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.484 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.4 Cg_endo -76.01 111.76 3.35 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.389 2.059 . . . . 0.0 110.816 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 38' ' ' ASN . 34.9 Cg_endo -77.57 179.61 6.35 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.46 2.106 . . . . 0.0 109.552 179.537 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.54 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 61.9 t -117.18 120.74 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.999 -1.063 . . . . 0.0 110.769 -179.576 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.485 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 90.6 m-85 -106.83 112.24 25.12 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 178.086 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.542 ' HG3' HG23 ' A' ' 17' ' ' VAL . 0.4 OUTLIER -150.28 148.26 28.65 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.976 -1.078 . . . . 0.0 110.237 -179.261 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.0 t -101.77 148.19 7.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.519 -0.738 . . . . 0.0 109.117 179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 1.077 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -150.54 164.32 36.27 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 179.85 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 1.077 ' N ' HD22 ' A' ' 45' ' ' LEU . 19.4 pt-20 -120.04 123.84 44.42 Favored 'General case' 0 C--N 1.291 -1.945 0 O-C-N 121.391 -0.818 . . . . 0.0 109.388 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.985 HG23 HD21 ' A' ' 45' ' ' LEU . 6.7 p -117.42 178.98 4.18 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 109.459 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 p -101.97 8.76 40.94 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.219 -0.926 . . . . 0.0 109.524 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.413 ' O ' ' C ' ' A' ' 50' ' ' ALA . 7.7 m-20 -125.25 8.72 7.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.178 -0.952 . . . . 0.0 109.572 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -43.9 148.78 0.72 Allowed Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.234 -0.916 . . . . 0.0 109.437 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.601 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 35.8 Cg_endo -77.97 -40.16 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 122.642 2.228 . . . . 0.0 110.384 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -131.71 94.04 3.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.284 -0.885 . . . . 0.0 109.43 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 99.19 -124.29 8.18 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.493 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 76.6 m-20 -155.06 20.33 0.43 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.241 -1.153 . . . . 0.0 109.556 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 10' ' ' PHE . 51.9 mttp -137.62 145.33 42.62 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.237 -0.914 . . . . 0.0 109.638 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.644 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.1 m -150.14 174.69 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.32 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.732 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -101.35 102.95 13.87 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 109.016 179.618 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.709 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.92 117.7 22.36 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.779 ' O ' HG23 ' A' ' 156' ' ' THR . 39.6 t -111.86 144.64 19.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.052 -1.03 . . . . 0.0 109.076 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.54 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 16.0 m -109.2 89.27 2.95 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.534 HG21 ' CD1' ' A' ' 157' ' ' ILE . 41.5 t -85.25 128.7 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.334 -0.854 . . . . 0.0 109.16 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -159.93 61.56 0.36 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.427 -0.795 . . . . 0.0 109.835 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 150.56 93.55 0.11 Allowed Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.69 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.4 m -79.86 -173.41 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.181 -1.188 . . . . 0.0 109.497 179.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -135.46 -162.02 9.52 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . 0.418 ' C ' ' OD1' ' A' ' 67' ' ' ASN . 23.0 t30 -89.82 10.28 24.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.213 -1.169 . . . . 0.0 109.453 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.594 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.0 m-20 -131.82 148.26 69.21 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.188 -0.945 . . . . 0.0 109.391 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.43 12.99 1.94 Allowed 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.568 2.179 . . . . 0.0 111.022 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.594 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.2 p90 -133.44 55.66 1.89 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.95 -1.094 . . . . 0.0 109.916 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.52 ' C ' HG23 ' A' ' 36' ' ' VAL . 0.3 OUTLIER -78.68 -68.31 0.66 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 108.862 179.535 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.412 ' HB ' ' HB2' ' A' ' 147' ' ' PHE . 2.8 mp -90.19 124.63 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.472 ' HB3' ' O ' ' A' ' 31' ' ' ASN . 1.6 tt0 -114.7 128.76 56.49 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.031 -1.043 . . . . 0.0 110.729 -179.137 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 1.083 ' HB3' ' CE1' ' A' ' 147' ' ' PHE . . . -131.43 107.67 9.07 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.558 HG22 ' N ' ' A' ' 75' ' ' ALA . 52.0 m -117.92 163.87 15.91 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.894 -1.129 . . . . 0.0 110.255 -178.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.558 ' N ' HG22 ' A' ' 74' ' ' THR . . . -119.19 137.26 53.75 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.234 -0.916 . . . . 0.0 109.214 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.54 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 0.6 OUTLIER 177.42 162.95 0.55 Allowed Pre-proline 0 N--CA 1.492 1.67 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -179.888 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.511 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.11 167.45 74.52 Favored 'Cis proline' 0 C--N 1.309 -1.52 0 C-N-CA 123.722 -1.366 . . . . 0.0 110.699 -0.242 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.541 ' CG1' ' HB1' ' A' ' 4' ' ' ALA . 69.5 t -125.37 151.04 30.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.396 -0.815 . . . . 0.0 108.819 179.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.593 ' O ' ' HB2' ' A' ' 4' ' ' ALA . 8.5 m-80 -117.15 113.24 21.97 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.077 -1.014 . . . . 0.0 109.933 -179.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.587 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.8 m -117.83 -176.24 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.192 -0.943 . . . . 0.0 109.449 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.722 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -134.91 144.97 52.7 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.319 -0.863 . . . . 0.0 109.236 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.474 ' HD2' ' HG3' ' A' ' 81' ' ' ARG . 34.8 Cg_endo -76.19 113.26 3.66 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.49 2.127 . . . . 0.0 110.553 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.6 -31.6 8.1 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.533 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -85.09 149.79 4.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.256 -1.144 . . . . 0.0 109.466 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 4.3 m -95.37 138.23 33.35 Favored 'General case' 0 C--N 1.292 -1.906 0 CA-C-O 121.296 0.57 . . . . 0.0 109.473 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.587 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 12.2 m-85 -117.93 157.4 26.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -0.936 . . . . 0.0 109.616 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 40.1 m -118.1 149.48 40.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.294 -0.879 . . . . 0.0 109.29 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.69 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 0.2 OUTLIER -125.97 107.98 10.97 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -0.891 . . . . 0.0 109.507 -179.884 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 161' ' ' GLY . 48.6 m -115.15 146.64 41.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.29 -0.882 . . . . 0.0 109.098 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.816 HD13 ' CD2' ' A' ' 103' ' ' PHE . 18.9 tt -150.48 163.32 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 120.884 -1.135 . . . . 0.0 109.465 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.601 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 21.0 m95 -131.37 127.1 36.87 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.971 -1.081 . . . . 0.0 109.526 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -115.47 146.96 41.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.364 -0.835 . . . . 0.0 109.316 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.501 ' HG3' ' CA ' ' A' ' 124' ' ' GLU . 28.2 ttt-85 -162.16 118.06 1.98 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.125 -0.985 . . . . 0.0 109.182 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.71 166.12 10.69 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.878 -179.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.0 mm-40 -59.46 -49.82 76.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.426 -0.796 . . . . 0.0 109.363 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.575 ' C ' HG22 ' A' ' 123' ' ' THR . 0.6 OUTLIER -112.35 148.38 34.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.335 -0.853 . . . . 0.0 109.252 179.879 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.778 ' N ' HG22 ' A' ' 123' ' ' THR . 2.1 t70 -68.81 163.14 24.87 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.205 -0.935 . . . . 0.0 109.487 -179.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.505 ' N ' ' OD1' ' A' ' 97' ' ' ASP . . . 93.42 39.5 5.03 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.905 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -119.02 142.59 47.68 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.278 -1.131 . . . . 0.0 109.044 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.443 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 54.3 t -118.87 149.69 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.205 -0.934 . . . . 0.0 110.909 -179.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.702 HG13 ' CE2' ' A' ' 147' ' ' PHE . 47.7 t -149.42 165.26 3.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.521 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 66.5 m -130.54 125.47 34.33 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.976 -1.077 . . . . 0.0 109.392 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.816 ' CD2' HD13 ' A' ' 90' ' ' ILE . 1.2 m-85 -122.38 104.18 9.23 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.235 -0.915 . . . . 0.0 110.095 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.541 HG22 ' CA ' ' A' ' 115' ' ' ARG . 17.4 p -121.67 163.49 18.92 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.113 -0.992 . . . . 0.0 109.87 179.437 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -112.62 118.0 56.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 C-N-CA 119.948 -0.701 . . . . 0.0 110.007 179.701 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -109.46 172.61 16.25 Favored Glycine 0 N--CA 1.487 2.086 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.552 ' CB ' ' O ' ' A' ' 111' ' ' GLN . 17.1 t30 -123.57 171.78 9.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.369 -1.077 . . . . 0.0 109.133 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.411 ' N ' ' CG ' ' A' ' 107' ' ' ASN . 19.1 mt-30 -59.06 -48.17 82.58 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.972 -1.08 . . . . 0.0 109.675 -179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.546 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 2.8 m -83.36 17.96 1.95 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.239 -0.913 . . . . 0.0 110.12 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.548 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.8 m-30 81.14 8.58 1.08 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.479 -0.763 . . . . 0.0 110.189 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.552 ' O ' ' CB ' ' A' ' 107' ' ' ASN . 5.4 mm-40 -71.02 121.82 18.9 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.955 -1.091 . . . . 0.0 108.807 179.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -106.17 139.5 40.59 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.817 -1.177 . . . . 0.0 109.949 -179.328 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.574 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 4.6 m-85 -107.3 -65.53 1.09 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.589 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -104.74 179.29 24.25 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.052 -1.619 . . . . 0.0 109.052 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.541 ' CA ' HG22 ' A' ' 104' ' ' THR . 0.0 OUTLIER 175.35 119.82 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.917 -1.343 . . . . 0.0 110.398 179.959 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.897 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -140.84 70.01 1.35 Allowed 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.25 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.544 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 17.7 p-80 -89.28 152.7 21.41 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.893 . . . . 0.0 110.129 -179.364 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 4.0 tt0 79.66 72.74 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.402 -0.811 . . . . 0.0 109.598 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.434 ' HG2' ' C ' ' A' ' 118' ' ' GLU . 14.0 mm-40 -134.67 130.18 35.94 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.357 -0.839 . . . . 0.0 109.45 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.696 ' O ' HD13 ' A' ' 121' ' ' ILE . 1.1 mp0 -66.41 152.66 44.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.269 -0.895 . . . . 0.0 109.013 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.696 HD13 ' O ' ' A' ' 120' ' ' GLN . 9.1 mm -136.08 136.07 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 O-C-N 121.068 -1.02 . . . . 0.0 110.099 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.427 HG22 ' OD2' ' A' ' 97' ' ' ASP . 0.6 OUTLIER -87.4 -179.04 6.31 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 121.651 0.738 . . . . 0.0 110.125 179.641 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.778 HG22 ' N ' ' A' ' 97' ' ' ASP . 30.5 p -76.45 1.15 17.3 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.35 179.519 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.501 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 8.6 mt-10 -111.64 -168.95 1.37 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 0.0 109.177 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.529 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 97.6 m95 -94.22 123.36 37.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.657 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.407 ' OE1' ' HD2' ' A' ' 127' ' ' PRO . 12.2 mm-40 -106.93 121.36 45.11 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.301 -0.875 . . . . 0.0 108.992 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.591 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.6 Cg_endo -80.02 104.51 1.68 Allowed 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.396 2.064 . . . . 0.0 110.947 -179.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -116.98 131.67 56.9 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.559 ' HG1' ' C ' ' A' ' 88' ' ' TYR . 14.4 t -151.76 177.09 10.75 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.936 -1.102 . . . . 0.0 110.745 -179.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.897 ' CE1' HD21 ' A' ' 116' ' ' LEU . 12.2 p90 -163.36 178.21 8.31 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.08 179.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 82.4 mt-10 -130.48 138.92 50.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.117 -0.989 . . . . 0.0 109.975 -179.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.589 ' CE2' ' HA2' ' A' ' 114' ' ' GLY . 0.3 OUTLIER -151.06 168.13 25.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.372 -0.83 . . . . 0.0 109.163 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.7 OUTLIER -127.82 146.57 50.56 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.115 -0.991 . . . . 0.0 109.409 -179.507 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.722 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.9 t -41.28 110.43 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.618 -0.676 . . . . 0.0 109.266 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -56.1 -46.94 78.92 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.318 -0.864 . . . . 0.0 109.043 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.472 ' O ' ' HG3' ' A' ' 137' ' ' GLN . 2.8 m-20 -118.49 -91.71 0.55 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.429 -0.794 . . . . 0.0 109.173 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . 0.472 ' HG3' ' O ' ' A' ' 136' ' ' ASP . 71.9 mt-30 -159.7 57.37 0.38 Allowed 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.47 -0.769 . . . . 0.0 108.929 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.565 ' O ' HG23 ' A' ' 80' ' ' VAL . 16.6 mm-40 -95.7 111.49 23.43 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.293 -0.88 . . . . 0.0 109.765 -179.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.38 -13.79 59.39 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.324 -0.86 . . . . 0.0 108.73 179.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 39.2 t -132.17 130.6 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.367 -0.833 . . . . 0.0 109.009 179.463 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.545 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -144.36 171.8 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.254 -0.903 . . . . 0.0 109.824 -179.812 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.507 ' HB2' ' HB3' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -146.47 131.83 18.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.489 -0.757 . . . . 0.0 109.522 179.86 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.613 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -93.34 110.54 47.27 Favored Pre-proline 0 N--CA 1.486 1.372 0 O-C-N 121.259 -0.9 . . . . 0.0 110.168 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.486 ' HD2' ' O ' ' A' ' 104' ' ' THR . 36.0 Cg_endo -77.46 111.06 3.09 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.297 1.998 . . . . 0.0 110.735 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 1.049 HD13 ' CZ2' ' A' ' 28' ' ' TRP . 1.2 mt -97.8 120.71 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 179.162 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.538 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 7.1 m80 -85.83 159.36 19.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.777 -1.202 . . . . 0.0 112.202 -176.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 1.083 ' CE1' ' HB3' ' A' ' 73' ' ' ALA . 61.6 m-85 -157.57 158.43 35.59 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 179.001 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.556 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 112.19 52.53 0.52 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.69 ' C ' HG11 ' A' ' 64' ' ' VAL . 41.8 m-85 -125.73 158.17 35.54 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.428 -1.042 . . . . 0.0 109.195 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.474 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.98 -29.51 69.38 Favored 'General case' 0 C--N 1.296 -1.734 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.86 -9.59 57.94 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 121.738 0.78 . . . . 0.0 109.327 179.299 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.905 ' OD1' ' HB1' ' A' ' 99' ' ' ALA . 2.1 t-20 -120.59 12.18 11.45 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.521 ' CG2' HG13 ' A' ' 64' ' ' VAL . 2.2 t -82.92 161.69 3.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 O-C-N 121.628 -0.67 . . . . 0.0 109.631 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.44 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.7 37.42 51.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.428 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.1 m-20 -160.32 138.37 9.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.128 -1.219 . . . . 0.0 110.17 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 59' ' ' VAL . 98.0 m -86.26 121.2 28.5 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.573 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 1.0 OUTLIER -101.87 117.27 46.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.865 -1.147 . . . . 0.0 110.224 -178.874 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.709 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.9 m-85 -95.96 135.77 37.28 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 178.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.634 HD13 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -129.16 137.66 56.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 120.819 -1.176 . . . . 0.0 110.12 -178.601 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.644 ' CB ' HG12 ' A' ' 56' ' ' VAL . 9.0 t0 -174.08 136.26 0.5 Allowed 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.307 -0.871 . . . . 0.0 109.018 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 128.0 -11.11 6.58 Favored Glycine 0 N--CA 1.485 1.958 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.334 179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.522 HD23 ' HB2' ' A' ' 75' ' ' ALA . 11.4 tp -59.63 110.19 1.08 Allowed 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.694 -1.474 . . . . 0.0 108.486 -179.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . 0.506 ' HA ' ' CB ' ' A' ' 5' ' ' ASN . . . -139.6 145.65 38.82 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.474 -0.766 . . . . 0.0 110.265 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.759 ' O ' ' HB3' ' A' ' 4' ' ' ALA . 2.3 mp -126.86 109.02 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.422 -0.799 . . . . 0.0 109.047 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.494 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . -126.87 146.94 50.1 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.083 -1.011 . . . . 0.0 109.826 -179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.586 ' HB2' ' CZ ' ' A' ' 86' ' ' TYR . 5.2 t -76.17 138.46 40.7 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.201 -0.937 . . . . 0.0 109.571 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.409 ' HB2' ' HD2' ' A' ' 168' ' ' PRO . 1.8 pt20 -136.06 158.24 74.18 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.257 -0.902 . . . . 0.0 109.48 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . 0.409 ' HD2' ' HB2' ' A' ' 167' ' ' GLN . 35.8 Cg_endo . . . . . 0 C--N 1.308 -1.565 0 C-N-CA 122.622 2.214 . . . . 0.0 110.45 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.2 ttt . . . . . 0 N--CA 1.492 1.634 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 26.1 mt -96.53 -162.5 0.96 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.262 -0.899 . . . . 0.0 109.453 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.992 HG23 ' HB2' ' A' ' 165' ' ' ALA . 3.2 p -162.99 178.15 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.226 -0.921 . . . . 0.0 109.363 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.632 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -68.79 -57.92 4.92 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.188 -0.945 . . . . 0.0 109.854 -179.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.875 ' HB3' HG22 ' A' ' 78' ' ' VAL . 8.5 p-10 -102.07 141.83 34.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.238 -0.914 . . . . 0.0 109.79 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.5 ' O ' ' HA3' ' A' ' 27' ' ' GLY . 1.8 mp -102.78 150.17 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 0.0 109.555 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.541 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.9 OUTLIER 66.63 17.98 10.69 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.254 -0.904 . . . . 0.0 110.0 179.464 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -59.02 -26.97 61.68 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.855 -1.698 . . . . 0.0 108.855 179.571 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.445 ' O ' ' OD1' ' A' ' 160' ' ' ASP . . . -115.38 37.57 3.42 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.605 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 1.1 m-85 43.58 46.09 5.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.328 -1.101 . . . . 0.0 109.417 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -77.08 -36.14 56.04 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.19 -0.944 . . . . 0.0 109.659 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.519 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 4.5 t -88.3 -21.68 24.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.227 -0.921 . . . . 0.0 109.499 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 1.03 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.2 m -70.81 113.92 22.65 Favored Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 12' ' ' SER . 35.7 Cg_endo -77.48 136.16 15.42 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.392 2.061 . . . . 0.0 110.502 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.6 ' HB2' ' HB2' ' A' ' 46' ' ' GLU . . . -40.21 154.46 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.897 -0.502 . . . . 0.0 109.65 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 136.52 131.1 2.96 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 -179.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.527 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.2 139.0 17.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.273 -1.134 . . . . 0.0 109.494 -179.591 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.438 HG13 ' HA2' ' A' ' 24' ' ' GLY . 53.7 t -86.52 142.86 12.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 CA-C-O 121.568 0.699 . . . . 0.0 110.122 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 19.6 p -93.75 -28.43 15.93 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -132.99 101.05 5.08 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 1.102 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -47.29 -30.21 2.96 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.247 -0.908 . . . . 0.0 109.873 -178.842 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.102 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.72 -47.74 84.46 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.559 -0.713 . . . . 0.0 109.857 -179.642 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -107.58 34.59 3.45 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.123 -0.985 . . . . 0.0 109.432 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.438 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -74.55 -50.02 10.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 1.03 HG13 ' OG1' ' A' ' 13' ' ' THR . 4.9 t -119.84 141.49 39.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.24 -1.153 . . . . 0.0 109.738 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -67.18 -47.18 71.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.345 -0.847 . . . . 0.0 109.433 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.541 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -89.29 0.66 81.49 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 0.696 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.6 OUTLIER -135.64 121.75 20.17 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.198 -1.177 . . . . 0.0 109.215 179.659 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.539 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -121.65 122.79 40.41 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.366 -0.834 . . . . 0.0 108.912 179.452 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.828 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -99.32 173.5 6.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.756 -179.308 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 62.7 m-80 -160.37 123.45 3.42 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.369 -0.832 . . . . 0.0 109.842 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.958 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.54 136.25 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.205 -0.935 . . . . 0.0 109.415 179.219 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.01 -178.91 26.5 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 70.2 m -58.79 -16.99 19.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -1.127 . . . . 0.0 109.538 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.492 ' HB3' ' HB2' ' A' ' 67' ' ' ASN . 2.8 p -60.99 -37.0 80.94 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.242 -0.911 . . . . 0.0 109.367 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.958 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -62.41 89.39 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 O-C-N 121.27 -0.894 . . . . 0.0 109.334 179.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 88.7 m -73.14 -28.07 62.03 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.362 -0.836 . . . . 0.0 108.864 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.638 ' O ' HG13 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -112.72 142.99 28.13 Favored Pre-proline 0 C--N 1.297 -1.703 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.584 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -76.41 111.38 3.25 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 122.384 2.056 . . . . 0.0 110.801 -179.599 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.542 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.8 Cg_endo -78.05 177.11 9.18 Favored 'Trans proline' 0 C--N 1.312 -1.365 0 C-N-CA 122.521 2.147 . . . . 0.0 109.391 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.543 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 63.2 t -118.03 120.87 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 120.873 -1.142 . . . . 0.0 110.829 -179.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.591 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 96.3 m-85 -110.01 112.89 25.17 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 178.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.527 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 22.8 tt0 -150.93 155.55 39.35 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.006 -1.059 . . . . 0.0 109.845 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.67 HG21 HG22 ' A' ' 13' ' ' THR . 85.2 t -94.49 141.52 14.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.203 179.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.507 HD22 ' HA ' ' A' ' 45' ' ' LEU . 0.3 OUTLIER -117.88 118.85 33.12 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.512 -0.743 . . . . 0.0 109.347 -179.663 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.6 ' HB2' ' HB2' ' A' ' 15' ' ' ALA . 6.3 mt-10 -103.55 109.85 21.67 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.61 -0.681 . . . . 0.0 109.394 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.483 ' O ' ' HB2' ' A' ' 54' ' ' ASN . 2.4 p -144.5 -179.54 6.62 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.46 -0.775 . . . . 0.0 109.386 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -102.13 29.71 4.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 109.367 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -119.5 -14.31 9.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 0.0 109.541 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.465 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -45.91 154.62 0.56 Allowed Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.147 -0.971 . . . . 0.0 109.521 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.542 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 36.0 Cg_endo -78.04 -34.01 1.86 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.596 2.198 . . . . 0.0 110.419 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -129.1 91.68 3.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.266 -0.896 . . . . 0.0 109.351 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.62 -120.98 6.31 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.544 -1.423 . . . . 0.0 109.544 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.483 ' HB2' ' O ' ' A' ' 47' ' ' THR . 11.9 p30 -160.02 30.16 0.18 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.239 -1.154 . . . . 0.0 109.472 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.528 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 8.2 mttp -135.09 130.74 36.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.305 -0.872 . . . . 0.0 109.547 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.678 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.0 m -149.05 175.62 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.372 -0.83 . . . . 0.0 109.145 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.731 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -105.81 100.91 10.44 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.032 -1.043 . . . . 0.0 108.998 179.441 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.618 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.62 117.87 22.33 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 178.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.767 ' O ' HG23 ' A' ' 156' ' ' THR . 40.9 t -115.15 144.92 21.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.069 -1.02 . . . . 0.0 109.168 -179.042 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.543 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 9.9 m -107.19 94.18 4.95 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.652 HG21 ' CD1' ' A' ' 157' ' ' ILE . 50.8 t -90.27 118.1 34.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.384 -0.823 . . . . 0.0 109.194 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.6 p30 -153.91 58.66 0.73 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.866 . . . . 0.0 109.941 -179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.51 ' O ' ' ND2' ' A' ' 38' ' ' ASN . . . 158.47 92.49 0.09 OUTLIER Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.744 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.7 m -84.36 -172.38 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.282 -1.128 . . . . 0.0 109.599 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -138.23 -157.17 7.36 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.4 m120 -96.06 10.03 38.88 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -1.121 . . . . 0.0 109.491 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.578 ' OD1' ' CZ2' ' A' ' 69' ' ' TRP . 17.5 m-80 -127.35 146.46 58.3 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.212 -0.93 . . . . 0.0 109.42 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.586 ' HG2' ' CZ3' ' A' ' 69' ' ' TRP . 35.8 Cg_endo -78.47 12.54 2.09 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.579 2.186 . . . . 0.0 110.957 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.586 ' CZ3' ' HG2' ' A' ' 68' ' ' PRO . 1.1 p90 -133.56 54.5 1.95 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.987 -1.07 . . . . 0.0 109.853 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.476 ' HA ' ' OG ' ' A' ' 35' ' ' SER . 0.8 OUTLIER -78.4 -69.0 0.59 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.185 -0.947 . . . . 0.0 108.838 179.464 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.542 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 3.2 mp -106.05 128.02 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.155 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.61 138.24 52.1 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.903 -1.123 . . . . 0.0 110.467 -179.195 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.828 ' HA ' HD23 ' A' ' 30' ' ' LEU . . . -120.35 132.15 55.16 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 178.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.531 HG22 ' N ' ' A' ' 75' ' ' ALA . 16.4 m -135.52 163.1 30.86 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.721 -1.237 . . . . 0.0 110.379 -178.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.56 ' HB2' ' NE1' ' A' ' 28' ' ' TRP . . . -122.66 137.56 54.87 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.433 -0.792 . . . . 0.0 109.145 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.539 ' CE2' ' CG ' ' A' ' 29' ' ' ASP . 1.6 p90 179.03 161.31 0.71 Allowed Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.516 -0.74 . . . . 0.0 109.103 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.531 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.3 Cg_endo -80.03 165.41 78.82 Favored 'Cis proline' 0 C--N 1.309 -1.514 0 C-N-CA 123.63 -1.404 . . . . 0.0 110.775 -0.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.875 HG22 ' HB3' ' A' ' 5' ' ' ASN . 92.6 t -120.34 156.47 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.381 -0.824 . . . . 0.0 108.918 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.571 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 4.5 m-80 -124.13 122.05 36.8 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.17 -0.956 . . . . 0.0 109.961 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.57 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 3.3 m -129.96 -174.01 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.153 -0.967 . . . . 0.0 109.54 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.652 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -137.12 143.88 43.79 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.394 -0.816 . . . . 0.0 109.148 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -76.14 115.46 4.14 Favored 'Trans proline' 0 C--N 1.308 -1.556 0 C-N-CA 122.475 2.117 . . . . 0.0 110.452 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.67 -27.36 20.61 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.512 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -85.86 149.81 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.186 -1.185 . . . . 0.0 109.549 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.434 ' O ' ' CB ' ' A' ' 166' ' ' SER . 39.0 m -97.14 132.99 42.37 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.57 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 12.9 m-85 -111.88 164.83 12.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.582 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.467 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 12.1 m -115.33 154.1 29.77 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.3 -0.875 . . . . 0.0 109.445 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.671 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 6.2 t80 -131.12 118.56 20.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.258 -0.901 . . . . 0.0 109.236 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.481 ' O ' ' O ' ' A' ' 161' ' ' GLY . 16.6 m -135.74 143.55 45.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.174 -0.954 . . . . 0.0 109.187 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.734 HD12 ' HB2' ' A' ' 162' ' ' LEU . 17.5 tt -150.51 163.71 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.868 -1.145 . . . . 0.0 109.588 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.542 ' HB2' ' CG ' ' A' ' 51' ' ' PRO . 18.2 m95 -130.4 126.34 36.8 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.037 -1.039 . . . . 0.0 109.247 179.626 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -115.79 149.22 38.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.275 -0.891 . . . . 0.0 109.541 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.576 ' HD3' ' CD1' ' A' ' 125' ' ' TRP . 4.9 ttp85 -164.02 120.61 1.66 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.196 -0.94 . . . . 0.0 109.145 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.479 ' HB1' ' O ' ' A' ' 156' ' ' THR . . . -105.4 160.56 15.04 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.324 -0.86 . . . . 0.0 110.012 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . 0.476 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 0.0 OUTLIER -57.26 -48.96 77.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.436 -0.79 . . . . 0.0 109.172 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.529 ' C ' HG22 ' A' ' 123' ' ' THR . 16.3 mt-30 -116.44 146.19 42.72 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.336 -0.852 . . . . 0.0 109.166 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.639 ' N ' HG22 ' A' ' 123' ' ' THR . 8.5 p30 -65.17 146.29 55.16 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.204 -0.935 . . . . 0.0 109.517 -179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 112.12 30.87 2.81 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.477 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -118.13 138.18 52.45 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.117 -1.226 . . . . 0.0 109.112 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.641 HG22 ' HA ' ' A' ' 120' ' ' GLN . 52.1 t -116.9 158.36 17.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 O-C-N 121.256 -0.902 . . . . 0.0 110.747 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.877 HG22 ' CE1' ' A' ' 147' ' ' PHE . 72.6 t -153.68 163.04 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.547 ' CB ' ' HB2' ' A' ' 117' ' ' HIS . 74.9 m -121.72 125.24 46.13 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.916 -1.115 . . . . 0.0 109.907 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.613 ' N ' ' CD1' ' A' ' 103' ' ' PHE . 0.2 OUTLIER -119.76 103.56 9.47 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.062 -1.024 . . . . 0.0 109.737 179.72 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.503 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 18.5 p -127.3 167.95 15.45 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.168 -0.958 . . . . 0.0 110.151 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.688 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -128.16 156.86 40.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.715 -0.615 . . . . 0.0 110.247 -179.793 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.503 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -173.92 -173.17 39.85 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.608 ' CB ' HG22 ' A' ' 141' ' ' ILE . 1.4 p30 -126.52 -169.37 2.01 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.18 -1.188 . . . . 0.0 109.049 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.531 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 5.6 mp0 -73.66 11.9 0.74 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.049 -1.032 . . . . 0.0 110.971 -179.4 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.499 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 1.0 OUTLIER -113.19 7.89 18.03 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 120.722 -1.236 . . . . 0.0 109.288 179.658 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.6 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.6 m-30 78.87 1.95 2.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.355 -0.841 . . . . 0.0 109.815 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.503 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 4.9 mm100 -76.04 159.47 30.77 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.106 -0.996 . . . . 0.0 108.729 179.466 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.495 ' HA ' ' HA2' ' A' ' 106' ' ' GLY . 5.2 tt0 -138.09 135.3 35.67 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.968 -1.083 . . . . 0.0 110.005 -179.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.568 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 6.5 m-85 -95.95 -70.62 0.71 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.06 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.586 ' HA3' ' CZ ' ' A' ' 130' ' ' PHE . . . -81.72 162.0 42.79 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.466 ' HA ' HG22 ' A' ' 104' ' ' THR . 7.7 ttm180 -158.05 103.95 1.87 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.974 -1.309 . . . . 0.0 110.337 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.72 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -144.1 72.85 1.36 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.335 -0.853 . . . . 0.0 108.784 179.087 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.547 ' HB2' ' CB ' ' A' ' 102' ' ' SER . 32.1 p-80 -115.82 162.79 16.81 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.121 -0.987 . . . . 0.0 110.049 -179.412 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.531 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 3.2 tt0 77.22 53.31 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.399 -0.813 . . . . 0.0 109.256 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.407 ' O ' HG13 ' A' ' 100' ' ' VAL . 53.2 mm-40 -126.4 141.69 51.8 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.378 -0.826 . . . . 0.0 109.599 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.641 ' HA ' HG22 ' A' ' 100' ' ' VAL . 46.9 mm-40 -73.64 156.55 37.88 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.62 HD13 ' O ' ' A' ' 120' ' ' GLN . 10.8 mm -133.5 136.9 53.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.025 -1.047 . . . . 0.0 110.129 -179.469 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.64 -179.31 7.1 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.541 -0.724 . . . . 0.0 110.121 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.639 HG22 ' N ' ' A' ' 97' ' ' ASP . 61.9 p -78.06 0.49 24.42 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.877 -0.729 . . . . 0.0 109.36 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.436 ' O ' ' HB2' ' A' ' 93' ' ' ARG . 2.8 mt-10 -110.06 -168.83 1.37 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -0.883 . . . . 0.0 109.327 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.576 ' CD1' ' HD3' ' A' ' 93' ' ' ARG . 85.6 m95 -98.01 121.91 40.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 109.562 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -106.83 121.35 45.22 Favored Pre-proline 0 N--CA 1.488 1.475 0 O-C-N 121.204 -0.935 . . . . 0.0 108.966 179.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.77 108.22 2.23 Favored 'Trans proline' 0 C--N 1.312 -1.381 0 C-N-CA 122.292 1.994 . . . . 0.0 110.96 -179.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -112.51 136.02 52.53 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.462 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.5 t -151.07 175.94 11.63 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 120.651 -1.28 . . . . 0.0 111.05 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.72 ' CE2' HD21 ' A' ' 116' ' ' LEU . 29.1 p90 -173.87 -178.29 1.53 Allowed 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.346 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -131.14 155.2 47.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.237 -0.914 . . . . 0.0 109.698 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.568 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.02 168.31 17.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.341 -0.849 . . . . 0.0 109.41 179.783 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.426 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -133.78 147.68 51.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.187 -0.946 . . . . 0.0 109.516 -179.745 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.652 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.2 t -42.01 110.3 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.511 -0.743 . . . . 0.0 109.272 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 67.5 m -58.7 -50.35 74.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 0.0 109.203 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -110.51 -90.79 0.47 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.436 -0.79 . . . . 0.0 109.202 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -163.31 56.31 0.18 Allowed 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.55 -0.719 . . . . 0.0 109.11 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.498 ' O ' HG23 ' A' ' 80' ' ' VAL . 50.0 mm-40 -95.66 112.9 24.52 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.271 -0.893 . . . . 0.0 109.809 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.1 p -79.37 -14.9 58.66 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.29 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.6 t -133.72 132.91 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.608 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.6 OUTLIER -143.52 172.22 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.184 -0.948 . . . . 0.0 110.285 -179.58 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.498 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.6 OUTLIER -140.79 133.22 28.42 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.57 -0.706 . . . . 0.0 109.111 179.978 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.688 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -92.48 110.48 45.18 Favored Pre-proline 0 C--N 1.305 -1.339 0 O-C-N 121.135 -0.978 . . . . 0.0 109.625 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.503 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.3 Cg_endo -76.49 110.96 3.16 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 C-N-CA 122.293 1.995 . . . . 0.0 111.089 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.531 ' HB ' ' O ' ' A' ' 73' ' ' ALA . 2.3 mm -97.45 135.3 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 178.523 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.513 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 8.8 m80 -102.24 158.55 16.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.438 -1.414 . . . . 0.0 111.335 -178.102 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.877 ' CE1' HG22 ' A' ' 101' ' ' VAL . 11.1 m-85 -159.1 160.2 35.42 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.327 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.537 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 106.71 48.11 0.99 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.744 ' C ' HG11 ' A' ' 64' ' ' VAL . 17.4 m-85 -125.35 159.35 32.01 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.435 -1.038 . . . . 0.0 109.166 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.499 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -64.83 -27.24 68.74 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.469 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.4 -19.42 63.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.367 -0.833 . . . . 0.0 109.199 179.522 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.494 ' N ' ' OD1' ' A' ' 152' ' ' ASN . 0.3 OUTLIER -107.96 10.17 28.45 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.42 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.538 HG23 HG13 ' A' ' 64' ' ' VAL . 2.2 t -84.65 163.98 2.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 121.437 -0.789 . . . . 0.0 109.686 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.477 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 49.88 31.57 17.23 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.441 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 2.2 t-20 -160.14 144.85 14.72 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.149 -1.207 . . . . 0.0 110.113 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.767 HG23 ' O ' ' A' ' 59' ' ' VAL . 52.6 m -92.55 128.83 38.55 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.733 HG21 ' CG2' ' A' ' 101' ' ' VAL . 1.2 mt -107.7 118.75 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.853 -1.154 . . . . 0.0 109.759 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.618 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 3.4 m-85 -102.96 133.14 48.56 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 178.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.86 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.3 mt -124.55 142.86 40.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.308 -178.694 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.678 ' CB ' HG12 ' A' ' 56' ' ' VAL . 19.4 t70 -174.23 136.38 0.49 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.418 -0.801 . . . . 0.0 109.064 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 124.32 -7.76 8.52 Favored Glycine 0 N--CA 1.486 1.988 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.537 179.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.734 ' HB2' HD12 ' A' ' 90' ' ' ILE . 3.7 tp -59.9 103.97 0.26 Allowed 'General case' 0 N--CA 1.487 1.406 0 O-C-N 120.741 -1.446 . . . . 0.0 108.901 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -136.08 145.65 46.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.514 -0.741 . . . . 0.0 109.86 -179.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.629 HD13 HG11 ' A' ' 78' ' ' VAL . 8.4 mt -128.69 109.07 18.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.367 -0.833 . . . . 0.0 109.392 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.992 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -153.52 152.38 30.88 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.119 -0.988 . . . . 0.0 109.637 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.477 ' HB3' ' HA ' ' A' ' 86' ' ' TYR . 80.5 p -110.91 162.15 15.12 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.28 -0.888 . . . . 0.0 109.425 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.468 ' HB3' ' HD2' ' A' ' 168' ' ' PRO . 2.4 mt-30 -95.63 158.67 34.05 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.431 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . 0.468 ' HD2' ' HB3' ' A' ' 167' ' ' GLN . 35.6 Cg_endo . . . . . 0 C--N 1.308 -1.56 0 C-N-CA 122.622 2.215 . . . . 0.0 110.419 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.452 -0.574 . . . . 0.0 109.452 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mp -85.09 109.81 18.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.241 -0.912 . . . . 0.0 109.425 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.857 HG23 ' HB2' ' A' ' 165' ' ' ALA . 3.9 p -100.98 173.17 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.9 . . . . 0.0 109.546 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.573 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -69.89 -58.85 3.38 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.272 -0.893 . . . . 0.0 109.569 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.614 ' HA ' HG22 ' A' ' 78' ' ' VAL . 7.7 t30 -77.46 134.49 38.35 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.145 -0.972 . . . . 0.0 109.558 -179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.513 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 62.3 mt -111.72 138.86 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.262 -0.899 . . . . 0.0 109.536 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.549 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 10.2 t-20 76.17 26.48 0.96 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.309 -0.869 . . . . 0.0 109.83 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.41 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -57.27 -34.93 68.64 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 179.284 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.52 ' HA3' ' OD1' ' A' ' 160' ' ' ASP . . . -119.76 34.44 4.22 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 108.85 -1.7 . . . . 0.0 108.85 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.697 ' HD2' HG11 ' A' ' 25' ' ' VAL . 8.4 m-85 43.84 53.76 6.02 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.375 -1.074 . . . . 0.0 109.358 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.422 ' HA ' ' HD3' ' A' ' 55' ' ' LYS . 31.7 mm-40 -83.96 -28.56 27.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.471 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.9 t -86.67 -41.98 13.77 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.293 -0.879 . . . . 0.0 109.541 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.966 HG21 HG22 ' A' ' 25' ' ' VAL . 90.8 m -71.97 127.73 90.22 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.247 -0.908 . . . . 0.0 109.503 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.9 Cg_endo -77.63 141.13 19.41 Favored 'Trans proline' 0 C--N 1.312 -1.383 0 C-N-CA 122.481 2.121 . . . . 0.0 110.568 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.468 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -41.7 164.35 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.742 -0.599 . . . . 0.0 109.582 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.66 133.7 3.32 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 108.931 -1.668 . . . . 0.0 108.931 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.466 ' CG2' ' HB2' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.89 140.2 15.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.277 -1.131 . . . . 0.0 109.207 -179.637 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.768 HG13 ' HA3' ' A' ' 24' ' ' GLY . 62.1 t -86.61 142.4 13.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 CA-C-O 121.638 0.732 . . . . 0.0 110.439 -179.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.35 -28.81 12.76 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -131.38 86.73 2.38 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 1.101 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -45.33 -29.85 1.14 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.268 -0.895 . . . . 0.0 110.006 -178.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.101 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -60.22 -49.0 79.34 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.494 -0.754 . . . . 0.0 110.232 -179.53 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -133.67 48.77 2.33 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.961 -1.087 . . . . 0.0 109.732 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.768 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -97.44 -12.37 48.42 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.966 HG22 HG21 ' A' ' 13' ' ' THR . 90.8 t -141.24 133.95 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.186 -1.185 . . . . 0.0 109.636 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.509 ' O ' ' ND2' ' A' ' 7' ' ' ASN . 17.7 tt0 -78.36 126.69 31.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.384 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.549 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 101.76 -16.17 56.37 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 1.015 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.2 OUTLIER -137.6 120.24 16.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -1.117 . . . . 0.0 108.426 179.164 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.529 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -121.94 110.66 16.12 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.32 -0.863 . . . . 0.0 109.209 179.935 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.837 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -91.7 173.6 7.79 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.286 -0.884 . . . . 0.0 109.339 -179.73 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.457 ' HA ' HD21 ' A' ' 21' ' ' LEU . 77.7 m-20 -160.62 123.45 3.31 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.205 -0.934 . . . . 0.0 110.366 -179.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.981 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -109.36 131.32 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.291 -0.88 . . . . 0.0 109.286 178.861 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.79 -172.54 22.76 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -56.67 -31.65 64.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.334 -1.098 . . . . 0.0 109.559 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.48 ' HB2' ' HA ' ' A' ' 70' ' ' ASP . 0.7 OUTLIER -45.98 -42.42 13.05 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.196 -0.94 . . . . 0.0 109.279 -179.869 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.981 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -60.77 89.84 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 121.188 -0.945 . . . . 0.0 109.529 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 94.7 m -74.05 -28.13 61.25 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.854 0.835 . . . . 0.0 108.789 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.649 ' O ' HG13 ' A' ' 36' ' ' VAL . 8.2 t30 -114.01 144.48 31.66 Favored Pre-proline 0 C--N 1.297 -1.681 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.405 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 34.2 Cg_endo -75.83 111.07 3.21 Favored 'Trans proline' 0 C--N 1.307 -1.627 0 C-N-CA 122.443 2.095 . . . . 0.0 111.011 -179.374 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.538 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 36.2 Cg_endo -78.97 174.41 12.22 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.558 2.172 . . . . 0.0 109.607 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.549 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 73.8 t -116.9 120.5 65.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.998 -1.064 . . . . 0.0 110.659 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.752 ' HZ ' HG23 ' A' ' 71' ' ' ILE . 60.6 m-85 -109.04 112.55 24.79 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 178.044 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.466 ' HB2' ' CG2' ' A' ' 17' ' ' VAL . 28.7 tt0 -150.59 146.96 26.87 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.11 -0.994 . . . . 0.0 109.904 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.7 t -95.49 148.61 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.392 -0.817 . . . . 0.0 109.232 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.867 HD21 ' CG2' ' A' ' 47' ' ' THR . 0.4 OUTLIER -132.64 147.23 52.33 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.175 -0.953 . . . . 0.0 108.895 -179.79 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.577 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 16.9 mt-10 -117.06 114.09 23.26 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.53 -0.731 . . . . 0.0 109.63 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.867 ' CG2' HD21 ' A' ' 45' ' ' LEU . 12.9 p -139.8 174.14 10.82 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.473 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.521 ' HA ' ' ND2' ' A' ' 54' ' ' ASN . 16.9 m -100.06 21.67 12.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.462 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.413 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.0 OUTLIER -111.82 -15.33 13.4 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.182 -0.949 . . . . 0.0 109.534 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.437 ' HB3' ' O ' ' A' ' 53' ' ' GLY . . . -44.17 147.19 0.99 Allowed Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.549 ' CG ' ' HB2' ' A' ' 91' ' ' TRP . 35.5 Cg_endo -78.06 -40.54 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.548 2.165 . . . . 0.0 110.389 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.4 ' O ' ' OE2' ' A' ' 11' ' ' GLU . 2.5 tp10 -117.87 79.71 1.4 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.272 -0.892 . . . . 0.0 109.432 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.449 ' O ' ' OD1' ' A' ' 54' ' ' ASN . . . 102.81 -139.41 14.42 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.521 ' ND2' ' HA ' ' A' ' 48' ' ' SER . 3.0 m120 -142.28 35.35 1.5 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -1.111 . . . . 0.0 109.463 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.537 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 8.9 mttt -144.64 138.3 27.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.279 -0.888 . . . . 0.0 109.555 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.598 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.8 m -150.32 174.39 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.344 -0.847 . . . . 0.0 109.281 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.791 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -108.13 103.51 12.73 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.072 -1.018 . . . . 0.0 108.893 179.45 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.719 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.59 119.17 23.45 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.826 ' O ' HG23 ' A' ' 156' ' ' THR . 41.3 t -114.66 144.83 21.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.092 -1.005 . . . . 0.0 109.075 -179.212 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.781 HG22 ' ND2' ' A' ' 62' ' ' ASN . 24.0 m -106.4 91.52 3.74 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 179.281 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.647 HG21 ' CD1' ' A' ' 157' ' ' ILE . 53.8 t -90.86 113.01 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.385 -0.822 . . . . 0.0 109.11 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.781 ' ND2' HG22 ' A' ' 60' ' ' THR . 2.5 p30 -153.46 58.02 0.76 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.312 -0.868 . . . . 0.0 109.831 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 162.09 85.09 0.05 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.569 HG11 ' C ' ' A' ' 149' ' ' TYR . 1.3 m -79.89 175.82 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.211 -1.17 . . . . 0.0 109.46 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -124.45 -149.91 7.76 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -95.15 -4.54 45.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.302 -1.116 . . . . 0.0 109.609 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.582 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 0.8 OUTLIER -114.78 147.89 39.2 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 109.283 179.991 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -79.02 14.25 1.78 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.717 2.278 . . . . 0.0 111.008 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.582 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 1.3 p90 -135.34 52.53 2.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.99 -1.069 . . . . 0.0 109.921 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.511 ' C ' HG23 ' A' ' 36' ' ' VAL . 0.4 OUTLIER -75.22 -66.45 0.76 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.046 -1.034 . . . . 0.0 108.966 179.552 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.752 HG23 ' HZ ' ' A' ' 42' ' ' PHE . 2.5 mt -101.23 127.79 54.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.305 -0.872 . . . . 0.0 108.659 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.465 ' O ' ' HB3' ' A' ' 30' ' ' LEU . 7.2 mt-10 -126.58 137.71 53.37 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.05 -1.031 . . . . 0.0 110.363 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 1.015 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -118.31 123.32 45.07 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 106.998 -1.482 . . . . 0.0 106.998 178.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.541 HG22 ' N ' ' A' ' 75' ' ' ALA . 18.0 m -128.61 163.31 25.31 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 120.441 -1.412 . . . . 0.0 110.459 -178.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.541 ' N ' HG22 ' A' ' 74' ' ' THR . . . -129.7 138.32 51.09 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.472 -0.768 . . . . 0.0 109.238 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.546 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 2.2 p90 177.99 160.48 0.59 Allowed Pre-proline 0 N--CA 1.492 1.647 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.526 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -81.65 166.75 71.9 Favored 'Cis proline' 0 C--N 1.31 -1.476 0 C-N-CA 123.686 -1.381 . . . . 0.0 110.799 -0.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.866 HG11 HD12 ' A' ' 164' ' ' ILE . 76.5 t -124.69 156.34 32.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.219 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.518 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 3.6 m120 -123.77 123.05 39.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.915 -1.116 . . . . 0.0 110.417 -179.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.685 HG12 ' CD2' ' A' ' 86' ' ' TYR . 3.0 m -128.19 -173.88 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.115 179.244 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.832 ' O ' HG21 ' A' ' 134' ' ' VAL . 1.7 mtt180 -126.96 145.16 52.86 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.246 -0.908 . . . . 0.0 109.438 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.41 120.78 5.38 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.437 2.091 . . . . 0.0 110.493 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.35 -27.43 17.18 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.6 t -85.94 149.72 4.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.271 -1.135 . . . . 0.0 109.439 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 20.8 m -97.74 122.4 40.78 Favored 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.685 ' CD2' HG12 ' A' ' 80' ' ' VAL . 3.6 m-85 -99.77 170.28 8.66 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.922 . . . . 0.0 109.619 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.477 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 6.5 m -118.23 154.09 32.82 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.404 -0.81 . . . . 0.0 109.431 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.627 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.8 t80 -128.11 121.23 29.1 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.256 -0.903 . . . . 0.0 109.266 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.468 ' O ' ' O ' ' A' ' 161' ' ' GLY . 19.6 m -135.54 145.97 47.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.191 -0.943 . . . . 0.0 109.317 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.688 HD13 ' HD2' ' A' ' 103' ' ' PHE . 16.7 tt -150.74 163.68 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 120.765 -1.209 . . . . 0.0 109.531 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.596 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 19.7 m95 -133.92 124.73 26.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.884 -1.135 . . . . 0.0 109.057 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -117.34 150.88 38.1 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.255 -0.903 . . . . 0.0 109.491 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.581 ' HD2' ' CE2' ' A' ' 125' ' ' TRP . 1.0 OUTLIER -164.27 121.83 1.72 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.187 -0.946 . . . . 0.0 108.971 179.981 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.69 167.49 9.73 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -0.922 . . . . 0.0 110.053 -179.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -58.52 -48.77 79.74 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.265 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.558 ' C ' HG22 ' A' ' 123' ' ' THR . 2.9 mt-30 -118.28 150.97 38.58 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.299 -0.876 . . . . 0.0 109.163 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.724 ' N ' HG22 ' A' ' 123' ' ' THR . 0.6 OUTLIER -66.34 145.13 56.06 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.255 -0.903 . . . . 0.0 109.701 -179.778 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 114.07 35.21 1.53 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.47 ' O ' HG12 ' A' ' 121' ' ' ILE . . . -120.2 139.54 52.49 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.269 -1.136 . . . . 0.0 109.246 179.698 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.468 ' HB ' ' OD1' ' A' ' 152' ' ' ASN . 54.2 t -117.94 157.86 19.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 121.325 -0.859 . . . . 0.0 110.759 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.692 HG22 ' CE1' ' A' ' 147' ' ' PHE . 62.1 t -154.94 162.25 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 179.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.525 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 4.8 m -116.78 129.49 56.13 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.085 -1.009 . . . . 0.0 109.392 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.688 ' HD2' HD13 ' A' ' 90' ' ' ILE . 0.2 OUTLIER -123.84 103.92 8.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.145 -0.972 . . . . 0.0 109.734 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.586 HG22 ' HA ' ' A' ' 115' ' ' ARG . 36.1 p -135.35 169.63 17.18 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.972 -1.08 . . . . 0.0 110.233 179.742 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.968 HG23 ' N ' ' A' ' 114' ' ' GLY . 0.0 OUTLIER -131.99 127.66 58.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-O 121.71 0.767 . . . . 0.0 110.41 179.121 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -122.01 165.78 14.8 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.119 -1.992 . . . . 0.0 108.119 178.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.595 ' OD1' ' CE1' ' A' ' 113' ' ' TYR . 0.0 OUTLIER -125.97 -170.82 2.26 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.922 -1.34 . . . . 0.0 109.272 -179.714 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 13.0 mt-30 -81.22 -19.86 42.31 Favored 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 118.791 -1.164 . . . . 0.0 109.588 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.505 ' HB2' ' HG2' ' A' ' 111' ' ' GLN . 2.4 m -82.09 8.78 9.89 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.462 ' HB2' ' O ' ' A' ' 109' ' ' SER . 16.8 m-30 65.3 24.03 12.14 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.313 -0.867 . . . . 0.0 108.674 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.525 ' OE1' ' CA ' ' A' ' 111' ' ' GLN . 0.7 OUTLIER -86.54 161.8 18.37 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.434 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.479 ' OE1' ' HG3' ' A' ' 115' ' ' ARG . 0.5 OUTLIER -107.68 101.35 10.67 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.336 -0.852 . . . . 0.0 109.891 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.952 ' OH ' HG13 ' A' ' 134' ' ' VAL . 2.0 m-30 -70.83 -64.43 0.9 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.586 -0.696 . . . . 0.0 109.72 178.607 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.968 ' N ' HG23 ' A' ' 105' ' ' VAL . . . -115.44 166.38 12.22 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 -179.384 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.611 ' NE ' ' CE1' ' A' ' 117' ' ' HIS . 0.0 OUTLIER -157.81 74.61 0.74 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.242 -1.152 . . . . 0.0 110.691 -179.706 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.953 HD21 ' CD2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -131.45 86.47 2.36 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.985 -1.072 . . . . 0.0 108.811 178.495 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.611 ' CE1' ' NE ' ' A' ' 115' ' ' ARG . 29.8 p-80 -121.53 163.32 19.04 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -0.862 . . . . 0.0 110.009 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 3.0 tt0 76.89 36.31 0.34 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.42 -0.8 . . . . 0.0 109.373 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 17.3 mm-40 -100.3 135.81 41.15 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.299 -0.876 . . . . 0.0 109.542 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.625 ' O ' HD13 ' A' ' 121' ' ' ILE . 20.5 mt-30 -71.29 156.03 39.99 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.388 -0.82 . . . . 0.0 108.944 179.685 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.625 HD13 ' O ' ' A' ' 120' ' ' GLN . 6.1 mm -134.37 133.42 55.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.092 -1.005 . . . . 0.0 110.132 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.87 -179.42 6.81 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.514 -0.741 . . . . 0.0 109.971 179.537 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.724 HG22 ' N ' ' A' ' 97' ' ' ASP . 37.9 p -73.96 -2.67 25.02 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.771 -0.772 . . . . 0.0 109.243 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.524 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 0.9 OUTLIER -110.02 175.42 5.45 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.334 -0.854 . . . . 0.0 109.177 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.581 ' CE2' ' HD2' ' A' ' 93' ' ' ARG . 95.0 m95 -81.77 122.35 27.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.83 121.02 46.29 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.252 -0.905 . . . . 0.0 108.833 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.596 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.6 Cg_endo -80.17 101.69 1.37 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.412 2.074 . . . . 0.0 111.177 -179.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -103.86 132.25 50.3 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 178.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.456 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -144.15 176.29 9.43 Favored 'General case' 0 C--N 1.295 -1.776 0 O-C-N 120.875 -1.141 . . . . 0.0 110.723 -179.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.953 ' CD2' HD21 ' A' ' 116' ' ' LEU . 25.3 p90 -175.11 152.56 1.47 Allowed 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 114.978 -1.01 . . . . 0.0 109.34 179.651 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -101.96 142.49 33.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.257 -0.902 . . . . 0.0 109.68 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.637 ' CD1' ' CE1' ' A' ' 130' ' ' PHE . 8.1 p90 -153.65 137.54 16.25 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.34 -0.85 . . . . 0.0 109.371 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.445 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.8 OUTLIER -98.72 146.58 25.73 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.256 -0.902 . . . . 0.0 108.836 179.923 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.952 HG13 ' OH ' ' A' ' 113' ' ' TYR . 4.1 t -41.55 108.96 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.443 -0.786 . . . . 0.0 109.171 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -48.17 -35.33 11.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.332 -0.855 . . . . 0.0 109.007 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -138.49 -90.79 0.21 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.452 -0.78 . . . . 0.0 109.293 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -158.35 56.05 0.45 Allowed 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.524 -0.735 . . . . 0.0 109.1 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.604 ' O ' HG23 ' A' ' 80' ' ' VAL . 31.8 mm-40 -92.58 111.06 22.51 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.2 p -79.31 -18.32 52.83 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 40.2 t -131.66 135.79 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.586 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -143.6 171.62 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.926 -1.109 . . . . 0.0 110.751 -179.177 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.512 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.7 OUTLIER -133.02 132.22 41.6 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.682 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.625 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -99.36 107.22 43.81 Favored Pre-proline 0 C--N 1.304 -1.374 0 O-C-N 120.976 -1.077 . . . . 0.0 109.382 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.534 ' HD2' ' HA ' ' A' ' 105' ' ' VAL . 34.9 Cg_endo -77.31 110.94 3.09 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.27 1.98 . . . . 0.0 111.341 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.738 HD12 ' CZ2' ' A' ' 28' ' ' TRP . 1.6 mt -99.57 138.91 22.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.581 ' O ' ' CD2' ' A' ' 147' ' ' PHE . 4.8 m80 -103.81 159.11 15.91 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.53 -1.356 . . . . 0.0 111.732 -177.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.692 ' CE1' HG22 ' A' ' 101' ' ' VAL . 17.1 m-85 -161.24 160.0 29.4 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.563 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 105.77 52.22 0.81 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 -179.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.569 ' C ' HG11 ' A' ' 64' ' ' VAL . 22.8 m-85 -129.0 158.88 37.63 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.531 -0.982 . . . . 0.0 109.165 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.33 -26.51 67.33 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.466 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -71.64 -15.81 62.25 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.534 -0.729 . . . . 0.0 109.367 179.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' A' ' 152' ' ' ASN . 0.2 OUTLIER -112.05 8.8 20.24 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.444 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.3 t -83.87 164.44 2.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 O-C-N 121.423 -0.798 . . . . 0.0 109.747 -179.303 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.492 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 55.89 26.29 47.45 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.911 -1.275 . . . . 0.0 109.911 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.464 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.7 t-20 -160.38 143.01 13.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.98 -1.306 . . . . 0.0 110.202 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.826 HG23 ' O ' ' A' ' 59' ' ' VAL . 46.1 m -89.4 121.48 31.69 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 178.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.647 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.1 mt -98.03 117.7 43.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 120.882 -1.136 . . . . 0.0 110.097 -178.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.719 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.4 m-85 -96.9 130.83 44.14 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.631 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.1 mt -121.03 142.41 37.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 120.726 -1.234 . . . . 0.0 110.154 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.598 ' CB ' HG12 ' A' ' 56' ' ' VAL . 9.0 t0 -174.14 136.24 0.5 Allowed 'General case' 0 N--CA 1.486 1.366 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.529 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 124.82 -7.73 8.24 Favored Glycine 0 N--CA 1.486 1.985 0 C-N-CA 119.329 -1.415 . . . . 0.0 110.633 179.403 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.619 ' CD1' ' CE2' ' A' ' 88' ' ' TYR . 3.2 tp -60.29 100.0 0.09 Allowed 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.58 -1.541 . . . . 0.0 108.895 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . 0.481 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -136.7 145.7 45.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.445 -0.785 . . . . 0.0 109.662 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.866 HD12 HG11 ' A' ' 78' ' ' VAL . 25.5 mt -128.58 108.8 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.239 -0.913 . . . . 0.0 109.431 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.857 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -146.47 147.36 31.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.177 -0.952 . . . . 0.0 109.576 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 2.7 p -67.11 -174.8 0.39 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.378 -0.826 . . . . 0.0 109.538 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.42 ' HB3' ' HD2' ' A' ' 168' ' ' PRO . 0.0 OUTLIER -72.77 168.48 23.94 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.322 -0.861 . . . . 0.0 109.44 -179.97 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . 0.42 ' HD2' ' HB3' ' A' ' 167' ' ' GLN . 35.8 Cg_endo . . . . . 0 C--N 1.309 -1.516 0 C-N-CA 122.623 2.216 . . . . 0.0 110.457 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.52 ' C ' HD22 ' A' ' 2' ' ' LEU . 6.4 ttt . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.666 ' N ' HD22 ' A' ' 2' ' ' LEU . 3.9 mm? -101.92 169.73 8.59 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.31 -0.869 . . . . 0.0 109.413 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.911 HG23 ' HB2' ' A' ' 165' ' ' ALA . 4.4 p -153.93 173.73 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.38 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.587 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -75.86 -39.63 56.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.192 -0.943 . . . . 0.0 109.714 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.527 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 1.2 t30 -92.1 129.45 38.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.706 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.468 ' O ' ' HB2' ' A' ' 7' ' ' ASN . 64.7 mt -113.55 129.96 68.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.243 -0.911 . . . . 0.0 109.346 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.545 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.7 OUTLIER 69.93 28.0 4.31 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.206 -0.934 . . . . 0.0 109.597 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -44.26 -26.95 1.04 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 160' ' ' ASP . . . -142.14 52.03 0.67 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.717 ' CD2' HG11 ' A' ' 25' ' ' VAL . 2.8 m-85 45.27 56.38 5.62 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.261 -1.14 . . . . 0.0 109.237 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -84.52 -29.64 25.77 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.139 -0.976 . . . . 0.0 110.249 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 10.6 p -95.0 -47.49 6.38 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.011 -1.056 . . . . 0.0 110.129 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.938 ' OG1' HG13 ' A' ' 25' ' ' VAL . 3.1 m -59.84 135.76 90.04 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.166 -0.959 . . . . 0.0 109.538 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.466 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.9 Cg_endo -77.36 146.14 24.53 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.561 2.174 . . . . 0.0 110.71 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.611 ' HB2' ' HG3' ' A' ' 46' ' ' GLU . . . -44.62 170.76 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 121.299 0.571 . . . . 0.0 109.798 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 140.33 130.56 2.66 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.097 -1.601 . . . . 0.0 109.097 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.568 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.07 139.21 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.224 -1.162 . . . . 0.0 109.166 -179.653 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.566 HG13 ' HA3' ' A' ' 24' ' ' GLY . 60.2 t -90.66 142.95 12.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-O 121.625 0.726 . . . . 0.0 110.442 -179.468 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 8.5 t -100.7 -29.44 12.29 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.071 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 19.4 m-20 -131.48 93.92 3.44 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 1.075 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -48.86 -29.32 4.53 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.264 -0.897 . . . . 0.0 110.135 -178.626 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.075 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.44 -57.04 14.72 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.495 -0.753 . . . . 0.0 110.119 -179.364 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -119.99 41.82 3.09 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.155 -0.965 . . . . 0.0 109.45 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.566 ' HA3' HG13 ' A' ' 18' ' ' VAL . . . -77.07 -39.87 26.36 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.952 -1.259 . . . . 0.0 109.952 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.938 HG13 ' OG1' ' A' ' 13' ' ' THR . 46.3 t -141.74 133.72 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.102 -1.234 . . . . 0.0 109.904 -179.62 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 20.6 tp10 -68.68 141.58 55.29 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -0.857 . . . . 0.0 109.224 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.545 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . 106.58 -32.14 7.58 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 0.929 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.1 OUTLIER -135.04 121.0 19.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.152 -1.205 . . . . 0.0 109.109 179.492 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -112.84 109.71 19.34 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.831 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -89.93 173.66 8.11 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.218 -0.926 . . . . 0.0 109.665 -179.139 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.497 ' O ' ' HB3' ' A' ' 72' ' ' GLU . 7.1 m120 -160.93 128.02 4.16 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.181 -0.949 . . . . 0.0 110.807 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.058 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -117.16 130.05 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.209 -0.932 . . . . 0.0 108.993 178.198 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.29 171.7 16.18 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.499 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.4 ' O ' ' C ' ' A' ' 35' ' ' SER . 0.7 OUTLIER -45.6 -29.89 1.34 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.377 -1.073 . . . . 0.0 109.419 179.951 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.505 ' HB2' ' CB ' ' A' ' 70' ' ' ASP . 0.4 OUTLIER -45.88 -53.41 9.85 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.369 -0.832 . . . . 0.0 109.116 179.943 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 1.058 HG21 HG12 ' A' ' 32' ' ' VAL . 34.7 t -47.63 102.57 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 O-C-N 121.251 -0.905 . . . . 0.0 110.084 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 40.8 m -81.63 -26.19 35.02 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 121.894 0.854 . . . . 0.0 108.764 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.682 ' O ' HG12 ' A' ' 36' ' ' VAL . 2.1 m-80 -111.67 147.75 37.43 Favored Pre-proline 0 C--N 1.296 -1.751 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.724 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -77.01 110.85 3.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.485 2.123 . . . . 0.0 110.654 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 38' ' ' ASN . 36.4 Cg_endo -80.05 160.98 23.74 Favored 'Trans proline' 0 C--N 1.311 -1.43 0 C-N-CA 122.475 2.117 . . . . 0.0 109.68 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.537 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 54.8 t -109.95 119.78 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.004 -1.06 . . . . 0.0 110.291 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.455 ' CD2' ' HB3' ' A' ' 21' ' ' LEU . 76.7 m-85 -105.9 112.16 25.1 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.568 ' HG3' HG23 ' A' ' 17' ' ' VAL . 1.3 tm-20 -155.01 147.06 23.64 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.005 -1.059 . . . . 0.0 109.872 -179.437 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.474 ' N ' ' HG2' ' A' ' 43' ' ' GLU . 53.1 t -91.89 148.54 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.493 -0.754 . . . . 0.0 109.193 179.574 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.675 HD21 ' CG2' ' A' ' 47' ' ' THR . 0.4 OUTLIER -131.97 146.9 52.37 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.207 -0.933 . . . . 0.0 108.888 -179.942 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.611 ' HG3' ' HB2' ' A' ' 15' ' ' ALA . 17.4 mt-10 -117.91 115.04 24.13 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.676 -0.64 . . . . 0.0 109.508 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.675 ' CG2' HD21 ' A' ' 45' ' ' LEU . 2.2 p -142.11 172.25 12.94 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.327 -0.858 . . . . 0.0 109.488 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.95 11.7 24.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.248 -0.908 . . . . 0.0 109.484 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -103.33 -15.81 15.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.158 -0.964 . . . . 0.0 109.434 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.64 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -50.33 145.68 9.91 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.234 -0.916 . . . . 0.0 109.403 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.569 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 35.9 Cg_endo -78.38 -41.91 0.25 Allowed 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.577 2.185 . . . . 0.0 110.375 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -110.91 108.34 18.09 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.255 -0.903 . . . . 0.0 109.298 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.16 -117.16 6.64 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.64 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 50.0 p30 -160.06 29.87 0.18 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.207 -1.173 . . . . 0.0 109.524 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.544 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 60.5 mttt -136.89 138.68 40.97 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.215 -0.928 . . . . 0.0 109.678 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.637 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.6 m -150.08 174.41 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.299 -0.876 . . . . 0.0 109.203 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.72 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -103.33 102.15 12.09 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.15 -0.969 . . . . 0.0 108.98 179.643 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.65 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.47 119.91 24.34 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.853 ' O ' HG23 ' A' ' 156' ' ' THR . 40.5 t -113.18 144.51 20.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.106 -0.997 . . . . 0.0 109.024 -179.172 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.537 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 19.9 m -110.7 90.59 3.37 Favored 'General case' 0 C--N 1.283 -2.284 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.519 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 43.9 t -86.48 127.78 40.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.273 -0.892 . . . . 0.0 109.211 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.417 HD22 HG22 ' A' ' 60' ' ' THR . 4.8 p30 -151.07 57.0 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.887 . . . . 0.0 109.844 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.433 ' HA3' ' CG ' ' A' ' 38' ' ' ASN . . . 147.66 103.44 0.33 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.817 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.3 m -79.94 -175.82 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.236 -1.155 . . . . 0.0 109.51 179.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -126.61 -178.5 15.34 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.666 -1.373 . . . . 0.0 109.666 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -68.73 -20.27 64.38 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.241 -1.152 . . . . 0.0 109.431 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.592 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 6.3 m-20 -106.98 152.54 41.02 Favored Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.28 -0.887 . . . . 0.0 109.492 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.41 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.2 Cg_endo -78.58 12.64 2.09 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 122.646 2.23 . . . . 0.0 110.973 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.592 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.2 p90 -135.57 54.58 1.91 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.991 -1.068 . . . . 0.0 109.631 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.522 ' HB3' ' N ' ' A' ' 36' ' ' VAL . 0.5 OUTLIER -83.37 -48.08 10.77 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.216 -0.927 . . . . 0.0 109.191 179.872 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.58 HD13 HG22 ' A' ' 36' ' ' VAL . 3.7 mm -98.72 149.09 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.254 -0.904 . . . . 0.0 108.776 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.534 ' HA ' ' HB3' ' A' ' 146' ' ' HIS . 58.0 tt0 -137.71 160.27 39.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.872 -1.143 . . . . 0.0 110.93 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.929 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -162.37 106.48 1.16 Allowed 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 179.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.591 HG22 ' N ' ' A' ' 75' ' ' ALA . 49.9 m -120.63 166.33 13.81 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.246 -1.534 . . . . 0.0 110.953 -178.004 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.591 ' N ' HG22 ' A' ' 74' ' ' THR . . . -124.7 137.91 54.32 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.476 -0.765 . . . . 0.0 108.96 179.07 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.547 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER 178.17 162.52 0.62 Allowed Pre-proline 0 N--CA 1.492 1.651 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 -179.728 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.532 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.82 167.14 73.74 Favored 'Cis proline' 0 C--N 1.31 -1.472 0 C-N-CA 123.641 -1.4 . . . . 0.0 110.778 -0.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.817 HG11 HD12 ' A' ' 164' ' ' ILE . 76.7 t -126.27 151.5 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.303 -0.873 . . . . 0.0 108.961 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.476 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 47.3 m-20 -114.75 122.79 47.48 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.045 -1.034 . . . . 0.0 109.812 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 138' ' ' GLU . 3.0 m -129.57 -173.82 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.21 -0.932 . . . . 0.0 109.458 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.625 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -138.74 145.87 47.92 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.364 -0.835 . . . . 0.0 109.306 179.896 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.489 ' HD2' ' HG2' ' A' ' 81' ' ' ARG . 35.3 Cg_endo -77.33 110.28 2.96 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.465 2.11 . . . . 0.0 110.47 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 113.91 -34.99 4.71 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.551 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.5 t -85.0 149.71 4.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.241 -1.152 . . . . 0.0 109.39 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.469 ' HA ' ' OG1' ' A' ' 133' ' ' THR . 11.6 t -95.3 145.31 25.18 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 109.354 -0.609 . . . . 0.0 109.354 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.564 ' HD2' HG22 ' A' ' 164' ' ' ILE . 8.6 m-85 -123.29 159.07 29.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.297 -0.877 . . . . 0.0 109.627 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.467 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 59.1 m -118.06 148.46 42.25 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.32 -0.862 . . . . 0.0 109.282 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.615 ' CD1' ' N ' ' A' ' 88' ' ' TYR . 0.2 OUTLIER -127.04 104.75 8.16 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.124 -0.985 . . . . 0.0 109.631 -179.927 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.476 ' O ' ' O ' ' A' ' 161' ' ' GLY . 54.7 m -112.8 148.08 35.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.365 -0.834 . . . . 0.0 108.955 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.676 HD12 ' HB2' ' A' ' 162' ' ' LEU . 19.4 tt -150.08 163.51 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 120.76 -1.212 . . . . 0.0 109.817 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.574 ' CZ2' ' HB3' ' A' ' 127' ' ' PRO . 70.3 m95 -125.77 129.55 49.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.156 -0.965 . . . . 0.0 109.281 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.99 145.96 47.62 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.283 -0.886 . . . . 0.0 109.513 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.584 ' HD2' ' CE2' ' A' ' 125' ' ' TRP . 16.4 ttt-85 -157.91 118.23 3.39 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.267 -0.896 . . . . 0.0 109.179 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -105.3 166.8 10.16 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.357 -0.84 . . . . 0.0 109.839 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -64.18 -52.04 60.87 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.373 -0.829 . . . . 0.0 109.615 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.428 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.0 OUTLIER -112.03 140.93 46.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 109.52 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.877 ' CG ' HG23 ' A' ' 123' ' ' THR . 1.1 m-20 -60.82 149.61 35.39 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.249 -0.907 . . . . 0.0 109.476 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 106.98 33.82 3.14 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.969 -1.253 . . . . 0.0 109.969 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.546 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -114.09 139.73 49.06 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.066 -1.255 . . . . 0.0 109.165 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.433 ' O ' ' CG ' ' A' ' 152' ' ' ASN . 73.8 t -120.65 149.43 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 110.421 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.587 ' HB ' ' CE1' ' A' ' 103' ' ' PHE . 48.4 t -144.94 166.75 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.471 -0.768 . . . . 0.0 109.029 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.615 ' O ' HG23 ' A' ' 145' ' ' ILE . 5.6 m -124.68 123.47 40.1 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.06 -1.025 . . . . 0.0 109.612 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.63 ' N ' ' CD1' ' A' ' 103' ' ' PHE . 1.4 m-85 -121.94 103.9 9.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -0.875 . . . . 0.0 109.902 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.523 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 16.5 p -121.38 174.34 6.8 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.098 -1.001 . . . . 0.0 109.88 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.646 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -131.72 154.0 39.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 CA-C-O 121.492 0.663 . . . . 0.0 110.282 -179.688 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.528 ' CA ' ' O ' ' A' ' 111' ' ' GLN . . . -174.92 158.11 25.7 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.53 ' OD1' ' N ' ' A' ' 108' ' ' GLN . 1.5 p30 -97.91 -169.32 1.8 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.099 -1.236 . . . . 0.0 109.37 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.53 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 4.5 mp0 -73.11 11.66 0.68 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.1 -1.0 . . . . 0.0 111.105 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.445 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 1.4 m -111.02 13.91 22.0 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 120.595 -1.316 . . . . 0.0 109.139 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.512 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 4.0 m-30 71.47 3.96 4.87 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.484 -0.76 . . . . 0.0 109.619 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.528 ' O ' ' CA ' ' A' ' 106' ' ' GLY . 29.4 tt0 -78.0 162.39 26.79 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.236 -0.915 . . . . 0.0 108.564 179.335 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.482 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 7.1 tt0 -138.22 143.47 40.17 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.994 -1.066 . . . . 0.0 109.89 -179.443 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.569 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 19.7 m-85 -102.4 -70.11 0.76 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.163 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.582 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -98.47 174.31 28.17 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.062 -1.615 . . . . 0.0 109.062 179.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.576 ' C ' HD23 ' A' ' 116' ' ' LEU . 0.0 OUTLIER -175.28 129.45 0.28 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.005 -1.291 . . . . 0.0 110.461 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.666 HD21 ' CE1' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -146.9 72.31 1.26 Allowed 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 179.145 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.541 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 15.1 p80 -93.31 150.79 20.21 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.321 -0.862 . . . . 0.0 110.181 -179.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.541 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 2.7 tt0 80.0 47.63 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.653 -0.654 . . . . 0.0 109.458 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 12.7 mm100 -107.98 125.45 51.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.387 -0.821 . . . . 0.0 109.333 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.626 ' O ' HD13 ' A' ' 121' ' ' ILE . 25.1 mt-30 -66.95 153.58 43.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.451 -0.781 . . . . 0.0 109.066 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.626 HD13 ' O ' ' A' ' 120' ' ' GLN . 6.6 mm -135.37 134.48 52.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.195 -0.94 . . . . 0.0 109.961 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -86.06 -179.37 6.74 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.425 -0.797 . . . . 0.0 110.075 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.877 HG23 ' CG ' ' A' ' 97' ' ' ASP . 39.6 p -76.96 -3.94 41.45 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.961 -0.696 . . . . 0.0 109.337 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.429 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 1.3 mt-10 -106.27 -173.24 2.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.257 -0.902 . . . . 0.0 109.263 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.584 ' CE2' ' HD2' ' A' ' 93' ' ' ARG . 98.2 m95 -91.01 118.04 30.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.571 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -106.86 121.24 45.54 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.176 -0.953 . . . . 0.0 108.953 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.574 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.5 Cg_endo -79.42 105.37 1.87 Allowed 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.311 2.007 . . . . 0.0 111.011 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -112.88 133.43 54.87 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.023 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -151.52 177.04 10.72 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 122.435 1.112 . . . . 0.0 110.724 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.666 ' CE1' HD21 ' A' ' 116' ' ' LEU . 3.6 p90 -161.48 -169.67 2.36 Favored 'General case' 0 C--N 1.292 -1.934 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.148 179.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . 0.567 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 68.9 mt-10 -138.6 144.1 39.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.006 -1.059 . . . . 0.0 109.982 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.582 ' CE2' ' HA2' ' A' ' 114' ' ' GLY . 1.0 OUTLIER -163.63 147.56 10.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.448 -0.783 . . . . 0.0 109.215 179.763 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.469 ' OG1' ' HA ' ' A' ' 85' ' ' THR . 0.5 OUTLIER -116.22 147.93 40.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.293 -0.879 . . . . 0.0 109.71 -179.537 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.625 HG21 ' O ' ' A' ' 81' ' ' ARG . 5.5 t -40.49 110.42 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.602 -0.686 . . . . 0.0 109.291 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 12.4 t -61.98 -53.34 57.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.274 -0.891 . . . . 0.0 109.295 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -101.77 -91.59 0.33 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.367 -0.833 . . . . 0.0 109.21 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -163.33 50.81 0.16 Allowed 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.469 -0.769 . . . . 0.0 109.087 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.484 ' O ' HG23 ' A' ' 80' ' ' VAL . 61.3 mm-40 -87.92 112.08 22.15 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.242 -0.911 . . . . 0.0 109.738 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.5 p -79.39 -14.95 58.61 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.214 -0.929 . . . . 0.0 108.584 179.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 25.8 t -134.29 128.67 52.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.47 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -139.52 171.83 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.174 -0.954 . . . . 0.0 110.147 -179.629 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.511 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.9 ptm180 -141.75 132.82 26.16 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.662 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -93.4 109.42 40.33 Favored Pre-proline 0 N--CA 1.486 1.365 0 O-C-N 121.228 -0.92 . . . . 0.0 110.202 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.523 ' HD2' ' O ' ' A' ' 104' ' ' THR . 35.1 Cg_endo -76.47 110.14 3.0 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.141 1.894 . . . . 0.0 110.9 179.399 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.838 HD11 HD22 ' A' ' 162' ' ' LEU . 3.0 mt -116.66 108.21 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 179.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.602 ' N ' ' ND1' ' A' ' 146' ' ' HIS . 0.1 OUTLIER -123.74 160.75 26.59 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.299 -1.501 . . . . 0.0 112.111 -177.142 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.774 ' CE2' HD11 ' A' ' 159' ' ' ILE . 0.1 OUTLIER -113.53 -168.37 1.33 Allowed 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.628 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 127.02 32.84 0.66 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.817 ' C ' HG11 ' A' ' 64' ' ' VAL . 28.6 m-85 -121.34 155.27 35.1 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.297 -1.119 . . . . 0.0 109.283 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.476 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -67.06 -26.27 66.66 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -179.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.465 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.78 -7.57 46.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.409 -0.807 . . . . 0.0 109.562 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.57 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 2.5 t30 -115.21 14.17 16.89 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.684 HG23 HG13 ' A' ' 64' ' ' VAL . 2.4 t -89.32 159.5 2.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.585 -0.697 . . . . 0.0 109.674 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.55 37.31 49.67 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.428 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 1.9 m-20 -160.31 136.28 8.49 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.074 -1.251 . . . . 0.0 110.175 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.853 HG23 ' O ' ' A' ' 59' ' ' VAL . 45.2 m -86.25 122.25 29.98 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 179.085 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.57 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.8 OUTLIER -102.93 117.93 49.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.881 -1.137 . . . . 0.0 110.34 -178.873 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.65 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 13.9 m-85 -96.57 144.59 26.49 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 178.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.774 HD11 ' CE2' ' A' ' 147' ' ' PHE . 1.3 mt -140.99 139.83 33.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.768 -1.207 . . . . 0.0 110.636 -178.813 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.637 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.5 OUTLIER -174.18 135.58 0.46 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.159 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 128.61 -6.65 6.59 Favored Glycine 0 N--CA 1.486 1.974 0 C-N-CA 119.127 -1.511 . . . . 0.0 111.21 179.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.838 HD22 HD11 ' A' ' 145' ' ' ILE . 8.0 tp -59.73 97.78 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.39 -1.653 . . . . 0.0 108.784 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . 0.49 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -121.94 145.59 47.96 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.565 -0.709 . . . . 0.0 109.931 -179.211 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.817 HD12 HG11 ' A' ' 78' ' ' VAL . 52.4 mt -125.65 108.85 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.328 -0.858 . . . . 0.0 109.291 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.911 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -152.36 149.84 29.07 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.144 -0.972 . . . . 0.0 109.661 -179.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.453 ' HB3' ' O ' ' A' ' 85' ' ' THR . 0.3 OUTLIER -87.67 159.5 18.5 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.285 -0.884 . . . . 0.0 109.47 179.92 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.448 ' HB2' ' HD2' ' A' ' 168' ' ' PRO . 17.7 pt20 -71.53 159.01 86.75 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.451 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 167' ' ' GLN . 35.7 Cg_endo . . . . . 0 C--N 1.309 -1.529 0 C-N-CA 122.631 2.221 . . . . 0.0 110.445 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.6 ttt . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.315 0.579 . . . . 0.0 109.459 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mp -87.45 178.83 6.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.23 -0.919 . . . . 0.0 109.506 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.565 HG22 ' H ' ' A' ' 4' ' ' ALA . 4.2 p -162.8 173.31 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.236 -0.915 . . . . 0.0 109.385 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.565 ' H ' HG22 ' A' ' 3' ' ' VAL . . . -68.06 -55.13 13.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.128 -0.982 . . . . 0.0 109.453 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.504 ' HB2' HG12 ' A' ' 164' ' ' ILE . 0.4 OUTLIER -69.56 148.74 49.01 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 109.112 179.949 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.523 HG22 ' ND2' ' A' ' 7' ' ' ASN . 15.4 mm -112.03 148.58 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.383 -0.823 . . . . 0.0 109.207 179.707 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.523 ' ND2' HG22 ' A' ' 6' ' ' ILE . 42.6 m-80 45.02 38.77 3.26 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.254 -0.904 . . . . 0.0 109.649 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.519 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -56.9 -40.77 90.9 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 107.968 -2.053 . . . . 0.0 107.968 179.077 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.525 ' CA ' ' OD2' ' A' ' 160' ' ' ASP . . . -112.9 18.2 22.04 Favored Glycine 0 N--CA 1.488 2.103 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 178.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.826 ' CD2' HG21 ' A' ' 25' ' ' VAL . 61.4 m-85 65.66 46.61 2.36 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.478 -1.013 . . . . 0.0 109.683 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -84.66 -28.05 26.67 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.283 -0.885 . . . . 0.0 109.549 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.411 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 0.7 OUTLIER -88.29 -30.78 19.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.592 -179.726 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 1.025 ' OG1' HG13 ' A' ' 25' ' ' VAL . 1.1 m -82.02 124.28 79.08 Favored Pre-proline 0 N--CA 1.489 1.497 0 O-C-N 121.216 -0.928 . . . . 0.0 109.564 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.452 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.6 Cg_endo -78.03 138.21 16.19 Favored 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 122.412 2.075 . . . . 0.0 110.457 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -40.32 161.01 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.54 0 CA-C-O 121.233 0.539 . . . . 0.0 109.741 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 140.42 131.08 2.71 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.577 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -57.07 140.63 15.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.282 -1.129 . . . . 0.0 109.187 -179.689 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.478 HG23 ' HA ' ' A' ' 43' ' ' GLU . 43.7 t -89.91 144.41 9.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.453 -0.779 . . . . 0.0 110.197 -179.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.462 HG23 ' OD2' ' A' ' 20' ' ' ASP . 9.0 t -98.24 -27.56 14.1 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.16 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.546 ' HB2' ' CG ' ' A' ' 23' ' ' GLU . 7.0 m-20 -136.41 103.51 5.3 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.272 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 1.095 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -45.84 -30.43 1.69 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.101 -0.999 . . . . 0.0 109.746 -178.781 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.095 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -60.05 -49.51 77.37 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 121.643 -0.66 . . . . 0.0 109.796 -179.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.546 ' CG ' ' HB2' ' A' ' 20' ' ' ASP . 1.8 pt-20 -101.13 31.07 3.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.424 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.446 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -67.2 -45.73 78.3 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 1.025 HG13 ' OG1' ' A' ' 13' ' ' THR . 77.0 t -141.91 145.28 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -1.166 . . . . 0.0 109.695 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.77 -46.91 70.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.207 -0.933 . . . . 0.0 109.749 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.466 ' HA3' ' O ' ' A' ' 6' ' ' ILE . . . -81.53 -6.55 89.08 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 1.059 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.2 OUTLIER -133.96 123.71 25.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.155 -1.203 . . . . 0.0 109.091 179.528 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.528 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.5 OUTLIER -126.62 126.98 44.51 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.35 -0.844 . . . . 0.0 108.934 179.586 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.906 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -106.43 170.08 8.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.12 -0.987 . . . . 0.0 109.586 -179.395 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.425 ' HA ' HD21 ' A' ' 21' ' ' LEU . 19.4 m120 -160.53 122.45 3.15 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 110.241 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.779 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -103.65 137.54 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.257 -0.902 . . . . 0.0 109.354 178.625 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -86.88 169.72 40.83 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -60.6 -14.44 20.25 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.15 -1.206 . . . . 0.0 109.185 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.443 ' HB3' ' OD1' ' A' ' 67' ' ' ASN . 5.7 p -67.46 -33.72 75.72 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.338 -0.851 . . . . 0.0 109.796 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.796 HG12 ' O ' ' A' ' 36' ' ' VAL . 2.2 t -67.03 86.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.016 -1.053 . . . . 0.0 109.385 -179.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 17.7 m -65.81 -29.04 69.46 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.086 -1.009 . . . . 0.0 108.3 179.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 41.8 t30 -131.57 101.08 15.97 Favored Pre-proline 0 C--N 1.295 -1.765 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.32 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.2 149.87 36.52 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.368 2.045 . . . . 0.0 110.592 -179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.541 ' CD ' HG12 ' A' ' 71' ' ' ILE . 36.0 Cg_endo -77.38 -165.49 0.33 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.588 2.192 . . . . 0.0 110.191 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 56.0 t -108.52 118.88 57.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.331 -0.856 . . . . 0.0 110.13 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.602 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 2.7 m-85 -97.37 111.61 23.79 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.038 -1.039 . . . . 0.0 108.221 178.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.577 ' HG3' HG23 ' A' ' 17' ' ' VAL . 3.3 tm-20 -153.01 148.51 27.15 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.125 -0.984 . . . . 0.0 110.099 -179.446 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.458 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 61.4 t -102.41 148.45 7.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.388 -0.82 . . . . 0.0 109.048 179.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 1.05 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -150.19 164.28 36.07 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.084 -1.01 . . . . 0.0 108.602 -179.938 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 1.05 ' N ' HD22 ' A' ' 45' ' ' LEU . 13.0 mt-10 -110.68 112.81 24.95 Favored 'General case' 0 C--N 1.293 -1.863 0 O-C-N 121.443 -0.785 . . . . 0.0 109.809 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 1.022 HG22 HD21 ' A' ' 45' ' ' LEU . 1.9 p -106.48 152.99 22.93 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.453 -0.78 . . . . 0.0 109.458 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 51.9 p -88.25 18.79 4.12 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.345 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.421 ' O ' ' C ' ' A' ' 50' ' ' ALA . 14.7 t0 -132.97 7.81 4.03 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 109.519 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.421 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -43.93 149.22 0.68 Allowed Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.276 -0.89 . . . . 0.0 109.351 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.596 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 35.2 Cg_endo -78.21 -32.96 2.16 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.697 2.265 . . . . 0.0 110.372 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -139.28 77.49 1.62 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.283 -0.885 . . . . 0.0 109.531 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 118.48 -127.15 7.15 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.489 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 6.9 t30 -157.57 22.51 0.28 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.26 -1.141 . . . . 0.0 109.413 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.551 ' CG ' ' HG2' ' A' ' 46' ' ' GLU . 17.8 mttp -136.58 142.76 43.36 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.29 -0.881 . . . . 0.0 109.412 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.572 HG11 ' CZ2' ' A' ' 125' ' ' TRP . 6.1 m -150.64 174.18 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.217 -0.927 . . . . 0.0 109.563 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.667 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -102.88 103.15 13.28 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.575 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.764 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -81.96 118.55 23.06 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.838 ' O ' HG23 ' A' ' 156' ' ' THR . 46.9 t -113.29 143.9 22.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.096 -1.003 . . . . 0.0 108.6 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.845 HG22 HD22 ' A' ' 62' ' ' ASN . 45.7 m -108.66 94.29 4.97 Favored 'General case' 0 C--N 1.283 -2.316 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.59 HG12 ' HA ' ' A' ' 153' ' ' VAL . 55.5 t -89.03 125.36 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.281 -0.887 . . . . 0.0 108.843 179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.845 HD22 HG22 ' A' ' 60' ' ' THR . 5.7 p30 -160.17 61.58 0.34 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.41 -0.806 . . . . 0.0 109.68 -179.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 149.24 89.81 0.08 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.7 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.5 m -79.91 -171.93 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.281 -1.129 . . . . 0.0 109.58 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -134.71 -164.43 10.52 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -92.3 19.1 7.39 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -1.139 . . . . 0.0 109.459 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.526 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 30.5 m120 -132.72 148.15 68.37 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.231 -0.918 . . . . 0.0 109.398 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.508 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.3 Cg_endo -78.52 12.52 2.12 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.578 2.186 . . . . 0.0 110.836 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.526 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -136.59 58.83 1.72 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.99 -1.069 . . . . 0.0 109.688 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.51 ' HB3' ' CG2' ' A' ' 36' ' ' VAL . 1.8 m-20 -77.71 -69.61 0.53 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.122 -0.986 . . . . 0.0 108.963 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.573 HD12 ' HA2' ' A' ' 148' ' ' GLY . 3.0 mt -106.26 126.82 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.396 -0.815 . . . . 0.0 108.904 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -121.92 128.79 51.94 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.078 -1.013 . . . . 0.0 110.504 -179.268 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 1.059 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -113.68 108.54 17.26 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.554 HG22 ' N ' ' A' ' 75' ' ' ALA . 40.9 m -115.28 162.48 17.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.513 -1.367 . . . . 0.0 110.137 -178.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.554 ' N ' HG22 ' A' ' 74' ' ' THR . . . -123.46 140.1 53.34 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.227 -0.92 . . . . 0.0 109.219 179.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.535 ' C ' ' CD1' ' A' ' 76' ' ' PHE . 3.1 p90 178.98 160.56 0.7 Allowed Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.416 -0.802 . . . . 0.0 109.22 -179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.53 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.9 Cg_endo -81.58 168.64 67.57 Favored 'Cis proline' 0 C--N 1.311 -1.418 0 C-N-CA 123.699 -1.375 . . . . 0.0 110.696 -0.468 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.535 HG11 HD11 ' A' ' 141' ' ' ILE . 33.3 t -121.22 131.58 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.233 -0.917 . . . . 0.0 108.87 179.355 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.522 ' O ' ' HB2' ' A' ' 4' ' ' ALA . 26.7 m-80 -94.03 103.97 16.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.079 -1.013 . . . . 0.0 109.975 -179.518 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.585 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 2.2 m -113.57 -176.6 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.402 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.709 ' O ' HG21 ' A' ' 134' ' ' VAL . 0.0 OUTLIER -133.42 142.61 44.77 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.302 -0.874 . . . . 0.0 109.346 179.88 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.449 ' HD3' HG22 ' A' ' 139' ' ' THR . 35.5 Cg_endo -77.63 106.47 2.2 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.448 2.099 . . . . 0.0 110.505 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 113.33 -30.68 7.14 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.5 ' HB ' ' HB3' ' A' ' 81' ' ' ARG . 2.5 t -84.51 149.74 4.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.23 -1.159 . . . . 0.0 109.47 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 19.7 m -90.6 123.65 34.41 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.585 ' CE2' ' HA ' ' A' ' 80' ' ' VAL . 6.3 m-85 -106.37 154.84 20.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.282 -0.886 . . . . 0.0 109.733 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.472 ' HB ' ' O ' ' A' ' 165' ' ' ALA . 59.0 m -118.04 154.36 32.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.433 -0.792 . . . . 0.0 109.238 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.688 ' CD1' ' CE2' ' A' ' 130' ' ' PHE . 0.1 OUTLIER -129.33 127.38 40.97 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.146 -0.971 . . . . 0.0 109.515 -179.84 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.511 ' O ' ' O ' ' A' ' 161' ' ' GLY . 21.6 m -130.5 145.54 51.87 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.266 -0.896 . . . . 0.0 108.78 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.726 HD13 ' HD2' ' A' ' 103' ' ' PHE . 16.9 tt -151.34 161.91 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 120.554 -1.341 . . . . 0.0 109.741 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.596 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 18.1 m95 -132.63 124.88 29.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.154 -0.966 . . . . 0.0 108.982 179.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -121.98 145.91 47.66 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.741 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.623 ' HA ' HG22 ' A' ' 121' ' ' ILE . 8.8 ptt180 -156.73 179.2 9.5 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -154.47 160.62 41.69 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.091 -1.006 . . . . 0.0 109.868 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -54.04 -41.19 67.8 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.383 -0.823 . . . . 0.0 109.452 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.472 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 57.4 mt-30 -130.34 143.38 50.74 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.225 -0.922 . . . . 0.0 109.442 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.79 ' OD1' HG23 ' A' ' 123' ' ' THR . 2.2 m-20 -57.14 149.37 19.7 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.293 -0.879 . . . . 0.0 109.505 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 111.23 36.99 1.71 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.841 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -125.19 141.8 51.88 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.072 -1.252 . . . . 0.0 109.32 179.695 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.52 ' O ' ' ND2' ' A' ' 152' ' ' ASN . 54.0 t -118.56 151.27 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 110.832 -179.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.64 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 40.7 t -150.02 162.11 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.527 ' HB3' ' CB ' ' A' ' 117' ' ' HIS . 54.4 m -124.42 128.83 49.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.09 -1.006 . . . . 0.0 109.31 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.726 ' HD2' HD13 ' A' ' 90' ' ' ILE . 0.2 OUTLIER -121.66 103.78 9.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.084 -1.01 . . . . 0.0 109.957 -179.788 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.488 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 20.9 p -128.4 165.02 21.43 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.216 -0.928 . . . . 0.0 109.927 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.655 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.0 OUTLIER -121.62 125.23 73.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.564 0.697 . . . . 0.0 110.167 179.876 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -115.1 179.02 18.14 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.551 ' CB ' ' O ' ' A' ' 111' ' ' GLN . 25.7 t30 -127.83 172.04 11.22 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.335 -1.097 . . . . 0.0 109.077 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.455 ' HB2' ' OE2' ' A' ' 138' ' ' GLU . 31.4 mt-30 -59.17 -47.63 84.59 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.007 -1.058 . . . . 0.0 109.608 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.538 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 46.9 t -84.37 19.36 1.92 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.219 -0.926 . . . . 0.0 110.117 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.56 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 2.1 m-30 80.61 7.79 1.36 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.36 -0.838 . . . . 0.0 110.186 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.551 ' O ' ' CB ' ' A' ' 107' ' ' ASN . 37.0 mm-40 -69.9 123.99 22.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.994 -1.066 . . . . 0.0 108.736 179.249 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.492 ' HG3' ' N ' ' A' ' 113' ' ' TYR . 1.2 tt0 -104.93 140.41 38.21 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.925 -1.109 . . . . 0.0 110.122 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.748 ' CE2' HG21 ' A' ' 141' ' ' ILE . 5.8 m-85 -108.37 -68.56 0.9 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.453 -0.779 . . . . 0.0 108.915 179.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.582 ' HA3' ' CE2' ' A' ' 130' ' ' PHE . . . -99.37 171.61 24.42 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 179.478 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.476 ' CG ' ' O ' ' A' ' 115' ' ' ARG . 0.2 OUTLIER -171.03 110.11 0.33 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.044 -1.268 . . . . 0.0 110.381 -179.867 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.91 HD21 ' CD1' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -145.38 77.29 1.51 Allowed 'General case' 0 N--CA 1.494 1.74 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.168 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.54 ' O ' ' CB ' ' A' ' 118' ' ' GLU . 18.5 p80 -104.27 158.04 16.73 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.354 -0.842 . . . . 0.0 110.11 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 30.0 tt0 79.1 78.52 0.06 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.513 -0.742 . . . . 0.0 109.689 179.687 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.451 ' OE1' ' O ' ' A' ' 118' ' ' GLU . 19.5 mm100 -144.24 131.74 21.02 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.251 -0.906 . . . . 0.0 109.467 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.793 ' O ' HD13 ' A' ' 121' ' ' ILE . 10.6 mt-30 -66.66 156.04 36.3 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 109.066 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.793 HD13 ' O ' ' A' ' 120' ' ' GLN . 13.9 mm -133.21 136.76 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 O-C-N 121.066 -1.021 . . . . 0.0 110.005 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -90.48 -179.17 5.52 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.908 0.861 . . . . 0.0 110.636 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.79 HG23 ' OD1' ' A' ' 97' ' ' ASP . 0.8 OUTLIER -68.69 -15.67 63.59 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.416 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.521 ' O ' ' CB ' ' A' ' 93' ' ' ARG . 3.8 mt-10 -100.36 -172.09 2.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.475 -0.766 . . . . 0.0 109.289 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.588 ' CE2' ' HD3' ' A' ' 51' ' ' PRO . 98.2 m95 -90.07 135.46 33.64 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.324 -0.86 . . . . 0.0 109.796 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.44 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 0.6 OUTLIER -106.83 121.37 45.16 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.233 -0.917 . . . . 0.0 108.977 179.751 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -79.64 110.1 2.57 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.447 2.098 . . . . 0.0 110.945 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -122.79 133.71 54.44 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 179.189 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.1 t -151.62 176.42 11.37 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 120.625 -1.297 . . . . 0.0 111.057 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.91 ' CD1' HD21 ' A' ' 116' ' ' LEU . 10.5 p90 -171.98 178.01 3.09 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.019 179.437 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . 0.474 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 33.5 mt-10 -133.7 153.57 51.6 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.061 -1.025 . . . . 0.0 110.041 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.565 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -165.14 160.76 19.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.458 -0.776 . . . . 0.0 109.147 179.746 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -119.11 146.2 45.31 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.18 -0.95 . . . . 0.0 109.293 -179.579 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.709 HG21 ' O ' ' A' ' 81' ' ' ARG . 2.5 t -56.72 111.94 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.362 -0.836 . . . . 0.0 109.264 179.611 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 3.8 m -83.61 -42.32 16.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.442 -0.786 . . . . 0.0 109.947 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.576 ' O ' ' CB ' ' A' ' 137' ' ' GLN . 33.1 t70 -85.91 -16.64 37.85 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.401 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . 0.691 ' H ' HG12 ' A' ' 134' ' ' VAL . 3.2 mm-40 86.32 28.38 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -178.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.523 ' CG ' ' OD1' ' A' ' 107' ' ' ASN . 3.0 mm-40 -74.48 119.4 18.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.606 -0.683 . . . . 0.0 109.795 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.449 HG22 ' HD3' ' A' ' 82' ' ' PRO . 17.3 p -79.34 -3.78 47.83 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.488 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.9 t -140.13 132.19 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.352 -0.843 . . . . 0.0 109.131 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.748 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.6 OUTLIER -144.53 171.98 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.259 -0.901 . . . . 0.0 109.821 -179.861 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.501 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.1 ptm180 -139.61 132.26 28.89 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.528 -0.732 . . . . 0.0 109.419 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.655 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -96.09 108.78 43.31 Favored Pre-proline 0 N--CA 1.486 1.339 0 O-C-N 121.219 -0.926 . . . . 0.0 110.029 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.501 ' HD3' ' O ' ' A' ' 142' ' ' ARG . 36.2 Cg_endo -77.73 112.51 3.32 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.324 2.016 . . . . 0.0 111.106 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.809 HD11 HD22 ' A' ' 162' ' ' LEU . 2.4 mt -99.14 134.19 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 178.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 12.8 m80 -97.2 154.83 17.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.34 -1.475 . . . . 0.0 111.607 -177.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.64 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 28.1 m-85 -155.1 157.21 37.16 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 179.284 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.573 ' HA2' HD12 ' A' ' 71' ' ' ILE . . . 108.11 53.59 0.65 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.7 ' C ' HG11 ' A' ' 64' ' ' VAL . 22.6 m-85 -129.03 159.47 35.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.245 -1.15 . . . . 0.0 109.39 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.414 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.67 -30.15 70.33 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -71.23 -11.6 61.01 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.369 -0.832 . . . . 0.0 109.049 179.265 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.841 ' OD1' ' HB1' ' A' ' 99' ' ' ALA . 1.8 t30 -116.86 13.07 14.93 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 179.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.59 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.2 t -85.15 162.22 2.95 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 O-C-N 121.635 -0.665 . . . . 0.0 109.695 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.446 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 54.06 33.19 50.76 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.472 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 2.0 m-20 -160.47 135.46 7.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.187 -1.184 . . . . 0.0 110.069 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.838 HG23 ' O ' ' A' ' 59' ' ' VAL . 42.2 m -85.13 122.43 29.33 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.067 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.55 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -101.13 118.72 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.832 -1.167 . . . . 0.0 110.331 -178.811 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.764 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 3.5 m-85 -95.12 130.81 41.68 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.636 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.4 mt -120.31 142.0 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.915 -1.115 . . . . 0.0 110.078 -178.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.564 ' CB ' HG12 ' A' ' 56' ' ' VAL . 0.8 OUTLIER -174.38 136.37 0.47 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.108 -0.995 . . . . 0.0 109.252 179.535 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 122.63 -10.4 9.1 Favored Glycine 0 N--CA 1.487 2.069 0 C-N-CA 119.322 -1.418 . . . . 0.0 111.014 179.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.809 HD22 HD11 ' A' ' 145' ' ' ILE . 9.9 tp -59.62 97.19 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.53 -1.571 . . . . 0.0 108.903 -179.643 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . 0.934 ' C ' HD13 ' A' ' 164' ' ' ILE . . . -134.57 145.55 48.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.537 -0.727 . . . . 0.0 109.985 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.934 HD13 ' C ' ' A' ' 163' ' ' ALA . 2.6 mm -119.65 108.5 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.284 -0.885 . . . . 0.0 109.204 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.525 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -140.78 145.01 35.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.127 -0.983 . . . . 0.0 109.527 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 4.2 p -74.37 176.67 6.53 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.294 -0.879 . . . . 0.0 109.559 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -154.71 150.63 21.96 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.241 -0.912 . . . . 0.0 109.376 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo . . . . . 0 C--N 1.309 -1.542 0 C-N-CA 122.638 2.226 . . . . 0.0 110.389 -179.98 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.7 ttt . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mt -102.36 105.92 16.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.32 -0.863 . . . . 0.0 109.396 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.798 HG22 ' O ' ' A' ' 164' ' ' ILE . 2.9 p -102.12 171.27 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.2 -0.937 . . . . 0.0 109.403 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.636 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -75.3 -46.57 32.63 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.186 -0.946 . . . . 0.0 109.587 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.511 ' HB2' ' CG1' ' A' ' 164' ' ' ILE . 0.9 OUTLIER -89.84 124.65 34.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.293 -0.88 . . . . 0.0 109.603 -179.945 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.492 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 1.8 mp -116.83 138.06 48.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.244 -0.91 . . . . 0.0 109.3 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.509 ' CB ' ' HA3' ' A' ' 27' ' ' GLY . 0.3 OUTLIER 74.99 16.52 2.87 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.219 -0.926 . . . . 0.0 109.627 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.502 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -60.11 -45.98 95.02 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.527 ' CA ' ' OD2' ' A' ' 160' ' ' ASP . . . -94.77 28.44 11.4 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 179.407 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.6 ' CE2' ' HB2' ' A' ' 57' ' ' LEU . 8.4 m-85 44.53 52.01 7.73 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.434 -1.039 . . . . 0.0 109.552 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.481 ' OE1' ' HA3' ' A' ' 53' ' ' GLY . 57.3 mm-40 -84.6 -28.24 26.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.298 -0.876 . . . . 0.0 109.639 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.423 ' HB2' ' OD1' ' A' ' 7' ' ' ASN . 0.9 OUTLIER -87.31 -37.08 17.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.198 -0.939 . . . . 0.0 109.762 -179.675 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.788 ' OG1' HG13 ' A' ' 25' ' ' VAL . 10.1 m -70.82 117.0 51.79 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.153 -0.967 . . . . 0.0 109.354 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 15' ' ' ALA . 35.2 Cg_endo -76.95 138.82 18.85 Favored 'Trans proline' 0 C--N 1.312 -1.378 0 C-N-CA 122.319 2.013 . . . . 0.0 110.396 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.441 ' C ' ' O ' ' A' ' 14' ' ' PRO . . . -39.31 153.88 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.516 0 CA-C-O 121.279 0.561 . . . . 0.0 109.857 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.49 131.37 2.41 Favored Glycine 0 N--CA 1.485 1.966 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.531 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.84 141.13 14.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.227 -1.16 . . . . 0.0 109.213 -179.602 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.642 HG13 ' HA2' ' A' ' 24' ' ' GLY . 47.8 t -86.58 142.37 13.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 CA-C-O 121.722 0.772 . . . . 0.0 110.365 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.411 ' C ' ' OD1' ' A' ' 20' ' ' ASP . 1.8 t -95.34 -28.53 14.92 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.069 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.426 ' O ' ' C ' ' A' ' 21' ' ' LEU . 1.0 OUTLIER -136.31 100.5 4.4 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.325 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 1.107 HD22 ' N ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -43.23 -29.02 0.36 Allowed 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.259 -0.9 . . . . 0.0 109.773 -178.868 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.107 ' N ' HD22 ' A' ' 21' ' ' LEU . . . -59.69 -55.06 39.13 Favored 'General case' 0 C--N 1.294 -1.823 0 O-C-N 121.599 -0.688 . . . . 0.0 109.822 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -101.5 31.6 3.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.135 -0.978 . . . . 0.0 109.349 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.642 ' HA2' HG13 ' A' ' 18' ' ' VAL . . . -67.56 -47.18 63.74 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.788 HG13 ' OG1' ' A' ' 13' ' ' THR . 4.3 t -126.61 144.83 35.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.093 -1.24 . . . . 0.0 109.842 -179.638 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -62.49 -65.56 0.67 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.331 -0.855 . . . . 0.0 110.084 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.509 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -76.31 2.5 56.93 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 0.687 ' CZ2' ' CD1' ' A' ' 145' ' ' ILE . 0.7 OUTLIER -133.99 122.11 22.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.028 -1.278 . . . . 0.0 109.124 179.549 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.537 ' CG ' ' CE2' ' A' ' 76' ' ' PHE . 0.8 OUTLIER -126.6 128.22 46.46 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.4 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.906 HD23 ' HA ' ' A' ' 73' ' ' ALA . 0.3 OUTLIER -104.67 175.98 5.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.972 -1.08 . . . . 0.0 110.236 -178.927 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.409 ' ND2' ' O ' ' A' ' 30' ' ' LEU . 16.8 m120 -160.2 122.09 3.22 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.47 -0.769 . . . . 0.0 109.629 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.785 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -110.6 136.53 46.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.217 -0.927 . . . . 0.0 109.494 179.417 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.45 -179.87 21.03 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.1 m -58.42 -16.3 14.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -1.165 . . . . 0.0 109.294 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.484 ' O ' ' HA3' ' A' ' 65' ' ' GLY . 37.7 m -60.37 -38.85 85.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.257 -0.902 . . . . 0.0 109.592 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.785 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -62.97 89.29 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.045 -1.034 . . . . 0.0 109.257 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.4 m -59.79 -29.23 68.07 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.242 -0.911 . . . . 0.0 108.69 179.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.693 ' O ' HG13 ' A' ' 36' ' ' VAL . 0.5 OUTLIER -129.07 128.79 23.36 Favored Pre-proline 0 C--N 1.296 -1.728 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.448 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.63 122.02 6.23 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.203 1.935 . . . . 0.0 110.523 -179.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.515 ' HG3' ' CD1' ' A' ' 71' ' ' ILE . 35.4 Cg_endo -77.3 -165.68 0.34 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.302 2.002 . . . . 0.0 109.905 179.697 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.513 ' HB ' ' CB ' ' A' ' 60' ' ' THR . 70.2 t -117.34 118.72 59.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.034 -1.041 . . . . 0.0 110.775 -179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.453 ' CG ' ' HB3' ' A' ' 21' ' ' LEU . 2.3 m-85 -102.33 111.97 24.48 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.163 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.538 ' HA ' HG23 ' A' ' 18' ' ' VAL . 1.3 tm-20 -154.1 151.52 29.39 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.062 -1.024 . . . . 0.0 110.118 -179.116 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.444 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 48.0 t -103.75 148.39 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.488 -0.757 . . . . 0.0 109.188 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 1.071 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -149.13 164.12 35.63 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.77 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 1.071 ' N ' HD22 ' A' ' 45' ' ' LEU . 9.9 pt-20 -125.47 124.89 42.37 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.333 -0.855 . . . . 0.0 109.551 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.92 HG23 HD21 ' A' ' 45' ' ' LEU . 1.3 p -127.24 166.77 17.12 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.388 -0.82 . . . . 0.0 109.461 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 95.6 p -88.24 18.58 4.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.912 . . . . 0.0 109.4 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 50' ' ' ALA . 0.1 OUTLIER -123.96 -0.81 8.39 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.277 -0.889 . . . . 0.0 109.584 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.34 145.84 1.32 Allowed Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.166 -0.959 . . . . 0.0 109.406 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.603 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 36.1 Cg_endo -78.44 -41.94 0.24 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.647 2.231 . . . . 0.0 110.396 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -128.26 89.61 2.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.315 -0.865 . . . . 0.0 109.413 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.481 ' HA3' ' OE1' ' A' ' 11' ' ' GLU . . . 105.49 -128.38 9.37 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.484 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 9.2 p-10 -152.63 18.24 0.61 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.201 -1.176 . . . . 0.0 109.704 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.466 ' O ' ' OD2' ' A' ' 160' ' ' ASP . 95.1 mttt -138.73 146.6 41.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.15 -0.969 . . . . 0.0 109.665 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.64 HG12 ' CB ' ' A' ' 160' ' ' ASP . 5.4 m -150.1 174.48 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.392 -0.817 . . . . 0.0 109.242 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.672 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.2 OUTLIER -100.43 103.75 15.13 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.12 -0.988 . . . . 0.0 108.964 179.475 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.721 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -82.04 121.9 27.14 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 178.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.789 ' O ' HG23 ' A' ' 156' ' ' THR . 44.0 t -115.46 144.17 23.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.113 -0.992 . . . . 0.0 109.084 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.858 HG22 ' ND2' ' A' ' 62' ' ' ASN . 95.9 m -107.79 88.48 2.74 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.196 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.699 HG21 ' CD1' ' A' ' 157' ' ' ILE . 60.1 t -86.77 120.91 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.419 -0.801 . . . . 0.0 109.291 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.858 ' ND2' HG22 ' A' ' 60' ' ' THR . 5.4 p30 -160.23 59.3 0.35 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.423 -0.798 . . . . 0.0 109.835 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 154.57 84.65 0.05 OUTLIER Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.719 HG12 ' C ' ' A' ' 148' ' ' GLY . 1.7 m -80.66 -176.54 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.24 -1.153 . . . . 0.0 109.396 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.484 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -126.99 -159.53 10.21 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 22.8 m-20 -89.48 -9.22 50.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.295 -1.121 . . . . 0.0 109.455 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.499 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 39.6 m-80 -104.77 148.06 35.46 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.241 -0.912 . . . . 0.0 109.388 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 67' ' ' ASN . 36.2 Cg_endo -78.85 13.54 1.92 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.651 2.234 . . . . 0.0 110.942 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.499 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 1.9 p90 -137.72 53.33 1.85 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.98 -1.075 . . . . 0.0 109.744 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.522 ' CB ' HG23 ' A' ' 36' ' ' VAL . 0.4 OUTLIER -75.48 -65.28 0.91 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.174 -0.953 . . . . 0.0 109.095 179.645 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.546 HG13 ' CG2' ' A' ' 36' ' ' VAL . 4.5 mt -105.05 128.68 58.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.275 -0.89 . . . . 0.0 108.709 179.523 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -130.69 130.44 43.86 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.822 -1.174 . . . . 0.0 110.545 -179.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.906 ' HA ' HD23 ' A' ' 30' ' ' LEU . . . -113.66 108.82 17.64 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.548 HG22 ' N ' ' A' ' 75' ' ' ALA . 54.5 m -109.23 162.3 14.42 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.688 -1.257 . . . . 0.0 110.134 -178.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.548 ' N ' HG22 ' A' ' 74' ' ' THR . . . -122.74 138.97 54.47 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.267 -0.895 . . . . 0.0 109.173 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.555 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 4.1 p90 179.36 161.57 0.76 Allowed Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.526 -0.734 . . . . 0.0 109.098 -179.723 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.555 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.7 Cg_endo -81.76 166.32 72.28 Favored 'Cis proline' 0 C--N 1.311 -1.444 0 C-N-CA 123.802 -1.333 . . . . 0.0 110.972 -0.364 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.72 HG11 HD13 ' A' ' 164' ' ' ILE . 86.7 t -127.19 156.64 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.636 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 69.1 m-20 -122.53 139.52 53.81 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.007 -1.058 . . . . 0.0 109.875 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.45 ' HA ' ' CE2' ' A' ' 86' ' ' TYR . 4.0 m -146.04 -174.04 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.226 -0.921 . . . . 0.0 109.758 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.542 ' O ' HG21 ' A' ' 134' ' ' VAL . 3.1 ttt85 -138.07 141.38 32.06 Favored Pre-proline 0 N--CA 1.49 1.534 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.513 ' HD2' ' CG ' ' A' ' 81' ' ' ARG . 34.9 Cg_endo -76.12 117.27 4.6 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.467 2.111 . . . . 0.0 110.778 -179.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 107.72 -33.53 6.26 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.454 ' HB ' ' HB3' ' A' ' 81' ' ' ARG . 2.7 t -88.59 149.72 3.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.221 -1.164 . . . . 0.0 109.584 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.3 t -94.19 147.54 23.07 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.631 ' CZ ' ' CB ' ' A' ' 166' ' ' SER . 7.6 m-85 -122.2 157.46 31.54 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.102 -0.999 . . . . 0.0 109.937 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 47.7 m -111.21 142.12 43.84 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.375 -0.828 . . . . 0.0 109.05 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.816 ' CD1' HG23 ' A' ' 164' ' ' ILE . 0.2 OUTLIER -134.19 128.25 33.62 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.093 -1.004 . . . . 0.0 109.548 -179.522 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.501 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.5 m -134.83 152.79 52.04 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.716 HD13 ' CD2' ' A' ' 103' ' ' PHE . 18.6 tt -150.9 163.4 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.787 -1.196 . . . . 0.0 109.343 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.603 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 17.2 m95 -130.66 124.87 32.61 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.076 -1.015 . . . . 0.0 109.566 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.465 ' HB3' HG23 ' A' ' 121' ' ' ILE . . . -113.49 146.81 39.01 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.3 -0.875 . . . . 0.0 109.204 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.494 ' HG3' ' O ' ' A' ' 123' ' ' THR . 6.5 ttp85 -162.34 119.68 2.08 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.144 -0.973 . . . . 0.0 109.228 -179.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.418 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.35 160.52 15.31 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.22 -0.925 . . . . 0.0 109.937 -179.61 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -55.08 -44.83 75.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.425 -0.797 . . . . 0.0 109.176 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.518 ' C ' HG22 ' A' ' 123' ' ' THR . 0.0 OUTLIER -117.68 151.62 36.88 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.872 . . . . 0.0 109.132 179.758 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.872 ' N ' HG22 ' A' ' 123' ' ' THR . 2.3 p-10 -73.59 146.01 45.02 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.139 -0.976 . . . . 0.0 109.566 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 113.56 37.89 1.26 Allowed Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' A' ' 151' ' ' ALA . . . -121.66 140.53 52.17 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.188 -1.184 . . . . 0.0 109.128 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.461 ' HB ' ' OD1' ' A' ' 152' ' ' ASN . 50.7 t -116.23 154.3 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.218 -0.926 . . . . 0.0 110.66 -179.427 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.69 HG22 ' CE1' ' A' ' 147' ' ' PHE . 61.6 t -155.02 166.49 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.592 ' HB2' ' CD2' ' A' ' 117' ' ' HIS . 30.8 t -136.18 130.81 33.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.027 -1.046 . . . . 0.0 109.643 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.716 ' CD2' HD13 ' A' ' 90' ' ' ILE . 0.3 OUTLIER -122.86 104.51 9.32 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.145 -0.972 . . . . 0.0 109.572 -179.965 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.614 ' O ' ' HB1' ' A' ' 143' ' ' ALA . 16.0 p -117.22 170.78 8.41 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.119 -0.988 . . . . 0.0 110.462 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.649 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -127.32 157.71 38.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.834 -0.541 . . . . 0.0 109.726 -179.924 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 111' ' ' GLN . . . 172.98 138.33 2.58 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.639 ' CB ' HG22 ' A' ' 141' ' ' ILE . 1.3 p30 -76.98 -169.88 1.46 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.123 -1.222 . . . . 0.0 109.334 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.521 ' N ' ' OD1' ' A' ' 107' ' ' ASN . 1.4 mp0 -77.28 14.91 0.83 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.04 -1.037 . . . . 0.0 110.925 -179.156 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.508 ' O ' ' CB ' ' A' ' 110' ' ' PHE . 0.9 OUTLIER -113.63 6.36 16.91 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 120.785 -1.197 . . . . 0.0 109.344 179.598 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.569 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 1.6 m-30 77.94 14.84 1.55 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.361 -0.837 . . . . 0.0 109.611 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.493 ' HG2' ' HB2' ' A' ' 109' ' ' SER . 7.9 mm-40 -90.0 94.39 9.78 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 108.655 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.53 ' CG ' ' O ' ' A' ' 105' ' ' VAL . 2.0 tt0 -81.92 142.08 32.77 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.362 -0.836 . . . . 0.0 110.34 -179.06 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.596 ' HB3' ' CD1' ' A' ' 132' ' ' PHE . 4.8 m-85 -109.69 -69.02 0.88 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.207 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.422 ' N ' HG23 ' A' ' 105' ' ' VAL . . . -89.34 177.67 44.19 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 179.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 1.01 ' O ' HD23 ' A' ' 116' ' ' LEU . 0.6 OUTLIER -177.87 135.83 0.17 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.951 -1.323 . . . . 0.0 110.393 -180.0 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 1.01 HD23 ' O ' ' A' ' 115' ' ' ARG . 0.5 OUTLIER -147.36 69.87 1.16 Allowed 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.304 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.592 ' CD2' ' HB2' ' A' ' 102' ' ' SER . 27.2 t-80 -93.77 141.57 28.35 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 110.295 -179.043 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.559 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 4.2 tt0 82.21 36.8 0.06 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.711 -0.618 . . . . 0.0 109.52 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 6.9 mm100 -88.55 120.34 29.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.355 -0.841 . . . . 0.0 109.165 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.71 ' O ' HD13 ' A' ' 121' ' ' ILE . 1.6 mt-30 -65.5 140.99 58.63 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.462 -0.774 . . . . 0.0 108.945 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.71 HD13 ' O ' ' A' ' 120' ' ' GLN . 5.9 mm -125.81 129.68 72.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.109 -0.995 . . . . 0.0 110.126 -179.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -89.86 -178.77 5.57 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.618 0.723 . . . . 0.0 110.094 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.872 HG22 ' N ' ' A' ' 97' ' ' ASP . 11.6 p -72.87 -2.08 19.32 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 119.914 -0.714 . . . . 0.0 109.352 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.47 ' HA ' ' HD2' ' A' ' 93' ' ' ARG . 0.4 OUTLIER -112.44 -168.73 1.36 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.166 -0.959 . . . . 0.0 108.981 179.727 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.534 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 95.3 m95 -91.95 130.26 37.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.145 -0.972 . . . . 0.0 109.613 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.439 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 12.1 mm-40 -109.51 121.45 42.33 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.156 -0.965 . . . . 0.0 109.109 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.17 100.41 1.26 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 C-N-CA 122.514 2.143 . . . . 0.0 111.141 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -110.9 137.83 48.05 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.14 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.1 t -144.18 176.21 9.5 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.565 -1.334 . . . . 0.0 111.058 -179.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.661 ' CE1' HD11 ' A' ' 116' ' ' LEU . 16.9 p90 -173.9 171.06 3.77 Favored 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 115.036 -0.983 . . . . 0.0 109.034 179.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . 0.516 ' HA ' ' CE2' ' A' ' 88' ' ' TYR . 34.3 mt-10 -143.64 142.18 30.92 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.089 -1.007 . . . . 0.0 109.904 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.702 ' CE2' ' CZ ' ' A' ' 88' ' ' TYR . 5.2 p90 -151.11 168.07 25.78 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.35 -0.844 . . . . 0.0 109.145 179.419 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.407 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -119.37 147.29 44.51 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.907 . . . . 0.0 109.623 -179.719 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.542 HG21 ' O ' ' A' ' 81' ' ' ARG . 3.6 t -43.51 110.43 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.46 -0.775 . . . . 0.0 108.977 179.546 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -58.52 -51.12 71.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.208 -0.932 . . . . 0.0 109.293 -179.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -110.65 -91.16 0.47 Allowed 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.399 -0.813 . . . . 0.0 109.209 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -160.94 55.2 0.3 Allowed 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.576 -0.702 . . . . 0.0 109.127 179.737 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.512 ' HG3' ' ND2' ' A' ' 107' ' ' ASN . 7.2 mm-40 -95.01 111.91 23.67 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.213 -0.93 . . . . 0.0 109.851 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.0 p -79.42 -13.46 59.58 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 41.6 t -134.03 136.42 53.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.212 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.639 HG22 ' CB ' ' A' ' 107' ' ' ASN . 0.7 OUTLIER -143.36 171.89 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.072 -1.018 . . . . 0.0 110.224 -179.498 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.501 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 3.4 ptm180 -141.37 132.43 26.23 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.649 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -94.22 109.67 43.78 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.331 -0.856 . . . . 0.0 110.286 -179.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.502 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.9 Cg_endo -77.2 110.68 3.06 Favored 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 122.023 1.816 . . . . 0.0 109.664 178.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.687 ' CD1' ' CZ2' ' A' ' 28' ' ' TRP . 3.3 mt -95.18 124.15 47.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.492 ' HB2' ' HB3' ' A' ' 102' ' ' SER . 12.8 m80 -84.5 149.36 25.99 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.926 -1.109 . . . . 0.0 111.638 -177.008 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.694 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 10.4 m-85 -154.55 158.43 39.79 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.063 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.719 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 109.33 38.77 1.74 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.66 ' C ' HG11 ' A' ' 64' ' ' VAL . 20.9 m-85 -113.99 158.08 21.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.444 -1.033 . . . . 0.0 109.207 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.21 -27.58 68.09 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.479 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -70.43 -14.99 62.77 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.447 -0.783 . . . . 0.0 109.328 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.521 ' O ' ' CG1' ' A' ' 61' ' ' VAL . 0.2 OUTLIER -109.62 11.25 24.77 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.371 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.529 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.4 t -85.79 163.88 2.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 O-C-N 121.523 -0.735 . . . . 0.0 109.881 -179.175 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.481 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.98 31.83 40.73 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.034 -1.227 . . . . 0.0 110.034 179.671 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.476 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 1.1 m-20 -160.61 139.36 10.28 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.147 -1.207 . . . . 0.0 110.27 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 59' ' ' VAL . 80.1 m -87.29 121.2 29.42 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.699 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.2 mt -101.89 118.2 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 120.868 -1.145 . . . . 0.0 110.383 -178.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.721 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 2.6 m-85 -97.24 138.78 34.2 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 178.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.694 HD11 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -130.35 139.78 50.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 C-N-CA 118.767 -1.173 . . . . 0.0 110.014 -178.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.64 ' CB ' HG12 ' A' ' 56' ' ' VAL . 1.0 OUTLIER -173.94 136.1 0.52 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.371 -0.831 . . . . 0.0 109.136 179.687 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.501 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 126.58 -8.08 7.39 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.688 179.397 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.565 ' HB2' HD12 ' A' ' 90' ' ' ILE . 10.4 tp -59.61 93.06 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.648 -1.501 . . . . 0.0 108.82 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . 0.475 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -118.22 145.75 44.76 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.694 -0.629 . . . . 0.0 109.9 -179.061 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.816 HG23 ' CD1' ' A' ' 88' ' ' TYR . 20.6 mt -132.68 127.28 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.362 -0.836 . . . . 0.0 109.095 179.607 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.573 ' O ' ' CD2' ' A' ' 86' ' ' TYR . . . -133.04 171.22 14.28 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -0.937 . . . . 0.0 109.599 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.631 ' CB ' ' CZ ' ' A' ' 86' ' ' TYR . 4.0 p -107.42 -15.63 14.57 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.183 -0.948 . . . . 0.0 109.464 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.431 ' HB3' ' HD2' ' A' ' 168' ' ' PRO . 13.0 mm-40 -134.06 163.12 53.44 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 109.568 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . 0.431 ' HD2' ' HB3' ' A' ' 167' ' ' GLN . 35.5 Cg_endo . . . . . 0 C--N 1.31 -1.489 0 C-N-CA 122.638 2.226 . . . . 0.0 110.344 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.4 ttt . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.8 mt -67.11 91.18 0.21 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.284 -0.885 . . . . 0.0 109.473 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.679 HG23 ' HB2' ' A' ' 165' ' ' ALA . 4.1 p -56.68 173.53 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.292 -0.88 . . . . 0.0 109.336 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.913 ' HB1' ' O ' ' A' ' 79' ' ' ASN . . . -77.61 -31.31 52.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 109.51 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.643 ' HB2' HD12 ' A' ' 164' ' ' ILE . 10.2 t-20 -92.19 124.67 36.44 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.24 -0.913 . . . . 0.0 109.689 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.512 ' O ' ' CB ' ' A' ' 7' ' ' ASN . 65.5 mt -110.38 121.63 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.323 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.525 ' OD1' ' CB ' ' A' ' 12' ' ' SER . 0.1 OUTLIER 76.83 43.8 0.12 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.243 -0.911 . . . . 0.0 109.169 -179.436 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.452 ' O ' ' HB3' ' A' ' 162' ' ' LEU . . . -47.76 -22.57 1.96 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.64 ' O ' ' CB ' ' A' ' 10' ' ' PHE . . . 164.2 60.35 0.02 OUTLIER Glycine 0 N--CA 1.487 2.082 0 C-N-CA 119.609 -1.281 . . . . 0.0 109.964 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.64 ' CB ' ' O ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER 118.4 1.06 0.0 OUTLIER 'General case' 0 N--CA 1.518 2.946 0 C-N-CA 122.832 0.453 . . . . 0.0 111.579 179.115 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.569 ' HG2' ' CD1' ' A' ' 10' ' ' PHE . 9.2 mm-40 -75.73 -60.79 2.16 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.418 -1.426 . . . . 0.0 110.831 -177.757 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.525 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.3 OUTLIER -75.11 -3.01 30.26 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.048 -1.032 . . . . 0.0 110.025 -179.201 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.642 ' OG1' HG13 ' A' ' 25' ' ' VAL . 4.4 m -126.1 123.8 24.49 Favored Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.029 -1.045 . . . . 0.0 109.411 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.454 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.4 Cg_endo -77.35 149.11 27.41 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 C-N-CA 122.46 2.107 . . . . 0.0 110.719 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.467 ' HA ' ' HB ' ' A' ' 44' ' ' VAL . . . -39.96 161.15 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.196 0.522 . . . . 0.0 109.676 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 134.35 134.49 3.42 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.654 HG23 ' HG3' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.47 140.87 14.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.392 -1.063 . . . . 0.0 108.969 -179.569 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.429 HG23 ' HA ' ' A' ' 43' ' ' GLU . 47.2 t -87.93 144.34 9.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.427 -0.796 . . . . 0.0 110.169 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 2.6 p -105.78 -21.2 13.23 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.391 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.403 ' HB3' ' HG3' ' A' ' 23' ' ' GLU . 7.7 m-20 -145.32 130.08 18.12 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.566 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 1.034 HD12 ' N ' ' A' ' 22' ' ' ALA . 1.7 pp -87.13 -38.31 16.57 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.088 -1.008 . . . . 0.0 110.179 -179.486 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.034 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -59.61 -24.93 64.21 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.155 -0.966 . . . . 0.0 108.87 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.403 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 2.0 pt-20 -138.66 34.63 2.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.452 -0.78 . . . . 0.0 109.215 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.98 -72.78 1.28 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.642 HG13 ' OG1' ' A' ' 13' ' ' THR . 1.6 t -86.08 127.85 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.288 -1.125 . . . . 0.0 109.134 179.73 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.5 ' HB3' ' HB3' ' A' ' 12' ' ' SER . 25.7 tt0 -54.71 -36.45 64.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.351 -0.843 . . . . 0.0 110.1 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.517 ' HA3' ' CB ' ' A' ' 7' ' ' ASN . . . -109.96 8.61 31.57 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.862 -1.161 . . . . 0.0 110.214 -179.367 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 0.749 ' CZ3' ' HB1' ' A' ' 73' ' ' ALA . 0.7 OUTLIER -140.57 119.67 12.81 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.089 -1.242 . . . . 0.0 109.125 179.313 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.585 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 7.3 m-20 -124.81 142.17 51.61 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.188 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.922 ' O ' HD13 ' A' ' 21' ' ' LEU . 3.3 mt -109.48 172.13 7.04 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.846 -1.159 . . . . 0.0 109.794 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -159.95 122.41 3.38 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.767 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.688 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.23 137.87 37.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.476 -0.765 . . . . 0.0 109.598 179.302 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -90.73 172.98 37.88 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 72.4 m -62.61 -12.28 22.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.17 -1.194 . . . . 0.0 109.38 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 20.9 p -72.23 -32.64 66.91 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.32 -0.863 . . . . 0.0 109.812 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.787 HG12 ' O ' ' A' ' 36' ' ' VAL . 2.2 t -70.34 87.1 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 O-C-N 121.112 -0.992 . . . . 0.0 109.318 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 22.2 m -63.96 -28.98 70.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.194 -0.941 . . . . 0.0 108.484 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.1 t30 -128.86 114.86 19.05 Favored Pre-proline 0 C--N 1.296 -1.74 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.44 ' HA ' ' HD3' ' A' ' 40' ' ' PRO . 34.8 Cg_endo -76.45 144.56 25.8 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.167 1.911 . . . . 0.0 110.492 -179.501 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.643 ' CG ' HG21 ' A' ' 71' ' ' ILE . 35.3 Cg_endo -77.27 -164.08 0.25 Allowed 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.557 2.171 . . . . 0.0 110.133 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 56.8 t -116.09 120.26 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.127 -0.983 . . . . 0.0 110.667 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.817 ' CD1' HD13 ' A' ' 30' ' ' LEU . 5.5 m-85 -101.78 112.21 24.72 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 178.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.654 ' HG3' HG23 ' A' ' 17' ' ' VAL . 0.4 OUTLIER -155.93 140.04 16.46 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.005 -1.059 . . . . 0.0 110.361 -179.451 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.473 ' N ' ' HG2' ' A' ' 43' ' ' GLU . 36.5 t -92.52 148.79 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 1.039 HD22 ' N ' ' A' ' 46' ' ' GLU . 0.0 OUTLIER -148.67 165.16 32.17 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.013 -1.055 . . . . 0.0 109.033 -179.558 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 1.039 ' N ' HD22 ' A' ' 45' ' ' LEU . 13.4 mt-10 -111.19 113.89 26.72 Favored 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.452 -0.78 . . . . 0.0 109.644 -178.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.941 ' CG2' HD21 ' A' ' 45' ' ' LEU . 7.7 p -111.71 165.82 11.71 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 41.8 t -94.67 -10.11 32.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.494 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 50' ' ' ALA . 1.3 m-20 -102.54 -1.79 29.77 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.263 -0.898 . . . . 0.0 109.59 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.482 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -44.1 147.38 0.94 Allowed Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.165 -0.959 . . . . 0.0 109.43 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.613 ' HB3' ' CE3' ' A' ' 91' ' ' TRP . 35.4 Cg_endo -78.34 -40.85 0.31 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.704 2.269 . . . . 0.0 110.325 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.14 107.06 11.73 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.418 ' O ' ' CG ' ' A' ' 54' ' ' ASN . . . 87.5 -120.5 5.56 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.482 ' HA ' ' HB3' ' A' ' 50' ' ' ALA . 27.7 m120 -160.16 36.28 0.17 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -1.169 . . . . 0.0 109.504 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.64 ' CD ' ' CD2' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -158.91 157.27 31.09 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.31 -0.869 . . . . 0.0 109.765 179.824 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.801 HG12 ' HB3' ' A' ' 160' ' ' ASP . 15.3 m -152.27 174.21 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.372 -0.83 . . . . 0.0 108.897 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.493 ' O ' ' HA ' ' A' ' 158' ' ' TYR . 0.2 OUTLIER -91.44 100.67 13.4 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 178.777 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.744 ' HB2' ' CE2' ' A' ' 158' ' ' TYR . . . -80.34 120.05 23.87 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 119.394 -0.922 . . . . 0.0 108.991 -179.812 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.841 ' O ' HG23 ' A' ' 156' ' ' THR . 41.3 t -112.97 144.48 20.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.841 HG22 ' ND2' ' A' ' 62' ' ' ASN . 59.7 m -109.87 91.14 3.53 Favored 'General case' 0 C--N 1.282 -2.327 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.537 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 52.4 t -89.95 122.82 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.311 -0.868 . . . . 0.0 108.799 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.841 ' ND2' HG22 ' A' ' 60' ' ' THR . 5.0 p30 -160.09 60.96 0.35 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.284 -0.885 . . . . 0.0 109.935 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 158.51 86.48 0.06 OUTLIER Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.729 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.3 m -82.23 -177.15 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.248 -1.148 . . . . 0.0 109.588 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -136.52 -157.86 7.87 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -96.0 23.73 6.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.326 -1.102 . . . . 0.0 109.566 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.502 ' HB3' ' NE1' ' A' ' 69' ' ' TRP . 7.0 m-80 -136.55 148.19 62.78 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.2 -0.937 . . . . 0.0 109.466 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.414 ' HG2' ' CE3' ' A' ' 69' ' ' TRP . 36.4 Cg_endo -78.24 11.93 2.22 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.662 2.242 . . . . 0.0 110.926 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.502 ' NE1' ' HB3' ' A' ' 67' ' ' ASN . 1.3 p90 -136.76 59.56 1.69 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.093 -1.004 . . . . 0.0 109.647 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.514 ' HB3' ' CG2' ' A' ' 36' ' ' VAL . 1.4 m-20 -76.6 -67.59 0.68 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.242 -0.911 . . . . 0.0 109.111 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.643 HG21 ' CG ' ' A' ' 40' ' ' PRO . 2.2 mt -116.57 123.37 71.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.433 -0.792 . . . . 0.0 109.12 179.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.517 ' CG ' ' O ' ' A' ' 145' ' ' ILE . 20.7 tt0 -129.12 134.33 48.02 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.972 -1.08 . . . . 0.0 110.335 -179.4 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.749 ' HB1' ' CZ3' ' A' ' 28' ' ' TRP . . . -115.91 107.69 15.31 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 178.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.56 HG22 ' N ' ' A' ' 75' ' ' ALA . 99.3 m -103.52 165.06 11.26 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.334 -0.854 . . . . 0.0 109.669 -179.24 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.56 ' N ' HG22 ' A' ' 74' ' ' THR . . . -122.98 137.49 54.94 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.026 -1.046 . . . . 0.0 109.227 179.027 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CZ ' ' HB2' ' A' ' 29' ' ' ASP . 11.2 p90 -176.05 160.32 1.89 Allowed Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.4 -0.812 . . . . 0.0 109.383 -179.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.519 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 37.0 Cg_endo -82.53 170.22 58.1 Favored 'Cis proline' 0 C--N 1.311 -1.395 0 O-C-N 123.652 1.343 . . . . 0.0 111.064 -0.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.674 HG11 HD13 ' A' ' 164' ' ' ILE . 96.4 t -131.75 156.9 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.239 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.913 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 76.1 m-20 -123.24 140.28 53.18 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.922 -1.111 . . . . 0.0 110.289 -179.459 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 138' ' ' GLU . 4.3 m -145.48 -173.51 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.304 -0.873 . . . . 0.0 109.387 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.766 ' O ' HG21 ' A' ' 134' ' ' VAL . 17.6 mmt180 -136.45 144.73 48.69 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.382 -0.824 . . . . 0.0 109.348 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.454 ' HD2' ' HD3' ' A' ' 81' ' ' ARG . 35.1 Cg_endo -77.73 126.87 8.4 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.457 2.105 . . . . 0.0 110.539 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.22 -25.17 21.61 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.424 HG12 ' CE1' ' A' ' 86' ' ' TYR . 2.6 t -86.32 149.61 4.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.239 -1.154 . . . . 0.0 109.496 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 32.8 m -94.86 131.96 40.18 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.502 ' HD2' HG22 ' A' ' 164' ' ' ILE . 14.6 m-85 -113.32 167.31 10.67 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.236 -0.915 . . . . 0.0 109.666 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.47 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 43.8 m -118.38 152.88 34.99 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.338 -0.851 . . . . 0.0 109.418 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.688 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 7.9 t80 -132.81 114.83 14.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.481 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.485 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.2 m -135.11 146.23 48.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.194 -0.941 . . . . 0.0 109.002 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.701 HD13 ' HD2' ' A' ' 103' ' ' PHE . 15.3 tt -150.96 163.78 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.796 -1.19 . . . . 0.0 109.5 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.613 ' CE3' ' HB3' ' A' ' 51' ' ' PRO . 37.3 m95 -128.76 135.41 49.15 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.862 -1.149 . . . . 0.0 109.375 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.425 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -130.0 148.09 51.82 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.213 -0.929 . . . . 0.0 109.747 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.636 ' CB ' ' CD2' ' A' ' 125' ' ' TRP . 11.6 ttt-85 -164.14 121.66 1.74 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.317 -0.864 . . . . 0.0 108.909 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -106.04 165.68 11.04 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.305 -0.872 . . . . 0.0 110.086 -179.403 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.07 -56.6 12.06 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.425 -0.797 . . . . 0.0 109.117 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.517 ' O ' ' ND2' ' A' ' 155' ' ' ASN . 0.5 OUTLIER -101.77 134.93 44.17 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.279 -0.888 . . . . 0.0 109.204 179.701 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.581 ' N ' ' CG2' ' A' ' 123' ' ' THR . 1.2 p30 -60.77 144.95 51.37 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.212 -0.93 . . . . 0.0 109.551 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 112.45 37.82 1.41 Allowed Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.536 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -118.78 139.31 51.8 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.204 -1.174 . . . . 0.0 109.224 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.449 HG22 ' HA ' ' A' ' 120' ' ' GLN . 76.0 t -116.46 149.93 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.205 -0.934 . . . . 0.0 110.407 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.813 HG13 ' CE2' ' A' ' 147' ' ' PHE . 43.0 t -146.15 165.77 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.34 -0.85 . . . . 0.0 109.45 179.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.556 ' CB ' ' HB2' ' A' ' 117' ' ' HIS . 24.2 m -124.77 133.42 53.16 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.146 -0.971 . . . . 0.0 109.681 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.701 ' HD2' HD13 ' A' ' 90' ' ' ILE . 1.0 OUTLIER -129.1 103.85 7.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.126 -0.984 . . . . 0.0 109.477 179.497 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.647 HG22 ' HA ' ' A' ' 115' ' ' ARG . 29.2 p -128.14 175.63 8.28 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.133 -0.979 . . . . 0.0 110.323 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.904 HG23 ' H ' ' A' ' 114' ' ' GLY . 0.0 OUTLIER -133.45 106.34 9.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-O 121.575 0.702 . . . . 0.0 110.316 179.175 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.459 ' O ' ' HG2' ' A' ' 142' ' ' ARG . . . -101.54 132.46 10.97 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 108.052 -2.019 . . . . 0.0 108.052 178.554 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.584 ' OD1' ' CE1' ' A' ' 113' ' ' TYR . 0.2 OUTLIER -96.87 -170.62 2.08 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.963 -1.316 . . . . 0.0 109.052 -179.399 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 62.1 mt-30 -81.28 -19.8 42.24 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 118.751 -1.18 . . . . 0.0 109.829 -179.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.539 ' HB3' ' CG ' ' A' ' 111' ' ' GLN . 0.6 OUTLIER -81.92 8.82 9.45 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.113 -0.992 . . . . 0.0 108.792 178.979 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.44 ' HB2' ' O ' ' A' ' 109' ' ' SER . 18.3 m-30 63.01 21.75 13.08 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.428 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.539 ' CG ' ' HB3' ' A' ' 109' ' ' SER . 2.0 mt-30 -88.36 161.61 17.01 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.649 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.82 102.12 12.22 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.447 -0.783 . . . . 0.0 109.768 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 1.016 ' OH ' HG13 ' A' ' 134' ' ' VAL . 1.9 m-30 -69.41 -67.14 0.5 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.401 -0.812 . . . . 0.0 108.941 178.553 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.904 ' H ' HG23 ' A' ' 105' ' ' VAL . . . -130.55 171.45 20.72 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.647 ' HA ' HG22 ' A' ' 104' ' ' THR . 0.2 OUTLIER -162.78 117.31 1.75 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.029 -1.277 . . . . 0.0 110.723 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.891 HD21 ' CD2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -150.62 74.31 1.17 Allowed 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 178.997 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.556 ' HB2' ' CB ' ' A' ' 102' ' ' SER . 22.4 p80 -118.3 169.15 9.97 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.193 -0.942 . . . . 0.0 110.134 -179.304 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.512 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 0.2 OUTLIER 77.53 41.04 0.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.517 -0.739 . . . . 0.0 109.294 179.925 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.452 ' HG3' HD11 ' A' ' 121' ' ' ILE . 0.8 OUTLIER -116.03 138.35 51.3 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.316 -0.865 . . . . 0.0 109.668 -179.836 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.486 ' O ' HD13 ' A' ' 121' ' ' ILE . 2.4 mt-30 -74.54 156.49 36.8 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.486 HD13 ' O ' ' A' ' 120' ' ' GLN . 5.2 mm -135.19 134.64 52.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.116 -0.99 . . . . 0.0 110.022 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -84.0 -179.43 7.25 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.523 -0.735 . . . . 0.0 109.947 179.477 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.581 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 70.2 p -75.98 -0.46 21.67 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 119.829 -0.748 . . . . 0.0 109.23 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.442 ' O ' ' HG3' ' A' ' 93' ' ' ARG . 22.5 mm-40 -102.4 -168.91 1.59 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.246 -0.909 . . . . 0.0 109.21 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.679 ' CH2' HG11 ' A' ' 56' ' ' VAL . 88.4 m95 -103.2 115.17 30.07 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 0.0 109.614 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 9.4 mt-30 -106.68 120.75 47.32 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.11 -0.994 . . . . 0.0 108.986 179.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.408 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.9 Cg_endo -80.58 116.28 3.22 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 C-N-CA 122.384 2.056 . . . . 0.0 111.175 -179.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -112.03 135.6 52.46 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.435 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 14.6 t -145.71 176.3 9.75 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 120.822 -1.174 . . . . 0.0 110.801 -179.348 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.891 ' CD2' HD21 ' A' ' 116' ' ' LEU . 21.2 p90 -176.89 152.7 0.96 Allowed 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.303 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -105.28 154.91 19.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.752 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 113' ' ' TYR . 0.2 OUTLIER -165.02 160.88 19.43 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.431 -0.793 . . . . 0.0 109.334 179.942 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.7 OUTLIER -124.13 146.42 48.65 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.214 -0.929 . . . . 0.0 108.937 -179.883 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 1.016 HG13 ' OH ' ' A' ' 113' ' ' TYR . 3.5 t -43.57 109.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.294 -0.879 . . . . 0.0 108.955 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -51.41 -40.05 58.53 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.123 -0.986 . . . . 0.0 109.149 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -129.81 -90.28 0.48 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.38 -0.825 . . . . 0.0 109.369 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -158.58 52.73 0.42 Allowed 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.479 -0.763 . . . . 0.0 109.279 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.6 ' O ' HG23 ' A' ' 80' ' ' VAL . 32.5 mm-40 -85.53 110.15 19.01 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.261 -0.9 . . . . 0.0 109.547 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 3.3 p -79.48 -16.25 56.38 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.249 -0.907 . . . . 0.0 108.71 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.515 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 42.4 t -132.24 134.31 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.725 HG21 ' CE2' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -139.81 172.28 12.69 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.051 -1.031 . . . . 0.0 110.447 -179.447 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.502 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 0.0 OUTLIER -143.73 132.07 22.07 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.895 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.848 ' HB3' HD21 ' A' ' 162' ' ' LEU . . . -99.31 106.58 39.88 Favored Pre-proline 0 N--CA 1.487 1.421 0 O-C-N 121.207 -0.933 . . . . 0.0 109.616 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.586 ' C ' HD13 ' A' ' 145' ' ' ILE . 36.1 Cg_endo -78.04 111.92 3.16 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.206 1.937 . . . . 0.0 110.827 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.705 HD13 ' N ' ' A' ' 145' ' ' ILE . 2.0 mm -94.31 139.56 18.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 178.343 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.539 ' C ' ' CD1' ' A' ' 147' ' ' PHE . 4.5 m80 -107.22 159.75 16.11 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.299 -1.501 . . . . 0.0 112.165 -177.007 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.813 ' CE2' HG13 ' A' ' 101' ' ' VAL . 39.0 m-85 -160.72 165.25 30.77 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.639 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 104.52 46.51 1.3 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.729 ' C ' HG11 ' A' ' 64' ' ' VAL . 23.9 m-85 -125.03 161.27 27.1 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.477 -1.013 . . . . 0.0 109.115 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.418 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -66.72 -28.47 68.45 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -75.78 -11.54 60.0 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.434 -0.791 . . . . 0.0 109.065 179.031 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.613 ' ND2' HD13 ' A' ' 157' ' ' ILE . 1.5 t30 -114.61 11.0 16.88 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.403 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.535 ' HA ' HG12 ' A' ' 61' ' ' VAL . 2.4 t -88.02 162.81 2.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.495 -0.753 . . . . 0.0 109.868 -179.223 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.466 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 52.42 34.04 41.07 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 96' ' ' GLN . 3.5 m-20 -160.39 138.71 10.09 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.177 -1.19 . . . . 0.0 110.013 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.841 HG23 ' O ' ' A' ' 59' ' ' VAL . 53.5 m -89.37 120.44 30.72 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.613 HD13 ' ND2' ' A' ' 152' ' ' ASN . 0.7 OUTLIER -100.37 117.44 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 120.902 -1.124 . . . . 0.0 110.222 -178.894 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.744 ' CE2' ' HB2' ' A' ' 58' ' ' ALA . 13.1 m-85 -92.52 143.63 26.16 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 178.381 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.656 ' CD1' ' CE2' ' A' ' 147' ' ' PHE . 1.2 mt -142.04 136.22 29.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.604 -1.31 . . . . 0.0 111.025 -178.014 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.801 ' HB3' HG12 ' A' ' 56' ' ' VAL . 4.7 t0 -173.23 136.24 0.62 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.245 -0.909 . . . . 0.0 108.586 179.144 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 89' ' ' THR . . . 133.35 -7.29 5.01 Favored Glycine 0 N--CA 1.484 1.896 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.422 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.848 HD21 ' HB3' ' A' ' 143' ' ' ALA . 7.3 tp -59.33 93.14 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.626 -1.514 . . . . 0.0 108.596 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . 0.444 ' N ' ' O ' ' A' ' 161' ' ' GLY . . . -123.62 145.98 48.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.594 -0.691 . . . . 0.0 109.965 -178.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.674 HD13 HG11 ' A' ' 78' ' ' VAL . 8.0 mt -132.41 119.58 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.325 -0.86 . . . . 0.0 109.258 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.679 ' HB2' HG23 ' A' ' 3' ' ' VAL . . . -153.01 144.55 23.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.772 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 86' ' ' TYR . 0.7 OUTLIER -43.71 -64.76 0.6 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.354 -0.841 . . . . 0.0 109.535 179.837 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.18 168.27 18.54 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.279 -0.888 . . . . 0.0 109.494 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo . . . . . 0 C--N 1.309 -1.528 0 C-N-CA 122.63 2.22 . . . . 0.0 110.401 -179.984 . . . . . . . . 0 0 . 1 stop_ save_